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Abstract 
This Thesis describes the development of telescoped rhodium(II)-catalysed transformations of α-
diazo(diethoxyphosphoryl)acetates for the formation of α-methylene-γ-butyrolactones. An 
overview of synthetic approaches to α-methylene-γ-butyrolactones is given in Chapter 1, in 
addition to a discussion of published Rh(II)-catalysed C–H insertion reactions. 
 
Previous efforts in the Taylor group have established effective methods for the synthesis of α-
methylene-γ-butyrolactones, although these require relatively complex functionality in the 
precursors. The research in this Thesis focuses on the development of a one-pot Rh(II)-catalysed 
C–H insertion/olefination sequence for the synthesis of α-methylene-γ-butyrolactones III from α-
diazo(diethoxyphosphoryl)acetates I, which are readily accessible from simple alcohols. The key 
C–H insertion step enables the formation of a new C–C bond in α-phosphonolactone II, via 
reaction of the rhodium carbenoid with a C–H bond typically considered completely unreactive. 
 
 
 
 
The scope of the reaction is explored in detail, concluding with the synthesis of two natural 
products, cedarmycins A and B (IV and V) and a Staphylococcus aureus inhibitor VI (Chapter 2). 
The scope of the reaction was extended to the use of conformationally restricted substrates, 
facilitating the synthesis of α-methylene-γ-butyrolactones with complete diastereoselectivity, 
demonstrated through the synthesis of the natural product α-cyclocostunolide VII (Chapter 3). 
Finally, the development of a related procedure is described (Chapter 4). The rhodium(II)-catalysed 
cyclopropanation of allylic α-diazo(diethoxyphosphoryl)acetates is discussed as an alternative 
approach to the α-methylene-γ-butyrolactone framework. This work has been applied to the first 
total synthesis of peperomin E VIII as well as savinin IX and gadain X (Chapter 4).  
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Chapter 1 –  Introduction 
1.1  α-Methylene-γ-butyrolactones 
1.1.1.  Prevalence in Nature 
 
The α-methylene-γ-butyrolactone functionality is prevalent in Nature, comprising approximately 
3% of all known natural products.1 This naturally occurring motif imparts a wide variety of 
biological effects including antibacterial, antifungal and anticancer activities. The simplest possible 
α-methylene-γ-butyrolactone is itself a natural product known as tulipalin A 1, possessing anti-
tumour properties and isolated from the common tulip Tulipa gesneriana.2 Many of these natural 
products are also isolated from flowering plants; for example, hispitolide A 2 is isolated from 
Parthenium hispitum,3 commonly known as feverfew, and ratibinolide 3 from Ratibida 
latipalearis, a genus of the daisy family (Figure 1).4 
 
 
Figure 1: Examples of α-methylene-γ-butyrolactone containing natural products. 
 
The majority of α-methylene-γ-butyrolactone natural products are sesquiterpenes, derived from 3 
isoprene units and containing 15 carbons. They can be further classified based on their structural 
frameworks (Figure 2). Many of these examples contain fused bicyclic rings, giving rise to both 
cis- and trans-skeletons (cf. hispitolide A and ratibinolide, Figure 1). In addition, there are many 
examples of diterpene α-methylene-γ-butyrolactones, containing 20 carbons, as well as non-
terpenoid examples.5  
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Figure 2: Commonly found sesquiterpene α-methylene-γ-butyrolactone frameworks and non-
terpenoid butanolides. 
 
Sesquiterpene lactones can also be found in food sources, with lettuce and chicory representing the 
most common method of consumption for humans. They also convey benefits for plants, acting as 
defence mechanism against fungi, bacteria and insects.6 In addition to their medicinal applications, 
sesquiterpene lactones can also have negative effects, most commonly allergic reactions; for 
example, the pollen from plants that produce sesquiterpene α-methylene-γ-butyrolactones can 
cause allergic contact dermatitis, leading to sensitisation of the skin.7  
 
The biological activity of sesquiterpene lactones stems from the electrophilic nature of the α,β-
unsaturated ester, making these compounds susceptible to 1,4-addition reactions. In vivo, L-
cysteine residues or thiol-containing enzymes react via conjugate addition to form adducts that 
reduce the growth of cells or aid drug-induced cell death.5 Whilst the α-methylene-γ-butyrolactone 
functionality provides the main mode of reactivity leading to a range of effects it is other functional 
groups that enhance activity through chemical or steric influences.6 
 
Studies have shown that the biosynthesis of α-methylene-γ-butyrolactones proceeds via the 
synthesis of a common precursor which then undergoes late-stage chemical transformations to 
form the array of natural product frameworks shown in Figure 2.7 The pathway that produces 
terpene based α-methylene-γ-butyrolactones begins with an intramolecular cyclisation of farnesyl 
pyrophosphate 4 (Scheme 1). A series of oxidations affords germacrene acid 7 and costunolide 8, 
further elaboration of which gives rise to the many different terpenoid frameworks. 
 
O
O
O
O
O
O
O O O O O O
O O
germacranolides eudesmanolides eremophilanolides
guaianolides pseudoguaianolides xanthanolides
carabanolides
O
O
R
butanolides
  3 
 
Scheme 1: Biosynthetic pathway towards terpenoid α-methylene-γ-butyrolactones. 
 
The biological activity of α-methylene-γ-butyrolactones is both wide-ranging and significant for 
the purpose of both medicinal treatments, for example as antivirals,8 and in agriculture as insect 
antifeedants,1,6 thus the development of new efficient methods for their synthesis is of much 
interest. 
 
1.1.2.  Existing routes 
 
There are many existing synthetic routes to make α-methylene-γ-butyrolactones, many of which 
have been thoroughly reviewed before,7 most recently in 2009.1 A short summary is given herein 
along with some more recent examples. 
 
The methylenation of lactones is one of the most common routes towards α-methylene-γ-
butyrolactones. For example, the dehydration of α-hydroxy-γ-lactones 10, either with or without 
prior derivatisation of the alcohol, generates α-methylene-γ-butyrolactone 11. Eschenmoser’s 
iminium salt 12, can be used as an alternative reagent to formaldehyde, forming aminomethyl 
lactone 13, which on alkylation in the presence of base generates the α-methylene-γ-butyrolactone 
11 via a Hofmann elimination.1,9 Another commonly used method to introduce the exo-methylene 
unit is by selenoxide elimination. Firstly, methylation of γ-butyrolactone 9 generates α-methyl-γ-
butyrolactone 14, which on treatment with phenylselenylchloride under basic conditions affords 
selenide 15. Subsequent oxidation and selenoxide elimination in the presence of hydrogen peroxide 
furnishes α-methylene-γ-butyrolactone 11 (Scheme 2).1 
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Scheme 2: Elimination-based methylenation approaches to α-methylene-γ-butyrolactones. 
 
The formation of α-methylene-γ-butyrolactones by lactonisation is another commonly employed 
technique. The simplest approach of this type is the cyclisation of a γ-alcohol and carbonyl such as 
an ester, acid or acid chloride, yet many of these approaches involve an initial reaction to install the 
γ-alkoxy/alkoxide ester, which then undergoes a lactonisation reaction to form the desired α-
methylene-γ-butyrolactone. For example, the treatment of crotylboronate 16 and aldehyde 17 with 
Lewis or Brønsted acid forms the γ-alkoxide ester, which subsequently undergoes in situ 
lactonisation delivering α-methylene-γ-butyrolactone 18 (Scheme 3).10 
 
 
Scheme 3: Crotylboronate derived route to α-methylene-γ-butyrolactones. 
 
A similar approach, an example of which is shown in Scheme 4, utilises a 2-bromomethylacrylic 
ester 19 and aldehyde 20 and is known as the Dreiding–Schmidt procedure.11 In this case, addition 
of zinc generates the organometallic reagent, which adds diastereostereoselectively into the 
aldehyde, before spontaneously cyclising to form the lactone 21. 
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Scheme 4: Dreiding–Schmidt procedure for synthesis of α-methylene-γ-butyrolactones. 
 
In 2011 Hodgson et al. reported a Barbier-type coupling,12 similar to that of the Dreiding–Schmidt 
procedure, that produced β-hydroxymethyl-α-methylene-γ-butyrolactones 24 via coupling of 
bromolactone 22 with aldehydes 23 as shown in Scheme 5. They found that both metallic zinc or 
Cr(II) salts could successfully be employed to efficiently convert the aromatic and aliphatic 
aldehydes, respectively in good yield, regio- and stereocontrol. 
 
 
Scheme 5: Hodgson’s Barbier-type allylation approach to α-methylene-γ-butyrolactones. 
 
Hodgson also developed a Rh(I)-catalysed asymmetric enyne rearrangement of alkynyl allyl ester 
25 to give α-methylene-γ-butyrolactone 26 (Scheme 6).13 The novel reaction was employed in the 
first reported total synthesis of (+)-anthecotulide, a butanolide type sesquiterpene lactone. 
 
 
 
Scheme 6: Hodgson’s enyne rearrangement approach to α-methylene-γ-butyrolactone 26. 
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A recent example of a lactone-forming approach is the Rauhut–Currier reaction (also known as a 
vinylogous Morita–Baylis–Hillman reaction) developed by Zhang and co-workers.14 They utilised 
a novel chiral sulfonamide phosphine 27 to catalyse the intramolecular Rauhut–Currier reaction, 
affording α-methylene-γ-butyrolactones 29 in excellent ee and high yield (Scheme 7). 
 
 
Scheme 7: Asymmetric Rauhut–Currier reaction affording α-methylene-γ-butyrolactones. 
 
Many natural products possess an α-alkylidene-γ-butyrolactone core. In many cases the additional 
substitution at the exocyclic alkene can be built into the alkylidenation or lactonisation reaction. 
However, alternative transformations of α-methylene-γ-butyrolactones are also commonplace; for 
example by olefin cross-metathesis15 and Heck cross-couplings.16 
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1.1.3.  Taylor group methodologies 
 
The synthesis of α-methylene-γ-butyrolactones has been the subject of much focus in the Taylor 
group in the past decade. Each of the routes developed comprises a lactonisation (via C–C bond 
formation) preceding a methylenation, with an emphasis towards developing one-pot tandem 
processes.17, 18 
 
The first reported approach was the telescoped intramolecular Michael/olefination (TIMO) 
sequence (Scheme 8).17 It was found that performing the two steps together was more efficient than 
sequentially with isolation of the intermediates. α-(Diethoxyphosphoryl)acetates 32 — readily 
prepared from alcohols 30 and diethoxyphosphonoacetic acid (DEPAA) 31 — are treated with base 
and, in the presence of the Michael acceptor, an intramolecular 1,4-addition occurs to afford 
bicyclic enolates 33 in a syn-selective fashion. Proton transfer and the addition of an aldehyde 
initiates a Horner–Wadsworth–Emmons (HWE) olefination reaction with paraformaldehyde to 
afford α-methylene-γ-butyrolactones 35 in an efficient, one-pot process. α-Arylidene-γ-
butyrolactones were also synthesised with the use of substituted aldehydes. 
 
 
Scheme 8: Taylor’s telescoped intramolecular Michael/olefination (TIMO) sequence. 
 
A related approach to TIMO, also a one-pot process, uses acylated phosphoranes 37 that can be 
readily synthesised from alcohols 30 and Bestmann’s ylide 36.18a The advantages of this route over 
TIMO are that it is one-pot from the alcohol 30 and is base-free although, as expected, the Wittig 
reaction was found to be slower than the analogous HWE olefination (Scheme 9). 
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Scheme 9: Taylor’s base-free Bestmann’s ylide approach to α-methylene-γ-butyrolactones. 
 
The TIMO methodology was successfully applied to the synthesis of three natural products, (+)-
paeonilactone B17a 40 and (±)-3-oxodiplophyllin 41 (synthesised using both the TIMO and 
Bestmann’s ylide approach), which was then converted into (±)-yomogin 42 (Figure 3).18b 
 
 
Figure 3: Natural products (+)-paeonilactone B, (±)-3-oxodiplophyllin and (±)-yomogin, 
successfully synthesised via TIMO methodology.  
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1.2  Rhodium(II)-catalysed C–H insertions 
 
The functionalisation of unactivated sp3 C–H bonds, normally considered inert, is an ambition for 
many within the synthetic community. With the development of a variety of achiral and chiral 
catalysts, the field of rhodium(II)-stabilised carbenoids derived from diazo compounds has 
blossomed.19 The ability to perform chemo-, regio- and stereoselective C–H insertions is now 
possible, representing the backbone of many target-based syntheses.  
 
Early studies within the area of diazo decomposition used copper to perform C–H insertion 
reactions.20 However, since the first example of a rhodium(II) catalyst being used for C–H 
insertions, the use of copper has become less common. Recently there has been a revival in the area 
of copper catalysed C–H insertions but there are only limited reports with yields or ee comparable 
to those achievable using Rh(II) catalysis.21 One reason for the relative lack of interest in copper is 
the high electrophilicity of the copper-carbenoids that tends to reduce chemo- and 
regioselectivity.22 
 
The field of rhodium(II)-catalysed diazo decomposition commenced in the 1970’s. Whilst working 
with Rh2(OAc)4, Teyssié reported the homogeneous rhodium(II)-catalysed insertion of ethyl 
diazoacetate 43 into the O–H bond of alcohols and other weak hydroxylic acids (Scheme 10).23 
 
 
Scheme 10: Teyssié’s original O–H insertion using Rh2(OAc)4. 
 
This initial discovery concerned an O–H insertion, but there has since been a great variety of 
applications including cyclopropanations, cyclopropenations, aromatic cycloadditions, ylide 
formations, N–H, and C–H insertions.24 It is the latter that is the focus of this overview. 
 
1.2.1.  Structure of Rh(II) catalysts 
 
Rh2(OAc)4 along with other rhodium(II) carboxylates and carboxamidates possesses a binuclear 
core structure with two bridging rhodium atoms that have a formal Rh–Rh single bond between 
them.25 The oxidation state of the dirhodium core is +4, giving each rhodium atom a formal +2 
oxidation state (d7 centre). The four acetate ligands in rhodium(II) acetate each bridge the rhodium 
atoms forming a cage-like structure, often referred to as a paddlewheel or lantern.25c,26 Rhodium(II) 
+
Rh2(OAc)4
O
O
O88%
H
N2
O
O O
H
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carboxylates 46 possess four oxygen atoms on each rhodium atom occupying the equatorial sites, 
giving overall D4h symmetry (Figure 4).24 In contrast, rhodium(II) carboxamidates 47 typically 
favour the binding of two nitrogen and two oxygen atoms to each rhodium atom, with the cis 
arrangement (cis-[2,2]) dominant, as displayed in Figure 4.27 
 
 
Figure 4: Rhodium(II) carboxylate and cis-[2,2]-carboxamidate catalysts, with lobes representing 
vacant axial sites. 
 
With the adjacent rhodium atom occupying one axial site the other is free for coordination, giving a 
total of two free coordination sites. These sites may be occupied by weakly-bound donor ligands or 
solvents, e.g. nitriles, amines, phosphines or sulfoxides.24,25c Typically C–H insertion reactions are 
performed in a non-coordinating aprotic solvent such as DCM, DCE or toluene. Solvents such as 
THF or pyridine coordinate to, and hence deactivate,28 the catalyst changing the electronic 
structure, which is usually discerned by a colour change. For example the characteristic green 
colour of rhodium(II) carboxylates can change to blue/green and red with oxygen and nitrogen 
donors, respectively.29 Sulfur and phosphorus containing ligands can also coordinate, again 
changing the colour of the catalyst. Doyle’s rhodium(II) carboxamidate catalysts typically appear 
red in the solid-state when coordinated by solvent molecules but blue under vacuum or in poorly 
coordinating solvents.27 
 
The scarcity of rhodium means that it is expensive, with Rh2(OAc)4 costing approximately 
£250/g.30 However, this cost is somewhat compensated for by its high activity with respect to diazo 
decomposition, considerably more so than copper(I).31 A variety of chiral and achiral rhodium(II) 
catalysts are also commercially available. There are many methods currently being used in an effort 
to make rhodium(II) catalysis cheaper, for example, by immobilisation of the catalyst on solid 
supports.32 
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1.2.1.1.  Preparation of Rh(II) catalysts 
 
Rh2(OAc)4 is prepared by refluxing RhCl3 in the presence of acetic anhydride in acetic acid. 
Rhodium(II) carboxylates, carboxamidates and other ligand families are typically prepared by 
ligand substitution from Rh2(OAc)4. A Soxhlet extractor is used, with an excess of the 
corresponding carboxylic acid or amide, refluxing in chlorobenzene, in the presence of base to trap 
the liberated acetic acid (Scheme 11).27,33 
 
 
Scheme 11: Synthesis of dirhodium(II) complexes from rhodium(III) chloride. 
 
Rhodium(II) carboxylates are stable to air and thermal degradation, whereas the carboxamidates, 
which are more readily oxidised, often require axially coordinated nitrile ligands in order to 
prolong their shelf-life.24 
 
1.2.2.  Mechanism of C–H insertion 
 
For many years the exact mechanism of the C–H insertion has been the subject of much debate and 
will form the structure of the following discussion. The first step of the process is widely accepted 
to be the nucleophilic attack of the diazo compound 48 to the electrophilic rhodium catalyst via one 
of the vacant axial sites, generating ylide 49.34  This is then followed by the rate-determining step,35 
the extrusion of nitrogen gas, in which the reactive rhodium-stabilised carbenoid 50 is formed, as 
shown in Scheme 12.  
 
 
Scheme 12: Diazo decomposition initiated by coordination to rhodium(II) species, [Rh] = Rh2L4. 
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It is believed that back-donation from the rhodium aids extrusion of the nitrogen gas. A simplified 
model of the orbital bonding interactions is shown in Figure 5. The rhodium carbenoid is singlet in 
nature with two paired electrons from the carbene sp2 orbital contributing to the Rh–C σ-bond. The 
empty p-orbital on the carbenoid carbon is able to accept electrons via back-bonding from the 
occupied Rh2 π* orbital.36 
 
  
Figure 5: Orbital interactions responsible for bonding in Rh(II) carbenoid.  
 
Following the diazo decomposition and formation of the carbenoid the C–H insertion step takes 
place. Doyle proposed one of the first transition state models for the C–H activation process. He 
suggested that the vacant p-orbital of the electrophilic carbene carbon atom overlaps with the σ-
bond of the reacting C–H bond. This proceeds with simultaneous dissociation of the carbene bound 
rhodium catalyst in a three-centred concerted transition state, as shown in Scheme 13.37 It should 
be noted that Taber et al. also suggested an alternative four-centred transition state, not shown.38 
 
  
Scheme 13: Doyle’s concerted three-centred transition state for C–H insertion. 
 
It is Doyle’s mechanism that is now widely accepted,39 however, the exact nature of the order of 
the events leading to product formation have since been investigated in more detail by Nakamura et 
al. with the aid of computational modelling based on the reaction of methyl diazoacetate with 
alkanes, catalysed by a rhodium(II) carboxylate;40 the proposed catalytic cycle is shown in Scheme 
14.  
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Firstly, diazo 52 undergoes nucleophilic addition to rhodium(II) carboxylate 51. This is followed 
by extrusion of nitrogen gas, aided by back-bonding from rhodium, forming carbenoid 54. The first 
event in the C–H insertion (transition state 56) is the hydride transfer from substrate 55, which is 
followed by reformation of the Rh–Rh bond and concomitant C–C bond formation (transition state 
57), delivering product 58 and reforming catalyst 51. 
 
 
Scheme 14: Nakamura’s model for the C–H insertion based on computational modelling. 
 
Nakamura’s findings are summarised below: 
 
− Just one rhodium atom (Rh1) takes part in the carbene binding process at any one time; the 
second rhodium atom (Rh2) acts as a bifunctional electron pool. Firstly, acting as a mobile 
ligand with cleavage of the Rh1–Rh2 bond during the carbene formation process, enhancing 
the electrophilicity of the carbene and secondly, facilitating cleavage of the Rh1–C bond 
during catalyst regeneration. 
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− During nitrogen extrusion, electron density is moved from the ligands but not Rh2. Thus, 
highly electrophilic ligands enhance diazo coordination but decelerate the nitrogen 
extrusion step. The ligands also act as a tether for Rh2. 
− Overall the C–H insertion is described as a concerted but non-synchronous three-centred 
transition state with hydride transfer from the substrate preceding C–C bond formation and 
catalyst regeneration. 
− The rhodium atoms do not directly interact with the C–H bond. 
 
In 2015, a report by Fürstner et al. documented the first crystal structure of a reactive dirhodium 
complex, an important milestone for future mechanistic investigations.41 
 
1.2.3.  General reactivity trends 
 
There are various factors that contribute towards the outcome of rhodium(II)-catalysed C–H 
insertion reactions of diazo compounds. The rhodium(II)-stabilised carbene is electrophilic, and 
through careful choice of the ligands around the dirhodium core as well as the groups adjacent to 
the carbene centre, this electrophilicity can be modulated. The nature of the substrate also 
influences the reaction outcome; based on electronic, steric and conformational effects.22 
 
1.2.3.1.  Stereoelectronic effects 
 
Taber et al. conducted early studies into the electronic and steric effects of substrates.42 By 
studying a series of β-keto esters it quickly became apparent there was a preference for which C–H 
bond is inserted into. In the case of substrate 59, tertiary C–H insertion, forming product 60 
predominated over that of the secondary C–H insertion product 61 (Scheme 15).43 
 
 
Scheme 15: Electronic effects of substrate. 
 
From Taber’s studies two important general observations were made:  
1) An order of reactivity exists for C–H bonds: 3°>2°>1°. This is due to inductive effects, 
which stabilise the build up of positive charge at the reacting centre.  
O
N2
OMe
O
Me
Me MeH
a
Hb
Rh2(OAc)4
O
OMe
OMe
Me
Me
O
OMe
O
Me
Me
Me
60
3° insertion product
61
2° insertion product
Ha Hb
23:1
59
84%
  15 
2) The formation of 5-membered rings is favoured over that of 4- or 6-membered rings, an 
observation that has been key to the development of this field ever since. 
 
More recently there have been examples in which 4- or 6-membered rings are favoured over 5-
membered rings, however the general rule is still widely applicable.44,45 The formation of 4-
membered rings often occurs when there is activation by a donor group such as oxygen or nitrogen 
which directs the C–H insertion. Conversely, electron-withdrawing groups such as esters and acetyl 
groups are strongly deactivating.22 The power of neighbouring group activation has even been 
demonstrated by the formation of 3-membered rings.46 Lack of conformational flexibility, or 
indeed varying bond lengths can lead to 6-membered rings being formed.47  
 
It was noted by Adams and Spero in 1991,48 and later confirmed by Davies,49 that sites capable of 
stabilising positive charge, such as allylic, benzylic and α-heteroatom positions (e.g. ethers), are 
more susceptible to C–H insertions by rhodium carbenoids.  
 
Taber also investigated the steric effects of substrates on reaction outcome.42b Using substrate 62 
that contains two similar methylene C–H insertion sites, one with a methyl substituent (Ha) and the 
other with t-butyl (Hb), it was found that the insertion occurred almost entirely into the least 
hindered C–H site (Ha) forming product 63 predominantly over product 64 (Scheme 16). 
 
 
Scheme 16: Steric effects of substrate in rhodium(II)-catalysed C–H insertions. 
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1.2.3.2.  Catalyst control 
 
The ligands surrounding the dirhodium core also have a significant effect on the reactivity of the 
catalyst towards diazo decomposition. The more electron-deficient the rhodium catalyst, the more 
reactive it will be towards the diazo compound.31  
The use of Rh2(OAc)4 for diazo decomposition was first observed by Teyssié and was found to be 
highly active for O–H bond insertions. Since then various studies by Doyle and Padwa have 
enabled reactivity trends to be established by variation of the bridging dirhodium ligands.25c,37,50 By 
careful selection of the catalyst the regio- and stereoselectivity of reactions can be tuned. The 
general trend of reactivity for ligands is shown in Figure 6.31 
 
 
Figure 6: Reactivity profile for rhodium(II) catalysts by variation of bridging ligands.  
 
The more electron-withdrawing perfluorobutyrate ligand (pfb) makes the rhodium catalyst more 
electrophilic thus more reactive towards diazo decomposition. However, this was also found to 
confer reduced regio- and stereoselectivity, as demonstrated by Doyle in 1989 (Table 1).51 Based 
on the observations by Taber, insertion into a primary C–H site over a tertiary was not expected. 
Yet, both Rh2(pfb)4 and Rh2(OAc)4 led to indiscriminate reaction with both sites of diazo 
compound 65, whereas the less reactive rhodium(II) acetamidate (Rh2(acam)4) was almost 
completely selective for the tertiary site. The more reactive catalysts led to reduced isolated yields 
of 66 and 67, with carbenoid dimerisation the major competing pathway.  
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Table 1: Rhodium(II) catalyst ligand effects on chemoselectivity. 
 
Rh2L4 Isolated Yield, % Relative ratio (66:67) 
Rh2(pfb)4 56 32:68 
Rh2(OAc)4 81 53:47 
Rh2(acam)4 96 >99:<1 
 
Ikegami et al. were able to demonstrate the importance of the ligand’s steric bulk. They showed 
that by using a more sterically hindered catalyst, namely rhodium(II) triphenylacetate (Rh2(tpa)4), 
the ratio of products could be dramatically improved compared to that of Rh2(OAc)4. The 
exceptional levels of diastereocontrol were best achieved in tethered cyclic systems in which 
bicyclic products are formed. For example, the C–H insertion of diazo compound 68 generated 
trans-bicyclic lactone 69 with excellent diastereoselectivity using Rh2(tpa)4, whereas with 
Rh2(OAc)4 a mixture of products was observed (Table 2).52 
 
Table 2: Exceptional diastereocontrol using a bulky rhodium catalyst, Rh2(tpa)4. 
 
Rh2L4 Relative ratio (69:70:71) 
Rh2(OAc)4 50:19:31 
Rh2(tpa)4 94:1:5 
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1.2.4.  α-Diazocarbonyl compounds 
 
One of the key controlling factors in C–H insertion reactions are the groups adjacent to the carbene 
centre. Variation of these groups impacts the electrophilicity and hence the reactivity, chemo-, 
regio- and stereoselectivity of the insertion reactions. Diazo compounds and their corresponding 
rhodium carbenoids can be classified into three major groups; donor/acceptor, acceptor and 
acceptor/acceptor.22  
 
 
Figure 7: Classes of diazo compound/rhodium(II) carbenoid.  
 
Acceptor groups are those that withdraw electron density through resonance making the diazo 
compound less nucleophilic, hence less reactive towards diazo decomposition. Conversely, once 
the carbenoid is formed the acceptor groups increase the reactivity, as electron density is 
withdrawn from the already electrophilic centre. Donor groups, in contrast increase the reactivity 
towards diazo decomposition and decrease carbenoid reactivity. Hence, the presence of a donor 
group attenuates the reactivity of the acceptor group,49 leading to enhanced chemo-, regio- and 
stereoselectivity. The use of chiral rhodium(II) catalysts for enantioselective C–H insertions has 
been reviewed previously,22,31,45,49,53 and a short insight is provided below with a particular focus 
towards the intramolecular reactions of acceptor/acceptor carbenoids. 
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1.2.4.1.  Donor/Acceptor Carbenoids 
 
Donor/acceptor-substituted carbenoids have received by far the most attention in recent years due 
to their unique reactivity.49 The opposing electronic characteristics allow the reactivity to be 
modulated, i.e. the donor group reduces the extreme reactivity given by the acceptor group. As 
such, chemo-, regio- and stereoselectivity can be carefully controlled and has led to the 
development of a variety of chiral rhodium(II) catalysts for asymmetric C–H insertions, many of 
which are derived from amino acids (Figure 8). 
 
 
Figure 8: Amino acid-derived rhodium(II) carboxylate catalysts. 
 
McKervey was the first to develop a series of rhodium(II) N-benzenesulfonyl protected prolinate 
catalysts,54 with Rh2(BSP)4 found to be the most promising.  Good levels of enantiocontrol could 
be obtained for the intramolecular C–H insertions of α-diazopropriophenones 72 (Scheme 17). 
 
 
Scheme 17: McKervey’s asymmetric intramolecular C–H insertion reactions of α-
diazopropriophenones. 
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More than any other research group, it is the work of Davies et al. that has driven the field of the 
donor/acceptor diazocarbonyls, following the development of various proline-derived catalysts 
including Rh2(S-DOSP)4 and Rh2(S-TBSP)4.55 These catalysts were found to provide exceptional 
levels of enantioselectivity for the intermolecular reactions of donor/acceptor diazocarbonyls, 
particularly using aryl- and vinyldiazocarbonyl compounds. For example, aryldiazoacetates 74 
performed well for the C–H insertion of cycloalkanes 75, yielding products 76 in good yields and 
ee (Scheme 18). Their effectiveness is believed to be due to the C–H insertion process occurring 
through a late-transition state,40 hence the enantiopure ligands can efficiently transfer chirality to 
the products.22 
 
 
Scheme 18: Davies’ asymmetric intermolecular C–H insertion reactions of aryldiazoacetates. 
 
Since these innovative findings, the use of aryl- and vinyldiazocarbonyl compounds has been 
extended to many other intermolecular C–H insertions reactions including; α-heteroatom sites (e.g. 
oxygen- and nitrogen-containing heterocycles),56 allylic sites,57 benzylic sites58 and formed the 
basis for the synthesis many natural product/bioactive targets.59 
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1.2.4.2.  Acceptor Carbenoids 
 
The field of acceptor-substituted carbenoids has been dominated by the work of Doyle and co-
workers. This species of diazo compound was found to be active towards decomposition by 
rhodium(II) carboxylate and carboxamidate catalysts, however it is the latter that provided more 
controlled reactivity and induced higher levels of selectivity.37,51 Following the success of achiral 
carboxamidate catalysts, Doyle began studying the use of chiral catalysts, leading to the 
development of Rh2(5R-MEPY)4. The intramolecular C–H insertion of diazoacetates 77 leading to 
lactones 78 was found to be particularly effective with Rh2(5R-MEPY)4 for insertion adjacent to 
heteroatoms. However, when tested on benzylic C–H bonds the yields and enantioselectivity 
decreased (Scheme 19). 
 
 
Scheme 19: Doyle’s asymmetric intramolecular C–H insertion reactions of diazoacetates. 
 
Further systematic studies revealed additional classifications of carboxamidate catalysts that were 
more amenable to benzylic and non-stabilised C–H insertion reactions (Figure 9).  
 
 
Figure 9: Rhodium(II) carboxamidate catalysts for intramolecular C–H insertions of acceptor-
substituted diazo compounds. 
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For example, the imidazolidinone catalyst Rh2(4S-MACIM)4 was shown to deliver excellent 
asymmetric induction for the formation of cis-bicyclic lactones 80 from cyclohexanol-derived 
diazo compounds 79 (Scheme 20).60 
 
 
Scheme 20: Doyle’s asymmetric intramolecular C–H insertion reactions of diazoacetates. 
 
These catalysts remain widely used for asymmetric intramolecular C–H insertions of acceptor-
substituted diazocarbonyls. Their use has been extended to the reactions of allylic61 and aromatic62 
C–H bonds, the formation of lactams63 as well as natural products.64 
 
Unlike donor/acceptor diazocarbonyl compounds, the acceptor diazocarbonyls have been shown to 
be less effective for asymmetric intermolecular C–H insertion reactions. The higher reactivity of 
the intermediate carbenoid often leads to indiscriminate reactions leading to multiple products 
including carbenoid dimerisation.22,65 For these more reactive species the benefits of intramolecular 
reactions, i.e. entropic factors leading to the formation of 5-membered rings, seems to be essential 
for good enantioselectivity to be obtained.66 
 
1.2.4.3.  Acceptor/Acceptor Carbenoids 
 
The third class of diazo compound contains two acceptor groups. These species are the most stable 
to diazo decomposition due to the stabilising effect of the acceptor groups. As such, more active 
catalysts, i.e. rhodium(II) carboxylates, are required to form the reactive carbenoid.33,67 Once 
formed, this class of carbenoid is by far the most reactive with the acceptor groups now 
destabilising the electrophilic carbenoid. This extreme reactivity often leads to less controlled 
reactions with reduced chemo-, regio- and stereoselectivity, perhaps accounting for the relatively 
underexplored asymmetric reactions of these species. Common side-reactions of acceptor/acceptor 
carbenoids are carbene dimerisation and extraneous water O–H insertion. This can be reduced by 
slow addition of the diazo species to a dilute rhodium(II) solution and with vigorous drying, 
respectively.64 
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The intermolecular reactions of acceptor/acceptor diazo carbenoids are in many ways analogous to 
those of acceptor diazocarbenoids; the absence of intramolecular driving forces leads to unselective 
reactions and lack of stereocontrol. This was demonstrated by Davies when comparing the reaction 
of donor/acceptor-diazo compound 81 with acceptor/acceptor-diazo compound 82. Using the 
Rh2(S-DOSP)4 catalyst for the reaction with cyclohexane generated C–H insertion products 83 and 
84 in 81% yield, 83% ee and 51% yield, 3% ee, respectively (Scheme 21).55 
 
 
Scheme 21: Davies’ asymmetric intermolecular C–H insertion reactions of aryldiazoacetates and 
diazoacetoacetates. 
 
As with acceptor-substituted carbenoids, the acceptor/acceptor compounds have also found their 
niche in the field of intramolecular C–H insertions. There are many examples of racemic C–H 
insertions catalysed by rhodium(II) carboxylates for the formation of cyclopentanones,52 γ-lactams 
and γ-lactones.37,68 In line with the general trend observed by Taber there is overwhelming 
preference for the formation of 5-membered rings. 
 
The first example of an asymmetric intramolecular C–H insertion of an acceptor/acceptor 
diazocarbonyl was reported by McKervey in 1990.69 Treatment of α-diazo-β-ketosulfone 85 with 
Rh2(S-BSP)4, previously developed within the group, delivered cyclopentanone 86 as a mixture of 
diastereomers. In order to determine ee more easily the acidic centre was epimerised, generating 
cyclopentanone 87 in good yield but with just 12% ee (Scheme 22). 
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Scheme 22: McKervey’s pioneering studies into asymmetric intramolecular C–H insertion 
reactions of acceptor/acceptor diazo compounds. 
 
α-Diazo-β-ketoesters have been much more extensively studied, with Ikegami and co-workers 
providing some of the first insights.70 Their studies focussed instead on an N-phthaloyl protected 
amino acid carboxylate catalyst, Rh2(S-PTPA)4 for the C–H insertions of diazo compounds 88 to 
cyclopentanones 89, as shown in Scheme 23.  Low ee was initially observed for methyl esters yet, 
by switching to a more bulky ester group, the ee was found to increase substantially. Other notable 
observations include the low temperature (0 °C) at which these reactions were performed as well as 
enhanced yields for insertion into benzylic sites compared to alkyl or allylic C–H bonds. The ee 
were determined following hydrolysis and decarboxylation to cyclopentanones 90. 
 
 
Scheme 23: Ikegami’s asymmetric intramolecular C–H insertion reactions of α-diazo-β-
ketoesters.53a 
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The asymmetric intramolecular C–H insertion of α-diazoacetoacetamides has also been extensively 
studied. The nitrogen atom provides a suitable handle for protecting group manipulation, which has 
enabled divergent reaction pathways to be selectively accessed. For example, substitution of the 
nitrogen atom with tBu, as in amide 91, allows for the selective formation of β-lactams 92, even 
when γ-lactams are possible, in excellent yields and good ee, as shown in Scheme 24.71 In contrast, 
when N-phenyl substituents are employed, as in amide 93, divergent pathways can be accessed 
dependent upon the chiral catalyst used and substrate functional groups; Rh2(S-PTPA)4 generated 
indolin-2-ones 94 whereas Rh2(S-PTTL)4 furnished γ-lactams 95 in good yield and ee.72 
 
 
Scheme 24: Hashimoto’s divergent intramolecular C–H insertion reactions of α-
diazoacetoacetamides affording β-, γ-lactams and indolin-2-ones.53a 
 
To the best of our knowledge, after a thorough examination of the literature, there are no reported 
examples of asymmetric induction for the intramolecular C–H insertion reactions of α-
diazocarbonylacetates that afford γ-lactone products.  
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1.2.4.4.  α-Diazophosphonocarbonyls 
 
Prior to this work, the rhodium(II)-catalysed intramolecular C–H insertion reactions of α-
diazophosphonocarbonyls was a relatively underexplored area. Of those examples published in the 
literature, there are 3 main groupings; α-diazophosphonoketones, α-diazophosphonoacetamides 
and α-diazophosphonoacetates. 
 
The earliest example of this class of C–H insertion was reported by Sturtz in 1987 for the synthesis 
of cyclopentanones from α-diazophosphonoketones, with Wolff rearrangements the major side-
reaction.73 Mikołajczyk again reported the use of α-diazophosphonoketones in 1989 as part of the 
total synthesis of (±)-sarkomycin,74 as well as in 1998 for the total synthesis of (±)-rosaprostol 
(Scheme 25).75 
 
 
Scheme 25: Mikołajczy’s intramolecular C–H insertion reaction of an α-diazophosphonoketone 
towards the synthesis of (±)-rosaprostol. 
 
The use of α-diazophosphonoacetamides for the synthesis of lactams has primarily been 
investigated by Afonso and co-workers. Their first report came in 2003 in which β- and γ-lactams 
could be selectively formed by variation of substituents to exploit electronic effects and steric 
effects.76 They reasoned that the phosphonate group was sufficiently bulky as to favour the 
formation of 5-membered rings with a trans-configuration (Scheme 26). This work was extended 
by use of chiral rhodium(II) carboxylates, including Rh2(S-DOSP)4, Rh2(S-TBSP)4 and Rh2(S-
PTPA)4, generating the products in good yields, but with poor ee.77 The group performed additional 
studies78 culminating in the use of water as an alternative to chlorinated solvents.79 Remarkably, the 
product of water O–H insertion was only observed in the absence of Rh2(OAc)4. A series of novel 
unprotected amino acid-derived rhodium(II) catalysts was also developed, displaying improved ee 
with water as the solvent.80 
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Scheme 26: Afonso’s model for trans-selectivity in β- and γ- lactam products of the intramolecular 
C–H insertion reactions of α-diazophosphonoacetamides. 
 
The only reported example of an intramolecular C–H insertion of α-diazophosphonoacetates 104 
also came from Afonso and co-workers.76 They observed a mixture of β- and γ-lactone products 
105–110 in moderate yields (Scheme 27). 
 
 
Scheme 27: Afonso’s intramolecular C–H insertion reactions of α-diazo 
(diethoxyphosphoryl)acetates. 
 
There are various other reports utilising α-diazophosphonoacetates, however they focus on 
intramolecular cyclopropanations81 and O–H insertions.82 
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1.3  Project Background and Aims 
 
A variety of synthetic approaches towards α-methylene-γ-butyrolactones have been described, 
including both lactonisation and methylenation based routes. Two approaches previously 
developed within the Taylor group, as discussed earlier, detailed a telescoped Michael 
addition/olefination sequence. Excellent selectivity and yields could be obtained, yet synthesis of 
the γ-hydroxy unsaturated carbonyl compound starting materials was not trivial. 
 
Whilst all of these routes have their merits, it was hoped that a more facile route to the α-
methylene-γ-butyrolactone framework could be developed. It was envisaged that by use of a C–H 
insertion reaction, the lactone ring may be formed by reaction with a C–H bond normally 
considered completely unreactive; hence, the α-methylene-γ-butyrolactone target molecules could 
be rapidly generated from relatively simple starting materials. As such, it was contemplated that the 
lactone ring may be formed via an intramolecular rhodium(II)-catalysed C–H insertion of α-
diazophosphonoacetates 111. As has been observed for many existing literature examples, the 
formation of 5-membered rings was expected to predominate for the intramolecular process, with 
γ-lactone 112 the desired product. Taking advantage of related Taylor group precedent, a 
subsequent Horner–Wadsworth–Emmons olefination should deliver the α-methylene-γ-
butyrolactone framework 113 (Scheme 28). 
 
 
Scheme 28: Proposed intramolecular Rh(II)-catalysed C–H insertion and HWE olefination of α-
diazophosphonoacetates towards α-methylene-γ-butyrolactones. 
 
In line with previous Taylor group methodologies it was hoped that following individual 
optimisation, these two steps could be combined as part of a more efficient telescoped procedure, 
avoiding the need for isolation and purification of the α-phosphonolactone intermediate. To the 
best of our knowledge, such a tandem sequence is without precedent. The requisite α-
diazophosphonoacetate functional group ought to be readily accessible in just 2 steps by an 
acylation and diazotisation from alcohols 114 (Scheme 29), thus increasing the generality of the 
procedure. 
 
N2
O
O
P
O
OEt
OEt
i) Base
ii) (CH2O)nRh(II)
111
C–H insertion
112
HWE olefination
O
O
P
O
OEt
OEt
113
O
O
  29 
  
Scheme 29: Proposed 2-step synthesis of α-diazophosphonoacetates from alcohols. 
 
Following the establishment of a reliable procedure, it was planned to demonstrate the efficacy of 
the procedure through the synthesis of natural products and other biologically active compounds. 
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Chapter 2 –  Rhodium(II)-catalysed C–H insertion/olefination 
methodology 
2.1  Preparation of diazo precursors 
 
The studies began with the preparation of the α-diazo(diethoxyphosphoryl)acetates from alcohols 
using a two-step esterification and Regitz diazo transfer sequence. The coupling of alcohols with 
acids is a well-established process with an extensive list of conditions including, amongst others, 
Mitsunobu coupling (DEAD, PPh3), Steglich (DCC, DMAP) and Fischer (acid catalysis) reactions. 
The Taylor group has previously taken advantage of a less well-known cyclic coupling agent 
known as propylphosphonic anhydride (T3P), and it was decided to exploit this method in this 
work (Scheme 30).83  
 
 
Scheme 30: T3P-mediated esterification. 
 
T3P has many advantages over other commonly used coupling agents including, being non-toxic, 
non-sensitising and easy to handle. In addition the by-product of the reaction, a water-soluble 
phosphate, can be readily removed by a simple aqueous workup, meaning column chromatography 
is usually not required. Thus, the reaction of a series of alcohols with the commercially-available 
diethylphosphonoacetic acid (DEPAA) 31 using T3P and DIPEA generated α-
(diethoxyphosphoryl)acetates 116a–161a in >95% yield in most cases. Substrates with greater 
steric hindrance, such as tertiary alcohols (cf. phosphonate 128a), were met with greater difficulty. 
The mechanism of the process is shown in Scheme 31, and the range of products formed in Figure 
10. 
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Figure 10: Range of products synthesised via T3P-mediated esterification. 
† Yield given as part of a multistep process. 
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Scheme 31: Mechanism of T3P-mediated coupling of DEPAA 31 and alcohol 114. 
 
There are many possible routes to form diazo carbonyl compounds, including dehydrogenation of 
hydrazones and diazotisation of amines.84 However, the most popular choice, particularly for 
doubly activated methylene compounds such as α-(diethoxyphosphoryl)acetates 115, is using the 
Regitz diazo transfer using azides.33,85 The mechanism of the process is shown in Scheme 32.86 
 
  
Scheme 32: Mechanism of the base-mediated diazo transfer from arylsulfonyl azide. 
 
The most commonly employed azides for the diazo transfer are electron deficient sulfonyl azides, 
many of which are commercially-available (Figure 11). 
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Figure 11: Sulfonyl azides available form commercial sources.* 
 
Historically, tosyl azide 163 was the most popular option for Regitz diazo transfer reactions, 
however more recently alternatives have been shown to possess lower thermal and shock 
sensitivity making them more attractive from a safety viewpoint.87 In addition to a lower propensity 
towards explosion, these newer derivatives also produce sulfonamide side-products that can be 
more readily separated form the desired diazo compound, particularly if the diazo compound is 
crystalline. Both mesyl and tosyl azide 162 and 163 have high shock sensitivities whereas azide 
164 is more stable but relatively expensive. p-Acetamidobenzenesulfonyl azide (p-ABSA) 165 
shows no shock sensitivity, is low cost and offers greater ease of removal, often by trituration.88 p-
Dodecylsufonyl azide (DBSA) 166 has also been shown to possess favourable properties; the liquid 
sulfonamide product offers ease of removal as well as providing a non-polar handle for column 
chromatography separation. This is particularly useful for very polar diazo compounds in which 
co-elution with the sulfonamide side-product becomes a problem. p-ABSA 165 was selected as the 
azide for the diazotisation of the α-(diethoxyphosphoryl)acetates, except in cases where undesired 
co-elution occured, in which DBSA 166 was employed. 
 
Following the T3P-mediated esterification, the α-(diethoxyphosphoryl)acetates 116a–161a were 
treated under basic conditions in the presence of an azide 165 or 166, undergoing a diazo transfer 
reaction affording α-diazo(diethoxyphosphoryl)acetates 116b–161b. The range of products formed 
using this method are shown in Figure 12. 
                                                
* Each of the azides shown are available from commercial sources, e.g. Sigma Aldrich, with the 
exception of mesyl azide 162 which is not available due to safety reasons. 
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Figure 12: Range of products synthesised via Regitz diazo transfer reaction. 
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α-Diazo(diethoxyphosphoryl)acetates are typically obtained as transparent yellow oils and are 
stable for a period of several months when stored at room temperature under an atmosphere of air. 
Diazo compounds 111 are UV active and less polar than their parent phosphonates 115, which are 
not UV active in the absence of other chromophores; as such, they are readily identifiable by TLC 
analysis. Purification by column chromatography is facile except when there is co-elution with by-
products of the sulfonyl azide diazotisation reagent. No issues associated with instability or 
decomposition of the azide reagents or diazo products were observed, with no special handling 
precautions required. The typical spectroscopic data for α-(diethoxyphosphoryl)acetates 115 and 
α-diazo(diethoxyphosphoryl)acetates 111 are shown in Figure 13. 
 
 
Figure 13: Typical spectroscopic data for α-(diethoxyphosphoryl)acetates 115 and α-
diazo(diethoxyphosphoryl)acetates 111. 
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2.1.1.  Studies towards an alternative homologated coupling agent 
 
The above route towards α-diazo(diethoxyphosphoryl)acetates 111 involves an esterification 
followed by a diazotisation. It was considered whether this could be reduced to a single step, 
improving overall efficiency, if pre-diazotised acid 167 could be prepared and used in the coupling 
reaction (Scheme 33).  
 
 
Scheme 33: Proposed one-step synthesis of α-diazo(diethoxyphosphoryl)acetates. 
 
The synthesis of acid 167 was envisaged via a protection/diazotisation/deprotection sequence 
(Scheme 34).  
 
 
Scheme 34: Proposed preparation of homologated acid 167. 
 
Firstly benzyl protection of DEPAA 31 furnished ester 168 in excellent yield but the subsequent 
diazotisation to generate diazoester 169 was low yielding. Unfortunately, the diazotised acid 167 
was not generated upon hydrogenation of diazoester 169. A series of side-products resulting from 
decarboxylation and/or loss of nitrogen were the only observed compounds (Figure 14). 
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Figure 14: Attempted hydrogenation of diazoester 169. 
 
An alternative route was proposed in which benzotriazole-activated acid 172 would be diazotised. 
This product could then be treated with alcohols to directly afford α-
diazo(diethoxyphosphoryl)acetates 111. Whilst amide 172 was obtained in good yield, the 
diazotisation to provide diazo compound 173 was unsuccessful, leading to the decomposition of 
ester 172 (Scheme 35).  
 
 
Scheme 35: Second proposed route, towards α-diazo(diethoxyphosphoryl)acetates 111. 
 
With the two-step procedure already providing good to excellent yields of the α-diazo 
(diethoxyphosphoryl)acetates no further investigations were conducted on this route. 
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2.2  Initial Studies on the insertion process 
2.2.1.  Rhodium(II)-catalysed C–H insertion 
 
The first objective of the C–H insertion/olefination methodology was to optimise the two steps 
separately prior to developing a telescoped sequence.† A substrate with general structure 111, 
shown in Figure 15, possesses two sites capable of undergoing C–H insertion, one affording the 
desired γ-lactone and the other the β-lactone regioisomer. It was hoped that the γ-lactone would 
predominate, in line with previous Rh(II)-catalysed C–H insertion observations. 
 
 
Figure 15: Possible C–H insertion products from Rh(II)-catalysed diazo decomposition. 
 
The investigation into the C–H insertion began by treating p-methoxyphenyl derivative 117b with a 
series of rhodium(II) catalysts. The substrate was selected on the basis that the electron-rich aryl 
unit would both increase the nucleophilicity of the C–H bond and stabilise the build up of +ve 
charge during the C–H insertion. As discussed earlier, rhodium(II) carboxylates are the catalysts of 
choice for acceptor/acceptor-substituted diazo compounds due to the greater reactivity towards 
diazo decomposition.  
 
Initially, diazo substrate 117b was treated with 5 mol% of Rh2(esp)2 in CH2Cl2 at 45 °C for 1 hour 
(Scheme 36). All of the starting material was consumed and analysis of the 1H NMR spectra of the 
unpurified reaction mixture revealed two compounds, each possessing diagnostic signals; 3.10 (dd, 
J = 23.8, J = 6.2) ppm and 3.38 (dd, J = 24.0, J = 8.7) ppm. The signals are consistent with a 
proton α to the phosphorus (which produces the large coupling constant observed), however this 
signal could be expected in both the γ- and β-lactone products. After purification by silica column 
chromatography a single product was isolated in 64% yield, with just one of these diagnostic 
                                                
† A telescoped process is one in which multiple reactions are performed without purification — in a 
single reaction vessel (one-pot), if required — with sequential addition of reagents.  
A tandem process is one in which all of the required reagents are added at the beginning of a multi-
reaction transformation. 
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signals, the dd at δ = 3.10 ppm, remaining. Analysis of its spectral data confirmed that the product 
was the desired γ-lactone. It is believed that the isolated compound is the trans-diastereomer based 
on thermodynamic considerations and that the other product observed in the crude 1H NMR 
spectrum was the cis-isomer, which epimerised during chromatography. 
 
  
Scheme 36: Rhodium(II)-catalysed intramolecular C–H insertion of α-diazo 
(diethoxyphosphoryl)acetate 117b, showing key characteristic data for product 117c. 
 
In order to confirm the proposed trans-assignment, the 1H-1H coupling constants were analysed by 
comparisons with similar compounds. Literature data for the coupling constant (3JH2-H3, Figure 16) 
demonstrated that values between 8–11 Hz indicates a trans-relationship and 4–6 Hz a cis-
relationship.89 The value observed for 3JH2-H3 in 117c is 6.2 Hz. The proximity of this value to the 
cis- and trans-boundaries meant that a definitive assignment could not be made.  
 
Confirmation of the trans-assignment was therefore sought using X-ray single crystal analysis, 
however lactone 117c was isolated as an oil. As such unsubstituted phenyl analogue 116c, which is 
a crystalline solid, was synthesised under similar conditions. A single crystal X-ray structure was 
obtained (Figure 16) and, as expected, was that of the trans-diastereomer. The similarity of the 3JH2-
H3 coupling constants of 117c (6.2 Hz) and 116c (5.9 Hz) was the basis for the trans-assignment of 
117c. 
                     
Figure 16: Single crystal X-ray structure of 116c (CCDC: 980606). Thermal ellipsoids set to 50% 
probability, shown in Olex2. 
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Attention then turned to screening other Rh(II) carboxylate catalysts to test the C–H insertion 
(Figure 17). 
 
 
Figure 17: Commercially available rhodium(II) carboxylate catalysts. 
 
Each catalyst was initially run with a loading of 5 mol% in CH2Cl2 at 45 °C for 24 h, with the 
reaction run in a round-bottom flask fitted with a reflux condenser (Table 3, Entries 1–4). The two 
least bulky catalysts, Rh2(OAc)4 and Rh2(oct)4, led to the highest yields. A reduction in catalyst 
loading did not change the outcome to any significant degree (Entry 5). More significantly, a 10-
fold decrease in concentration led to just 30% of the γ-lactone being isolated (Entry 6). The major 
product 117d, isolated in 51% yield, is the result of the carbenoid insertion into the O–H bond of 
water (Figure 18). This presumably occurred due to a greater quantity of expeditious water in the 
additional CH2Cl2 solvent and emphasised that the reaction must be kept under strictly anhydrous 
conditions. As such, the set-up changed from a large round-bottom flask to a smaller oven-dried 
sealable tube flushed with argon. 
 
The original reactions were then repeated under the new conditions. No improvement was observed 
with Rh2(OAc)4 (Entries 7–8), but with Rh2(oct)4 there was a significant increase in isolated yield 
of lactone 117c (Entries 9–11), especially so with a reduced catalyst loading of 2 mol%. This set of 
conditions (Entry 11) was chosen as optimal for investigations into reaction scope of the telescoped 
sequence, discussed later. 
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Table 3: Screening of rhodium(II) carboxylate catalysts for C–H insertion reactions of α-
diazo(diethoxyphosphoryl)acetate 117b. 
 
Entry Rh(II) catalyst Loading 
(mol%) 
Concn 
(mL/mmol) 
Conditionsa Time 
(h) 
Yield of 
117c (%) 
1 Rh2(oct)4 5 20 A 24 66 
2 Rh2(OAc)4 5 20 A 24 74 
3 Rh2(tpa)4 5 20 A 24 59 
4 Rh2(esp)2 5 20 A 24 57 
5 Rh2(oct)4 2 20 A 24 70 
6 Rh2(oct)4 2 200 A 24 30b 
7 Rh2(OAc)4 5 20 B 23 77 
8 Rh2(OAc)4 2 20 B 23 71 
9 Rh2(oct)4 5 20 B 6.5 80 
10 Rh2(oct)4 10 20 B 4 87 
11 Rh2(oct)4 2 20 B 23 89 
 
a General Conditions: 117b (0.200 mmol), CH2Cl2, 45 °C, time (h); Conditions A = 25 mL round-
bottom flask, reflux condenser; Conditions B = 10 mL oven-dried sealable tube, argon atmosphere; 
b 117d, 51% isolated. 
 
 
Figure 18: Alcohol product 117d arising from water O–H bond insertion, showing key 
characteristic data. 
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2.2.2.  Horner–Wadsworth–Emmons Olefination 
 
With an optimal set of conditions for the C–H insertion in hand attention turned to the Horner–
Wadsworth–Emmons (HWE) reaction. Previous work within the Taylor group on TIMO 
methodology also utilised the HWE reaction.17-18 As such, similar conditions were employed, using 
KOBu-t as base and paraformaldehyde as the trapping agent (Table 4). α-Phosphonolactone 117c 
was selected to test the HWE reaction, affording α-methylene-γ-butyrolactone 117e, with the key 
characterisation data shown in Figure 19. 
 
 
Figure 19: α-Methylene-γ-butyrolactone product 117e showing key characteristic data. 
 
Table 4: Optimisation of HWE olefination for α-phosphonolactone 117c. 
 
Entry Solvent KOBu-t (Equiv.)  (CH2O)n (Equiv.) Yield of 117e (%) 
1 CH2Cl2 0.9 10 56 
2 THF 0.9 10 56 
3 CH2Cl2 1.0 5 68 
4 CH2Cl2 1.0 2 75 
5 CH2Cl2 1.2 5 82 
General Conditions: i) 117c (~0.200 mmol), CH2Cl2, KOBu-t, 0 °C, 30 mins; ii) (CH2O)n, −78–0 
°C, 2 h; 
 
Variation of the solvent from CH2Cl2 to THF had no impact on the isolated yield of lactone 117e 
(Entries 1–2). Previous studies within the Taylor group found that a sub-stoichiometric quantity of 
base was optimal due to the high base-sensitivity of the α-methylene-γ-butyrolactone products,17a 
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but it was found that during the reaction of α-phosphonolactone 117c there was no product 
degradation in the presence of excess base. In fact a small excess of base and a reduction in the 
equivalents of paraformaldehyde gave rise to higher reaction yields (Entries 3–5). 
 
2.2.3.  Telescoped C–H insertion/olefination process 
 
It was envisioned that the two steps discussed above could be combined into a telescoped one-pot 
process, given that the only side-product of the C–H insertion reaction is nitrogen gas. In doing so 
the efficiency of the procedure may be improved with a reduction in the number of purification 
steps and amount of solvent used. 
 
Having demonstrated the tolerance of the HWE olefination to CH2Cl2 and THF, each was trialled 
for the combined one-pot C–H insertion olefination sequence (Scheme 37). The process was 
implemented by taking the unpurified C–H insertion reaction mixture and performing the HWE 
olefination. Using CH2Cl2 throughout gratifyingly gave the α-methylene lactone 117e in 65% 
yield. Yet, when the solvent was switched to THF after the C–H insertion (by evaporation of the 
CH2Cl2), the reaction was cleaner and gave an improved yield of 71% of lactone 117e. 
 
 
Scheme 37: One-pot C–H insertion/olefination sequence. 
 
Given the ease with which the solvent can be switched (simply concentrate in vacuo then 
redissolve in THF) these conditions were taken forward for examination of the reaction scope. 
i) Rh2(oct)4 (2 mol%), CH2Cl2 
ii) KOtBu (1.5 eq.), CH2Cl2
iii) (CH2O)n (2 eq.)
O
O
O
O
P
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2.3  One-pot C–H insertion/olefination sequence; scope & limitations 
2.3.1.  Benzylic systems 
 
With an optimised set of conditions in hand the telescoped one-pot procedure was applied to a 
series of α-diazo(diethoxyphosphoryl)acetates to investigate steric, electronic and selectivity 
effects. The first series of substrates tested contained benzylic C–H insertion sites, which benefit 
from stabilisation of positive charge build up during the transition state. It was reasoned that more 
electron-rich aromatic rings would favour the C–H insertion more so than electron-deficient 
systems due to greater charge stabilisation. As such, the effect of electronic changes on the C–H 
insertions were investigated by manipulation of substituents on the aromatic ring (Figure 21).  
 
Most examples were tested using the optimised conditions but some substrates performed better 
using modified conditions involving changes in the quantity of base or temperature of the HWE 
olefination reaction. As expected, each of the reactions furnished solely the γ-lactone products, 
with none of the β-lactone regioisomers observed. All products were fully characterised, with 
diagnostic data shown in Figure 20. The α-methylene protons H-5a and 5b are very distinguishable 
and observed as sharp doublets with a small coupling constant. The 2JHH geminal coupling and 
corresponding COSY correlations are, in general, not observed. The coupling constant arises from 
4JHH with the proton H-3. The significantly downfield shift of H-5a is due to the deshielding effect 
of the proximal carbonyl. The 13C NMR shift and IR stretch of the carbonyl group are observed at 
values as would be typically expected. 
 
 
Figure 20: Diagnostic data for a general α-methylene-γ-butyrolactone. 
 
O
O
Key characterisation data for
α-methylene-γ−butyrolactones
1H NMR: δ5a ≈ 6.30–6.45 (d, 4JHH ≈ 3.0) ppm
                 δ5b ≈ 5.45–5.60 (d, 4JHH ≈ 2.7) ppm
13C NMR: δC=O = 169–171 ppm
νC=O = 1740–1765 cm-1
R H
Ha
Hb5
3
1
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Figure 21: One-pot C–H insertion/olefination sequence for substrates with α-aryl C–H insertion 
sites, with isolated yields shown. Conditionsa given in parentheses. 
a Conditions A: (i) Rh2(oct)4 (2 mol %), CH2Cl2 (0.05 M), 45 °C, 20 h; (ii) Remove CH2Cl2 in 
vacuo, add THF, (iii) KOBu-t (1.2 or 1.5 equiv.), 0 to −78 °C; (iv) (CH2O)n (2 equiv.), −78 to RT. 
Conditions B: (i) Rh2(oct)4 (2 mol %), CH2Cl2 (0.05 M), 45 °C, 20 h; (ii) KOBu-t (1.2 or 1.5 
equiv.), 0 to −78 °C; (iv) (CH2O)n (2 equiv.), −78 to 0 °C. 
Conditions C: (i) Rh2(oct)4 (5 mol %), CH2Cl2 (0.05 M), 45 °C, 20 h; (ii) KOBu-t (0.9 equiv.), 0 to 
−78 °C; (iv) (CH2O)n (10 equiv.), −78 to 0 °C. 
b Rh2(esp)2 used in place of Rh2(oct)4. c No HWE performed. d Starting material recovered. 
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Unsubstituted phenyl substrate 116b afforded the desired lactone 116d in good yield. Interestingly 
the more electron-rich systems 117e, 118c and 119c were not obtained in greater yields as first 
expected. In fact, the reverse trend was observed in that the more electron-rich the system was, the 
lower the isolated yield became. It is possible that the increasing number of heteroatoms present in 
the substrates has a detrimental effect during the rhodium(II)-catalysed C–H insertion, possibly by 
competing side-reactions. Naphthyl derivative 120c was also obtained in good yield. 
 
Electron-poor derivatives were then examined. As anticipated, the most electron-deficient p-CF3- 
and p-NO2-substrates 121b and 122b afforded the lactones 121c and 122c respectively, in low 
yields. Competing side-reactions may account for the reduced yield of desired product. The less 
electron-deficient p-Br-substrate 123b afforded lactone 123c in good yield, making the 
methodology more attractive for further derivatisation, e.g. for use in cross-coupling reactions. 
 
Dimethylaniline 124b was the only para-substituted system tested to afford none of the desired 
product. In this case, the C–H insertion did not proceed, with all starting material recovered. This 
was to be expected based on reports that Lewis basic compounds are able to deactivate rhodium(II) 
catalysts by coordination to one of the vacant sites.28,29b 
 
Heteroaromatic substrates were then examined. Thiophene 125b did afford the desired lactone 
125c, albeit in low yield. Indole derivative 126b did undergo the C–H insertion based on TLC and 
1H NMR analysis of the reaction mixture, however the HWE reaction was unsuccessful with 
decomposition observed. As with the dimethylaniline substrate 124b, pyridine 127b did not 
undergo the C–H insertion, again with complete recovery of starting material. Interestingly an 
immediate colour change from the characteristic green to deep red was observed upon addition of 
127b to a solution of the Rh(II) catalyst (Figure 22). 
 
 
Figure 22: Colour change of rhodium(II) catalyst from green to red on addition of 127b. 
127b
127b
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The initial studies above demonstrated that α-diazo(diethoxyphosphoryl)acetates with benzylic C–
H insertion sites do readily undergo C–H insertions. As expected electron-rich aromatic systems 
are, in general, favoured for the stabilisation of +ve charge. However, there are notable examples in 
which the presence of coordinating heteroatoms reduce the isolated yield of the lactone product or 
suppress the C–H insertion reaction. 
 
Focus then turned to examining more substituted systems with competing C–H insertion sites 
(Table 5). Dimethylphenyl substrate 128b possesses two C–H insertions sites, one benzylic and one 
primary. As with related literature precedent it was expected that the benzylic site would be 
favoured over the primary site based on electronic considerations. Unfortunately, both of the 
possible products were isolated with the benzylic insertion product 128c slightly favoured over the 
compound 128d (Entry 1). This result did, however, represent the highest yielding example thus 
far. Diazo compound 129b, which possesses a tertiary benzylic site, also worked well under the 
conditions to generate lactone 129c, possessing a quaternary centre (Entry 2). 
 
Diphenyl substrate 131b gave the desired product 131c in excellent yield and pleasingly as a single 
diastereomer (Entry 3). It was hoped that by differentiating two benzylic sites one might be 
preferred over the other. As such, a competition experiment was designed by variation of the 
substituents on the phenyl rings, making one site more electron-rich, and therefore more biased 
towards C–H insertion than the other. Hence, p-methoxyphenyl analogue 132c was synthesised. It 
was anticipated that the C–H insertion would take place preferentially at the more electron-rich 
benzylic site, α- to the PMP. Under the one-pot conditions it was found that this was indeed the 
case with the product 132c being formed in preference to the regioisomer 132d (Entry 4), but 
unlike the unsubstituted dibenzyl product 131c there was a loss of diastereoselectivity (1.6:1). In 
line with previously examined electron-rich substrates there was a small drop in isolated yield. The 
assignment of the regioselectivity was based on HMBC correlations (Figure 23). The observed 
correlations could only be present in regioisomer 132c and not in isomer 132d. 
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Table 5: One-pot C–H insertion/olefination sequence for substrates with α-aryl C–H insertion 
sites.a  
Entry Diazo Compound Product(s) Isolated Yield, % 
1 
 
128b 
       
128c                    128d 
89 (A) 
 
1.45:1 
(128c:128d) 
2 
 
129b 
 
129c 
59 (A) 
3 
 
131b 
 
131c 
84 (B) 
4 
 
132b 
 
132c 
65 (B) 
 
dr 1.6:1 
 
a Conditions A: (i) Rh2(oct)4 (2 mol %), CH2Cl2 (0.05 M), 45 °C, 20 h; (ii) Remove CH2Cl2 in 
vacuo, add THF, (iii) KOBu-t (1.2 or 1.5 equiv.), 0 to −78 °C; (iv) (CH2O)n (2 equiv.), −78 to RT. 
Conditions B: (i) Rh2(oct)4 (2 mol %), CH2Cl2 (0.05 M), 45 °C, 20 h; (ii) KOBu-t (1.2 equiv.), 0 to 
−78 °C; (iv) (CH2O)n (2 equiv.), −78 to 0 °C. 
 
 
Figure 23: Observed HMBC correlations of lactone 132c. 
O
O
P OEt
O
OEt
Ph
N2
Me
Me
O
O
PhMeMe
O
O
Me
Ph
O
O
P OEt
O
OEt
Ph
N2Me
O
O
Ph
Me
O
O
P OEt
O
OEt
Ph
N2
Ph Ph
O
O
Ph
O
O
P OEt
O
OEt
PMP
N2
Ph Ph
O
O
PMP
O
O
OMe
73
611
12
13
O
O
MeO
Observed HMBC
 correlations
H-7 to C-3
H-13 to C-11
H-11 to C-12
132c
65%
dr 1.6:1 132dnot observed
  49 
2.3.2.  Non-benzylic systems 
 
As discussed earlier, previous literature precedent shows that C–H insertion can occur with 
aliphatic C–H bonds even if not stabilised by aryl groups.49 As such, n-heptanol derived diazo 
compound 134b was subject to the one-pot conditions (Figure 24) yielding the desired γ-lactone 
134c in good yield with no observed regioisomeric side-products, further expanding the scope of 
the reaction. 
 
The effect of steric hindrance close to the C–H insertion site was examined by installation of i-Pr 
and t-Bu groups in substrates 135b and 136b respectively. As anticipated, when subject to the one-
pot conditions the increasing steric hindrance led to a decrease in isolated yield of the desired 
products 135c and 136c respectively. It is believed the increased steric hindrance leads to undesired 
side-reactions.  
 
Dimethyl substrate 130b, which possesses a tertiary C–H insertion site, reacted cleanly under the 
one-pot conditions, yet the desired lactone product 130c was obtained in a disappointing 23% 
yield, although this may be accounted for by the product’s volatility. 
 
 
Figure 24: One-pot C–H insertion/olefination sequence for substrates with non-benzylic secondary 
C–H insertion sites.a 
a (i) Rh2(oct)4 (2 mol %), CH2Cl2, 45 °C, 20 h; (ii) Remove CH2Cl2 in vacuo, add THF, KOBu-t 
(1.2 or 1.5 equiv.), 0 to −78 °C; (iii) (CH2O)n (2 equiv.), −78 to 0 °C. b Warmed to RT for HWE. 
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It was hoped that installation of a silyl group β- to the C–H insertion site would allow stabilisation 
of the positive charge, via the β-silicon effect, without the associated steric hindrance. Pleasingly 
TMS diazo derivative 137b worked well under the one-pot conditions affording the desired lactone 
137c in very good yield. 
 
The installation of oxygen functionality α- to the C–H insertion site was seen as of particular 
importance given the substructure is present in over 3000 natural products. The TBS protected 
alcohol derivative 138b was prepared from 1,3-propanediol. When subjected to the one-pot 
conditions, two products were isolated; the desired γ-lactone 138c as well as the regioisomeric β-
lactone 138d, both in poor yield (Table 6, Entry 1). The formation of the β-lactone and low isolated 
yields may be accounted for by the steric hindrance of the TBS protecting group. If the C–H 
insertion sites are relatively inaccessible, competing reactions may take place given the high 
reactivity of the rhodium carbenoid. This conjecture is somewhat supported in that moving the 
OTBS functionality one methylene unit further away from the C–H insertion site, as in compound 
139b, both increases isolated yield and sees just a single γ-lactone product 139c observed (Entry 2). 
 
Substrate 140b was prepared as an interesting chemoselectivity test, as it contains two reaction 
sites. Reaction of the carbenoid with the allylic C–H bond would generate a γ-lactone whereas 
reaction with the olefin would generate an oxabicyclo[4.1.0]heptan-2-one, the product of 
cyclopropanation. Typically, 5-membered ring products predominate in intramolecular 
rhodium(II)-catalysed C–H insertions, as such, the γ-lactone was expected to be formed selectively. 
Following reaction of diazo 140b with Rh2(oct)4 (Entry 3), a single product was observed by TLC 
analysis. Completion of the one-pot process revealed two compounds 140c and 140d, each arising 
from C–H insertion, with no evidence of a cyclopropanation product. The major product had the 
structure of desired lactone 140c and interestingly the second was the product of olefin 
isomerisation. This is favourable as it brings the vinyl substituent into conjugation. No other 
products were isolated to account for the low yield. 
 
C–H insertion into primary C–H bonds is known to be disfavoured, but it was considered whether 
it may be still be possible due the high reactivity of the acceptor/acceptor carbenoid. Substrate 
133b, which possesses a primary C–H bond was synthesised, and on treatment under the standard 
Rh(II) conditions decomposition was observed with no starting material, C–H insertion or other 
products observed by 1H NMR analysis. 
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Table 6: One-pot C–H insertion/olefination sequence for substrates with non-benzylic secondary 
C–H insertion sites.a  
 
Entry Diazo Compound Product(s) Isolated Yield, % 
1 
 
138b 
  
138c                138d 
18 (138c) 
16 (138d)b 
2 
 
139b 
 
139c 
49b 
3 
 
140b 
       
140c         140d 
38 (140c) 
9 (140d)b 
4 
 
133b 
 
133c 
0c 
 
a (i) Rh2(oct)4 (2 mol %), CH2Cl2, 45 °C, 20 h; (ii) Remove CH2Cl2 in vacuo, add THF, KOBu-t 
(1.2 or 1.5 equiv.), 0 to −78 °C; (iii) (CH2O)n (2 equiv.), −78 to 0 °C. b Warmed to RT for HWE. c 
No HWE performed. 
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2.3.2.1.  β-Benzyl-substituted systems 
 
α-Methylene/alkylidene-γ-butyrolactones containing β-benzylic groups are prevalent in Nature. 
Many of these compounds possess benzene rings with varying degrees of oxygenation. For 
example, the 3,4-methylenedioxy framework is particularly common in Nature, as found in the 
natural product savinin 174 (Figure 25).  
 
 
Figure 25: α-Methylene-γ-butyrolactone natural product, savinin 174. 
 
Access to this general framework was seen as an important extension of the current methodology, 
and as such a series of α-diazo(diethoxyphosphoryl)acetates were prepared and subjected to the 
one-pot C–H insertion olefination conditions. Firstly, the unsubstituted system 148b was treated 
under the standard conditons (Scheme 38), generating γ-lactone 148c in good yield, with no β or δ-
lactone products observed.  
 
 
Scheme 38: One-pot C–H insertion/olefination sequence for substrate 148b. 
 
Given this successful result, the 3,4-methylenedioxy substrate 149b, the precursor to savinin 174, 
was then tested (Scheme 39). On addition of Rh2(oct)4 to a solution of diazo compound 149b a 
deep orange/brown was observed instead of the usual green colour. 1H NMR and TLC analysis 
indicated the starting material had not been consumed and that diazo decomposition had not 
occurred. None of the desired C–H insertion product 149c was observed. 
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Scheme 39: Attempted C–H insertion reaction of 3,4-methylenedioxy substrate 149b.  
 
This result was puzzling given that both the unsubstituted substrate 148b and methylenedioxy 
substrate 118b, tested earlier, were successful in the one-pot sequence (Figure 26). 
 
 
Figure 26: Comparison of C–H insertion reaction outcomes for α-diazo 
(diethoxyphosphoryl)acetates 148b, 118b and 149b. 
 
Given the dramatic colour change of the solution from green to red/brown, in the case of diazo 
compound 149b, it was considered whether this may be due competing coordination of the oxygen 
lone pairs to the vacant sites on the rhodium catalyst, deactivating it towards diazo decomposition. 
This, however, seemed unlikely based on the earlier result of diazo compound 118b, which also 
possesses the 3,4-methylenedioxy framework. This compound contains one methylene unit less in 
the tether, yet worked well under the standard conditions, remaining green during the rhodium(II) 
addition, thus implying that the presence of oxygen atoms in the substrate is not in itself a 
detrimental factor. 
 
This led to consideration of an alternative explanation: it could be that diazo decomposition is 
occurring to a small extent but, instead of undergoing C–H insertion the lone pairs from the oxygen 
atom are coordinating to the carbenoid centre, shutting down the catalytic cycle and rendering the 
catalyst inert. The small amount of starting material consumed and the appearance of a 
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decomposition product may not be observable using 1H NMR spectroscopy given the low catalyst 
loading. It is thought that the increased flexibility may be conferred by the additional methylene 
unit in the tether potentially enabling coordination of the meta-oxygen lone pairs to the carbenoid 
centre, resulting in a non-productive pathway, as shown in Scheme 40.  
 
 
Scheme 40: Proposed unproductive pathway following the formation of carbenoid 149d. 
 
In an effort to further explore this possibility it was hoped that by removing the meta-oxygen this 
coordination would no longer be possible. As such, 4-methoxy derivative 150b was synthesised 
and as anticipated successfully generated lactone 150c, albeit in moderate yield (Scheme 41). 
 
 
Scheme 41: One-pot C–H insertion/olefination sequence for diazo compound 150b. 
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As controls, the 3-methoxy and 3,4-dimethoxy derivatives 151b and 152b were also synthesised 
and subjected to the one-pot C–H insertion olefination conditions (Scheme 42). Remarkably, each 
substrate was also successful, again in moderate but unoptimised yield. 
 
 
Scheme 42: One-pot C–H insertion/olefination sequence for diazo compounds 151b and 152b. 
 
This again required the anomalous result of 3,4-methylenedioxy substrate 149b to be reconsidered. 
It seems that the conformational flexibility provided by the length of the tether is an important 
factor, but this alone does not fully account for the observed result. It is possible that the methylene 
unit joining the oxygen atoms in substrate 149b, changes the alignment of the oxygen lone pair, 
thus restricting conjugation into the aromatic ring, thereby making the lone pairs more available for 
coordination to the carbenoid centre. 
 
The above substrates have been shown to work successfully in general, although the isolated yields 
are low. This complements the earlier results, which also showed reduced yields for oxygenated 
benzene rings. The reason for this is not known but likely stems from the oxygen lone pairs, 
leading to competing side-reactions and the formation of by-products. 
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2.3.2.2.  Spirocyclic fused rings 
 
Focus then turned to disubstituted non-benzylic systems possessing tertiary C–H bonds, which 
generate spirocyclic α-methylene-γ-butyrolactones (Figure 27). α-
Diazo(diethoxyphosphoryl)acetates 141b, 142b, 143b and 144b were prepared and subjected to the 
standard one-pot C–H insertion/olefination conditions. Pleasingly, the spiro-butyl, -pentyl and -
hexyl products 142c, 143c and 144c were obtained in good yields, but unfortunately the 
spiropropyl product 141c was not formed, with decomposition observed. 
 
 
Figure 27: One-pot C–H insertion/olefination sequence for α-diazo(diethoxyphosphoryl)-acetates 
affording spirocyclic α-methylene-γ-butyrolactones.a  
a (i) Rh2(oct)4 (2 mol %), CH2Cl2, 45 °C, 20 h; (ii) Remove CH2Cl2 in vacuo, add THF, KOBu-t 
(1.2 or 1.5 equiv.), 0 to −78 °C; (iii) (CH2O)n (2 equiv.), −78 °C to RT. b No HWE performed. 
 
2.3.3.  Buchner cyclisation 
 
The reaction of triphenyl diazo compound 153b with Rh2(oct)4 under the standard conditions did 
not afford any of the desired C–H insertion product 153c, with a trace amount of an unknown side-
product and starting material being recovered (Scheme 43). Switching to toluene and replacing the 
catalyst with the more stable90 Rh2(esp)2 with heating at 100 °C for 4 h saw complete consumption 
of the starting material and formation of the same unknown product in an unoptimised 50% yield. 
Analysis of the 1H NMR data indicated the substrate had undergone a Buchner ring expansion; the 
carbene undergoes cyclopropanation with one of the aromatic rings affording norcaradiene 153d, 
which may be in equilibrium with cycloheptatriene 153e. As with Rh(II)-catalysed C–H insertions, 
the formation of 5-membered rings is favoured, hence the cyclopropanation occurs with one of the 
phenyl groups α to the oxygen. 
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Scheme 43: Rh(II)-catalysed Buchner ring expansion of diazo 153b. 
 
The Buchner ring expansion was first observed by Buchner and Curtius in 1885.91 It is an 
intramolecular cyclopropanation between a carbene and an aromatic π-system. A lot of energy is 
required for the Buchner ring expansion to occur because the aromaticity of the benzene ring is 
broken. There have since been many examples of the Buchner ring expansion using rhodium-
stabilised carbenoids,92 as well as a thorough review.93  
 
After the cyclopropanation, the bicyclo[4.1.0]heptane (norcaradiene) 153d can undergo a 
thermally-allowed reversible electrocyclic ring-opening to the cycloheptatriene 153e. In solution 
the norcaradiene and cycloheptatriene forms typically equilibrate. In the solid state one form may 
predominate, usually determined by substitution patterns and the effect of electronic and steric 
interactions. This topic has been well reviewed93 and a summary is given below.  
 
The cyclopropane possesses an occupied anti-bonding HOMO orbital, located in the C1–C6 bond. 
Substitution at C-7 with π-acceptor groups such as –CN, –CO2R, –P(O)(OR)2 and –CHO, 
withdraws electron density away from the anti-bonding HOMO orbital, shortening the bond, thus 
giving it more bonding character and hence stabilising the norcaradiene form. Cyclopropanes are 
known to be weak π-donors, but were found to favour the norcaradiene form, along with σ-donor 
substituents. Conversely, when C-7 is substituted with σ-acceptor groups, such as –CF3, the 
norcaradiene form is destabilised, favouring the cycloheptatriene form (Figure 28). 
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Figure 28: Electronic effect of substituents on norcaradiene/cycloheptatriene equilibrium. 
 
From this analysis it would be expected that the equilibrium between 153d and 153e would lie 
towards norcaradiene 153d, due to the two π-acceptors. Given that the two possible compounds 
were expected to possess similar 1H NMR spectra and may be equilibrating in solution, a single 
crystal X-ray structure was obtained (Figure 29). 
 
  
Figure 29: Single crystal X-ray structure of cycloheptatriene 153e (CCDC: 1013524).‡ Thermal 
ellipsoids set to 50% probability, shown in Olex2. 
 
Contrary to expectations, the cycloheptatriene 153e was the only compound observed. The 
predominance of the norcaradiene may only apply when in solution, with the more crystalline 
cycloheptatriene being favoured in the solid state. Alternatively, steric effects arising from the 
bulky phenyl and phosphonate functionalities may override the electronic bias towards the 
norcaradiene. 
 
                                                
‡ The crystal exhibited complete disorder of the entire molecule. The molecule was modelled in 
two positions with refined occupancies of 0.8902:0.1098(18). The two forms are related by an 
approximate inversion about a plane defined by the P=O and C=O vectors. Only the major form is 
shown. Full details can be found via The Cambridge Crystallographic Data Centre. 
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Given the single crystal X-ray structure revealed the cycloheptatriene form, the 1H NMR spectrum 
was assigned as such, with the key assignments shown in Figure 30. The presence of five proton 
signals in the δ = 5.30 – 6.40 ppm region adds weight to the argument that the cycloheptatriene is 
predominant as only four signals might be expected in this region for the norcaradiene form. The 
signal at δ = 5.31 ppm was assigned to H-7 with one coupling to the adjacent proton and the other 
to the phosphorus atom. 
 
Figure 30: Key 1H NMR data for cycloheptatriene 153e. 
 
The 13C NMR data were also intriguing. The key signal, at C-7, should provide conclusive 
evidence of which form is favoured; in the norcaradiene it is sp3 hybridised whereas in the 
cycloheptatriene it is sp2 hybridised. Yet no clear resonance could be assigned to C-7 until careful 
analysis of the 1H-13C HSCQ spectrum revealed an extremely weak signal at δ = 119.1 ppm. The 
chemical shift of this resonance seems to clearly indicate the cycloheptatriene form is favoured. 
The low strength of the signal is puzzling given that the carbon is tertiary. However, coupling with 
the nearby phosphorus atom would halve the signal intensity, yet a simple doublet is not observed. 
 
This result represents an interesting example of the Buchner ring expansion, contradicting the 
expected models, which predict the norcaradiene form should predominate over the 
cycloheptatriene. 
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2.3.4.  Variation of the aldehyde: α-Alkylidene-γ-butyrolactones 
 
In addition to α-methylene-γ-butyrolactones the one-pot methodology can be used to synthesise α-
alkylidene/arylidene-γ-butyrolactones. This class of compounds also features prominently in 
Nature, for example, in compounds like heteroplexisolide E94 and savinin95 (Figure 31). 
 
 
Figure 31: α-Alkylidene/arylidene-γ-butyrolactone natural products. 
 
Simply by replacing the paraformaldehyde with aliphatic or aromatic aldehydes it is possible to 
gain access to α-alkylidene/arylidene-γ-butyrolactones in good yields (Figure 32). In all cases a 
mixture of E- and Z-isomers was obtained, with a propensity towards the Z-isomer in most cases. 
HWE reactions tend to provide E isomers. A combination of the tertiary phosphonate and the 
proximity of the β-position substitution likely disfavours the formation of the E-isomer. 
 
The p-OMe diazo substrate 117b was selected in order to test a range of aldehydes using the one-
pot conditions (Figure 32). As expected, electron-deficient aldehydes performed best, with 4-
nitrobenzaldehyde affording the desired product 176 at 0 °C. In each of the other cases the HWE 
reactions were warmed to RT affording products 178–182, while electron-rich piperonal required 
heating to reflux in order to obtain product 177. One aromatic and one aliphatic aldehyde were then 
screened against a range of α-diazo(diethoxyphosphoryl)acetates, 116b, 134b and 143b, generally 
affording the desired products 183–188 in good yield. All products were fully characterised. 
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Figure 32: One-pot C–H insertion/olefination sequence using alkyl and aryl aldehydes.a  
 a (i) Rh2(oct)4 (2 mol %), CH2Cl2, 45 °C, 20 h; (ii) Remove CH2Cl2 in vacuo, add THF, KOBu-t 
(1.5 equiv.), 0 to −78 °C; (iii) RCHO (2 equiv.), −78 °C to RT. Z-isomer shown in products. b HWE 
was performed at 0 °C. c HWE was performed at reflux. 
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2.4  Asymmetric studies 
 
The ability to synthesise a range of α-methylene-γ-butyrolactones using an efficient one-pot 
process has been demonstrated. However, with many examples of enantio-induction using chiral 
Rh(II) catalysts in the literature,22 and a wide range of these catalysts available, it seemed logical to 
test the methodology in order to gain access to enantio-enriched α-methylene-γ-butyrolactones. 
 
As discussed earlier, to the best of our knowledge, there are no literature examples of asymmetric 
induction for the intramolecular C–H insertion reactions of α-diazocarbonylacetates that afford γ-
lactone products. The work of Gois et al. exhibits the only examples of asymmetric induction of 
acceptor/acceptor diazo compounds that contain phosphonate groups. Their work on α-
diazophosphonoacetamides with various rhodium(II) carboxylates generated lactam products in 
good yields but poor ee. 
 
The one-pot conditions were applied to substrate 117b using Rh2(S-DOSP)4, one of the most 
common Rh(II) carboxylate catalysts used for asymmetric C–H insertions (Figure 33).  
 
 
Figure 33: Rh2(S-DOSP)4 catalysed C–H insertion of an α-diazo(diethoxyphosphoryl)-acetate. 
 
The desired product 117d was formed in good yield, comparable with those using Rh2(oct)4. 
Following column chromatography purification, the specific rotation of the ‘enriched’ sample was 
measured, giving  [α]D = –18.0. This result was of the same sign as the catalyst, so was treated with 
caution. Nevertheless attempts were made to separate the enantiomers on a non-enriched sample 
using chiral HPLC techniques. Unfortunately, despite screening a variety of different column types 
and eluting conditions no clear separation of the enantiomers was observed. 
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Further attempts were made to determine the ee using 1H NMR spectroscopy by utilising a chiral 
shift reagent in order to generate distinguishable diastereomeric complexes. Firstly the racemic 
sample of lactone 117d was tested by adding Eu(hfc)3 (30 mol%) to the sample. The peaks in the 
1H NMR spectra were shifted downfield relative to the undoped sample, but no peak separation 
was observed (Figure 34). A further increase in loading of the europium reagent increased the 
downfield shifting but also introduced peak broadening, such that the ee could not be determined. 
 
 
 
Figure 34: 1H NMR spectra of racemic 117d (above, left) with various quantities of Eu(hfc)3 
(above, right); a) No additive, b) 0.3 eq. of Eu(hfc)3, c) 0.56 eq. of Eu(hfc)3. 
 
Another technique that has previously been used to determine the ee of γ-butyrolactones is by the 
addition of enantiopure 1-(9-anthryl)-2,2,2-trifluoroethanol (known as Pirkle’s alcohol). The 
binding of Pirkle’s alcohol through the oxygen atoms of the lactone creates diastereomeric 
complexes (Figure 35)96 “causing predictable differences in shielding that occur for the two 
configurations of the lactone”.97 Differentiation of the diastereomeric complexes becomes possible 
and should be observed in both the 1H and 13C NMR spectra.  
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Figure 35: Binding mode of (R)-(–)-1-(9-anthryl)-2,2,2-trifluoroethanol with a γ-lactone. 
The addition of Pirkle’s alcohol to both the racemic and enantioenriched lactone 117d did produce 
a splitting of the peaks in both the 1H (Figure 36) and 13C NMR spectra (Figure 37). The 1H NMR 
spectra (Figure 36, spectra b and c) show that on addition of (R)-Pirkle’s alcohol to the γ-lactone 
there is splitting of the peaks, corresponding to the two diastereomeric complexes. Comparison of 
spectrum b (racemic 117d) with spectrum c (‘enriched’ 117d) shows that there is negligible 
difference indicating that there is little to no ee for the enriched sample. Unfortunately the peaks 
are not well defined enough to obtain an accurate ee.  
 
 
Figure 36: 1H NMR spectra of: a) racemic 117d with no additive, b) racemic 117d with 2 eq. (R)-
Pirkle’s alcohol, c) ‘enriched’ 117d with 2 eq. (R)-Pirkle’s alcohol. 
 
The 13C NMR spectrum (Figure 37) of the enriched sample containing (R)-Pirkle’s alcohol also 
induced peak splitting, but of only one peak, corresponding to the carbonyl carbon. The peaks were 
insufficiently separated for an accurate ee determination by integration. 
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Figure 37: 13C NMR spectrum of enantiomerically enriched 117d with 2 eq. (R)-Pirkle’s alcohol. 
 
Despite the good yield with the chiral Rh(II) carboxylate catalyst it appears that there is little to no 
ee imparted. Further work with alternative catalysts, for example the N-phthaloyl-protected, amino 
acid-derived rhodium(II) carboxylates used by Ikegami,70 e.g. Rh2(S-PTPA)4 may be required to 
induce any enantioselectivity. However, a prerequisite to any further studies is an effective method 
for the determination of ee. 
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2.5  Synthesis of biologically relevant α-methylene-γ-butyrolactones 
 
One of the principal aims of this project was to apply use the one-pot Rh(II)-catalysed C–H 
insertion/HWE olefination methodology as a platform to generate products with a relatively high 
level of complexity from simple, readily accessible starting materials. The total synthesis of two 
natural products, cedarmycins A and B, as well as a bioactive MRSA inhibitor is described.  
 
2.5.1.   (±) Cedarmycins A and B 
 
Two related antibiotics, cedarmycins A and B, 189 and 190 (Figure 38) were identified in 2001 by 
Furumai et al. after isolation from a cultured broth of the genus Streptomyces strain TP-A0456.98 
The butyrolactone metabolites were isolated from the plant of Cryptomeria Japonica (Japanese 
cedar) in Toyama, Japan. The group’s biological studies centred on comparisons to the well-known 
antifungal drug amphotericin B 191,99 also isolated from Streptomyces. They discovered that both 
cedarmycins exhibited their most potent activity against Candida glabrata, a yeast strain, with 
cedarmycin A in particular showing similar activity to amphotericin B (MIC = 0.40 µg/mL). Both 
compounds also exhibited weak activity against a broad range of other bacteria and yeasts. 
 
 
Figure 38: Structure of cedarmycins A and B and amphotericin B. 
 
The structures of cedarmycins A and B were elucidated with typical spectroscopic techniques; both 
natural products were found to possess a specific rotation, yet the absolute configuration of both 
compounds were not determined. 
 
Prior to this research there are no published works reporting the synthesis of cedarmycin A 189 and 
to date there has been only one published synthesis of cedarmycin B 190, by Xu et al. in 2009.100 
Their route focused on the use of an intermolecular Barbier reaction to install the primary alcohol 
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functionality in compound 194, which can undergo a simple acylation to directly afford 
cedarmycin B 190 (Figure 39). 
 
 
Figure 39: Xu’s synthesis of (±)-cedarmycin B. 
 
At 7 steps and 8% overall yield the route is relatively concise, but a lot of manipulation is required 
to install relatively simple functional groups. Furthermore, given the simplicity of the final step, O-
acylation, it seemed unusual for the group not to have synthesised cedarmycin A also.  
 
2.5.1.1.  Synthesis of (±)-cedarmycins A and B 
 
The synthesis of both cedarmycins A and B seemed attainable using the one-pot C–H 
insertion/olefination methodology, requiring C–H insertion into a methylene site with no apparent 
chemoselectivity issues. The retrosynthetic analysis of cedarmycins A and B (Figure 40) shows 
that the substrates should be readily accessible starting from propane-1,3-diol, and so the planned 
route to cedarmycins A and B using the novel one-pot C–H insertion/olefination methodology 
should be shorter than the original synthesis completed by Xu. 
 
 
Figure 40: Retrosynthetic analysis of cedarmycins A and B. 
 
First, mono-acetylation of propane-1,3,diol 196 furnished alcohol 197, which under the standard 
T3P coupling conditions afforded phosphonate 198 (Figure 41). 
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Figure 41: Attempted direct synthesis of cedarymcin B by C–H insertion. 
 
Diazotisation generated diazo compound 199 in 41% yield over 3 steps. However, on treatment 
with Rh2(oct)4, decomposition of the diazo starting material occurred based on TLC analysis, but 
the desired C–H insertion to generate product 200 did not take place. A complex mixture of 
decomposition products was observed. The methodology studies showed that the insertion reaction 
is tolerant to many functional groups, but it appears in this case that the presence of an ester α to 
the insertion site may have a detrimental effect, possibly by coordination of the oxygen lone pair to 
the carbenoid centre.101 
 
The above failed attempt to synthesise cedarmycin B led to a reconsideration of the route, instead 
necessitating a late stage installation of the hexanoyl functionality. This method would require 
prior protection of the alcohol functionality in order for the C–H insertion step to take place. 
 
During the methodology studies into the one-pot C–H insertion/olefination sequence, TBS-
protected lactone 138c was successfully synthesised in 18% yield, alongside the β-lactone 138d in 
16% yield (Table 6, Entry 1). Nevertheless, the regioisomers were separable by column 
chromatography, and thus γ-lactone 138c was taken forward for the synthesis of cedarmycins A 
and B (Figure 42). 
 
Treatment of lactone 138c with TBAF furnished known alcohol 194 in good yield with the Michael 
acceptor still intact. To conclude, treatment of the alcohol with the corresponding acid chlorides 
provided (±)-cedarmycins A 189 and B 190 in good yields. The observed spectroscopic data were 
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in full accord with those reported in the isolation publication (see Appendix I for comparison tables 
and spectra).98 This represents the first reported synthesis of (±)-cedarmycin A 189. 
 
 
Figure 42: Synthesis of (±)-cedarmycins A and B. 
 
These total syntheses have highlighted some limitations of the C–H insertion methodology. The 
presence of ester functionality as well as steric hindrance in proximity to the reactive carbenoid 
centre has been shown to be detrimental, leading to competing processes.  Despite the low yield 
and lack of selectivity in the C–H insertion steps, the overall route is marginally shorter than that 
previously reported. 
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2.5.2.  Staphylococcus aureus (MRSA) virulence inhibitors 
 
In 2014 Sieber et al. identified a collection of α-methylene-γ-butyrolactones (Figure 43) which 
possess significant activity against methicillin-resistant Staphylococcus aureus (MRSA);102 a lack 
of novel and effective antibiotics as well as rising concerns about the ‘antibiotic apocalypse’ due to 
multidrug resistant bacteria were cited as reasons behind their research. They reasoned that 
bacterial growth could be attenuated by targeting virulence factors contributing to the growth of the 
bacteria. One such virulence factor is a protein called α-hemolysin, a toxin released by the 
Staphylococcus aureus bacterium.  
 
As is most commonly the case, the reactivity of the α-methylene-γ-butryolactone stems from the 
α,β-unsaturated ester functional group reacting with cysteine residues in proteins. The modification 
of these residues in DNA binding proteins reduced their DNA affinity, hindering the transcription 
of α-hemolysin. The compounds were also found to reduce the invasion efficiency of the 
bacterium. The four compounds shown in Figure 43 were tested against S. aureus strains. 
Compounds 203 and 204 exhibited IC50 values for hemolytic activity of 4 µM and 2 µM, 
respectively. 
 
 
Figure 43: α-Methylene-γ-butyrolactones screened for inhibition of S. aureus. 
 
The α-methylene-γ-butyrolactones were designed with the same core structure with differing side 
chains but all possessing terminal alkynes for later modification in order to be identified in protein 
profiling studies (by click chemistry with functionalised azides). Sieber’s route focused on the use 
of a Reformatsky reaction to directly afford the α-methylene-γ-butyrolactone moiety. The route 
began with a Wittig olefination with benzaldehyde to generate α,β-unsaturated ester 206, followed 
by an allylic bromination affording the Reformatsky precursor 207. Treatment of compound 207 
with zinc and 5-hexynal delivered diastereomeric lactones 203 and 204. 
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Figure 44: Sieber’s synthesis of α-methylene-γ-butyrolactone MRSA inhibitors. 
 
Lactone 203 was identified as a suitable target for the one-pot C–H insertion/olefination 
methodology, with retrosynthetic analysis shown in Figure 45. The trans-diastereomer 203 was 
expected to be favoured, but accompanying formation of cis-diastereomer 204 could be expected 
based on earlier results. The other targets identified in the studies, lactones 201 and 202, were 
deemed unsuitable for the one-pot C–H insertion/olefination methodology as they would require 
selective C–H insertion into a primary site over two secondary sites.  
 
 
Figure 45: Retrosynthetic analysis of MRSA virulence inhibitor 203.  
 
Whilst the one-pot conditions were expected to work well on substrate 208 based on observations 
from the methodology scoping studies, it did present a regioselectivity issue. There are two 
possible C–H insertion sites β to the oxygen but it was expected that the desired insertion site, the 
benzylic position, would be favoured over the non-benzylic site due to greater stabilisation of 
positive charge in the transition state. 
 
The synthesis began with the formation of Weinreb amide 211 from commercial acid 210, followed 
by addition of a single equivalent of benzylmagnesium chloride to generate ketone 212. Sodium 
borohydride reduction to the alcohol 209 followed by the customary acylation and diazotization 
procedures furnished α-diazo(diethoxyphosphoryl)acetate 208 in excellent yield. This was then 
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reacted under the standard one-pot C–H insertion/olefination conditions. As anticipated, the 
reaction yielded the desired α-methylene-γ-butyrolactone 203 along with the undesired regioisomer 
214, in 49% and 19% yields, respectively. Notably, the reaction was diastereoselective for the 
trans-isomer 203. During the biological studies by Seiber the trans-lactone 203 was found to be 
markedly more potent for the inhibition of S. aureus than the cis-isomer 204. The observed 
spectroscopic data were in full accord with those reported by Sieber.102 
 
 
Figure 46: Synthesis of S. aureus inhibitor 203. 
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2.6  Conclusion 
 
A one-pot procedure for the efficient conversion of α-diazophosphonoacetates into α-methylene-γ-
butyrolactones has been developed. The transformation incorporates a C–H insertion reaction of 
otherwise inert C–H bonds for the selective formation of γ-lactones. A subsequent Horner–
Wadsworth–Emmons olefination concludes the one-pot process, circumventing the need to isolate 
and purify the intermediate α-phosphonolactone. A variety of α-methylene-γ-butyrolactones have 
been synthesised, having explored the effects of electronic and steric modifications. Excellent 
yields were obtained for insertion into both benzylic and non-stabilised C–H bonds, with the almost 
exclusive formation of γ-lactone products. The reaction was extended to the use of aldehydes other 
than formaldehyde, enabling the synthesis of α-alkylidene-γ-butyrolactones.  
 
It is anticipated that this methodology will be of significant value to the synthetic community. The 
one-pot C–H insertion/olefination sequence is a highly selective process, reacting with C–H bonds 
typically considered unreactive, generating α-methylene-γ-butyrolactones in excellent yields. 
Additionally, the requisite α-diazophosphonoacetate functional group can be readily installed in 
just two steps from alcohols by way of a T3P-mediated esterification and Regitz diazo transfer 
reaction, enabling the efficient synthesis of substrates. The use of just 2 mol% of Rh2(oct)4 and 
broad substrate scope make the methodology attractive for wide-spread implementation in natural 
product and small molecule synthesis. 
 
The methodology was applied to the synthesis of two antibacterial natural products, (±)-
cedarmycins A and B, the former of which is the first reported synthesis. Additionally, a 
Staphylococcus aureus inhibitor was successfully synthesised in an efficient sequence, with 
complete trans-diastereoselectivity. 
 
Selected research described in this Chapter is contained within published articles (see Appendix III 
and IV).103 
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Chapter 3 –  Synthesis of conformationally restricted α-
methylene-γ-butyrolactones 
3.1  Introduction 
 
Following the successful C–H insertion reactions of a variety of non-stabilised aliphatic α-
diazo(diethoxyphosphoryl)acetates, the methodology was extended to bicyclic lactones. These 
systems are amongst the most important in relation to naturally occurring compounds; 
sesquiterpene lactones, as discussed earlier, are the largest family of naturally occurring α-
methylene-γ-butyrolactone natural products. All of the sesquiterpene sub-classes are cyclic, 
comprising 5,5-, 6,5-, or 7,5-fused bicyclic lactone frameworks. As such, simple cycloalkanol 
systems were prepared in order to examine the potential of the one-pot C–H insertion/olefination 
methodology for the synthesis of bicyclic α-methylene-γ-butyrolactones. The diazo derivatives of 
cyclopentanol 145b, cyclohexanol 146b and cycloheptanol 147b, were expected to deliver the 5,5-, 
6,5-, and 7,5-, fused bicyclic lactones, respectively (Scheme 44). 
 
 
Scheme 44: Proposed synthesis of bicyclic α-methylene-γ-butyrolactones using the one-pot C–H 
insertion/olefination sequence. 
 
Firstly, 5-membered derivative 145b was treated with Rh2(oct)4 (Scheme 45), but unfortunately 
only decomposition was observed based on TLC analysis, with no evidence for the formation of 
145c. This was unexpected given that related literature precedent saw successful C–H insertions 
take place, although these examples were either with α-diazo(cyclopentylmethylketo)acetates52 or 
acceptor-substituted carbenoids.104 
 
 
Scheme 45: Attempted C–H insertion reaction cyclopentanol derivative 145b. 
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The cyclohexanol derivative 146b performed better under the one-pot C–H insertion olefination 
sequence (Scheme 46), but three products were isolated; the cis- and trans-fused 5,6-bicylic lactone 
146c (10:1 trans:cis) were obtained, as well as a smaller quantity of spirocyclic β-lactone 146d. It 
is unclear why the overall isolated yield is so low, but given the number of products isolated is 
seems likely that other undesired side-reactions are taking place. The mixture of products likely 
arises due to the flexible nature of the cyclohexane ring, which can undergo ring-flipping. As such, 
the prochiral C–H bonds become difficult to distinguish and so a mixture of C–H insertion products 
is observed. 
 
 
Scheme 46: One-pot C–H insertion/olefination sequence for cyclohexanol derivative 146b. 
 
More pleasingly, the cycloheptanol derivative 147b (Scheme 47) formed solely the γ-lactone 147c 
in good yield, albeit as a mixture of isomers (3.5:1 trans:cis), which were identified by comparison 
with literature data.105 
 
 
Scheme 47: One-pot C–H insertion/olefination sequence for cycloheptanol derivative 147b. 
 
Studies performed by Taber, Doyle and others into intramolecular C–H insertions have identified 
the preference for rhodium carbenoids to react with equatorially aligned C–H bonds in 
cyclohexane-based systems;43,60,106 for example, menthyl α-diazoacetoacetate 215 selectively forms 
γ-lactone 216 when treated with Rh2(OAc)4 (Figure 47).51 In these examples various substituent 
effects led to a bias towards one conformer by differentiating the axial and equatorial C–H bonds 
leading to high levels of diastereoselectivity. One reason cited for the equatorial selectivity of the 
insertion reaction is steric effects; axial C–H insertion would invoke unfavourable 1,3-diaxial 
interactions.107 
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Figure 47: Doyle’s diastereoselective intramolecular equatorial C–H insertion.51 
 
3.2  Conformationally restricted α-diazo(diethoxyphosphoryl)acetates 
 
This observed selectivity led to a re-examination of cyclohexanol-derived systems. It was 
anticipated that simply restricting the conformation of the cyclohexane ring by substitution with so-
called locking groups would distinguish the C–H insertion sites and deliver diastereoselective 
reactions with fewer by-products and improved yields. The 6-membered systems were selected, 
given the preference for chair conformations. As such, a series of tert-butyl cyclohexanol 
derivatives were prepared and subjected to the standard one-pot C–H insertion/olefination 
sequence.  
 
Firstly, the 4-tert-butyl-cyclohexanol systems 154b and 155b were prepared. The functionalised 
tether in syn-diazo compound 154b is fixed in an axial orientation meaning that only equatorial C–
H insertion is possible, whereas for anti-diazo compound 155b the pendant functional group is 
equatorial with the potential for both axial and equatorial C–H insertion, and therefore 
chemoselectivity. Each substrate was subjected to the standard one-pot sequence and two products 
were identified in each case; a γ- and β-lactone (Scheme 48). As hoped, each γ-lactone, 154c and 
155c, was identified as resulting solely from equatorial C–H insertion. The concurrent formation of 
separable β-lactones 154d and 155d was disappointing, however, the overall isolated yields were 
moderately improved compared to the unsubstituted cyclohexane systems. 
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Scheme 48: One-pot C–H insertion/olefination sequence for 4-tert-butyl-cyclohexanol derivatives 
154b and 155b. 
 
The earlier studies demonstrated that steric effects could have a profound influence on the 
selectivity of the C–H insertion reactions often leading to different product distributions. It was 
postulated that by bringing the tert-butyl group closer to the pendant functional group (and C–H 
insertion site) the unwanted β-lactone formation might be disfavoured. As a consequence the 2-
tert-butyl-cyclohexanol derivatives 156b and 157b were prepared and treated under the standard 
one-pot C–H insertion/olefination conditions (Scheme 49). 
 
Gratifyingly, a single product was observed from the reaction of each diazo compound; the γ-
lactones derived from equatorial C–H insertion, 156c and 157c, respectively, were obtained in 
excellent yields. Neither of the corresponding β-lactones were observed. In these cases the benefit 
of the tert-butyl group appears to be twofold: locking the conformation of the cyclohexane ring and 
providing a steric barrier to competing β-lactone formation. 
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Scheme 49: One-pot C–H insertion/olefination sequence for 2-tert-butyl-cyclohexanol derivatives 
156b and 157b. 
 
This steric effect was then further examined by the preparation of additional diazo substrates 
derived from menthol and decalinol, each possessing substitution in the 2-position (Table 7). 
Menthol derivative 158b delivered the desired diastereomer, lactone 158c, in good yield when 
subject to the one-pot conditions. Similarly the two trans-decalinol derivatives, 159b and 160b 
afforded their corresponding γ-equatorial C–H insertion products 159c and 160c, respectively, 
again in good yield. As a final example adamantane-derived diazo compound 161b was 
synthesised and when treated under the standard one-pot conditions delivered the γ-lactone 161c, 
the only possible product, in excellent yield. 
 
From these results it became apparent that restricted conformation was an important feature for 
diastereoselective intramolecular C–H insertions, with steric influences playing a significant role in 
minimising competing β-lactone formation. The above examples illustrated that substitution in the 
2-positon, relative to the pendant functional group, disfavoured β-lactone formation. As an 
extension, substitution at the 3-position was investigated to discover the degree to which steric 
effects play a role.  
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Table 7: One-pot C–H insertion/olefination sequence for conformationally restricted cyclohexyl α-
diazo(diethoxyphosphoryl)acetates. 
 
Entry Diazo Compound Product Isolated Yield, % 
1 
 
158b 
 
158c 
73 
2 
 
159b 
 
159c 
68 
3 
 
160b 
 
160c 
64 
4 
 
161b 
 
161c 
79 
    
Conditions: (i) Rh2(oct)4 (2 mol %), CH2Cl2, 45 °C, 20 h; (ii) Remove CH2Cl2 in vacuo, add THF, 
KOBu-t (1.2 or 1.5 equiv.), 0 to −78 °C; (iii) (CH2O)n (2 equiv.), −78 °C to RT. 
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3.2.1.  Steroidal α-diazo(diethoxyphosphoryl)acetates 
 
Next, in order to further explore synthetic potential, a series of steroid-derived diazo compounds 
were prepared and subjected to the standard one-pot C–H insertion/olefination conditions. Firstly, 
cholestanol derivative 217b led to a mixture of three products; an inseperable mixture of γ-lactones 
217c and 217d, each arising from equatorial C–H insertion and β-lactone 217e, which was 
separable from the γ-lactones (Scheme 50). Despite the lack of regioselectivity, this result 
demonstrated that substitution as remote as the 3-position (relative to the functionalised tether) is 
insufficient to fully impede β-lactone formation. 
 
Scheme 50: One-pot C–H insertion/olefination sequence for cholestanol derivative 217b. R = (R)-
6-methylheptan-2-yl. 
 
Similarly, the cholesterol-derived system 218b (Scheme 51), delivered a small amount of the 
undesired β-lactone 218d, but a single, separable γ-lactone product 218c was obtained. These 
observations correspond to similar investigations performed by Doyle with cholestanol and 
cholesterol derivatives,106b but no explanation was provided on the formation of a single γ-
regioisomer from the cholesterol system. This result is curious in that allylic or benzylic C–H 
bonds are typically favoured for C–H insertion over non-stabilised C–H bonds. 
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Scheme 51: One-pot C–H insertion/olefination sequence for cholesterol derivative 218b. R = (R)-
6-methylheptan-2-yl. 
 
To conclude, a final steroid-based system with substitution at the 2-position (relative to the 
functional tether) was investigated in order to reaffirm the theory regarding proximity of the steric 
influence in reference to β-lactone formation. The diazo compound 219b, derived from 11α-
hydroxyprogesterone, was prepared and pleasingly generated the desired pentacyclic lactone 219c 
as the single product, albeit in a disappointing yield (Scheme 52). An increased temperature (65 
°C) was required in order to drive the C–H insertion reaction to completion, possibly due to the 
extreme steric hindrance surrounding the insertion site. 
 
 
Scheme 52: One-pot C–H insertion/olefination sequence for 11α-hydroxyprogesterone derivative 
219b. 
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In summary, by installation of appropriate functionality on the cyclohexane ring, the outcome of 
the one-pot C–H insertion/olefination, in terms of product distribution, stereoselectivity and yield, 
can be improved. The following principles were identified: 
 
• As previously observed, restricting the conformation of the cyclohexane ring biases the C–
H insertion to equatorial sites, reducing undesired reactions hence improving yields. 
• Installation of a sterically hindering group in the 2-position relative to the functional tether 
eliminates β-lactone formation; but 3- or 4-substitution does not confer the same effect. 
 
3.3  Applications to eudesmanolide natural product synthesis 
3.3.1.  Introduction 
 
The next progression was to apply these findings to natural product targets. Sesquiterpene lactones 
constitute the vast majority of naturally occurring α-methylene-γ-butyrolactones.1,6 These 
structures are constructed from three isoprene units and possess a variety of configurational 
isomers and oxidation patterns, but almost all are cyclic. As discussed earlier, these sesquiterpene 
lactones can be subdivided into a series of smaller classes based on their structural arrangement, 
one of which are known as eudesmanolides; this class is characterised by a 6,6,5-tricyclic, γ-
lactone framework 220 as shown in Figure 48 alongside some examples of trans-annelated natural 
products.108 
 
  
Figure 48: Eudesmanolide core framework with examples of trans-annelated natural products. 
 
Eudesmanolides containing a cis-fused decalin core are rare but there are some examples; 
melanolepin B 224,109 eudesmadiene-12,6-olide 225110 and muscicolide B 226 amongst others.111 
The assignment of the cis-ring junction of the decalin core is ordinarily based on the 13C NMR shift 
for the ring junction methyl group, which appears more downfield in cis-systems than trans. 
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Figure 49: Examples of cis-annelated eudesmanolide natural products. 
 
3.3.2.  Synthesis of eudesmanolide natural product frameworks 
 
Results from the extended methodology studies included two decalin-derived diazo compounds 
159b and 160b (Table 7, Entries 2–3), which when subjected to the one-pot C–H 
insertion/olefination sequence generated the same core 6,6,5-tricyclic scaffold as eudesmanolides. 
As such, the possibility of utilising the one-pot C–H insertion/olefination methodology to 
synthesise eudesmanolide natural products was conceived. 
 
At the outset, no particular eudesmanolide natural product was targeted; instead a general approach 
to a cis- or trans-decalin framework, that could later be modified, was visualised. The decalin 
substrates, used during the earlier methodology studies, are two carbon atoms short of the 
eudesmanolide core. This necessitated the installation of the quaternary ring-junction methyl group, 
and the exocyclic carbon atom, before commencing these studies. It was anticipated that neither of 
these modifications would have a detrimental effect on the diastereoselectivity of the C–H insertion 
reaction as they will not introduce additional conformational flexibility.  
 
The retrosynthetic strategy towards the generalised eudesmanolide 227 is shown in Scheme 53. 
The tricyclic eudesmanolide framework should be accessible using the one-pot C–H 
insertion/olefination methodology as the key step from diazo compound 228. This will be derived 
from β-hydroxyketone 229 following FGI of the ketone. It is envisaged that the β-hydroxyketone 
229 should be generated by intramolecular aldol addition from keto-aldehyde 230. Installation of 
the quaternary methyl unit, by conjugate addition into enone 231, will necessitate prior protection 
of the aldehyde functionality. The enone 231 may be derived from an overall conjugate addition of 
an alkyl halide 233 to readily available cyclohexenone 232. 
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Scheme 53: Retrosynthetic strategy towards the generalized eudesmanolide framework 227. 
 
Initial efforts focussed on the synthesis of ketoaldehyde 231, albeit with the aldehyde functionality 
protected as an acetal. As such, the 1,2-additon of chloride 234 to cyclohexenone 232 was 
attempted by formation of the Grignard reagent. Unfortunately this was met with difficulty and as 
an alternative, a lithium naphthalenide catalysed 1,2-addition was implemented,112 delivering 
allylic alcohol 235 in near quantitative yield (Scheme 54). A subsequent PCC-mediated oxidative 
rearrangement furnished enone 236 in 52% yield. 
 
  
Scheme 54: Synthesis of enone 236 via a catalytic lithium naphthalenide addition/oxidation 
sequence. 
 
With enone 236 in hand, the installation of the quaternary methyl group via a 1,4-addition of a 
methyl organometallic reagent was investigated. A series of attempts were made using the 
traditional lower-order Gilman reagent (Me2CuLi generated from MeLi and CuI) but unfortunately 
were not met with success. A procedure developed from literature precedent was applied, utilising 
catalytic CuI, MeMgCl and TMSCl as an in situ quench.113 Pleasingly this generated the 1,4-adduct 
237 in near quantitative yield with no requirement for column chromatography purification 
(Scheme 55). Given the high acid lability of both the silyl enol ether and acetal functionalities, 
substrate 237 was simply refluxed in the presence of aqueous acid in order to execute a double-
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deprotection and aldol cyclisation in one step. An analogous reaction performed by Tanaka in 2001 
was reported to generate a single diastereomer of β-hydroxyketone 238, but the relative 
stereochemistry was not specified.114 We were pleased to also observe the same single diastereomer 
of the β-hydroxyketone 238, in addition to some of the dehydrated enone 239, with all spectral data 
found to be in accord with those reported by Tanaka. 
 
 
Scheme 55: Synthesis of β-hydroxyketone 238 via aldol cyclisation. 
 
The spectral data of β-hydroxyketone 238 was analysed in order to identify the relative 
stereochemistry; with 3 stereocentres present there are 4 possible diastereomers 238a–d, as shown 
in Figure 50. 
 
 
Figure 50: The four possible diastereomers of β-hydroxyketone 238.  
 
The most distinguishable feature of the 1H NMR spectrum was the resonance associated with the 
proton β to the carbonyl: δH = 4.00 (1 H, app. tt, J = 10.5, J = 5.1) ppm. The two large coupling 
constants indicate the presence of two contiguous trans-diaxial proton arrangements. This can only 
arise from two diastereomers, 238a and 238d, as shown by the highlighted protons in Figure 51. 
The other two diastereomers can therefore be ruled out. 
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Figure 51: Comparison of β-hydroxyketone diastereomers based on 1H NMR J values. The trans-
diaxial arrangements are shown in red. 
 
The differentiation of trans-decalin 238a from cis-decalin 238d was more challenging, but was 
achieved by comparing the 13C NMR chemical shifts of the ring junction methyl groups, with those 
previously reported for related compounds.115  Cis-decalins with this core structure typically 
generate chemical shift ca. δC ≈ 27 ppm, whereas trans-decalins produce a more upfield shift ca. δC 
≈ 17 ppm. The observed chemical shift of this carbon is δC = 27.7 ppm, strongly inferring a cis-6,6-
ring junction and therefore that β-hydroxyketone 238d is the sole product (Figure 52). This was 
somewhat surprising, as under the reaction conditions we expected the trans-decalin to 
predominate, on thermodynamic grounds. 
 
 
Figure 52: Key spectroscopic data for β-hydroxyketone 238d. 
 
With cis-decalin 238d in-hand it was decided to target eudesmanolide natural products containing 
the cis-decalin core. A literature search revealed two relatively simple compounds with the 
eudesmanolide core and possessing no additional oxidation. The C–H bond to be inserted using the 
one-pot C–H insertion/olefination procedure is in the requisite equatorial position; as such, it was 
hoped their synthesis could be readily accomplished. The two structures in question were isolated 
as part of a series of eudesmanolides reported by Dominguez et al. in 1985 and assigned as novel 
natural products morifolins A and B, 240 and 241, respectively. However, a later publication by 
Herz in 2004 shed doubt upon the original assignments, instead suggesting their data were identical 
to that of two diastereomeric natural products that had been previously isolated by Bohlmann in 
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1983. Herz proposed that the structures of lactones 240 and 241 were in fact the natural products 
isocritonilide 242 and critonilide 243, respectively (Figure 53). 
 
  
Figure 53: Assigned structures of morifolins A, B and their proposed true identities, isocritonilide 
and critonilide, respectively. 
 
The lack of clarity over the matter stems from the insufficient data provided in the Dominguez 
publication, which contains partial 1H NMR, IR and MS but no 13C or 2D correlation NMR. Given 
that the one-pot C–H insertion/olefination methodology had thus far only be trialled on trans-
decalins it was seen as an interesting opportunity to explore the applicability of cis-decalins whilst 
also clearing up confusion in the literature. As such the structures assigned to morifolins A and B, 
240 and 241, were targeted. 
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3.3.3.  Synthesis of proposed structure of morifolin A 
 
Morifolin A 240, containing the endocyclic alkene was targeted first of all, beginning with silyl 
ether protection of β-hydroxyketone 238d, delivering ketone 244 (not shown) which was then 
converted into the vinyl triflate 245 under kinetic conditions (LHMDS, Tf2O, −40 °C) (Scheme 
56). Interestingly, thermodynamic vinyl triflate-forming conditions (DTBMP, Tf2O, RT) were 
unsuccessful in this case. Following literature precedent,116 an iron-catalysed cross-coupling of 
vinyl triflate 245 with MeMgCl furnished the desired endocyclic alkene 246 in excellent yield. 
Subsequent desilylation, acylation and diazotisation proved facile, affording diazo 249 in 78% 
yield over 3 steps. We were now in a position to investigate the C–H insertion/olefination sequence 
on a cis-decalin and were delighted to observe a single product from the reaction under the 
standard conditions affording the desired equatorial insertion product 240 in 64% yield. In accord 
with the trans-decalin model substrates, no β-lactone or axial C–H insertion products were 
observed. The structure of lactone 240 was proved unambiguously following acquisition of an X-
ray single crystal structure (Figure 54). 
 
 
Scheme 56: Synthesis of the proposed structure of morifolin A, lactone 240. 
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Figure 54: Single crystal X-ray structure of lactone 240 (CCDC: 1421158). Thermal ellipsoids set 
to 50% probability, shown in Olex2. 
 
On comparison of the data obtained for lactone 240 with those provided by Dominguez117 there was 
a discrepancy in the 1H NMR data (Table 8), corroborating Herz’s118 theory that the structure 
assigned to morifolin A 240 was in error and that the correct structure is most likely that of 
isocritonilide 242.119 No 13C NMR data were provided by Dominguez.  
 
Table 8: Comparison of the 1H NMR data (CDCl3) of synthetic lactone 240, ‘isolated morifolin A’ 
240 and isocritonilide 242. 
 
  
Assignment 
Data for synthetic 
lactone 240 
(400 MHz) 
Data for ‘isolated’ 
morifolin A 240 
(200 MHz)117 
Data for 
isocritonilide 242 
(270 MHz)119a 
11 0.98 (4 H, m) 
0.82 
(3 H, s) 
0.86 
(3 H, s) 
12 1.83–1.86 (4 H, m) 
1.81 
(3 H, s) 
1.85 
(3 H, s) 
7 2.45–2.53 (1 H, m) 
3.24 
(1 H, m) 
3.28 
(1 H, ddddd, 
J = 7.5, J = 5.0, J = 3.5, 
J = 3.5, J = 3.0) 
8 
3.73 
(1 H, app. t, 
J = 10.9) 
4.58 
(1 H, dd, 
J = 11.2, J = 11.0) 
4.61 
(1 H, dd, 
J = 11.0, J = 7.5) 
2 5.39–5.43 (1 H, m) 
5.38 
(1 H, m) 
5.42 
(1 H, br. s) 
15b 5.39 (1 H, d,  J = 3.1) 
5.50 
(1 H, d, J = 3.2) 
5.53 
(1 H, d, J = 3.5) 
15a 6.06 (1 H, d, J = 3.3) 
6.25 
(1 H, d, J = 3.5) 
6.28 
(1 H, d, J = 3.5) 
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3.3.4.  Synthesis of proposed structure of morifolin B 
 
The synthesis of the exo-methylene analogue morifolin B 241 commenced with common precursor 
ketone 244 (Scheme 57). Its treatment with (trimethylsilyl)methyl lithium cleanly afforded 1,2-
adduct 250 before a base-mediated Peterson olefination generated exocyclic alkene 251. Again, 
desilylation, acylation and diazotisation were performed without complication, delivering the key 
diazo compound 254 in 52% yield over 3 steps. Upon submission to the standard one-pot C–H 
insertion/olefination sequence, the desired γ-lactone 256 was synthesised with complete regio- and 
diastereoselectivity, albeit in a disappointing 31% yield. Isolation of cyclopropanation side-product 
255, resulting from the proximity of the alkene to the pendant carbenoid, in 22% yield provided 
some explanation for the relatively low yield of γ-lactone 241. Interestingly, we found that by 
changing the catalyst to the less-bulky Rh2(OAc)4, the yield of γ-lactone 241 could be improved to 
45%, with just 11% of the cyclopropane side-product 255. 
 
 
Scheme 57: Synthesis of the proposed structure of morifolin B, lactone 241. 
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The 1H NMR data for lactone 241 conflicted with those of morifolin B provided by Dominguez 
(Table 9).117 Again, the acquisition of a single crystal X-ray structure (Figure 55) unambiguously 
proved the identity of lactone 241, thus indicating that the structure assigned to morifolin B was in 
error and that the true structure is likely that of critonilide 243,119 as proposed by Herz.118 No 13C 
NMR data were provided by Dominguez. 
 
      
Figure 55: Single crystal X-ray structure of lactone 241 (CCDC: 1421154). Thermal ellipsoids set 
to 50% probability, shown in Olex2. 
 
Table 9: Comparison of the 1H NMR data (CDCl3) of synthetic lactone 241, ‘isolated morifolin B’ 
241 and critonilide 243. 
 
  
Assignment 
Data for synthetic 
lactone 241 
(400 MHz) 
Data for ‘isolated’ 
morifolin B 241 
(200 MHz)117 
Data for 
critonilide 243 
(270 MHz)119a 
11 1.00  (3 H, s) 
0.75 
(3 H, s) 
0.79 
(3 H, s) 
9 2.09–2.23  (3 H, m) 
1.63 
(1 H, d, J = 11.2) 
1.67 
(1 H, br. d, J = 11.0) 
8 
4.11  
(1 H, app. t,  
J 11.1) 
4.77 
(1 H, dd, 
J = 11.2, J = 10.3) 
4.81 
(1 H, dd, 
J = 11.0, J = 7.5) 
7 
2.45  
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(1 H, d, J = 1.0) 
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(1 H, br. s) 
12b 4.88  (1 H, app. t, J 2.0) 
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(1 H, d, J = 1.0) 
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(1 H, br. s) 
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3.3.5.  Synthesis of α-Cyclocostunolide 
 
Following the synthesis of lactones 240 and 241, attention returned to the synthesis of a trans-
decalin derived natural product via the same methodology. Two simple examples, α- and β-
cyclocostunolide 256 and 257, respectively, each possess a trans-decalin core (Figure 56). 
Additonally, the C–C bond that would be formed using the one-pot C–H insertion/olefination 
sequence is equatorially aligned in each compound, therefore suitable for the methodology. β-
Cyclocostunolide 257 contains the exocyclic alkene functionality that introduced chemoselectivity 
issues for diazo compound 254. As such, α-cyclocostunolide 256, containing an endocyclic alkene, 
was selected as a suitable target. 
 
 
Figure 56: trans-Annelated eudesmanolide natural products, α- and β-cyclocostunolide. 
 
Unfortunately, all attempts to directly isomerise cis-decalin 238d, already in-hand, to the more 
thermodynamically stable trans-decalin 238a were unsuccessful. Instead, a simple oxidation-
reduction sequence of β-hydroxyketone 238d was envisioned. Treatment with DMP delivered 
diketone 258, which was found to exist primarily as the keto-enol tautomer 258’, as demonstrated 
by the spectroscopic data (Scheme 58). Following slow addition of NaBH4 to a solution of diketone 
258 in MeOH, a mixture of products was observed by TLC analysis. Separation by column 
chromatography allowed these compounds to be identified as β-hydroxyketones 238a and 238c and 
complex mixture of diastereomers of over-reduction product 259, albeit in low overall yield. The 
determination of cis- or trans-geometry at the ring junction was again carried out using the 13C 
NMR chemical shifts of the quaternary methyl groups. For β-hydroxyketone 238c the signal is 
observed at δC = 26.5 ppm, whereas for β-hydroxyketone 238a it is observed at δC = 17.9 ppm, thus 
indicating that they are cis- and trans-decalins respectively. Each β-hydroxyketone was protected 
as the TBS ether; the cis-decalin 260 was obtained as an oil, whereas the trans-decalin 261 was 
sufficiently crystalline to obtain a single crystal X-ray structure (Figure 57), confirming the 
proposed framework.  
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Scheme 58: Oxidation-reduction sequence for the synthesis of β-hydroxyketones 238a and 238c. 
 
      
Figure 57: Single crystal X-ray structure of trans-decalin 261 (CCDC: 1421164). Thermal 
ellipsoids set to 50% probability, shown in Olex2. 
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Following the sequence developed earlier, trans-decalinone 261 was converted into vinyl triflate 
262 in 67% yield, but this time requiring thermodynamic conditions as the kinetic conditions, used 
earlier, were unsuccessful (Scheme 59). These results demonstrate a general trend for vinyl triflate 
formation in that cis-decalinones require kinetic conditions whereas trans-decalinones require 
thermodynamic conditions.  
 
Conversion of vinyl triflate 262 into endocyclic alkene 263 proceeded in 92% yield. The customary 
desilylation, acylation and diazotisation were performed without complication, affording diazo 
compound 266 in 80% yield over 3 steps. With the key diazo precursor in hand, the one-pot C–H 
insertion/olefination procedure was applied. We were delighted to observe α-cyclocostunolide 256 
as the single product from the reaction in reasonable yield. All of the observed data correlated with 
those published in the literature (see Appendix I for comparison tables and spectra).120  
 
 
Scheme 59: Synthesis of α-cyclocostunolide 256. 
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To conclude, cis-decalinone 260, prepared earlier, was also subjected to the synthetic sequence, 
firstly being transformed into vinyl triflate 267 under kinetic conditions in 62% yield (Scheme 60). 
Successive iron-catalysed cross coupling, desilylation, acylation and diazotisation successfully 
delivered diazo 271 in a moderate yield over 4 steps. Once again we were pleased to observe a 
single diastereomeric product, novel lactone 272, in 66% yield from the standard one-pot C–H 
insertion/olefination sequence. Given the large number of related natural products it is possible that 
lactone 272 may be found to occur naturally, in due course. 
 
 
Scheme 60: Synthesis of lactone 272. 
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3.4  Conclusion 
 
The one-pot C–H insertion/olefination methodology has been successfully applied to a series of 
conformationally restricted cyclohexane derived diazo compounds. The differentiation of the 
equatorial and axial C–H bonds through conformational restriction has enabled the 
diastereoselective synthesis of a range of bicyclic α-methylene-γ-butyrolactones. The effect of 
conformationally restricting functional groups has been shown to not only modify the conformation 
of the cyclohexane rings, but also to provide a steric barrier to β-lactone side-product formation.  
 
The one-pot C–H insertion/olefination procedure was then extended to a series of more complex 
derivatives in order to generate eudesmanolide natural product frameworks. Two cis-decalin 
derived lactones 240 and 241 were synthesised, clarifying ambiguity within previous literature 
regarding their identity. The eudesmanolide natural product α-cyclocostunolide 256 has also been 
also synthesised. 
 
The exceptional levels of diastereoselectivity observed for the reactions of conformationally 
restricted α-diazophosphonoacetates complements existing literature precedent for related systems 
and should serve as a valuable synthetic tool for further applications in natural product and target 
based syntheses. 
 
Selected results described in this Chapter are contained within recently published articles (see 
Appendix V).121 
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Chapter 4 –  Rhodium(II)-catalysed cyclopropanations of 
allylic α-diazo(diethoxyphosphoryl)acetates 
4.1  Introduction 
 
Following the development of the rhodium(II)-catalysed C–H insertion reactions of α-
diazophosphonoacetates, it was envisioned that this work could be extended to encompass the 
rhodium(II)-catalysed cyclopropanation of allylic α-diazophosphonoacetates, shown in Scheme 61.  
 
 
Scheme 61: Proposed rhodium(II)-catalysed cyclopropanation of allylic α-diazophosphonoacetates 
273 to generate α-phosphoryl-3-oxabicyclo[3.1.0]hexanones 274. 
 
The α-phosphoryl-3-oxabicyclo[3.1.0]hexanone products 274 are members of a compound class 
known as donor-acceptor cyclopropanes and are seen as privileged structures due to the presence of 
the two electron-withdrawing substituents which create a push-pull effect with polarisation of the 
C–C bond.122 This distinctive zwitterionic relationship enables a wide variety of reactions to take 
place including: ring-openings, cycloadditions and rearrangements (Figure 58).123  
 
 
Figure 58: Modes of reactivity for donor-acceptor cyclopropanes.123 
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4.2  Rhodium(II)-catalysed cyclopropanations 
 
One of the first examples of a rhodium(II)-catalysed cyclopropanation was reported in 1976 by 
Teyssié and co-workers.124 This work focussed on the intermolecular reactions of acceptor-
substituted diazocarbaronyl compounds with simple olefins (Scheme 62). 
 
 
Scheme 62: Teyssié’s intramolecular rhodium(II)-catalysed cyclopropanations. 
 
Intramolecular rhodium(II)-catalysed cyclopropanations were first reported in 1985 by Kametani et 
al., as shown in Scheme 63.125 
 
 
Scheme 63: Kametani’s intramolecular rhodium(II)-catalysed cyclopropanation. 
 
To the best of our knowledge there are just 3 published examples of intramolecular 
cyclopropanations of α-diazophosphonoacetates; these examples are contained within one report, 
by Vandewalle, which was published in 1984 (one of these examples shown in Scheme 64).81a The 
reactions were performed using copper metal (30–60 eq.) to generate the intermediate carbenoid, 
with Rh2(OAc)4 stated to be ineffective as a catalyst for the same transformation. 
 
 
Scheme 64: Copper-mediated cyclopropanation of α-diazophosphonoacetates. 
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4.3  Aims and Objectives 
 
It was envisaged that α-phosphoryl-3-oxabicyclo[3.1.0]hexanones could be prepared via a 
rhodium(II)-catalysed intramolecular cyclopropanation reaction of allylic α-
diazophosphonoacetates. It was then planned to explore the scope of the reaction and demonstrate 
the effectiveness of the procedure through the synthesis of α-methylene-γ-butyrolactone natural 
products. 
 
Following the synthesis of the α-phosphoryl-3-oxabicyclo[3.1.0]hexanone 274 a transformation 
such as a ring-opening reaction, would generate phosphonolactones 282, which could then be 
exploited in a HWE olefination to deliver the α-methylene-γ-butyrolactone framework 283 
(Scheme 65).  
 
While this process would deliver the same type of products as the previously described C–H 
insertion methodology, a number of advantages to this cyclopropanation procedure were identified 
at the outset. Given that the cyclopropanation reaction is a cheletropic process,126 the olefin 
geometry preinstalled in the α-diazo(diethoxyphosphoryl)acetate precursors 273 should be 
transferred directly to the cyclopropane product 274, with just a single diastereomer expected. In 
the case of a subsequent nucleophilic ring-opening reaction, the stereochemical information should 
then be inverted during an SN2 process; therefore the ability to control olefin geometry at the sp2 
hybridised site in diazo compound 273 could be directly transferred to an sp3 centre in the ring-
opened product 283. 
 
 
Scheme 65: Stereoselectivity transfer via rhodium(II)-catalysed cyclopropanation/nucleophilic 
ring-opening sequence.  
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The cyclopropanation reaction results in the formation of two new C–C bonds, which must be on 
the same face. This provides a significant advantage over the C–H insertion reaction, in which a 
single C–C bond is formed, because it bestows a greater degree of diastereocontrol. For example, 
in the cyclopropanation of cyclic diazo precursors 284, the tricyclic product 285 should form the 
diastereomer in which two new C–C bonds are on the same face as the C–O bond, as shown in 
Scheme 66. This is based on consideration of the least strained diastereomer, which is thought to be 
cis-diasteromer 285. A subsequent nucleophilic  ring-opening reaction would selectively deliver a 
cis-fused bicyclic lactone product 286. 
 
This is a major advantage over the C–H insertion methodology, developed earlier, in which 
conformational restriction was found to be essential in order to furnish bicyclic rings 
diastereoselectively.  
 
 
Scheme 66: Selective formation of cis-bicyclic lactones via rhodium(II)-catalysed 
cyclopropanation/nucleophilic ring-opening sequence. 
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4.4  Scope and Limitations 
 
Our initial effort foccussed on the reaction of allyl alcohol-derived diazo compound 287b, which 
was treated with 2 mol% of Rh2(oct)4 in CH2Cl2 at 45 °C for 16 hours. Pleasingly, a single product 
was obtained and identified as the desired cyclopropane 287c in 78% yield. All spectroscopic data 
were consistent with those found in the literature.127 This result was interesting as earlier studies, 
performed by Vandewalle,81a stated that the rhodium(II)-catalysed intramolecular cyclopropanation 
of α-diazophosphonolactones was ineffective. 
 
 
Scheme 67: Rhodium(II)-catalysed intramolecular cyclopropanation of allyl α-
diazo(diethoxyphosphoryl)acetate 287c forming bicyclic lactone 287b. 
 
Accordingly, several allylic α-diazo(diethoxyphosphoryl)acetates were prepared in order to fully 
examine the scope of the cyclopropanation reaction. It was observed that our standard diazotisation 
conditions (LHMDS, −78 °C–RT, then addition of azide), developed for the C–H insertion 
methodology, led to poor yields of the allylic α-diazo(diethoxyphosphoryl)acetates in some cases, 
with the major by-product being the allylic alcohol, resulting from hydrolysis. Thankfully, it was 
found that adding DBU to a pre-mixed solution of the α-(diethoxyphosphoryl)acetate and azide 
substantially improved the yields (Scheme 68). Additionally, the purification process was much 
more facile than the previous procedure, simply requiring the reaction mixture to be filtered 
through a pad of Celite and silica, followed by chromatographic purification of the filtrate.  
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Scheme 68: Diazotisation of allylic α-phosphorylacetates. 
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4.4.1.  Aliphatic-substituted systems 
Our first efforts focussed on the use of olefins with aliphatic groups. Disappointingly, in the case of 
both E- and Z- (4:1 Z:E dr) crotyl alcohol-derived diazo compounds 288b and 289b, the starting 
material was not fully consumed following treatment with Rh2(oct)4. Using 1H NMR analysis of 
the unpurified reaction mixture, a trace amount of the desired cyclopropanes 288c and 289c was 
observed,§ alongside the water O–H insertion products 288d and 289d, respectively (Scheme 69), 
but none of the compounds were isolated for full characterisation. 
 
 
Scheme 69: Rhodium(II)-catalysed diazo decomposition of crotyl derivatives 288b and 289b. 
 
Next, E- and Z-hexenol derivatives 290b and 291b were prepared and treated with Rh2(oct)4 
(Scheme 70). Similarly to the previous crotyl examples, E-derivative 290b was not fully consumed, 
with the desired cyclopropane 290c again formed alongside the corresponding water O–H insertion 
product 290d.** In contrast, the Z-derivative 291b reacted well under the same conditions, with 
complete consumption of starting material, affording cyclopropane 291c as the sole product in 66% 
isolated yield, which was fully characterised. Lower steric hindrance may favour addition to the Z-
olefin. Interestingly, E-diene substrate 292b furnished allyl cyclopropane 292c in 48% yield under 
the same conditions, indicating that the incorporation of additional unsaturation is beneficial to the 
cyclopropanation process, offering E-olefins enhanced reactivity, possibly through additional 
charge stabilisation. 
                                                
§ Diagnostic 1H NMR signals: 288c, δ = 2.53 (dt, J = 10.2, J = 5.0, CHCH2O); 288d, δ = 4.51 (dd, J = 15.8, J 
= 6.7, OCHP); 289c, δ = 2.67 (ddd, J = 11.4, J = 7.6, J = 5.1, CHCH2O); 289d, δ = 4.50 (dd, J = 8.9, J = 7.0, 
OCHP). 
** Diagnostic 1H NMR signals: 290c, δ = 2.53 (dt, J = 10.3, J = 5.0, CHCH2O); 290d, δ = 4.51 (dd, J = 15.8, 
J = 6.8, OCHP). 
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Scheme 70: Rhodium(II)-catalysed diazo decomposition of hexenol-derivatives 290b–292b. 
 
Trisubstituted aliphatic substrates 293b, derived from prenol, and 294b, derived from geraniol, 
delivered the desired cyclopropanes 293c and 294c, respectively, in good yields and as single 
diastereomers (Scheme 71). It is thought that the additional substitution makes the olefin more 
electron-rich and hence more nucleophilic, leading to improved yields of the desired cyclopropanes 
and reduced by-product formation. The increased substitution may also enable greater stabilisation 
of the positive charge than the disubstituted olefins, potentially proceeding through a more SN1-like 
process (i.e. not cheletropic). However, given that single diastereomers were obtained, the 
cyclopropanation still appears to be concerted. 
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Scheme 71: Rhodium(II)-catalysed diazo decomposition of prenol and geraniol derivatives 293b 
and 294b. 
 
One of the key aims at the outset of this work was to synthesise cis-fused bicyclic α-methylene-γ-
butyrolactones via tricyclic phosphonates. As such, 2-cyclohexen-1-ol diazo derivative 295b was 
prepared and treated with Rh2(oct)4. Pleasingly, the desired tricyclic product 295c was formed, 
albeit in a disappointing 24% yield (Scheme 72).  
 
 
Scheme 72: Rhodium(II)-catalysed diazo decomposition of cyclohexenol derivative 295b. 
 
The major by-product, observed by 1H NMR analysis of the unpurified reaction mixture, was 
cyclohexenone 232. This is believed to arise from an initial C–H insertion reaction to form a β-
lactone 295d,128 which may then undergo a [2+2]-cycloreversion reaction, forming cyclohexenone 
232 and a phosphonoketene 300, which undergoes further reactions (Scheme 73). Given that the 
C–H bond in question is both allylic and α- to a heteroatom it therefore is not unreasonable that 
this appears to be a significant competing pathway for this class of diazo compound. 
 
 
Scheme 73: Proposed competing C–H insertion leading to β-lactone 295d and subsequent [2+2]-
cycloreversion to cyclohexenone 232. 
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4.4.2.  Aromatic-substituted systems 
 
Next, the procedure was extended to the use of cinnamyl alcohol-derived diazo compounds 296b–
298b (Scheme 74). Pleasingly, each of these substrates delivered the respective cyclopropanes 
296c–298c, with complete diastereocontrol and in good to excellent yield.  
 
   
Scheme 74: Rhodium(II)-catalysed intramolecular cyclopropanation of cinnamyl α-
diazo(diethoxyphosphoryl)acetates 296b–298b forming bicyclic lactones 296c–298c. 
 
The relative configuration of cyclopropane 296c was confirmed following the acquisition of a 
single crystal X-ray structure (Figure 59), and it is assumed that 297c and 298c have the same 
configuration based on similar diagnostic 1H NMR signals.†† 
 
           
Figure 59: Single crystal X-ray structure of cyclopropane 296c (CCDC: 1465173). Thermal 
ellipsoids set to 50% probability, shown in Olex2. 
                                                
†† Diagnostic 1H NMR signals:  
296c, δ = 2.81 (app. t, J = 6.1, CHAr), δ = 3.30 (app. dt, J = 10.6, J = 5.2, CHCH2O),  
297c, δ = 2.73 (app. t, J = 6.1, CHAr), δ = 3.24 (app. dt, J = 10.6, J = 5.2, CHCH2O), 
298c, δ = 2.71 (app. t, J = 6.0, CHAr), δ = 3.24 (app. dt, J = 10.7, J = 5.2, CHCH2O), 
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Following the success of these reactions it was decided to investigate cinnamyl derivatives that 
contain a 3,4-methylenedioxy unit, as this substructure is found in many natural products. The 
saturated substrate investigated during the C–H insertion methodology studies, compound 149b, 
was unsuccessful (Chapter 2, Scheme 39). It is thought that the oxygen lone pairs coordinate to the 
carbenoid centre, leading to an unproductive pathway (Scheme 75). It is proposed that the 
introduction of unsaturation will confer additional rigidity in the molecule, minimising the 
coordination of the oxygen lone pairs to the carbenoid, enabling the desired reaction to occur. 
 
 
Scheme 75: Proposed unproductive pathway following the formation of carbenoid 149d. 
 
Pleasingly, on reaction of diazo compound 299b under the standard Rh2(oct)4 conditions, the 
desired bicyclic lactone 299c was generated in excellent yield and with complete 
diastereoselectivity (Scheme 76). It was hoped that this compound could be further elaborated for 
the synthesis of α-methylene-γ-butyrolactone natural products containing the 3,4-methylenedioxy 
framework, the synthesis of which will be discussed later, in Section 4.6. 
 
 
Scheme 76: Rhodium(II)-catalysed intramolecular cyclopropanation of 3,4-
methylenedioxycinnamyl diazo compounds 299b. 
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4.5  Ring-opening reactions of cyclopropanes 
 
The opening of cyclopropane rings can be performed by many different types of reactions and in 
the case of donor/acceptor cyclopropanes (such as the α-phosphoryl-[3.1.0]-bicyclic lactones being 
studied here) there is the possibility of performing cycloadditions,129 rearrangements and direct 
ring-opening reactions including nucleophilic, electrophilic and reductive methods. There are many 
examples of nucleophilic ring-openings using sulfur,130 nitrogen,131 oxygen,132 carbon131,133 and 
halogen134 nucleophiles. Additionally, there have been various instances demonstrating reductive 
ring-openings using lithium in ammonia,135 samarium diiodide,136 and other reductants.137 
 
In fused bicyclic systems, steric and electronic factors govern the selectivity of nucleophilic and 
reductive ring-opening reactions, which often proceed with excellent regioselectivity with respect 
to which of the cyclopropane bonds is broken. For example, in the case of π-stabilised bicylic 
cyclopropane systems such as compound 301, Figure 60, the selectivity of this process is 
determined by the degree of orbital overlap of the cyclopropane C–C bond with the π-system of the 
adjacent carbonyl unit. The bond possessing the greatest degree of orbital overlap is that which is 
broken.138 In the case of model system 301 a nucleophilic ring-opening would see attack at one of 
the cyclopropane carbons β- to the carbonyl group, with electrons flowing towards the π-system. 
As such, bonds ‘a’ or ‘b’ could be broken, resulting in cyclopentanone 302 or cyclohexanone 303, 
respectively. In the majority of cases discussed within the literature, only bond ‘a’ is broken due to 
it having greater overlap with the carbonyl π* orbital, making the process regioselective. This 
selectivity has been observed in many of the aforementioned literature examples, as well as in ring-
opening reactions of aziridines.139 There have, however, been some recent examples in which the 
selectivity has been switched, with 6-membered rings formed in preference.133b  
 
  
Figure 60: Orbital interactions responsible for high regioselectivity in ring-opening reactions of 
carbonyl-containing bicyclic rings, showing C–C σ* and C=O π* orbitals. 
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4.5.1.  Initial studies into the ring-opening reactions of α-phosphoryl-3-
oxabicyclo[3.1.0]hexanones 
 
Initial efforts for the ring-opening reactions of α-phosphoryl-3-oxabicyclo[3.1.0]hexanone 
focussed on nucleophilic ring-openings of the ‘unsubstituted’ compound 287c. Pleasingly, 
treatment with sodium ethanethiolate delivered the desired ring-opened γ-lactone product 304 in an 
unoptimised 37% yield (Scheme 77), with complete diastereoselectivity, although the relative 
configuration could not be proven definitively based on the coupling constants (which were 
discussed earlier in Chapter 2, page 39). The reaction was also completely regioselective, with 
attack at cyclopropane CH2 leading to just a single C–C bond being broken.  
 
 
Scheme 77: Thiolate ring-opening of bicyclic lactone 287c. 
 
Pleasingly, the reaction of phenyl-substituted bicyclic lactone 296c with sodium ethanethiolate also 
furnished the desired product 305, although in just 19% isolated yield, but with excellent regio- and 
diastereocontrol (Scheme 78). 
 
 
Scheme 78: Thiolate ring-opening of bicyclic lactone 296c. 
 
 Next, the use of carbon nucleophiles was investigated. The formation of the cuprate from 
phenylmagnesium bromide was necessary (the Grignard by itself led to 1,2-addition), generating 
the desired product 306 in good yield (Scheme 79). This substrate is already accessible using the 
C–H insertion methodology, but demonstrates the potential for forming ring-opened products, 
which may be useful for more complex systems. 
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Scheme 79: Organocuprate ring-opening of bicyclic lactone 287c. 
 
Attention then turned to reductive ring-openings, which were first attempted using samarium(II) 
iodide;136 the treatment of phenyl-substituted cyclopropane 296c with a freshly prepared solution of 
SmI2 afforded lactone 306 in moderate unoptimised yield, but with complete regio- and 
diastereoselectivity (Scheme 80). 
 
 
Scheme 80: Samarium(II) iodide-mediated reductive ring-opening of cyclopropane 296c. 
 
These initial studies have demonstrated the propensity of α-phosphoryl-3-oxabicyclohexanones to 
undergo a variety of reactions, clearly exhibiting regioselective C–C bond breaking in ring-opening 
reactions. Initial studies into the development of a one-pot ring-opening/HWE reaction for the 
direct formation of α-methylene-γ-butyrolactones have proven challenging. 
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4.6  Natural product targets: (±)-savinin and (±)-gadain 
 
Following the successful synthesis of bicyclic lactone 299c, which contains the 3,4-
methylenedioxyphenyl unit, the synthesis of isomeric natural products savinin 174 (E-isomer, also 
known as hibalactone) and gadain 307 (Z-isomer, also known as isohibalactone), shown in Figure 
61, were attempted. The isolation of (−)-savinin was first reported in 1953 by Hartwell,95 although 
a thorough NMR assignment was not made until 1990.140 Studies have since revealed cytoxicity140 
as well as insecticidal141 and antiviral142 activities. (+)-Gadain was isolated separately in 1984 and 
found to isomerise to (+)-savinin in acidic solution.143 The synthesis of savinin and gadain has been 
performed previously, but not via cyclopropane intermediates.141,144 
 
Figure 61: Isomeric α-alkylidene-γ-butyrolactone natural products, (−)-savinin 174 and (+)-gadain 
307. 
 
It was anticipated that treatment of the bicyclic lactone 299c with SmI2 would deliver the ring-
opened phosphonolactone 149c, which could not be accessed using the C–H insertion methodology 
earlier (Chapter 2, Scheme 39). Gratifyingly, treatment of cyclopropane 299c with freshly prepared 
SmI2 generated the desired γ-lactone 149c in 38% yield, as a single diastereomer. Using conditions 
established during the earlier methodology studies, an HWE olefination was performed on lactone 
149c delivering a separable mixture of (±)-savinin 174 and (±)-gadain 307, in an overall 53% yield 
(1.9:1 174:307). The data for both natural products is in agreement with those found in the 
literature (see Appendix I for comparison tables and spectra).141 Isomerisation of gadain to savinin, 
the E-isomer, can be performed according to literature precedent.141,144a 
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Scheme 81: Synthesis of (±)-savinin and (±)-gadain. 
 
4.7  Natural product targets: (±)-peperomin E 
4.7.1.  Introduction 
 
Peperomins E and F, 308 and 309, respectively, were identified by Govindachari et al. in 1998 
following isolation from Peperomia dindigulensis, a succulent herb.145 Their structures, shown in 
Figure 62, were elucidated using typical spectroscopic techniques. Their absolute configuration 
was assigned by comparing their optical rotatory dispersion to that of peperomins A and C, which 
have known absolute stereochemistry. 
 
 
Figure 62: Lignan natural products peperomins E and F. 
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Peperomin E has been shown to possess a variety of biological activities including: antifeedant-
activity,145 cytotoxicity,146 inhibition of malignant lung tumour cells (IC50 = 1.93 µM),147 anti-
angiogenic activity,148 inhibition of cancer cell lines149 and anti-inflammatory activity.150  
 
To the best of our knowledge, prior to this research, there have been no reported syntheses of 
peperomin E. Three other lignans from the peperomin family: A, C and D, (310, 311 and 312 
respectively), have been previously synthesised, however.151 Peperomin A is a saturated analogue 
of peperomin E, whilst peperomins C and D are also saturated, they have different substitution 
patterns on the aromatic rings (Figure 63). 
 
 
Figure 63: Lignan natural products peperomins A, C and D. 
 
Peperomin A (and C, D) has been synthesised previously and enantioselectively using a chiral 
oxazolidinone auxiliary 313. Firstly, cinnamoyl-derived auxiliary 315, containing one of the 
requisite aryl units, was prepared. This was followed by installation of the second aryl unit via a 
copper-catalysed 1,4-addition of the corresponding Grignard reagent. As the aryl units are identical 
there were no diastereoselectivity issues. Next, enolate formation and trapping with iodide 317, 
delivered the desired α,γ-dicarbonyl compound 318 with excellent de. Reduction and cyclisation 
generated γ-lactone 319 in good yield. The synthesis of peperomin A 310 was completed following 
installation of the exocyclic methyl group in excellent de. Peperomins C and D were prepared by 
similar routes. 
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Scheme 82: First asymmetric total synthesis of (+)-peperomins A by Sibi and co-workers. 
 
4.7.2.  Retrosynthetic Analysis 
 
Two possible retrosynthetic strategies for (±)-peperomin E 308 were conceived (Scheme 83): one 
requiring a nucleophilic ring-opening of tertiary cyclopropane 321 and the other a reductive ring-
opening of quaternary cyclopropane 323.  
 
 
Scheme 83: Retrosynthetic analyses for peperomin E. Ar = 3-methoxy-4,5-
methylenedioxybenzene. 
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From the above retrosynthetic analyses it is clear that the two diazo substrates 321 and 323 are 
structurally related, and it was hoped that both would be accessible in order to attempt each route, 
although the latter approach was initially selected on the basis that the reductive ring-opening had 
already been successfully performed on related systems. 
 
The retrosynthetic approach to diazo compounds 320 and 322 is shown in Scheme 84. It was 
envisaged that both diazo compounds could be derived from cinnamate 326 as a common 
precursor. Diarylacrylate 327 could be constructed via a cross-coupling reaction between 
cinnamate 326 and aryl iodide 325, which each in turn could originate from the same 
commercially-available aldehyde 324. 
 
 
Scheme 84: Retrosynthetic strategy for diazo compounds 320 and 322. 
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4.7.3.  Model studies 
 
Prior to attempting the synthesis of the natural product target, it was decided to test an 
unsubstituted-phenyl analogue as a model system to confirm that the proposed synthesis of the 
extremely sterically hindered cyclopropane was achievable. Accordingly, diphenylacrylate 329 was 
prepared by utilising a double Heck arylation of ethyl acrylate 328, as reported by Chen and co-
workers.152 Subsequent DIBAL reduction, acylation and diazotisation generated key substrate 332, 
which was then subjected to the standard Rh2(oct)4 conditions, and pleasingly, furnished the 
desired quaternary cyclopropane 333, in 51% isolated yield (Scheme 85). The modest yield was 
attributed to the formation of aldehyde 334, which was considered to arise from β-lactone 
formation and subsequent a [2+2]-cycloreversion reaction, as proposed earlier (see Scheme 73). 
Cyclopropane 333 was then taken forward and reacted with SmI2 in THF, delivering 
phosphonolactone 335. To conclude, a HWE olefination generated the analogue of peperomin E, 
α-methylene-γ-butyrolactone 336, as a fully characterised product in a reasonable unoptimised 
yield. 
 
 
Scheme 85: Model studies for peperomin E. 
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4.7.4.  Total synthesis of (±)-peperomin E 
 
Having completed the model studies, the synthesis of peperomin E commenced with the efficient 
synthesis of cinnamate 326, via Wittig olefination with 
(carbethoxymethylene)triphenylphosphorane 337 and aldehyde 324. The synthesis of iodide 325 
then began by treating aldehyde 324 with concentrated nitric acid,153 delivering the desired 
nitrobenzene 338 via nitrodeformylation. Penta-substituted nitrobenzene side-product 339 was also 
isolated. The desired tetra-substituted nitrobenzene was then reduced with Pd on carbon in the 
presence of ammonium formate delivering aniline 340,154 before diazotisation with tert-butyl nitrite 
and fluoroboric acid generated aryldiazonium salt 341.155 Diazonium salts can be tailored to be less 
thermally sensitive by utilising tetrafluoroborate counterions,156 but even so, the salt was swiftly 
treated with KI, completing the synthesis of aryl iodide 325. 
 
 
Scheme 86: Divergent synthesis of cinnamate 326 and iodide 325 from aldehyde 324. 
 
With iodide 325 and cinnamate 326 in-hand, the cross-coupling was investigated. Two Heck 
approaches were available to us: 1) diarylation of ethyl acrylate 328 or 2) monoarylation of 
cinnamate 326. Both were performed to assess the most efficient route (Scheme 87). The 
palladium-catalysed double Heck reaction was tested first, using conditions developed by Chen et 
al.,152 and this delivered the desired diarylacrylate 327, albeit in a modest 35% yield. In contrast, 
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the monoarylation of cinnamate 326 using conditions, developed by Moreno-Mañas,157 also using 
iodide 325, supplied diarylacrylate 327 in a much more practical 87% yield. 
 
 
Scheme 87: Alternative approaches to diarylacrylate 327. 
 
4.7.4.1.  Alternative C–H insertion route 
 
Prior to attempting the cyclopropanation route, we decided that an alternative approach, using the 
C–H insertion methodology developed earlier, could first be attempted, given that we had a 
sufficient quantity of diarylacrylate 327 in-hand. This route (Scheme 88) was speculative, as 
previous attempts to incorporate the 3,4-methylenedioxybenzene group were unsuccessful. 
 
 
Scheme 88: Proposed C–H insertion route towards peperomin E via phosphonate 343. 
 
Following the preparation of diarylacrylate 327, a simple DIBAL reduction and T3P-mediated 
acylation afforded phosphonate 345, which was then was reduced under a hydrogen atmosphere 
using Pd on carbon, forming saturated phosphonate 346 in 61% yield (Scheme 89).  Unfortunately, 
side-product 347 was formed in 29% yield, arising from an unforeseen π-allyl formation, β-hydride 
elimination and olefin reduction sequence. Even so, the diazotisation of phosphonate 346 
successfully generated the key diazo compound 342 in 51% yield. Following treatment of diazo 
compound 342 with Rh2(oct)4 in CH2Cl2 for 18 h, the solution had turned from the characteristic 
green colour to a red-brown. As anticipated, the desired C–H insertion product 343 was not 
observed by either TLC or 1H NMR analysis, however, the starting material did remain. Evidently, 
the presence of the 3,4-methylenedioxy units appears to be detrimental to the catalytic process, 
probably due to coordination of the oxygen lone pairs to the rhodium carbenoid. 
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Scheme 89: Attempted synthesis of peperomin E via a C–H insertion approach.  
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4.7.4.2.  Cyclopropanation route 
 
Continuing with the originally designed cyclopropanation route, phosphonate 345 was diazotised, 
furnishing diazo compound 322 in excellent yield. We were then in a position to test the key 
rhodium(II)-catalysed cyclopropanation step. The treatment of diazo compound 322 under the 
standard Rh2(oct)4 conditions delivered the desired bicyclic lactone 323, although in just 35% 
yield. A modest improvement could be made, with a 41% isolated yield, by switching to the more 
bulky Rh2(tpa)4 catalyst. Then, samarium(II) iodide-mediated reductive ring-opening delivered the 
monocyclic lactone 343 in good yield. 
 
 
Scheme 90: Preparation of diazo precursor 322 for the Rh(II)-catalysed cyclopropanation and 
Sm(II) iodide-mediated ring-opening steps towards peperomin E. 
 
Finally, a facile HWE olefination of phosphonate 343 afforded (±)-peperomin E 308 in excellent 
yield (Scheme 91), completing its first known synthesis. Spectroscopic data were in accord with 
those reported in the isolation paper (see Appendix I for comparison tables and spectra).145 
 
 
Scheme 91: Horner–Wadsworth–Emmons olefination delivering (±)-peperomin E 308. 
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4.8  Conclusions 
 
A simple procedure has been developed for the efficient synthesis of α-phosphoryl-3-
oxabicyclo[3.1.0]hexanones, the first successful examples of a rhodium(II)-catalysed 
cyclopropanation route to this class of compound. A variety of aliphatic and aromatic substituted 
systems were prepared, exploring the effects of substitution on reaction outcome. As hoped, these 
systems have been shown to perform well in ring-opening reactions, in line with other donor-
acceptor substituted cyclopropanes. The nucleophilic and reductive ring-opening reactions have 
thus far generated products with complete regio- and diastereoselectivity. 
 
The methodology was successfully applied to the synthesis of three α-methylene-γ-butyrolactone 
natural products: (±)-savinin 174, (±)-gadain 307 and notably, the first total synthesis of (±)-
peperomin E 308. 
 
4.9  Future Work 
 
Following the successful synthesis of peperomin E via the reductive ring-opening of quaternary 
bicyclic lactone 323, a natural extension of the work would be to perform the synthesis using the 
second proposed route; the nucleophilic ring-opening of tertiary cyclopropane 321, discussed 
earlier (see, Scheme 83). Preliminary work towards this goal was performed with the requisite 
bicyclic lactone 321 synthesised from diazo compound 320 in good yield (Scheme 92). An ensuing 
ring-opening with the corresponding aryl unit would afford γ-lactone 343, completing the formal 
synthesis, but there was insufficient time to complete this sequence. 
 
 
Scheme 92: Rhodium(II)-catalysed cyclopropanation and proposed nucleophilic ring-opening route 
towards peperomin E. 
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nitrogen and sulfur would also be valuable. The phosphonate functional group provides a useful 
synthetic handle for the installation of olefins, potentially expanding the range of heterocyclic 
products that could be prepared. The push-pull nature of the donor-acceptor moiety also allows the 
possibility of performing cycloadditions and annulations (Scheme 93). These reactions need not be 
limited to bicyclic lactones, with the synthesis of the analogous cyclopentanones and γ-lactams also 
appearing to be feasible.  
 
 
Scheme 93: Proposed elaboration of α-phosphoryl-3-oxabicyclo[3.1.0]hexanones. 
 
In addition to the above proposed work, the scope of the rhodium(II)-catalysed cyclopropanation 
reaction could be further examined for the purpose of identifying additional synthetically valuable 
frameworks. Furthermore, in line with previous precedent within the Taylor group, the 
development of tandem processes and combining multiple aspects of these reactions would also 
serve to increase the impact of these procedures, with the development of a one-pot ring-opening 
and HWE olefination procedure for the synthesis of α-methylene-γ-butyrolactones, being the 
ultimate goal. 
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Chapter 5 –  Experimental 
5.1  General Experimental Details 
 
Except where stated, all reagents were purchased from commercial sources and used without 
further purification. Except where stated, all experimental procedures were carried out under an 
atmosphere of argon or nitrogen. Anhydrous CH2Cl2, toluene and DMF were obtained from an 
Innovative Technology Inc. PureSolv® solvent purification system. Anhydrous THF was obtained 
by distillation over sodium benzophenone ketyl immediately before use. 1H NMR, 13C NMR and 
31P NMR spectra were recorded on a JEOL ECX400 or JEOL ECS400 spectrometer, operating at 
400 MHz, 100 MHz and 162 MHz respectively. All spectral data were acquired at 295 K. Chemical 
shifts (δ) are quoted in parts per million (ppm). The residual solvent peak, δH 7.26 and δC 77.0 for 
CDCl3, δH 2.50 and δC 39.5 for DMSO-d6 and δH 7.16 and δC 128.1 for benzene-d6 was used as a 
reference. Coupling constants (J) are reported in Hertz (Hz) to the nearest 0.1 Hz. The multiplicity 
abbreviations used are: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Signal 
assignment was achieved by analysis of DEPT, COSY, NOESY, HMBC and HSQC experiments 
where required. Spectra were processed using ‘iNMR’ software which can be obtained free of 
charge online. Infrared (IR) spectra were recorded on either a ThermoNicolet IR-100 spectrometer 
with NaCl plates as a thin film dispersed from either CH2Cl2 or CDCl3, or a PerkinElmer UATR 
Two spectrometer. Mass-spectra were obtained by the University of York Mass Spectrometry 
Service, using electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI) on 
a Bruker Daltonics, Micro-tof spectrometer. Melting points were determined using Gallenkamp 
apparatus and are uncorrected. Thin layer chromatography was carried out on Merck silica gel 
60F254 pre-coated aluminium foil sheets and were visualised using UV light (254 nm) and stained 
with basic aqueous potassium permanganate. Flash column chromatography was carried out using 
slurry packed Fluka silica gel (SiO2), 35–70 µm, 60 Å, under a light positive pressure, eluting with 
the specified solvent system. No issues associated with instability or decomposition of the azide 
reagents or diazo products were observed, with no special handling precautions required. 
Numbering schemes for compounds refer to NMR assignments not to compound naming. 
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General procedure A: Esterifications using T3P 
 
 
To a stirred solution of alcohol A (8.00 mmol) in toluene (40 mL) under an atmosphere of argon, 
was added sequentially DEPAA (8.40 mmol, 1.05 eq.), DIPEA (20.8 mmol, 2.6 eq.) and T3P (10.4 
mmol, 1.3 eq., 50% w/w solution in EtOAc/THF). The solution was stirred at RT for 1–4 h after 
which time it was diluted with water (50 mL) and extracted with EtOAc (3 × 100 mL) followed by 
sequential washing of the combined organic extracts with 10% aq. HCl (50 mL), sat. aq. NaHCO3 
(50 mL) and brine (50 mL). The organic extract was then dried over MgSO4 and concentrated in 
vacuo, affording the α-(diethoxyphosphoryl)acetate product B, which was used without further 
purification. 
General procedure B: Diazotisation reactions using LHMDS or NaH 
 
 
To a stirred solution of α-(diethoxyphosphoryl)acetate B (5.0 mmol) in THF (25 mL, 5 mL/mmol), 
cooled to −78 °C under an atmosphere of argon, was added LHMDS (6.0 mmol, 1.2 eq., 1.0 M 
solution in THF) or NaH (6.0 mmol, 1.2 eq., 60% dispersion in mineral oil).  The solution was 
allowed to warm at RT and stirred for 10 mins, after which time p-ABSA or DBSA (6.0 mmol, 1.2 
eq.) was added to the solution. After stirring for 1 h at RT the mixture was diluted with diethyl 
ether (100 mL) and water (25 mL) prior to extraction with diethyl ether (3 × 50 mL). The combined 
organic extracts were washed with sat. aq. NaHCO3 (2 × 25 mL), dried over MgSO4, concentrated 
in vacuo and purified by column chromatography affording the α-
diazo(diethoxyphosphoryl)acetate product C. 
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General procedure C: Diazotisation reactions using DBU 
 
 
To a stirred solution of α-(diethoxyphosphoryl)acetate B (5.0 mmol) and p-ABSA or DBSA (7.5 
mmol, 1.5 eq.) in CH2Cl2 (50 mL, 10 mL/mmol) cooled to 0 °C under an atmosphere of argon, was 
added DBU (7.5 mmol, 1.5 eq.) dropwise. The solution was stirred overnight with warming at RT, 
after which time the mixture was filtered through a pad of Celite and silica. The filtrate was 
concentrated in vacuo then purified by column chromatography affording the α-
diazo(diethoxyphosphoryl)acetate product C. 
General procedure D: One-pot Rh(II)-catalysed C-H insertion/olefination (CH2Cl2 
with THF switch) 
 
 
To an oven dried sealable tube containing α-diazo(diethoxyphosphoryl)acetate C (0.200 mmol) 
flushed with argon was added CH2Cl2 (4.0 mL) followed by Rh2(oct)4 or Rh2(esp)2 (2 or 5 mol%). 
The solution was stirred at 45 °C for 20 h and then concentrated in vacuo. The residue was diluted 
with THF (4.0 mL) and cooled to 0 °C prior to the addition of KOBu-t (0.9, 1.2 or 1.5 equiv.) 
which was stirred at 0 °C for 60 mins and then cooled to −78 °C. Aldehyde (2.0, 5.0 or 10.0 equiv.) 
was added to the solution and stirred for 15 mins at −78 °C and a further 2 h at either 0 °C, RT or 
reflux. The solution was quenched with sat. aq. NH4Cl (10 mL) and then diluted with CH2Cl2 (20 
mL). The organic layer was separated and the aqueous extracted with EtOAc (2 × 20 mL). The 
organic extracts were dried over Na2SO4, concentrated in vacuo and purified by column 
chromatography affording the α-methylene/alkylidene-γ-butyrolactone product D. 
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General procedure E: One-pot Rh(II)-catalysed C-H insertion/olefination (CH2Cl2) 
 
 
 
To an oven dried sealable tube containing α-diazo(diethoxyphosphoryl)acetate C (0.200 mmol) 
flushed with argon was added CH2Cl2 (4.0 mL) followed by Rh2(oct)4 or Rh2(esp)2 (2 or 5 mol%). 
The solution was stirred at 45 °C for 20 h. The solution was cooled to 0 °C prior to the addition of 
KOBu-t (0.9, 1.2 or 1.5 equiv.) which was stirred at 0 °C for 60 mins and then cooled to −78 °C. 
Aldehyde (2.0, 5.0 or 10.0 equiv.) was added to the solution and stirred for 15 mins at −78 °C and a 
further 2 h at either 0 °C, RT or reflux. The solution was quenched with sat. aq. NH4Cl (10 mL) 
and then diluted with CH2Cl2 (20 mL). The organic layer was separated and the aqueous extracted 
with EtOAc (2 × 20 mL). The combined organic extracts were dried over Na2SO4, concentrated in 
vacuo and purified by column chromatography affording the α-methylene/alkylidene-γ-
butyrolactone product D. 
General procedure F: Rh(II)-catalysed cyclopropanation 
 
 
 
To an oven dried sealable tube containing α-diazo-α-(dialkoxyphosphoryl)acetate E (0.200 mmol) 
flushed with argon was added CH2Cl2 (4.0 mL) followed by Rh2(oct)4 (2 mol%). The solution was 
stirred at 45 °C for 20 h and then concentrated in vacuo. The residue was purified by column 
chromatography affording the 3-oxabicyclo[3.1.0]hexan-2-one product F. 
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Preparation of samarium(II) iodide in THF (~0.1 M) 
 
To an oven dried 100 mL one-neck RBF equipped with oven dried Teflon-coated magnetic stirrer 
bar, was added samarium metal (825 mg, 6.50 mmol, 99.9% REO (Rare Earth Oxide basis), 
powder, Strem). [The samarium appeared as silvery/grey and metallic at this point.] The flask was 
tightly sealed with a suba-seal and wrapped in Parafilm®, then purged with argon (balloon) for 10 
mins. This was stirred under a positive pressure of argon and stirred at medium to high speed for 16 
h. [The samarium appeared as a fine black powder at this point (A).] THF (22.5 mL) was added, 
followed by iodine (698 mg, 2.75 mmol) dissolved in THF (5 mL). [The solution immediately 
turned from a black suspension to an orange/brown suspension (B).] The suba-seal was again 
wrapped with Parafilm® and stirring was continued for 2 h. [The mixture turned from 
orange/brown to green then to dark blue, almost black, typically within the first 5–15 mins (C–F).] 
The solution of SmI2 (~0.1 M) was allowed to settle prior to use. 
See images below for colour changes. 
 
    
A                                                   B                                                    C 
 
   
D                                                   E                                                    F 
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5.2  Reaction procedures and compound characterisations 
5.2.1.  Chapter 2 
5.2.1.1.  Preparation of α-methylene-γ-butyrolactones 
 
Experimental procedures and full characterisation data are provided for all novel compounds. 
Literature compounds are not reported, but were prepared according to the available procedures, 
where provided, or adapted from similar procedures. 
Phenethyl 2-(diethoxyphosphoryl)acetate (116a) 
 
 
 
Synthesised using general procedure A with phenethyl alcohol 116 (977 mg, 8.00 mmol), toluene 
(40 mL), DEPAA (1.35 mL, 8.40 mmol), DIPEA (3.62 mL, 20.8 mmol) and T3P (6.62 g, 10.4 
mmol, 50% w/w solution in EtOAc) affording the title compound 116a as a yellow oil (2.40 g, 
100%). No further purification was required; Rf 0.34 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2984s, 1738s, 1269m, 1052m, 1025m; δH (400 MHz, CDCl3) 1.31 (6 H, td, J = 7.1, J = 0.5, H-4), 
2.96 (2 H, t, J = 7.2, H-6), 2.96 (2 H, d, J = 21.6, H-2), 4.13 (4 H, dq, J = 8.3, J = 7.1, H-3), 4.35 (2 
H, t, J = 7.2, H-5), 7.20–7.25 (3 H, m, H-8/9,10), 7.28–7.33 (2 H, m, H-8/9); δC (100 MHz, CDCl3) 
16.3 (d, J = 6.2, C-4), 34.3 (d, J = 134.3, C-2), 34.8 (C-6), 62.6 (d, J = 6.4, C-3), 66.0 (C-5), 126.6 
(C-10), 128.5 (C-9), 128.8 (C-8), 137.4 (C-7), 165.7 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.2; 
HRMS (ESI+): Found: 323.1020; C14H21NaO5P (MNa+) Requires 323.1019 (−0.3 ppm error), 
Found: 301.1200; C14H22O5P (MH+) Requires 301.1199 (−0.1 ppm error). 
Lab notebook reference: MGL/02/55 
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Phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (116b) 
 
 
 
Synthesised using general procedure B with phenethyl 2-(diethoxyphosphoryl)acetate 116a (2.39 g, 
7.96 mmol), THF (40 mL), LHMDS (9.55 mL, 9.55 mmol, 1.0 M solution in THF) and p-ABSA 
(2.29 g, 9.55 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded the title 
compound 116b as a golden yellow oil (1.42 g, 55%); Rf 0.48 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 2984m, 2925m, 2129s, 1709s, 1280s, 1022s; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 
7.1, J = 0.7, H-4), 2.97 (2 H, t, J = 6.9, H-6), 4.04–4.23 (4 H, m, H-3), 4.41 (2 H, t, J = 6.9, H-5), 
7.19–7.26 (3 H, m, H-8/9,10), 7.28–7.34 (2 H, m, H-8/9); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-
4), 35.0 (C-6), 53.8 (d, J = 226.7, C-2), 63.5 (d, J = 5.9, C-3), 65.9 (C-5), 126.6 (C-10), 128.4 (C-
9), 128.8 (C-8), 137.2 (C-7), 163.2 (d, J = 12.3, C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): 
Found: 349.0921; C14H19N2NaO5P (MNa+) Requires 349.0929 (2.4 ppm error), Found: 327.1100; 
C14H20N2O5P (MH+) Requires 327.1110 (3.2 ppm error). 
Lab notebook reference: MGL/01/03, 02/56 
Diethyl ((3SR,4RS)-2-oxo-4-phenyltetrahydrofuran-3-yl)phosphonate (116c)  
 
 
 
To an oven dried sealable tube containing phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 116b 
(51 mg, 0.160 mmol) flushed with argon was added CH2Cl2 (3.2 mL) followed by Rh2(oct)4 (6.1 
mg, 7.8 µmol). The solution was stirred at 45 °C for 23 h. Concentration in vacuo and purification 
by column chromatography (1:1 petrol:EtOAc) afforded the title compound 116c as a colourless oil 
that crystallised on standing (24 mg, 51%); Rf 0.25 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
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2984w, 2912w, 1775s, 1253w, 1205m; m.p. 73–77 °C; δH (400 MHz, CDCl3) 1.26 (3 H, td, J = 7.1, 
J = 0.5, H-6/6’), 1.31 (3 H, td, J = 7.1, J = 0.5, H-6/6’), 3.16 (1 H, dd, J = 23.8, J = 5.9, H-2), 4.00–
4.26 (5 H, m, H-3,5,5’), 4.35 (1 H, dd, J = 9.1, J = 5.1, H-4), 4.77 (1 H, dd, J = 9.1, J = 7.8, H-4), 
7.23–7.27 (2 H, m, H-8), 7.28–7.33 (1 H, m, H-10), 7.34–7.39 (2 H, m, H-9); δC (100 MHz, 
CDCl3) 16.2 (d, J = 6.2, C-6/6’), 16.3 (d, J = 6.1, C-6/6’), 43.5 (d, J = 2.1, C-3), 47.2 (d, J = 140.4, 
C-2), 63.1 (d, J = 6.9, C-5/5’), 63.8 (d, J = 6.6, C-5/5’), 73.7 (d, J = 6.8, C-4), 126.7 (C-8), 128.0 
(C-10), 129.2 (C-9), 140.2 (d, J = 7.9, C-7), 171.6 (d, J = 2.9, C-1); δP (162 MHz, CDCl3) 19.8; 
HRMS (ESI+): Found: 321.0855; C14H19NaO5P (MNa+) Requires 321.0862 (2.4 ppm error), Found: 
299.1035; C14H20O5P (MH+) Requires 299.1043 (2.5 ppm error). 
Lab notebook reference: MGL/01/04, 01/05 
 
Note: The 1H NMR data of compound 116c match those reported158 with the exception of the H-3 
resonance: 4.00−4.26  (5 H, m, H-3,5a,5b) [lit. 3.65 (dd, J = 6.5 Hz, 3JPH = 6.0 Hz, 1H, H-3)]. In 
view of the fact that the X-ray structure of 116c was solved it seems likely that there is an error in 
the previously reported data. 
(SR)-3-Methylene-4-phenyldihydrofuran-2(3H)-one (116d) 
 
 
 
Synthesised using general procedure E with phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 116b 
(71 mg, 0.218 mmol), CH2Cl2 (4.4 mL), Rh2(oct)4 (3.4 mg, 4.4 µmol), KOBu-t (29.3 mg, 0.262 
mmol) and paraformaldehyde (13.1 mg, 0.436 mmol). Purification by column chromatography (5:1 
petrol:EtOAc) afforded the title compound as a colourless oil (28 mg, 74%); Rf 0.52 (4:1 
petrol:EtOAc); νmax (thin film)/cm-1 2919s, 1763s, 1108s, 1018s; δH (400 MHz, CDCl3) 4.21–4.31 
(2 H, m, H-3,4), 4.68–4.77 (1 H, m, H-4), 5.49 (1 H, d, J = 2.7, H-5b), 6.39 (1 H, d, J = 3.1, H-5a), 
7.21–7.25 (2 H, m, H-7), 7.29–7.34 (1 H, m, H-9), 7.35–7.41 (2 H, m, H-8); δC (100 MHz, CDCl3) 
45.6 (C-3), 72.7 (C-4), 124.0 (C-5), 127.8 (C-7/8/9), 127.8 (C-7/8/9) 129.2 (C-7/8/9), 138.8 (C-
2/6), 139.5 (C-2/6), 170.1 (C-1); HRMS (ESI+): Found: 197.0571; C11H10NaO2 (MNa+) Requires 
197.0578 (3.6 ppm error), Found: 175.0752; C11H11O2 (MH+) Requires 175.0759 (3.8 ppm error). 
Lab notebook reference: MGL/03/03, 01/10 
Obtained data in accord with reported literature.159 
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4-Methoxyphenethyl 2-(diethoxyphosphoryl)acetate (117a) 
 
 
 
Synthesised using general procedure A with 4-methoxyphenethyl alcohol 117 (3.00 g, 19.7 mmol), 
toluene (100 mL), DEPAA (3.32 mL, 20.7 mmol), DIPEA (8.93 mL, 51.3 mmol) and T3P (16.3 g, 
25.6 mmol, 50% w/w solution in THF) affording the title compound 117a as a yellow oil (6.53 g, 
100%). No further purification was required; Rf 0.21 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
3419w, 2937s, 1709s, 1491m, 1229s, 1098w, 1011s, 955w; δH (400 MHz, CDCl3) 1.32 (6 H, td, J 
= 7.1, J = 0.5, H-4), 2.89 (2 H, t, J = 7.2, H-6), 2.95 (2 H, d, J = 21.6, H-2), 3.78 (3 H, s, H-11), 
4.13 (4 H, dq, J = 8.2, J = 7.1, H-3), 4.31 (2 H, t, J = 7.2, H-5), 6.84 (2 H, d, J = 8.7, H-9), 7.14 (2 
H, d, J = 8.7, H-8); δC (100 MHz, CDCl3) 16.3 (d, J = 6.3, C-4), 34.0 (C-6), 34.3 (d, J = 134.2, C-
2), 55.2 (C-11), 62.6 (d, J = 6.2, C-3), 66.2 (C-5), 113.9 (C-9), 129.4 (C-7), 129.8 (C-8), 158.7 (C-
10), 165.9 (d, J = 6.3, C-1); δP (162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 353.1117; 
C15H23NaO6P (MNa+) Requires 353.1124 (2.2 ppm error), Found: 331.1302; C15H24O6P (MH+) 
Requires 331.1305 (0.9 ppm error). 
Lab notebook reference: MGL/01/16 
O
O
P O
O
O
7
8
9
10
65
1
2
3
4
117a117
OH T3P
DIPEA
DEPAA
PhMe
OMe OMe11
 132
4-Methoxyphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (117b) 
 
 
 
Synthesised using general procedure B with 4-methoxyphenethyl 2-(diethoxyphosphoryl)acetate 
117a (3.30 g, 10.0 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) 
and p-ABSA (2.88 g, 12.0 mmol). Purification by column chromatography (2:1 petrol:EtOAc) 
afforded the title compound 117b as a pale yellow oil (2.00 g, 56%); Rf 0.43 (1:1 petrol:EtOAc); 
νmax (thin film)/cm-1 3434m, 2939s, 2794s, 2097s, 1682s, 1491m, 1261m, 1230w, 1007w, 964w; δH 
(400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.8, H-4), 2.90 (2 H, t, J = 6.9, H-6), 3.78 (3 H, s, H-
11), 4.04–4.22 (4 H, m, H-3), 4.36 (2 H, t, J = 6.9, H-5), 6.83 (2 H, d, J = 8.8, H-9), 7.12 (2 H, d, J 
= 8.8, H-8); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 34.2 (C-6), 53.7 (d, J = 226.0, C-2), 55.2 
(C-11) 63.5 (d, J = 5.6, C-3), 66.1 (C-5), 113.9 (C-9), 129.2 (C-7), 129.8 (C-8), 158.3 (C-10), 
163.2 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 379.1011; 
C15H21N2NaO6P (MNa+) Requires 379.1029 (4.8 ppm error), Found: 357.1196; C15H22N2O6P 
(MH+) Requires 357.1210 (4.0 ppm error). 
Lab notebook reference: MGL/01/18 
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Diethyl ((3SR,4RS)-4-(4-methoxyphenyl)-2-oxotetrahydrofuran-3-yl)phosphonate 
(117c) 
 
 
 
To an oven dried sealable tube containing 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (62 mg, 0.174 mmol) flushed with argon was added CH2Cl2 (3.5 
mL) followed by Rh2(esp)2 (11.0 mg, 14.0 µmol). The solution was stirred at 45 °C for 23 h. 
Concentration in vacuo and purification by column chromatography (1:1 petrol:EtOAc) afforded 
the title compound 117c as a colourless oil (67 mg, 64%); Rf 0.26 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 3412s, 2937s, 2870s, 2796w, 1748s, 1588w, 1493m, 1233m, 1162w, 1011m, 959w; δH 
(400 MHz, CDCl3) 1.25 (3 H, td, J = 7.1, J = 0.5, H-6/6’), 1.30 (3 H, td, J = 7.1, J = 0.5, H-6/6’), 
3.10 (1 H, dd, J = 23.8, J = 6.2, H-2), 3.78 (3 H, s, H-11), 3.95–4.24 (5 H, m, H-3,5), 4.28 (1 H, dd, 
J = 9.1, J = 5.3, H-4), 4.72 (1 H, dd, J = 9.1, J = 7.8, H-4), 6.87 (2 H, d, J = 8.7, H-9), 7.15 (2 H, d, 
J = 8.7, H-8); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-6/6’), 16.3 (d, J = 6.2, C-6/6’), 42.7 (d, J = 
2.2, C-3), 47.3 (d, J = 140.4, C-2), 55.3 (C-11), 62.9 (d, J = 6.8, C-5/5’), 63.7 (d, J = 6.4, C-5/5’), 
73.8 (d, J = 7.0, C-4), 114.5 (C-9), 127.7 (C-8), 132.0 (d, J = 7.8, C-7), 159.1 (C-10), 171.6 (d, J = 
2.7, C-1); δP (162 MHz, CDCl3) 19.9; HRMS (ESI+): Found: 351.0961; C15H21NaO6P (MNa+) 
Requires 351.0968 (1.9 ppm error), Found: 329.1160; C15H22O6P (MH+) Requires 329.1149 (−3.6 
ppm error). 
Lab notebook reference: MGL/01/19  
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4-Methoxyphenethyl 2-(diethoxyphosphoryl)-2-hydroxyacetate (117d) 
 
 
 
To a solution of 4-methoxyphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 117b (75.0 mg, 0.210 
mmol) in CH2Cl2 (40 mL) in a 100 mL rbf, fitted with a reflux condenser flushed with argon was 
added Rh2(oct)4 (3.3 mg, 4.2 µmol). The solution was stirred at 45 °C for 24 h. Concentration in 
vacuo and purification by column chromatography (1:2 petrol:EtOAc) afforded the title compound 
117d as a colourless oil (37 mg, 51%); Rf 0.17 (1:2 petrol:EtOAc); νmax (thin film)/cm-1 3272br, 
2983w, 2845w, 1748s, 1613w, 1514s, 1246s, 1178w, 1101m, 1023s, 975m; δH (400 MHz, CDCl3) 
1.32 (6 H, t, J = 7.1, H-4,4’), 2.95 (2 H, t, J = 7.2, H-6), 3.25 (1 H, br s, OH), 3.78 (3 H, s, H-11), 
4.11–4.23 (4 H, m, H-3), 4.44 (2 H, t, J = 7.2, H-5), 4.52 (1 H, d, J = 15.7, H-2), 6.84 (2 H, d, J = 
8.7, H-9), 7.15 (2 H, d, J = 8.7, H-8); δC (100 MHz, CDCl3) 16.4 (d, J = 5.9, C-4,4’), 34.0 (C-6), 
55.2 (C-11), 63.5 (d, J = 6.8, C-3/3’), 63.8 (d, J = 6.8, C-3/3’), 67.3 (C-5), 68.8 (d, J = 154.8, C-2), 
114.0 (C-9), 128.9 (C-7), 129.9 (C-8), 158.5 (C-10), 169.5 (C-1); δP (162 MHz, CDCl3) 16.1; 
HRMS (ESI+): Found: 369.1064; C15H23NaO7P (MNa+) Requires 369.1074 (2.5 ppm error). 
Lab notebook reference: MGL/02/50B 
(SR)-4-(4-Methoxyphenyl)-3-methylenedihydrofuran-2(3H)-one (117e) 
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (68 mg, 0.191 mmol), CH2Cl2 (3.8 mL), Rh2(oct)4 (3.0 mg, 3.8 
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µmol), THF (3.8 mL), KOBu-t (32.1 mg, 0.287 mmol) and paraformaldehyde (11.5 mg, 0.382 
mmol). Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compound 
117e as a colourless oil (30 mg, 71%); Rf 0.30 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 3456s, 
2914m, 2872s, 2795s, 1740s, 1587m, 1491s, 1273w, 1233m, 1163w, 1094w, 1016w, 821w; δH 
(400 MHz, CDCl3) 3.81 (3 H, s, H-10), 4.16–4.24 (2 H, m, H-3,4), 4.64–4.74 (1 H, m, H-4), 5.46 
(1 H, d, J = 2.7, H-5b), 6.36 (1 H, d, J = 3.0, H-5a), 6.90 (2 H, d, J = 8.7, H-8), 7.14 (2 H, d, J = 
8.7, H-7); δC (100 MHz, CDCl3) 45.0 (C-3), 55.3 (C-10), 72.9 (C-4), 114.5 (C-8), 123.7 (C-5), 
129.0 (C-7) 131.3 (C-6), 139.1 (C-2), 159.1 (C-9), 170.2 (C-1); HRMS (ESI+): Found: 227.0688; 
C12H12NaO3 (MNa+) Requires 227.0679 (−4.3 ppm error). 
Lab notebook reference: MGL/03/94, 01/20 
2-(1,3-Benzodioxol-5-yl)ethyl 2-(diethoxyphosphoryl)acetate (118a) 
 
 
 
Synthesised using general procedure A with 2-(1,3-benzodioxol-5-yl)ethanol 118 (1.31 g, 7.85 
mmol), toluene (40 mL), DEPAA (1.33 mL, 8.25 mmol), DIPEA (3.56 mL, 20.4 mmol) and T3P 
(6.50 g, 10.2 mmol, 50% w/w solution in EtOAc) affording the title compound 118a as an orange 
oil (2.69 g, 100%). No further purification was required; Rf 0.35 (1:2 petrol:EtOAc); νmax (thin 
film)/cm-1 2938s, 2865s, 1710s, 1468m, 1230s, 1013m; δH (400 MHz, CDCl3) 1.31 (6 H, td, J = 
7.1, J = 0.4, H-4), 2.86 (2 H, t, J = 7.1, H-6), 2.94 (2 H, d, J = 21.6, H-2), 4.13 (4 H, dq, J = 8.3, J = 
7.1, H-3), 4.28 (2 H, t, J = 7.1, H-5), 5.91 (2 H, s, H-11), 6.65 (1 H, dd, J = 7.9, J = 1.7, H-8), 6.71 
(1 H, d, J = 1.7, H-13), 6.72 (1 H, d, J = 7.9, H-9); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 
34.3 (d, J = 134.3, C-2), 34.6 (C-6), 62.6 (d, J = 6.2, C-3), 66.1 (C-5), 100.8 (C-11), 108.2 (C-9), 
109.2 (C-13), 121.8 (C-8), 131.1 (C-7), 146.2 (C-10), 147.6 (C-12), 165.7 (d, J = 6.1, C-1); δP (162 
MHz, CDCl3) 20.2; HRMS (ESI+): Found: 367.0908; C15H21NaO7P (MNa+) Requires 367.0917 
(2.5 ppm error), Found: 345.1090; C15H22O7P (MH+) Requires 345.1098 (2.2 ppm error). 
Lab notebook reference: MGL/01/34 
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2-(1,3-Benzodioxol-5-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (118b) 
 
 
 
Synthesised using general procedure B with 2-(1,3-benzodioxol-5-yl)ethyl 2-
(diethoxyphosphoryl)acetate 118a (3.44 g, 10.00 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 
mmol, 1.0 M solution in THF) and p-ABSA (2.88 g, 12.0 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 118b as a yellow oil (2.02 g, 
55%); Rf 0.38 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2939s, 2098s, 1683s, 1468w, 1262s, 1229w, 
1008m; δH (400 MHz, CDCl3) 1.33 (6 H, td, J = 7.1, J = 0.8, H-4), 2.87 (2 H, t, J = 6.9, H-6), 4.06–
4.24 (4 H, m, H-3), 4.34 (2 H, t, J = 6.9, H-5), 5.92 (2 H, s, H-11), 6.64 (1 H, dd, J = 7.9, J = 1.7, 
H-8), 6.70 (1 H, d, J = 1.7, H-13), 6.73 (1 H, d, J = 7.9, H-9); δC (100 MHz, CDCl3) 16.1 (d, J = 
6.9, C-4), 34.8 (C-6), 53.9 (d, J = 227.3, C-2), 63.6 (d, J = 5.5, C-3), 66.1 (C-5), 100.9 (C-11), 
108.3 (C-9), 109.3 (C-13), 121.8 (C-8), 131.0 (C-7), 146.3 (C-10), 147.7 (C-12), 163.3 (d, J = 12.3, 
C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 393.0807; C15H19N2NaO7P (MNa+) 
Requires 393.0822 (3.9 ppm error), Found: 371.1000; C15H20N2O7P (MH+) Requires 371.1003 (0.8 
ppm error). 
Lab notebook reference: MGL/01/35 
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(SR)-4-(1,3-Benzodioxol-5-yl)-3-methylenedihydrofuran-2(3H)-one (118c) 
 
 
 
Synthesised using general procedure E with 2-(1,3-benzodioxol-5-yl)ethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 118b (79 mg, 0.213 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.3 
µmol), KOBu-t (28.7 mg, 0.256 mmol) and paraformaldehyde (12.8 mg, 0.426 mmol). Purification 
by column chromatography (4:1 petrol:EtOAc) afforded the title compound 118c as a white solid 
(30 mg, 64%); Rf 0.47 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 2873s, 1737s, 1481w, 1466m, 
1229s, 1022m; δH (400 MHz, CDCl3) 4.14–4.23 (2 H, m, H-3,4), 4.64–4.72 (1 H, m, H-4), 5.50 (1 
H, d, J = 2.7, H-5b), 5.97 (2 H, s, H-10), 6.39 (1 H, dd, J = 3.0, H-5a), 6.68 (1 H, d, J = 1.8, H-12), 
6.69 (1 H, dd, J = 7.8, J = 1.8, H-7), 6.79 (1 H, d, J = 7.8, H-8); δC (100 MHz, CDCl3) 45.5 (C-3), 
72.7 (C-4), 101.3 (C-10), 107.8 (C-12), 108.6 (C-8), 121.5 (C-7), 124.0 (C-5), 133.1 (C-6), 138.8 
(C-2), 147.2 (C-9), 148.4 (C-11), 170.1 (C-1); HRMS (ESI+): Found: 241.0482; C12H10NaO4 
(MNa+) Requires 241.0471 (−4.3 ppm error), Found: 219.0657; C12H11O4 (MH+) Requires 
219.0652 (−2.5 ppm error). 
Lab notebook reference: MGL/03/04, 01/39, 01/40 
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3,4,5-Trimethoxyphenethyl 2-(diethoxyphosphoryl)acetate (119a) 
 
 
 
Synthesised using general procedure A with 2-(3,4,5-trimethoxyphenyl)ethanol 119 (205 mg, 0.966 
mmol), toluene (4.80 mL), DEPAA (0.16 mL, 1.01 mmol), DIPEA (0.44 mL, 2.51 mmol) and T3P 
(0.80 g, 1.26 mmol, 50% w/w solution in THF) affording the title compound 119a as a yellow oil 
(360 mg, 95%). No further purification was required; Rf 0.10 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2939w, 2841w, 1733s, 1590s, 1508m, 1459m, 1422m, 1852w, 1238s, 1154w, 1123s, 
1047w, 1018s, 967s, 827m, 778m; δH (400 MHz, CDCl3) 1.28–1.31 (6 H, m, H-4), 2.88 (2 H, t, J = 
7.2, H-6), 2.94 (2 H, d, J = 21.5, H-2), 3.79 (3 H, s, H-11), 3.82 (6 H, s, H-12), 4.07–4.15 (4 H, m, 
H-3), 4.32 (2 H, t, J = 7.2, H-5), 6.41 (2 H, s, H-8); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-4), 
34.2 (d, J = 134.3, C-2), 35.2 (C-6), 56.0 (C-12), 60.7 (C-11), 62.6 (d, J = 6.3, C-3), 65.9 (C-5), 
105.7 (C-8), 132.9 (C-7), 136.6 (C-10), 153.1 (C-9), 165.7 (d, J = 6.0, C-1); δP (162 MHz, CDCl3) 
20.2; HRMS (ESI+): Found: 413.1351; C17H27NaO8P (MNa+) Requires 413.1336 (−3.6 ppm error), 
Found: 391.1528; C17H28O8P (MH+) Requires 391.1516 (−2.9 ppm error). 
Lab notebook reference: MGL/05/11S 
3,4,5-Trimethoxyphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (119b) 
 
 
 
Synthesised using general procedure B with 3,4,5-trimethoxyphenethyl 2-
(diethoxyphosphoryl)acetate 119a (350 mg, 0.90 mmol), THF (4.5 mL), LHMDS (1.08 mL, 1.08 
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mmol, 1.0 M solution in THF) and p-ABSA (259 mg, 1.08 mmol). Purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 119b as a yellow oil (202 mg, 
54%); Rf 0.21 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2983w, 2940w, 2841w, 2125s, 1704s, 
1590s, 1508m, 1459s, 1422m, 1389m, 1352w, 1274s, 1238s, 1155w, 1124s, 1012s, 977s, 815m, 
745m, 589m, 559m; δH (400 MHz, CDCl3) 1.29 (6 H, td, J = 7.1, J = 0.7, H-4), 2.87 (2 H, t, J = 
6.9, H-6), 3.77 (3 H, s, H-11), 3.80 (6 H, s, H-12), 4.02–4.19 (4 H, m, H-3), 4.36 (2 H, t, J = 6.9, 
H-5), 6.38 (2 H, s, H-8); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 35.4 (C-6), 53.5 (d, J = 
227.1, C-2), 55.9 (C-12), 60.6 (C-11), 63.5 (d, J = 5.6, C-3), 65.9 (C-5), 105.6 (C-8), 132.8 (C-7), 
136.6 (C-10), 153.1 (C-9), 163.1 (d, J = 12.5, C-1); δP (162 MHz, CDCl3) 10.4; HRMS (ESI+): 
Found: 439.1234; C17H25N2NaO8P (MNa+) Requires 439.1241 (1.6 ppm error), Found: 417.1423; 
C17H26N2O8P (MH+) Requires 417.1421 (−0.3 ppm error). 
Lab notebook reference: MGL/05/11 
3-Methylene-4-(3,4,5-trimethoxyphenyl)dihydrofuran-2(3H)-one (119c) 
 
 
 
Synthesised using general procedure D with 3,4,5-trimethoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 119b (77 mg, 0.185 mmol), CH2Cl2 (3.7 mL), Rh2(oct)4 (2.9 mg, 3.7 
µmol), THF (3.7 mL), KOBu-t (31.1 mg, 0.278 mmol) and paraformaldehyde (11.1 mg, 0.370 
mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 
119c as a colourless oil (22 mg, 45%); Rf 0.26 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 2937w, 
1763s, 1660w, 1591m, 1509m, 1461m, 1425m, 1347w, 1242m, 1124s, 1013m; δH (400 MHz, 
CDCl3) 3.83 (3 H, s, H-10), 3.84 (6 H, s, H-11), 4.17–4.24 (2 H, m, H-3,4), 4.68–4.75 (1 H, m, H-
4), 5.56 (1 H, d, J = 2.6, H-5b), 6.40–6.41 (3 H, m, H-5a,7); δC (100 MHz, CDCl3) 45.9 (C-3), 56.2 
(C-11), 60.8 (C-10), 72.7 (C-4), 104.7 (C-7), 124.3 (C-5), 135.2 (C-6), 137.4 (C-9), 138.5 (C-2), 
153.7 (C-8), 170.1 (C-1); HRMS (ESI+): Found: 287.0892; C14H16NaO5 (MNa+) Requires 287.0890 
(−0.5 ppm error), Found: 265.1071; C14H17O5 (MH+) Requires 265.1071 (−0.1 ppm error). 
Lab notebook reference: MGL/05/25 
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2-(Naphthalen-1-yl)ethyl 2-(diethoxyphosphoryl)acetate (120a) 
 
 
 
Synthesised using general procedure A with 2-(naphthalen-1-yl)ethanol 120 (861 mg, 5.00 mmol), 
toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in THF) affording the title compound 120a as a yellow oil (1.74 g, 
99%). No further purification was required; Rf 0.20 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2982w, 1735s, 1598w, 1510w, 1496w, 1445w, 1395w, 1257s, 1163w, 1113m, 1048w, 1019s, 965s, 
838w, 798w, 777s, 731s, 696m; δH (400 MHz, CDCl3) 1.31 (6 H, t, J = 7.1, H-4), 2.97 (2 H, d, J = 
21.6, H-2), 3.44 (2 H, t, J = 7.5, H-6), 4.10–4.17 (4 H, m, H-3), 4.48 (2 H, t, J = 7.5, H-5), [7.36–
7.43 (2 H, m), 7.47–7.56 (2 H, m), 7.75–7.77 (1 H, m), 7.85–7.87 (1 H, m), 8.07–8.09 (1 H, m) (H-
8,9,10,11,12,13,14)]; δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 32.0 (C-6), 34.3 (d, J = 134.2, C-
2), 62.6 (d, J = 6.2, C-3), 65.4 (C-5), [123.4, 125.4, 125.6, 126.2, 127.0, 127.5, 128.8 (C-
8,9,10,11,12,13,14)], [131.9, 133.2, 133.8 (C-7,15,16)], 165.8 (d, J = 6.1, C-1); δP (162 MHz, 
CDCl3) 20.3; HRMS (ESI+): Found: 373.1171; C18H23NaO5P (MNa+) Requires 373.1175 (1.2 ppm 
error), Found: 351.1353; C18H24O5P (MH+) Requires 351.1356 (0.9 ppm error). 
Lab notebook reference: MGL/05/15S 
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2-(Naphthalen-1-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (120b) 
 
 
 
Synthesised using general procedure B with 2-(naphthalen-1-yl)ethyl 2-
(diethoxyphosphoryl)acetate 120a (1.70 g, 4.85 mmol), THF (24 mL), LHMDS (5.82 mL, 5.82 
mmol, 1.0 M solution in THF) and p-ABSA (1.40 g, 5.82 mmol). Purification by column 
chromatography (2:1 hexane:EtOAc) afforded the title compound 120b as a yellow oil (859 mg, 
47%); Rf 0.41 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2984w, 2127s, 1708s, 1597w, 1511w, 
1445w, 1388w, 1279s, 1215s, 1164w, 1095w, 1020s, 978m, 799m, 778m, 745w; δH (400 MHz, 
CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.8, H-4), 3.45 (2 H, t, J = 7.2, H-6), 4.04–4.22 (4 H, m, H-3), 
4.55 (2 H, t, J = 7.2, H-5), [7.35–7.43 (2 H, m), 7.47–7.57 (2 H, m), 7.76–7.78 (1 H, m), 7.85–7.88 
(1 H, m), 8.06–8.08 (1 H, m) (H-8,9,10,11,12,13,14)]; δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 
32.2 (C-6), 53.5 (d, J = 226.9, C-2), 63.6 (d, J = 5.9, C-3), 65.5 (C-5), [123.4, 125.4, 125.7, 126.3, 
127.1, 127.6, 128.8 (C-8,9,10,11,12,13,14)], [131.9, 133.1, 133.8 (C-7,15,16)], 163.2 (d, J = 12.2, 
C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 399.1075; C18H21N2NaO5P (MNa+) 
Requires 399.1080 (1.2 ppm error), Found: 377.1257; C18H22N2O5P (MH+) Requires 377.1261 (0.9 
ppm error). 
Lab notebook reference: MGL/05/15 
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3-Methylene-4-(naphthalen-1-yl)dihydrofuran-2(3H)-one (120c) 
 
 
 
Synthesised using general procedure D with 2-(naphthalen-1-yl)ethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 120b (82 mg, 0.218 mmol), CH2Cl2 (4.4 mL), Rh2(oct)4 (3.4 mg, 4.4 
µmol), THF (4.4 mL), KOBu-t (36.7 mg, 0.327 mmol) and paraformaldehyde (13.1 mg, 0.436 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
120c as a colourless oil (28 mg, 57%); Rf 0.45 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 3050w, 
2918w, 1759s, 1662w, 1598w, 1511w, 1398m, 1261w, 1230w, 1111s, 1022m, 948w, 802m, 780s; 
δH (400 MHz, CDCl3) 4.36 (1 H, dd, J = 9.0, J = 6.3, H-4), 4.89 (1 H, app. t, J = 9.0, H-4), 5.03–
5.08 (1 H, m, H-3), 5.60 (1 H, d, J = 2.7, H-5b), 6.51 (1 H, d, J = 3.0, H-5a), [7.38–7.40 (1 H, m), 
7.47 (1 H, app. t, J = 7.7), 7.53–7.60 (2 H, m), 7.81–7.88 (2 H, m), 7.91–7.95 (1 H, m) (H-
7,8,9,10,11,12,13)]; δC (100 MHz, CDCl3) 41.6 (C-3), 72.0 (C-4), 124.5 (C-5), [122.6, 125.0, 
125.5, 126.1, 126.7, 128.5, 129.3 (C-7,8,9,10,11,12,13)], [131.0, 134.2, 135.6, 137.6 (C-
2,6,14,15)], 170.4 (C-1); HRMS (ESI+): Found: 247.0728; C15H12NaO2 (MNa+) Requires 247.0730 
(0.5 ppm error), Found: 225.0902; C15H13O2 (MH+) Requires 225.0910 (3.6 ppm error). 
Lab notebook reference: MGL/05/31 
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4-Trifluoromethylphenethyl 2-(diethoxyphosphoryl)acetate (121a) 
 
 
 
Synthesised using general procedure A with 4-trifluoromethylphenethyl alcohol 121 (497 mg, 2.61 
mmol), toluene (10 mL), DEPAA (0.44 mL, 2.74 mmol), DIPEA (1.19 mL, 6.80 mmol) and T3P 
(2.16 g, 3.40 mmol, 50% w/w solution in EtOAc) affording the title compound 121a as a yellow oil 
(963 mg, 100%). No further purification was required; Rf 0.19 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 2940s, 2890w, 1712s, 1307m, 1251m, 1146w, 1099m, 1007m, 956w; δH (400 MHz, 
CDCl3) 1.30 (6 H, td, J = 7.1, J = 0.5, H-4), 2.94 (2 H, d, J = 21.6, H-2), 3.02 (2 H, t, J = 6.8, H-6), 
4.11 (4 H, dq, J = 8.8, J = 7.1, H-3), 4.37 (2 H, t, J = 6.8, H-5), 7.35 (2 H, d, J = 8.0, H-8), 8.17 (2 
H, d, J = 8.0, H-9); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 34.3 (d, J = 134.4, C-2), 34.7 (C-
6), 62.7 (d, J = 6.2, C-3), 65.3 (C-5), 125.4 (q, J = 3.7, C-9), 126.9 (q, J = 271.1, C-11), 129.2 (C-
8), 129.7 (q, J = 32.5, C-10), 141.7 (C-7), 165.7 (d, J = 6.1, C-1); δF (376 MHz, CDCl3) −62.4; δP 
(162 MHz, CDCl3) 20.1; HRMS (ESI+): Found: 391.0878; C15H20F3NaO5P (MNa+) Requires 
391.0893 (3.7 ppm error), Found: 369.1064; C15H21F3O5P (MH+) Requires 369.1073 (2.5 ppm 
error). 
Lab notebook reference: MGL/03/10, 01/21 
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4-Trifluoromethylphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (121b) 
 
 
 
Synthesised using general procedure B with 4-trifluoromethylphenethyl 2-
(diethoxyphosphoryl)acetate 121a (1.00 g, 2.72 mmol), THF (14 mL), LHMDS (3.30 mL, 3.30 
mmol, 1.0 M solution in THF) and p-ABSA (785 mg, 3.26 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 121b as a pale yellow oil (386 mg, 
36%); Rf 0.44 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2941s, 2099s, 1686s, 1308m, 1262m, 
1147w, 1106w, 1051w, 1006w; δH (400 MHz, CDCl3) 1.31 (6 H, td, J = 7.1, J = 0.8, H-4), 3.03 (2 
H, t, J = 6.7, H-6), 4.03–4.21 (4 H, m, H-3), 4.43 (2 H, t, J = 6.7, H-5), 7.34 (2 H, d, J = 8.0, H-8), 
7.56 (2 H, d, J = 8.0, H-9); δC (100 MHz, CDCl3) 16.1 (d, J = 6.8, C-4), 34.9 (C-6), 53.9 (d, J = 
228.8, C-2), 63.6 (d, J = 5.6, C-3), 65.3 (C-5), 125.4 (q, J = 3.8, C-9), 124.1 (q, J = 271.9, C-11), 
129.1 (q, J = 32.3, C-10), 129.3 (C-8), 141.5 (C-7), 163.3 (d, J = 11.6, C-1); δF (376 MHz, CDCl3) 
−62.4; δP (162 MHz, CDCl3) 10.4; HRMS (ESI+): Found: 417.0779; C15H18F3N2NaO5P (MNa+) 
Requires 417.0798 (4.5 ppm error), Found: 395.0964; C15H19F3N2O5P (MH+) Requires 395.0978 
(3.7 ppm error).  
Lab notebook reference: MGL/01/26 
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(SR)-3-Methylene-4-(4-(trifluoromethyl)phenyl)dihydrofuran-2(3H)-one (121c) 
 
 
 
Synthesised using general procedure E with 4-trifluoromethylphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 121b (64 mg, 0.162 mmol), CH2Cl2 (1.6 mL), Rh2(oct)4 (6.3 mg, 8.1 
µmol), KOBu-t (16.4 mg, 0.146 mmol) and paraformaldehyde (48.6 mg, 1.62 mmol). Purification 
by column chromatography (5:1 petrol:EtOAc) afforded the title compound 121c as a colourless oil 
(15 mg, 38%); Rf 0.59 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 2875w, 1741s, 1307s, 1097m, 
1053w; δH (400 MHz, CDCl3) 4.24 (1 H, dd, J = 9.0, J = 7.1, H-4), 4.33–4.38 (1 H, m, H-3), 4.75 
(1 H, app. t, J = 9.0, H-4), 5.50 (1 H, d, J = 2.9, H-5b), 6.44 (1 H, d, J = 2.9, H-5a), 7.37 (2 H, d, J 
= 8.0, H-7), 7.65 (2 H, d, J = 8.0, H-8); δC (100 MHz, CDCl3) 45.3 (C-3), 72.2 (C-4), 123.8 (q, J = 
272.2, C-10), 124.7 (C-5), 126.2 (q, J = 3.8, C-8), 128.3 (C-7), 130.2 (q, J = 32.1, C-9), 138.1 (C-
2), 143.7 (C-6), 169.6 (C-1); δF (376 MHz, CDCl3) −62.6; HRMS (ESI+): Found: 265.0447; 
C12H9F3NaO2 (MNa+) Requires 265.0447 (0.0 ppm error). 
Lab notebook reference: MGL/02/63, 03/33 
4-Nitrophenethyl 2-(diethoxyphosphoryl)acetate (122a) 
 
 
 
Synthesised using general procedure A with 4-nitrophenethyl alcohol 122 (2.50 g, 15.0 mmol), 
toluene (78 mL), DEPAA (2.52 mL, 15.7 mmol), DIPEA (6.80 mL, 38.9 mmol) and T3P (12.4 g, 
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19.4 mmol, 50% w/w solution in THF) affording the title compound 122a as an orange oil (4.72 g, 
91%). No further purification was required; Rf 0.12 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2936s, 
1712s, 1577m, 1495s, 1371m, 1325m, 1249m, 1145w, 1095m, 1009m, 955w, 842w; δH (400 MHz, 
CDCl3) 1.31 (6 H, t, J = 7.1, H-4), 2.94 (2 H, d, J = 21.6, H-2), 3.08 (2 H, t, J = 6.7, H-6), 4.13 (4 
H, dq, J = 8.3, J = 7.1, H-3), 4.39 (2 H, t, J = 6.7, H-5), 7.41 (2 H, d, J = 8.8, H-8), 8.17 (2 H, d, J = 
8.8, H-9); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 34.3 (d, J = 134.6, C-2), 34.7 (C-6), 62.7 (d, 
J = 6.2, C-3), 64.9 (C-5), 123.7 (C-9), 129.8 (C-8), 145.3 (C-7/10), 146.9 (C-7/10), 165.6 (d, J = 
6.0, C-1); δP (162 MHz, CDCl3) 20.0; HRMS (ESI+): Found: 368.0875; C14H20NNaO7P (MNa+) 
Requires 368.0870 (−1.3 ppm error), Found: 346.1055; C14H21NO7P (MH+) Requires 346.1050 
(−1.3 ppm error). 
Lab notebook reference: MGL/01/11 
4-Nitrophenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (122b) 
 
 
 
Synthesised using general procedure B with 4-nitrophenethyl 2-(diethoxyphosphoryl)acetate 122a 
(212 mg, 0.614 mmol), THF (3.0 mL), LHMDS (0.740 mL, 0.740 mmol, 1.0 M solution in THF) 
and p-ABSA (177 mg, 0.737 mmol). Purification by column chromatography (1:1 petrol:EtOAc) 
afforded the title compound 122b as a colourless oil (111 mg, 49%); Rf 0.53 (1:2 petrol:EtOAc); 
νmax (thin film)/cm-1 2099s, 1681s, 1497s, 1326s, 1261s, 1006m; δH (400 MHz, CDCl3) 1.32 (6 H, 
td, J = 7.1, J = 0.8, H-4), 3.09 (2 H, t, J = 6.6, H-6), 4.05–4.23 (4 H, m, H-3), 4.45 (2 H, t, J = 6.6, 
H-5), 7.40 (2 H, d, J = 8.8, H-8), 8.18 (2 H, d, J = 8.8, H-9); δC (100 MHz, CDCl3) 16.1 (d, J = 6.8, 
C-4), 34.9 (C-6), 53.8 (d, J = 228.4, C-2), 63.6 (d, J = 5.7, C-3), 64.9 (C-5), 123.7 (C-9), 129.8 (C-
8), 145.1 (C-7/10), 146.9 (C-7/10), 163.2 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.3; HRMS 
(ESI+): Found: 394.0762; C14H18N3NaO7P (MNa+) Requires 394.9775 (3.2 ppm error), Found: 
372.0956; C14H19N3O7P (MH+) Requires 372.0955 (−0.2 ppm error). 
Lab notebook reference: MGL/01/15 
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(SR)-3-Methylene-4-(4-nitrophenyl)dihydrofuran-2(3H)-one (122c) 
 
 
 
Synthesised using general procedure E with 4-nitrophenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 122b (37 mg, 0.100 mmol), CH2Cl2 (2.0 mL), Rh2(esp)2 (3.8 mg, 5.0 
µmol), KOBu-t (10.1 mg, 0.090 mmol) and paraformaldehyde (30.0 mg, 0.997 mmol). Purification 
by column chromatography (2:1 petrol:EtOAc) afforded the title compound 122c as a colourless oil 
(4 mg, 18%); Rf 0.58 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2878s, 2809s, 1737s, 1575w, 
1496m, 1327m, 1092w, 1004w, 843w; δH (400 MHz, CDCl3) 4.27 (1 H, dd, J = 9.1, J = 6.8, H-4), 
4.39–4.45 (1 H, m, H-3), 4.78 (1 H, app. t, J = 9.1, H-4), 5.53 (1 H, d, J = 2.7, H-5b), 6.48 (1 H, d, 
J = 3.1, H-5a), 7.44 (2 H, d, J = 8.8, H-7), 8.26 (2 H, d, J = 8.8, H-8); δC (100 MHz, CDCl3) 45.2 
(C-3), 71.9 (C-4), 124.5 (C-8), 125.1 (C-5), 128.8 (C-7), 137.7 (C-2), 147.0 (C-6/9), 147.6 (C-6/9), 
169.2 (C-1); HRMS (ESI+): Found: 242.0427; C11H9NNaO4 (MNa+) Requires 242.0424 (−1.5 ppm 
error), Found: 220.0614; C11H10NO4 (MH+) Requires 220.0604 (−4.5 ppm error). 
Lab notebook reference: MGL/01/17 
4-Bromophenethyl 2-(diethoxyphosphoryl)acetate (123a) 
 
 
 
Synthesised using general procedure A with 2-(4-bromophenyl)ethanol 123 (1.01 g, 5.00 mmol), 
toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in THF) affording the title compound 123a as a yellow oil (1.80 g, 
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96%). No further purification was required; Rf 0.23 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2982w, 1735s, 1489m, 1443w, 1393w, 1256s, 1163w, 1114m, 1049w, 1020s, 964s, 804m; δH (400 
MHz, CDCl3) 1.29 (6 H, td, J = 7.1, J = 0.5, H-4), 2.89 (2 H, t, J = 6.9, H-6), 2.92 (2 H, d, J = 21.6, 
H-2), 4.06–4.13 (4 H, m, H-3), 4.30 (2 H, t, J = 6.9, H-5), 7.08 (2 H, d, J = 8.5, H-8/9), 7.39 (2 H, 
d, J = 8.5, H-8/9); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-4), 34.2 (d, J = 134.3, C-2), 34.2 (C-6), 
62.6 (d, J = 6.2, C-3), 65.5 (C-5), 120.4 (C-10), 130.6 (C-8/9), 131.5 (C-8/9), 136.4 (C-7), 165.6 (d, 
J = 6.1, C-1); δP (162 MHz, CDCl3) 20.1; HRMS (ESI+): Found: 401.0124; C14H2079BrNaO5P 
(MNa+) Requires 401.0124 (−0.1 ppm error), Found: 379.0303; C14H2179BrO5P (MH+) Requires 
379.0304 (0.4 ppm error). 
Lab notebook reference: MGL/05/08S 
4-Bromophenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (123b) 
 
 
 
Synthesised using general procedure B with 4-bromophenethyl 2-(diethoxyphosphoryl)acetate 
123a (1.78 g, 4.69 mmol), THF (24 mL), LHMDS (5.63 mL, 5.63 mmol, 1.0 M solution in THF) 
and p-ABSA (1.35 g, 5.63 mmol). Purification by column chromatography (2:1 hexane:EtOAc) 
afforded the title compound 123b as a yellow oil (969 mg, 51%); νmax (thin film)/cm-1 2983w, 
2129s, 1708s, 1489w, 1384w, 1279s, 1216w, 1164w, 1094w, 1022s, 979m, 815w, 596w, 560w; δH 
(400 MHz, CDCl3) 1.30 (6 H, td, J = 7.1, J = 0.8, H-4), 2.90 (2 H, t, J = 6.7, H-6), 4.02–4.19 (4 H, 
m, H-3), 4.36 (2 H, t, J = 6.7, H-5), 7.07 (2 H, d, J = 8.5, H-8), 7.40 (2 H, d, J = 8.5, H-9); δC (100 
MHz, CDCl3) 16.0 (d, J = 6.8, C-4), 34.5 (C-6), 53.8 (d, J = 228.5, C-2), 63.5 (d, J = 5.8, C-3), 
65.4 (C-5), 120.5 (C-10), 130.6 (C-8), 131.5 (C-9), 136.2 (C-7), 163.1 (d, J = 12.3, C-1); δP (162 
MHz, CDCl3) 10.4; HRMS (ESI+): Found: 427.0038; C14H1879BrN2NaO5P (MNa+) Requires 
427.0029 (−2.2 ppm error), Found: 405.0224; C14H1979BrN2O5P (MH+) Requires 405.0209 (−3.7 
ppm error). 
Lab notebook reference: MGL/05/08 
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4-(4-Bromophenyl)-3-methylenedihydrofuran-2(3H)-one (123c) 
 
 
 
Synthesised using general procedure D with 4-bromophenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 123b (90 mg, 0.222 mmol), CH2Cl2 (4.4 mL), Rh2(oct)4 (3.5 mg, 4.4 
µmol), THF (4.4 mL), KOBu-t (37.4 mg, 0.333 mmol) and paraformaldehyde (13.3 mg, 0.444 
mmol). Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compound 
123c as a pale yellow oil (31 mg, 55%); Rf 0.40 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2972w, 
2913w, 1761s, 1666w, 1590w, 1489m, 1412m, 1274w, 1231m, 1107s, 1010s, 947w, 825s; δH (400 
MHz, CDCl3) 4.17–4.27 (2 H, m, H-3,4), 4.71 (1 H, app. t, J = 8.4, H-4), 5.48 (1 H, d, J = 2.7, H-
5b), 6.39 (1 H, d, J = 3.0, H-5a), 7.11 (2 H, d, J = 8.5, H-7), 7.50 (2 H, d, J = 8.5, H-8); δC (100 
MHz, CDCl3) 45.1 (C-3), 72.3 (C-4), 121.8 (C-2/6/9), 124.3 (C-5), 129.5 (C-7), 132.3 (C-8), 138.3 
(C-2/6/9), 138.5 (C-2/6/9), 169.8 (C-1); HRMS (ESI+): Found: 274.9679; C11H979BrNaO2 (MNa+) 
Requires 274.9678 (−0.4 ppm error), Found: 252.9859; C11H1079BrO2 (MH+) Requires 252.9859 
(−0.1 ppm error). 
Lab notebook reference: MGL/05/21 
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4-(Dimethylamino)phenethyl 2-(diethoxyphosphoryl)acetate (124a) 
 
 
 
Synthesised using general procedure A with 4-(N,N-dimethylamino)phenethyl alcohol 124 (835 
mg, 5.05 mmol), toluene (25 mL), DEPAA (0.85 mL, 5.31 mmol), DIPEA (2.29 mL, 13.1 mmol) 
and T3P (4.18 g, 6.57 mmol, 50% w/w solution in EtOAc) affording the title compound 124a as an 
orange oil (1.77 g, 100%). No further purification was required; Rf 0.44 (1:2 petrol:EtOAc); νmax 
(thin film)/cm-1 2988w, 1733s, 1522s, 1258s, 1114w, 1019s; δH (400 MHz, CDCl3) 1.32 (6 H, td, J 
= 7.1, J = 0.5, H-4), 2.86 (2 H, t, J = 7.3, H-6), 2.91 (6 H, s, H-11), 2.96 (2 H, d, J = 21.5, H-2), 
4.14 (4 H, dq, J = 8.2, J = 7.1, H-3), 4.29 (2 H, t, J = 7.3, H-5), 6.69 (2 H, d, J = 8.7, H-9), 7.10 (2 
H, d, J = 8.7, H-8); δC (100 MHz, CDCl3) 16.3 (d, J = 6.4, C-4), 33.9 (C-6), 34.3 (d, J = 134.2, C-
2), 40.7 (C-11), 62.6 (d, J = 6.2, C-3), 66.5 (C-5), 112.8 (C-9), 125.1 (C-7), 129.5 (C-8), 149.5 (C-
10), 165.8 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 366.1444; 
C16H26NNaO5P (MNa+) Requires 366.1441 (−0.8 ppm error), Found: 344.1616; C16H27NO5P 
(MH+) Requires 344.1621 (1.7 ppm error). 
Lab notebook reference: MGL/02/33 
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4-(Dimethylamino)phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate (124b) 
 
 
 
Synthesised using general procedure B with 4-(dimethylamino)phenethyl 2-
(diethoxyphosphoryl)acetate 124a (1.03 g, 3.00 mmol), THF (15 mL), LHMDS (3.60 mL, 3.60 
mmol, 1.0 M solution in THF) and p-ABSA (865 mg, 3.60 mmol). Purification by column 
chromatography (3:1 petrol:EtOAc) afforded the title compound 124b as a yellow oil (327 mg, 
30%); Rf 0.48 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2985w, 2128s, 1704s, 1616w, 1523m, 
1277s, 1020s; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.6, H-4), 2.85 (2 H, t, J = 7.0, H-6), 
2.90 (6 H, s, H-11), 4.04–4.21 (4 H, m, H-3), 4.33 (2 H, t, J = 7.0, H-5), 6.67 (2 H, d, J = 8.7, H-9), 
7.06 (2 H, d, J = 8.7, H-8); δC (100 MHz, CDCl3) 15.9 (d, J = 6.9, C-4), 34.0 (C-6), 40.5 (C-11), 
53.4 (d, J = 226.5, C-2), 63.4 (d, J = 5.8, C-3), 66.3 (C-5), 112.6 (C-9), 124.8 (C-7), 129.4 (C-8), 
149.3 (C-10), 163.1 (d, J = 12.3, C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 
392.1338; C16H24N3NaO5P (MNa+) Requires 392.1346 (1.9 ppm error), Found: 370.1520; 
C16H25N3O5P (MH+) Requires 370.1526 (1.8 ppm error). 
Lab notebook reference: MGL/02/54 
2-(Thiophen-3-yl)ethyl 2-(diethoxyphosphoryl)acetate (125a) 
 
 
 
Synthesised using general procedure A with 2-(thiophen-3-yl)ethanol 125 (1.03 g, 8.00 mmol), 
toluene (40 mL), DEPAA (1.35 mL, 8.40 mmol), DIPEA (3.62 mL, 20.8 mmol) and T3P (6.62 g, 
10.4 mmol, 50% w/w solution in EtOAc) affording the title compound 125a as a yellow oil (2.41 g, 
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99%). No further purification was required; Rf 0.33 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2983w, 1734s, 1393w, 1258s, 1115w, 1049w, 1020s, 968s; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 
7.1, J = 0.5, H-4), 2.97 (2 H, d, J = 21.6, H-2), 3.00 (2 H, t, J = 6.9, H-6), 4.14 (4 H, dq, J = 8.3, J = 
7.1, H-3), 4.35 (2 H, td, J = 6.9, J = 0.5, H-5), 6.98 (1 H, dd, J = 4.9, J = 1.3, H-8), 7.06 (1 H, ddt, J 
= 3.0, J = 1.3, J = 0.9, H-10), 7.27 (1 H, dd, J = 4.9, J = 3.0, H-9); δC (100 MHz, CDCl3) 16.3 (d, J 
= 6.4, C-4), 29.4 (C-6), 34.3 (d, J = 134.4, C-2), 62.7 (d, J = 6.5, C-3), 65.4 (C-5), 121.7 (C-10), 
125.6 (C-9), 128.2 (C-8), 137.6 (C-7), 165.8 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.2; HRMS 
(ESI+): Found: 329.0582; C12H19NaO5PS (MNa+) Requires 329.0583 (0.4 ppm error), Found: 
307.0768; C12H20O5PS (MH+) Requires 307.0764 (−1.6 ppm error). 
Lab notebook reference: MGL/03/01 
2-(Thiophen-3-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (125b) 
 
 
 
Synthesised using general procedure B with 2-(thiophen-3-yl)ethyl 2-(diethoxyphosphoryl)acetate 
125a (1.53 g, 5.00 mmol), THF (25 mL), LHMDS (6.00 mL, 6.00 mmol, 1.0 M solution in THF) 
and p-ABSA (1.44 g, 6.00 mmol). Purification by column chromatography (2:1 petrol:EtOAc) 
afforded the title compound 125b as a yellow oil (871 mg, 52%); Rf 0.43 (1:1 petrol:EtOAc); νmax 
(thin film)/cm-1 2989w, 2126s, 1703s, 1274s, 1017s, 977m; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 
7.1, J = 0.8, H-4), 2.99 (2 H, t, J = 6.8, H-6), 4.05–4.22 (4 H, m, H-3), 4.39 (2 H, t, J = 6.8, H-5), 
6.95 (1 H, dd, J = 4.9, J = 1.3, H-8), 7.03 (1 H, ddt, J = 2.9, J = 1.3, J = 0.7, H-10), 7.25 (1 H, dd, J 
= 4.9, J = 2.9, H-9); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 29.5 (C-6), 53.8 (d, J = 228.2, C-
2), 63.5 (d, J = 5.6, C-3), 65.3 (C-5), 121.7 (C-10), 125.6 (C-9), 128.1 (C-8), 137.4 (C-7), 163.3 (d, 
J = 12.2, C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 355.0488; C12H17N2NaO5PS 
(MNa+) Requires 355.0488 (0.1 ppm error), Found: 333.0671; C12H18N2O5PS (MH+) Requires 
333.0669 (−0.8 ppm error). 
Lab notebook reference: MGL/03/09 
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(SR)-3-Methylene-4-(thiophen-3-yl)dihydrofuran-2(3H)-one (125c) 
 
 
 
Synthesised using general procedure E with 2-(thiophen-3-yl)ethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 125b (69 mg, 0.208 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.2 mg, 4.2 
µmol), KOBu-t (28.0 mg, 0.250 mmol) and paraformaldehyde (12.5 mg, 0.416 mmol). Purification 
by column chromatography (5:1 petrol:EtOAc) afforded the title compound 125c as a colourless oil 
(12 mg, 32%); Rf 0.59 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 3110w, 2910w, 1761s, 1404w, 
1250m, 1109m, 1018m; δH (400 MHz, CDCl3) 4.23 (1 H, dd, J = 8.9, J = 7.3, H-4), 4.38–4.44 (1 
H, m, H-3), 4.68 (1 H, app. t, J = 8.9, J = 8.9, H-4), 5.56 (1 H, d, J = 2.8, H-5b), 6.38 (1 H, d, J = 
3.1, H-5a), 6.95 (1 H, dd, J = 5.0, J = 1.4, H-7), 7.15 (1 H, ddd, J = 3.0, J = 1.4, J = 0.5, H-9), 7.38 
(1 H, dd, J = 5.0, J = 3.0, H-8); δC (100 MHz, CDCl3) 41.0 (C-3), 71.9 (C-4), 122.6 (C-9), 123.8 
(C-5), 126.1 (C-7), 127.4 (C-8), 138.1 (C-2), 139.4 (C-6), 170.0 (C-1); HRMS (ESI+): Found: 
203.0134; C9H8NaO2S (MNa+) Requires 203.0137 (1.4 ppm error). 
Lab notebook reference: MGL/03/12 
2-(1H-Indol-3-yl)ethyl 2-(diethoxyphosphoryl)acetate (126a) 
 
 
 
Synthesised using general procedure A with 3-(2-hydroxyethyl)indole 126 (806 mg, 5.00 mmol), 
toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 126a as a pale yellow oil 
(1.62 g, 95%). No further purification was required; Rf 0.12 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 3269br, 2983w, 1733s, 1457w, 1441w, 1392w, 1340w, 1244s, 1163w, 1113m, 1019s, 
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969s, 787w, 767w, 737s; δH (400 MHz, CDCl3) 1.31 (6 H, t, J = 7.1, H-4), 2.98 (2 H, d, J = 21.5, 
H-2), 3.11 (2 H, t, J = 7.2, H-6), 4.10–4.18 (4 H, m, H-3), 4.41 (2 H, t, J = 7.2, H-5), 7.06 (1 H, d, J 
= 2.3, H-7), 7.10–7.14 (1 H, m, H-10/11), 7.17–7.21 (1 H, m, H-10/11), 7.35–7.37 (1 H, m, H-
9/12), 7.60–7.62 (1 H, m, H-9/12), 8.40 (1 H, br s, NH); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-
4), 24.5 (C-6), 34.3 (d, J = 134.3, C-2), 62.7 (d, J = 6.2, C-3), 65.6 (C-5), 111.2 (C-9/12), 111.3 (C-
8), 118.5 (C-9/12), 119.3 (C-10/11), 121.9 (C-10/11), 122.3 (C-7), 127.3 (C-14), 136.2 (C-13), 
165.8 (d, J = 6.0, C-1); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 362.1130; 
C16H22NNaO5P (MNa+) Requires 363.1128 (−0.7 ppm error), Found: 340.1309; C16H23NO5P 
(MH+) Requires 340.1308 (−0.1 ppm error). 
Lab notebook reference: MGL/05/36S 
2-(1H-Indol-3-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (126b) 
 
 
 
Synthesised using general procedure B with 2-(1H-indol-3-yl)ethyl 2-(diethoxyphosphoryl)acetate 
126a (598 mg, 1.76 mmol), THF (9.0 mL), LHMDS (2.11 mL, 2.11 mmol, 1.0 M solution in THF) 
and DBSA (0.71 mL, 2.22 mmol). Purification by column chromatography (1:1 hexane:EtOAc) 
afforded the title compound 126b as a yellow oil (276 mg, 43%); Rf 0.23 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 3410w, 3280br, 2984w, 2929w, 2126s, 1702s, 1457w, 1387w, 1275s, 1163w, 
1096m, 1018s, 980m, 742s; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.5, H-4), 3.14 (2 H, t, 
J = 7.1, H-6), 4.05–4.26 (4 H, m, H-3), 4.48 (2 H, t, J = 7.1, H-5), 7.05 (1 H, d, J = 2.2, H-7), 7.11–
7.15 (1 H, m, H-10/11), 7.17–7.22 (1 H, m, H-10/11), 7.35–7.37 (1 H, m, H-9/12), 7.60–7.62 (1 H, 
m, H-9/12), 8.47 (1 H, br s, NH); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 24.8 (C-6), 53.5 (d, J 
= 228.2, C-2), 63.6 (d, J = 5.8, C-3), 65.7 (C-5), 111.1 (C-8), 111.2 (C-9/12), 118.4 (C-9/12), 119.3 
(C-10/11), 121.9 (C-10/11), 122.3 (C-7), 127.2 (C-14), 136.1 (C-13), 163.3 (d, J = 12.4, C-1); δP 
(162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 388.1028; C16H20N3NaO5P (MNa+) Requires 
388.1033 (1.2 ppm error), Found: 366.1208; C16H21N3O5P (MH+) Requires 366.1213 (1.6 ppm 
error). 
Lab notebook reference: MGL/05/36 
2-(Pyridin-3-yl)ethyl 2-(diethoxyphosphoryl)acetate (127a) 
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Synthesised using general procedure A with 2-(pyridin-3-yl)ethanol 127 (2.00 g, 16.2 mmol), 
toluene (80 mL), DEPAA (2.74 mL, 17.1 mmol), DIPEA (7.35 mL, 42.2 mmol) and T3P (13.4 g, 
21.1 mmol, 50% w/w solution in EtOAc) affording the title compound 127a as a yellow oil (4.49 g, 
92%). No further purification was required; Rf 0.44 (10:1 CH2Cl2:MeOH); νmax (thin film)/cm-1 
2938s, 2887w, 1711s, 1468m, 1249s, 1100w, 1034w, 1010m, 957w; δH (400 MHz, CDCl3) 1.31 (6 
H, td, J = 7.1, J = 0.5, H-4), 2.95 (2 H, d, J = 21.6, H-2), 2.97 (2 H, t, J = 6.8, H-6), 4.13 (4 H, dq, J 
= 8.3, J = 7.1, H-3), 4.36 (2 H, t, J = 6.8, H-5), 7.25 (1 H, ddd, J = 7.8, J = 4.8, J = 0.8, H-9), 7.60 
(1 H, ddd, J = 7.8, J = 2.3, J = 1.7, H-8), 8.48–8.51 (2 H, m, H-10,11); δC (100 MHz, CDCl3) 16.3 
(d, J = 6.1, C-4), 32.1 (C-6), 34.3 (d, J = 134.3, C-2), 62.7 (d, J = 6.5, C-3), 65.2 (C-5), 123.5 (C-
9), 133.1 (C-7), 136.5 (C-8), 148.0 (C-10), 150.1 (C-11), 165.7 (d, J = 6.1, C-1); δP (162 MHz, 
CDCl3) 20.0; HRMS (ESI+): Found: 324.0976; C13H20NNaO5P (MNa+) Requires 324.0971 (1.5 
ppm error), Found: 302.1140; C13H21NO5P (MH+) Requires 302.1152 (3.9 ppm error). 
Lab notebook reference: MGL/02/10 
2-(Pyridin-3-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (127b) 
 
 
 
Synthesised using general procedure B with 2-(pyridin-3-yl)ethyl 2-(diethoxyphosphoryl)acetate 
127a (2.00 g, 6.64 mmol), THF (35 mL), LHMDS (7.97 mL, 7.97 mmol, 1.0 M solution in THF) 
and p-ABSA (1.91 g, 7.97 mmol). Purification by column chromatography (7% MeOH in CH2Cl2) 
afforded the title compound 127b as a yellow oil (497 mg, 23%); Rf 0.44 (7% MeOH in CH2Cl2); 
νmax (thin film)/cm-1 2939s, 2098s, 1684s, 1262s, 1104w, 1078w, 1008s, 964w; δH (400 MHz, 
CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.8, H-4), 2.98 (2 H, t, J = 6.7, H-6), 4.05–4.22 (4 H, m, H-3), 
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4.41 (2 H, t, J = 6.7, H-5), 7.24 (1 H, ddd, J = 7.8, J = 4.8, J = 0.7, H-9), 7.56 (1 H, ddd, J = 7.8, J 
= 2.3, J = 1.7, H-8), 8.47–8.51 (2 H, m, H-10,11); δC (100 MHz, CDCl3) 15.8 (d, J = 6.9, C-4), 32.0 
(C-6), 53.5 (d, J = 226.1, C-2), 63.3 (d, J = 5.8, C-3), 65.0 (C-5), 123.1 (C-9), 132.7 (C-7), 136.1 
(C-8), 147.9 (C-10), 149.9 (C-11), 162.9 (d, J = 12.1, C-1); δP (162 MHz, CDCl3) 10.4; HRMS 
(ESI+): Found: 350.0876; C13H18N3NaO5P (MNa+) Requires 350.0876 (0.1 ppm error), Found: 
328.1052; C13H19N3O5P (MH+) Requires 328.1057 (1.6 ppm error). 
Lab notebook reference: MGL/02/11 
2-Methyl-1-phenylpropan-2-yl 2-(diethoxyphosphoryl)acetate (128a) 
 
 
 
Synthesised using general procedure A with 2-methyl-1-phenyl-2-propanol 128 (2.20 mL, 14.3 
mmol), toluene (70 mL), DEPAA (2.41 mL, 15.0 mmol), DIPEA (6.45 mL, 37.1 mmol) and T3P 
(11.8 g, 18.5 mmol, 50% w/w solution in EtOAc) affording the title compound 128a as a yellow oil 
(3.45 g, 74%); Rf 0.28 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2937s, 2889m, 1703s, 1241m, 
1094w, 1037m; δH (400 MHz, CDCl3) 1.31 (6 H, td, J = 7.1, J = 0.4, H-4), 1.46 (6 H, s, H-11), 2.89 
(2 H, d, J = 21.5, H-2), 3.06 (2 H, s, H-6), 4.12 (4 H, dq, J = 8.3, J = 7.1, H-3), 7.17–7.30 (5 H, m, 
H-8,9,10); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 25.6 (C-11), 35.6 (d, J = 133.8, C-2), 46.6 
(C-6), 62.4 (d, J = 6.3, C-3), 83.9 (C-5), 126.5 (C-10), 127.9 (C-9), 130.6 (C-8), 136.9 (C-7), 165.0 
(d, J = 6.2, C-1); δP (162 MHz, CDCl3) 21.0; HRMS (ESI+): Found: 351.1321; C16H25NaO5P 
(MNa+) Requires 351.1332 (3.0 ppm error). 
Lab notebook reference: MGL/02/20 
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2-Methyl-1-phenylpropan-2-yl 2-diazo-2-(diethoxyphosphoryl)acetate (128b) 
 
 
 
Synthesised using general procedure B with 2-methyl-1-phenylpropan-2-yl 2-
(diethoxyphosphoryl)acetate 128a (2.00 g, 6.10 mmol), THF (31 mL), LHMDS (7.31 mL, 7.31 
mmol, 1.0 M solution in THF) and p-ABSA (1.76 g, 7.31 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 128b as a yellow oil (1.92 g, 
89%); Rf 0.56 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2937m, 2095s, 1672s, 1268m, 1008m; δH 
(400 MHz, CDCl3) 1.31 (6 H, td, J = 7.1, J = 0.8, H-4), 1.50 (6 H, s, H-11), 3.09 (2 H, s, H-6), 
4.03–4.21 (4 H, m, H-3), 7.15–7.18 (2 H, m, H-8), 7.21–7.30 (3 H, m, H-9,10); δC (100 MHz, 
CDCl3) 16.1 (d, J = 7.0, C-4), 26.2 (C-11), 46.6 (C-6), 54.2 (d, J = 227.4, C-2), 63.4 (d, J = 5.9, C-
3), 84.7 (C-5), 126.6 (C-10), 128.0 (C-9), 130.5 (C-8), 136.6 (C-7), 162.6 (d, J = 12.4, C-1); δP 
(162 MHz, CDCl3) 11.3; HRMS (ESI+): Found: 377.1230; C16H23N2NaO5P (MNa+) Requires 
377.1237 (1.8 ppm error). 
Lab notebook reference: MGL/02/23 
(SR)-5,5-Dimethyl-3-methylene-4-phenyldihydrofuran-2(3H)-one (128c) and (SR)-5-
Benzyl-5-methyl-3-methylenedihydrofuran-2(3H)-one (128d) 
  
 
 
Synthesised using general procedure D with 2-methyl-1-phenylpropan-2-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 128b (71 mg, 0.200 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 
µmol), THF (4.0 mL), KOBu-t (33.7 mg, 0.300 mmol) and paraformaldehyde (12.0 mg, 0.400 
mmol). The HWE was performed at RT. Purification by column chromatography (8:1 
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petrol:EtOAc) afforded a mixture of the title compounds (128c:128d 1.45:1), as a colourless oil (36 
mg, 89%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for 128c; Rf 0.63 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2979w, 1763s, 1257m, 1089m; δH 
(400 MHz, CDCl3) 1.02 (3 H, s, H-10/10’), 1.56 (3 H, s, H-10/10’), 4.04 (1 H, dd, J = 3.3, J = 3.0, 
H-3), 5.57 (1 H, d, J = 3.0, H-5b), 6.48 (1 H, d, J = 3.3, H-5a), 7.20–7.23 (2 H, m, H-7/8), 7.31–
7.40 (3 H, m, H-7/8,9); δC (100 MHz, CDCl3) 25.0 (C-10/10’), 28.0 (C-10/10’), 57.1 (C-3), 85.5 
(C-4), 123.9 (C-5), 127.9 (C-9), 128.7 (C-7/8), 129.2 (C-7/8), 136.5 (C-6), 139.2 (C-2), 169.8 (C-
1); HRMS (ESI+): Found: 203.1067; C13H15O2 (MH+) Requires 203.1067 (0.0 ppm error). 
 
Data for 128d; Rf 0.46 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2979w, 2928w, 1757s, 1481w, 
1276m, 1055w; δH (400 MHz, CDCl3) 1.43 (3 H, s, H-11), 2.63 (1 H, ddd, J = 16.8, J = 2.8, J = 
2.5, H-3), 2.90 (1 H, ddd, J = 16.8, J = 2.8, J = 2.5, H-3), 2.88–3.03 (3 H, m, H-3,6), 5.46 (1 H, 
app. t, J = 2.5, H-5b), 6.07 (1 H, app. t, J = 2.8, H-5a), 7.19–7.32 (5 H, m, H-8,9,10); δC (100 MHz, 
CDCl3) 27.1 (C-11), 38.6 (C-3), 46.8 (C-6), 83.2 (C-4), 121.7 (C-5), 127.0 (C-10), 128.4 (C-9), 
130.6 (C-8), 135.3 (C-2/7), 135.5 (C-2/7), 169.8 (C-1); HRMS (ESI+): Found: 203.1066; C13H15O2 
(MH+) Requires 203.1067 (0.3 ppm error). 
Lab notebook reference: MGL/03/87, 02/25 
2-Phenylpropyl 2-(diethoxyphosphoryl)acetate (129a) 
 
 
 
Synthesised using general procedure A with 2-phenyl-1-propanol 129 (2.00 g, 14.9 mmol), toluene 
(75 mL), DEPAA (2.51 mL, 15.6 mmol), DIPEA (6.75 mL, 38.7 mmol) and T3P (12.3 g, 19.4 
mmol, 50% w/w solution in EtOAc) affording the title compound 129a as a dark orange oil (4.67 g, 
100%). No further purification was required; Rf 0.25 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2936s, 1710s, 1252s, 1036w, 1009m; δH (400 MHz, CDCl3) 1.30 (3 H, td, J = 7.1, J = 0.5, H-4/4’), 
1.31 (3 H, td, J = 7.1, J = 0.5, H-4/4’), 1.30 (3 H, d, J = 7.0, H-11), 2.94 (2 H, d, J = 21.6, H-2), 
3.12 (1 H, dqd, J = 7.4, J = 7.0, J = 6.8, H-6), 4.06–4.16 (4 H, m, H-3,3’), 4.19 (1 H, dd, J = 10.8, J 
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= 7.4, H-5), 4.27 (1 H, dd, J = 10.8, J = 6.8, H-5), 7.20–7.25 (3 H, m, H-8,10), 7.28 (2 H, m, H-9); 
δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4,4’), 18.0 (C-11), 34.2 (d, J = 134.1, C-2), 38.8 (C-6), 
62.6 (d, J = 6.2, C-3), 70.4 (C-5), 126.7 (C-10), 127.3 (C-8), 128.5 (C-9), 142.8 (C-7), 165.8 (d, J = 
6.2, C-1); δP (162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 337.1189; C15H23NaO5P (MNa+) 
Requires 337.1175 (−3.9 ppm error). 
Lab notebook reference: MGL/02/21 
2-Phenylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate (129b) 
 
 
 
Synthesised using general procedure B with 2-phenylpropyl 2-(diethoxyphosphoryl)acetate 129a 
(2.00 g, 6.36 mmol), THF (32 mL), LHMDS (7.64 mL, 7.64 mmol, 1.0 M solution in THF) and p-
ABSA (1.83 g, 7.64 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded 
the title compound 129b as a yellow oil (1.33 g, 61%); Rf 0.35 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 2983w, 2125s, 1700s, 1390w, 1272s, 1015s; δH (400 MHz, CDCl3) 1.24–1.28 (9 H, m, 
H-4,11), 3.08 (1 H, app. sex., J = 7.0, H-6), 3.95–4.14 (4 H, m, H-3), 4.20 (1 H, dd, J = 10.7, J = 
6.9, H-5/5’), 4.28 (1 H, dd, J = 10.7, J = 7.1, H-5/5’), 7.15–7.19 (3 H, m, H-8,10), 7.23–7.28 (2 H, 
m, H-9); δC (100 MHz, CDCl3) 15.8 (d, J = 6.9, C-4), 17.5 (C-11), 38.7 (C-6), 53.6 (d, J = 226.7, 
C-2), 63.2 (d, J = 5.9, C-3), 70.0 (C-5), 126.5 (C-10), 127.0 (C-8), 128.2 (C-9), 142.4 (C-7), 163.0 
(d, J = 11.9, C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 363.1081; C15H21N2NaO5P 
(MNa+) Requires 363.1080 (−0.2 ppm error), Found: 341.1261; C15H22N2O5P (MH+) Requires 
341.1261 (0.0 ppm error). 
Lab notebook reference: MGL/02/24 
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(SR)-4-Methyl-3-methylene-4-phenyldihydrofuran-2(3H)-one (129c) 
 
 
 
Synthesised using general procedure D with 2-phenylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate 
129b (73 mg, 0.215 mmol), CH2Cl2 (4.3 mL), Rh2(oct)4 (3.3 mg, 4.3 µmol), THF (4.3 mL), KOBu-
t (39.4 mg, 0.323 mmol) and paraformaldehyde (12.9 mg, 0.430 mmol). Purification by column 
chromatography (8:1 hexane:EtOAc) afforded the title compound 129c as a colourless oil (24 mg, 
59%); Rf 0.33 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2922w, 1761s, 1661w, 1496w, 1446w, 
1406w, 1291w, 1253w, 1211w, 1103m, 1012m, 949w, 816w, 765w, 700m; δH (400 MHz, CDCl3) 
1.67 (3 H, s, H-6), 4.26 (1 H, d, J = 9.0, H-4), 4.52 (1 H, d, J = 9.0, H-4), 5.53 (1 H, s, H-5b), 6.42 
(1 H, s, H-5a), 7.27–7.39 (5 H, m, H-8,9,10); δC (100 MHz, CDCl3) 26.1 (C-6), 46.8 (C-3), 79.5 
(C-4), 123.0 (C-5), 126.2 (C-8/9/10), 127.3 (C-8/9/10), 128.8 (C-8/9/10), 143.5 (C-7), 144.1 (C-2), 
170.3 (C-1); HRMS (ESI+): Found: 211.0738; C12H12NaO2 (MNa+) Requires 211.0730 (−3.8 ppm 
error), Found: 189.0911; C12H13O2 (MH+) Requires 189.0910 (−0.4 ppm error). 
Lab notebook reference: MGL/03/95 
2-Methylpropyl 2-(diethoxyphosphoryl)acetate (130a) 
 
 
 
Synthesised using general procedure A with 2-methylpropanol 130 (593 mg, 8.00 mmol), toluene 
(40 mL), DEPAA (1.35 mL, 8.40 mmol), DIPEA (3.62 mL, 20.8 mmol) and T3P (6.62 g, 10.4 
mmol, 50% w/w solution in EtOAc) affording the title compound 130a as a yellow oil (2.02 g, 
100%). No further purification was required; Rf 0.24 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2965m, 1735s, 1394w, 1265s, 1117w, 1052w, 1024s; δH (400 MHz, CDCl3) 0.94 (6 H, d, J = 6.7, 
H-7), 1.32 (6 H, t, J = 7.1, H-4), 1.95 (1 H, app. nonet, J = 6.7, H-6), 2.97 (2 H, d, J = 21.6, H-2), 
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3.92 (2 H, d, J = 6.7, H-5), 4.17 (4 H, dq, J = 8.3, J = 7.1, H-3); δC (100 MHz, CDCl3) 16.3 (d, J = 
6.5, C-4), 19.0 (C-7), 27.6 (C-6), 34.3 (d, J = 134.0, C-2), 62.6 (d, J = 6.2, C-3), 71.6 (C-5), 165.9 
(d, J = 6.4, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 275.1018; C10H21NaO5P 
(MNa+) Requires 275.1019 (0.3 ppm error), Found: 253.1202; C10H22O5P (MH+) Requires 
253.1199 (−1.1 ppm error). 
Lab notebook reference: MGL/03/16 
Obtained data in accord with reported literature.76 
2-Methylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate (130b) 
 
 
 
Synthesised using general procedure B with 2-methylpropyl 2-(diethoxyphosphoryl)acetate 130a 
(2.02 g, 8.00 mmol), THF (40 mL), LHMDS (9.60 mL, 9.60 mmol, 1.0 M solution in THF) and p-
ABSA (2.31 g, 9.60 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded 
the title compound 130b as a pale yellow oil (1.62 g, 73%); Rf 0.50 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 2966m, 2127s, 1702s, 1276s, 1115w, 1019s, 978m; δH (400 MHz, CDCl3) 0.89 (6 H, d, 
J = 6.7, H-7), 1.31 (6 H, td, J = 7.1, J = 0.8, H-4), 1.91 (1 H, app. nonet, J = 6.7, J = 6.6, H-6), 3.93 
(2 H, d, J = 6.6, H-5), 4.06–4.22 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 18.7 
(C-7), 27.7 (C-6), 53.7 (d, J = 227.9, C-2), 63.4 (d, J = 5.7, C-3), 71.5 (C-5), 163.4 (d, J = 11.9, C-
1); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 301.0913; C10H19N2NaO5P (MNa+) Requires 
301.0924 (3.5 ppm error), Found: 279.1104; C10H20N2O5P (MH+) Requires 279.1104 (0.2 ppm 
error). 
Lab notebook reference: MGL/03/21 
Obtained data in accord with reported literature.76 
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4,4-Dimethyl-3-methylenedihydrofuran-2(3H)-one (130c)  
 
 
 
Synthesised using general procedure D with 2-methylpropyl 2-diazo-2-
(diethoxyphosphoryl)acetate 130b (85 mg, 0.305 mmol), CH2Cl2 (6.1 mL), Rh2(oct)4 (3.4 mg, 6.1 
µmol), KOBu-t (41.1 mg, 0.366 mmol) and paraformaldehyde (18.3 mg, 0.610 mmol). Purification 
by column chromatography (8:1 hexane:EtOAc) afforded the title compound 130c as a colourless 
oil (9 mg, 23%); Rf 0.39 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2966w, 2929w, 1760s, 1668w, 
1464w, 1410w, 1371w, 1294m, 1169w, 1107m, 1014m; δH (400 MHz, CDCl3) 1.26 (6 H, s, H-6), 
4.03 (2 H, s, H-4), 5.54 (1 H, s, H-5b), 6.20 (1 H, s, H-5a); δC (100 MHz, CDCl3) 26.9 (C-6), 38.9 
(C-3), 78.3 (C-4), 119.9 (C-5), 144.7 (C-2), 170.8 (C-1); HRMS (ESI+): Found: 127.0758; C7H11O2 
(MH+) Requires 127.0754 (−3.6 ppm error). 
Lab notebook reference: MGL/03/42 
Obtained data in accord with reported literature.160 
1,3-Diphenylpropan-2-yl 2-(diethoxyphosphoryl)acetate (131a) 
 
 
 
Synthesised using general procedure A with 1,3-diphenylpropan-2-ol 130 (2.50 g, 11.8 mmol), 
toluene (60 mL), DEPAA (2.00 mL, 12.4 mmol), DIPEA (5.30 mL, 30.6 mmol) and T3P (9.74 g, 
15.3 mmol, 50% w/w solution in EtOAc) affording the title compound 131a as a yellow oil (4.48 g, 
98%). No further purification was required; Rf 0.26 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2938s, 
2883s, 1708s, 1249s, 1097w, 1036w, 1011m, 955w; δH (400 MHz, CDCl3) 1.29 (6 H, td, J = 7.1, J 
= 0.5, H-4), 2.82–2.96 (4 H, m, H-6), 2.87 (2 H, d, J = 21.5, H-2), 4.01–4.11 (4 H, m, H-3), 5.31–
5.39 (1 H, m, H-5), 7.18–7.24 (6 H, m, H-8,10), 7.26–7.31 (4 H, m, H-9); δC (100 MHz, CDCl3) 
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16.3 (d, J = 6.2, C-4), 34.3 (d, J = 134.4, C-2), 39.5 (C-6), 62.5 (d, J = 6.2, C-3), 76.8 (C-5), 126.5 
(C-10), 128.3 (C-9), 129.4 (C-8), 137.1 (C-7), 165.2 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.3; 
HRMS (ESI+): Found: 413.1472; C21H27NaO5P (MNa+) Requires 413.1488 (3.9 ppm error), Found: 
391.1661; C21H28O5P (MH+) Requires 391.1669 (1.9 ppm error). 
Lab notebook reference: MGL/01/25 
1,3-Diphenylpropan-2-yl 2-diazo-2-(diethoxyphosphoryl)acetate (131b) 
 
 
 
Synthesised using general procedure B with 1,3-diphenylpropan-2-yl 2-
(diethoxyphosphoryl)acetate 131a (1.00 g, 2.56 mmol), THF (13 mL), LHMDS (3.07 mL, 3.07 
mmol, 1.0 M solution in THF) and p-ABSA (739 mg, 3.07 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 131b as a yellow oil (778 mg, 
73%); Rf 0.62 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2939m, 2096s, 1683s, 1257s, 1009m; δH 
(400 MHz, CDCl3) 1.25 (6 H, td, J = 7.1, J = 0.7, H-4), 2.91 (4 H, d, J = 6.6, H-6), 3.88–4.10 (4 H, 
m, H-3), 4.45 (1 H, quin., J = 6.6, H-5), 7.17–7.25 (6 H, m, H-8,10), 7.26–7.37 (4 H, m, H-9); δC 
(100 MHz, CDCl3) 16.0 (d, J = 7.0, C-4), 40.1 (C-6), 54.0 (d, J = 226.5, C-2), 63.5 (d, J = 5.5, C-
3), 76.7 (C-5), 126.6 (C-10), 128.4 (C-9), 129.4 (C-8), 137.0 (C-7), 163.2 (d, J = 12.2, C-1); δP 
(162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 439.1382; C21H25N2NaO5P (MNa+) Requires 
439.1393 (2.7 ppm error), Found: 417.1565; C21H26N2O5P (MH+) Requires 417.1574 (2.0 ppm 
error). 
Lab notebook reference: MGL/01/27 
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(4RS,5SR)-5-Benzyl-3-methylene-4-phenyldihydrofuran-2(3H)-one (131c) 
 
 
 
Synthesised using general procedure E with 1,3-diphenylpropan-2-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 131b (81 mg, 0.195 mmol), CH2Cl2 (3.9 mL), Rh2(oct)4 (3.0 mg, 3.9 
µmol), KOBu-t (26.3 mg, 0.234 mmol) and paraformaldehyde (11.7 mg, 0.390 mmol). Purification 
by column chromatography (5:1 petrol:EtOAc) afforded the title compound 131c as a colourless oil 
(43 mg, 84%); Rf 0.52 (6:1 petrol:EtOAc); νmax (thin film)/cm-1 2877s, 2807w, 1738s, 895m, 721m; 
δH (400 MHz, CDCl3) 3.03 (1 H, dd, J = 14.5, J = 6.7, H-10), 3.11 (1 H, dd, J = 14.5, J = 4.6, H-
10), 3.86 (1 H, ddd, J = 7.4, J = 3.2, J = 2.9, H-3), 4.67 (1 H, ddd, J = 7.4, J = 6.7, J = 4.6, H-4), 
5.36 (1 H, dd, J = 2.9, H-5b), 6.33 (1 H, dd, J = 3.2, H-5a), 7.12–7.14 (2 H, m, ArH), 7.22–7.37 (8 
H, m, ArH); δC (100 MHz, CDCl3) 39.8 (C-10), 51.0 (C-3), 85.2 (C-4), 123.7 (C-5), [127.0, 127.8, 
128.3, 128.5, 129.1, 129.7 (C-7/8/9/12/13/14)], 135.5 (C-2/6/11), 138.8 (C-2/6/11), 140.0 (C-
2/6/11), 169.5 (C-1); HRMS (ESI+): Found: 287.1048; C18H16NaO2 (MNa+) Requires 287.1043 
(−2.1 ppm error), Found: 265.1229; C18H17O2 (MH+) Requires 265.1223 (−2.4 ppm error).  
Lab notebook reference: MGL/03/06, 01/32, 01/37 
1-(4-Methoxyphenyl)-3-phenylpropan-2-yl 2-(diethoxyphosphoryl) acetate (132a) 
 
 
 
Synthesised using general procedure A with 1-(4-methoxyphenyl)-3-phenylpropan-2-ol 132 (530 
mg, 2.19 mmol), toluene (15 mL), DEPAA (0.370 mL, 2.30 mmol), DIPEA (0.99 mL, 5.69 mmol) 
and T3P (1.81 g, 2.84 mmol, 50% w/w solution in EtOAc) affording an orange oil (972 mg) as 
crude. Purification by column chromatography (1:1 petrol:EtOAc) afforded the title compound 
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132a as a colourless oil (850 mg, 92%); Rf 0.26 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2937s, 
2872s, 1708s, 1490m, 1231s, 1012s; δH (400 MHz, CDCl3) 1.27–1.31 (6 H, m, H-4,4’), 2.75–2.93 
(4 H, m, H-6,12), 2.87 (2 H, d, J = 21.5, H-2), 3.79 (3 H, s, H-11), 4.02–4.13 (4 H, m, H-3,3’), 
5.25–5.33 (1 H, m, H-5), 6.82 (2 H, d, J = 8.7, H-9), 7.12 (2 H, d, J = 8.7, H-8), 7.17–7.24 (3 H, m, 
H-14,16), 7.25–7.31 (2 H, m, H-15); δC (100 MHz, CDCl3) 16.3 (d, J = 6.1, C-4), 34.3 (d, J = 
134.5, C-2), 38.7 (C-6), 39.5 (C-12), 55.2 (C-11), 62.3 (d, J = 6.3, C-3), 77.2 (C-5), 113.8 (C-9), 
126.5 (C-16), 128.4 (C-15), 129.1 (C-7), 129.4 (C-14), 130.4 (C-8), 137.2 (C-13), 158.3 (C-10), 
165.2 (d, J = 6.0, C-1); δP (162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 443.1587; C22H29NaO6P 
(MNa+) Requires 443.1594 (1.7 ppm error), Found: 421.1787; C22H30O6P (MH+) Requires 
421.1775 (−3.0 ppm error). 
Lab notebook reference: MGL/01/54 
1-(4-Methoxyphenyl)-3-phenylpropan-2-yl 2-diazo-2-(diethoxyphosphoryl) acetate 
(132b) 
 
 
 
Synthesised using general procedure B with 1-(4-methoxyphenyl)-3-phenylpropan-2-yl 2-
(diethoxyphosphoryl) acetate 132a (828 mg, 1.97 mmol), THF (10 mL), LHMDS (2.36 mL, 2.36 
mmol, 1.0 M solution in THF) and p-ABSA (568 mg, 2.36 mmol). Purification by column 
chromatography (1:1 petrol:EtOAc) afforded the title compound 132b as a yellow oil (621 mg, 
71%); Rf 0.40 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2939s, 2889w, 2094s, 1683s, 1490m, 
1258s, 1231w, 1009s; δH (400 MHz, CDCl3) 1.26 (6 H, td, J = 7.1, J = 0.8, H-4/4’), 2.86 (2 H, d, J 
= 6.5, H-6), 2.90 (2 H, d, J = 6.9, H-12), 3.78 (3 H, s, H-11), 3.89–4.00 (2 H, m, H-3/3’), 4.01–4.12 
(2 H, m, H-3/3’), 5.37 (1 H, m, H-5), 6.82 (2 H, d, J = 8.7, H-9), 7.10 (2 H, d, J = 8.7, H-8), 7.16–
7.24 (3 H, m, H-14,16), 7.25–7.31 (2 H, m, H-15); δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4/4’), 
16.1 (d, J = 6.9, C-4/4’), 39.2 (C-6), 40.0 (C-12), 53.2 (d, J = 232.8, C-2), 55.1 (C-11), 63.5 (d, J = 
5.4, C-3/3’), 76.8 (C-5), 113.8 (C-9), 126.6 (C-16), 128.4 (C-15), 128.9 (C-7), 129.3 (C-14), 130.3 
(C-8), 137.0 (C-13), 158.3 (C-10), 162.5 (d, J = 12.7, C-1); δP (162 MHz, CDCl3) 10.5; HRMS 
(ESI+): Found: 469.1485; C22H27N2NaO6P (MNa+) Requires 469.1499 (2.9 ppm error), Found: 
447.1680; C22H28N2NaO6P (MH+) Requires 447.1679 (−0.2 ppm error).  
Lab notebook reference: MGL/01/55 
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5-Benzyl-4-(4-methoxyphenyl)-3-methylenedihydrofuran-2(3H)-one (132c) 
 
 
 
Synthesised using general procedure E with 1-(4-methoxyphenyl)-3-phenylpropan-2-yl 2-diazo-2-
(diethoxyphosphoryl) acetate 132b (95 mg, 0.213 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.3 
µmol), KOBu-t (28.7 mg, 0.256 mmol) and paraformaldehyde (12.8 mg, 0.426 mmol). The HWE 
was performed at 0 °C. Purification by column chromatography (8:1 petrol:EtOAc) afforded the 
title compound 132c as an inseparable mixture of diastereomers A:B (1.6:1) as a colourless oil (41 
mg, 65%); Rf 0.71 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 2937w, 1764s, 1513m, 1251m, 1131w, 
1032w; δH (400 MHz, CDCl3) 2.91–3.12 (2 H, m, H-11A,B), 3.78–3.85 (4 H, m, H-3A,B, H-
10A,B), 4.58–4.65 (2 H, m, H-4A,B), 5.34–5.35 (1 H, m, H-5b(A,B)), 6.30–6.31 (1 H, m, H-
5a(A,B)), 6.83 (2 H, d, J = 8.7, H-8B), 6.88 (2 H, d, J = 8.7, H-8A), 7.05 (2 H, d, J = 8.7, H-7A), 
7.14 (2 H, d, J = 8.7, H-7B), 7.12–7.38 (5 H, m, H-13/14/15(A,B)); δC (100 MHz, CDCl3) 38.7 (C-
11B), 39.6 (C-11A), 50.4 (C-3A), 50.8 (C-3B), 55.2 (C-10B), 55.3 (C-10A), 85.3 (C-4B), 85.4 (C-
4A), 114.0 (C-8B), 114.5 (C-8A), 123.5 (C-5A), 123.6 (C-5B), [127.0, 127.4, 127.8, 128.3, 128.5, 
129.1, 129.4, 129.7, 130.5, 130.8 (C-6/7/13/14/15(A/B))], 135.6 (C-12A), 138.9 (C-12B), 140.1 
(C-2B), 140.3 (C-2A), 158.6 (C-9B), 159.1 (C-9A), 169.6 (C-1B), 169.6 (C-1A); HRMS (ESI+): 
Found: 317.1144; C19H18NaO3 (MNa+) Requires 317.1148 (1.2 ppm error), Found: 295.1326; 
C19H19O3 (MH+) Requires 295.1329 (0.8 ppm error). 
Lab notebook reference: MGL/03/07, 02/28 
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1-Phenylethyl 2-(diethoxyphosphoryl)acetate (133a) 
 
 
 
Synthesised using general procedure A with 1-phenylethanol 133 (0.60 mL, 5.00 mmol), toluene 
(25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 
mmol, 50% w/w solution in EtOAc) affording the title compound 133a as a pale orange oil (1.48 g, 
99%). No further purification was required; Rf 0.31 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2983w, 2933w, 1731s, 1496w, 1452w, 1393w, 1259s, 1208w, 1163w, 1113m, 1048w, 1019s, 960s, 
888w, 836w, 795w, 761m, 699s; δH (400 MHz, CDCl3) 1.26 (3 H, td, J = 7.1, J = 0.4, H-4/4’), 1.29 
(3 H, td, J = 7.1, J = 0.4, H-4/4’), 1.56 (3 H, d, J = 6.6, H-6), 2.97 (2 H, d, J = 21.6, H-2), 4.05–
4.16 (4 H, m, H-3,3’), 5.92 (1 H, q, J = 6.6, H-5), 7.26–7.38 (5 H, m, H-8,9,10); δC (100 MHz, 
CDCl3) 16.2 (d, J = 6.3, C-4/4’), 16.2 (d, J = 6.3, C-4/4’), 21.9 (C-6), 34.6 (d, J = 133.7, C-2), 62.6 
(d, J = 6.2, C-3/3’), 62.6 (d, J = 6.2, C-3/3’), 73.6 (C-5), 126.1 (C-8/9), 128.0 (C-10), 128.4 (C-
8/9), 140.9 (C-7), 165.0 (d, J = 6.3, C-1); δP (162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 
323.1017; C14H21NaO5P (MNa+) Requires 323.1019 (0.6 ppm error), Found: 301.1198; C14H22O5P 
(MH+) Requires 301.1199 (0.6 ppm error). 
Lab notebook reference: MGL/05/05S 
1-Phenylethyl 2-diazo-2-(diethoxyphosphoryl)acetate (133b) 
 
 
 
Synthesised using general procedure B with 1-phenylethyl 2-(diethoxyphosphoryl)acetate 133a 
(1.43 g, 4.76 mmol), THF (24 mL), LHMDS (5.71 mL, 5.71 mmol, 1.0 M solution in THF) and p-
ABSA (1.37 g, 5.71 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded 
the title compound 133b as a yellow oil (1.38 g, 89%); Rf 0.56 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2984w, 2129s, 1700s, 1496w, 1453w, 1332w, 1275s, 1209w, 1164w, 1115w, 1019s, 
979m, 797w, 762w, 746w, 700m, 588m, 553m; δH (400 MHz, CDCl3) 1.28–1.33 (6 H, m, H-4,4’), 
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1.57 (3 H, d, J = 6.6, H-6), 4.05–4.24 (4 H, m, H-3,3’), 5.98 (1 H, q, J = 6.6, H-5), 7.27–7.36 (5 H, 
m, H-8,9,10); δC (100 MHz, CDCl3) 16.0 (d, J = 7.0, C-4/4’), 16.0 (d, J = 7.0, C-4/4’), 22.3 (C-6), 
54.2 (d, J = 224.3, C-2), 63.5 (d, J = 5.5, C-3/3’), 63.5 (d, J = 5.9, C-3/3’), 73.8 (C-5), 125.9 (C-
8/9), 128.0 (C-10), 128.5 (C-8/9), 140.9 (C-7), 162.8 (d, J = 11.8, C-1); δP (162 MHz, CDCl3) 10.6; 
HRMS (ESI+): Found: 349.0919; C14H19N2NaO5P (MNa+) Requires 349.0924 (1.4 ppm error). 
Lab notebook reference: MGL/05/05 
Heptyl 2-(diethoxyphosphoryl)acetate (134a) 
 
 
 
Synthesised using general procedure A with 1-heptanol 134 (930 mg, 8.00 mmol), toluene (40 
mL), DEPAA (1.35 mL, 8.40 mmol), DIPEA (3.62 mL, 20.8 mmol) and T3P (6.62 g, 10.4 mmol, 
50% w/w solution in EtOAc) affording the title compound 134a as a yellow oil (2.36 g, 100%). No 
further purification was required; Rf 0.38 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2959w, 2931m, 
2859w, 1738s, 1393w, 1267s, 1116w, 1053w, 1025s; δH (400 MHz, CDCl3) 0.84 (3 H, t, J = 6.7, 
H-11), 1.19–1.35 (8 H, m, H-7,8,9,10), 1.31 (6 H, td, J = 7.1, J = 0.2, H-4), 1.61 (2 H, app. quin., J 
= 7.3, H-6), 2.93 (2 H, d, J = 21.6, H-2), 4.09 (2 H, br t, J = 6.8, H-5), 4.14 (4 H, dq, J = 8.4, J = 
7.1, H-3); δC (100 MHz, CDCl3) 14.0 (C-11), 16.2 (d, J = 6.2, C-4), 22.5 (C-10), 25.6 (C-7), 28.4 
(C-6), 28.8 (C-8), 31.6 (C-9), 34.3 (d, J = 134.2, C-2), 62.5 (d, J = 6.2, C-3), 65.6 (C-5), 165.8 (d, J 
= 6.2, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 317.1486; C13H27NaO5P (MNa+) 
Requires 317.1488 (0.6 ppm error), Found: 295.1675; C13H28O5P (MH+) Requires 295.1669 (−2.2 
ppm error). 
Lab notebook reference: MGL/03/17 
134a134
T3P
DIPEA
DEPAA
PhMe
O
O
P O
O
O
8
10
65
1
2
3
4
9
11
7
OH
  169 
Heptyl 2-diazo-2-(diethoxyphosphoryl)acetate (134b) 
 
 
 
 
Synthesised using general procedure B with heptyl 2-(diethoxyphosphoryl)acetate 134a (2.36 g, 
8.00 mmol), THF (40 mL), LHMDS (9.60 mL, 9.60 mmol, 1.0 M solution in THF) and p-ABSA 
(2.31 g, 9.60 mmol). Purification by column chromatography (3:1 petrol:EtOAc) afforded the title 
compound 134b as a pale yellow oil (1.50 g, 74%); Rf 0.65 (1:1 petrol:EtOAc); νmax (thin film)/cm-
1 2931m, 2859w, 2127s, 1705s, 1280s, 1023s, 978m; δH (400 MHz, CDCl3) 0.81 (3 H, t, J = 7.0, H-
11), 1.15–1.32 (8 H, m, H-7,8,9,10), 1.29 (6 H, td, J = 7.1, J = 0.8, H-4), 1.59 (2 H, app. quin., J = 
7.2, H-6), 4.04–4.20 (6 H, m, H-3,5); δC (100 MHz, CDCl3) 13.8 (C-11), 16.0 (d, J = 6.9, C-4), 
22.4 (C-10), 25.5 (C-7), 28.5 (C-6), 28.6 (C-8), 31.5 (C-9), 53.6 (d, J = 226.9, C-2), 63.4 (d, J = 
5.9, C-3), 65.6 (C-5), 163.3 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 
343.1390; C13H25N2NaO5P (MNa+) Requires 343.1393 (1.0 ppm error), Found: 321.1576; 
C13H26N2O5P (MH+) Requires 321.1574 (−0.6 ppm error). 
Lab notebook reference: MGL/03/22 
(SR)-3-Methylene-4-pentyldihydrofuran-2(3H)-one (134c) 
 
 
 
Synthesised using general procedure D with heptyl 2-diazo-2-(diethoxyphosphoryl)acetate 134b 
(78 mg, 0.244 mmol), CH2Cl2 (4.9 mL), Rh2(oct)4 (3.8 mg, 4.9 µmol), THF (4.9 mL), KOBu-t 
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(32.9 mg, 0.293 mmol) and paraformaldehyde (14.7 mg, 0.488 mmol). Purification by column 
chromatography (8:1 hexane:EtOAc) afforded the title compound 134c as a pale yellow oil (27 mg, 
66%); Rf 0.46 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2957w, 2929m, 2859w, 1763s, 1405w, 
1268m, 1112m, 1009w; δH (400 MHz, CDCl3) 0.87–0.90 (3 H, m, H-10), 1.24–1.38 (6 H, m, H-7, 
8, 9), 1.45–1.54 (1 H, m, H-6), 1.64–1.73 (1 H, m, H-6), 3.03 (1 H, app. ttt, J = 8.5, J = 5.6, J = 2.6, 
H-3), 3.97 (1 H, dd, J = 9.0, J = 5.6, H-4), 4.45 (1 H, app. t, J = 8.5, H-4), 5.59 (1 H, d, J = 2.6, H-
5b), 6.25 (1 H, d, J = 2.6, H-5a); δC (100 MHz, CDCl3) 13.9 (C-10), 22.4 (C-9), 26.0 (C-7), 31.6 
(C-8), 33.7 (C-6), 38.8 (C-3), 71.2 (C-4), 121.7 (C-5), 138.5 (C-2), 170.9 (C-1); HRMS (ESI+): 
Found: 191.1040; C10H16NaO2 (MNa+) Requires 191.1043 (1.4 ppm error). 
Lab notebook reference: MGL/03/40, 39  
3-Methylbutyl 2-(diethoxyphosphoryl)acetate (135a) 
 
 
 
Synthesised using general procedure A with 3-methyl-1-butanol 135 (882 mg, 10.0 mmol), toluene 
(50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P (8.27 g, 13.0 
mmol, 50% w/w solution in EtOAc) affording the title compound 135a as an orange oil (2.67 g, 
100%). No further purification was required; Rf 0.28 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2960w, 1735s, 1466w, 1392w, 1261s, 1116m, 1021s, 969m; δH (400 MHz, CDCl3) 0.90 (6 H, d, J 
= 6.6, H-8), 1.33 (6 H, td, J = 7.1, J = 0.4, H-4), 1.52 (2 H, app. q, J = 6.9, H-6), 1.63–1.76 (1 H, 
m, H-7), 2.94 (2 H, d, J = 21.6, H-2), 4.12–4.19 (6 H, m, H-3,5); δC (100 MHz, CDCl3) 16.3 (d, J = 
6.2, C-4), 22.3 (C-8), 24.8 (C-7), 34.3 (d, J = 134.2, C-2), 37.1 (C-6), 62.6 (d, J = 6.2, C-3), 64.2 
(C-5), 165.9 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 289.1356; 
C11H23NaO5P (MNa+) Requires 289.1175 (−1.9 ppm error), Found: 267.1356; C11H24O5P (MH+) 
Requires 267.1356 (0.0 ppm error). 
Lab notebook reference: MGL/03/47 
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3-Methylbutyl 2-diazo-2-(diethoxyphosphoryl)acetate (135b) 
 
 
 
Synthesised using general procedure B with 3-methylbutyl 2-(diethoxyphosphoryl)acetate 135a 
(1.60 g, 6.00 mmol), THF (30 mL), LHMDS (7.20 mL, 7.20 mmol, 1.0 M solution in THF) and p-
ABSA (1.73 g, 7.20 mmol). Purification by column chromatography (5:1 hexane:EtOAc) afforded 
the title compound 135b as a pale yellow oil (1.18 g, 67%); Rf 0.65 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2960w, 2125s, 1701s, 1389w, 1272s, 1215w, 1164w, 1116w, 1091w, 1016s, 977m; δH 
(400 MHz, CDCl3) 0.91 (6 H, d, J = 6.6, H-8), 1.35 (6 H, td, J = 7.1, J = 0.8, H-4), 1.54 (2 H, app. 
q, J = 6.8, H-6), 1.62–1.75 (1 H, m, H-7), 4.10–4.26 (4 H, m, H-3), 4.22 (2 H, t, J = 6.8, H-5); δC 
(100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 22.2 (C-8), 24.8 (C-7), 37.2 (C-6), 53.5 (d, J = 228.2, C-
2), 63.4 (d, J = 5.7, C-3), 64.1 (C-5), 163.3 (d, J = 12.0, C-1); δP (162 MHz, CDCl3) 10.8; HRMS 
(ESI+): Found: 315.1084; C11H21N2NaO5P (MNa+) Requires 315.1080 (−1.2 ppm error), Found: 
293.1263; C11H22N2O5P (MH+) Requires 293.1261 (−0.7 ppm error). 
Lab notebook reference: MGL/03/51 
(SR)-4-Isopropyl-3-methylenedihydrofuran-2(3H)-one (135c) 
 
 
 
Synthesised using general procedure D with 3-methylbutyl 2-diazo-2-(diethoxyphosphoryl)acetate 
135b (56 mg, 0.191 mmol), CH2Cl2 (3.8 mL), Rh2(oct)4 (3.0 mg, 3.8 µmol), THF (3.8 mL), KOBu-
t (25.7 mg, 0.229 mmol) and paraformaldehyde (11.5 mg, 0.382 mmol). Purification by column 
chromatography (8:1 pentane:diethyl ether) afforded the title compound 135c as a colourless oil (15 
mg, 56%); Rf 0.30 (8:1 pentane:diethyl ether); νmax (thin film)/cm-1 2963m, 1762s, 1409w, 1267w, 
1117m, 1039w, 979w; δH (400 MHz, CDCl3) 0.92 (3 H, d, J = 6.8, H-7/7’), 0.95 (3 H, d, J = 6.8, 
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H-7/7’), 1.87–1.99 (1 H, m, H-6), 2.93–2.99 (1 H, m, H-3), 4.16 (1 H, dd, J = 9.3, J = 4.0, H-4), 
4.35 (1 H, dd, J = 9.3, J = 8.1, H-4), 5.62 (1 H, d, J = 2.2, H-5b), 6.34 (1 H, d, J = 2.5, H-5a); δC 
(100 MHz, CDCl3) 17.7 (C-7/7’), 19.1 (C-7/7’), 31.4 (C-6), 44.6 (C-3), 68.3 (C-4), 123.1 (C-5), 
136.9 (C-2), 171.2 (C-1); HRMS (ESI+): Found: 163.0722; C8H12NaO2 (MNa+) Requires 163.0730 
(4.9 ppm error). 
Lab notebook reference: MGL/03/58 
3,3-Dimethylbutyl 2-(diethoxyphosphoryl)acetate (136a) 
 
 
 
Synthesised using general procedure A with 3,3-dimethyl-1-butanol 136 (1.02 g, 10.0 mmol), 
toluene (50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P (8.27 g, 
13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 136a as an orange oil (2.70 
g, 97%). No further purification was required; Rf 0.41 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 
2958w, 2870w, 1736s, 1478w, 1396w, 1261s, 1116m, 1023s, 971m; δH (400 MHz, CDCl3) 0.92 (9 
H, s, H-8), 1.33 (6 H, td, J = 7.1, J = 0.5, H-4), 1.57 (2 H, t, J = 7.7, H-6), 2.94 (2 H, d, J = 21.6, H-
2), 4.12–4.19 (6 H, m, H-3,5); δC (100 MHz, CDCl3) 16.3 (d, J = 6.3, C-4), 29.5 (C-8), 29.6 (C-7), 
34.3 (d, J = 134.3, C-2), 41.5 (C-6), 62.6 (d, J = 6.3, C-3), 63.4 (C-5), 165.9 (d, J = 6.0, C-1); δP 
(162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 303.1323; C12H25NaO5P (MNa+) Requires 
303.1332 (3.0 ppm error), Found: 281.1505; C12H26O5P (MH+) Requires 281.1512 (2.7 ppm error). 
Lab notebook reference: MGL/03/48 
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3,3-Dimethylbutyl 2-diazo-2-(diethoxyphosphoryl)acetate (136b) 
 
 
 
Synthesised using general procedure B with 3,3-dimethylbutyl 2-(diethoxyphosphoryl)acetate 136a 
(1.68 g, 6.00 mmol), THF (30 mL), LHMDS (7.20 mL, 7.20 mmol, 1.0 M solution in THF) and p-
ABSA (1.73 g, 7.20 mmol). Purification by column chromatography (3:1 hexane:EtOAc) afforded 
the title compound 136b as a pale yellow oil (1.22 g, 66%); Rf 0.49 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2959m, 2880w, 2125s, 1702s, 1276s, 1216w, 1164w, 1119w, 1095w, 1016s, 976m; δH 
(400 MHz, CDCl3) 0.89 (9 H, s, H-8), 1.31 (6 H, td, J = 7.1, J = 0.8, H-4), 1.54 (2 H, t, J = 7.4, H-
6), 4.06–4.22 (4 H, m, H-3), 4.21 (2 H, t, J = 7.4, H-5); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-
4), 29.4 (C-8), 29.6 (C-7), 41.6 (C-6), 53.5 (d, J = 228.5, C-2), 63.3 (C-5), 63.4 (d, J = 5.6, C-3), 
163.3 (d, J = 12.3, C-1); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 329.1223; 
C12H23N2NaO5P (MNa+) Requires 329.1237 (4.1 ppm error), Found: 307.1409; C12H24N2O5P 
(MH+) Requires 307.1417 (2.8 ppm error). 
Lab notebook reference: MGL/03/52 
(SR)-4-(tert-Butyl)-3-methylenedihydrofuran-2(3H)-one (136c) 
 
 
 
Synthesised using general procedure D with 3,3-dimethylbutyl 2-diazo-2-
(diethoxyphosphoryl)acetate 136b (58 mg, 0.189 mmol), CH2Cl2 (3.8 mL), Rh2(oct)4 (3.0 mg, 3.8 
µmol), THF (3.8 mL), KOBu-t (25.5 mg, 0.227 mmol) and paraformaldehyde (11.4 mg, 0.378 
mmol). Purification by column chromatography (8:1 pentane:diethyl ether) afforded the title 
compound 136c as a colourless oil (10 mg, 34%); Rf 0.24 (8:1 pentane:diethyl ether); νmax (thin 
film)/cm-1 2962m, 1765s, 1492w, 1401w, 1364w, 1274m, 1250w, 1119m, 1041w, 969w, 822w; δH 
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(400 MHz, CDCl3) 0.94 (9 H, s, H-7), 2.74–2.78 (1 H, m, H-3), 4.26–4.34 (2 H, m, H-4), 5.66 (1 
H, dd, J = 1.9, J = 0.7, H-5b), 6.38 (1 H, d, J = 2.1, H-5a); δC (100 MHz, CDCl3) 26.3 (C-7), 33.5 
(C-6), 49.1 (C-3), 67.8 (C-4), 124.5 (C-5), 136.2 (C-2), 171.3 (C-1); HRMS (ESI+): Found: 
177.0878; C9H14NaO2 (MNa+) Requires 177.0886 (4.7 ppm error), Found: 155.1063; C9H15O2 
(MH+) Requires 155.1067 (2.6 ppm error). 
Lab notebook reference: MGL/03/60 
3-(Trimethylsilyl)propyl 2-(diethoxyphosphoryl)acetate (137a) 
 
 
 
Synthesised using general procedure A with 3-(trimethylsilyl)-1-propanol 137 (882 mg, 10.0 
mmol), toluene (50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P 
(8.27 g, 13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 137a as an orange 
oil (3.11 g, 100%). No further purification was required; Rf 0.48 (1:2 hexane:EtOAc); νmax (thin 
film)/cm-1 2953w, 1735s, 1394w, 1248s, 1116m, 1021s, 969m; δH (400 MHz, CDCl3) −0.03 (9 H, 
s, H-8), 0.45–0.50 (2 H, m, H-7), 1.32 (6 H, td, J = 7.1, J = 0.4, H-4), 1.57–1.65 (2 H, m, H-6), 
2.94 (2 H, d, J = 21.6, H-2), 4.07 (2 H, t, J = 7.0, H-5), 4.11–4.19 (4 H, m, H-3); δC (100 MHz, 
CDCl3) −1.9 (C-8), 12.2 (C-7), 16.3 (d, J = 6.2, C-4), 23.1 (C-6), 34.3 (d, J = 134.1, C-2), 62.6 (d, J 
= 6.2, C-3), 68.1 (C-5), 165.8 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 
333.1251; C12H27NaO5PSi (MNa+) Requires 333.1258 (2.1 ppm error), Found: 311.1432; 
C12H28O5PSi (MH+) Requires 311.1438 (1.9 ppm error). 
Lab notebook reference: MGL/03/49 
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3-(Trimethylsilyl)propyl 2-diazo-2-(diethoxyphosphoryl)acetate (137b) 
 
 
 
Synthesised using general procedure B with 3-(trimethylsilyl)propyl 2-(diethoxyphosphoryl)acetate 
137a (1.86 g, 6.00 mmol), THF (30 mL), LHMDS (7.20 mL, 7.20 mmol, 1.0 M solution in THF) 
and p-ABSA (1.73 g, 7.20 mmol). Purification by column chromatography (3:1 hexane:EtOAc) 
afforded the title compound 137b as a pale yellow oil (1.26 g, 63%); Rf 0.65 (1:1 hexane:EtOAc); 
νmax (thin film)/cm-1 2953w, 2126s, 1702s, 1276s, 1249w, 1216w, 1165w, 1119w, 1092w, 1020s, 
977m; δH (400 MHz, CDCl3) 0.04 (9 H, s, H-8), 0.44–0.48 (2 H, m, H-7), 1.33 (6 H, td, J = 7.1, J = 
0.8, H-4), 1.57–1.65 (2 H, m, H-6), 4.08–4.24 (4 H, m, H-3), 4.12 (2 H, t, J = 7.0, H-5); δC (100 
MHz, CDCl3) −1.8 (C-8), 12.3 (C-7), 16.2 (d, J = 6.9, C-4), 23.4 (C-6), 53.9 (d, J = 228.0, C-2), 
63.6 (d, J = 5.6, C-3), 68.3 (C-5), 163.5 (d, J = 12.1, C-1); δP (162 MHz, CDCl3) 10.8; HRMS 
(ESI+): Found: 359.1151; C12H25N2NaO5PSi (MNa+) Requires 359.1163 (3.3 ppm error), Found: 
337.1332; C12H26N2O5PSi (MH+) Requires 337.1343 (3.2 ppm error). 
Lab notebook reference: MGL/03/53 
(SR)-3-Methylene-4-((trimethylsilyl)methyl)dihydrofuran-2(3H)-one (137c) 
 
 
 
Synthesised using general procedure D with 3-(trimethylsilyl)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate 137b (61 mg, 0.197 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 3.9 
µmol), THF (4.0 mL), KOBu-t (33.2 mg, 0.296 mmol) and paraformaldehyde (11.8 mg, 0.394 
mmol). Purification by column chromatography (8:1 petrol:EtOAc) afforded the title compound 
137c as a colourless oil (27 mg, 75%); Rf 0.33 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2955w, 
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2898w, 1768s, 1403w, 1251s, 1109m, 1017m, 841s, 693w; δH (400 MHz, CDCl3) 0.06 (9 H, s, H-
7), 0.73 (1 H, dd, J = 14.8, J = 10.9, H-6), 1.08 (1 H, dd, J = 14.8, J = 3.8, H-6), 3.05–3.14 (1 H, m, 
H-3), 3.80 (1 H, dd, J = 8.7, J = 7.6, H-4), 4.49 (1 H, app. t, J = 8.6, H-4), 5.58 (1 H, d, J = 2.8, H-
5b), 6.24 (1 H, d, J = 3.1, H-5a); δC (100 MHz, CDCl3) −0.98 (C-7), 20.8 (C-6), 35.9 (C-3), 72.7 
(C-4), 120.8 (C-5), 141.1 (C-2), 170.8 (C-1); HRMS (ESI+): Found: 207.0807; C9H16NaO2Si 
(MNa+) Requires 207.0812 (2.4 ppm error), Found: 185.0986; C9H17O2Si (MH+) Requires 
185.0992 (3.6 ppm error). 
Lab notebook reference: MGL/03/62,82 
3-((tert-Butyldimethylsilyl)oxy)propyl 2-(diethoxyphosphoryl)acetate (138a) 
 
 
 
To a solution of NaH (60% dispersion in mineral oil) (480 mg, 12.0 mmol) in THF (20 mL) cooled 
to 0 °C was added 1,3-propanediol 196 (0.80 mL, 11.0 mmol) dropwise over 5 mins. The solution 
was allowed to warm at RT and stirred for 30 mins after which TBSCl (1.51 g, 10.0 mmol) was 
added then stirred at RT for 1 h. The solution was diluted with water (25 mL), extracted with 
diethyl ether (2 × 25 mL), washed with brine (25 mL), dried over MgSO4 and concentrated in 
vacuo to afford the crude alcohol 138, which was treated under the conditions of general procedure 
A with toluene (50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P 
(8.27 g, 13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 138a as a yellow oil 
(3.32 g, 90% over 2 steps); Rf 0.22 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2956w, 2930m, 
2857w, 1738s, 1473w, 1392w, 1258s, 1100m, 1054w, 1025s, 970m, 836s, 777m; δH (400 MHz, 
CDCl3) 0.04 (6 H, s, H-10), 0.88 (9 H, s, H-9), 1.34 (6 H, t, J = 7.1, H-4), 1.85 (2 H, tt, J = 6.5, J = 
6.0, H-6), 2.96 (2 H, d, J = 21.6, H-2), 3.69 (2 H, t, J = 6.0, H-7), 4.13–4.20 (4 H, m, H-3), 4.24 (2 
H, t, J = 6.5, H-5); δC (100 MHz, CDCl3) −5.4 (C-10), 16.3 (d, J = 6.2, C-4), 18.2 (C-8), 25.8 (C-9), 
31.7 (C-6), 34.3 (d, J = 134.3, C-2), 59.2 (C-7), 62.6 (d, J = 6.3, C-3), 62.6 (C-5), 165.8 (d, J = 6.1, 
C-1); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 391.1691; C15H33NaO6PSi (MNa+) 
Requires 391.1676 (−3.8 ppm error), Found: 369.1859; C15H34O6PSi (MH+) Requires 369.1857 
(−0.5 ppm error). 
Lab notebook reference: MGL/04/01 
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 3-((tert-Butyldimethylsilyl)oxy)propyl 2-diazo-2-(diethoxyphosphoryl) acetate (138b) 
 
 
 
Synthesised using general procedure B with 3-((tert-butyldimethylsilyl)oxy)propyl 2-
(diethoxyphosphoryl) acetate 138a (2.21 g, 6.00 mmol), THF (30 mL), LHMDS (7.20 mL, 7.20 
mmol, 1.0 M solution in THF) and p-ABSA (1.73 g, 7.20 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 138b as a yellow oil (1.42 g, 
60%); Rf 0.30 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 2964w, 2931w, 2866w, 2128s, 1707s, 
1474w, 1395w, 1281s, 1097m, 1024s, 838m, 777w; δH (400 MHz, CDCl3) −0.05 (6 H, s, H-10), 
0.79 (9 H, s, H-9), 1.26 (6 H, td, J = 7.1, J = 0.8, H-4), 1.77 (2 H, tt, J = 6.4, J = 6.0, H-6), 3.69 (2 
H, t, J = 6.0, H-7), 4.02–4.17 (4 H, m, H-3), 4.24 (2 H, t, J = 6.4, H-5); δC (100 MHz, CDCl3) −5.7 
(C-10), 15.9 (d, J = 6.9, C-4), 18.0 (C-8), 25.6 (C-9), 31.6 (C-6), 53.5 (d, J = 230.0, C-2), 58.8 (C-
7), 62.4 (C-5), 63.3 (d, J = 5.9, C-3), 163.1 (d, J = 11.6, C-1); δP (162 MHz, CDCl3) 10.6; HRMS 
(ESI+): Found: 417.1590; C15H31N2NaO6PSi (MNa+) Requires 417.1581 (−2.1 ppm error), Found: 
395.1768; C15H32N2O6PSi (MH+) Requires 395.1762 (−1.7 ppm error). 
Lab notebook reference: MGL/04/03 
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4-(((tert-Butyldimethylsilyl)oxy)methyl)-3-methylenedihydrofuran-2(3H)-one (138c) 
and 4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-3-methyleneoxetan-2-one (138d) 
 
 
 
Synthesised using general procedure D with 3-((tert-butyldimethylsilyl)oxy)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate 138b (83 mg, 0.210 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (35.3 mg, 0.315 mmol) and paraformaldehyde (12.6 mg, 0.420 
mmol). Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compounds 
4-(((tert-butyldimethylsilyl)oxy)methyl)-3-methylenedihydrofuran-2(3H)-one 138c as a colourless 
oil (9 mg, 18%) and 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methyleneoxetan-2-one 138d as a 
colourless oil (8 mg, 16%). 
 
Data for 138c; Rf 0.49 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2955m, 2930m, 2857m, 1766s, 
1663w, 1472m, 1408w, 1362w, 1258m, 1115s, 1039m, 1004m, 940w, 837s, 815w, 778m; δH (400 
MHz, CDCl3) 0.05 (3 H, s, H-9), 0.05 (3 H, s, H-9), 0.88 (9 H, s, H-8), 3.20–3.27 (1 H, m, H-3), 
3.65 (1 H, dd, J = 9.9, J = 7.2, H-6), 3.72 (1 H, dd, J = 9.9, J = 5.9, H-6), 4.21 (1 H, dd, J = 9.3, J = 
4.3, H-4), 4.42 (1 H, dd, J = 9.3, J = 8.2, H-4), 5.69 (1 H, d, J = 2.2, H-5b), 6.31 (1 H, d, J = 2.5, 
H-5a); δC (100 MHz, CDCl3) −5.6 (C-9), −5.5 (C-9), 18.2 (C-7), 25.7 (C-8), 41.2 (C-3), 64.8 (C-6), 
68.4 (C-4), 123.2 (C-5), 135.6 (C-2), 170.6 (C-1); HRMS (ESI+): Found: 265.1223; C12H22NaO3Si 
(MNa+) Requires 265.1230 (2.7 ppm error), Found: 243.1406; C12H23O3Si (MH+) Requires 
243.1411 (1.9 ppm error). 
 
Data for 138d; Rf 0.60 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2955m, 2930m, 2858m, 1826s, 
1472w, 1408w, 1362w, 1257m, 1208w, 1099s, 1049m, 946w, 834s, 778m; δH (400 MHz, CDCl3) 
0.07 (3 H, s, H-9), 0.07 (3 H, s, H-9), 0.90 (9 H, s, H-8), 2.00–2.09 (2 H, m, H-3), 3.80 (2 H, app. 
dd, J = 6.6, J = 5.2, H-6), 5.16 (1 H, app. ddt, J = 7.5, J = 5.7, J = 1.8, H-4), 5.47 (1 H, app. t, J = 
1.7, H-5b), 5.93 (1 H, app. t, J = 1.9, H-5a); δC (100 MHz, CDCl3) −5.5 (C-9), −5.4 (C-9), 18.3 (C-
7), 25.9 (C-8), 36.5 (C-3), 58.6 (C-6), 77.1 (C-4), 115.3 (C-5), 146.4 (C-2), 163.6 (C-1); HRMS 
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(ESI+): Found: 265.1227; C12H22NaO3Si (MNa+) Requires 265.1230 (1.3 ppm error), Found: 
243.1402; C12H23O3Si (MH+) Requires 243.1411 (3.8 ppm error). 
Lab notebook reference: MGL/04/05 
4-((tert-Butyldimethylsilyl)oxy)butyl 2-(diethoxyphosphoryl)acetate (139a) 
 
 
 
To a solution of NaH (60% dispersion in mineral oil) (240 mg, 6.00 mmol) in THF (10 mL) cooled 
to 0 °C was added 1,4-butanediol S1 (0.44 mL, 5.50 mmol) dropwise over 5 mins. The solution 
was allowed to warm at RT and stirred for 30 mins after which TBSCl (754 mg, 5.00 mmol) was 
added then stirred at RT for 1 h. The solution was diluted with water (25 mL), extracted with 
diethyl ether (2 × 25 mL), washed with brine (25 mL), dried over MgSO4 and concentrated in 
vacuo to afford the crude alcohol 139, which was treated under the conditions of general procedure 
A with toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P 
(4.14 g, 6.50 mmol, 50% w/w solution in THF) affording the title compound 139a as a yellow oil 
(1.76 g, 92% over 2 steps). No further purification was required; Rf 0.43 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2955w, 2929w, 2857w, 1737s, 1472w, 1391w, 1255s, 1164w, 1097s, 1052w, 
1023s, 968s, 892w, 834s, 774s; δH (400 MHz, CDCl3) 0.01 (6 H, s, H-11), 0.85 (9 H, s, H-10), 1.31 
(6 H, td, J = 7.1, J = 0.5, H-4), 1.51–1.58 (2 H, m, H-7), 1.65–1.72 (2 H, m, H-6), 2.93 (2 H, d, J = 
21.6, H-2), 3.60 (2 H, t, J = 6.2, H-8), 4.10–4.17 (6 H, m, H-3,5); δC (100 MHz, CDCl3) −5.4 (C-
11), 16.3 (d, J = 6.2, C-4), 18.2 (C-9), 25.1 (C-6), 25.8 (C-10), 28.9 (C-7), 34.2 (d, J = 134.2, C-2), 
62.4 (C-8), 62.6 (d, J = 6.4, C-3), 65.5 (C-5), 165.8 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.4; 
HRMS (ESI+): Found: 405.1833; C16H35NaO6PSi (MNa+) Requires 405.1833 (0.0 ppm error), 
Found: 383.2010; C16H36O6PSi (MH+) Requires 383.2013 (0.8 ppm error). 
Lab notebook reference: MGL/05/12S 
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4-((tert-Butyldimethylsilyl)oxy)butyl 2-diazo-2-(diethoxyphosphoryl)acetate (139b) 
 
 
 
Synthesised using general procedure B with 4-((tert-butyldimethylsilyl)oxy)butyl 2-
(diethoxyphosphoryl)acetate 139a (1.70 g, 4.44 mmol), THF (22 mL), LHMDS (5.33 mL, 5.33 
mmol, 1.0 M solution in THF) and p-ABSA (1.28 g, 5.33 mmol). Purification by column 
chromatography (2:1 hexane:EtOAc) afforded the title compound 139b as a yellow oil (1.05 g, 
58%); Rf 0.74 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2954w, 2930w, 2857w, 2126s, 1703s, 
1473w, 1389w, 1275s, 1257w, 1164w, 1095s, 1019s, 977s, 892w, 834s, 813w, 774s, 746w, 662w, 
589m, 560m; δH (400 MHz, CDCl3) −0.05 (6 H, s, H-11), 0.79 (9 H, s, H-10), 1.26 (6 H, td, J = 
7.1, J = 0.8, H-4), 1.45–1.52 (2 H, m, H-7), 1.61–1.68 (2 H, m, H-6), 3.54 (2 H, t, J = 6.2, H-8), 
4.02–4.18 (6 H, m, H-3,5); δC (100 MHz, CDCl3) −5.6 (C-11), 15.9 (d, J = 6.9, C-4), 18.0 (C-9), 
25.2 (C-6), 25.7 (C-10), 28.7 (C-7), 53.5 (d, J = 227.3, C-2), 62.2 (C-8), 63.3 (d, J = 6.0, C-3), 65.4 
(C-5), 163.2 (d, J = 11.9, C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 431.1748; 
C16H33N2NaO6PSi (MNa+) Requires 431.1738 (−2.4 ppm error), Found: 409.1928; C16H34N2O6PSi 
(MH+) Requires 409.1918 (−2.4 ppm error). 
Lab notebook reference: MGL/05/12 
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4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-3-methylenedihydrofuran-2(3H)-one (139c) 
 
 
 
Synthesised using general procedure D with 4-((tert-butyldimethylsilyl)oxy)butyl 2-diazo-2-
(diethoxyphosphoryl)acetate 139b (87 mg, 0.213 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 
mol), THF (4.2 mL), KOBu-t (35.9 mg, 0.320 mmol) and paraformaldehyde (12.8 mg, 0.426 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
139c as a colourless oil (27 mg, 49%); Rf 0.50 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2954m, 
2929m, 2857m, 1767s, 1472w, 1257s, 1103s, 1020m, 940w, 836s, 777m; δH (400 MHz, CDCl3) 
0.05 (3 H, s, H-10), 0.05 (3 H, s, H-10), 0.89 (9 H, s, H-9), 1.72 (1 H, dddd, J = 14.0, J = 9.1, J = 
7.5, J = 5.1, H-6), 1.91 (1 H, app. ddt, J = 14.0, J = 5.7, J = 4.9, H-6), 3.17–3.26 (1 H, m, H-3), 
3.65–3.76 (2 H, m, H-7), 4.07 (1 H, dd, J = 9.1, J = 6.1, H-4), 4.51 (1 H, dd, J = 9.1, J = 8.4, H-4), 
5.60 (1 H, d, J = 2.6, H-5b), 6.27 (1 H, d, J = 2.9, H-5a); δC (100 MHz, CDCl3) −5.5 (C-10), −5.5 
(C-10), 18.2 (C-8), 25.8 (C-9), 36.3 (C-6), 36.8 (C-3), 60.5 (C-7), 71.7 (C-4), 121.7 (C-5), 138.4 
(C-2), 170.8 (C-1); HRMS (ESI+): Found: 279.1393; C13H24NaO3Si (MNa+) Requires 279.1387 
(2.1 ppm error), Found: 257.1573; C13H25O3Si (MH+) Requires 257.1567 (2.2 ppm error). 
Lab notebook reference: MGL/05/26 
But-3-en-1-yl 2-(diethoxyphosphoryl)acetate (140a) 
 
 
 
Synthesised using general procedure A with but-3-en-1-ol 140 (0.43 mL, 5.00 mmol), toluene (25 
mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 
50% w/w solution in EtOAc) affording the title compound 140a as a pale yellow oil (1.24 g, 99%). 
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No further purification was required; Rf 0.20 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2983w, 
1735s, 1643w, 1445w, 1393w, 1257s, 1163w, 1115m, 1049w, 1019s, 964s, 839w, 782w, 733w; δH 
(400 MHz, CDCl3) 1.33 (6 H, td, J = 7.1, J = 0.4, H-4), 2.40 (2 H, app. qt, J = 6.8, J = 1.4, H-6), 
2.96 (2 H, d, J = 21.6, H-2), 4.12–4.20 (6 H, m, H-3,5), 5.05–5.14 (2 H, m, H-8), 5.78 (1 H, ddt, J 
= 17.1, J = 10.3, J = 6.8, H-7); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 32.8 (C-6), 34.2 (d, J = 
134.3, C-2), 62.6 (d, J = 6.3, C-3), 64.6 (C-5), 117.4 (C-8), 133.6 (C-7), 165.8 (d, J = 6.1, C-1); δP 
(162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 273.0868; C10H19NaO5P (MNa+) Requires 
273.0862 (−2.2 ppm error), Found: 251.1048; C10H20O5P (MH+) Requires 251.1043 (−2.0 ppm 
error). 
Lab notebook reference: MGL/05/06S 
But-3-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (140b) 
 
 
 
Synthesised using general procedure B with but-3-en-1-yl 2-(diethoxyphosphoryl)acetate 140a 
(1.20 g, 4.80 mmol), THF (24 mL), LHMDS (5.76 mL, 5.76 mmol, 1.0 M solution in THF) and p-
ABSA (1.38 g, 5.76 mmol). Purification by column chromatography (1:1 hexane:EtOAc) afforded 
the title compound 140b as a yellow oil (790 mg, 60%);Rf 0.43 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2984w, 2126s, 1702s, 1643w, 1445w, 1384w, 1276s, 1164w, 1117w, 1092w, 1019s, 
978s, 797m, 746m; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.8, H-4), 2.38 (2 H, app. qt, J 
= 6.7, J = 1.3, H-6), 4.07–4.23 (6 H, m, H-3,5), 5.03–5.11 (2 H, m, H-8), 5.74 (1 H, ddt, J = 17.1, J 
= 10.3, J = 6.7, H-7); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 33.0 (C-6), 53.7 (d, J = 226.3, 
C-2), 63.5 (d, J = 5.9, C-3), 64.5 (C-5), 117.5 (C-8), 133.4 (C-7), 163.3 (d, J = 12.1, C-1); δP (162 
MHz, CDCl3) 10.6; HRMS (ESI+): Found: 299.0768; C10H17N2NaO5P (MNa+) Requires 299.0767 
(−0.1 ppm error), Found: 277.0952; C10H18N2O5P (MH+) Requires 277.0948 (−1.5 ppm error). 
Lab notebook reference: MGL/05/06 
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(SR)-3-Methylene-4-vinyldihydrofuran-2(3H)-one (140c) and 3-Methyl-4-vinylfuran-
2(5H)-one (140d) 
 
 
 
Synthesised using general procedure D with but-3-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate 
140b (58 mg, 0.210 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 µmol), THF (4.2 mL), KOBu-
t (35.3 mg, 0.315 mmol) and paraformaldehyde (12.6 mg, 0.420 mmol). Purification by column 
chromatography (8:1 pentane:diethyl ether) afforded the title compounds 3-methylene-4-
vinyldihydrofuran-2(3H)-on 140c as a colourless oil (10 mg, 38%) and 3-methyl-4-vinylfuran-
2(5H)-one 140d as a colourless oil (2.3 mg, 9%). 
  
Data for 140c;161 Rf 0.54 (4:1 pentane:diethyl ether); νmax (thin film)/cm-1 2965, 2919, 2851, 1766, 
1238, 1112; δH (400 MHz, CDCl3) 3.68–3.76 (1 H, m, H-3), 4.02 (1 H, dd, J = 9.1, J = 7.4, H-4), 
4.53 (1 H, app. t, J = 9.0, H-4), 5.23–5.28 (2 H, m, H-7), 5.62 (1 H, d, J = 2.8, H-5b), 5.71 (1 H, 
ddd, J = 16.6, J = 10.4, J = 8.2, H-6), 6.33 (1 H, d, J = 3.2, H-5a); δC (100 MHz, CDCl3) 44.0 (C-
3), 70.0 (C-4), 119.2 (C-7), 123.4 (C-5), 135.0 (C-6), 137.0 (C-2), 170.1 (C-1); HRMS (ESI+): 
Found: 147.0411; C7H8NaO2 (MNa+) Requires 147.0417 (3.5 ppm error).  
 
Data for 140d;162 Rf 0.29 (4:1 pentane:diethyl ether); νmax (thin film)/cm-1 2925, 2855, 1752, 1663, 
1432, 1337, 1208, 1077, 1045; δH (400 MHz, CDCl3) 1.94 (3 H, s, H-5), 4.88–4.89 (2 H, m, H-4), 
5.49–5.56 (2 H, m, H-7), 6.72 (1 H, dd, J = 17.8, J = 11.0, H-6); δC (100 MHz, CDCl3) 8.8 (C-5), 
69.2 (C-4), 121.0 (C-7), 124.3 (C-2), 126.9 (C-6), 152.0 (C-3), 178.1 (C-1); HRMS (ESI+): Found: 
147.0417; C7H8NaO2 (MNa+) Requires 147.0417 (−0.4 ppm error), Found: 125.0598; C7H9O2 
(MH+) Requires 125.0597 (−0.7 ppm error). 
Lab notebook reference: MGL/05/20 
Obtained data in accord with reported literature.161-162 
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Cyclopropylmethyl 2-(diethoxyphosphoryl)acetate (141a) 
 
 
 
Synthesised using general procedure A with cyclopropylmethanol 141 (0.41 mL, 5.00 mmol), 
toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in THF) affording the title compound 141a as a yellow oil (1.23 g, 
98%). No further purification was required; Rf 0.23 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2984w, 1731s, 1446w, 1394w, 1369w, 1346w, 1257s, 1164w, 1115m, 1049w, 1018s, 966s, 943w, 
889w, 839m; δH (400 MHz, CDCl3) 0.27–0.31 (2 H, m, H-7), 0.55–0.59 (2 H, m, H-7), 1.09–1.20 
(1 H, m, H-6), 1.34 (6 H, t, J = 7.1, H-4), 2.98 (2 H, d, J = 21.5, H-2), 3.97 (2 H, d, J = 7.3, H-5), 
4.14–4.21 (4 H, m, H-3); δC (100 MHz, CDCl3) 3.3 (C-7), 9.6 (C-6),  16.3 (d, J = 6.4, C-4), 34.4 (d, 
J = 134.2, C-2), 62.7 (d, J = 6.3, C-3), 70.3 (C-5), 165.9 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 
20.4; HRMS (ESI+): Found: 273.0862; C10H19NaO5P (MNa+) Requires 273.0862 (0.1 ppm error), 
Found: 251.1047; C10H20O5P (MH+) Requires 251.1043 (−1.6 ppm error). 
Lab notebook reference: MGL/05/14S 
Cyclopropylmethyl 2-diazo-2-(diethoxyphosphoryl)acetate (141b) 
 
 
 
Synthesised using general procedure B with cyclopropylmethyl 2-(diethoxyphosphoryl)acetate 
141a (1.20 g, 4.80 mmol), THF (24 mL), LHMDS (5.75 mL, 5.75 mmol, 1.0 M solution in THF) 
and p-ABSA (1.38 g, 5.75 mmol). Purification by column chromatography (2:1 hexane:EtOAc) 
afforded the title compound 141b as a yellow oil (850 mg, 64%); Rf 0.43 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2986w, 2908w, 2125s, 1700s, 1446w, 1394w, 1348m, 1275s, 1216w, 1164w, 
1115w, 1082w, 1018s, 977w, 958s, 796m, 746m, 590m, 560m; δH (400 MHz, CDCl3) 0.25–0.29 (2 
H, m, H-7), 0.52–0.57 (2 H, m, H-7), 1.07–1.17 (1 H, m, H-6), 1.33 (6 H, t, J = 7.1, H-4), 4.01 (2 
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H, d, J = 7.3, H-5), 4.10–4.25 (4 H, m, H-3); δC (100 MHz, CDCl3) 3.2 (C-7), 9.8 (C-6), 16.1 (d, J 
= 6.9, C-4), 53.9 (d, J = 226.8, C-2), 63.6 (d, J = 5.6, C-3), 70.3 (C-5), 163.5 (d, J = 12.2, C-1); δP 
(162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 299.0771; C10H17N2NaO5P (MNa+) Requires 
299.0767 (−1.4 ppm error), Found: 277.0958; C10H18N2O5P (MH+) Requires 277.0948 (−3.7 ppm 
error). 
Lab notebook reference: MGL/05/14 
Cyclobutylmethyl 2-(diethoxyphosphoryl)acetate (142a) 
 
 
 
Synthesised using general procedure A with cyclobutylmethanol 142 (0.47 mL, 5.00 mmol), 
toluene (25 mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in THF) affording the title compound 142a as a yellow oil (1.31 g, 
99%). No further purification was required; Rf 0.22 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2980w, 2941w, 1733s, 1445w, 1393w, 1334w, 1259s, 1163w, 1115m, 1049w, 1019s, 964s, 838m, 
783m, 609m; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.5, H-4), 1.71–1.96 (4 H, m, H-7,8), 
2.00–2.08 (2 H, m, H-7), 2.61 (1 H, app. heptet, J = 7.4, H-6), 2.95 (2 H, d, J = 21.6, H-2), 4.08–
4.19 (6 H, m, H-3,5); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 18.3 (C-8), 24.6 (C-7), 33.9 (C-
6), 34.3 (d, J = 133.8, C-2), 62.6 (d, J = 6.2, C-3), 69.2 (C-5), 165.9 (d, J = 6.2, C-1); δP (162 MHz, 
CDCl3) 20.4; HRMS (ESI+): Found: 287.1033; C11H21NaO5P (MNa+) Requires 287.1019 (−5.0 
ppm error). 
Lab notebook reference: MGL/05/13S 
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Cyclobutylmethyl 2-diazo-2-(diethoxyphosphoryl)acetate (142b) 
 
 
 
Synthesised using general procedure B with cyclobutylmethyl 2-(diethoxyphosphoryl)acetate 142a 
(1.28 g, 4.84 mmol), THF (24 mL), LHMDS (5.81 mL, 5.81 mmol, 1.0 M solution in THF) and p-
ABSA (1.40 g, 5.81 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded 
the title compound 142b as a brown oil (949 mg, 68%); Rf 0.50 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2981w, 2942w, 2869w, 2125s, 1700s, 1445w, 1391w, 1335w, 1276s, 1216w, 1164w, 
1117w, 1095w, 1019w, 977m, 797m, 747m, 590m, 560m; δH (400 MHz, CDCl3) 1.34 (6 H, td, J = 
7.1, J = 0.8, H-4), 1.72–1.97 (4 H, m, H-7,8), 1.99–2.08 (2 H, m, H-7), 2.57–2.68 (1 H, m, H-6), 
4.09–4.25 (6 H, m, H-3,5); δC (100 MHz, CDCl3) 16.1 (d, J = 7.0, C-4), 18.3 (C-8), 24.5 (C-7), 
34.0 (C-6), 53.8 (d, J = 228.6, C-2), 63.5 (d, J = 5.9, C-3), 69.2 (C-5), 163.6 (d, J = 12.0, C-1); δP 
(162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 313.0917; C11H19N2NaO5P (MNa+) Requires 
313.0924 (2.1 ppm error), Found: 291.1097; C11H20N2O5P (MH+) Requires 291.1104 (2.5 ppm 
error). 
Lab notebook reference: MGL/05/13 
8-Methylene-6-oxaspiro[3.4]octan-7-one (142c) 
 
 
 
Synthesised using general procedure D with cyclobutylmethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 142b (59 mg, 0.203 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.2 mg, 4.1 
µmol), THF (4.0 mL), KOBu-t (34.2 mg, 0.305 mmol) and paraformaldehyde (12.2 mg, 0.406 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
142c as a colourless oil (22 mg, 78%); Rf 0.42 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2935w, 
1760s, 1662w, 1408w, 1296m, 1117m, 1005m, 942w, 814w; δH (400 MHz, CDCl3) 1.95–2.04 (2 
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H, m, H-7), 2.18–2.30 (4 H, m, H-6), 4.32 (2 H, s, H-4), 5.80 (1 H, s, H-5b), 6.26 (1 H, s, H-5a); δC 
(100 MHz, CDCl3) 15.3 (C-7), 34.5 (C-6), 44.5 (C-3), 78.1 (C-4), 119.9 (C-5), 143.1 (C-2), 169.8 
(C-1); HRMS (ESI+): Found: 161.0571; C8H10NaO2 (MNa+) Requires 161.0573 (1.5 ppm error), 
Found: 139.0748; C8H11O2 (MH+) Requires 139.0754 (3.9 ppm error). 
Lab notebook reference: MGL/05/29 
Cyclopentylmethyl 2-(diethoxyphosphoryl)acetate (143a) 
 
 
 
Synthesised using general procedure A with cyclopentanemethanol 143 (1.00 g, 10.0 mmol), 
toluene (50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P (8.27 g, 
13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 143a as an orange oil (2.78 
g, 100%). No further purification was required; Rf 0.27 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2964s, 2872w, 1736s, 1450w, 1395w, 1271s, 1116m, 1026s, 976m; δH (400 MHz, CDCl3) 1.19–
1.29 (2 H, m, H-7), 1.32 (6 H, td, J = 7.1, J = 0.4, H-4), 1.48–1.64 (4 H, m, H-8), 1.69–1.78 (2 H, 
m, H-7), 2.20 (1 H, app. heptet, J = 7.5, H-6), 2.95 (2 H, d, J = 21.6, H-2), 4.00 (2 H, d, J = 7.2, H-
5), 4.11–4.19 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 25.2 (C-8), 29.2 (C-7), 
34.2 (d, J = 134.1, C-2), 38.4 (C-6), 62.6 (d, J = 6.2, C-3), 69.4 (C-5), 165.9 (d, J = 6.1, C-1); δP 
(162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 301.1185; C12H23NaO5P (MNa+) Requires 
301.1175 (−3.1 ppm error), Found: 279.1362; C12H24O5P (MH+) Requires 279.1356 (−2.4 ppm 
error). 
Lab notebook reference: MGL/03/70 
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Cyclopentylmethyl 2-diazo-2-(diethoxyphosphoryl)acetate (143b) 
 
 
 
Synthesised using general procedure B with cyclopentylmethyl 2-(diethoxyphosphoryl)acetate 
143a (1.39 g, 5.00 mmol), THF (25 mL), LHMDS (6.00 mL, 6.00 mmol, 1.0 M solution in THF) 
and p-ABSA (1.44 g, 6.00 mmol). Purification by column chromatography (2:1 petrol:EtOAc) 
afforded the title compound 143b as a pale yellow oil (1.08 g, 71%); Rf 0.61 (1:1 petrol:EtOAc); 
νmax (thin film)/cm-1 2956m, 2872w, 2128s, 1702s, 1389w, 1279s, 1022s, 978m; δH (400 MHz, 
CDCl3) 1.18–1.27 (2 H, m, H-7), 1.33 (6 H, td, J = 7.1, J = 0.8, H-4), 1.46–1.63 (4 H, m, H-8), 
1.68–1.76 (2 H, m, H-7), 2.19 (1 H, app. heptet, J = 7.5, H-6), 4.06 (2 H, d, J = 7.1, H-5), 4.08–
4.24 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 25.2 (C-8), 29.1 (C-7), 38.5 (C-6), 
53.7 (d, J = 226.5, C-2), 63.5 (d, J = 5.9, C-3), 69.4 (C-5), 163.5 (d, J = 12.1, C-1); δP (162 MHz, 
CDCl3) 10.8; HRMS (ESI+): Found: 327.1068; C12H21N2NaO5P (MNa+) Requires 327.1080 (3.8 
ppm error), Found: 305.1258; C12H22N2O5P (MH+) Requires 305.1261 (1.0 ppm error). 
Lab notebook reference: MGL/03/77 
4-Methylene-2-oxaspiro[4.4]nonan-3-one (143c) 
 
 
 
Synthesised using general procedure D with cyclopentylmethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 143b (68 mg, 0.223 mmol), CH2Cl2 (4.4 mL), Rh2(oct)4 (3.5 mg, 4.7 
µmol), THF (4.4 mL), KOBu-t (37.5 mg, 0.335 mmol) and paraformaldehyde (13.4 mg, 0.446 
mmol). Purification by column chromatography (8:1 petrol:EtOAc) afforded the title compound 
143c as a colourless oil (27 mg, 79%); Rf 0.55 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2957m, 
2872w, 1765s, 1456w, 1414w, 1286w, 1112m, 1021w, 1000w; δH (400 MHz, CDCl3) 1.68–1.87 (8 
H, m, H-6,7), 4.11 (2 H, s, H-4), 5.54 (1 H, s, H-5b), 6.19 (1 H, s, H-5a); δC (100 MHz, CDCl3) 
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24.5 (C-7), 39.3 (C-6), 49.9 (C-3), 78.2 (C-4), 119.6 (C-5), 143.6 (C-2), 171.1 (C-1); HRMS 
(ESI+): Found: 175.0729; C9H12NaO2 (MNa+) Requires 175.0730 (0.4 ppm error), Found: 
153.0911; C9H13O2 (MH+) Requires 153.0910 (−0.4 ppm error). 
Lab notebook reference: MGL/03/81,80 
Cyclohexylmethyl 2-(diethoxyphosphoryl)acetate (144a)  
 
 
 
Synthesised using general procedure A with cyclohexanemethanol 144 (569 mg, 4.98 mmol), 
toluene (50 mL), DEPAA (0.84 mL, 5.23 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.12 g, 
6.47 mmol, 50% w/w solution in EtOAc) affording the title compound 144a as a yellow oil (1.44 g, 
99%). No further purification was required; Rf 0.53 (EtOAc); νmax (thin film)/cm-1 2927s, 2854m, 
1737s, 1269s, 1053w, 1026s; δH (400 MHz, CDCl3) 0.86–0.96 (2 H, m, H-6/7/8/9), 1.04–1.24 (3 H, 
m, H-6/7/8/9), 1.28 (6 H, t, J = 7.1, H-4), 1.54–1.70 (6 H, m, H-6/7/8/9), 2.91 (2 H, d, J = 21.6, H-
2), 3.89 (2 H, d, J = 6.6, H-5), 4.07–4.14 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-
4), 25.5 (C-7/8/9), 26.1 (C-7/8/9), 29.3 (C-7/8/9), 34.1 (d, J = 134.2, C-2), 36.8 (C-6), 62.5 (d, J = 
6.2, C-3), 70.5 (C-5), 165.7 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 
315.1338; C13H25NaO5P (MNa+) Requires 315.1332. 
Note: This compound was synthesised by another person. 
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Cyclohexylmethyl 2-diazo-2-(diethoxyphosphoryl)acetate (144b)  
 
 
 
Synthesised using general procedure B with cyclohexylmethyl 2-(diethoxyphosphoryl)acetate 144a 
(597 mg, 1.98 mmol), THF (25 mL), NaH (95.0 mg, 2.37 mmol, 60% dispersion in mineral oil) and 
p-ABSA (1.44 g, 6.00 mmol). Purification by column chromatography (3:1 petrol:EtOAc) afforded 
the title compound 144b as a yellow oil (410 mg, 68%); Rf 0.85 (EtOAc); νmax (thin film)/cm-1 
2930s, 2131s, 1705s, 1280s, 1024s; δH (400 MHz, CDCl3) 0.93–1.04 (2 H, m, H-6/7/8/9), 1.11–
1.30 (3 H, m, H-6/7/8/9), 1.36 (6 H, td, J = 7.1, J = 0.8), 1.55–1.77 (6 H, m, H-6/7/8/9), 4.01 (2 H, 
d, J = 6.5, H-5), 4.11–4.27 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.0 (d, J = 7.1, C-4), 25.5 (C-
7/8/9), 26.2 (C-7/8/9), 29.3 (C-7/8/9), 37.1 (C-6), 53.7 (d, J = 227.4, C-2), 63.5 (d, J = 5.6, C-3), 
70.6 (C-5), 163.5 (d, J = 12.0, C-1); δP (162 MHz, CDCl3) 10.9; HRMS (ESI+): Found: 341.1228; 
C13H23N2NaO5P (MNa+) Requires 341.1237. 
Note: This compound was synthesised by another person. 
4-Methylene-2-oxaspiro[4.5]decan-3-one (144c) 
 
 
 
Synthesised using general procedure D with cyclohexylmethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 144b (57 mg, 0.179 mmol), CH2Cl2 (3.6 mL), Rh2(oct)4 (2.8 mg, 3.6 
µmol), THF (3.6 mL), KOBu-t (30.2 mg, 0.269 mmol) and paraformaldehyde (10.8 mg, 0.358 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
144c as a colourless oil (15 mg, 50%); Rf 0.63 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2926m, 
2854w, 1759s, 1661w, 1451m, 1407w, 1305m, 1254m, 1113s, 1013s, 943m, 815m; δH (400 MHz, 
CDCl3) 1.24–1.75 (10 H, m, H-6,7,8), 4.15 (2 H, s, H-4), 5.54 (1 H, s, H-5b), 6.22 (1 H, s, H-5a); 
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δC (100 MHz, CDCl3) 22.5 (C-7), 25.0 (C-8), 36.2 (C-6), 42.4 (C-3), 75.3 (C-4), 120.7 (C-5), 144.4 
(C-2), 171.3 (C-1); HRMS (ESI+): Found: 189.0891; C10H14NaO2 (MNa+) Requires 189.0886 (−2.8 
ppm error), Found: 167.1065; C10H15O2 (MH+) Requires 167.1067 (1.1 ppm error). 
Lab notebook reference: MGL/05/33 
Cyclopentyl 2-(diethoxyphosphoryl)acetate (145a) 
 
 
 
Synthesised using general procedure A with cyclopentanol 145 (0.45 mL, 5.00 mmol), toluene (25 
mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 
50% w/w solution in THF) affording the title compound 145a as a yellow oil (1.12 g, 85%). No 
further purification was required; Rf 0.24 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2974m, 2874w, 
1730s, 1443w, 1393w, 1368w, 1259s, 1165m, 1114m, 1050w, 1019s, 966s, 839m, 780m; δH (400 
MHz, CDCl3) 1.34 (6 H, td, J = 7.1, J = 0.4, H-4), 1.54–1.90 (8 H, m, H-6,7), 2.92 (2 H, d, J = 
21.6, H-2), 4.16 (4 H, dq, J = 8.1, J = 7.1, H-3), 5.20 (1 H, tt, J = 5.6, J = 2.7, H-5); δC (100 MHz, 
CDCl3) 16.2 (d, J = 6.2, C-4), 23.6 (C-7), 32.4 (C-6), 34.5 (d, J = 133.5, C-2), 62.5 (d, J = 6.2, C-
3), 78.4 (C-5), 165.5 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.7; HRMS (ESI+): Found: 
287.1020; C11H21NaO5P (MNa+) Requires 287.1019 (−0.4 ppm error), Found: 265.1201; C11H22O5P 
(MH+) Requires 265.1199 (−0.5 ppm error). 
Lab notebook reference: MGL/05/10S 
Cyclopentyl 2-diazo-2-(diethoxyphosphoryl)acetate (145b) 
 
 
 
Synthesised using general procedure B with cyclopentyl 2-(diethoxyphosphoryl)acetate 145a (1.10 
g, 4.16 mmol), THF (21 mL), LHMDS (5.00 mL, 5.00 mmol, 1.0 M solution in THF) and p-ABSA 
(1.20 g, 5.00 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title 
compound 145b as a yellow oil (1.00 g, 83%); Rf 0.54 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
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2972m, 2875w, 2125s, 1696s, 1478w, 1443w, 1393w, 1321w, 1274s, 1218w, 1165m, 1121m, 
1089w, 1018s, 977m, 959m, 796m, 749m; δH (400 MHz, CDCl3) 1.29 (6 H, td, J = 7.1, J = 0.8, H-
4), 1.49–1.86 (8 H, m, H-6,7), 4.04–4.19 (4 H, m, H-3), 5.21 (1 H, tt, J = 5.6, J = 2.7, H-5); δC (100 
MHz, CDCl3) 16.0 (d, J = 7.0, C-4), 23.4 (C-7), 32.6 (C-6), 53.8 (d, J = 227.0, C-2), 63.3 (d, J = 
5.6, C-3), 78.6 (C-5), 163.0 (d, J = 11.7, C-1); δP (162 MHz, CDCl3) 10.9; HRMS (ESI+): Found: 
313.0930; C11H19N2NaO5P (MNa+) Requires 313.0924 (−2.0 ppm error), Found: 291.1111; 
C11H20N2O5P (MH+) Requires 291.1104 (−2.1 ppm error). 
Lab notebook reference: MGL/05/10 
Cyclohexyl 2-(diethoxyphosphoryl)acetate (146a) 
 
 
 
Synthesised using general procedure A with cyclohexanol 146 (1.59 g, 15.9 mmol), toluene (80 
mL), DEPAA (2.68 mL, 16.7 mmol), DIPEA (7.19 mL, 41.3 mmol) and T3P (13.1 g, 20.6 mmol, 
50% w/w solution in EtOAc) affording the title compound 146a as a dark orange oil (4.43 g, 
100%). No further purification was required; Rf 0.33 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2985w, 2937s, 2862m, 1729s, 1258s, 1114w, 1016s, 964s; δH (400 MHz, CDCl3) 1.16–1.52 (6 H, 
m, H-6/7/8), 1.30 (6 H, td, J = 7.1, J = 0.5, H-4), 1.65–1.73 (2 H, m, H-6/7/8), 1.77–1.84 (2 H, m, 
H-6/7/8), 2.90 (2 H, d, J = 21.6, H-2), 4.12 (4 H, dq, J = 8.4, J = 7.1, H-3), 4.76 (1 H, tt, J = 8.7, J 
= 4.2, H-5); δC (100 MHz, CDCl3) 16.2 (d, J = 6.2, C-4), 23.5 (C-7), 25.2 (C-8), 31.3 (C-6), 34.5 
(d, J = 133.4, C-2), 62.4 (d, J = 6.3, C-3), 73.9 (C-5), 165.1 (d, J = 6.4, C-1); δP (162 MHz, CDCl3) 
20.6; HRMS (ESI+): Found: 301.1162; C12H23NaO5P (MNa+) Requires 301.1175 (4.3 ppm error), 
Found: 279.1345; C12H24O5P (MH+) Requires 279.1356 (4.0 ppm error). 
Lab notebook reference: MGL/02/43 
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Cyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate (146b) 
 
 
 
Synthesised using general procedure B with cyclohexyl 2-(diethoxyphosphoryl)acetate 146a (2.78 
g, 10.0 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) and p-ABSA 
(2.88 g, 12.0 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded the title 
compound 146b as a pale yellow oil (2.68 g, 88%);Rf 0.50 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2990w, 2937s, 2864m, 2124s, 1694s, 1279s, 1260s, 1115w, 1013s, 976s; δH (400 MHz, CDCl3) 
1.18–1.50 (6 H, m, H-6/7/8), 1.31 (6 H, td, J = 7.1, J = 0.8, H-4), 1.64–1.71 (2 H, m, H-6/7/8), 
1.77–1.82 (2 H, m, H-6/7/8), 4.06–4.22 (4 H, m, H-3), 4.84 (1 H, tt, J = 8.4, J = 4.1, H-5); δC (100 
MHz, CDCl3) 16.0 (d, J = 7.2, C-4), 23.2 (C-7), 25.1 (C-8), 31.4 (C-6), 53.8 (d, J = 228.0, C-2), 
63.4 (d, J = 5.7, C-3), 74.0 (C-5), 162.8 (d, J = 11.8, C-1); δP (162 MHz, CDCl3) 10.9; HRMS 
(ESI+): Found: 327.1082; C12H21N2NaO5P (MNa+) Requires 327.1010 (−0.6 ppm error), Found: 
305.1263; C12H22N2O5P (MH+) Requires 305.1261 (−0.6 ppm error). 
Lab notebook reference: MGL/02/62 
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3-Methylene-1-oxaspiro[3.5]nonan-2-one (146d), (3aSR,7aRS)-3-
Methylenehexahydrobenzofuran-2(3H)-one (trans-146c) and (3aRS,7aRS)-3-
Methylenehexahydrobenzofuran-2(3H)-one (cis-146c)  
 
 
 
Synthesised using general procedure E with cyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate 
146b (84 mg, 0.276 mmol), CH2Cl2 (5.4 mL), Rh2(oct)4 (4.3 mg, 0.006 mmol), KOBu-t (37.2 mg, 
0.331 mmol) and paraformaldehyde (16.6 mg, 0.552 mmol). Purification by column 
chromatography (20:1 hexane:EtOAc) afforded the title compounds (146d trans-146c:cis-146c 
6:10:1) (18 mg, 43%); HRMS (ESI+): Found: 175.0726; C9H12NaO2 (MNa+) Requires 175.0730 
(1.9 ppm error), Found: 153.0914; C9H13O2 (MH+) Requires 153.0910 (−2.5 ppm error). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for 146d;163 Rf 0.70 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2937, 2861, 1814, 1450, 1177, 
1107, 1011; δH (400 MHz, CDCl3) 1.41–1.96 (10 H, m, H-4,5,6), 5.41 (1 H, d, J = 1.9, H-9b), 5.80 
(1 H, d, J = 1.9, H-9a); δC (100 MHz, CDCl3) 23.0, 24.6, 34.5, 87.2, 113.0, 150.1, 163.8.  
  
Data for trans-146c;164 Rf 0.65 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2940, 2864, 1770, 1251, 
1132, 1026, 996; δH (400 MHz, CDCl3) [1.32–1.44 (3 H, m), 1.57–1.67 (1 H, m), 1.83–1.87 (1 H, 
m), 1.95–1.98 (1 H, m), 2.11–2.15 (1 H, m), 2.24–2.29 (1 H, m), 2.37–2.44 (1 H, m) H-3,5,6,7,8)], 
3.71 (1 H, ddd, J = 11.5, J = 10.8, J = 3.7, H-4), 5.38 (1 H, d, J = 3.1, H-9b), 6.06 (1 H, d, J = 3.3, 
H-9a); δC (100 MHz, CDCl3) 24.0, 24.8, 25.8, 30.4, 48.9, 83.1, 117.1, 139.6, 170.7. 
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Data for cis-146c;164 Rf 0.57 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2936, 2864, 1763, 1263, 
1127, 965; δH (400 MHz, CDCl3) 1.31–1.94 (8 H, m, H-5,6,7,8), 2.99–3.05 (1 H, m, H-3), 4.52–
4.56 (1 H, m, H-4), 5.51 (1 H, d, J = 2.3, H-9b), 6.20 (1 H, d, J = 2.5, H-9a); δC (100 MHz, CDCl3) 
20.5, 21.1, 26.3, 28.9, 39.6. 76.9, 119.8, 139.9, 171.0. 
Lab notebook reference: MGL/03/32 
Obtained data in accord with reported literature.163, 164 
Cycloheptyl 2-(diethoxyphosphoryl)acetate (147a) 
 
 
 
Synthesised using general procedure A with cycloheptanol 147 (571 mg, 5.00 mmol), toluene (25 
mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 
50% w/w solution in THF) affording the title compound 147a as a colourless oil (1.45 g, 99%). No 
further purification was required; Rf 0.31 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2982w, 2929m, 
2861w, 1728s, 1446w, 1394w, 1266s, 1113m, 1051w, 1021s, 969s; δH (400 MHz, CDCl3) 1.32 (6 
H, td, J = 7.1, J = 0.5, H-4), 1.35–1.69 (10 H, m, H-6/7/8), 1.85–1.92 (2 H, m, H-6/7/8), 2.91 (2 H, 
d, J = 21.5, H-2), 4.10–4.18 (4 H, m, H-3), 4.95 (1 H, tt, J = 8.3, J = 4.3, H-5); δC (100 MHz, 
CDCl3) 16.3 (d, J = 6.5, C-4), 22.7 (C-6/7/8), 28.2 (C-6/7/8), 33.5 (C-6/7/8), 34.6 (d, J = 133.5, C-
2), 62.5 (d, J = 6.2, C-3), 76.5 (C-5), 165.1 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.7; HRMS 
(ESI+): Found: 293.1502; C13H26O5P (MH+) Requires 293.1512 (3.5 ppm error). 
Lab notebook reference: MGL/05/45 
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Cycloheptyl 2-diazo-2-(diethoxyphosphoryl)acetate (147b) 
 
 
 
Synthesised using general procedure B with cycloheptyl 2-(diethoxyphosphoryl)acetate 147a (1.40 
g, 4.79 mmol), THF (24 mL), LHMDS (5.75 mL, 5.75 mmol, 1.0 M solution in THF) and p-ABSA 
(1.38 g, 5.75 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title 
compound 147b as a yellow oil (1.35 g, 89%); Rf 0.52 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2987w, 2930m, 2861w, 2125s, 1694s, 1446w, 1369w, 1322w, 1270s, 1215w, 1164w, 1120m, 
1015s, 961s, 885w, 974m, 746s, 590s, 555s; δH (400 MHz, CDCl3) 1.26 (6 H, td, J = 7.1, J = 0.8, 
H-4), 1.31–1.66 (10 H, m, H-6/7/8), 1.77–1.85 (2 H, m, H-6/7/8), 4.01–4.17 (4 H, m, H-3), 4.96 (1 
H, tt, J = 8.1, J = 4.2, H-5); δC (100 MHz, CDCl3) 15.8 (d, J = 7.0, C-4), 22.4 (C-6/7/8), 27.9 (C-
6/7/8), 33.5 (C-6/7/8), 53.7 (d, J = 227.0, C-2), 63.2 (d, J = 6.0, C-3), 76.5 (C-5), 162.7 (d, J = 
11.9, C-1); δP (162 MHz, CDCl3) 10.9; HRMS (ESI+): Found: 341.1226; C13H23N2NaO5P (MNa+) 
Requires 341.1237 (3.1 ppm error), Found: 319.1410; C13H24N2O5P (MH+) Requires 319.1417 (2.4 
ppm error). 
Lab notebook reference: MGL/05/47 
 
(3aSR,8aRS)-3-Methyleneoctahydro-2H-cyclohepta[b]furan-2-one (trans-147c) and 
(3aRS,8aRS)-3-Methyleneoctahydro-2H-cyclohepta[b]furan-2-one (cis-147c) 
 
 
 
Synthesised using general procedure D with cycloheptyl 2-diazo-2-(diethoxyphosphoryl)acetate 
147b (72 mg, 0.226 mmol), CH2Cl2 (4.5 mL), Rh2(oct)4 (3.5 mg, 4.5 µmol), THF (4.5 mL), KOBu-
t (38.0 mg, 0.339 mmol) and paraformaldehyde (13.6 mg, 0.452 mmol). Purification by column 
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chromatography (4:1 hexane:EtOAc) afforded the title compounds (trans-147c:cis-147c 3.5:1) (19 
mg, 51%). 
 
A small quantity of the major (trans-147c) compound was separated for characterisation. The 
minor (cis-147c) compound was characterised from a mixture.  
  
Data for trans-147c;105a,165 Colourless oil; Rf 0.50 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2929, 
2861, 1761, 1667, 1454, 1400, 1313, 1262, 1246, 998; δH (400 MHz, CDCl3) 1.40–1.82 (8 H, m, 
H-5,6,7,8,9), 2.12–2.20 (1 H, m, H-9), 2.33–2.42 (1 H, m, H-5), 2.73–2.81 (1 H, m, H-3), 4.15 (1 H 
, ddd, J = 10.6, J = 9.3, J = 4.4, H-4), 5.46 (1 H, d, J = 3.2, H-10b), 6.18 (1 H, d, J = 3.5, H-10a); 
δC (100 MHz, CDCl3) 25.1, 25.3, 27.3, 28.0, 33.0, 45.6, 83.3, 119.6, 141.0, 170.5; HRMS (ESI+): 
Found: 189.0889; C10H14NaO2 (MNa+) Requires 189.0886 (−1.8 ppm error), Found: 167.1063; 
C10H15O2 (MH+) Requires 167.1067 (2.4 ppm error). 
 
Data for cis-147c;105b Rf 0.43 (4:1 hexane:EtOAc); δH (400 MHz, CDCl3) 1.17–1.97 (9 H, m, H-
5,6,7,8,9), 2.03–2.09 (1 H, m, H-5), 3.19–3.27 (1 H, m, H-3), 4.71 (1 H , ddd, J = 10.6, J = 8.6, J = 
3.6, H-4), 5.55 (1 H, d, J = 2.7, H-10b), 6.27 (1 H, d, J = 3.1, H-10a); δC (100 MHz, CDCl3) 24.2, 
27.4, 30.6, 31.2, 31.8, 43.1, 82.3, 122.0, 140.3, 170.4. 
Lab notebook reference: MGL/05/48 
Obtained data in accord with reported literature.105 
3-Phenylpropyl 2-(diethoxyphosphoryl)acetate (148a) 
 
 
 
Synthesised using general procedure A with 3-phenyl-1-propanol 148 (1.36 g, 10.0 mmol), toluene 
(50 mL), DEPAA (2.49 mL, 15.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P (8.27 g, 13.0 
mmol, 50% w/w solution in EtOAc), with heating to 80 °C for 2 h, affording the title compound 
148a as a yellow oil (3.04 g, 97%). No further purification was required; Rf 0.23 (1:1 
hexane:EtOAc); νmax (thin film)/cm-1 2983w, 1734s, 1455w, 1393w, 1266m, 1116w, 1050w, 
1020s; δH (400 MHz, CDCl3) 1.34 (6 H, t, J = 7.1, H-4), 1.93–2.01 (2 H, m, H-6), 2.70 (2 H, t, J = 
7.7, H-7), 2.96 (2 H, d, J = 21.6, H-2), 4.13–4.21 (6 H, m, H-3,5), 7.16–7.29 (5 H, m, H-8,9,10); δC 
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(100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 30.0 (C-6), 31.9 (C-7), 34.3 (d, J = 133.9, C-2), 62.6 (d, J 
= 6.5, C-3), 64.8 (C-5), 126.0 (C-11), 128.4 (C-9/10), 128.4 (C-9/10), 141.0 (C-8), 165.8 (d, J = 
6.1, C-1); δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 337.1166; C15H23NaO5P (MNa+) 
Requires 337.1175 (2.9 ppm error), Found: 315.1349; C15H24O5P (MH+) Requires 315.1356 (2.2 
ppm error). 
Lab notebook reference: MGL/03/46 
3-Phenylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate (148b) 
 
 
 
Synthesised using general procedure B with 3-phenylpropyl 2-(diethoxyphosphoryl)acetate 148a 
(1.89 g, 6.00 mmol), THF (30 mL), LHMDS (7.20 mL, 7.20 mmol, 1.0 M solution in THF) and p-
ABSA (1.73 g, 7.20 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded 
the title compound 148b as a pale yellow oil (1.18 g, 59%); Rf 0.45 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2984w, 2128s, 1702s, 1390w, 1275s, 1216w, 1164w, 1122w, 1098w, 1017s, 978m; δH 
(400 MHz, CDCl3) 1.34 (6 H, td, J = 7.1, J = 0.8, H-4), 1.93–2.01 (2 H, m, H-6), 2.68 (2 H, t, J = 
7.6, H-7), 4.10–4.26 (6 H, m, H-3,5), 7.13–7.19 (3 H, m, H-9,11), 7.24–7.28 (2 H, m, H-10); δC 
(100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 30.1 (C-6), 31.8 (C-7), 53.7 (d, J = 228.2, C-2), 63.4 (d, J 
= 5.7, C-3), 64.7 (C-5), 126.0 (C-11), 128.2 (C-9/10), 128.3 (C-9/10), 140.7 (C-8), 163.3 (d, J = 
12.1, C-1); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 363.1066; C15H21N2NaO5P (MNa+) 
Requires 363.1080 (4.0 ppm error), Found: 341.1251; C15H22N2O5P (MH+) Requires 341.1261 (2.8 
ppm error). 
Lab notebook reference: MGL/03/50 
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(SR)-4-Benzyl-3-methylenedihydrofuran-2(3H)-one (148c) 
 
 
 
Synthesised using general procedure D with 3-phenylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate 
148b (73 mg, 0.215 mmol), CH2Cl2 (4.3 mL), Rh2(oct)4 (3.3 mg, 4.3 µmol), THF (4.3 mL), KOBu-
t (29.0 mg, 0.258 mmol) and paraformaldehyde (12.9 mg, 0.430 mmol). Purification by column 
chromatography (8:1 petrol:EtOAc) afforded the title compound 148c as a colourless oil (25 mg, 
62%); Rf 0.29 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2912w, 1760s, 1661w, 1497w, 1455w, 
1406w, 1268m, 1116m, 999m; δH (400 MHz, CDCl3) 2.81 (1 H, dd, J = 13.8, J = 8.9, H-6), 2.98 (1 
H, dd, J = 13.8, J = 6.9, H-6), 3.33–3.42 (1 H, m, H-3), 4.07 (1 H, dd, J = 9.2, J = 5.2, H-4), 4.34 (1 
H, dd, J = 9.2, J = 8.0, H-4), 5.43 (1 H, d, J = 2.3, H-5b), 6.27 (1 H, d, J = 2.6, H-5a), 7.16–7.19 (2 
H, m, H-8), 7.24–7.28 (1 H, m, H-10), 7.30–7.35 (2 H, m, H-9); δC (100 MHz, CDCl3) 39.9 (C-6), 
40.1 (C-3), 70.6 (C-4), 122.7 (C-5), 126.9 (C-10), 128.7 (C-8/9), 128.9 (C-8/9), 137.4 (C-2/7), 
137.5 (C-2/7), 170.7 (C-1); HRMS (ESI+): Found: 211.0721; C12H12NaO2 (MNa+) Requires 
211.0730 (4.1 ppm error), Found: 189.0902; C12H13O2 (MH+) Requires 189.0910 (4.4 ppm error). 
Lab notebook reference: MGL/03/54,57 
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3-(1,3-Benzodioxol-5-yl) 2-(diethoxyphosphoryl)acetate (149a) 
 
 
 
To powdered LiAlH4 (1.516 g, 30.5 mmol) under argon was added ether (120 mL) via cannula 
whilst being cooled to 0 °C. A solution of (E)-ethyl 3-(1,3-benzodioxol-5-yl)acrylate S2 (1.68 g, 
7.63 mmol) in ether (20 mL) was added dropwise via cannula to the suspension over 5 mins and 
stirred at 0 °C for 1 h then at RT for 30 mins. The suspension was quenched at 0 °C dropwise with 
water (1.5 mL) followed by 15% aq. NaOH (1.5 mL) and again with water (4.5 mL) then stirred for 
30 mins at RT. The solution was filtered through a pad of Celite and washed with ether (50 mL). 
The filtrate was concentrated in vacuo affording the allylic alcohol 299, which was used without 
further purification. To a solution of alcohol 299 in methanol (30 mL) was added palladium on 
carbon (10% wt. % loading, 100 mg). The flask was purged 4 times with argon then 4 times with 
hydrogen. The mixture was stirred at RT for 16 h. The mixture was filtered through a pad of Celite 
and washed with methanol (50 mL). The filtrate was concentrated in vacuo to afford the saturated 
alcohol 149, which was used without further purification. Using general procedure A with alcohol 
149, toluene (40 mL), DEPAA (1.29 mL, 8.01 mmol), DIPEA (3.46 mL, 19.8 mmol) and T3P 
(6.31 g, 9.92 mmol, 50% w/w solution in EtOAc) afforded the title compound 149a as a colourless 
oil (2.21 g, 81% over 3 steps); Rf 0.28 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2988w, 1735s, 
1511s, 1493m, 1450w, 1246s, 1116w, 1024s, 970m; δH (400 MHz, CDCl3) 1.34 (6 H, td, J = 7.1, J 
= 0.5, H-4), 1.88–1.96 (2 H, m, H-6), 2.62 (2 H, t, J = 7.6, H-7), 2.97 (2 H, d, J = 21.6, H-2), 4.11–
4.21 (6 H, m, H-3,5), 5.91 (2 H, s, H-12), 6.61–6.63 (1 H, m, H-9), 6.66–6.67 (1 H, m, H-14), 6.72 
(1 H, d, J = 7.8, H-10); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 30.3 (C-6), 31.6 (C-7), 34.3 (d, 
J = 134.2, C-2), 62.7 (d, J = 6.3, C-3), 64.6 (C-5), 100.8 (C-12), 108.2 (C-10), 108.8 (C-14), 121.2 
(C-9), 134.8 (C-8), 145.8 (C-11/13), 147.6 (C-11/13), 165.8 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 
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20.5; HRMS (ESI+): Found: 381.1061; C16H23NaO7P (MNa+) Requires 381.1074 (3.3 ppm error), 
Found: 359.1245; C16H24O7P (MH+) Requires 359.1254 (2.6 ppm error). 
Lab notebook reference: MGL/03/73, 67, 68 
3-(1,3-Benzodioxol-5-yl)propyl 2-diazo-2-(diethoxyphosphoryl)acetate (149b) 
 
 
 
Synthesised using general procedure B with 3-(1,3-benzodioxol-5-yl)propyl 2-
(diethoxyphosphoryl)acetate 149a (2.09 g, 5.83 mmol), THF (29 mL), LHMDS (7.00 mL, 7.00 
mmol, 1.0 M solution in THF) and p-ABSA (1.68 g, 7.00 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 149b as a pale yellow oil (1.35 g, 
60%);  Rf 0.66 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2984w, 2130s, 1704s, 1504w, 1490m, 
1390w, 1280s, 1246w, 1099w, 1020s, 978w; δH (400 MHz, CDCl3) 1.35 (6 H, td, J = 7.1, J = 0.7, 
H-4), 1.88–1.95 (2 H, m, H-6), 2.60 (2 H, t, J = 7.5, H-7), 4.10–4.26 (6 H, m, H-3,5), 5.90 (2 H, s, 
H-12), 6.59 (1 H, dd, J = 7.9, J = 1.7, H-9), 6.64 (1 H, d, J = 1.7, H-14), 6.70 (1 H, d, J = 7.9, H-
10); δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 30.4 (C-6), 31.5 (C-7), 53.8 (d, J = 228.5, C-2), 
63.5 (d, J = 5.6, C-3), 64.6 (C-5), 100.7 (C-12), 108.1 (C-10), 108.7 (C-14), 121.0 (C-9), 134.5 (C-
8), 145.8 (C-11/13), 147.6 (C-11/13), 163.3 (d, J = 12.0, C-1); δP (162 MHz, CDCl3) 10.8; HRMS 
(ESI+): Found: 407.0967; C16H21N2NaO7P (MNa+) Requires 407.0979 (2.9 ppm error), Found: 
385.1147; C16H22N2O7P (MH+) Requires 385.1159 (3.1 ppm error). 
Lab notebook reference: MGL/03/76 
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3-(4-Methoxyphenyl)propyl 2-(diethoxyphosphoryl)acetate (150a) 
 
 
 
Synthesised using general procedure A with 3-(4-methoxyphenyl)propan-1-ol 150 (831 mg, 5.00 
mmol), toluene (25.0 mL), DEPAA (1.03 g, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P 
(4.14 g, 6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 150a as a yellow oil 
(1.66 g, 96%); Rf 0.09 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2982w, 1733s, 1612w, 1513s, 
1243s, 1177m, 1114m, 1019s, 964s, 834m, 813m, 783w; δH (400 MHz, CDCl3) 1.32 (6 H, t, J = 
7.1, H-12), 1.88–1.95 (2 H, m, H-7), 2.62 (2 H, t, J = 7.6, H-6), 2.95 (2 H, d, J = 21.6, H-10), 3.75 
(3 H, s, H-5), 4.10–4.19 (6 H, m, H-8,11), 6.80 (2 H, d, J = 8.7, H-2), 7.07 (2 H, d, J = 8.7, H-3); δC 
(100 MHz, CDCl3) 16.2 (d, J = 6.4, C-12), 30.2 (C-7), 30.9 (C-6), 34.2 (d, J = 134.1, C-10), 55.1 
(C-5), 62.5 (d, J = 6.3, C-11), 64.7 (C-8), 113.7 (C-2), 129.2 (C-3), 132.9 (C-4), 157.8 (C-1), 165.7 
(d, J = 6.1, C-9); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 367.1286; C16H25NaO6P 
(MNa+) Requires 367.1281 (−1.4 ppm error). 
Lab notebook reference: MGL/08/14 
3-(4-Methoxyphenyl)propyl 2-diazo-2-(diethoxyphosphoryl)acetate (150b) 
 
 
 
Synthesised using general procedure C with 3-(4-methoxyphenyl)propyl 2-
(diethoxyphosphoryl)acetate 150a (1.66 g, 4.82 mmol), DBSA (2.42 mL, 7.23 mmol), DBU (1.08 
mL, 7.23 mmol) and CH2Cl2 (48.0 mL). Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 150b as a pale yellow oil (1.70 mg, 95%); Rf 0.57 (1:4 
hexane:EtOAc); νmax (thin film)/cm-1 2985w, 2128s, 1702s, 1613w, 1513s, 1389w, 1276s, 1246s, 
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1018s, 978m, 813m, 746m, 591m, 560m; δH (400 MHz, CDCl3) 1.36 (6 H, td, J = 7.1, J = 0.8, H-
12), 1.91–1.98 (2 H, m, H-7), 2.63 (2 H, t, J = 7.6, H-6), 3.78 (3 H, s, H-5), 4.11–4.27 (6 H, m, H-
8,11), 6.82 (2 H, d, J = 8.7, H-2), 7.08 (2 H, d, J = 8.7, H-3); δC (100 MHz, CDCl3) 16.1 (d, J = 7.3, 
C-12), 30.4 (C-7), 30.9 (C-6), 54.0 (d, J = 226.6, C-10), 55.1 (C-5), 63.5 (d, J = 5.9, C-11), 64.8 
(C-8), 113.8 (C-2), 129.2 (C-3), 132.7 (C-4), 157.9 (C-1), 163.3 (d, J = 12.3, C-9); δP (162 MHz, 
CDCl3) 10.8; HRMS (ESI+): Found: 393.1196; C16H23N2NaO6P (MNa+) Requires 393.1186 (−2.6 
ppm error). 
Lab notebook reference: MGL/08/18 
4-(4-Methoxybenzyl)-3-methylenedihydrofuran-2(3H)-one (150c) 
 
 
 
Synthesised using general procedure D with 3-(4-methoxyphenyl)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate 150b (78 mg, 0.211 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (28.4 mg, 0.253 mmol) and paraformaldehyde (12.7 mg, 0.422 
mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 
150c as a colourless oil (20 mg, 43%); Rf 0.53 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 2912w, 
1760w, 1611m, 1513s, 1301m, 1248s, 1179m, 1114s, 1033m, 815m; δH (400 MHz, CDCl3) 2.75 (1 
H, dd, J = 13.9, J = 8.8, H-6), 2.90 (1 H, dd, J = 13.9, J = 7.0, H-6), 3.28–3.36 (1 H, m, H-3), 3.80 
(3 H, s, H-11), 4.05 (1 H, dd, J = 9.2, J = 5.1, H-4), 4.33 (1 H, dd, J = 9.2, J = 8.1, H-4), 5.42 (1 H, 
d, J = 2.3, H-5b), 6.26 (1 H, d, J = 2.6, H-5a), 6.85 (2 H, d, J = 8.6, H-9), 7.09 (2 H, d, J = 8.6, H-
8); δC (100 MHz, CDCl3) 39.0 (C-6), 40.3 (C-3), 55.2 (C-11), 70.6 (C-4), 114.1 (C-9), 122.7 (C-5), 
129.4 (C-7), 129.9 (C-8), 137.6 (C-2), 158.5 (C-10), 170.7 (C-1); HRMS (ESI+): Found: 241.0827; 
C13H14NaO3 (MNa+) Requires 241.0835 (3.5 ppm error). 
Lab notebook reference: MGL/08/31 
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3-(3-Methoxyphenyl)propyl 2-(diethoxyphosphoryl)acetate (151a) 
 
 
 
Synthesised using general procedure A with 3-(3-methoxyphenyl)propan-1-ol 151 (831 mg, 5.00 
mmol), toluene (25.0 mL), DEPAA (1.03 g, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P 
(4.14 g, 6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 151a as a yellow oil 
(1.66 g, 96%); Rf 0.09 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2982w, 1736s, 1601w, 1585w, 
1489w, 1392w, 1262s, 1154w, 1117w, 1025s, 970s; δH (400 MHz, CDCl3) 1.33 (6 H, t, J = 7.1, H-
14), 1.92–2.00 (2 H, m, H-9), 2.67 (2 H, t, J = 7.7, H-8), 2.96 (2 H, d, J = 21.6, H-12), 3.78 (3 H, s, 
H-7), 4.13–4.20 (6 H, m, H-10,13), 6.72–6.77 (3 H, m, H-2,4,6), 7.16–7.21 (1 H, m, H-5); δC (100 
MHz, CDCl3) 16.3 (d, J = 6.5, C-14), 29.9 (C-9), 31.9 (C-8), 34.2 (d, J = 133.8, C-12), 55.0 (C-7), 
62.6 (d, J = 6.6, C-13), 64.7 (C-10), 111.2 (C-2/4/6), 114.2 (C-2/4/6), 120.7 (C-2/4/6), 129.3 (C-5), 
142.6 (C-3), 159.6 (C-1), 165.8 (d, J = 6.1, C-11); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): 
Found: 367.1272; C16H25NaO6P (MNa+) Requires 367.1281 (2.5 ppm error). 
Lab notebook reference: MGL/08/13 
3-(3-Methoxyphenyl)propyl 2-diazo-2-(diethoxyphosphoryl)acetate (151b) 
 
 
 
Synthesised using general procedure C with 3-(3-methoxyphenyl)propyl 2-
(diethoxyphosphoryl)acetate 150a (1.66 g, 4.82 mmol), DBSA (2.42 mL, 7.23 mmol), DBU (1.08 
mL, 7.23 mmol) and CH2Cl2 (48.0 mL). Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 151b as a pale yellow oil (1.61 g, 90%); Rf 0.57 (1:4 
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hexane:EtOAc); νmax (thin film)/cm-1 2983w, 2127s, 1701s, 1602m, 1584m, 1489m, 1455m, 
1389m, 1273s, 1015s, 976s, 780m, 745m, 590m, 559m; δH (400 MHz, CDCl3) 1.36 (6 H, td, J = 
7.1, J = 0.7, H-14), 1.94–2.01 (2 H, m, H-9), 2.67 (2 H, t, J = 7.6, H-8), 3.78 (3 H, s, H-7), 4.11–
4.27 (6 H, m, H-10,13), 6.71–6.77 (3 H, m, H-2,4,6), 7.20 (1 H, app. t, J = 7.8, H-5); δC (100 MHz, 
CDCl3) 16.1 (d, J = 6.9, C-14), 30.0 (C-9), 31.8 (C-8), 53.9 (d, J = 226.6, C-12), 55.0 (C-7), 63.5 
(d, J = 6.2, C-13), 64.8 (C-10), 111.1 (C-2/4/6), 114.2 (C-2/4/6), 120.6 (C-2/4/6), 129.34 (C-5), 
142.3 (C-3), 159.6 (C-1), 163.3 (d, J = 12.1, C-11); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): 
Found: 393.1177; C16H23N2NaO6P (MNa+) Requires 393.1186 (2.2 ppm error). 
Lab notebook reference: MGL/08/17 
4-(3-Methoxybenzyl)-3-methylenedihydrofuran-2(3H)-one (151c) 
 
 
 
Synthesised using general procedure D with 3-(3-methoxyphenyl)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate 151b (77 mg, 0.208 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.2 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (28.0 mg, 0.250 mmol) and paraformaldehyde (12.5 mg, 0.416 
mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 
151c as a colourless oil (20 mg, 44%); Rf 0.52 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 2915w, 
1762s, 1601w, 1490w, 1262s, 1154w, 1116m, 1040m; δH (400 MHz, CDCl3) 2.77 (1 H, dd, J = 
13.8, J = 9.0, H-6), 2.96 (1 H, dd, J = 13.8, J = 6.8, H-6), 3.33–3.42 (1 H, m, H-3), 3.80 (3 H, s, H-
13), 4.06 (1 H, dd, J = 9.2, J = 5.2, H-4), 4.35 (1 H, dd, J = 9.2, J = 8.0, H-4), 5.47 (1 H, d, J = 2.4, 
H-5b), 6.28 (1 H, d, J = 2.7, H-5a), 6.71–6.72 (1 H, m, H-12), 6.77 (1 H, br. d, J = 7.5, H-8/10), 
6.79 (1 H, dd, J = 8.3, J = 2.5, H-8/10), 7.23 (1 H, app. t, J = 7.9, H-9); δC (100 MHz, CDCl3) 40.0 
(C-6), 40.1 (C-3), 55.3 (C-13), 70.7 (C-4), 112.1 (C-8/10), 114.9 (C-12), 121.3 (C-8/10), 122.8 (C-
5), 129.9 (C-9), 137.7 (C-2/7), 139.1 (C-2/7), 159.9 (C-11), 170.8 (C-1); HRMS (ESI+): Found: 
241.0846; C13H14NaO3 (MNa+) Requires 241.0835 (−4.5 ppm error). 
Lab notebook reference: MGL/08/30 
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3-(3,4-Dimethoxyphenyl)propyl 2-(diethoxyphosphoryl)acetate (152a) 
 
 
 
Synthesised using general procedure A with 3-(3,4-dimethoxyphenyl)propan-1-ol 152 (981 mg, 
5.00 mmol), toluene (25.0 mL), DEPAA (1.03 g, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and 
T3P (4.14 g, 6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 152a as a 
yellow oil (1.87 g, 100%); Rf 0.09 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2936w, 1732s, 1515s, 
1465m, 1257s, 1236w, 1157m, 1140m, 1116m, 1019s, 965s; δH (400 MHz, CDCl3) 1.31 (6 H, td, J 
= 7.1, J = 0.4, H-15), 1.89–1.96 (2 H, m, H-10), 2.62 (2 H, t, J = 7.6, H-9), 2.95 (2 H, d, J = 21.6, 
H-13), 3.82 (3 H, s, H-7/8), 3.84 (3 H, s, H-7/8), 4.11–4.18 (6 H, m, H-11,14), 6.68–6.77 (3 H, m, 
H-3,5,6); δC (100 MHz, CDCl3) 16.2 (d, J = 6.4, C-15), 30.2 (C-10), 31.4 (C-9), 34.2 (d, J = 134.0, 
C-13), 55.7 (C-7/8), 55.8 (C-7/8), 62.5 (d, J = 6.7, C-14), 64.7 (C-11), 111.1 (C-3/5/6), 111.5 (C-
3/5/6), 120.1 (C-3/5/6), 133.5 (C-4), 147.2 (C-1/2), 148.7 (C-1/2), 165.7 (d, J = 6.4, C-12); δP (162 
MHz, CDCl3) 20.4; HRMS (ESI+): Found: 397.1392; C17H27NaO7P (MNa+) Requires 397.1387 
(−1.4 ppm error). 
Lab notebook reference: MGL/08/12 
3-(3,4-Dimethoxyphenyl)propyl 2-diazo-2-(diethoxyphosphoryl)acetate (152b) 
 
 
 
Synthesised using general procedure C with 3-(3,4-dimethoxyphenyl)propyl 2-
(diethoxyphosphoryl)acetate 152a (1.87 g, 5.00 mmol), DBSA (2.42 mL, 7.25 mmol), DBU (1.08 
mL, 7.25 mmol) and CH2Cl2 (50.0 mL). Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 152b as a pale yellow oil (1.97 mg, 98%); Rf 0.53 (1:4 
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hexane:EtOAc); νmax (thin film)/cm-1 2936w, 2127s, 1701s, 1515s, 1465w, 1274s, 1260s, 1156w, 
1015s, 976s, 799m, 731s, 589s, 558s; δH (400 MHz, CDCl3) 1.36 (6 H, td, J = 7.1, J = 0.8, H-15), 
1.93–2.00 (2 H, m, H-10), 2.64 (2 H, t, J = 7.6, H-9), 3.85 (3 H, s, H-7/8), 3.87 (3 H, s, H-7/8), 
4.12–4.28 (6 H, m, H-11,14), 6.69–6.80 (3 H, m, H-3,5,6); δC (100 MHz, CDCl3) 16.0 (d, J = 7.2, 
C-15), 30.3 (C-10), 31.3 (C-9), 53.7 (d, J = 229.3, C-13), 55.6 (C-7/8), 55.7 (C-7/8), 63.5 (d, J = 
6.1, C-14), 64.7 (C-11), 111.1 (C-3/5/6), 111.5 (C-3/5/6), 120.0 (C-3/5/6), 133.2 (C-4), 147.2 (C-
1/2), 148.7 (C-1/2), 163.2 (d, J = 12.5, C-12); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 
423.1275; C17H25N2NaO7P (MNa+) Requires 423.1292 (3.9 ppm error). 
Lab notebook reference: MGL/08/16 
4-(3,4-Dimethoxybenzyl)-3-methylenedihydrofuran-2(3H)-one (152c) 
 
 
 
Synthesised using general procedure D with 3-(3,4-dimethoxyphenyl)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate 152b (86 mg, 0.215 mmol), CH2Cl2 (4.3 mL), Rh2(oct)4 (3.4 mg, 4.3 
µmol), THF (4.3 mL), KOBu-t (29.0 mg, 0.258 mmol) and paraformaldehyde (12.9 mg, 0.430 
mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 
152c as a colourless oil (20 mg, 37%); Rf 0.26 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 2911w, 
2836w, 1759s, 1590m, 1515s, 1465m, 1260s, 1157m, 1141m, 1115m, 1026m; δH (400 MHz, 
CDCl3) 2.75 (1 H, dd, J = 13.9, J = 8.8, H-6), 2.90 (1 H, dd, J = 13.9, J = 7.0, H-6), 3.29–3.38 (1 
H, m, H-3), 3.86 (3 H, s, H-13/14), 3.86 (3 H, s, H-13/14), 4.06 (1 H, dd, J = 9.2, J = 5.0, H-4), 
4.34 (1 H, dd, J = 9.2, J = 8.0, H-4), 5.43 (1 H, d, J = 2.3, H-5b), 6.26 (1 H, d, J = 2.6, H-5a), 6.68 
(1 H, d, J = 2.0, H-12), 6.71 (1 H, dd, J = 8.1, J = 2.0, H-8), 6.81 (1 H, d, J = 8.1, H-9); δC (100 
MHz, CDCl3) 39.6 (C-6), 40.3 (C-3), 55.8 (2 C, C-13,14), 70.5 (C-4), 111.2 (C-9), 111.9 (C-12), 
120.9 (C-12), 122.7 (C-5), 129.9 (C-7), 137.5 (C-2), 147.9 (C-10/11), 149.0 (C-10/11), 170.7 (C-
1); HRMS (ESI+): Found: 271.0950; C14H16NaO4 (MNa+) Requires 271.0941 (−3.3 ppm error). 
Lab notebook reference: MGL/08/29 
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5.2.1.1.  Buchner cyclisation 
1,1,2-Triphenylethyl 2-(diethoxyphosphoryl)acetate (153a)  
 
 
 
The procedure for the Grignard addition was followed according to the literature procedure.166  
To benzylmagnesium chloride solution (20 mL, 40 mmol, 2.0 M in THF) cooled to 0 °C under an 
atmosphere of argon, was added benzophenone S3 (5.47 g, 30 mmol). After 2 h stirring at RT a 
further addition of benzylmagnesium chloride (10 mL, 20 mmol) was made. The suspension was 
stirred overnight at RT. The suspension was quenched with sat. aq. NH4Cl. The organic layer was 
removed and the aqueous extracted with EtOAc (3 × 25 mL). The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo to afford the crude product 153 as a white powder 
(9.03 g). A portion of the crude material (3.35 g) was treated under the conditions of general 
procedure A with toluene (60 mL), DEPAA (2.06 mL, 12.8 mmol), DIPEA (5.52 mL, 31.7 mmol) 
and T3P (10.1 g, 15.8 mmol, 50% w/w solution in EtOAc). Purification by column 
chromatography (1:2 petrol:EtOAc) afforded the title compound 153a as a colourless oil (389 mg, 
8% over 2 steps); Rf 0.25 (1:2 petrol:EtOAc); νmax (thin film)/cm-1 2937s, 1711s, 1251s, 1218w, 
1012s; δH (400 MHz, CDCl3) 1.25 (6 H, td, J = 7.1, J = 0.3, H-4), 2.94 (2 H, d, J = 21.5, H-2), 
4.02–4.13 (6 H, m, H-3,6), 6.60–6.65 (2 H, m, ArH), 7.06–7.18 (3 H, m, ArH), 7.20–7.35 (10 H, 
m, ArH); δC (100 MHz, CDCl3) 16.2 (d, J = 6.3, C-4), 35.2 (d, J = 134.4, C-2), 42.7 (C-6), 62.4 (d, 
J = 6.2, C-3), 87.6 (C-5), 126.3 (C-12/13), 126.4 (C-10), 127.1 (C-14), 127.5 (C-8/9), 127.8 (C-
12/13), 130.4 (C-8/9), 135.3 (C-7), 143.9 (C-11), 163.8 (d, J = 6.4, C-1); δP (162 MHz, CDCl3) 
20.3; HRMS (ESI+): Found: 475.1636; C26H29NaO5P (MNa+) Requires 475.1645 (1.8 ppm error). 
Lab notebook reference: MGL/01/61,63 
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1,1,2-Triphenylethyl 2-diazo-2-(diethoxyphosphoryl)acetate (153b)  
 
 
 
Synthesised using general procedure B with 1,1,2-triphenylethyl 2-(diethoxyphosphoryl)acetate 
153a (308 mg, 0.681 mmol), THF (3.4 mL), LHMDS (0.82 mL, 0.82 mmol, 1.0 M solution in 
THF) and p-ABSA (196 mg, 0.82 mmol). Purification by column chromatography (2:1 
petrol:EtOAc) afforded the title compound 153b as a white crystalline solid (171 mg, 53%); Rf 0.77 
(1:2 petrol:EtOAc); νmax (thin film)/cm-1 2938w, 2884w, 2100s, 1675s, 1264s, 1219w, 1005m; m.p. 
68–72 °C; δH (400 MHz, CDCl3) 1.19 (6 H, td, J = 7.1, J = 0.7, H-4), 3.81–3.93 (2 H, m, H-3), 
4.03–4.13 (2 H, m, H-3), 4.14 (2 H, s, H-6), 6.61–6.65 (2 H, m, ArH), 7.06–7.18 (3 H, m, ArH), 
7.22–7.34 (10 H, m, ArH); δC (100 MHz, CDCl3) 15.9 (d, J = 7.6, C-4), 43.3 (C-6), 55.2 (d, J = 
227.8, C-2), 63.1 (d, J = 5.4, C-3), 88.3 (C-5), 126.1 (C-12/13), 126.5 (C-10), 127.2 (C-14), 127.5 
(C-8/9), 128.0 (C-12/13), 130.3 (C-8/9), 135.3 (C-7), 144.1 (C-11), 162.2 (d, J = 10.2, C-1); δP 
(162 MHz, CDCl3) 11.0; HRMS (ESI+): Found: 501.1527; C26H27N2NaO5P (MNa+) Requires 
501.1550 (4.5 ppm error).  
Lab notebook reference: MGL/02/05 
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Diethyl ((1SR,3aSR)-1-benzyl-3-oxo-1-phenyl-3,3a-dihydro-1H-cyclohepta[c]furan-
3a-yl)phosphonate (153e)  
 
 
 
To a solution of 1,1,2-triphenylethyl 2-diazo-2-(diethoxyphosphoryl)acetate 153b (47 mg, 0.098 
mmol) in toluene (5 mL) flushed with argon was added Rh2(esp)2 (3.7 mg, 4.9 µmol). The mixture 
was stirred at 100 °C for 4 h. Concentration in vacuo and purification by column chromatography 
(1:1 petrol:EtOAc) afforded the title compound 153e as an off-white solid (22 mg, 50%); Rf 0.22 
(1:1 petrol:EtOAc); m.p. 92–95 °C; νmax (thin film)/cm-1 2936w, 1744s, 1230m, 1034w, 1009m; δH 
(400 MHz, CDCl3) 1.35 (3 H, td, J = 7.1, J = 0.4, H-6/6’), 1.38 (3 H, td, J = 7.1, J = 0.4, H-6/6’), 
3.65 (1 H, d, J = 14.6, H-12), 4.10–4.28 (4 H, m, H-5,5’), 4.11 (1 H, d, J = 14.6, H-12), 5.31 (1 H, 
dd, J = 10.0, J = 6.3, H-7), 6.15–6.22 (2 H, m, 2 × CH), 6.27–6.36 (2 H, m, 2 × CH), 7.09–7.16 (5 
H, m, H-ArH), 7.19–7.30 (3 H, m, ArH), 7.32–7.36 (2 H, m, ArH); δC (100 MHz, CDCl3) 16.4 (d, J 
= 5.6, C-6/6’), 16.7 (d, J = 5.3, C-6/6’), 45.6 (C-12), 56.0 (d, J = 145.2, C-2), 63.8 (d, J = 7.5, C-
5/5’), 64.4 (d, J = 7.3, C-5/5’), 90.0 (d, J = 3.8, C-4), 119.1 (C-7), 124.2 (d, J = 7.2, C-8/11), 125.6 
(ArCH), 126.6 (C-9/10/16/20), 127.7 (C-9/10/16/20), 127.8 (ArCH), 128.4 (ArCH), 128.5 (d, J = 
7.4, C-8/11), 129.0 (C-9/10/16/20), 129.9 (C-9/10/16/20), 130.7 (ArCH), 134.4 (C-3), 135.0 (C-
13), 141.3 (C-17), 172.7 (d, J = 3.6, C-1); δP (162 MHz, CDCl3) 17.3; HRMS (ESI+): Found: 
473.1477; C26H27NaO5P (MNa+) Requires 473.1488 (2.5 ppm error), Found: 451.1660; C26H28O5P 
(MNa+) Requires 451.1669 (2.1 ppm error). 
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5.2.1.2.  α-Alkylidene-γ-butyrolactones 
 
Note: The assignment of Z- and E-configurations for α-alkylidene/arylidene-γ-butyrolactones is 
based on literature data for similar compounds.167 The isomers can be readily distinguished by 
comparison of the alkylidene proton, which is more downfield in the E-isomer (adjacent to the 
carbonyl). 
(SR,E)-4-(4-Methoxyphenyl)-3-(4-nitrobenzylidene)dihydrofuran-2(3H)-one (E-176) 
and (SR,Z)-4-(4-Methoxyphenyl)-3-(4-nitrobenzylidene) dihydrofuran-2(3H)-one (Z-
176) 
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (70 mg, 0.196 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 3.9 
µmol), THF (4.0 mL), KOBu-t (33.0 mg, 0.294 mmol) and 4-nitrobenzaldehyde (59.2 mg, 0.392 
mmol). The HWE was performed at 0 °C. Purification by column chromatography (4:1 
hexane:EtOAc) afforded the title compounds as an inseparable mixture of (E) and (Z) isomers (E-
176:Z-176 1:1.3), as an orange oil (44 mg, 69%); Rf 0.40 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 
2971w, 2916w, 2838w, 1752s, 1599s, 1513s, 1344s, 1248m, 1177m, 1031m; HRMS (ESI+): 
Found: 348.0850; C18H15NNaO5 (MNa+) Requires 348.0842 (−2.3 ppm error).  
 
The two isomers were characterized from the mixture. 
 
Data for E-176; δH (400 MHz, CDCl3) 3.76 (3 H, s, H-14), 4.29 (1 H, dd, J = 8.8, J = 3.4, H-4), 
4.56 (1 H, ddd, J = 8.0, J = 3.4, J = 2.5, H-3), 4.74 (1 H, dd, J = 8.8, J = 8.0, H-4), 6.83 (2 H, d, J = 
8.8, H-12), 7.09 (2 H, d, J = 8.8, H-11), 7.47 (2 H, d, J = 8.8, H-7), 7.81 (1 H, d, J = 2.5, H-5), 8.09 
(2 H, d, J = 8.8, H-8); δC (100 MHz, CDCl3) 43.8 (C-3), 55.4 (C-14), 74.2 (C-4), 115.0 (C-12), 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
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123.8 (C-8), 128.1 (C-11), 131.1 (C-7), 131.5 (C-2), 131.6 (C-10), 136.2 (C-5), 139.6 (C-6), 147.9 
(C-9), 159.3 (C-13), 171.7 (C-1). 
 
Data for Z-176; δH (400 MHz, CDCl3) 3.83 (3 H, s, H-14), 4.33 (1 H, dd, J = 8.4, J = 8.1, H-4), 
4.40 (1 H, ddd, J = 8.4, J = 8.1, J = 2.8, H-3), 4.74 (1 H, app. t, J = 8.4, J = 8.4, H-4), 6.69 (1 H, d, 
J = 2.8, H-5), 6.95 (2 H, d, J = 8.8, H-12), 7.23 (2 H, d, J = 8.8, H-11), 7.87 (2 H, d, J = 8.8, H-7), 
8.17 (2 H, d, J = 8.8, H-8); δC (100 MHz, CDCl3) 48.3 (C-3), 55.5 (C-14), 72.6 (C-4), 114.9 (C-12), 
123.3 (C-8), 129.5 (C-11), 130.8 (C-2), 131.4 (C-7), 133.6 (C-10), 138.3 (C-5), 139.4 (C-6), 147.8 
(C-9), 159.5 (C-13), 168.2 (C-1).  
Lab notebook reference: MGL/03/11, 04/15 
(SR,Z)-3-(1,3-Benzodioxol-5-ylmethylene)-4-(4-methoxyphenyl) dihydrofuran-2(3H)-
one (Z-177) and (SR,E)-3-(1,3-Benzodioxol-5-ylmethylene)-4-(4-
methoxyphenyl)dihydrofuran-2(3H)-one (E-177)  
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (70 mg, 0.196 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 3.9 
µmol), THF (4.0 mL), KOBu-t (33.0 mg, 0.294 mmol) and piperonal (58.9 mg, 0.392 mmol). The 
HWE was performed at reflux. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compounds as mixture of (Z) and (E) isomers (Z-177:E-177 1.2:1), as an orange 
oil (36 mg, 56%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for Z-177; Rf 0.33 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2907w, 1743s, 1611m, 1513s, 
1489w, 1448m, 1248s, 1158s, 1073m, 1036s, 930w; δH (400 MHz, CDCl3) 3.82 (3 H, s, H-17), 
4.26 (1 H, dd, J = 8.4, J = 7.8, H-4), 4.34 (1 H, app. td, J = 8.1, J = 2.4, H-3), 4.68 (1 H, app. t, J = 
8.4, H-4), 5.99 (2 H, s, H-10), 6.52 (1 H, d, J = 2.4, H-5), 6.76 (1 H, d, J = 8.2, H-8), 6.92 (2 H, d, J 
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= 8.7, H-15), 7.15 (1 H, dd, J = 8.2, J = 1.7, H-7), 7.21 (2 H, d, J = 8.7, H-14), 7.82 (1 H, d, J = 
1.7, H-12); δC (100 MHz, CDCl3) 48.4 (C-3), 55.3 (C-17), 72.6 (C-4), 101.4 (C-10), 107.8 (C-8), 
110.9 (C-12), 114.6 (C-15), 126.7 (C-2), 127.2 (C-7), 128.0 (C-6), 129.4 (C-14), 132.2 (C-13), 
141.6 (C-5), 147.6 (C-11), 149.1 (C-9), 159.1 (C-16), 169.1 (C-1); HRMS (ESI+): Found: 
347.0873; C19H16NaO5 (MNa+) Requires 347.0890 (4.8 ppm error), Found: 325.1065; C19H17O5 
(MH+) Requires 325.1071 (1.6 ppm error). 
 
Data for E-177; Rf 0.26 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2908w, 1744s, 1644m, 1611m, 
1511s, 1491w, 1448m, 1341w, 1263m, 1218m, 1172s, 1036s, 927w; δH (400 MHz, CDCl3) 3.78 (3 
H, s, H-17), 4.26 (1 H, dd, J = 8.7, J = 2.7, H-4), 4.49–4.52 (1 H, m, H-3), 4.68 (1 H, dd, J = 8.7, J 
= 7.9, H-4), 5.94 (1 H, d, J = 1.3, H-10), 5.95 (1 H, d, J = 1.3, H-10), 6.73 (1 H, d, J = 8.1, H-8), 
6.80 (1 H, d, J = 1.8, H-12), 6.86 (2 H, d, J = 8.7, H-15), 6.93 (1 H, dd, J = 8.1, J = 1.8, H-7), 7.14 
(2 H, d, J = 8.7, H-14), 7.70 (1 H, d, J = 2.1, H-5); δC (100 MHz, CDCl3) 43.6 (C-3), 55.3 (C-17), 
74.0 (C-4), 101.5 (C-10), 108.6 (C-8), 109.6 (C-12), 114.7 (C-15), 124.3 (C-2/6), 127.0 (C-7), 
127.9 (C-2/6), 128.0 (C-14), 132.6 (C-13), 139.0 (C-5), 148.0 (C-9/11), 149.3 (C-9/11), 158.9 (C-
16), 172.9 (C-1); HRMS (ESI+): Found: 347.0873; C19H16NaO5 (MNa+) Requires 347.0890 (4.8 
ppm error), Found: 325.1066; C19H17O5 (MH+) Requires 325.1071 (1.5 ppm error). 
Lab notebook reference: MGL/03/74,88 
(SR,Z)-3-Benzylidene-4-(4-methoxyphenyl)dihydrofuran-2(3H)-one (Z-178) and 
(SR,E)-3-Benzylidene-4-(4-methoxyphenyl)dihydrofuran-2(3H)-one (E-178) 
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (66 mg, 0.185 mmol), CH2Cl2 (3.9 mL), Rh2(oct)4 (2.9 mg, 3.7 
µmol), THF (3.9 mL), KOBu-t (31.0 mg, 0.278 mmol) and freshly distilled benzaldehyde (37.6 µL, 
0.370 mmol). The HWE was performed at RT. Purification by column chromatography (8:1 
petrol:EtOAc) afforded the title compounds as mixture of (Z) and (E) isomers (Z-178:E-178 1:1), 
as a pale yellow oil (34 mg, 65%).  
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Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-178; Rf 0.33 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2887m, 2869m, 1724s, 1490s, 
1229m, 1136m; δH (400 MHz, CDCl3) 3.83 (3 H, s, H-14), 4.28 (1 H, dd, J = 8.5, J = 7.8, H-4), 
4.37 (1 H, ddd, J = 8.5, J = 7.8, J = 2.7, H-3), 4.71 (1 H, dd, J = 8.5, J = 8.5, H-4), 6.67 (1 H, d, J = 
2.7, H-5), 6.94 (2 H, d, J = 8.7, H-12), 7.23 (2 H, d, J = 8.7, H-11), 7.31–7.39 (3 H, m, H-8,9), 
7.79–7.83 (2 H, m, H-7); δC (100 MHz, CDCl3) 48.2 (C-3), 55.3 (C-14), 72.4 (C-4), 114.6 (C-12), 
128.1 (C-8), 129.1 (C-2), 129.4 (C-11), 129.7 (C-9), 130.8 (C-7), 131.9 (C-10), 133.4 (C-6), 141.7 
(C-5), 159.2 (C-13), 168.8 (C-1); HRMS (ESI+): Found: 303.0979; C18H16NaO3 (MNa+) Requires 
303.0992 (4.1 ppm error), Found: 281.1183; C18H17O3 (MH+) Requires 281.1172 (−3.8 ppm error). 
 
Data for E-178; Rf 0.25 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2877m, 1724s, 1488s, 1228m, 
1153m; δH (400 MHz, CDCl3) 3.77 (3 H, s, H-14), 4.29 (1 H, dd, J = 8.7, J = 2.7, H-4), 4.56 (1 H, 
ddd, J = 7.9, J = 2.7, J = 2.2, H-3), 4.69 (1 H, dd, J = 8.7, J = 7.9, H-4), 6.84 (2 H, d, J = 8.8, H-
12), 7.14 (2 H, d, J = 8.8, H-11), 7.26–7.31 (3 H, m, H-8,9), 7.33–7.37 (2 H, m, H-7), 7.81 (1 H, d, 
J = 2.2, H-5); δC (100 MHz, CDCl3) 43.6 (C-3), 55.3 (C-14), 74.1 (C-4), 114.6 (C-12), 126.8 (C-2), 
128.0 (C-11), 128.7 (C-8), 130.0 (C-9), 130.6 (C-7), 132.6 (C-10), 133.6 (C-6), 139.2 (C-5), 158.9 
(C-13), 172.7 (C-1); HRMS (ESI+): Found: 303.0998; C18H16NaO3 (MNa+) Requires 303.0992 
(−2.0 ppm error), Found: 281.1167; C18H17O3 (MH+) Requires 281.1172 (1.9 ppm error). 
Lab notebook reference: MGL/03/89 
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(SR,Z)-3-(2-Fluorobenzylidene)-4-(4-methoxyphenyl)dihydrofuran-2(3H)-one (Z-179) 
and (SR,E)-3-(2-Fluorobenzylidene)-4-(4-methoxyphenyl) dihydrofuran-2(3H)-one 
(E-179)  
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (71 mg, 0.199 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 
µmol), THF (4.0 mL), KOBu-t (33.5 mg, 0.299 mmol) and 2-fluorobenzaldehyde (41.6 µL, 0.398 
mmol). The HWE was performed at RT. Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compounds as mixture of (Z) and (E) isomers (Z-179:E-179 
1.5:1), as a colourless oil (54 mg, 91%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for Z-179; Rf 0.40 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2919m, 2842w, 1757s, 1611m, 
1514s, 1484m, 1456w, 1371w, 1249s, 1160m, 1107m, 1072w, 1025m, 833w, 754m; δH (400 MHz, 
CDCl3) 3.83 (3 H, s, H-16), 4.28 (1 H, dd, J = 8.7, J = 7.8, H-4), 4.36–4.41 (1 H, m, H-3), 4.71 (1 
H, app. t, J = 8.7, H-4), 6.86 (1 H, d, J = 2.1, H-5), 6.94 (2 H, d, J = 8.7, H-14), 7.00–7.05 (1 H, m, 
H-10), 7.14 (1 H, app. td, J = 7.7, J = 1.0, H-8), 7.23 (2 H, d, J = 8.7, H-13), 7.29–7.35 (1 H, m, H-
9), 8.01 (1 H, app. td, J = 7.7, J = 1.6, H-7); δC (100 MHz, CDCl3) 47.9 (C-3), 55.3 (C-16), 72.5 
(C-4), 114.6 (C-14), 115.1 (d, J = 22.0, C-10), 121.4 (d, J = 12.3, C-6), 123.6 (d, J = 3.8, C-7/8/9), 
129.3 (C-13), 131.4 (C-2/12), 131.4 (d, J = 8.7, C-7/8/9), 131.5 (C-2/12), 131.7 (d, J = 1.5, C-
7/8/9), 133.0 (d, J = 5.4, C-5), 159.2 (C-15), 160.4 (d, J = 251.0, C-11), 168.5 (C-1); HRMS 
(ESI+): Found: 321.0886; C18H15FNaO3 (MNa+) Requires 321.0897 (3.6 ppm error), Found: 
299.1071; C18H16FNaO3 (MNa+) Requires 299.1078 (2.4 ppm error). 
 
Data for E-179; Rf 0.27 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2922m, 2852w, 1752s, 1649m, 
1611m, 1581w, 1512s, 1486m, 1458w, 1351w, 1302w, 1248s, 1211s, 1174s, 1154w, 1100w, 
1064w, 1032s, 832w, 808w, 792w, 758s; δH (400 MHz, CDCl3) 3.75 (3 H, s, H-16), 4.24 (1 H, dd, 
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J = 8.7, J = 3.7, H-4), 4.50–4.54 (1 H, m, H-3), 4.71 (1 H, app. t, J = 8.4, H-4), 6.79 (2 H, d, J = 
8.7, H-14), 6.92–6.96 (1 H, m, H-7/8/9), 6.98–7.03 (1 H, m, H-10), 7.08 (2 H, d, J = 8.7, H-13), 
7.15–7.20 (1 H, m, H-7/8/9), 7.22–7.28 (1 H, m, H-7/8/9), 7.99 (1 H, d, J = 2.4, H-5); δC (100 
MHz, CDCl3) 43.8 (C-3), 55.2 (C-16), 74.0 (C-4), 114.5 (C-14), 115.7 (d, J = 22.1, C-10), 121.8 
(d, J = 12.1, C-6), 123.9 (d, J = 3.7, C-7/8/9), 128.2 (C-13), 129.4 (C-2), 130.1 (d, J = 2.2, C-
7/8/9), 130.9 (d, J = 5.4, C-5), 131.6 (d, J = 8.8, C-7/8/9), 132.0 (C-12), 158.8 (C-15), 161.2 (d, J = 
253.4, C-11), 172.0 (C-1); HRMS (ESI+): Found: 321.0887; C18H15FNaO3 (MNa+) Requires 
321.0897 (3.4 ppm error), Found: 299.1074; C18H16FNaO3 (MNa+) Requires 299.1078 (1.2 ppm 
error). 
Lab notebook reference: MGL/03/92 
(SR,Z)-3-([1,1'-Biphenyl]-4-ylmethylene)-4-(4-methoxyphenyl) dihydrofuran-2(3H)-
one (Z-180) and (SR,E)-3-([1,1'-Biphenyl]-4-ylmethylene)-4-(4-
methoxyphenyl)dihydrofuran-2(3H)-one (E-180)  
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (70 mg, 0.196 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 3.9 
µmol), THF (4.0 mL), KOBu-t (33.0 mg, 0.294 mmol) and 4-biphenylcarboxyaldehyde (71.4 mg, 
0.392 mmol). The HWE was performed at RT. Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compounds as mixture of (Z) and (E) isomers (Z-180:E-180 1:1), 
as a pale yellow oil (43 mg, 61%).  
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for Z-180; Rf 0.37 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2928m, 1749s, 1638m, 1611m, 
1513s, 1487m, 1464w, 1416w, 1371m, 1305w, 1248s, 1179w, 1155s, 1115w, 1074m, 1030s, 
915w, 834m; δH (400 MHz, CDCl3) 3.83 (3 H, s, H-18), 4.30 (1 H, app. t, J = 8.2, H-4), 4.39 (1 H, 
Rh2(oct)4, CH2Cl2
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app. td, J = 8.2, J = 2.6, H-3), 4.72 (1 H, app. t, J = 8.6, H-4), 6.69 (1 H, d, J = 2.6, H-5), 6.95 (2 H, 
d, J = 8.7, H-16), 7.24 (2 H, d, J = 8.7, H-15), 7.34–7.38 (1 H, m, H-13), 7.42–7.46 (2 H, m, H-12), 
7.58–7.62 (4 H, m, H-8,11), 7.92 (2 H, d, J = 8.4, H-7); δC (100 MHz, CDCl3) 48.4 (C-3), 55.3 (C-
18), 72.5 (C-4), 114.6 (C-16), 126.7 (C-8/11), 127.1 (C-8/11), 127.7 (C-13), 128.8 (C-12), 128.9 
(C-2), 129.4 (C-15), 131.5 (C-7), 132.0 (C-6), 132.4 (C-14), 140.3 (C-10), 141.2 (C-5), 142.4 (C-
9), 159.2 (C-17), 168.9 (C-1); HRMS (ESI+): Found: 379.1294; C24H20NaO3 (MNa+) Requires 
379.1305 (2.9 ppm error). 
 
Data for E-180; Rf 0.29 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 3030w, 2970w, 2934w, 2915w, 
2836w, 1749s, 1645m, 1607m, 1511s, 1487w, 1360w, 1248s, 1170s, 1033m, 834m, 766m, 698w; 
δH (400 MHz, CDCl3) 3.77 (3 H, s, H-18), 4.30 (1 H, dd, J = 8.6, J = 2.7, H-4), 4.60 (1 H, ddd, J = 
7.9, J = 2.7, J = 2.1, H-3), 4.71 (1 H, dd, J = 8.6, J = 7.9, H-4), 6.86 (2 H, d, J = 8.7, H-16), 7.17 (2 
H, d, J = 8.7, H-15), 7.33–7.37 (1 H, m, H-13), 7.40–7.45 (4 H, m, H-7/8/11/12), 7.50–7.56 (4 H, 
m, H-7/8/11/12), 7.85 (1 H, d, J = 2.1, H-5); δC (100 MHz, CDCl3) 43.8 (C-3), 55.4 (C-18), 74.2 
(C-4), 114.8 (C-16), 126.6 (C-2/6/9/10/14), 127.1 (C-7/8/11/12), 127.4 (C-7/8/11/12), 128.0 (C-
13), 128.2 (C-15), 129.0 (C-7/8/11/12), 131.3 (C-7/8/11/12), 132.6 (C-2/6/9/10/14), 132.7 (C-
2/6/9/10/14), 138.9 (C-5), 140.0 (C-2/6/9/10/14), 142.8 (C-2/6/9/10/14), 159.0 (C-17), 172.8 (C-1); 
HRMS (ESI+): Found: 357.1489; C24H21O3 (MH+) Requires 357.1485 (−1.1 ppm error). 
Lab notebook reference: MGL/03/90 
(SR,Z)-3-Ethylidene-4-(4-methoxyphenyl)dihydrofuran-2(3H)-one (Z-181) and 
(SR,E)-3-Ethylidene-4-(4-methoxyphenyl)dihydrofuran-2(3H)-one (E-181) 
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (71 mg, 0.199 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 
µmol), THF (4.0 mL), KOBu-t (33.5 mg, 0.299 mmol) and acetaldehyde (22.0 µL, 0.398 mmol). 
The HWE was performed at RT. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compounds as mixture of (Z) and (E) isomers (Z-181:E-181 1:1.2), as a colourless 
oil (17 mg, 39%). 
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Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for Z-181; Rf 0.33 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2913w, 1752s, 1672w, 1612w, 
1514s, 1441w, 1352w, 1305w, 1280w, 1249s, 1207w, 1180m, 1114m, 1021m; δH (400 MHz, 
CDCl3) 2.18 (3 H, dd, J = 7.4, J = 2.5, H-6), 3.81 (3 H, s, H-11), 4.12–4.19 (2 H, m, H-3,4), 4.57–
4.64 (1 H, m, H-4), 6.05 (1 H, qd, J = 7.4, J = 2.4, H-5), 6.89 (2 H, d, J = 8.8, H-9), 7.13 (2 H, d, J 
= 8.8, H-8); δC (100 MHz, CDCl3) 13.9 (C-6), 46.3 (C-3), 55.3 (C-11), 72.6 (C-4), 114.4 (C-9), 
129.1 (C-8), 130.0 (C-2), 132.3 (C-7), 140.9 (C-5), 159.0 (C-10), 170.0 (C-1); HRMS (ESI+): 
Found: 241.0832; C13H14NaO3 (MNa+) Requires 241.0835 (1.4 ppm error), Found: 219.1008; 
C13H15O3 (MH+) Requires 219.1016 (3.7 ppm error). 
 
Data for E-181; Rf 0.23 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2917w, 1756s, 1675w, 1611w, 
1512s, 1464w, 1372w, 1304w, 1246s, 1218m, 1179m, 1132w, 1023s; δH (400 MHz, CDCl3) 1.63 
(3 H, dd, J = 7.3, J = 1.8, H-6), 3.80 (3 H, s, H-11), 4.18 (1 H, dd, J = 8.9, J = 4.7, H-4), 4.22–4.27 
(1 H, m, H-3), 4.67 (1 H, app. t, J = 8.8, H-4), 6.87 (2 H, d, J = 8.7, H-9), 6.99 (1 H, qd, J = 7.3, J 
= 2.6, H-5), 7.11 (2 H, d, J = 8.7, H-8); δC (100 MHz, CDCl3) 15.3 (C-6), 42.5 (C-3), 55.3 (C-11), 
73.7 (C-4), 114.4 (C-9), 128.2 (C-8), 130.3 (C-2), 133.1 (C-7), 138.8 (C-5), 158.8 (C-10), 171.1 
(C-1); HRMS (ESI+): Found: 241.0836; C13H14NaO3 (MNa+) Requires 241.0835 (−0.5 ppm error), 
Found: 219.1010; C13H15O3 (MH+) Requires 219.1016 (2.8 ppm error). 
Lab notebook reference: MGL/04/20 
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(SR,Z)-4-(4-Methoxyphenyl)-3-pentylidenedihydrofuran-2(3H)-one (Z-182) and 
(SR,E)-4-(4-Methoxyphenyl)-3-pentylidenedihydrofuran-2(3H)-one (E-182)  
 
 
 
Synthesised using general procedure D with 4-methoxyphenethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 117b (69 mg, 0.194 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.0 mg, 3.9 
µmol), THF (4.0 mL), KOBu-t (32.7 mg, 0.291 mmol) and valeraldehdye (41.3 µL, 0.388 mmol). 
The HWE was performed at RT. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compounds as mixture of (E) and (Z) isomers (Z-182:E-182 1:3.7), as a colourless 
oil (34 mg, 67%).  
 
Small quantities of each compound were isolated separately for characterisation purposes. 
 
Data for Z-182; Rf 0.42 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2958m, 2929m, 2859w, 1754s, 
1668w, 1612w, 1514s, 1465w, 1372w, 1249m, 1177m, 1127m, 1028m, 833w; δH (400 MHz, 
CDCl3) 0.88 (3 H, t, J = 7.2, H-9), 1.25–1.42 (4 H, m, H-7,8), 2.66–2.81 (2 H, m, H-6), 3.81 (3 H, 
s, H-14), 4.13–4.19 (2 H, m, H-3,4), 4.58–4.64 (1 H, m, H-4), 5.96 (1 H, app. td, J = 7.8, J = 2.3, 
H-5), 6.90 (2 H, d, J = 8.8, H-12), 7.13 (2 H, d, J = 8.8, H-11); δC (100 MHz, CDCl3) 13.9 (C-9), 
22.3 (C-8), 27.2 (C-6), 31.1 (C-7), 46.3 (C-3), 55.3 (C-14), 72.6 (C-4), 114.4 (C-12), 129.0 (C-2), 
129.1 (C-11), 132.3 (C-10), 146.6 (C-5), 159.0 (C-13), 169.9 (C-1); HRMS (ESI+): Found: 
283.1299; C16H20NaO3 (MNa+) Requires 283.1305 (2.0 ppm error), Found: 261.1473; C16H21O3 
(MH+) Requires 261.1485 (4.8 ppm error). 
  
Data for E-182; Rf 0.33 (4:1 petrol:EtOAc); νmax (thin film)/cm-1 2930s, 1759s, 1673w, 1612w, 
1513s, 1465w, 1249s, 1180m, 1029m, 832w; δH (400 MHz, CDCl3) 0.77 (3 H, t, J = 7.2, H-9), 
1.12–1.34 (4 H, m, H-7,8), 1.87–2.02 (2 H, m, H-6), 3.80 (3 H, s, H-14), 4.16–4.25 (2 H, m, H-
3,4), 4.67 (1 H, app. t J 8.4, H-4), 6.86 (2 H, d, J = 8.7, H-12), 6.90 (1 H, app. td, J = 7.7, J = 2.5, 
H-5), 7.11 (2 H, d, J = 8.7, H-11); δC (100 MHz, CDCl3) 13.7 (C-9), 22.3 (C-8), 29.2 (C-6), 30.0 
(C-7), 42.6 (C-3), 55.3 (C-14), 73.7 (C-4), 114.4 (C-12), 128.2 (C-11), 129.2 (C-2), 133.6 (C-10), 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
nBuCHO
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144.2 (C-5), 158.8 (C-13), 171.3 (C-1); HRMS (ESI+): Found: 283.1309; C16H20NaO3 (MNa+) 
Requires 283.1305 (−1.7 ppm error), Found: 261.1484; C16H21O3 (MH+) Requires 261.1485 (0.6 
ppm error). 
Lab notebook reference: MGL/03/93 
(SR,Z)-3-(4-Nitrobenzylidene)-4-phenyldihydrofuran-2(3H)-one (Z-183) and (SR,E)-
3-(4-Nitrobenzylidene)-4-phenyldihydrofuran-2(3H)-one (E-183) 
 
 
 
Synthesised using general procedure D with phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 
116b (75 mg, 0.230 mmol), CH2Cl2 (4.6 mL), Rh2(oct)4 (3.6 mg, 4.6 µmol), THF (4.6 mL), KOBu-
t (38.7 mg, 0.345 mmol) and 4-nitrobenzaldehyde (69.5 mg, 0.460 mmol). The HWE was 
performed at 0 °C. Purification by column chromatography (10:1 hexane:EtOAc) afforded the title 
compounds as mixture of (Z) and (E) isomers (Z-183:E-183 1:1) (44 mg, 65%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-183; Pale yellow oil; Rf 0.40 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2920w, 1754s, 
1597w, 1518s, 1345s, 1161s, 1074w, 1023w; δH (400 MHz, CDCl3) 4.39 (1 H, app. t, J = 8.0, H-4), 
4.45 (1 H, app. td, J = 7.8, J = 2.7, H-3), 4.78 (1 H, app. t, J = 8.4, H-4), 6.72 (1 H, d, J = 2.7, H-5), 
7.30–7.32 (2 H, m, H-11/12), 7.35–7.39 (1 H, m, H-13), 7.41–7.46 (2 H, m, H-11/12), 7.88 (2 H, d, 
J = 8.9, H-7), 8.19 (2 H, d, J = 8.9, H-8); δC (100 MHz, CDCl3) 48.8 (C-3), 72.4 (C-4), 123.2 (C-8), 
128.2 (C-11/12), 128.2 (C-13), 129.5 (C-11/12), 131.3 (C-7), 133.2 (C-2/6/10), 138.5 (C-5), 139.2 
(C-2/6/10), 139.3 (C-2/6/10), 147.8 (C-9), 168.0 (C-1); HRMS (ESI+): Found: 318.0749; 
C17H13NNaO4 (MNa+) Requires 318.0737 (−3.8 ppm error). 
 
Data for E-183; Pale yellow oil; Rf 0.32 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2923w, 2854w, 
1755s, 1691w, 1653w, 1598m, 1518s, 1343s, 1300w, 1226m, 1173s, 1021w; δH (400 MHz, CDCl3) 
4.33 (1 H, dd, J = 8.9, J = 3.5, H-4), 4.61 (1 H, app. dt, J = 8.1, J = 3.0, H-3), 4.78 (1 H, app. t, J = 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
4-O2NC6H4CHO
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8.5, H-4), 7.17–7.19 (2 H, m, H-11/12), 7.24–7.34 (3 H, m, H-11/12,13), 7.45 (2 H, d, J = 8.8, H-
7), 7.84 (1 H, d, J = 2.4, H-5), 8.08 (2 H, d, J = 8.8, H-8); δC (100 MHz, CDCl3) 44.5 (C-3), 73.8 
(C-4), 123.6 (C-8), 127.0 (C-11/12), 128.0 (C-13), 129.5 (C-11/12), 130.8 (C-7), 131.4 (C-2/6/10), 
136.3 (C-5), 139.6 (C-2/6/10), 139.6 (C-2/6/10), 147.9 (C-9), 171.4 (C-1); HRMS (ESI+): Found: 
318.0746; C17H13NNaO4 (MNa+) Requires 318.0737 (−2.8 ppm error). 
Lab notebook reference: MGL/05/38 
(SR,Z)-3-Pentylidene-4-phenyldihydrofuran-2(3H)-one (Z-184) and (SR,E)-3-
Pentylidene-4-phenyldihydrofuran-2(3H)-one (E-184) 
 
 
 
Synthesised using general procedure D with phenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 
116b (73 mg, 0.224 mmol), CH2Cl2 (4.5 mL), Rh2(oct)4 (3.5 mg, 4.5 µmol), THF (4.5 mL), KOBu-
t (37.7 mg, 0.336 mmol) and valeraldehyde (44.8 µL, 0.448 mmol). The HWE was performed at 
reflux. Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compounds 
as mixture of (Z) and (E) isomers (Z-184:E-184 3.3:1) (29 mg, 56%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-184; Pale yellow oil; Rf 0.53 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2957m, 2928m, 
2871w, 1755s, 1667w, 1455w, 1373w, 1175m, 1127m, 1025s; δH (400 MHz, CDCl3) 0.88 (3 H, t, J 
= 7.1, H-9), 1.25–1.43 (4 H, m, H-7,8), 2.66–2.82 (2 H, m, H-6), 4.18–4.24 (2 H, m, H-3,4), 4.61–
4.67 (1 H, m, H-4), 5.99 (1 H, td, J = 7.8, J = 2.2, H-5), 7.20–7.23 (2 H, m, H-11), 7.28–7.32 (1 H, 
m, H-13), 7.34–7.39 (2 H, m, H-12); δC (100 MHz, CDCl3) 13.8 (C-9), 22.3 (C-8), 27.2 (C-6), 31.1 
(C-7), 46.9 (C-3), 72.5 (C-4), 127.6 (C-13), 128.0 (C-11), 128.8 (C-12), 129.1 (C-2/10), 140.7 (C-
2/10), 146.9 (C-5), 169.8 (C-1); HRMS (ESI+): Found: 253.1188; C15H18NaO2 (MNa+) Requires 
253.1199 (4.5 ppm error), Found: 231.1380; C15H19O2 (MH+) Requires 231.1380 (−0.2 ppm error). 
 
Data for E-184; Pale yellow oil; Rf 0.44 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2957m, 2928s, 
2858m, 1759s, 1672w, 1456w, 1378w, 1184m, 1026m; δH (400 MHz, CDCl3) 0.76 (3 H, t, J = 7.2, 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
nBuCHO
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H-9), 1.10–1.33 (4 H, m, H-7,8), 1.88–2.01 (2 H, m, H-6), 4.20–4.29 (2 H, m, H-3,4), 4.70 (1 H, 
app. t, J = 8.2, H-4), 6.92 (1 H, td, J = 7.7, J = 2.3, H-5), 7.19–7.21 (2 H, m, H-11), 7.26–7.29 (1 H, 
m, H-13), 7.31–7.36 (2 H, m, H-12); δC (100 MHz, CDCl3) 13.6 (C-9), 22.2 (C-8), 29.2 (C-6), 29.9 
(C-7), 43.4 (C-3), 73.5 (C-4), 127.2 (C-11), 127.4 (C-13), 129.0 (C-2/10), 129.1 (C-12), 141.7 (C-
2/10), 144.3 (C-5), 171.2 (C-1); HRMS (ESI+): Found: 253.1187; C15H18NaO2 (MNa+) Requires 
253.1199 (4.9 ppm error), Found: 231.1376; C15H19O2 (MH+) Requires 231.1380 (1.7 ppm error). 
Lab notebook reference: MGL/05/39 
(SR,Z)-3-(4-Nitrobenzylidene)-4-pentyldihydrofuran-2(3H)-one (Z-185) and (SR,E)-3-
(4-Nitrobenzylidene)-4-pentyldihydrofuran-2(3H)-one (E-185) 
 
 
 
Synthesised using general procedure D with heptyl 2-diazo-2-(diethoxyphosphoryl)acetate 134b 
(68 mg, 0.212 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 µmol), THF (4.2 mL), KOBu-t 
(35.7 mg, 0.318 mmol) and 4-nitrobenzaldehyde (62.6 mg, 0.424 mmol). The HWE was performed 
at 0 °C. Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compounds 
as mixture of (Z) and (E) isomers (Z-185:E-185 1:1) (42 mg, 68%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-185; Yellow oil; Rf 0.46 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2928m, 2857m, 
1752s, 1651w, 1597m, 1518s, 1466w, 1378w, 1344s, 1175s, 1112w; δH (400 MHz, CDCl3) 0.91 (3 
H, t, J = 7.0, H-14), 1.25–1.45 (6 H, m, H-11,12,13), 1.57–1.68 (1 H, m, H-10), 1.73–1.82 (1 H, m, 
H-10), 3.15–3.22 (1 H, m, H-3), 4.09 (1 H, dd, J = 8.9, J = 5.1, H-4), 4.52 (1 H, dd, J = 8.9, J = 7.7, 
H-4), 6.93 (1 H, d, J = 2.2, H-5), 7.89 (2 H, d, J = 8.8, H-7), 8.21 (2 H, d, J = 8.8, H-8); δC (100 
MHz, CDCl3) 14.0 (C-14), 22.5 (C-13), 26.0 (C-11), 31.7 (C-12), 34.1 (C-10), 42.0 (C-3), 70.8 (C-
4), 123.2 (C-8), 131.1 (C-7), 133.0 (C-2), 136.1 (C-5), 139.7 (C-6), 147.6 (C-9), 168.6 (C-1); 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
4-O2NC6H4CHO
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HRMS (ESI+): Found: 312.1210; C16H19NNaO4 (MNa+) Requires 312.1206 (−0.6 ppm error), 
Found: 290.1392; C16H20NO4 (MH+) Requires 290.1387 (−1.6 ppm error). 
 
Data for E-185; Pale yellow solid; Rf 0.41 (4:1 hexane:EtOAc); m.p. 114–117 °C; νmax (thin 
film)/cm-1 2929m, 2858m, 1754s, 1598m, 1520s, 1344s, 1225m, 1183s, 1112w; δH (400 MHz, 
CDCl3) 0.86 (3 H, t, J = 7.0, H-14), 1.18–1.42 (6 H, m, H-11,12,13), 1.50–1.67 (2 H, m, H-10), 
3.53–3.60 (1 H, m, H-3), 4.28 (1 H, dd, J = 9.1, J = 2.0, H-4), 4.45 (1 H, ddd, J = 9.1, J = 7.0, J = 
0.7, H-4), 7.56 (1 H, d, J = 2.1, H-5), 7.67 (2 H, d, J = 8.8, H-7), 8.29 (2 H, d, J = 8.8, H-8); δC 
(100 MHz, CDCl3) 13.0 (C-14), 22.4 (C-13), 26.4 (C-11), 31.4 (C-12), 32.4 (C-10), 38.1 (C-3), 
70.7 (C-4), 124.1 (C-8), 130.3 (C-7), 133.4 (C-2), 133.8 (C-5), 140.3 (C-6), 147.8 (C-9), 171.6 (C-
1); HRMS (ESI+): Found: 312.1205; C16H19NNaO4 (MNa+) Requires 312.1206 (0.4 ppm error), 
Found: 290.1388; C16H20NO4 (MH+) Requires 290.1387 (−0.3 ppm error). 
Lab notebook reference: MGL/05/01 
(SR,Z)-4-Pentyl-3-pentylidenedihydrofuran-2(3H)-one (Z-186) and (SR,E)-4-Pentyl-3-
pentylidenedihydrofuran-2(3H)-one (E-186) 
 
 
 
Synthesised using general procedure D with heptyl 2-diazo-2-(diethoxyphosphoryl)acetate 134b 
(67 mg, 0.209 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 µmol), THF (4.2 mL), KOBu-t 
(35.2 mg, 0.314 mmol) and valeraldehyde (45.0 µL, 0.418 mmol). The HWE was performed at RT. 
Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compounds as 
mixture of (Z) and (E) isomers (Z-186:E-186 2.7:1) (36 mg, 77%). 
Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-186; Colourless oil; Rf 0.75 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2957s, 2928s, 
2858s, 1754s, 1668m, 1466m, 1378m, 1185m, 1127s, 1027s; δH (400 MHz, CDCl3) 0.87–0.92 (6 
H, m, H-9,14), 1.24–1.49 (11 H, m, H-7,8,10,11,12,13), 1.56–1.65 (1 H, m, H-10), 2.69–2.75 (2 H, 
m, H-6), 2.88–2.97 (1 H, m, H-3), 3.92 (1 H, dd, J = 8.8, J = 5.3, H-4), 4.37 (1 H, dd, J = 8.8, J = 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
nBuCHO
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7.9, H-4), 6.12 (1 H, td, J = 7.7, J = 1.6, H-5); δC (100 MHz, CDCl3) 13.9 (C-9/14), 14.0 (C-9/14), 
22.3 (C-8), 22.5 (C-13), 25.9 (C-11), 27.1 (C-6), 31.3 (C-7), 31.7 (C-12), 34.2 (C-10), 40.1 (C-3), 
70.8 (C-4), 128.3 (C-2), 144.1 (C-5), 170.5 (C-1); HRMS (ESI+): Found: 247.1670; C14H24NaO2 
(MNa+) Requires 247.1669 (−0.7 ppm error), Found: 225.1857; C14H25O2 (MH+) Requires 
225.1849 (−3.6 ppm error). 
 
Data for E-186; Colourless oil; Rf 0.66 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2961s, 2930s, 
2859m, 1760s, 1676m, 1466m, 1380w, 1193m, 1021m; δH (400 MHz, CDCl3) 0.87–0.94 (6 H, m, 
H-9,14), 1.22–1.57 (12 H, m, H-7,8,10,11,12,13), 2.15–2.28 (2 H, m, H-6), 3.04–3.10 (1 H, m, H-
3), 4.12 (1 H, dd, J = 9.1, J = 2.2, H-4), 4.31 (1 H, dd, J = 9.1, J = 7.3, H-4), 6.73 (1 H, td, J = 7.7, 
J = 2.0, H-5); δC (100 MHz, CDCl3) 13.8 (C-9/14), 14.0 (C-9/14), [22.4, 22.5, 26.1, 29.4, 30.7, 
31.7, 34.2 (C-6,7,8,10,11,12,13)], 37.1 (C-3), 70.8 (C-4), 129.8 (C-2), 141.5 (C-5), 171.7 (C-1); 
HRMS (ESI+): Found: 247.1666; C14H24NaO2 (MNa+) Requires 247.1669 (1.1 ppm error), Found: 
225.1851; C14H25O2 (MH+) Requires 225.1849 (−1.0 ppm error). 
Lab notebook reference: MGL/05/02 
(SR,Z)-4-(4-Nitrobenzylidene)-2-oxaspiro[4.4]nonan-3-one (Z-187) and (SR,E)-4-(4-
Nitrobenzylidene)-2-oxaspiro[4.4]nonan-3-one (E-187) 
 
 
 
Synthesised using general procedure D with cyclopentylmethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 143b (61 mg, 0.200 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 
µmol), THF (4.0 mL), KOBu-t (33.7 mg, 0.300 mmol) and 4-nitrobenzaldehyde (60.5 mg, 0.400 
mmol). The HWE was performed at 0 °C. Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compounds as an inseparable mixture of (Z) and (E) isomers (Z-
187:E-187 1:1.4), as a white solid (30 mg, 55%); Rf 0.32 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 
2959w, 2874w, 1755s, 1646w, 1597m, 1518s, 1492w, 1453w, 1344s, 1257w, 1227w, 1201w, 
1160m, 1096m, 1023m, 910w, 851m; δH (400 MHz, CDCl3) 1.61–1.96 (16 H, m, H-10E and Z,11E 
and Z), 4.04 (3 H, s, H-4E), 4.16 (3 H, s, H-4Z), 6.87 (1 H, s, H-5Z), 7.52 (2 H, dd, J = 8.9, J = 0.6, 
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
4-O2NC6H4CHO
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H-7E), 7.65 (1 H, s, H-5E), 7.86 (2 H, dd, J = 8.9, J = 0.5, H-7Z), 8.19 (2 H, d, J = 8.9, H-8Z), 8.25 
(2 H, d, J = 8.9, H-8E); δC (100 MHz, CDCl3) 24.6 (C-11E/Z), 25.3 (C-11E/Z), 37.1 (C-10E), 39.3 
(C-10Z), 50.3 (C-3E), 52.5 (C-3Z), 77.5 (C-4Z), 79.4 (C-4E), 123.1 (C-8Z), 123.5 (C-8E), 130.0 
(C-7E), 131.1 (C-7Z), 134.0 (C-5Z), 134.3 (C-5E), 136.6 (C-2E), 137.3 (C-2Z), 139.8 (C-6Z), 
140.9 (C-6E), 147.5 (C-9E/Z), 147.6 (C-9E/Z), 168.9 (C-1Z), 171.9 (C-1E); HRMS (ESI+): Found: 
296.0899; C15H15NNaO4 (MNa+) Requires 296.0893 (−1.8 ppm error), Found: 274.1082; 
C15H16NO4 (MH+) Requires 274.1074 (−2.9 ppm error). 
Lab notebook reference: MGL/05/03 
(SR,Z)-4-Pentylidene-2-oxaspiro[4.4]nonan-3-one (Z-188) and (SR,E)-4-Pentylidene-
2-oxaspiro[4.4]nonan-3-one (E-188) 
 
 
 
Synthesised using general procedure D with cyclopentylmethyl 2-diazo-2-
(diethoxyphosphoryl)acetate 143b (63 mg, 0.207 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.2 mg, 4.1 
µmol), THF (4.2 mL), KOBu-t (34.8 mg, 0.311 mmol) and valeraldehyde (44.0 µL, 0.414 mmol). 
The HWE was performed at reflux. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compounds as mixture of (Z) and (E) isomers (Z-188:E-188 2.4:1) (14 mg, 32%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
  
Data for Z-188; Colourless oil; Rf 0.67 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2956m, 2929w, 
2871m, 1752s, 1665m, 1453m, 1370m, 1164w, 1128w, 1105m, 1025s; δH (400 MHz, CDCl3) 0.91 
(3 H, t, J = 7.2, H-9), 1.24–1.46 (4 H, m, H-7,8), 1.62–1.81 (8 H, m, H-10,11), 2.72 (2 H, app. q, J 
= 7.4, H-6), 4.02 (2 H, s, H-4), 6.08 (1 H, t, J = 7.7, H-5); δC (100 MHz, CDCl3) 13.9 (C-9), 22.3 
(C-7/8), 24.5 (C-10/11), 26.9 (C-6), 31.4 (C-7/8), 39.2 (C-10/11), 50.8 (C-3), 77.7 (C-4), 132.8 (C-
2), 141.9 (C-5), 170.1 (C-1); HRMS (ESI+): Found: 231.1354; C13H20NaO2 (MNa+) Requires 
231.1356 (0.6 ppm error), Found: 209.1536; C13H21O2 (MH+) Requires 209.1536 (−0.2 ppm error). 
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Data for E-188; Colourless oil; Rf 0.54 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2956s, 2934s, 
2872s, 1758s, 1668m, 1455m, 1383w, 1362w, 1164w, 1028s; δH (400 MHz, CDCl3) 0.93 (3 H, t, J 
= 7.1, H-9), 1.20–2.00 (12 H, m, H-7,8,10,11), 2.29 (2 H, app. q, J = 7.5, H-6), 4.00 (2 H, s, H-4), 
6.70 (1 H, t, J = 8.0, H-5); δC (100 MHz, CDCl3) 13.8 (C-9), 22.5 (C-7/8), 25.5 (C-10/11), 27.7 (C-
6), 31.0 (C-7/8), 38.6 (C-10/11), 48.8 (C-3), 79.8 (C-4), 132.5 (C-2), 141.6 (C-5), 171.4 (C-1); 
HRMS (ESI+): Found: 231.1352; C13H20NaO2 (MNa+) Requires 231.1356 (1.4 ppm error), Found: 
209.1537; C13H21O2 (MH+) Requires 209.1536 (−0.3 ppm error). 
Lab notebook reference: MGL/05/37 
 
5.2.1.3.  Cedarmycins A and B 
3-Hydroxypropyl hexanoate (197) 
 
 
 
Prepared according to the literature procedure.168   
To a solution of 1,3-propanediol (10.8 mL, 150 mmol) and triethylamine (31.4 mL, 225 mmol) in 
CH2Cl2 (100 mL) was added a solution of hexanoyl chloride (14.0 mL, 100 mmol) in CH2Cl2 (50 
mL) over 2 h. The solution was stirred at RT for a further 4 h and then concentrated in vacuo. 
Purification by column chromatography (2:1 petrol:EtOAc) afforded the title compound 197 as a 
colourless liquid (10.3 g, 59%); Rf 0.37 (2:1 petrol:EtOAc); νmax (thin film)/cm-1 3426, 2957, 2931, 
2873, 1734, 1247, 1171, 1052; δH (400 MHz, CDCl3) 0.89 (3 H, t, J = 7.0, H-6), 1.25–1.37 (4 H, m, 
H-4,5), 1.59–1.66 (2 H, m, H-3), 1.87 (2 H, app. quin., J = 6.1, H-8), 1.93 (1 H, br t, J = 5.7, OH), 
2.31 (2 H, t, J = 7.6, H-2), 3.69 (2 H, app. q, J = 5.8, H-9), 4.24 (2 H, t, J = 6.1, H-7); δC (100 
MHz, CDCl3) 13.9, 22.3, 24.6, 31.3, 31.8, 34.3, 59.2, 61.1, 174.4; HRMS (ESI+): Found: 197.1142; 
C9H18NaO3 (MNa+) Requires 197.1148 (2.9 ppm error). 
Lab notebook reference: MGL/03/63 
Obtained data in accord with reported literature.168 
197
n-pentylCOCl
NEt3
CH2Cl2
196
OH
OH
OH
O
O
1
5 6
8
7
9
2
3 4
  227 
3-(2-(Diethoxyphosphoryl)acetoxy)propyl hexanoate (198) 
 
 
 
Synthesised using general procedure A with 3-hydroxypropyl hexanoate 197 (1.74 g, 10.0 mmol), 
toluene (50 mL), DEPAA (1.69 mL, 10.5 mmol), DIPEA (4.53 mL, 26.0 mmol) and T3P (8.27 g, 
13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 198 as an orange oil (3.55 g, 
100%). No further purification was required; Rf 0.30 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2960w, 2929w, 2866w, 1736s, 1459w, 1393w, 1268s, 1170m, 1114m, 1024s, 970m; δH (400 MHz, 
CDCl3) 0.88 (3 H, t, J = 7.0, H-13), 1.23–1.36 (4 H, m, H-11,12), 1.33 (6 H, td, J = 7.1, J = 0.5, H-
4), 1.58–1.64 (2 H, m, H-10), 1.98 (2 H, app. quin., J = 6.3, H-6), 2.28 (2 H, t, J = 7.6, H-9), 2.96 
(2 H, d, J = 21.6, H-2), 4.12–4.23 (8 H, m, H-3,5,7); δC (100 MHz, CDCl3) 13.9 (C-13), 16.3 (d, J 
= 6.2, C-4), 22.3 (C-12), 24.6 (C-10), 27.9 (C-6), 31.2 (C-11), 34.1 (C-9), 34.2 (d, J = 134.2, C-2), 
60.5 (C-7), 62.1 (C-5), 62.7 (d, J = 6.2, C-3), 165.7 (d, J = 6.2, C-1), 173.7 (C-8); δP (162 MHz, 
CDCl3) 20.2; HRMS (ESI+): Found: 375.1525; C15H29NaO7P (MNa+) Requires 375.1543 (4.7 ppm 
error), Found: 353.1712; C15H30O7P (MH+) Requires 353.1724 (3.3 ppm error). 
Lab notebook reference: MGL/03/65 
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3-(2-Diazo-2-(diethoxyphosphoryl)acetoxy)propyl hexanoate (199) 
 
 
 
Synthesised using general procedure B with 3-(2-(diethoxyphosphoryl)acetoxy)propyl hexanoate 
198 (1.76 g, 5.00 mmol), THF (25 mL), LHMDS (6.00 mL, 6.00 mmol, 1.0 M solution in THF) 
and p-ABSA (1.44 g, 6.00 mmol). Purification by column chromatography (2:1 petrol:EtOAc) 
afforded the title compound 199 as a pale yellow oil (1.32 g, 70%); Rf 0.50 (1:1 petrol:EtOAc); 
νmax (thin film)/cm-1 2960m, 2933m, 2873w, 2127s, 1735w, 1703s, 1458w, 1392w, 1276s, 1214w, 
1167m, 1097w, 1016s, 976m; δH (400 MHz, CDCl3) 0.82 (3 H, t, J = 7.0, H-13), 1.18–1.30 (4 H, 
m, H-11,12), 1.29 (6 H, td, J = 7.1, J = 0.8, H-4), 1.51–1.58 (2 H, m, H-10), 1.93 (2 H, app. quin., J 
= 6.3, H-6), 2.22 (2 H, t, J = 7.6, H-9), 4.04–4.23 (8 H, m, H-3,5,7); δC (100 MHz, CDCl3) 13.7 (C-
13), 16.0 (d, J = 6.9, C-4), 22.1 (C-12), 24.4 (C-10), 27.9 (C-6), 31.1 (C-11), 34.0 (C-9), 53.8 (d, J 
= 227.5, C-2), 60.2 (C-7), 62.0 (C-5), 63.5 (d, J = 5.6, C-3), 163.1 (d, J = 12.0, C-1), 173.5 (C-8); 
δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 401.1430; C15H27N2NaO7P (MNa+) Requires 
401.1448 (4.5 ppm error), Found: 379.1611; C15H28N2O7P (MH+) Requires 379.1629 (4.7 ppm 
error). 
Lab notebook reference: MGL/03/75 
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(SR)-4-(Hydroxymethyl)-3-methylenedihydrofuran-2(3H)-one (194) 
 
 
 
To a solution of 4-(((tert-butyldimethylsilyl)oxy)methyl)-3-methylenedihydrofuran-2(3H)-one 
138c (29 mg, 0.120 mmol) in THF (0.6 mL) cooled to 0 °C under an atmosphere of argon, was 
added TBAF (144 µL, 0.144, 1.0 M in THF) dropwise. The solution was stirred at 0 °C for 1 h then 
quenched with sat. aq. NH4Cl (10 mL) and extracted with diethyl ether (2 × 25 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (1:2 hexane:EtOAc) afforded the title compound 194 as a pale yellow oil (12 mg, 
78%); Rf 0.29 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 3417br, 2924m, 1756s, 1407w, 1268m, 
1120m, 1017m, 816m; δH (400 MHz, CDCl3) 3.26–3.34 (1 H, m, H-3), 3.76–3.78 (2 H, m, H-6), 
4.27 (1 H, dd, J = 9.4, J = 4.5, H-4), 4.47 (1 H, dd, J = 9.4, J = 8.2, H-4), 5.75 (1 H, d, J = 2.3, H-
5b), 6.36 (1 H, d, J = 2.6, H-5a); δC (100 MHz, CDCl3) 40.9 (C-3), 64.1 (C-6), 68.2 (C-4), 123.6 
(C-5), 135.2 (C-2), 170.4 (C-1); HRMS (ESI+): Found: 151.0360; C6H8NaO3 (MNa+) Requires 
151.0366 (3.5 ppm error). 
Lab notebook reference: MGL/04/22 
Obtain data in accord with reported literature.100 
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Cedarmycin A (189) 
 
 
 
To a solution of 4-(hydroxymethyl)-3-methylenedihydrofuran-2(3H)-one 194 (5 mg, 0.039 mmol) 
and triethylamine (8.2 µL, 0.059 mmol) in CH2Cl2 (0.20 mL) was added 5-methylhexanoyl 
chloride (10 µL). After 2 h additional 5-methylhexanoyl chloride (10 µL) was added and stirred for 
16 h. The solution was quenched with sat. aq. NH4Cl (1 mL) and extracted with CH2Cl2 (3 × 10 
mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 189 as a 
colourless oil (6 mg, 85%); Rf 0.75 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2956m, 2871w, 
1768s, 1739s, 1468w, 1252w, 1170m, 1115m, 1019w; δH (400 MHz, CDCl3) 0.88 (6 H, d, J = 6.6, 
H-12), 1.15–1.21 (2 H, m, H-10), 1.51–1.65 (3 H, m, H-9,11), 2.31 (2 H, t, J = 7.6, H-8), 3.39–3.47 
(1 H, m, H-3), 4.16 (1 H, dd, J = 11.2, J = 7.3, H-6), 4.18 (1 H, dd, J = 9.4, J = 4.9, H-4), 4.25 (1 
H, dd, J = 11.2, J = 5.6, H-6), 4.48 (1 H, dd, J = 9.4, J = 8.4, H-4), 5.76 (1 H, d, J = 2.3, H-5b), 
6.39 (1 H, d, J = 2.7, H-5a); δC (100 MHz, CDCl3) 22.4 (C-12), 22.7 (C-9), 27.7 (C-11), 34.3 (C-8), 
38.0 (C-3), 38.3 (C-10), 64.7 (C-6), 68.1 (C-4), 124.2 (C-5), 134.5 (C-2), 169.8 (C-1), 173.5 (C-7); 
HRMS (ESI+): Found: 263.1251; C13H20NaO4 (MNa+) Requires 263.1254 (1.2 ppm error). 
Lab notebook reference: MGL/04/24 
Obtain data in accord with reported literature.98,100 
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Cedarmycin B (190) 
 
 
 
To a solution of 4-(hydroxymethyl)-3-methylenedihydrofuran-2(3H)-one 194 (3 mg, 0.023 mmol) 
and triethylamine (4.8 µL, 0.035 mmol) in CH2Cl2 (0.12 mL) was added hexanoyl chloride (3.9 
µL, 0.035 mmol). The solution was stirred at RT for 10 mins then quenched with sat. aq. NH4Cl (1 
mL) and extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. Purification by column chromatography (4:1 hexane:EtOAc) 
afforded the title compound 190 as a colourless oil (3 mg, 57%); Rf 0.76 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2959m, 2936m, 2864w, 1768s, 1738s, 1270w, 1246w, 1168m, 1115m, 1018w; δH 
(400 MHz, CDCl3) 0.90 (3 H, t, J = 7.0, H-12), 1.25–1.36 (4 H, m, H-10,11), 1.62 (2 H, app. quin., 
J = 7.5, H-9), 2.32 (2 H, t, J = 7.5, H-8), 3.39–3.47 (1 H, m, H-3), 4.16 (1 H, dd, J = 11.2, J = 7.3, 
H-6), 4.18 (1 H, dd, J = 9.4, J = 4.9, H-4), 4.25 (1 H, dd, J = 11.2, J = 5.6, H-6), 4.48 (1 H, dd, J = 
9.4, J = 8.4, H-4), 5.76 (1 H, d, J = 2.4, H-5b), 6.38 (1 H, d, J = 2.7, H-5a); δC (100 MHz, CDCl3) 
13.9 (C-12), 22.3 (C-11), 24.5 (C-9), 31.2 (C-10), 34.0 (C-8), 38.1 (C-3), 64.7 (C-6), 68.1 (C-4), 
124.1 (C-5), 134.5 (C-2), 169.8 (C-1), 173.5 (C-7); HRMS (ESI+): Found: 249.1099; C12H18NaO4 
(MNa+) Requires 249.1097 (−0.8 ppm error). 
Lab notebook reference: MGL/04/11 
Obtain data in accord with reported literature.98,100 
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5.2.1.4.  Staphyloccous aureus inhibitor 
N-Methoxy-N-methylhex-5-ynamide (211) 
 
 
 
To a solution of 5-hexynoic acid 210 (2.24 g, 20.0 mmol) in CH2Cl2 (50 mL) was added 
sequentially N,O-dimethylhydroxylamine hydrochloride (2.15 g, 22.0 mmol) and DIPEA (10.5 mL, 
60.0 mmol) and T3P (19.1 g, 30.0 mmol, 50% w/w solution in EtOAc). The solution was stirred at 
RT for 1 h. The reaction was quenched with 10% aq. HCl (25 mL). The phases were separated and 
the organic washed with 2M NaOH (25 mL) and brine (25 mL), dried over MgSO4 and 
concentrated in vacuo to afford the title compound 211 as colourless oil (3.00 g, 97%). No further 
purification was required; Rf 0.70 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 3291m, 2940m, 2117w, 
1656s, 1417m, 1386m, 1179m, 1108m, 994s; δH (400 MHz, CDCl3) 1.81 (2 H, app. quin., J = 7.2, 
H-3), 1.93 (1 H, t, J = 2.7, H-6), 2.24 (2 H, td, J = 6.9, J = 2.7, H-4), 2.53 (2 H, t, J = 7.3, H-2), 
3.14 (3 H, s, H-7) 3.66 (3 H , s, H-8); δC (100 MHz, CDCl3) 17.8 (C-4), 23.0 (C-3), 30.3 (C-2), 
32.0 (C-7), 61.1 (C-8), 68.8 (C-6), 83.7 (C-5), 173.7 (C-1); HRMS (ESI+): Found: 178.0847; 
C8H13NNaO2 (MNa+) Requires 178.0838 (−5.0 ppm error), Found: 156.1021; C8H14NO2 (MH+) 
Requires 156.1019 (−1.0 ppm error). 
Lab notebook reference: MGL/04/50 
Obtained data in accord with reported literature.169 
O
N OMe
Me
12
8
7
6
5
4 3
211210
O
OH
MeNH(OMe).HCl
DIPEA
T3P
CH2Cl2
  233 
1-Phenylhept-6-yn-2-one (212) 
 
 
 
To a solution of N-methoxy-N-methylhex-5-ynamide 211 (1.24 g, 8.00 mmol) in THF (40 mL) 
cooled to −78 °C was added was added benzylmagnesium chloride (8.0 mL, 16.0 mmol, 2 M in 
THF). The solution was warmed to 0 °C and stirred for 30 mins then quenched with sat. aq. NH4Cl 
(50 mL). The phases were separated and the aqueous extracted with diethyl ether (3 × 50 mL). The 
combined organics were dried over MgSO4 and concentrated in vacuo. Purification by column 
chromatography (8:1 petrol:EtOAc) afforded the title compound 212 as a colourless oil (860 mg, 
58%); Rf 0.55 (8:1 petrol:EtOAc); νmax (thin film)/cm-1 3292m, 2940m, 2120w, 1709s, 1496m, 
1454m, 1366m, 1092m; δH (400 MHz, CDCl3) 1.77 (2 H, app. quin., J = 7.0, H-3), 1.93 (1 H, t, J = 
2.7, H-6), 2.19 (2 H, td, J = 6.9, J = 2.7, H-4), 2.61 (2 H, t, J = 7.2, H-2), 3.70 (2 H, s, H-7), 7.19–
7.22 (2 H, m, H-9), 7.25–7.29 (1 H, m, H-11), 7.31–7.33 (2 H, m, H-10); δC (100 MHz, CDCl3) 
17.6 (C-4), 22.2 (C-3), 40.3 (C-2), 50.2 (C-7), 69.0 (C-6), 83.5 (C-5), 127.0 (C-11), 128.7 (C-10), 
129.4 (C-9), 134.1 (C-8), 207.7 (C-1); HRMS (ESI+): Found: 209.0932; C13H14NaO (MNa+) 
Requires 209.0937 (2.6 ppm error), Found: 187.1110; C13H15O (MH+) Requires 187.1117 (3.9 ppm 
error). 
Lab notebook reference: MGL/04/51 
1-Phenylhept-6-yn-2-ol (209) 
 
 
 
To a solution of 1-phenylhept-6-yn-2-one 212 (840 mg, 4.51 mmol) in MeOH (21 mL) cooled to 0 
°C under an atmosphere of argon, was added NaBH4 (512 mg, 13.5 mmol) in 4 portions over 15 
mins. The solution was stirred at RT for 3 h then quenched with sat. aq. NaHCO3 (4 mL) and 
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concentrated in vacuo. The resulting white residue was dissolved in CH2Cl2 (15 mL) and water (15 
mL). The organic was separated and the aqueous extracted with CH2Cl2 (2 × 15 mL). The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to afford the title 
compound 209 as a colourless oil (852 mg, 100%). No further purification was required; Rf 0.48 
(4:1 petrol:EtOAc); νmax (thin film)/cm-1 3406br, 3296s, 3028w, 2937s, 2871w, 2120w, 1496m, 
1454m, 1084m, 1031w, 998w, 747m, 701s; δH (400 MHz, CDCl3) 1.52 (1 H, s, OH), 1.56–1.81 (4 
H, m, H-2,3), 1.96 (1 H, t, J = 2.7, H-6), 2.22–2.26 (2 H, m, H-4), 2.66 (1 H, dd, J = 13.6, J = 8.6, 
H-7), 2.85 (1 H, dd, J = 13.6, J = 4.2, H-7), 7.20–7.26 (3 H, m, H-9,11), 7.30–7.35 (2 H, m, H-10); 
δC (100 MHz, CDCl3) 18.4 (C-4), 24.7 (C-3), 35.7 (C-2), 44.1 (C-7), 68.5 (C-6), 72.2 (C-1), 84.3 
(C-5), 126.5 (C-11), 128.6 (C-10), 129.4 (C-9), 138.3 (C-8); HRMS (ESI+): Found: 211.1093; 
C13H16NaO (MNa+) Requires 211.1093 (0.0 ppm error). 
Lab notebook reference: MGL/04/52 
1-Phenylhept-6-yn-2-yl 2-(diethoxyphosphoryl)acetate (213) 
 
 
 
Synthesised using general procedure A with 1-phenylhept-6-yn-2-ol 209 (846 mg, 4.49 mmol), 
toluene (22.5 mL), DEPAA (0.76 mL, 4.72 mmol), DIPEA (2.03 mL, 11.7 mmol) and T3P (3.71 g, 
5.84 mmol, 50% w/w solution in EtOAc) affording the title compound 213 as a yellow oil (1.60 g, 
97%). No further purification was required; Rf 0.29 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
3291w, 2983w, 2932w, 1732s, 1496w, 1455w, 1393w, 1264s, 1164w, 1114w, 1050w, 1023s, 970s; 
δH (400 MHz, CDCl3) 1.30 (3 H, td, J = 7.1, J = 0.4, H-4/4’), 1.31 (3 H, td, J = 7.1, J = 0.4, H-
4/4’), 1.46–1.71 (4 H, m, H-11,12), 1.89 (1 H, t, J = 2.7, H-15), 2.13–2.16 (2 H, m, H-13), 2.77–
2.96 (4 H, m, H-2,6), 4.08–4.16 (4 H, m, H-3,3’), 5.08–5.14 (1 H, m, H-5), 7.16–7.21 (3 H, m, H-
8,10), 7.24-7.28 (2 H, m, H-9); δC (100 MHz, CDCl3) 16.2 (d, J = 6.6, C-4), 18.0 (C-13), 24.0 (C-
12), 32.2 (C-11), 34.3 (d, J = 134.2, C-2), 40.3 (C-6), 62.5 (d, J = 6.2, C-3), 68.6 (C-15), 75.6 (C-
5), 83.6 (C-14), 126.5 (C-10), 128.3 (C-9), 129.3 (C-8), 136.9 (C-7), 165.3 (d, J = 6.2, C-1); δP 
(162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 389.1499; C19H27NaO5P (MNa+) Requires 
389.1488 (−2.7 ppm error), Found: 367.1674; C19H27O5P (MH+) Requires 367.1669 (−1.4 ppm 
error). 
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Lab notebook reference: MGL/04/53 
1-Phenylhept-6-yn-2-yl 2-diazo-2-(diethoxyphosphoryl)acetate (208) 
 
 
 
Synthesised using general procedure B with 1-phenylhept-6-yn-2-yl 2-(diethoxyphosphoryl)acetate 
213 (1.47 g, 4.00 mmol), THF (20 mL), LHMDS (4.80 mL, 4.80 mmol, 1.0 M solution in THF) 
and p-ABSA (1.15 g, 4.80 mmol). Purification by column chromatography (2:1 hexane:EtOAc) 
afforded the title compound 208 as a yellow oil (1.29 g, 82%); Rf 0.27 (2:1 hexane:EtOAc); νmax 
(thin film)/cm-1 3294w, 2984w, 2934w, 2126s, 1698s, 1455w, 1392w, 1366w, 1271s, 1216w, 
1164w, 1121w, 1016s, 976s; δH (400 MHz, CDCl3) 1.31 (3 H, td, J = 7.1, J = 0.7, H-4/4’), 1.33 (3 
H, td, J = 7.1, J = 0.7, H-4/4’), 1.52–1.79 (4 H, m, H-11,12), 1.94 (1 H, t, J = 2.6, H-15), 2.20 (2 H, 
td, J = 7.0, J = 2.6, H-13), 2.85–2.95 (2 H, m, H-6), 3.96–4.22 (4 H, m, H-3,3’), 5.19–5.25 (1 H, m, 
H-5), 7.19–7.31 (5 H, m, H-8,9,10); δC (100 MHz, CDCl3) 15.9 (d, J = 6.8, C-4/4’), 16.0 (d, J = 
6.8, C-4/4’), 17.9 (C-13), 24.0 (C-12), 32.5 (C-11), 40.4 (C-6), 53.5 (d, J = 226.6, C-2), 63.3 (d, J = 
5.7, C-3/3’), 63.4 (d, J = 5.7, C-3/3’), 68.7 (C-15), 75.6 (C-5), 83.4 (C-14), 126.4 (C-10), 128.2 (C-
9), 129.2 (C-8), 136.7 (C-7), 162.7 (d, J = 12.0, C-1); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): 
Found: 415.1398; C19H25N2NaO5P (MNa+) Requires 415.1393 (−1.2 ppm error), Found: 393.1579; 
C19H26N2O5P (MH+) Requires 393.1574 (−1.3 ppm error). 
Lab notebook reference: MGL/04/54 
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(4RS,5SR)-3-Methylene-5-(pent-4-yn-1-yl)-4-phenyldihydrofuran-2(3H)-one (203) 
and (4RS,5SR)-5-Benzyl-4-(but-3-yn-1-yl)-3-methylenedihydrofuran-2(3H)-one (214) 
 
 
 
Synthesised using general procedure D with 1-phenylhept-6-yn-2-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 208 (70 mg, 0.178 mmol), CH2Cl2 (3.6 mL), Rh2(oct)4 (2.8 mg, 3.6 
µmol), THF (3.6 mL), KOBu-t (30.0 mg, 0.267 mmol) and paraformaldehyde (10.7 mg, 0.356 
mmol). Purification by column chromatography (10:1 hexane:EtOAc) afforded the title compounds 
203 (21 mg, 49%) and 214 (8 mg, 19%) both as a colourless oils. 
 
Data for 203; Rf 0.52 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 3291w, 2928w, 2117w, 1764s, 
1455w, 1284w, 1230m, 1132m; δH (400 MHz, CDCl3) 1.55–1.65 (1 H, m, H-11), 1.73–1.96 (4 H, 
m, H-10,11,14), 2.22 (2 H, td, J = 6.8, J = 2.7, H-12), 3.79 (1 H, app. dt, J = 7.5, J = 3.2, H-3), 4.40 
(1 H, app. td, J = 7.9, J = 4.1, H-4), 5.40 (1 H, d, J = 2.9, H-5b), 6.36 (1 H, d, J = 3.3, H-5a), 7.19–
7.22 (2 H, m, H-7/8), 7.30–7.35 (1 H, m, H-9), 7.36–7.41 (2 H, m, H-7/8); δC (100 MHz, CDCl3) 
18.1 (C-12), 24.2 (C-11), 33.6 (C-10), 52.6 (C-3), 69.0 (C-14), 83.4 (C-13), 84.9 (C-4), 123.8 (C-
5), 127.9 (C-9), 128.3 (C-7/8), 129.2 (C-7/8), 138.9 (C-6), 140.2 (C-2), 169.6 (C-1); HRMS (ESI+): 
Found: 263.1038; C16H16NaO2 (MNa+) Requires 263.1043 (1.7 ppm error), Found: 241.1219; 
C16H17O2 (MH+) Requires 241.1223 (1.8 ppm error). 
Obtained data in accord with reported literature.102 
 
Data for 214; Rf 0.42 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 3288w, 2924m, 2117w, 1761s, 
1454w, 1268m, 1135m; δH (400 MHz, CDCl3) 1.70–1.76 (2 H, m, H-11), 2.00 (1 H, t, J = 2.7, H-
14), 2.17–2.23 (2 H, m, H-12), 2.92–3.05 (3 H, m, H-3,10), 4.45–4.49 (1 H, m, H-4), 5.61 (1 H, d, 
Rh2(oct)4, CH2Cl2
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J = 2.2, H-5b), 6.25 (1 H, d, J = 2.5, H-5a), 7.21–7.36 (5 H, m, H-7,8,9); δC (100 MHz, CDCl3) 
15.4 (C-12), 32.5 (C-11), 41.7 (C-10), 42.0 (C-3), 69.9 (C-14), 82.4 (C-13), 82.9 (C-4), 123.1 (C-
5), 127.1 (C-9), 128.7 (C-8), 129.6 (C-7), 135.4 (C-6), 138.1 (C-2), 169.8 (C-1); HRMS (ESI+): 
Found: 263.1043; C16H16NaO2 (MNa+) Requires 263.1043 (0.0 ppm error), Found: 241.1222; 
C16H17O2 (MH+) Requires 241.1223 (0.3 ppm error). 
 
5.2.2.  Chapter 3 
5.2.2.1.  Conformationally restricted systems 
syn-4-(tert-Butyl)cyclohexyl 2-(diethoxyphosphoryl)acetate (154a) 
 
 
 
Synthesised using general procedure A with syn-4-(tert-butyl)cyclohexanol 154 (285 mg, 1.82 
mmol), toluene (9.3 mL), DEPAA (381 mg, 1.94 mmol), DIPEA (0.84 mL, 4.81 mmol) and T3P 
(1.53 g, 2.41 mmol, 50% w/w solution in EtOAc) affording the title compound 154a as a yellow oil 
(575 mg, 94%). No further purification was required; Rf 0.21 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2945s, 1731s, 1446m, 1393m, 1363m, 1267s, 1108s, 1051w, 1022s, 965s; δH (400 MHz, 
CDCl3) 0.84 (9 H, s, H-6), 1.00 (1 H, tt, J = 12.0, J = 3.0), 1.23–1.35 (8 H, m), 1.41–1.50 (2 H, m), 
1.55–1.59 (2 H, m), 1.91–1.98 (2 H, m), 2.96 (2 H, d, J = 21.5, H-8), 4.12–4.20 (4 H, m, H-9,9’), 
5.05 (1 H, quin., J = 2.8, H-1); δC (100 MHz, CDCl3) 16.3 (d, J = 6.5, C-10,10’), 21.6 (CH2), 27.4 
(C-6), 30.4 (CH2), 32.4 (C-5), 34.7 (d, J = 133.4, C-8), 47.5 (C-4), 62.5 (d, J = 6.1, C-9,9’), 70.9 
(C-1), 165.3 (d, J = 6.6, C-7); δP (162 MHz, CDCl3) 20.9; HRMS (ESI+): Found: 357.1814; 
C16H31NaO5P (MNa+) Requires 357.1801 (−3.4 ppm error). 
Lab notebook reference: MGL/06/62 
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syn-4-(tert-Butyl)cyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate (154b) 
 
 
 
Synthesised using general procedure B with syn-4-(tert-butyl)cyclohexyl 2-
(diethoxyphosphoryl)acetate 154a (540 mg, 1.61 mmol), THF (8.0 mL), LHMDS (1.94 mL, 1.94 
mmol, 1.0 M solution in THF) and p-ABSA (466 mg, 1.94 mmol). Purification by column 
chromatography (2:1 hexane:EtOAc) afforded the title compound 154b as a yellow oil (505 mg, 
87%); Rf 0.51 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2946s, 2128s, 1694s, 1479m, 1446m, 
1361s, 1287s, 1269s, 1104s, 1017s, 975s, 793s, 747s, 590s, 560s; δH (400 MHz, CDCl3) 0.83 (9 H, 
s, H-6), 1.01 (1 H, tt, J = 12.0, J = 3.0), 1.21–1.35 (8 H, m), 1.42–1.52 (2 H, m), 1.55–1.59 (2 H, 
m), 1.89–1.96 (2 H, m), 4.08–4.24 (4 H, m, H-9,9’), 5.12 (1 H, quin., J = 2.7, H-1); δC (100 MHz, 
CDCl3) 16.1 (d, J = 7.0, C-10,10’), 21.4 (CH2), 27.3 (C-6), 30.6 (CH2), 32.4 (C-5), 47.3 (C-4), 54.1 
(d, J = 228.0, C-8), 63.3 (d, J = 6.0, C-9,9’), 71.2 (C-1), 162.9 (d, J = 12.0, C-7); δP (162 MHz, 
CDCl3) 11.3; HRMS (ESI+): Found: 383.1714; C16H29N2NaO5P (MNa+) Requires 383.1706 (−1.9 
ppm error). 
Lab notebook reference: MGL/06/64 
(3aRS,5SR,7aRS)-5-(tert-Butyl)-3-Methylenehexahydrobenzofuran-2(3H)-one (154c) 
and syn-7-(tert-Butyl)-3-Methylene-1-oxaspiro[3.5]nonan-2-one (154d) 
 
 
 
Synthesised using general procedure D with syn-4-(tert-butyl)cyclohexyl 2-diazo-2-
(diethoxyphosphoryl)acetate 154b (72 mg, 0.200 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 
µmol), THF (4.0 mL), KOBu-t (33.7 mg, 0.300 mmol) and paraformaldehyde (12.0 mg, 0.400 
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mmol). Purification by column chromatography (10:1 hexane:EtOAc) afforded the title compounds 
154c (12 mg, 29%) and 154d (8 mg, 19%). 
 
Data for 154c; white solid; Rf 0.24 (8:1 hexane:EtOAc); m.p. 48–51 °C; νmax (thin film)/cm-1 
2952s, 1763s, 1359m, 1259s, 1181s, 1124s, 1100s, 990s, 964s, 917m; δH (400 MHz, CDCl3) 0.84 
(9 H, s, H-8), 0.94–1.42 (3 H, m, H-3,4,5), 1.61–1.70 (2 H, m, H-2,3), 1.77–1.82 (1 H, m, H-5), 
2.26 (1 H, dq, J = 15.3, J = 3.4, H-2), 2.86–2.92 (1 H, m, H-6), 4.43 (1 H, q, J = 3.9, H-1), 5.53 (1 
H, s, H-10b), 6.08 (1 H, s, H-10a); δC (100 MHz, CDCl3) 20.6 (C-3), 27.2 (C-8), 27.9 (C-2), 30.2 
(C-5), 32.4 (C-7), 41.0 (C-6), 44.9 (C-4), 76.2 (C-1), 119.6 (C-10), 142.7 (C-9), 171.1 (C-11); 
HRMS (ESI+): Found: 231.1363; C13H20NaO2 (MNa+) Requires 231.1356 (−3.3 ppm error), Found: 
209.1538; C13H21O2 (MH+) Requires 209.1536 (−0.9 ppm error). 
 
Data for 154d; white solid; Rf 0.36 (8:1 hexane:EtOAc); m.p. 111–114 °C; νmax (thin film)/cm-1 
2960s, 1797s, 1438w, 1366m, 1160m, 1091m, 952m, 796m; δH (400 MHz, CDCl3) 0.88 (9 H, s, H-
6), 1.08 (1 H, tt, J = 12.2, J = 2.9, H-4), 1.25–1.42 (2 H, m, H-3), 1.70–1.81 (4 H, m, H-2,3), 2.01–
2.08 (2 H, m, H-2), 5.31 (1 H, d, J = 1.9, H-8b), 5.81 (1 H, d, J = 1.9, H-8a); δC (100 MHz, CDCl3) 
23.0 (C-3), 27.4 (C-6), 32.5 (C-5), 34.5 (C-2), 46.7 (C-4), 87.3 (C-1), 112.9 (C-8), 149.8 (C-7), 
164.0 (C-9); HRMS (ESI+): Found: 231.1352; C13H20NaO2 (MNa+) Requires 231.1356 (1.4 ppm 
error). 
Lab notebook reference: MGL/06/67 
anti-4-(tert-Butyl)cyclohexyl 2-(diethoxyphosphoryl)acetate (155a) 
 
 
 
Synthesised using general procedure A with anti-4-(tert-butyl)cyclohexanol 155 (1.56 g, 10.0 
mmol), toluene (50 mL), DEPAA (2.06 g, 10.5 mmol), DIPEA (4.52 mL, 26.0 mmol) and T3P 
(8.27 g, 13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 155a as a yellow oil 
(3.23 g, 97%). No further purification was required; Rf 0.21 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2947s, 2866m, 1730s, 1451w, 1394m, 1366m, 1260s, 1113m, 1019s, 966s; δH (400 
MHz, CDCl3) 0.82 (9 H, s, H-6), 0.92–1.12 (3 H, m), 1.26–1.36 (8 H, m), 1.75–1.81 (2 H, m), 
1.98–2.04 (2 H, m), 2.91 (2 H, d, J = 21.6, H-8), 4.10–4.17 (4 H, m, H-9,9’), 4.65 (1 H, tt, J = 11.3, 
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J = 4.5, H-1); δC (100 MHz, CDCl3) 16.3 (d, J = 6.1, C-10,10’), 25.3 (CH2), 27.5 (C-6), 31.8 (CH2), 
32.2 (C-5), 34.7 (d, J = 133.6, C-8), 46.9 (C-4), 62.5 (d, J = 6.1, C-9,9’), 75.0 (C-1), 165.3 (d, J = 
5.8, C-7); δP (162 MHz, CDCl3) 20.6; HRMS (ESI+): Found: 357.1790; C16H31NaO5P (MNa+) 
Requires 357.1801 (3.1 ppm error), Found: 335.1970; C16H32O5P (MH+) Requires 335.1982 (3.5 
ppm error). 
Lab notebook reference: MGL/06/63 
anti-4-(tert-Butyl)cyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate (155b) 
 
 
 
Synthesised using general procedure B with anti-4-(tert-butyl)cyclohexyl 2-
(diethoxyphosphoryl)acetate 155a (3.22 g, 9.63 mmol), THF (48 mL), LHMDS (11.6 mL, 11.6 
mmol, 1.0 M solution in THF) and p-ABSA (2.78 g, 11.6 mmol). Purification by column 
chromatography (2:1 hexane:EtOAc) afforded the title compound 155b as a yellow oil (2.99 g, 
86%); Rf 0.51 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2949s, 2866m, 2126s, 1698s, 1453w, 
1363w, 1279s, 1020s, 977m; δH (400 MHz, CDCl3) 0.83 (9 H, s, H-6), 0.94–1.14 (3 H, m), 1.27–
1.37 (8 H, m), 1.76–1.84 (2 H, m), 2.00–2.06 (2 H, m), 4.07–4.25 (4 H, m, H-9,9’), 4.72 (1 H, tt, J 
= 11.3, J = 4.5, H-1); δC (100 MHz, CDCl3) 15.7 (d, J = 7.3, C-10,10’), 24.9 (CH2), 27.1 (C-6), 
31.7 (CH2), 31.8 (C-5), 46.5 (C-4), 53.4 (d, J = 226.5, C-8), 63.1 (d, J = 6.3, C-9,9’), 74.8 (C-1), 
162.5 (d, J = 12.3, C-7); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 383.1711; 
C16H29N2NaO5P (MNa+) Requires 383.1706 (−1.2 ppm error). 
Lab notebook reference: MGL/06/65 
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(3aRS,5SR,7aSR)-5-(tert-Butyl)-3-Methylenehexahydrobenzofuran-2(3H)-one (155c) 
and anti-7-(tert-Butyl)-3-Methylene-1-oxaspiro[3.5]nonan-2-one (155d) 
 
 
 
Synthesised using general procedure D with anti-4-(tert-butyl)cyclohexyl 2-diazo-2-
(diethoxyphosphoryl)acetate 155b (73 mg, 0.203 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.2 mg, 4.1 
µmol), THF (4.0 mL), KOBu-t (34.2 mg, 0.305 mmol) and paraformaldehyde (12.2 mg, 0.406 
mmol). Purification by column chromatography (10:1 hexane:EtOAc) afforded the title compounds 
155c (20 mg, 47%) and 155d (5 mg, 12%). 
 
Data for 155c; colourless oil; Rf 0.36 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2954s, 2870m, 
1772s, 1395m, 1366m, 1251s, 1132s, 1079m, 1034m, 1019s, 993m; δH (400 MHz, CDCl3) 0.91 (9 
H, s, H-8), 1.06–1.34 (3 H, m, H-3,4,5), 1.62 (1 H, qd, J = 11.9, J = 3.7, H-2), 1.98–2.04 (1 H, m, 
H-3), 2.18 (1 H, dq, J = 12.5, J = 3.7, H-5), 2.29 (1 H, dq, J = 11.5, J = 3.7, H-2), 2.41 (1 H, tq, J = 
11.1, J = 3.2, H-6), 3.65 (1 H, td, J = 11.1, J = 3.7, H-1), 5.39 (1 H, d, J = 3.1, H-9b), 6.06 (1 H, d, 
J = 3.2, H-9a); δC (100 MHz, CDCl3) 25.0 (C-3), 26.4 (C-5), 27.7 (C-8), 30.1 (C-2), 32.6 (C-7), 
47.1 (C-4), 48.7 (C-6), 83.2 (C-1), 116.9 (C-10), 139.8 (C-9), 171.0 (C-11); HRMS (ESI+): Found: 
231.1362; C13H20NaO2 (MNa+) Requires 231.1356 (−2.7 ppm error), Found: 209.1532; C13H21O2 
(MH+) Requires 209.1536 (1.8 ppm error). 
 
Data for 155d; white needles; Rf 0.45 (8:1 hexane:EtOAc); m.p. 69–73 °C; νmax (thin film)/cm-1 
2969s, 2872w, 1820s, 1368m, 1193m, 1087m, 1024m, 959m, 857m, 808m; δH (400 MHz, CDCl3) 
0.90 (9 H, s, H-6), 0.94–1.46 (3 H, m, H-3,4), 1.87–1.99 (4 H, m, H-2,3), 2.04–2.12 (2 H, m, H-2), 
5.49 (1 H, d, J = 1.8, H-8b), 5.80 (1 H, d, J = 1.8, H-8a); δC (100 MHz, CDCl3) 25.0 (C-3), 27.5 (C-
6), 32.3 (C-5), 35.0 (C-2), 46.3 (C-4), 87.1 (C-1), 113.2 (C-8), 150.1 (C-7), 163.5 (C-9); HRMS 
(ESI+): Found: 231.1352; C13H20NaO2 (MNa+) Requires 231.1356 (1.5 ppm error). 
Lab notebook reference: MGL/06/68 
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(1SR,2SR)-2-(tert-Butyl)cyclohexyl 2-(diethoxyphosphoryl)acetate (156) 
 
 
 
Synthesised using general procedure A with (1SR,2SR)-2-(tert-butyl)cyclohexanol 156 (1.56 g, 
10.0 mmol), toluene (50 mL), DEPAA (2.06 g, 10.5 mmol), DIPEA (4.52 mL, 26.0 mmol) and 
T3P (8.27 g, 13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 156a as a pink 
oil (3.28 g, 98%). No further purification was required; Rf 0.33 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2938s, 2868m, 1728s, 1447m, 1396m, 1366m, 1262s, 1115m, 1051w, 1020s, 966s; δH 
(400 MHz, CDCl3) 0.83 (9 H, s, H-8), 1.09 (1 H, ddd, J = 12.4, J = 3.5, J = 2.0), 1.14–1.34 (8 H, 
m), 1.40–1.62 (4 H, m), 1.73–1.80 (1 H, m), 1.90–1.97 (1 H, m), 2.83–2.98 (2 H, m, H-10), 4.08–
4.16 (4 H, m, H-11,11’), 5.24–5.27 (1 H, m, H-1); δC (100 MHz, CDCl3) 16.1 (d, J = 6.7, C-
12/12’), 16.1 (d, J = 6.7, C-12/12’), 20.2 (CH2), 22.0 (CH2), 26.3 (CH2), 28.3 (C-8), 31.1 (CH2), 
32.4 (C-7), 34.6 (d, J = 134.4, C-10), 49.8 (C-2), 62.3 (app. t, J = 6.5, C-11,11’), 72.6 (C-1), 165.0 
(d, J = 6.3, C-9); δP (162 MHz, CDCl3) 20.7; HRMS (ESI+): Found: 357.1791; C16H31NaO5P 
(MNa+) Requires 357.1801 (2.9 ppm error). 
Lab notebook reference: MGL/06/69 
(1SR,2SR)-2-(tert-Butyl)cyclohexyl 2-diazo-2-diethoxyphosphoryl)acetate (156b) 
 
 
 
Synthesised using general procedure B with (1SR,2SR)-2-(tert-butyl)cyclohexyl 2-
(diethoxyphosphoryl)acetate 156a (1.67 g, 5.00 mmol), THF (25 mL), LHMDS (6.00 mL, 6.00 
mmol, 1.0 M solution in THF) and p-ABSA (1.44 g, 6.00 mmol). Purification by column 
chromatography (4:1 hexane:EtOAc) afforded the title compound 156b as a yellow oil (1.47 g, 
82%); Rf 0.63 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2939s, 2868m, 2125s, 1693s, 1480m, 
1447m, 1368m, 1277s, 1269s, 1222m, 1018s, 976m; δH (400 MHz, CDCl3) 0.84 (9 H, s, H-8), 
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1.10–1.49 (12 H, m), 1.57–1.64 (1 H, m), 1.74–1.82 (1 H, m), 1.86–1.93 (1 H, m), 4.05–4.23 (4 H, 
m, H-11,11’), 5.40–5.43 (1 H, m, H-1); δC (100 MHz, CDCl3) 16.0 (d, J = 7.2, C-12/12’), 16.0 (d, J 
= 7.5, C-12/12’), 20.3 (CH2), 21.9 (CH2), 26.4 (CH2), 28.3 (C-8), 31.7 (CH2), 32.4 (C-7), 50.2 (C-
2), 54.0 (d, J = 226.6, C-10), 63.3 (d, J = 5.9, C-11/11’), 63.4 (d, J = 5.9, C-11/11’), 72.6 (C-1), 
162.5 (d, J = 12.1, C-9); δP (162 MHz, CDCl3) 11.2; HRMS (ESI+): Found: 383.1690; 
C16H29N2NaO5P (MNa+) Requires 383.1706 (4.3 ppm error). 
Lab notebook reference: MGL/06/72 
(3aRS,7SR,7aRS)-7-(tert-Butyl)-3-methylenehexahydrobenzofuran-2(3H)-one (156c) 
 
 
 
Synthesised using general procedure D with (1SR,2SR)-2-(tert-butyl)cyclohexyl 2-diazo-2-
diethoxyphosphoryl)acetate 156b (75 mg, 0.208 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.2 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (35.0 mg, 0.312 mmol) and paraformaldehyde (12.5 mg, 0.416 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
156c as a white solid (39 mg, 90%); Rf 0.49 (4:1 hexane:EtOAc); m.p. 57–60 °C; νmax (thin 
film)/cm-1 2944s, 2866m, 1762s, 1669w, 1366m, 1261s, 1175m, 1145s, 1117s, 1078m, 962s, 
945m, 896m, 818m; δH (400 MHz, CDCl3) 1.00 (9 H, s, H-8), 1.15–1.34 (4 H, m), 1.65–1.79 (3 H, 
m), 2.81–2.86 (1 H, m), 4.58–4.60 (1 H, m, H-1), 5.49 (1 H, d, J = 0.8, H-10b), 6.05 (1 H, d, J = 
0.8, H-10a); δC (100 MHz, CDCl3) 20.2 (C-3/4/5), 23.8 (C-3/4/5), 28.3 (C-8), 28.5 (C-3/4/5), 32.9 
(C-7), 41.5 (C-2/6), 48.1 (C-2/6), 78.0 (C-1), 119.1 (C-10), 141.9 (C-9), 171.4 (C-11); HRMS 
(ESI+): Found: 231.1361; C13H20NaO2 (MNa+) Requires 231.1356 (−2.5 ppm error), Found: 
209.1538; C13H21O2 (MH+) Requires 209.1536 (−0.9 ppm error). 
Lab notebook reference: MGL/06/75 
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(1RS,2SR)-2-(tert-Butyl)cyclohexyl 2-(diethoxyphosphoryl)acetate (157a) 
 
 
 
Synthesised using general procedure A with (1RS,2SR)-2-(tert-butyl)cyclohexanol 157 (1.56 g, 
10.0 mmol), toluene (50 mL), DEPAA (2.06 g, 10.5 mmol), DIPEA (4.52 mL, 26.0 mmol) and 
T3P (8.27 g, 13.0 mmol, 50% w/w solution in EtOAc) affording the title compound 157a as a 
yellow oil (3.27 g, 98%). No further purification was required; Rf 0.31 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2937s, 2865m, 1727s, 1479m, 1449m, 1396m, 1368m, 1263s, 1164w, 1113s, 
1051w, 1022s, 967s, 835m, 780m; δH (400 MHz, CDCl3) 0.86 (9 H, s, H-8), 0.90–1.41 (11 H, m), 
1.60–1.67 (2 H, m), 1.80–1.86 (1 H, m), 1.94–1.99 (1 H, m), 2.81–2.95 (2 H, m, H-10), 4.09–4.16 
(4 H, m, H-11,11’), 4.72 (1 H, td, J = 10.2, J = 4.5, H-1); δC (100 MHz, CDCl3) 16.2 (d, J = 6.4, C-
12,12’), 24.4 (CH2), 25.7 (CH2), 26.6 (CH2), 28.9 (C-8), 32.7 (C-7), 32.8 (CH2), 34.8 (d, J = 134.9, 
C-10), 50.1 (C-2), 62.4 (d, J = 6.7, C-11/11’), 62.5 (d, J = 6.7, C-11/11’), 76.8 (C-1), 165.0 (d, J = 
6.0, C-9); δP (162 MHz, CDCl3) 20.6; HRMS (ESI+): Found: 357.1785; C16H31NaO5P (MNa+) 
Requires 357.1801 (4.6 ppm error), Found: 335.1989; C16H32O5P (MH+) Requires 335.1982 (−2.3 
ppm error). 
Lab notebook reference: MGL/06/70 
(1RS,2SR)-2-(tert-Butyl)cyclohexyl 2-diazo-2-diethoxyphosphoryl)acetate (157b) 
 
 
 
Synthesised using general procedure B with (1RS,2SR)-2-(tert-butyl)cyclohexyl 2-
(diethoxyphosphoryl)acetate 157a (1.67 g, 5.00 mmol), THF (25 mL), LHMDS (6.00 mL, 6.00 
mmol, 1.0 M solution in THF) and p-ABSA (1.44 g, 6.00 mmol). Purification by column 
chromatography (4:1 hexane:EtOAc) afforded the title compound 157b as a yellow oil (1.37 g, 
76%); Rf 0.60 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2936s, 2865m, 2122s, 1698s, 1478m, 
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1449m, 1395w, 1367m, 1319w, 1272s, 1220s, 1164w, 1130w, 1108w, 1018s, 976s, 951s, 817s, 
795s, 743s; δH (400 MHz, CDCl3) 0.82–1.40 (20 H, m), 1.61–1.67 (2 H, m), 1.81–1.87 (1 H, m), 
1.92–1.96 (1 H, m), 4.04–4.23 (4 H, H-11,11’), 4.84 (1 H, td, J = 10.1, J = 4.5, H-1); δC (100 MHz, 
CDCl3) 16.0 (d, J = 7.4, C-12,12’), 24.4 (CH2), 25.5 (CH2), 26.6 (CH2), 28.8 (C-8), 32.8 (C-7), 
33.4 (CH2), 50.3 (C-2), 53.8 (d, J = 227.2, C-10), 63.4 (d, J = 5.9, C-11/11’), 63.5 (d, J = 5.9, C-
11/11’), 76.6 (C-1), 162.4 (d, J = 13.0, C-9); δP (162 MHz, CDCl3) 10.9; HRMS (ESI+): Found: 
383.1705; C16H29N2NaO5P (MNa+) Requires 383.1706 (0.4 ppm error). 
Lab notebook reference: MGL/06/73 
(3aRS,7SR,7aSR)-7-(tert-Butyl)-3-methylenehexahydrobenzofuran-2(3H)-one (157c) 
 
 
 
Synthesised using general procedure D with (1RS,2SR)-2-(tert-butyl)cyclohexyl 2-diazo-2-
diethoxyphosphoryl)acetate 157b (75 mg, 0.208 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.2 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (35.0 mg, 0.312 mmol) and paraformaldehyde (12.5 mg, 0.416 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
157c as a yellow oil (33 mg, 76%); Rf 0.57 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2938s, 
2868m, 1770s, 1447w, 1408w, 1367m, 1255m, 1239s, 1151s, 1127s, 1081m, 1032m, 1009s, 995s, 
933m; δH (400 MHz, CDCl3) 0.97 (9 H, s, H-8), 1.05–1.16 (1 H, m, H-3), 1.22–1.32 (1 H, m, H-5), 
1.41 (1 H, app. qt, J = 13.1, J = 4.0, H-4), 1.56–1.64 (1 H, m, H-2), 1.85–1.96 (2 H, m, H-3,4), 
2.06–2.12 (1 H, m, H-5), 2.49 (1 H, app. tq, J = 10.8, J = 3.4, H-6), 3.63 (1 H, app. t, J = 10.6, H-
1), 5.37 (1 H, d, J = 3.1, H-10b), 6.06 (1 H, d, J = 3.3, H-10a); δC (100 MHz, CDCl3) 25.2 (C-4), 
26.0 (C-5), 26.4 (C-3), 28.1 (C-8), 32.6 (C-7), 49.0 (C-6), 51.5 (C-2), 85.4 (C-1), 117.2 (C-10), 
139.3 (C-9), 170.8 (C-11); HRMS (ESI+): Found: 231.1356; C13H20NaO2 (MNa+) Requires 
231.1356 (0.0 ppm error). 
Lab notebook reference: MGL/06/76 
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(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-(diethoxyphosphoryl)acetate (158a) 
 
 
 
Synthesised using general procedure A with L-menthol 158 (781 mg, 5.00 mmol), toluene (25 mL), 
DEPAA (1.03 g, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 50% 
w/w solution in EtOAc) affording the title compound 158a as a colourless oil (1.67 g, 100%). No 
further purification was required; Rf 0.44 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2955s, 2931s, 
2870m, 1728s, 1456m, 1390m, 1369m, 1264s, 1114m, 1052w, 1023s, 966s; δH (400 MHz, CDCl3) 
0.73 (3 H, d, J = 6.9), 0.82–1.07 (9 H, m), 1.14–1.52 (8 H, m), 1.63–1.69 (2 H, m), 1.91–2.02 (2 H, 
m), 2.92 (2 H, d, J = 21.7, H-11), 4.10–4.18 (4 H, m, H-12,12’), 4.70 (1 H, app. td, J = 10.9, J = 
4.4, H-1); δC (100 MHz, CDCl3) 16.0 (CH3), 16.2 (d, J = 6.0, C-13,13’), 20.7 (CH3), 21.9 (CH3), 
23.1 (CH2), 25.7 (CH), 31.3 (CH), 34.1 (CH2), 34.5 (d, J = 133.3, C-11), 40.6 (CH2), 46.8 (CH), 
62.5 (app. t, J = 5.8, C-12,12’), 75.6 (C-1), 165.3 (d, J = 6.3, C-10); δP (162 MHz, CDCl3) 20.7; 
HRMS (ESI+): Found: 357.1801; C16H31NaO5P (MNa+) Requires 357.1801 (0.2 ppm error). 
Lab notebook reference: MGL/06/54 
(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate 
(158b) 
 
 
 
Synthesised using general procedure B with (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-
(diethoxyphosphoryl)acetate 158a (1.64 g, 4.90 mmol), THF (25.0 mL), LHMDS (5.90 mL, 5.90 
mmol, 1.0 M solution in THF) and p-ABSA (1.41 g, 5.90 mmol). Purification by column 
chromatography (2:1 hexane:EtOAc) afforded the title compound 158b as a yellow solid (1.59 g, 
90%); Rf 0.67 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2956s, 2127s, 1697s, 1457m, 1369m, 
1275s, 1119m, 1021s, 980s, 957s; δH (400 MHz, CDCl3) 0.75 (3 H, d, J = 7.0), 0.80–1.08 (9 H, m), 
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1.32–1.52 (8 H, m), 1.64–1.70 (2 H, m), 1.81–1.92 (1 H, m), 1.99–2.04 (1 H, m), 4.07–4.25 (4 H, 
m, H-12,12’), 4.77 (1 H, app. td, J = 10.9, J = 4.4, H-1); δC (100 MHz, CDCl3) 16.0 (CH3), 16.0 (d, 
J = 6.9, C-13,13’), 16.1 (CH3), 20.7 (CH3), 21.9 (CH3), 23.2 (CH2), 26.1 (CH), 31.4 (CH), 34.0 
(CH2), 41.0 (CH2), 47.1 (CH), 53.8 (d, J = 223.2, C-11), 63.4 (d, J = 5.7, C-12,12’), 75.9 (C-1), 
163.1 (d, J = 11.4, C-10); δP (162 MHz, CDCl3) 10.9; HRMS (ESI+): Found: 383.1718; 
C16H29N2NaO5P (MNa+) Requires 383.1706 (−3.1 ppm error). 
Lab notebook reference: MGL/06/61 
(3aR,4R,7S,7aS)-7-Isopropyl-4-methyl-3-methylenehexahydrobenzofuran-2(3H)-one 
(158c) 
 
 
 
Synthesised using general procedure D with (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-diazo-
2-(diethoxyphosphoryl)acetate 158b (71 mg, 0.197 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 
3.9 µmol), THF (4.0 mL), KOBu-t (33.2 mg, 0.296 mmol) and paraformaldehyde (11.8 mg, 0.394 
mmol). Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compound 
158c as a colourless oil (30 mg, 73%); Rf 0.41 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2958m, 
1766s, 1462m, 1388w, 1249s, 1133s, 1042s, 980s; δH (400 MHz, CDCl3) 0.88 (3 H, d, J = 7.0, H-
8/8’), 0.94 (3 H, d, J = 7.0, H-8/8’), 1.02–1.34 (5 H, m), 1.62–1.82 (4 H, m), 1.99 (1 H, hept.d, J = 
7.0, J = 3.4, H-7), 2.19 (1 H, app. tt, J = 10.5, J = 3.1, H-2), 3.60 (1 H, app. t, J = 10.7, H-1), 5.63 
(1 H, d, J = 3.0, H-11b), 6.09 (1 H, d, J = 3.2, H-11a); δC (100 MHz, CDCl3) 17.6 (C-8/8’), 19.3 
(C-9), 19.9 (C-8/8’), 24.5 (C-4/5), 28.1 (C-7), 33.5 (C-3), 35.4 (C-4/5), 46.8 (C-6), 53.9 (C-2), 84.0 
(C-1), 118.3 (C-11), 139.6 (C-10), 171.0 (C-12); HRMS (ESI+): Found: 231.1354; C13H20NaO2 
(MNa+) Requires 231.1356 (0.8 ppm error), Found: 209.1532; C13H21O2 (MH+) Requires 209.1536 
(1.8 ppm error). 
Lab notebook reference: MGL/06/66 
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(1RS,4aRS,8aSR)-Decahydronaphthalen-1-yl 2-(diethoxyphosphoryl)acetate (159a) 
 
 
 
Synthesised using general procedure A with (1RS,4aRS,8aSR)-decahydronaphthalen-1-ol 159 (201 
mg, 1.30 mmol), toluene (10 mL), DEPAA (0.22 mL, 1.37 mmol), DIPEA (0.60 mL, 3.38 mmol) 
and T3P (1.08 g, 1.70 mmol, 50% w/w solution in EtOAc) affording the title compound 159a as a 
yellow oil (425 mg, 98%). No further purification was required; Rf 0.54 (3:7 petrol:EtOAc); νmax 
(thin film)/cm-1 2982, 2924, 2853, 1731, 1448, 1394, 1263, 1114, 1021, 960; δH (400 MHz, CDCl3) 
0.79–1.95 (22 H, m), 2.94–3.00 (2 H, m), 4.13–4.20 (4 H, m), 4.93–4.96 (1 H, m); δC (100 MHz, 
CDCl3) 16.3 (d, J = 6.3), 16.3 (d, J = 6.3), 20.4, 26.2, 26.4, 29.1, 30.6, 33.4, 34.2, 34.6 (d, J = 
134.0), 36.3, 45.7, 62.5 (d, J = 6.3), 75.0, 165.4 (d, J = 6.8); δP (162 MHz, CDCl3) 20.9; HRMS 
(ESI+): Found: 355.1638; C16H29NaO5P (MNa+) Requires 355.1645 (1.9 ppm error), Found: 
333.1818; C16H30O5P (MH+) Requires 333.1825 (2.2 ppm error).  
Note: This compound was synthesised by Mariantonietta D’Acunto. 
(1RS,4aRS,8aSR)-Decahydronaphthalen-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate 
(159b) 
 
 
 
Synthesised using general procedure B with (1RS,4aRS,8aSR)-decahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate 159a (475 mg, 1.43 mmol), THF (9.0 mL), NaH (68.6 mg, 1.72 
mmol, 60% dispersion in mineral oil) and p-ABSA (412 mg, 1.72 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 159b as a yellow oil (350 mg, 
68%); Rf 0.80 (3:7 petrol:EtOAc); νmax (thin film)/cm-1 2927, 2857, 2126, 1698, 1448, 1290, 1277, 
1118, 1023, 981; δH (400 MHz, CDCl3) 0.87–1.97 (22 H, m), 4.11–4.29 (4 H, m), 5.02–5.04 (1 H, 
m); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9), 16.1 (d, J = 6.9), 20.3, 26.1, 26.3, 29.2, 30.8, 33.3, 
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34.0, 36.3, 45.7, 54.0 (d, J = 227.6), 63.2 (d, J = 5.5), 63.2 (d, J = 5.4), 75.3, 163.3 (d, J = 11.1); δP 
(162 MHz, CDCl3) 11.6; HRMS (ESI+): Found: 381.1556; C16H27N2NaO5P (MNa+) Requires 
381.1550 (−1.7 ppm error), Found: 359.1731; C16H30N2O5P (MH+) Requires 359.1730 (−0.2 ppm 
error).  
Note: This compound was synthesised by Mariantonietta D’Acunto. 
(3aSR,5aRS,9aSR,9bSR)-3-Methylenedecahydronaphtho[1,2-b]furan-2(9bH)-one 
(159c) 
 
 
 
Synthesised using general procedure D with (1RS,4aRS,8aSR)-decahydronaphthalen-1-yl 2-diazo-
2-(diethoxyphosphoryl)acetate 159b (82 mg, 0.229 mmol), CH2Cl2 (4.6 mL), Rh2(oct)4 (3.6 mg, 
4.6 µmol), THF (4.6 mL), KOBu-t (38.5 mg, 0.344 mmol) and paraformaldehyde (13.8 mg, 0.458 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
159c as a colourless oil (32 mg, 68%); Rf 0.56 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 2923s, 
2854m, 1761s, 1447w, 1260s, 1144s, 1117m, 1081m, 949m; δH (400 MHz, CDCl3) 0.89–1.06 (2 H, 
m), 1.18–1.35 (5 H, m), 1.46–1.85 (7 H, m), 2.84–2.90 (1 H, m, H-3), 4.25 (1 H, dd, J = 4.6, J = 
2.6, H-4), 5.49 (1 H, d, J = 1.0, H-5b), 6.04 (1 H, d, J = 1.1, H-5a); δC (100 MHz, CDCl3) 26.0 
(CH2), 26.7 (CH2), 28.7 (CH2), 28.8 (CH2), 31.0 (CH2), 33.7 (CH2), 34.9 (C-8/9), 40.8 (C-3), 43.8 
(C-8/9), 80.6 (C-4), 119.1 (C-5), 142.5 (C-2), 171.0 (C-1); HRMS (ESI+): Found: 229.1207; 
C13H18NaO2 (MNa+) Requires 229.1199 (−3.4 ppm error), Found: 207.1384; C13H19O2 (MH+) 
Requires 207.1380 (−2.0 ppm error). 
Lab notebook reference: MGL/05/35 
Obtained data in accord with reported literature.165 
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(1SR,4aRS,8aSR)-Decahydronaphthalen-1-yl 2-(diethoxyphosphoryl)acetate (160a) 
 
 
 
Synthesised using general procedure A with (1SR,4aRS,8aSR)-decahydronaphthalen-1-ol 160 (271 
mg, 1.76 mmol), toluene (15 mL), DEPAA (0.30 mL, 1.85 mmol), DIPEA (0.82 mL, 4.60 mmol) 
and T3P (1.46 g, 2.30 mmol, 50% w/w solution in EtOAc) affording the title compound 160a as a 
yellow oil (390 mg, 67%). No further purification was required; Rf 0.36 (3:7 petrol:EtOAc); νmax 
(thin film)/cm-1 2983, 2921, 2855, 1730, 1447, 1394, 1264, 1114, 1023, 963; δH (400 MHz, CDCl3) 
0.78–2.02 (22 H, m), 2.93 (2 H, d, J = 21.7), 4.11–4.18 (4 H, m), 4.50 (1 H, app. td, J = 10.3, J = 
4.4); δC (100 MHz, CDCl3) 16.3 (d, J = 6.6), 16.3 (d, J = 6.3), 23.7, 25.8, 26.1, 28.7, 31.9, 33.0, 
33.8, 34.5 (d, J = 133.7), 41.2, 47.2, 62.5 (d, J = 6.2), 62.5 (d, J = 6.2), 78.6, 165.5 (d, J = 6.6); δP 
(162 MHz, CDCl3) 20.8; HRMS (ESI+): Found: 355.1648; C16H29NaO5P (MNa+) Requires 
355.1645 (−0.8 ppm error), Found: 333.1830; C16H30O5P (MH+) Requires 333.1825 (−1.3 ppm 
error).  
Note: This compound was synthesised by Mariantonietta D’Acunto. 
(1SR,4aRS,8aSR)-Decahydronaphthalen-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate 
(160b) 
 
 
 
Synthesised using general procedure B with (1SR,4aRS,8aSR)-decahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate 160a (390 mg, 1.17 mmol), THF (7.0 mL), NaH (56.2 mg, 1.40 
mmol, 60% dispersion in mineral oil) and p-ABSA (337 mg, 1.40 mmol). Purification by column 
chromatography (2:1 petrol:EtOAc) afforded the title compound 160b as a yellow oil (330 mg, 
78%); Rf 0.67 (3:7 petrol:EtOAc); νmax (thin film)/cm-1 2983, 2925, 2853, 2132, 1697, 1448, 1344, 
1275, 1120, 1019, 978; δH (400 MHz, CDCl3) 0.84–2.05 (22 H, m), 4.10–4.27 (4 H, m), 4.58 (1 H, 
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app. td, J = 10.2, J = 4.2); δC (100 MHz, CDCl3) 16.0 (d, J = 7.1), 16.0 (d, J = 7.1), 23.6, 25.7, 
26.0, 28.7, 32.2, 32.9, 33.4, 41.2, 47.4, 53.8 (d, J = 226.6), 63.4 (d, J = 5.7), 79.1, 163.3 (d, J = 
12.0); δP (162 MHz, CDCl3) 11.0; HRMS (ESI+): Found: 381.1532; C16H27N2NaO5P (MNa+) 
Requires 381.1550 (4.7 ppm error), Found: 359.1718; C16H30N2O5P (MH+) Requires 359.1730 (3.4 
ppm error).  
Note: This compound was synthesised by Mariantonietta D’Acunto. 
(3aSR,5aRS,9aSR,9bRS)-3-Methylenedecahydronaphtho[1,2-b]furan-2(9bH)-one 
(160c) 
 
 
 
Synthesised using general procedure D with (1SR,4aRS,8aSR)-decahydronaphthalen-1-yl 2-diazo-
2-(diethoxyphosphoryl)acetate 160b (79 mg, 0.221 mmol), CH2Cl2 (4.4 mL), Rh2(oct)4 (3.4 mg, 
4.4 µmol), THF (4.4 mL), KOBu-t (37.2 mg, 0.332 mmol) and paraformaldehyde (13.3 mg, 0.442 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
160c as a white solid (29 mg, 64%); Rf 0.72 (4:1 hexane:EtOAc); m.p. 80–83 °C (lit.165 75–77 °C); 
νmax (thin film)/cm-1 2924s, 2852m, 1766s, 1672w, 1449m, 1256m, 1241m, 1125m, 990m, 967m; 
δH (400 MHz, CDCl3) 0.98–1.46 (8 H, m), 1.65–1.77 (4 H, m), 2.08–2.13 (2 H, m), 2.43–2.51 (1 H, 
m, H-3), 3.44 (1 H, app. t, J = 10.6, H-4), 5.36 (1 H, d, J = 3.1, H-5b), 6.04 (1 H, d, J = 3.3, H-5a); 
δC (100 MHz, CDCl3) 25.1 (CH2), 25.2 (CH2), 26.1 (CH2), 29.0 (CH2), 32.6 (CH2), 32.8 (CH2), 
41.6 (C-8), 47.0 (C-9), 48.6 (C-3), 86.7 (C-4), 117.0 (C-5), 139.9 (C-2), 171.0 (C-1); HRMS 
(ESI+): Found: 229.1203; C13H18NaO2 (MNa+) Requires 229.1199 (−1.6 ppm error), Found: 
207.1380; C13H19O2 (MH+) Requires 207.1380 (0.0 ppm error).  
Lab notebook reference: MGL/05/34 
Obtained data in accord with reported literature.165 
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Adamantan-1-yl 2-(diethoxyphosphoryl)acetate (161a) 
 
 
 
Synthesised using general procedure A with adamantan-1-ol 161 (761 mg, 5.00 mmol), toluene (25 
mL), DEPAA (0.84 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 
50% w/w solution in THF) affording the title compound 161a as a colourless oil (1.53 g, 93%). No 
further purification was required; Rf 0.30 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2981w, 2910s, 
2853w, 1728s, 1584w, 1457w, 1393w, 1369w, 1355w, 1321w, 1259s, 1164w, 1103m, 1049w, 
1020s, 967s, 890m, 836w, 814w; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.5, H-4), 1.57–
1.69 (6 H, m, H-8), 2.09–2.14 (9 H, m, H-6,7), 2.85 (2 H, d, J = 21.4, H-2), 4.10–4.18 (4 H, m, H-
3); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 30.7 (C-7), 35.7 (d, J = 132.8, C-2), 36.0 (C-8), 
41.1 (C-6), 62.4 (d, J = 6.2, C-3), 82.0 (C-5), 164.5 (d, J = 6.3, C-1); δP (162 MHz, CDCl3) 21.2; 
HRMS (ESI+): Found: 353.1489; C16H27NaO5P (MNa+) Requires 353.1488 (−0.2 ppm error), 
Found: 331.1668; C16H28O5P (MH+) Requires 331.1669 (0.2 ppm error). 
Lab notebook reference: MGL/05/09S 
Adamantan-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (161b) 
 
 
 
Synthesised using general procedure B with adamantan-1-yl 2-(diethoxyphosphoryl)acetate 161a 
(1.51 g, 4.57 mmol), THF (23 mL), LHMDS (5.48 mL, 5.48 mmol, 1.0 M solution in THF) and p-
ABSA (1.32 g, 5.48 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded 
the title compound 161b as a white solid (1.21 g, 74%); Rf 0.63 (1:1 hexane:EtOAc); m.p. 51–54 
°C; νmax (thin film)/cm-1 2912s, 2855w, 2125s, 1697s, 1457w, 1321m, 1269s, 1219w, 1164w, 
1122w, 1023s, 966m; δH (400 MHz, CDCl3) 1.30 (6 H, td, J = 7.1, J = 0.8, H-4), 1.60–1.61 (6 H, 
m, H-8), 2.07–2.15 (9 H, m, H-6,7), 4.05–4.20 (4 H, m, H-3); δC (100 MHz, CDCl3) 16.0 (d, J = 
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6.8, C-4), 30.7 (C-7), 35.9 (C-8), 41.4 (C-6), 53.9 (d, J = 228.4, C-2), 63.3 (d, J = 5.6, C-3), 82.9 
(C-5), 162.0 (d, J = 12.0, C-1); δP (162 MHz, CDCl3) 11.3; HRMS (ESI+): Found: 379.1384; 
C16H25N2NaO5P (MNa+) Requires 379.1393 (2.5 ppm error), Found: 357.1567; C16H26N2O5P 
(MH+) Requires 357.1574 (2.0 ppm error). 
Lab notebook reference: MGL/05/09 
6-Methylene-4-oxatetracyclo[6.3.1.13,10.03,7]tridecan-5-one (161c) 
 
 
 
Synthesised using general procedure D with adamantan-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 161b (75 mg, 0.210 mmol), CH2Cl2 (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 
µmol), THF (4.2 mL), KOBu-t (35.3 mg, 0.315 mmol) and paraformaldehyde (12.6 mg, 0.420 
mmol). Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 
161c as a white solid (34 mg, 79%); Rf 0.47 (4:1 hexane:EtOAc); m.p. 88–90 °C; νmax (thin 
film)/cm-1 2921s, 2856m, 1967w, 1764s, 1675w, 1451w, 1279w, 1262m, 1242w, 1211m, 1151m, 
1042s, 949s; δH (400 MHz, CDCl3) [1.57–1.89 (8 H, m), 1.99–2.15 (3 H, m), 2.30–2.35 (1 H, m) 
(H-6,7,8,10,11,12,13)], 2.44–2.48 (1 H, m, H-9), 2.81–2.84 (1 H, m, H-4), 5.36 (1 H, d, J = 3.2, H-
5b), 6.14 (1 H, d, J = 3.4, H-5a); δC (100 MHz, CDCl3) 29.2 (C-9), 29.2 (C-6/8/10/12/13), 29.6 (C-
7/11), 30.9 (C-7/11), [35.8, 37.6, 39.8, 41.1 (C-6/8/10/12/13)], 53.5 (C-4), 80.4 (C-5), 117.4 (C-3), 
138.6 (C-2), 170.8 (C-1); HRMS (ESI+): Found: 227.1050; C13H16NaO2 (MNa+) Requires 227.1043 
(−3.5 ppm error), Found: 205.1230; C13H17O2 (MH+) Requires 205.1223 (−3.2 ppm error). 
Lab notebook reference: MGL/05/22 
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5-α-Cholestan-3-β-yl 2-(diethoxyphosphoryl)acetate (217a) 
 
 
 
Synthesised using general procedure A with 5-α-cholestan-3-β-ol 217 (1.94 g, 5.00 mmol), toluene 
(25 mL), DEPAA (1.03 g, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 
50% w/w solution in EtOAc) affording the title compound 217a as a white solid (2.78 g, 98%). No 
further purification was required; Rf 0.25 (1:1 hexane:EtOAc); m.p. 102–105 °C; νmax (thin 
film)/cm-1 2935s, 2915s, 2867m, 2851m, 1734s, 1469m, 1385m, 1282s, 1258s, 1201s, 1115s, 
1047m, 1029s, 969s; δH (400 MHz, CDCl3) 0.64 (3 H, s), 0.81 (3 H, s), 0.85 (3 H, d, J = 6.6), 0.86 
(3 H, d, J = 6.6), 0.89 (3 H, d, J = 6.5), 0.96–1.84 (36 H, m), 1.95 (1 H, dt, J = 12.5, J = 3.3), 2.93 
(2 H, d, J = 21.6), 4.13–4.20 (4 H, m), 4.74 (1 H, tt, J = 11.0, J = 5.3); δC (100 MHz, CDCl3) 12.0 
(CH3), 12.2 (CH3), 16.3 (d, J = 5.9, CH3), 18.6 (CH3), 21.2 (CH2), 22.5 (CH3), 22.8 (CH3), 23.8 
(CH2), 24.2 (CH2), 27.3 (CH2), 28.0 (CH), 28.2 (CH2), 28.5 (CH2), 31.9 (CH2), 33.8 (CH2), 34.6 (d, 
J = 133.7, CH2), 35.4 (C), 35.4 (CH), 35.8 (CH), 36.1 (CH2), 36.7 (CH2), 39.5 (CH2), 39.9 (CH2), 
42.5 (C), 44.6 (CH), 54.2 (CH), 56.2 (CH), 56.4 (CH), 62.6 (d, J = 5.9, CH2), 75.1 (CH), 165.4 (d, 
J = 6.2, C); δP (162 MHz, CDCl3) 20.6; HRMS (ESI+): Found: 589.3980; C33H59NaO5P (MNa+) 
Requires 589.3992 (2.0 ppm error). 
Lab notebook reference: MGL/06/49 
5-α-Cholestan-3-β-yl 2-diazo-2-(diethoxyphosphoryl)acetate (217b) 
 
 
 
Synthesised using general procedure B with 5-α-cholestan-3-β-yl 2-(diethoxyphosphoryl)acetate 
217a (2.75 g, 4.85 mmol), THF (24.3 mL), LHMDS (5.82 mL, 5.82 mmol, 1.0 M solution in THF) 
and p-ABSA (1.40 g, 5.82 mmol). Purification by column chromatography (2:1 hexane:EtOAc) 
afforded the title compound 217b as a white solid (2.38 g, 83%); Rf 0.70 (1:1 hexane:EtOAc); m.p. 
95–98 °C; νmax (thin film)/cm-1 2932s, 2867w, 2129s, 1698s, 1469w, 1375w, 1331w, 1289s, 
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1119m, 1023s, 978m; δH (400 MHz, CDCl3) 0.64 (3 H, s), 0.81 (3 H, s), 0.85 (3 H, d, J = 6.6), 0.85 
(3 H, d, J = 6.6), 0.88 (3 H, d, J = 6.5), 0.95–1.86 (36 H, m), 1.95 (1 H, dt, J = 12.5, J = 3.2), 4.10–
4.26 (4 H, m), 4.79 (1 H, tt, J = 11.0, J = 5.3); δC (100 MHz, CDCl3) 12.0 (CH3), 12.2 (CH3), 16.1 
(d, J = 7.1, CH3), 18.6 (CH3), 21.2 (CH2), 22.5 (CH3), 22.8 (CH3), 23.8 (CH2), 24.2 (CH2), 27.6 
(CH2), 28.0 (CH), 28.2 (CH2), 28.5 (CH2), 31.9 (CH2), 34.1 (CH2), 35.4 (C), 35.4 (CH), 35.8 (CH), 
36.1 (CH2), 36.7 (CH2), 39.5 (CH2), 39.9 (CH2), 42.3 (C), 44.6 (CH), 53.7 (d, J = 225.5, C), 54.1 
(CH), 56.2 (CH), 56.3 (CH), 63.6 (d, J = 5.8, CH2), 75.5 (CH), 163.0 (d, J = 11.9, C); δP (162 
MHz, CDCl3) 10.8; HRMS (ESI+): Found: 615.3875; C33H57N2NaO5P (MNa+) Requires 615.3897 
(3.6 ppm error). 
Lab notebook reference: MGL/06/53 
(1R,3aS,3bR,5aS,6aR,9aS,10aS,10bS,12aR)-10a,12a-Dimethyl-9-methylene-1-((R)-6-
methylheptan-2-yl)hexadecahydro-1H-cyclopenta[7,8]phenanthro[2,3-b]furan-8(2H)-
one (217c), (3aS,5aR,5bS,7aR,8R,10aS,10bS,12aS,12bR)-5a,7a-Dimethyl-1-methylene-
8-((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[7,8]phenanthro[2,1-
b]furan-2(12bH)-one (217d), (2'S,5S,8R,9S,10S,13R,14S,17R)-10,13-Dimethyl-3'-
methylene-17-((R)-6-methylheptan-2-
yl)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-oxetan]-4'-one (217e) 
 
 
 
Synthesised using general procedure D with 5-α-cholestan-3-β-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 217b (116 mg, 0.196 mmol), CH2Cl2 (3.9 mL), Rh2(oct)4 (3.1 mg, 3.9 
µmol), THF (3.9 mL), KOBu-t (33.0 mg, 0.294 mmol) and paraformaldehyde (11.8 mg, 0.392 
mmol). Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compounds 
217e (6 mg, 7%) along with an inseparable mixture of compounds 217c and 217d (38 mg, 44%). 
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Note: The γ-regioisomers were isolated as an inseparable 1.18:1 mixture A:B, however the β-
regioisomer could be separated for characterisation purposes. 
 
Data for 217c and 217d; white solid; Rf 0.51 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2932s, 
2867s, 1773s, 1713m, 1466m, 1383m, 1234m, 1128m, 1001m, 910m, 732s; δH (400 MHz, CDCl3) 
0.63–2.13 (86 H, m, A, B), 2.22–2.42 (2 H, m, A,B), 2.49 (1 H, tt, J = 10.6, J = 3.0, A), 2.61 (1 H, 
tq, J = 11.5, J = 3.0, B), 3.66–3.74 (2 H, m, A,B), 5.32 (1 H, d, J = 3.0, B), 5.62 (1 H, d, J = 3.0, 
A), 6.03 (1 H, d, J = 3.2, B), 6.10 (1 H, d, J = 3.2, A); δC (100 MHz, CDCl3) 11.4, 12.0, 12.1, 13.7, 
14.2, 18.6, 21.3, 21.4, 22.5, 22.8, 23.8, 24.1, 24.2, 26.2, 28.0, 28.2, 28.2, 28.6, 28.9, 31.4, 31.7, 
32.0, 33.1, 34.9, 35.3, 35.4, 35.6, 35.7, 36.1, 36.1, 37.7, 37.8, 38.2, 38.5, 39.5, 39.8, 42.2, 42.5, 
42.6, 44.5, 44.7, 45.8, 46.4, 46.7, 48.1, 53.7, 54.0, 54.2, 56.2, 56.2, 56.2, 56.3, 83.3, 83.4, 116.1, 
118.8, 139.7, 140.3, 170.9, 171.2; HRMS (ESI+): Found: 463.3535; C30H48NaO2 (MNa+) Requires 
463.3547 (2.4 ppm error). 
 
Data for 217e; yellow gum; Rf 0.59 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2931s, 2869s, 1832s, 
1467m, 1382m, 1198m, 837m; δH (400 MHz, CDCl3) 0.64–2.13 (46 H, m), 5.54 (1 H, d, J = 1.8), 
5.78 (1 H, d, J = 1.8); δC (100 MHz, CDCl3) 11.5 (CH3), 12.1 (CH3), 18.6 (CH3), 21.3 (CH2), 22.5 
(CH3), 22.8 (CH3), 23.8 (CH2), 24.2 (CH2), 28.0 (CH), 28.2 (CH2), 28.5 (CH2), 30.8 (CH2), 31.8 
(CH2), 35.4 (C), 35.4 (CH), 35.8 (CH), 36.1 (CH2), 36.5 (CH2), 37.2 (CH2), 39.5 (CH2), 39.9 
(CH2), 42.6 (C), 44.7 (CH), 54.3 (CH), 56.3 (CH), 56.4 (CH), 87.2 (C), 112.9 (CH2), 150.4 (C), 
163.7 (C); HRMS (ESI+): Found: 463.3540; C30H48NaO2 (MNa+) Requires 463.3547 (1.5 ppm 
error). 
Lab notebook reference: MGL/06/57 
Cholesteryl 2-(diethoxyphosphoryl)acetate (218a) 
 
 
 
Synthesised using general procedure A with cholesterol 218 (1.00 g, 2.59 mmol), toluene (13 mL), 
DEPAA (533 mg, 2.72 mmol), DIPEA (1.17 mL, 6.73 mmol) and T3P (2.14 g, 3.37 mmol, 50% 
w/w solution in EtOAc) affording the title compound 218a as a yellow solid (1.46 g, 100%). No 
further purification was required; Rf 0.36 (1:1 hexane:EtOAc); m.p. 75–77 °C; νmax (thin film)/cm-1 
2934s, 2868w, 1733s, 1467m, 1368w, 1271s, 1115s, 1051m, 1024s, 967s; δH (400 MHz, CDCl3) 
0.66 (3 H, s), 0.82–1.66 (39 H, m), 1.77–2.02 (5 H, m), 2.34 (2 H, d, J = 7.6), 2.94 (2 H, d, J = 
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21.6), 4.13–4.20 (4 H, m), 4.65 (1 H, dtd, J = 11.9, J = 8.1, J = 3.9), 5.37 (1 H, d, J = 3.6); δC (100 
MHz, CDCl3) 11.8 (CH3), 16.3 (d, J = 6.4, CH3), 18.7 (CH3), 19.3 (CH3), 21.0 (CH2), 22.5 (CH3), 
22.8 (CH3), 23.8 (CH2), 24.2 (CH2), 27.6 (CH2), 28.0 (CH), 28.2 (CH2), 31.8 (CH), 31.8 (CH2), 
34.6 (d, J = 133.6, CH2), 35.7 (CH), 36.1 (CH2), 36.5 (C), 36.9 (CH2), 37.9 (CH2), 39.5 (CH2), 39.7 
(CH2), 42.3 (C), 49.9 (CH), 56.1 (CH), 56.6 (CH), 62.6 (d, J = 6.3, CH2), 75.3 (CH), 122.9 (CH), 
139.3 (C), 165.2 (d, J = 6.7, C); δP (162 MHz, CDCl3) 20.6; HRMS (ESI+): Found: 587.3830; 
C33H57NaO5P (MNa+) Requires 587.3836 (1.0 ppm error). 
Lab notebook reference: MGL/06/47 
Cholesteryl 2-diazo-2-(diethoxyphosphoryl)acetate (218b) 
 
 
 
Synthesised using general procedure B with cholesteryl 2-(diethoxyphosphoryl)acetate 218a (1.37 
g, 2.43 mmol), THF (12 mL), LHMDS (2.91 mL, 2.91 mmol, 1.0 M solution in THF) and p-ABSA 
(699 mg, 2.91 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the 
title compound 218b as a yellow gum (890 mg, 62%); Rf 0.70 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2935s, 2868w, 2128s, 1698s, 1468w, 1369w, 1279s, 1121m, 1022s, 976m; δH (400 
MHz, CDCl3) 0.67 (3 H, s), 0.82–2.02 (44 H, m), 2.28–2.39 (2 H, m), 4.11–4.26 (4 H, m), 4.70 (1 
H, tdd, J = 10.8, J = 6.4, J = 4.4), 5.37 (1 H, d, J = 5.1); δC (100 MHz, CDCl3) 11.8 (CH3), 16.1 (d, 
J = 6.8, CH3), 18.7 (CH3), 19.3 (CH3), 21.0 (CH2), 22.5 (CH3), 22.8 (CH3), 23.8 (CH2), 24.2 (CH2), 
27.9 (CH2), 28.0 (CH), 28.2 (CH2), 31.8 (CH), 31.9 (CH2), 35.7 (CH), 36.1 (CH2), 36.5 (C), 36.9 
(CH2), 38.2 (CH2), 39.5 (CH2), 39.7 (CH2), 42.3 (C), 49.9 (CH), 53.8 (d, J = 225.9, C), 56.1 (CH), 
56.6 (CH), 63.5 (d, J = 5.8, CH2), 75.6 (CH), 123.1 (CH), 139.2 (C), 162.9 (d, J = 12.3, C); δP (162 
MHz, CDCl3) 10.8; HRMS (ESI+): Found: 613.3721; C33H55N2NaO5P (MNa+) Requires 613.3741 
(3.2 ppm error). 
Lab notebook reference: MGL/06/52 
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(1R,3bS,6aR,9aS,10aR,10bS,12aR)-10a,12a-Dimethyl-9-methylene-1-((R)-6-
methylheptan-2-yl)-3,3a,3b,4,6,6a,9,9a,10,10a,10b,11,12,12a-tetradecahydro-1H-
cyclopenta[7,8]phenanthro[2,3-b]furan-8(2H)-one (218c), 
(2'S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-3'-methylene-17-((R)-6-methylheptan-2-
yl)-1,2,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-oxetan]-4'-one (218d) 
 
 
 
Synthesised using general procedure D with cholesteryl 2-diazo-2-(diethoxyphosphoryl)acetate 
218b (118 mg, 0.200 mmol), CH2Cl2 (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 µmol), THF (4.0 mL), 
KOBu-t (33.7 mg, 0.300 mmol) and paraformaldehyde (12.0 mg, 0.400 mmol). Purification by 
column chromatography (8:1 hexane:EtOAc) afforded the title compounds 218c:218d (2:1) (35 
mg, 40%). 
 
Small quantities of each compound were isolated separately for characterisation purposes.  
 
Data for 218c; white solid; Rf 0.69 (1:1 hexane:EtOAc); m.p. 104–109 °C; νmax (thin film)/cm-1 
2935s, 2866m, 1778s, 1462m, 1382m, 1254m, 1132s, 1000s, 926m, 813m; δH (400 MHz, CDCl3) 
0.69 (3 H, s), 0.83–1.62 (32 H, m), 1.79–1.89 (1 H, m), 1.99–2.07 (2 H, m), 2.19 (1 H, dd, J = 12.7, 
J = 3.4), 2.55–2.64 (2 H, m), 2.68–2.76 (1 H, m), 3.61 (1 H, td, J = 10.8, J = 5.7), 5.37 (1 H, d, J = 
3.0), 5.51 (1 H, d, J = 5.3), 6.07 (1 H, d, J = 3.2); δC (100 MHz, CDCl3) 11.9 (CH3), 18.7 (CH3), 
20.6 (CH3), 21.1 (CH2), 22.5 (CH3), 22.8 (CH3), 23.8 (CH2), 24.2 (CH), 28.0 (CH), 28.2 (CH2), 
31.7 (CH), 31.8 (CH2), 35.8 (CH), 36.1 (CH2), 38.1 (CH2), 38.3 (CH2), 38.4 (C), 39.5 (CH2), 39.6 
(CH2), 42.3 (C), 44.6 (CH), 50.1 (CH), 56.1 (CH), 56.6 (CH), 82.8 (CH), 117.1 (CH2), 126.1 (CH), 
137.8 (C), 139.8 (C), 170.8 (C); HRMS (ESI+): Found: 461.3387; C30H46NaO2 (MNa+) Requires 
461.3390 (0.6 ppm error). 
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Data for 218d; yellow gum; Rf 0.79 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2933s, 1821s, 
1465m, 1378m, 1260m, 1191m, 1086m, 1034m, 908s, 806s, 731s; δH (400 MHz, CDCl3) 0.70–
2.33 (42 H, m), 2.92–2.97 (1 H, m), 5.34 (1 H, d, J = 1.3), 5.44–5.46 (1 H, m), 5.74 (1 H, d, J = 
1.3); δC (100 MHz, CDCl3) 11.8 (CH3), 18.7 (CH3), 18.8 (CH3), 21.1 (CH2), 22.5 (CH3), 22.8 
(CH3), 23.8 (CH2), 24.3 (CH), 28.0 (CH), 28.2 (CH2), 31.0 (CH2), 31.8 (CH2), 32.0 (CH2), 35.8 
(CH), 36.1 (C), 36.6 (CH2), 36.8 (CH2), 39.5 (CH2), 39.6 (CH2), 41.4 (CH2), 42.3 (C), 50.3 (CH), 
56.1 (CH), 56.6 (CH), 86.9 (C), 113.8 (CH2), 124.5 (CH), 138.2 (C), 148.9 (C), 163.5 (C); HRMS 
(ESI+): Found: 461.3377; C30H46NaO2 (MNa+) Requires 461.3390 (2.9 ppm error). 
Lab notebook reference: MGL/06/56 
11-α-(2-(Diethoxyphosphoryl)acetoxy)progesterone (219a) 
 
 
 
Synthesised using general procedure A with 11α-hydroxyprogesterone 219 (1.26 g, 3.81 mmol), 
toluene (19 mL), DEPAA (785 mg, 4.00 mmol), DIPEA (1.73 mL, 9.91 mmol) and T3P (3.15 g, 
4.96 mmol, 50% w/w solution in EtOAc) affording the title compound 219a as a pale yellow solid 
(1.92 g, 99%). No further purification was required; Rf 0.16 (1:8 hexane:EtOAc); m.p. 108–111 °C; 
νmax (thin film)/cm-1 2971s, 2938s, 1729s, 1703s, 1670s, 1613w, 1447w, 1391m, 1358m, 1267s, 
1115m, 1048m, 1024s, 969s; δH (400 MHz, CDCl3) 0.72 (3 H, s), 1.08–1.36 (12 H, m), 1.46–1.53 
(2 H, m), 1.59–1.77 (3 H, m), 1.85–2.06 (3 H, m), 2.09 (3 H, s), 2.16–2.45 (6 H, m), 2.55 (1 H, t, J 
= 9.1), 2.85–2.99 (2 H, m), 4.13–4.21 (4 H, m), 5.28 (1 H, app. td, J = 10.6, J = 5.1), 5.75 (1 H, s); 
δC (100 MHz, CDCl3) 14.0 (CH3), 16.4 (d, J = 6.7, 2 × CH3), 18.1 (CH3), 22.9 (CH2), 24.2 (CH2), 
31.3 (CH3), 31.5 (CH2), 33.3 (CH2), 34.0 (CH2), 35.0 (d, J = 134.9, CH2), 35.0 (CH), 36.6 (CH2), 
39.7 (C), 43.7 (C), 44.9 (CH2), 54.8 (CH), 55.3 (CH), 62.7 (app. t, J = 6.3, 2 × CH2), 62.9 (CH), 
72.3 (CH), 124.9 (CH), 165.0 (d, J = 5.9, C), 169.1 (C), 199.2 (C), 208.2 (C); δP (162 MHz, 
CDCl3) 20.0; HRMS (ESI+): Found: 531.2484; C27H41NaO7P (MNa+) Requires 531.2482 (−0.3 
ppm error), Found: 509.2663; C27H42O7P (MH+) Requires 509.2663 (0.0 ppm error). 
Lab notebook reference: MGL/06/71 
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11-α-(2-Diazo-2-(diethoxyphosphoryl)acetoxy)progesterone (219b) 
 
 
 
Synthesised using general procedure B with 11-α-(2-(diethoxyphosphoryl)acetoxy)progesterone 
219a (970 mg, 1.91 mmol), THF (9.5 mL), LHMDS (2.29 mL, 2.29 mmol, 1.0 M solution in THF) 
and p-ABSA (550 g, 2.29 mmol). Purification by column chromatography (1:20 hexane:EtOAc) 
afforded the title compound 219b as a pale yellow solid (747 mg, 73%); Rf 0.28 (1:20 
hexane:EtOAc); m.p. 143–146 °C; νmax (thin film)/cm-1 2968s, 2934s, 2129s, 1702s, 1674s, 1446w, 
1391w, 1276s, 1219w, 1164w, 1120w, 1020s, 978m, 949m; δH (400 MHz, CDCl3) 0.73 (3 H, s), 
1.09–1.38 (12 H, m), 1.45–1.54 (2 H, m), 1.60–2.00 (6 H, m), 2.10 (3 H, s), 2.15–2.46 (6 H, m), 
2.53 (1 H, t, J = 9.0), 4.09–4.28 (4 H, m), 5.40 (1 H, app. td, J = 10.6, J = 5.2), 5.75 (1 H, s); δC 
(100 MHz, CDCl3) 13.9 (CH3), 16.1 (d, J 6.6, CH3), 16.2 (d, J 6.6, CH3), 18.0 (CH3), 22.9 (CH2), 
24.2 (CH2), 31.3 (CH3), 31.5 (CH2), 33.2 (CH2), 33.9 (CH2), 34.9 (CH), 36.5 (CH2), 39.7 (C), 43.7 
(C), 45.5 (CH2), 54.6 (d, J 224.4, C), 54.6 (CH), 55.4 (CH), 62.8 (CH), 63.5 (d, J 5.8, CH2), 63.7 
(d, J 5.8, CH2), 72.1 (CH), 124.9 (CH), 162.5 (d, J 12.9, C), 168.8 (C), 198.8 (C), 208.2 (C); δP 
(162 MHz, CDCl3) 10.4; HRMS (ESI+): Found: 557.2388; C27H39N2NaO7P (MNa+) Requires 
557.2387 (−0.2 ppm error), Found: 535.2560; C27H40N2O7P (MH+) Requires 535.2568 (1.5 ppm 
error). 
Lab notebook reference: MGL/06/77 
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(1S,3aS,3bS,9aR,9bS,9cS,12aR,12bR)-1-Acetyl-9a,12b-dimethyl-12-methylene-
3,3a,4,5,8,9,9a,9b,9c,12,12a,12b-dodecahydro-1H-cyclopenta[1,2]phenanthro[4,3-
b]furan-7,11(2H,3bH)-dione (219c) 
 
 
 
Synthesised using general procedure D with 11-α-(2-diazo-2-
(diethoxyphosphoryl)acetoxy)progesterone 219b (107 mg, 0.200 mmol), CH2Cl2 (4.0 mL), 
Rh2(oct)4 (3.1 mg, 4.0 mol), THF (4.0 mL), KOBu-t (33.7 mg, 0.300 mmol) and paraformaldehyde 
(12.0 mg, 0.400 mmol). Purification by column chromatography (1:4 hexane:EtOAc) afforded the 
title compound 219c as a pale yellow solid (18 mg, 24%); Rf 0.69 (EtOAc); m.p. 152–156 °C; νmax 
(thin film)/cm-1 2940m, 2878w, 1767s, 1706s, 1666s, 1616w, 1417w, 1353m, 1250m, 1236m, 
1170m, 1134m, 1049m, 975m, 734m; δH (400 MHz, CDCl3) 0.73–2.75 (26 H, m), 4.16 (1 H, app. 
t, J = 10.8), 5.41 (1 H, d, J = 2.9), 5.76 (1 H, s), 6.18 (1 H, d, J = 3.1); δC (100 MHz, CDCl3) 10.1 
(CH3), 17.9 (CH3), 23.8 (CH2), 27.5 (CH2), 30.6 (CH2), 32.8 (CH2), 33.0 (CH3), 33.8 (CH2), 34.4 
(CH), 36.9 (CH2), 38.8 (C), 45.6 (C), 56.4 (CH), 58.3 (CH), 58.8 (CH), 60.2 (CH), 79.1 (CH), 
120.9 (CH2), 125.3 (CH), 135.7 (C), 168.1 (C), 170.0 (C), 199.4 (C), 211.4 (C); HRMS (ESI+): 
Found: 405.2025; C24H30NaO4 (MNa+) Requires 405.2036 (2.9 ppm error).  
Lab notebook reference: MGL/06/79 
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5.2.2.3.  Eudesmanolide frameworks 
1-(3-(1,3-Dioxolan-2-yl)propyl)cyclohex-2-enol (235) 
 
 
 
Procedure developed based on literature precedent.112 Lithium naphthalenide could be effectively 
prepared using literature precedent.170 
 
Lithium naphthalenide was prepared from freshly chopped lithium wire (333 mg, 48.0 mmol) and 
naphthalene (103 mg, 0.80 mmol) in dry THF (33 mL) under an atmosphere of argon,. The dark 
green mixture was cooled to –78 °C and neat 2-(3-chloropropyl)-1,3-dioxolane 234 (3.31 g, 22.0 
mmol) was added over 5 mins during which time the mixture turned light green then colourless. 
The mixture was stirred at –78 °C for 1 h. To the now yellow solution was added freshly distilled 
neat 2-cyclohexen-1-one 232 (1.92 g, 20.0 mmol) dropwise over 5 mins and stirred for 16 h with 
warming at RT. The mixture was diluted with sat. aq. NH4Cl (200 mL) and extracted with EtOAc 
(2 × 250 mL). The combined organic extracts were washed with brine (200 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the title compound 235 as a colourless oil (4.00 g, 
94%), which was used without further purification; Rf 0.30 (2:1 hexane:EtOAc); νmax (thin 
film)/cm-1 3447, 2933, 2872, 1704, 1408, 1140, 1031, 941, 733; δH (400 MHz, CDCl3) 1.40–2.09 
(12 H, m), 3.83–3.98 (4 H, m), 4.86 (1 H, t, J = 4.8), 5.62 (1 H, d, J = 10.0), 5.80 (1 H, ddd, J = 
10.0, J = 4.5, J = 2.9); δC (100 MHz, CDCl3) 18.2, 19.0, 25.2, 34.3, 35.3, 42.1, 64.8, 69.6, 104.5, 
130.0, 132.6; HRMS (ESI+): Found: 235.1311; C12H20NaO3 (MNa+) Requires 235.1305 (−2.5 ppm 
error). 
Lab notebook reference: MGL/05/90 
Obtained data in accord with those reported in the literature.114 
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3-(3-(1,3-Dioxolan-2-yl)propyl)cyclohex-2-enone (236) 
 
 
 
Prepared according to the literature procedure.114 
To a suspension of PCC (4.31 g, 20.0 mmol) and Al2O3 (4.08 g, 40.0 mmol) in CH2Cl2 (50 mL) 
cooled to 0 °C was added 1-(3-(1,3-dioxolan-2-yl)propyl)cyclohex-2-enol 235 (2.12 g, 10.0 mmol) 
and stirred at RT for 1 h. The mixture was filtered through a pad of Celite and silica. The filtrate 
was concentrated in vacuo and purified by column chromatography (1:1 hexane:EtOAc) to afford 
the title compound 236 as a pale yellow oil (1.11 g, 52%); Rf 0.40 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2948, 2874, 1665, 1623, 1130, 1041; δH (400 MHz, CDCl3) 1.59–1.70 (4 H, m), 1.98 (2 
H, app. quin., J = 6.5), 2.24–2.29 (4 H, m), 2.35 (2 H, t, J = 6.7), 3.83–3.97 (4 H, m), 4.86 (1 H, t, J 
= 3.9), 5.88 (1 H, s); δC (100 MHz, CDCl3) 21.2, 22.7, 29.5, 33.2, 37.3, 37.7, 64.9, 104.0, 125.8, 
165.9, 199.8; HRMS (ESI+): Found: 233.1153; C12H18NaO3 (MNa+) Requires 233.1148 (−2.2 ppm 
error), Found: 211.1336; C12H19O3 (MNa+) Requires 211.1329 (−3.6 ppm error). 
Lab notebook reference: MGL/05/92 
Obtained data in accord with reported literature.114 
((3-(3-(1,3-Dioxolan-2-yl)propyl)-3-methylcyclohex-1-en-1-yl)oxy)trimethylsilane 
(237) 
 
 
 
Procedure developed based on literature precedent.113  
LiCl (90.0 mg, 2.12 mmol) and CuI (202 mg, 1.06 mmol) were thoroughly heat-dried under 
vacuum then dissolved in dry THF (106 mL) under an atmosphere of argon, at RT. The solution 
was cooled to –40 °C at which time 3-(3-(1,3-dioxolan-2-yl)propyl)cyclohex-2-enone 236 (4.46 g, 
21.2 mmol) and freshly distilled TMSCl (2.96 mL, 23.3 mmol) were added and the solution stirred 
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for 10 mins. MeMgCl (10.6 mL, 31.8 mmol, 3.0 M solution in THF) was added dropwise over 5 
mins and stirred at –40 °C for 45 mins. The reaction mixture was then poured onto sat. aq. NH4Cl 
(300 mL) and extracted with EtOAc (3 × 300 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo to afford the title compound 237 as a yellow oil (6.18 g, 98%), 
which was used without further purification; Rf 0.81 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 
2951s, 2871m, 1662s, 1363s, 1251s, 1204m, 1192m, 1132s, 964m, 884s, 839s; δH (400 MHz, 
CDCl3) 0.17 (9 H, s, H-13), 0.94 (3 H, s, H-12), 1.22–1.43 (6 H, m), 1.58–1.72 (4 H, m), 1.82–2.02 
(2 H, m), 3.80–4.00 (4 H, m, H-11), 4.65 (1 H, s, H-2), 4.84 (1 H, t, J = 4.8, H-10); δC (100 MHz, 
CDCl3) 0.3 (C-13), 18.9 (CH2), 19.6 (CH2), 27.9 (C-12), 29.9 (CH2), 34.5 (CH2), 34.6 (C-3), 34.7 
(CH2), 43.4 (CH2), 64.8 (C-11), 104.7 (C-10), 114.6 (C-2), 149.2 (C-1); HRMS (ESI+): Found: 
321.1846; C16H30NaO3Si (MNa+) Requires 321.1856 (3.2 ppm error), Found: 299.2031; C16H31O3Si 
(MH+) Requires 299.2037 (1.9 ppm error). 
Lab notebook reference: MGL/05/93, 06/04, 06/82 
(4aSR,8RS,8aRS)-8-Hydroxy-4a-methyloctahydronaphthalen-1(2H)-one (238d) 
 
 
 
Procedure Developed based on literature precedent.114  
To a solution of ((3-(3-(1,3-dioxolan-2-yl)propyl)-3-methylcyclohex-1-en-1-yl)oxy)trimethylsilane 
237 (298 mg, 1.00 mmol), in MeOH (3.0 mL) was added 10% aq. HCl (1.6 mL) and refluxed at 80 
°C for 1 h. The reaction mixture was neutralised by sat. aq. NaHCO3 and concentrated in vacuo. 
The aqueous layer was extracted with EtOAc (3 × 50 mL) and the combined organic extracts dried 
over MgSO4 and concentrated in vacuo. Purification by column chromatography afforded the title 
compound 238d as a brown solid (119 mg, 65%); Rf 0.32 (1:1 hexane:EtOAc); m.p. 52–55 °C; νmax 
(thin film)/cm-1 3406, 2931, 2870, 1702, 1048; δH (400 MHz, CDCl3) 0.93 (3 H, s), 1.10–1.25 (3 H, 
m), 1.50 (1 H, dtd, J = 13.8, J = 3.3, J = 1.1), 1.60–1.67 (2 H, m), 1.71–2.10 (6 H, m), 2.26 (1 H, 
ddq, J = 14.5, J = 4.8, J = 1.7), 2.53 (1 H, ddd, J = 14.5, J = 13.3, J = 7.3), 4.00 (1 H, app. tt, J = 
10.5, J = 5.1); δC (100 MHz, CDCl3) 19.8 (CH2), 22.1 (CH2), 27.7 (CH3), 29.8 (CH2), 35.0 (CH2), 
37.1 (CH2), 38.5 (CH2), 39.4 (C), 67.4 (CH), 69.6 (CH), 215.0 (CO); HRMS (ESI+): Found: 
205.1204; C11H18NaO2 (MNa+) Requires 205.1199 (−2.2 ppm error), Found: 183.1382; C11H19O2 
(MH+) Requires 183.1380 (−1.6 ppm error). 
Lab notebook reference: MGL/05/94, 06/05 
Obtained data in accord with reported literature.114  
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(4aSR,8RS,8aRS)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one (244) 
 
 
 
To a solution of (4aSR,8RS,8aRS)-8-hydroxy-4a-methyloctahydronaphthalen-1(2H)-one 238d (273 
mg, 1.50 mmol) in CH2Cl2 (15 mL) at 0 °C was added 2,6-lutidine (0.44 mL, 3.75 mmol) then 
TBSOTf (0.38 mL, 1.65 mmol). The solution was stirred at 0 °C for 1 h then quenched with NH4Cl 
(50 mL) and the organic fraction separated. The aqueous layer was extracted with CH2Cl2 (2 × 50 
mL) and the combined organic fractions dried over MgSO4 and concentrated in vacuo. Purification 
by column chromatography (4:1 hexane:EtOAc) afforded the title compound 244 as a white 
crystalline solid (440 mg, 99%); Rf 0.67 (4:1 hexane:EtOAc); m.p. 55–58 °C; νmax (thin film)/cm-1 
2929s, 2857s, 1713s, 1472w, 1462m, 1252s, 1089s, 832s, 774s; δH (400 MHz, CDCl3) −0.01 (3 H, 
s), 0.03 (3 H, s), 0.82 (9 H, s), 0.94 (3 H, s), 1.10–1.29 (3 H, m), 1.45 (1 H, dtd, J = 13.7, J = 3.8, J 
= 0.7), 1.53–1.67 (2 H, m), 1.80–2.04 (5 H, m), 2.18 (1 H, dddd, J = 13.7, J = 4.6, J = 3.1, J = 1.5), 
2.46 (1 H, ddd, J = 13.5, J = 12.7, J = 6.7), 4.12 (1 H, app. td, J = 9.9, J = 4.2); δC (100 MHz, 
CDCl3) −4.9 (CH3), −3.8 (CH3), 17.9 (C), 19.7 (CH2), 22.6 (CH2), 25.6 (CH3), 27.9 (CH3), 31.2 
(CH2), 35.1 (CH2), 37.9 (CH2), 38.3 (CH2), 39.6 (C), 67.0 (CH), 70.5 (CH), 212.7 (C); HRMS 
(ESI+): Found: 319.2055; C17H32NaO2Si (MNa+) Requires 319.2064 (2.8 ppm error), Found: 
297.2232; C17H33O2Si (MH+) Requires 297.2244 (4.1 ppm error). 
Lab notebook reference: MGL/06/11,28 
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(4aSR,8RS,8aRS)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate (245) 
 
 
 
To a solution of (4aSR,8RS,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one 244 (720 mg, 2.43 mmol) in THF (12.2 mL) cooled to −40 °C under an atmosphere of 
argon, was added LHMDS (7.28 mL, 7.28 mmol, 1.0 M solution in THF) dropwise. The solution 
was stirred at −40 °C for 1 h then trifluoromethanesulfonic anhydride (1.23 mL, 7.28 mmol) was 
added dropwise. The solution was stirred at −40 °C for 20 mins then quenched by addition of water 
(25 mL). The mixture was extracted with diethyl ether (3 × 50 mL) and the combined organic 
extracts dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (40:1 hexane:diethyl ether) afforded the title compound 245 as a colourless oil 
(835 mg, 80%); Rf 0.77 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2931s, 2858m, 1416s, 1246s, 
1205s, 1144s, 1116m, 1082m, 1028m, 934m, 874m, 836s, 775m, 628m, 601s; δH (400 MHz, 
CDCl3) 0.02 (3 H, s), 0.03 (3 H, s), 0.88 (9 H, s), 1.02–1.08 (4 H, m), 1.25–1.49 (4 H, m), 1.57–
1.64 (1 H, m), 1.68–1.81 (2 H, m), 1.97 (1 H, d, J = 8.5), 2.24–2.29 (2 H, m), 3.69 (1 H, td, J = 9.3, 
J = 3.7), 5.68 (1 H, t, J = 3.9); δC (100 MHz, CDCl3) −4.8 (CH3), −4.9 (CH3), 17.9 (C), 19.3 (CH2), 
21.5 (CH2), 25.8 (CH3), 26.9 (CH3), 28.0 (CH2), 35.4 (CH2), 35.7 (C), 38.1 (CH2), 52.9 (CH), 74.3 
(CH), 117.7 (CH), 118.5 (q, J = 319.9, C), 151.9 (C); HRMS (ESI+): Found: 451.1546; 
C18H31F3NaO4SSi (MNa+) Requires 451.1557 (2.4 ppm error), Found: 429.1737; C18H32F3O4SSi 
(MH+) Requires 429.1737 (0.1 ppm error). 
Lab notebook reference: MGL/07/30 
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tert-Butyl(((1RS,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-
yl)oxy)dimethylsilane (246) 
 
 
 
Prepared according to a modified literature procedure.116 
To a solution of (4aSR,8RS,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate 245 (355 mg, 0.828 mmol) in THF (1.24 mL) 
and NMP (3.31 mL) under an atmosphere of argon, was added Fe(acac)3 (322 mg, 0.911 mmol). 
The solution was cooled to −25 °C and methylmagnesium chloride (2.76 mL, 8.28 mmol, 3.0 M 
solution in THF) was added dropwise. The orange solution was stirred at −25 °C for 1 h then 
quenched by careful addition of sat. aq. NH4Cl (25 mL). The mixture was extracted with diethyl 
ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, filtered and concentrated 
in vacuo. Purification by column chromatography (hexane) afforded the title compound 246 as a 
colourless oil (201 mg, 82%); Rf 0.45 (hexane); νmax (thin film)/cm-1 2928s, 2858s, 1462m, 1373m, 
1251s, 1095m, 1071s, 1041s, 921s, 860m, 834s, 773s; δH (400 MHz, CDCl3) 0.01 (3 H, s), 0.03 (3 
H, s), 0.87–0.95 (12 H, m), 1.19–1.55 (7 H, m), 1.69–1.79 (5 H, m), 1.98–2.15 (2 H, m), 3.61 (1 H, 
app. td, J = 9.6, J = 3.8), 5.24–5.30 (1 H, m); δC (100 MHz, CDCl3) −4.6 (CH3), −4.5 (CH3), 18.1 
(C), 19.9 (CH2), 23.0 (CH2), 26.0 (CH3), 26.4 (CH3), 27.4 (CH3), 28.0 (CH2), 34.0 (C), 36.4 (CH2), 
39.0 (CH2), 54.1 (CH), 75.8 (CH), 120.1 (CH), 136.6 (C); HRMS (ESI+): Found: 317.2265; 
C18H34NaOSi (MNa+) Requires 317.2271 (2.0 ppm error). 
Lab notebook reference: MGL/07/34,37 
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(1RS,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-ol (247) 
 
 
 
To a solution of tert-butyl(((1RS,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-
1-yl)oxy)dimethylsilane 246 (321 mg, 1.09 mmol) in THF (5.5 mL) under an atmosphere of argon, 
at RT was added TBAF (5.45 mL, 5.00 mmol, 1.0 M in THF). The solution was refluxed for 1 h, 
allowed to cool at RT, then quenched by addition of water (25 mL). The aqueous layer was 
extracted with diethyl ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compound 247 as a white solid (172 mg, 88%); Rf 0.39 (8:1 hexane:EtOAc); m.p. 
65–67 °C; νmax (thin film)/cm-1 3337br, 2924s, 2863s, 2842s, 1450s, 1373m, 1353m, 1180w, 
1133w, 1080m, 1061s, 1027s, 1008s, 854s, 804s; δH (400 MHz, CDCl3) 0.86–0.91 (4 H, m), 1.21–
1.31 (2 H, m), 1.37–1.56 (5 H, m), 1.69–1.77 (1 H, m), 1.85–1.91 (4 H, m), 2.04–2.08 (2 H, m), 
3.56 (1 H, ddd, J = 11.2, J = 9.7, J = 4.3), 5.34–5.37 (1 H, m); δC (100 MHz, CDCl3) 20.1 (CH2), 
23.1 (CH2), 26.5 (CH3), 27.0 (CH3), 27.1 (CH2), 34.0 (C), 36.6 (CH2), 39.7 (CH2), 54.6 (CH), 75.6 
(CH), 120.9 (CH), 135.9 (C); HRMS (ESI+): Found: 203.1405; C12H20NaO (MNa+) Requires 
203.1406 (0.5 ppm error). 
Lab notebook reference: MGL/07/38 
(1RS,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate (248) 
 
 
 
Synthesised using general procedure A with (1RS,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-ol 247 (145 mg, 0.804 mmol), toluene (4.0 mL), DEPAA (166 mg, 0.844 
mmol), DIPEA (0.36 mL, 2.09 mmol) and T3P (665 mg, 1.05 mmol, 50% w/w solution in THF) 
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affording the title compound 248 as a yellow oil (288 mg, 100%). No further purification was 
required; Rf 0.33 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2978w, 2931s, 2869m, 1731s, 1450m, 
1393m, 1375m, 1261s, 1111s, 1051s, 1020s, 967s; δH (400 MHz, CDCl3) 0.89–0.97 (4 H, m), 
1.23–1.36 (8 H, m), 1.41–1.58 (3 H, m), 1.68 (1 H, d, J = 9.9), 1.72–1.80 (4 H, m), 1.96–2.13 (3 H, 
m), 2.86–3.01 (2 H, m), 4.13–4.21 (4 H, m), 4.82 (1 H, app. td, J = 10.4, J = 4.2),  5.32–5.37 (1 H, 
m); δC (100 MHz, CDCl3) 16.2 (d, J = 5.7, CH3), 16.3 (d, J = 5.7, CH3), 19.4 (CH2), 22.8 (CH2), 
25.4 (CH3), 26.9 (CH3), 27.4 (CH2), 31.9 (CH2), 34.0 (C), 34.6 (d, J = 135.1, CH2), 38.9 (CH2), 
50.5 (CH), 62.5 (app. t, J = 5.3, 2 × CH2), 79.2 (CH), 122.0 (CH), 134.0 (C), 165.2 (d, J = 5.8, C); 
δP (162 MHz, CDCl3) 20.5; HRMS (ESI+): Found: 381.1802; C18H31NaO5P (MNa+) Requires 
381.1801 (−0.1 ppm error), Found: 359.1981; C18H32O5P (MH+) Requires 359.1982 (0.1 ppm 
error). 
Lab notebook reference: MGL/07/41 
(1RS,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-diazo-
2-diethoxyphosphoryl)acetate (249) 
 
 
 
Synthesised using general procedure B with (1RS,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diethoxyphosphoryl)acetate 248 (279 mg, 0.778 mmol), THF (3.9 
mL), LHMDS (0.93 mL, 0.934 mmol, 1.0 M solution in THF) and p-ABSA (224 mg, 0.934 mmol). 
Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 249 as a 
pale yellow oil (265 mg, 89%); Rf 0.63 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2932s, 2870w, 
2124s, 1705s, 1451w, 1376w, 1286s, 1273s, 1022s, 980m; δH (400 MHz, CDCl3) 0.91–0.99 (4 H, 
m), 1.24–1.38 (8 H, m), 1.43–1.60 (3 H, m), 1.68–1.79 (5 H, m), 1.92–2.15 (3 H, m), 4.10–4.28 (4 
H, m), 4.95 (1 H, app. td, J = 10.2, J = 4.2),  5.35–5.39 (1 H, m); δC (100 MHz, CDCl3) 16.0 (d, J = 
7.2, 2 × CH3), 19.3 (CH2), 22.8 (CH2), 25.1 (CH3), 26.9 (CH3), 27.6 (CH2), 32.3 (CH2), 34.1 (C), 
38.7 (CH2), 50.6 (CH), 53.7 (d, J = 227.8, C), 63.4 (d, J = 5.8, CH2), 63.5 (d, J = 5.8, CH2), 79.1 
(CH), 122.4 (CH), 133.6 (C), 162.7 (d, J = 12.5, C); δP (162 MHz, CDCl3) 11.0; HRMS (ESI+): 
Found: 407.1704; C18H29N2NaO5P (MNa+) Requires 407.1706 (0.5 ppm error). 
Lab notebook reference: MGL/07/42 
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(3aRS,5aRS,9aSR,9bRS)-5a,9-Dimethyl-3-methylene-3a,4,5,5a,6,7,9a,9b-
octahydronaphtho[1,2-b]furan-2(3H)-one (240) 
 
 
 
Synthesised using general procedure D with (1RS,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diazo-2-diethoxyphosphoryl)acetate 249 (72 mg, 0.187 mmol), CH2Cl2 
(3.7 mL), Rh2(oct)4 (2.9 mg, 3.7 µmol), THF (3.7 mL), KOBu-t (31.5 mg, 0.281 mmol) and 
paraformaldehyde (11.2 mg, 0.374 mmol). Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compound 240 as a white crystalline solid (28 mg, 64%); Rf 0.33 
(8:1 hexane:EtOAc); m.p. 63–66 °C; νmax (thin film)/cm-1 2931m, 2871w, 1771s, 1451m, 1378m, 
1278m, 1244s, 1081m, 1127s, 1014s, 980s; δH (400 MHz, CDCl3) 0.98–1.04 (4 H, m), 1.42–1.77 
(4 H, m), 1.83–1.86 (4 H, m, H-9,12), 1.93–1.97 (1 H, m, H-6), 2.06–2.12 (2 H, m), 2.45–2.53 (1 
H, m, H-7), 3.73 (1 H, app. t, J = 10.9, H-8), 5.39 (1 H, d, J = 3.1, H-15b), 5.39–5.43 (1 H, m, H-
2), 6.06 (1 H, d, J = 3.3, H-15a); δC (100 MHz, CDCl3) 21.8 (C-6), 22.8 (C-3), 24.7 (C-12), 26.7 
(C-11), 27.9 (C-4), 34.9 (C-10), 40.2 (C-5), 49.2 (C-7), 50.5 (C-9), 87.4 (C-8), 117.3 (C-15), 121.1 
(C-2), 133.4 (C-1), 139.3 (C-14), 170.9 (C-13); HRMS (ESI+): Found: 255.1355; C15H20NaO2 
(MNa+) Requires 255.1356 (0.2 ppm error), Found: 233.1545; C15H21O2 (MH+) Requires 233.1536 
(−4.0 ppm error). 
Lab notebook reference: MGL/07/43 
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(4aSR,8RS,8aRS)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyl-1-
((trimethylsilyl)methyl)decahydronaphthalen-1-ol (250) 
  
 
 
To a solution of (trimethylsilyl)methyllithium (4.63 mL, 4.63 mmol, 1.0 M in pentane) cooled to 
−78 °C under an atmosphere of argon, was added dropwise via cannula a solution of 
(4aSR,8RS,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-1(2H)-one 244 
(458 mg, 1.54 mmol) in THF (2.5 mL) pre-cooled to −78 °C. The solution was stirred at −78 °C for 
30 mins and then at RT for 1 h. The solution was quenched by careful addition of water (10 mL) 
and stirred for 10 mins. The aqueous layer was extracted with diethyl ether (3 × 25 mL) and the 
combined organic extracts dried over MgSO4, filtered and concentrated in vacuo. Purification by 
column chromatography (20:1 hexane:EtOAc) afforded the title compound 250 as a colourless oil 
(497 mg, 84%); Rf 0.58 (8:1 hexane:EtOAc); νmax (thin film)/cm-1 2928s, 2857m, 1462m, 1361w, 
1249s, 1056m, 1027s, 1005m, 862m, 836s, 772s; δH (400 MHz, CDCl3) 0.05 (3 H, s), 0.06 (3 H, s), 
0.07 (9 H, s), 0.89 (9 H, s), 0.92–1.00 (2 H, m), 1.12 (3 H, s), 1.16–1.97 (14 H, m), 4.33–4.36 (1 H, 
m); δC (100 MHz, CDCl3) −4.6 (CH3), −4.2 (CH3), 0.6 (CH3), 16.9 (CH2), 17.6 (CH2), 17.9 (C), 
25.8 (CH3), 32.0 (CH3), 32.3 (CH2), 33.1 (C), 33.8 (CH2), 34.2 (CH2), 42.0 (CH2), 42.7 (CH2), 56.4 
(CH), 69.1 (CH), 74.7 (C); HRMS (ESI+): Found: 407.2754; C21H44NaO2Si2 (MNa+) Requires 
407.2772 (4.3 ppm error). 
Lab notebook reference: MGL/06/42,29,33,90 
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tert-Butyldimethyl(((1RS,4aRS,8aRS)-4a-methyl-8-methylenedecahydronaphthalen-1-
yl)oxy)silane (251) 
  
 
 
Sodium hydride was purified by washing with hexane and drying in vacuo immediately prior to the 
reaction. 
 
To a suspension of sodium hydride (827 mg, 20.7 mmol) in THF (6.5 mL) under an atmosphere of 
argon, was added via cannula a solution of (4aSR,8RS,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-
methyl-1-((trimethylsilyl)methyl)decahydronaphthalen-1-ol 250 (497 mg, 1.29 mmol) in THF (3 
mL). The mixture was heated to reflux and stirred for 4 h then cooled at RT. The mixture was 
carefully poured into sat. aq. NH4Cl (100 mL) and extracted with diethyl ether (3 × 100 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo affording the 
title compound 251 as a yellow oil (385 mg, 100%). No further purification was required; Rf 0.88 
(8:1 hexane:EtOAc); νmax (thin film)/cm-1 2929s, 2856m, 1650w, 1461m, 1362m, 1248s, 1096s, 
1082s, 1055m, 919m, 888s, 833s, 772s; δH (400 MHz, CDCl3) −0.03 (3 H, s), 0.01 (3 H, s), 0.84 (9 
H, s), 0.89 (3 H, s), 0.91–0.97 (1 H, m), 1.16–1.28 (2 H, m), 1.37 (1 H, app. dtd, J = 13.5, J = 3.2, J 
= 1.6), 1.44–1.67 (4 H, m), 1.70–1.78 (2 H, m), 1.92 (1 H, app. ddtd, J = 12.5, J = 4.7, J = 3.2, J = 
1.6), 2.00–2.13 (2 H, m), 3.76 (1 H, ddd, J = 10.8, J = 10.0, J = 4.6), 4.66 (1 H, app. dd, J = 2.8, J 
= 1.2), 4.76 (1 H, app. t, J = 2.1); δC (100 MHz, CDCl3) −4.8 (CH3), −4.1 (CH3), 18.1 (C), 20.0 
(CH2), 23.3 (CH2), 25.9 (CH3), 28.4 (CH3), 31.0 (CH2), 31.3 (CH2), 36.0 (C), 36.4 (CH2), 40.1 
(CH2), 60.0 (CH), 68.9 (CH), 112.0 (CH2), 146.4 (C); HRMS (ESI+): Found: 317.2267; 
C18H34NaOSi (MNa+) Requires 317.2271 (1.4 ppm error). 
Lab notebook reference: MGL/06/43,36,91 
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(1RS,4aRS,8aRS)-4a-Methyl-8-methylenedecahydronaphthalen-1-ol (252) 
  
 
 
To a solution of tert-butyldimethyl(((1RS,4aRS,8aRS)-4a-methyl-8-
methylenedecahydronaphthalen-1-yl)oxy)silane 251 (85 mg, 0.289 mmol) in THF (1.5 mL) under 
an atmosphere of argon, at RT was added TBAF (1.44 mL, 1.44 mmol, 1.0 M in THF). The 
solution was refluxed for 1 h, allowed to cool at RT, then quenched by addition of water (10 mL). 
The aqueous layer was extracted with diethyl ether (3 × 25 mL) and the combined organic extracts 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compound 252 as a pale yellow oil (42 mg, 81%); Rf 0.31 (8:1 
hexane:EtOAc); νmax (thin film)/cm-1 3431br, 3068w, 2933s, 2867s, 1646m, 1450s, 1264w, 1159w, 
1064s, 1049s, 1022m, 1011m, 896s; δH (400 MHz, CDCl3) 0.89 (3 H, s), 0.97 (1 H, app. dddt, J = 
13.3, J = 3.9, J = 2.6, J = 1.3), 1.11–1.27 (2 H, m), 1.39–1.80 (8 H, m), 2.03–2.18 (3 H, m), 3.70 (1 
H, ddd, J = 11.0, J = 10.2, J = 4.4), 4.78 (1 H, app. t, J = 2.2), 4.91 (1 H, app. t, J = 2.1); δC (100 
MHz, CDCl3) 19.7 (CH2), 22.7 (CH2), 28.3 (CH3), 30.2 (CH2), 30.8 (CH2), 33.6 (CH2), 35.7 (C), 
39.9 (CH2), 60.2 (CH), 67.1 (CH), 112.8 (CH2), 146.9 (C); HRMS (ESI+): Found: 203.1400; 
C12H20NaO (MNa+) Requires 203.1406 (3.3 ppm error). 
Lab notebook reference: MGL/06/37,45,97 
(1RS,4aRS,8aRS)-4a-Methyl-8-methylenedecahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate (253) 
 
 
 
Synthesised using general procedure A with (1RS,4aRS,8aRS)-4a-methyl-8-
methylenedecahydronaphthalen-1-ol 252 (108 mg, 0.600 mmol), toluene (3.0 mL), DEPAA (124 
mg, 0.630 mmol), DIPEA (0.27 mL, 1.56 mmol) and T3P (496 mg, 0.780 mmol, 50% w/w solution 
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in THF) affording the title compound 253 as a yellow oil (176 mg, 82%). No further purification 
was required; Rf 0.14 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 2978w, 2932s, 2869w, 1731s, 
1648w, 1445w, 1393w, 1267s, 1113m, 1051w, 1024s, 965s; δH (400 MHz, CDCl3) 0.89 (3 H, s), 
0.94–1.00 (1 H, m), 1.16–1.66 (13 H, m), 1.78 (1 H, td, J = 13.5, J = 4.6), 1.85 (1 H, d, J = 10.8), 
1.96–2.07 (2 H, m), 2.13–2.22 (1 H, m), 2.83 (1 H, dd, J = 21.4, J = 14.5), 2.90 (1 H, dd, J = 21.4, 
J = 14.5), 4.09–4.17 (4 H, m), 4.62 (1 H, app. t, J = 2.0), 4.73 (1 H, app. t, J = 2.3), 5.15 (1 H, app. 
td, J = 11.2, J = 4.5); δC (100 MHz, CDCl3) 16.3 (d, J = 6.5, 2 × CH3), 19.7 (CH2), 22.7 (CH2), 28.0 
(CH3), 30.3 (CH2), 30.7 (CH2), 31.8 (CH2), 34.2 (d, J = 134.6, CH2), 36.3 (C), 39.6 (CH2), 56.8 
(CH), 62.5 (app. t, J = 5.7, 2 × CH2), 72.0 (CH), 112.0 (CH2), 145.8 (C), 165.1 (d, J = 5.9, C); δP 
(162 MHz, CDCl3) 20.7; HRMS (ESI+): Found: 381.1783; C18H31NaO5P (MNa+) Requires 
381.1801 (4.7 ppm error). 
Lab notebook reference: MGL/06/51  
(1RS,4aRS,8aRS)-4a-Methyl-8-methylenedecahydronaphthalen-1-yl 2-diazo-2-
diethoxyphosphoryl)acetate (254) 
 
 
 
Synthesised using general procedure B with (1RS,4aRS,8aRS)-4a-methyl-8-
methylenedecahydronaphthalen-1-yl 2-diethoxyphosphoryl)acetate 253 (175 mg, 0.488 mmol), 
THF (2.5 mL), LHMDS (0.59 mL, 0.585 mmol, 1.0 M solution in THF) and p-ABSA (141 mg, 
0.585 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title 
compound 254 as a colourless oil (146 mg, 78%); Rf 0.28 (2:1 hexane:EtOAc); νmax (thin film)/cm-1 
2982w, 2934s, 2870m, 2124s, 1703s, 1445w, 1361w, 1289w, 1273s, 1218m, 1161m, 1120w, 
1021s, 978s; δH (400 MHz, CDCl3) 0.91 (3 H, s), 0.96–1.02 (1 H, m), 1.17–1.67 (13 H, m), 1.78 (1 
H, td, J = 13.5, J = 4.6), 1.86 (1 H, d, J = 10.8), 1.98–2.09 (2 H, m), 2.16–2.25 (1 H, m), 4.03–4.24 
(4 H, m), 4.64 (1 H, app. t, J = 2.1), 4.74 (1 H, app. t, J = 2.3), 5.22 (1 H, app. td, J = 11.2, J = 4.5); 
δC (100 MHz, CDCl3) 16.1 (app. t, J = 7.6, 2 × CH3), 19.8 (CH2), 22.7 (CH2), 28.0 (CH3), 30.3 
(CH2), 30.7 (CH2), 32.1 (CH2), 36.4 (C), 39.5 (CH2), 53.0 (d, J = 225.1, C), 57.2 (CH), 63.4 (d, J = 
5.5, CH2), 63.5 (d, J = 5.7, CH2), 72.2 (CH), 111.9 (CH2), 146.1 (C), 162.6 (d, J = 12.4, C); δP (162 
MHz, CDCl3) 11.0; HRMS (ESI+): Found: 385.1884; C18H30N2O5P (MH+) Requires 385.1887 (0.7 
ppm error). 
Lab notebook reference: MGL/06/55, 06/39, 07/13 
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(3aRS,5aRS,9aRS,9bRS)-5a-Methyl-3,9-dimethylenedecahydronaphtho[1,2-b]furan-
2(9bH)-one (241) and Diethyl ((3aRS,3a1SR,6aRS)-6a-methyl-2-
oxododecahydrobenzo[de]cyclopropa[c]chromen-1a-yl)phosphonate (255) 
 
 
 
Synthesised using general procedure D with (1RS,4aRS,8aRS)-4a-methyl-8-
methylenedecahydronaphthalen-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate 254 (77 mg, 0.200 
mmol), CH2Cl2 (4.0 mL), Rh2(OAc)4 (1.8 mg, 4.0 µmol), THF (4.0 mL), KOBu-t (33.7 mg, 0.300 
mmol) and paraformaldehyde (12.0 mg, 0.400 mmol). Purification by column chromatography (8:1 
hexane:EtOAc → 1:4 hexane:EtOAc) afforded the title compounds 241 as a white crystalline solid 
(21 mg, 45%) and 255 as a pale yellow oil (8 mg, 11%).  
 
Data for 241: Rf 0.39 (4:1 hexane:EtOAc); m.p. 66–68 °C; νmax (thin film)/cm-1 2932s, 2869w, 
1770s, 1650w, 1456m, 1378m, 1247s, 1171m, 1131s, 1024s, 991s, 964m, 936m, 892m; δH (400 
MHz, CDCl3) 1.00 (3 H, s, H-15), 1.07 (1 H, dddt, J = 13.6, J = 3.9, J = 2.6, J = 1.3, H-1), 1.42–
1.71 (5 H, m, H-2,8,9), 1.77 (1 H, td, J = 13.6, J = 4.6, H-1), 1.96–2.02 (1 H, m, H-8), 2.09–2.23 (3 
H, m, H-3,5), 2.45 (1 H, app. tq, J = 11.1, J = 3.2, H-7), 4.11 (1 H, app. t, J = 11.1, H-6), 4.80 (1 H, 
app. t, J = 1.8, H-14a), 4.88 (1 H, app. t, J = 2.0, H-14b), 5.40 (1 H, d, J = 3.0, H-12b), 6.07 (1 H, 
d, J = 3.2, H-12a); δC (100 MHz, CDCl3) 21.9 (C-8), 22.9 (C-2), 27.6 (C-15), 30.0 (C-3), 31.7 (C-
1), 37.3 (C-10), 40.0 (C-9), 48.8 (C-7), 55.9 (C-5), 80.6 (C-6), 112.7 (C-14), 117.3 (C-12), 139.8 
(C-11), 144.0 (C-4), 170.6 (C-13); HRMS (ESI+): Found: 255.1362; C15H20NaO2 (MNa+) Requires 
255.1356 (−2.5 ppm error), Found: 233.1541; C15H21O2 (MH+) Requires 233.1536 (−2.2 ppm 
error). 
 
Data for 255: Rf 0.33 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2980w, 2934s, 2868m, 1735s, 
1452s, 1392w, 1375w, 1317m, 1296m, 1249s, 1208s, 1051m, 1031s, 971s; δH (400 MHz, CDCl3) 
0.58 (1 H, d, J = 9.8, H-5), 1.07–1.14 (4 H, m), 1.20–1.68 (15 H, m), 1.80 (1 H, dd, J = 17.5, J = 
4.8, H-11), 1.85–1.93 (1 H, m), 2.05–2.08 (1 H, m), 2.13–2.22 (1 H, m, H-7), 4.09–4.34 (4 H, m, 
H-15,15’), 4.47 (1 H, ddd, J = 10.9, J = 9.9, J = 5.7, H-6); δC (100 MHz, CDCl3) 16.2 (d, J = 6.8, 
C-16/16’), 16.3 (d, J = 6.6, C-16/16’), 18.4 (C-2/8), 19.6 (C-2/8), 24.5 (d, J = 182.9, C-12), 26.4 (d, 
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J = 4.8, C-3), 26.7 (d, J = 3.9, C-3), 29.1 (C-14), 29.6 (d, J = 3.2, C-11), 31.6 (C-7), 32.1 (C-1/9), 
34.3 (C-10), 40.2 (C-1/9), 55.4 (d, J = 2.0, C-5), 62.4 (d, J = 7.4, C-15/15’), 63.2 (d, J = 5.7, C-
15/15’), 78.4 (C-6), 168.3 (d, J = 6.0, C-13); δP (162 MHz, CDCl3) 21.6; HRMS (ESI+): Found: 
379.1635; C18H29NaO5P (MNa+) Requires 379.1645 (2.7 ppm error), Found: 357.1817; C18H30O5P 
(MH+) Requires 357.1825 (2.2 ppm error). 
Lab notebook reference: MGL/07/14, 06/40, 06/58 
4a-Methylhexahydronaphthalene-1,8(2H,8aH)-dione (258) 
 
 
 
To a solution of (4aSR,8RS,8aRS)-8-hydroxy-4a-methyloctahydronaphthalen-1(2H)-one 238d (182 
mg, 1.00 mmol) in CH2Cl2 (10 mL), cooled to 0 °C was added DMP (467 mg, 1.10 mmol). The 
solution was stirred for 15 mins at 0 °C and then for 30 mins at RT after which a mixture of 1:1 sat. 
aq. NaHCO3: sat. aq. Na2S2O3 (50 mL) and CH2Cl2 (50 mL) was added and stirred vigourously for 
1 h. The organic phase was separated and the aqueous phase extracted with CH2Cl2 (2 × 50 mL). 
The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 258 as a 
yellow solid (142 mg, 79%); N.B. The product appears as two spots by TLC, a major (less polar) 
and minor (more polar); Rf 0.94 (major), 0.71 (minor) (2:1 hexane:EtOAc); m.p. 50–53 °C; νmax 
(thin film)/cm-1 2940s, 1593s, 1457m, 1407m, 1336w, 1248m, 1168w, 1081w, 1038w, 962m, 
829m; δH (400 MHz, CDCl3) 1.03 (3 H, s), 1.37 (2 H, td, J = 13.4, J = 4.0), 1.54 (2 H, dt, J = 13.0, 
J = 3.4), 1.69–1.77 (2 H, m), 1.87–1.99 (2 H, m), 2.28–2.43 (4 H, m), 16.02 (1 H, s); δC (100 MHz, 
CDCl3) 17.1, 26.7, 32.1, 32.8, 37.4, 114.4, 189.9; HRMS (ESI+): Found: 203.1036; C11H16NaO2 
(MNa+) Requires 203.1043 (3.1 ppm error), Found: 181.1215; C11H17O2 (MH+) Requires 181.1223 
(4.7 ppm error). 
Lab notebook reference: MGL/06/87 
 
Note: The spectroscopic data suggests the enol form 258’ predominates. 
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(4aSR,8SR,8aSR)-8-Hydroxy-4a-methyloctahydronaphthalen-1(2H)-one (238a) and 
(4aSR,8SR,8aRS)-8-Hydroxy-4a-methyloctahydronaphthalen-1(2H)-one (238c) 
 
 
 
To a solution of 4a-methylhexahydronaphthalene-1,8(2H,8aH)-dione 258 (2.04 g, 11.3 mmol) in 
MeOH (57 mL) cooled to 0 °C under an atmosphere of argon, was added NaBH4 (470 mg, 12.4 
mmol) in small portions over 1 h. The solution was stirred at 0 °C for 1 h then quenched with sat. 
aq. NaHCO3 (25 mL) and concentrated in vacuo. To the resulting white residue was added CH2Cl2 
(50 mL) and water (50 mL). The organic layer was separated and the aqueous layer extracted with 
CH2Cl2 (2 × 50 mL). The combined organic extracts were dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by column chromatography (1:1 hexane:diethyl ether → 
EtOAc) affording the title compounds 238a (216 mg, 10%) and 238c (333 mg, 16%) in addition to 
mixed 238a and 238c (202 mg, 10%) and diol 258 (478 mg, 23%). 
 
Data for 238a: Colourless oil, Rf 0.61 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 3554br, 2931s, 
1699s, 1458m, 1384m, 1275m, 1178m, 1087m, 1056s, 1038m, 936w; δH (400 MHz, CDCl3) 0.80 
(3 H, s, H-11), 1.17–1.36 (2 H, m), 1.41–1.47 (1 H, m), 1.49–1.67 (4 H, m), 1.82–2.02 (3 H, m), 
2.12 (1 H, d, J 9.8, H-9), 2.25–2.36 (2 H, m), 3.17 (1 H, s, OH), 3.94 (1 H, app. td, J 10.6, J 4.5, H-
8); δC (100 MHz, CDCl3) 17.9 (C-11), 19.8 (CH2), 22.2 (CH2), 32.9 (CH2), 39.7 (CH2), 40.2 (CH2), 
40.8 (C-10), 41.4 (CH2), 64.5 (C-9), 65.5 (C-8), 214.7 (C-1); HRMS (ESI+): Found: 205.1206; 
C11H18NaO2 (MNa+) Requires 205.1199 (−3.4 ppm error). 
 
Data for 238c: Colourless oil, Rf 0.68 (4:1 hexane:EtOAc); νmax (thin film)/cm-1 3420br, 2937s, 
1692s, 1458m, 1421m, 1380w, 1321m, 1267m, 1233m, 1189w, 1141w, 1057s; δH (400 MHz, 
CDCl3) 0.97–1.02 (1 H, m), 1.07 (3 H, s, H-11), 1.34 (1 H, td, J 13.0, 4.2), 1.46–1.71 (5 H, m), 
1.80–1.93 (3 H, m), 2.19–2.33 (2 H, m), 2.45–2.46 (1 H, m, H-9), 3.70–3.81 (2 H, m, H-8, OH); δC 
(100 MHz, CDCl3) 20.3 (CH2), 21.2 (CH2), 26.5 (C-11), 31.1 (CH2), 31.8 (CH2), 39.2 (CH2), 40.8 
(C-10), 42.3 (CH2), 59.2 (C-9), 68.4 (C-8), 216.0 (C-1); HRMS (ESI+): Found: 205.1192; 
C11H18NaO2 (MNa+) Requires 205.1199 (3.5 ppm error). 
 
Lab notebook reference: MGL/07/12,15 
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(4aSR,8SR,8aSR)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one (261) 
 
 
 
To a solution of (4aSR,8SR,8aSR)-8-hydroxy-4a-methyloctahydronaphthalen-1(2H)-one 238a (205 
mg, 1.12 mmol) in CH2Cl2 (11.2 mL) at 0 °C was added 2,6-lutidine (0.33 mL, 2.80 mmol) then 
TBSOTf (0.28 mL, 1.24 mmol). The solution was stirred at 0 °C for 1 h then quenched with NH4Cl 
(50 mL) and the organic fraction separated. The aqueous layer was extracted with CH2Cl2 (2 × 50 
mL) and the combined organic fractions dried over MgSO4 and concentrated in vacuo. Purification 
by column chromatography (4:1 hexane:EtOAc) afforded the title compound 261 as a white 
crystalline solid (1.12 g, 100%); Rf 0.24 (20:1 hexane:EtOAc); m.p. 36–39 °C; νmax (thin film)/cm-1 
2925s, 2853s, 1714s, 1470m, 1381m, 1358m, 1242s, 1142m, 1094s, 1077s, 1031m, 1004m, 940m, 
901m, 830s, 779s, 666m; δH (400 MHz, benzene-d6) 0.28 (3 H, s, H-12/12’), 0.38 (3 H, s, H-
12/12’), 0.57 (3 H, s, H-11), 0.90–1.44 (17 H, m), 1.48–1.61 (1 H, m), 1.87–1.95 (2 H, m), 2.09–
2.15 (2 H, m), 4.01–4.07 (1 H, m, H-8); δC (100 MHz, benzene-d6) −4.3 (C-12/12’), –4.1 (C-
12/12’), 17.7 (C-11), 18.4 (C-13), 20.2 (CH2), 23.6 (CH2), 26.4 (C-14), 36.3 (CH2), 40.2 (CH2), 
40.9 (CH2), 41.8 (C-10), 42.5 (CH2), 64.8 (C-9), 65.7 (C-8), 208.6 (C-1); HRMS (ESI+): Found: 
319.2062; C17H32NaO2Si (MNa+) Requires 319.2064 (0.5 ppm error), Found: 297.2244; C17H33O2Si 
(MH+) Requires 297.2244 (0.0 ppm error). 
Lab notebook reference: MGL/07/40 
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(4aSR,8SR,8aSR)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate (262) 
 
 
 
To a solution of (4aSR,8SR,8aSR)-8-((tert-butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one 261 (95 mg, 0.320 mmol) and trifluoromethanesulfonic anhydride (64.0 µL, 0.384 
mmol) in CH2Cl2 (1.6 mL) at RT under an atmosphere of argon, was added 2,6-di-tert-butyl-4-
methylpyridine (99 mg, 0.480 mmol) in one portion. The suspension was stirred for 2 h at RT then 
concentrated in vacuo. The residue was taken up in hexane (25 mL), filtered and washed with 
hexane (3 × 25 mL). The solution was concentrated in vacuo. Purification by column 
chromatography (20:1 hexane:EtOAc) afforded the title compound 262 as a yellow oil (92 mg, 
67%); Rf 0.55 (20:1 hexane:EtOAc); νmax (thin film)/cm-1 2930m, 2856m, 1669w, 1416s, 1245m, 
1198s, 1142s, 1079s, 1032m, 1005w, 974m, 940m, 894m, 857m, 833s, 776s, 602s; δH (400 MHz, 
CDCl3) 0.09 (3 H, s, H-12/12’), 0.10 (3 H, s, H-12/12’), 0.89–0.93 (12 H, m, H-11,14), 1.19–1.46 
(5 H, m), 1.55–1.73 (2 H, m), 2.00–2.06 (1 H, m), 2.11–2.38 (3 H, m), 3.94 (1 H, app. td, J = 10.3, 
J = 4.3, H-8), 5.70–5.73 (1 H, m, H-2); δC (100 MHz, CDCl3) −4.2 (C-12/12’), −3.2 (C-12/12’), 
16.9 (C-11), 18.4 (C-13), 20.2 (CH2), 21.1 (CH2), 26.4 (C-14), 36.8 (CH2), 36.9 (C-10), 38.3 (CH2), 
38.7 (CH2), 52.9 (C-9), 69.2 (C8), 118.8 (q, J = 321.6, C-15), 119.1 (q, J = 1.7, C-2), 151.0 (C-1); 
HRMS (ESI+): Found: 451.1545; C18H31F3NaO4SSi (MNa+) Requires 451.1557 (2.5 ppm error), 
Found: 429.1732; C18H32F3O4SSi (MH+) Requires 429.1737 (1.2 ppm error). 
Lab notebook reference: MGL/07/47 
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tert-Butyl(((1SR,4aSR,8aRS)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-
yl)oxy)dimethylsilane (263) 
 
 
 
Prepared according to a modified literature procedure.116 
To a solution of (4aSR,8SR,8aSR)-8-((tert-butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate 262 (154 mg, 0.359 mmol) in THF (0.54 mL) 
and NMP (1.44 mL) under an atmosphere of argon, was added Fe(acac)3 (139 mg, 0.395 mmol). 
The solution was cooled to −25 °C and methylmagnesium chloride (1.20 mL, 3.59 mmol, 3.0 M 
solution in THF) was added dropwise. The orange solution was stirred at −25 °C for 1 h then 
quenched by careful addition of sat. aq. NH4Cl (25 mL). The mixture was extracted with diethyl 
ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, filtered and concentrated 
in vacuo. Purification by column chromatography (hexane) afforded the title compound 263 as a 
colourless oil (97 mg, 92%); Rf 0.50 (hexane); νmax (thin film)/cm-1 2927s, 2855m, 1461m, 1378w, 
1362w, 1255s, 1119m, 1069s, 1006w, 946w, 884s, 832s, 772s, 666m; δH (400 MHz, CDCl3) 0.06 
(3 H, s, H-12/12’), 0.09 (3 H, s, H-12/12’), 0.80 (3 H, s, H-11), 0.90 (9 H, s, H-14), 1.11–1.66 (7 H, 
m), 1.82–1.84 (3 H, m, H-15), 1.89–2.12 (4 H, m), 3.79 (1 H, app. td, J = 10.3, J = 4.7, H-8), 5.28–
5.32 (1 H, m, H-2); δC (100 MHz, CDCl3) −3.5 (C-12/12’), −2.8 (C-12/12’), 16.8 (C-11), 18.3 (C-
13), 20.3 (CH2), 22.9 (CH2), 25.5 (C-15), 26.7 (C-14), 34.9 (C-10), 38.6 (CH2), 38.7 (CH2), 40.1 
(CH2), 53.5 (C-9), 70.7 (C-8), 122.5 (C-2), 135.9 (C-1); HRMS (ESI+): Found: 317.2261; 
C18H34NaOSi (MNa+) Requires 317.2271 (3.3 ppm error). 
Lab notebook reference: MGL/07/48 
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(1SR,4aSR,8aRS)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-ol (264) 
 
 
 
To a solution of tert-butyl(((1SR,4aSR,8aRS)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-
1-yl)oxy)dimethylsilane 263 (90 mg, 0.306 mmol) in THF (1.5 mL) under an atmosphere of argon, 
at RT was added TBAF (1.53 mL, 1.53 mmol, 1.0 M in THF). The solution was refluxed for 1 h, 
allowed to cool at RT, then quenched by addition of water (25 mL). The aqueous layer was 
extracted with diethyl ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compound 264 as a white solid (51 mg, 92%); Rf 0.27 (8:1 hexane:EtOAc); m.p. 
59–61 °C; νmax (thin film)/cm-1 3350br, 2910s, 2848s, 1446s, 1375m, 1352m, 1267m, 1163m, 
1079m, 1058s, 1018s, 933s, 8966m, 843m; δH (400 MHz, CDCl3) 0.79 (3 H, s, H-11), 1.10–1.44 (6 
H, m), 1.54–1.70 (2 H, m), 1.77–1.82 (1 H, m, H-9), 1.88 (3 H, s, H-12), 1.95–2.12 (3 H, m), 3.95 
(1 H, app. td, J = 10.4, J = 4.4, H-8), 5.31–5.35 (1 H, m, H-2); δC (100 MHz, CDCl3) 16.6 (C-11), 
20.2 (CH2), 23.0 (CH2), 24.6 (C-12), 34.8 (C-10), 38.2 (CH2), 38.2 (CH2), 40.0 (CH2), 53.5 (C-9), 
69.3 (C-8), 123.3 (C-2), 134.8 (C-1); HRMS (ESI+): Found: 203.1403; C12H20NaO (MNa+) 
Requires 203.1406 (1.7 ppm error). 
Lab notebook reference: MGL/07/49 
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(1SR,4aSR,8aRS)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate (265) 
 
 
 
Synthesised using general procedure A with (1SR,4aSR,8aRS)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-ol 264 (49 mg, 0.272 mmol), toluene (1.4 mL), DEPAA (56 mg, 0.285 
mmol), DIPEA (0.12 mL, 0.707 mmol) and T3P (225 mg, 0.354 mmol, 50% w/w solution in THF) 
affording the title compound 265 as a yellow oil (97 mg, 99%). No further purification was 
required; Rf 0.39 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2928s, 1729s, 1444m, 1393w, 1261s, 
1208w, 1163w, 1114m, 1051w, 1021s, 967s, 823m, 783m; δH (400 MHz, CDCl3) 0.81 (3 H, s, H-
11), 1.11–1.71 (16 H, m), 1.93–2.14 (4 H, m), 2.82–2.97 (2 H, m, H-14), 4.10–4.18 (4 H, m, H-
15,15’), 4.90 (1 H, app. td, J = 11.0, J = 4.9, H-8), 5.29–5.33 (1 H, m, H-2); δC (100 MHz, CDCl3) 
16.2–16.3 (3 C, m, C-11,16,16’), 19.7 (CH2), 22.7 (CH2), 23.4 (C-12), 33.2 (CH2), 34.8 (d, J = 
135.1, C-14), 34.9 (C-10), 38.0 (CH2), 39.5 (CH2), 49.3 (C-9), 62.5 (d, J = 6.4, C-15/15’), 62.5 (d, 
J = 6.4, C-15/15’), 74.1 (C-8), 123.7 (C-2), 133.2 (C-1), 165.3 (d, J = 5.8, C-13); δP (162 MHz, 
CDCl3) 20.5; HRMS (ESI+): Found: 381.1806; C18H31NaO5P (MNa+) Requires 381.1801 (−1.1 
ppm error), Found: 359.1977; C18H32O5P (MH+) Requires 359.1982 (1.3 ppm error). 
Lab notebook reference: MGL/07/50 
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(1SR,4aSR,8aRS)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-diazo-
2-diethoxyphosphoryl)acetate (266) 
 
 
 
Synthesised using general procedure B with (1SR,4aSR,8aRS)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diethoxyphosphoryl)acetate 265 (96 mg, 0.268 mmol), THF (1.34 
mL), LHMDS (0.32 mL, 0.321 mmol, 1.0 M solution in THF) and p-ABSA (77 mg, 0.321 mmol). 
Purification by column chromatography (4:1 hexane:EtOAc) afforded the title compound 266 as a 
pale yellow oil (91 mg, 88%); Rf 0.74 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2929m, 2122s, 
1697s, 1445m, 1368m, 1318w, 1297w, 1270s, 1163w, 1017s, 977m, 957m, 804s, 743s, 590s, 553s; 
δH (400 MHz, CDCl3) 0.80 (3 H, s, H-11), 1.10–1.71 (16 H, m), 1.92–2.12 (4 H, m), 4.04–4.24 (4 
H, m, H-15,15’), 4.98 (1 H, app. td, J = 11.0, J = 5.0, H-8), 5.30–5.33 (1 H, m, H-2); δC (100 MHz, 
CDCl3) 16.0 (C-16/16’), 16.1 (C-16/16’), 16.3 (C-11), 19.7 (CH2), 22.7 (CH2), 23.0 (C-12), 33.8 
(CH2), 35.0 (C-10), 37.9 (CH2), 39.4 (CH2), 49.4 (C-9), 54.0 (d, J = 229.1, C-14), 63.4 (d, J = 5.7, 
C-15/15’), 63.6 (d, J = 5.9, C-15/15’), 74.2 (C-8), 123.8 (C-2), 132.9 (C-1), 162.7 (d, J = 12.2, C-
13); δP (162 MHz, CDCl3) 10.8; HRMS (ESI+): Found: 407.1716; C18H29N2NaO5P (MNa+) 
Requires 407.1706 (−2.3 ppm error). 
Lab notebook reference: MGL/07/51 
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(3aSR,5aRS,9aRS,9bSR)-5a,9-Dimethyl-3-methylene-3a,4,5,5a,6,7,9a,9b-
octahydronaphtho[1,2-b]furan-2(3H)-one (α-cyclocostunolide) (256) 
 
 
 
Synthesised using general procedure D with (1SR,4aSR,8aRS)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diazo-2-diethoxyphosphoryl)acetate 266 (90 mg, 0.234 mmol), CH2Cl2 
(4.7 mL), Rh2(oct)4 (3.6 mg, 4.7 µmol), THF (4.7 mL), KOBu-t (39.4 mg, 0.351 mmol) and 
paraformaldehyde (14.1 mg, 0.468 mmol). Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compound 256 as a white crystalline solid (28 mg, 52%); Rf 0.38 
(8:1 hexane:EtOAc); m.p. 80–82 °C (lit.171 83–84 °C); νmax (thin film)/cm-1 2920s, 2851m, 1771s, 
1445w, 1377w, 1344w, 1286w, 1249s, 1220w, 1132m, 1118m, 1076w, 1046w, 1014w, 982m; δH 
(400 MHz, CDCl3) 0.90 (3 H, s, H-11), 1.21–1.74 (6 H, m), 1.83 (3 H, s, H-12), 1.97–2.18 (2 H, 
m), 2.34 (1 H, d, J = 11.2, H-9), 2.52 (1H, app. tq, J = 11.2, J = 3.5, H-7), 3.86 (1 H, app. t, J = 
11.0, H-8), 5.35–5.38 (2 H, m, H-2,15b), 6.05 (1 H, d, J = 3.2, H-15a); δC (100 MHz, CDCl3) 17.4 
(C-11), 21.5 (C-6), 22.8 (C-3), 23.7 (C-12), 35.9 (C-10), 37.7 (C-4), 39.2 (C-5), 51.2 (C-9), 51.5 
(C-9), 82.2 (C-8), 116.4 (C-15), 122.4 (C-2), 133.0 (C-1), 139.4 (C-14), 171.0 (C-13); HRMS 
(ESI+): Found: 255.1360; C15H20NaO2 (MNa+) Requires 255.1356 (−1.7 ppm error). 
Lab notebook reference: MGL/07/52 
Obtained data in accord with reported literature.120,171 
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(4aSR,8SR,8aRS)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one (260) 
 
 
 
To a solution of (4aSR,8SR,8aRS)-8-hydroxy-4a-methyloctahydronaphthalen-1(2H)-one 238c (316 
mg, 1.73 mmol) in CH2Cl2 (17.3 mL) at 0 °C was added 2,6-lutidine (0.50 mL, 4.33 mmol) then 
TBSOTf (0.44 mL, 1.91 mmol). The solution was stirred at 0 °C for 1 h then quenched with NH4Cl 
(50 mL) and the organic fraction separated. The aqueous layer was extracted with CH2Cl2 (2 × 50 
mL) and the combined organic fractions dried over MgSO4 and concentrated in vacuo. Purification 
by column chromatography (4:1 hexane:EtOAc) afforded the title compound 260 as a pale yellow 
oil (491 mg, 96%); Rf 0.20 (20:1 hexane:EtOAc); νmax (thin film)/cm-1 2951m, 2930s, 2856s, 
1699s, 1471m, 1462m, 1383m, 1255s, 1226m, 1172m, 1150m, 1060m, 1033s, 973s, 961s, 900s, 
836s, 775s, 688m; δH (400 MHz, benzene-d6) −0.09 (3 H, s, H-12/12’), −0.04 (3 H, s, H-12/12’), 
0.73 (3 H, s, H-11), 0.81–1.41 (14 H, m), 1.57–1.68 (3 H, m), 1.84 (1 H, qt, J = 13.1, J = 3.3), 
1.94–1.96 (1 H, m, H-9), 2.33–2.56 (3 H, m), 4.02 (1 H, app. q, J = 3.2, H-8); δC (100 MHz, 
benzene-d6) −5.0 (C-12/12’), –4.9 (C-12/12’), 16.3 (CH2), 18.1 (C-13), 20.7 (CH2), 26.1 (C-14), 
29.5 (C-11), 31.7 (CH2), 33.8 (CH2), 35.4 (C-10), 39.6 (CH2), 40.6 (CH2), 61.7 (C-9), 69.9 (C-8), 
212.3 (C-1); HRMS (ESI+): Found: 319.2068; C17H32NaO2Si (MNa+) Requires 319.2064 (−1.4 
ppm error), Found: 297.2249; C17H33O2Si (MH+) Requires 297.2244 (-1.5 ppm error). 
Lab notebook reference: MGL/07/39 
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(4aSR,8SR,8aRS)-8-((tert-Butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate (267) 
 
 
 
To a solution of (4aSR,8SR,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-methyloctahydronaphthalen-
1(2H)-one 260 (325 mg, 1.10 mmol) in THF (5.5 mL) cooled to −40 °C under an atmosphere of 
argon, was added LHMDS (3.29 mL, 3.29 mmol, 1.0 M solution in THF) dropwise. The solution 
was stirred at −40 °C for 1 h then trifluoromethanesulfonic anhydride (0.55 mL, 3.29 mmol) was 
added dropwise. The solution was stirred at −40 °C for 20 mins then quenched by addition of water 
(25 mL). The mixture was extracted with diethyl ether (3 × 50 mL) and the combined organic 
extracts dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (hexane) afforded the title compound 267 as a colourless oil (291 mg, 62%); Rf 
0.74 (20:1 hexane:EtOAc); νmax (thin film)/cm-1 2931m, 2857s, 1416s, 1246s, 1205s, 1143s, 1074s, 
1042s, 990m, 977m, 939m, 908m, 878s, 837s, 802m, 776m, 604m; δH (400 MHz, CDCl3) −0.02 (3 
H, s, H-12/12’), 0.02 (3 H, s, H-12/12’), 0.84–0.94 (13 H, m), 1.26–1.40 (3 H, m), 1.51–1.59 (1 H, 
m), 1.74–1.86 (2 H, m), 1.94 (1 H, d, J = 3.1, H-9), 2.12–2.32 (3 H, m), 4.11 (1 H, app. q, J = 2.8, 
H-8), 5.75–5.77 (1 H, m, H-2); δC (100 MHz, CDCl3) −5.5 (C-12/12’), −4.9 (C-12/12’), 15.4 
(CH2), 17.8 (C-13), 21.6 (CH2), 25.7 (C-14), 28.0 (CH2), 28.2 (C-11), 33.2 (CH2), 33.7 (C-10), 39.9 
(CH2), 50.2 (C-9), 65.9 (C-8), 118.5 (q, J = 320.2, C-15), 119.2 (C-2), 149.0 (C-1); HRMS (ESI+): 
Found: 451.1541; C18H31F3NaO4SSi (MNa+) Requires 451.1557 (3.4 ppm error). 
Lab notebook reference: MGL/07/55 
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tert-Butyl(((1SR,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-
yl)oxy)dimethylsilane (268) 
 
 
 
Prepared according to a modified literature procedure.116 
To a solution of (4aSR,8SR,8aRS)-8-((tert-butyldimethylsilyl)oxy)-4a-methyl-3,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl trifluoromethanesulfonate 267 (270 mg, 0.630 mmol) in THF (0.95 mL) 
and NMP (2.52 mL) under an atmosphere of argon, was added Fe(acac)3 (245 mg, 0.693 mmol). 
The solution was cooled to −25 °C and methylmagnesium chloride (2.10 mL, 6.30 mmol, 3.0 M 
solution in THF) was added dropwise. The orange solution was stirred at −25 °C for 1 h then 
quenched by careful addition of sat. aq. NH4Cl (25 mL). The mixture was extracted with diethyl 
ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, filtered and concentrated 
in vacuo. Purification by column chromatography (hexane) afforded the title compound 268 as a 
colourless oil (110 mg, 59%); Rf 0.93 (hexane); νmax (thin film)/cm-1 2928s, 2855w, 1446m, 
1378m, 1251s, 1153s, 1079s, 1060s, 1040s, 977s, 907s, 834s, 798s, 772s, 679m; δH (400 MHz, 
CDCl3) −0.04 (3 H, s, H-12/12’), 0.00 (3 H, s, H-12/12’), 0.77–0.89 ( 13 H, m), 1.23–1.49 (5 H, 
m), 1.63–1.65 (3 H, m, H-15), 1.74–1.88 (2 H, m), 1.98–2.04 (2 H, m), 2.28–2.35 (1 H, m), 4.06 (1 
H, app. q, J = 2.7, H-8), 5.37–5.39 (1 H, m, H-2); δC (100 MHz, CDCl3) −5.2 (C-12/12’), −4.7 (C-
12/12’), 16.1 (CH2), 18.0 (C-13), 22.5 (C-15), 23.3 (CH2), 25.7 (C-14), 28.6 (CH2), 28.8 (C-11), 
31.9 (C-10), 34.4 (CH2), 40.8 (CH2), 51.5 (C-9), 67.2 (C-8), 122.6 (C-2), 131.9 (C-1); HRMS 
(APCI+): Found: 295.2443; C18H35OSi (MH+) Requires 295.2452 (2.9 ppm error). 
Lab notebook reference: MGL/07/56 
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(1SR,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-ol (269) 
 
 
 
To a solution of tert-butyl(((1SR,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-
1-yl)oxy)dimethylsilane 268 (99 mg, 0.336 mmol) in THF (1.68 mL) under an atmosphere of 
argon, at RT was added TBAF (1.68 mL, 1.68 mmol, 1.0 M in THF). The solution was refluxed for 
24 h, allowed to cool at RT, then quenched by addition of water (25 mL). The aqueous layer was 
extracted with diethyl ether (3 × 25 mL) and the combined organic extracts dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (8:1 hexane:EtOAc) 
afforded the title compound 269 as a colourless oil (43 mg, 71%); Rf 0.45 (8:1 hexane:EtOAc); νmax 
(thin film)/cm-1 3354br, 2929s, 2871s, 2842s, 1448s, 1389m, 1377m, 1342w, 1255s, 1199w, 
1162m, 1072m, 1012s, 963s, 949s, 831s; δH (400 MHz, CDCl3) 0.80 (3 H, s, H-11), 0.87–0.92 (1 
H, m), 1.22–1.86 (10 H, m), 1.97–2.17 (4 H, m), 3.98 (1 H, app. q, J = 3.0, H-8), 5.65–5.68 (1 H, 
m, H-2); δC (100 MHz, CDCl3) 15.8 (CH2), 21.9 (C-12), 22.8 (CH2), 28.4 (CH2), 28.5 (C-11), 31.3 
(C-10), 31.6 (CH2), 40.4 (CH2), 51.2 (C-9), 65.3 (C-8), 125.1 (C-2), 132.3 (C-1); HRMS (ESI+): 
Found: 203.1406; C12H20NaO (MNa+) Requires 203.1406 (0.0 ppm error). 
Lab notebook reference: MGL/07/58 
(1SR,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-
(diethoxyphosphoryl)acetate (270) 
 
 
 
Synthesised using general procedure A with (1SR,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-ol 269 (21 mg, 0.116 mmol), toluene (0.58 mL), DEPAA (24 mg, 0.122 
mmol), DIPEA (0.05 mL, 0.302 mmol) and T3P (96 mg, 0.151 mmol, 50% w/w solution in THF). 
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Purification by column chromatography (1:1 hexane:EtOAc) afforded the title compound 270 as a 
pale yellow oil (26 mg, 63%); Rf 0.38 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2929m, 1732s, 
1448m, 1393w, 1261s, 1113w, 1021s, 968s, 813m; δH (400 MHz, CDCl3) 0.83–0.91 (4 H, m), 
1.24–1.54 (9 H, m), 1.58 (1 H, d, J = 2.6, H-9), 1.62–1.64 (3 H, m, H-12), 1.67–1.92 (2 H, m), 
1.98–2.16 (3 H, m), 2.79–2.94 (2 H, m, H-14), 4.10–4.18 (4 H, m, H-15,15’), 5.32 (1 H, app. q, J = 
3.1, H-8), 5.38–5.41 (1 H, m, H-2); δC (100 MHz, CDCl3) 16.2–16.3 (2 C, m, C-16,16’), 16.4 
(CH2), 22.3 (C-12), 22.8 (CH2), 28.0 (CH2), 28.3 (C-11), 30.4 (CH2), 31.6 (C-10), 34.5 (d, J = 
134.5, C-14), 40.0 (CH2), 49.4 (C-9), 62.4 (d, J = 6.5, C-15/15’), 62.5 (d, J = 6.5, C-15/15’), 70.4 
(C-8), 122.9 (C-2), 131.1 (C-1), 164.8 (d, J = 6.1, C-13); δP (162 MHz, CDCl3) 20.9; HRMS 
(ESI+): Found: 381.1802; C18H31NaO5P (MNa+) Requires 381.1801 (−0.3 ppm error), Found: 
359.1975; C18H32O5P (MH+) Requires 359.1982 (2.0 ppm error). 
Lab notebook reference: MGL/07/59 
(1SR,4aSR,8aSR)-4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl 2-diazo-
2-diethoxyphosphoryl)acetate (271) 
 
 
 
Synthesised using general procedure B with (1SR,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diethoxyphosphoryl)acetate 270 (26 mg, 72.5 µmol), THF (0.36 mL), 
LHMDS (0.09 mL, 87.1 µmol, 1.0 M solution in THF) and p-ABSA (20.9 mg, 87.1 µmol). 
Purification by column chromatography (2:1 hexane:EtOAc) afforded the title compound 271 as a 
pale yellow solid (21 mg, 75%); Rf 0.67 (1:1 hexane:EtOAc); m.p. 65–68 °C; νmax (thin film)/cm-1 
2932m, 2123s, 1706s, 1448w, 1368w, 1271s, 1217w, 1021s, 977m; δH (400 MHz, CDCl3) 0.86 (3 
H, s, H-11), 0.89–0.93 (1 H, m), 1.17–1.55 (9 H, m), 1.61–1.72 (5 H, m), 1.89–2.12 (3 H, m), 4.06–
4.25 (4 H, m, H-15,15’), 5.39–5.43 (2 H, m, H-2,8); δC (100 MHz, CDCl3) 16.0 (d, J = 7.4, C-
16/16’), 16.1 (d, J = 6.7, C-16/16’), 16.3 (CH2), 22.3 (C-12), 22.8 (CH2), 28.0 (CH2), 28.3 (C-11), 
30.7 (CH2), 31.6 (C-10), 40.0 (CH2), 49.5 (C-9), 52.9 (d, J = 226.5, C-14), 63.4 (d, J = 5.7, C-
15/15’), 63.6 (d, J = 5.7, C-15/15’), 70.5 (C-8), 122.9 (C-2), 131.2 (C-1), 162.6 (d, J = 13.1, C-13); 
δP (162 MHz, CDCl3) 11.3; HRMS (ESI+): Found: 407.1707; C18H29N2NaO5P (MNa+) Requires 
407.1706 (−0.2 ppm error). 
Lab notebook reference: MGL/07/60 
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(3aRS,5aRS,9aSR,9bSR)-5a,9-Dimethyl-3-methylene-3a,4,5,5a,6,7,9a,9b-
octahydronaphtho[1,2-b]furan-2(3H)-one 
 
 
 
Synthesised using general procedure D with (1SR,4aSR,8aSR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl 2-diazo-2-diethoxyphosphoryl)acetate 271 (20 mg, 52.0 µmol), CH2Cl2 
(1.04 mL), Rh2(oct)4 (0.8 mg, 1.04 µmol), THF (1.04 mL), KOBu-t (8.8 mg, 78.0 µmol) and 
paraformaldehyde (3.1 mg, 104 µmol). Purification by column chromatography (8:1 
hexane:EtOAc) afforded the title compound 272 as a pale yellow oil (8 mg, 66%); Rf 0.36 (4:1 
hexane:EtOAc); νmax (thin film)/cm-1 2928s, 2865w, 1759s, 1452w, 1402w, 1380w, 1346w, 
1263m, 1156w, 1143m, 1130m, 1080m, 957m; δH (400 MHz, CDCl3) 0.91 (3 H, s, H-11), 1.05–
1.09 (1 H, m), 1.21-1.81 (9 H, m), 2.00–2.09 (2 H, m), 3.00–3.06 (1 H, m, H-7), 4.74 (1 H, dd, J = 
6.1, J = 3.8, H-8), 5.57–5.59 (2 H, m, H-2,15b), 6.19 (1 H, d, J = 1.6, H-15a); δC (100 MHz, 
CDCl3) 22.1 (C-12), 22.5 (C-3), 24.9 (C-6), 27.1 (C-11), 30.4 (C-10), 30.7 (C-4), 35.8 (C-5), 39.7 
(C-7), 46.5 (C-9), 76.9 (C-8), 121.0 (C-15), 124.3 (C-2), 129.5 (C-1), 142.0 (C-14), 170.6 (C-13); 
HRMS (ESI+): Found: 255.1359; C15H20NaO2 (MNa+) Requires 255.1356 (−1.3 ppm error), Found: 
233.1536; C15H21O2 (MH+) Requires 233.1536 (−0.1 ppm error). 
Lab notebook reference: MGL/07/64 
272
Rh2(oct)4, CH2Cl2
then KOBu-t, THF,
(CH2O)n
271
Me
OH
O
P
O
O
OMe
N2
Me
Me
H 8
4
7
3 6
2
5
1
9
10
11
12
14O
O
Ha
Hb
13
15
  291 
5.2.3.  Chapter 4 
5.2.3.1.  Rhodium(II)-catalysed cyclopropanations 
Allyl 2-(diethoxyphosphoryl)acetate (287a) 
 
 
 
Synthesised using general procedure A with allyl alcohol 287 (1.16 g, 20.0 mmol), toluene (100 
mL), DEPAA (3.38 mL, 21.0 mmol), DIPEA (9.06 mL, 52.0 mmol) and T3P (16.5 g, 26.0 mmol, 
50% w/w solution in EtOAc) affording the title compound 287a as an orange oil (4.63 g, 98%). No 
further purification was required; Rf 0.26 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2985w, 1738s, 
1394w, 1261s, 1117w, 1050w, 1023s, 971m; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.5, 
H-4), 2.98 (2 H, d, J = 21.6, H-2), 4.12–4.19 (4 H, m, H-3), 4.61–4.64 (1 H, m, H-5), 5.24 (1 H, 
app. dq, J = 10.4, J = 1.3, H-7a), 5.35 (1 H, app. dq, J = 17.2, J = 1.5, H-7b), 5.90 (2 H, ddt, J = 
17.2, J = 10.4, J = 5.7, H-6); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4), 34.2 (d, J = 134.3, C-2), 
62.7 (d, J = 6.2, C-3), 66.1 (C-5), 118.7 (C-7), 131.5 (C-6), 165.5 (d, J = 6.1, C-1); δP (162 MHz, 
CDCl3) 20.1; HRMS (ESI+): Found: 259.0708; C9H17NaO5P (MNa+) Requires 259.0706 (−0.8 ppm 
error), Found: 237.0890; C9H18O5P (MH+) Requires 237.0886 (−1.6 ppm error). 
Lab notebook reference: MGL/03/26 
Allyl 2-diazo-2-(diethoxyphosphoryl)acetate (287b) 
 
 
 
Synthesised using general procedure C with 3-(4-methoxyphenyl)propyl 2-
(diethoxyphosphoryl)acetate 287a (2.19 g, 9.27 mmol), DBSA (4.89 g, 13.9 mmol), DBU (2.08 
mL, 13.9 mmol) and CH2Cl2 (93.0 mL). Purification by column chromatography (2:1 
petrol:EtOAc) affording the title compound 287b as a pale yellow oil (2.02 g, 83%); Rf 0.43 (1:1 
petrol:EtOAc); νmax (thin film)/cm-1 2992w, 2932w, 2129s, 1707s, 1368w, 1276s, 1020s, 983m; δH 
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(400 MHz, CDCl3) 1.33 (6 H, td, J = 7.1, J = 0.8, H-4), 4.09–4.25 (4 H, m, H-3), 4.67 (1 H, app. dt, 
J = 5.6, J = 1.4, H-5), 5.24 (1 H, app. dq, J = 10.5, J = 1.3, H-7a), 5.32 (1 H, app. dq, J = 17.2, J = 
1.5, H-7b), 5.89 (2 H, ddt, J = 17.2, J = 10.5, J = 5.6, H-6); δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, 
C-4), 53.9 (d, J = 226.1, C-2), 63.6 (d, J = 5.6, C-3), 65.9 (C-5), 118.7 (C-7), 131.4 (C-6), 163.1 (d, 
J = 12.0, C-1); δP (162 MHz, CDCl3) 10.4; HRMS (ESI+): Found: 285.0603; C9H15N2NaO5P 
(MNa+) Requires 285.0611 (2.9 ppm error), Found: 263.0792; C9H16N2O5P (MH+) Requires 
263.0791 (−0.2 ppm error). 
Lab notebook reference: MGL/08/32 
Diethyl ((1RS,5SR)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate (287c) 
 
 
 
Synthesised using general procedure F with allyl 2-diazo-2-(diethoxyphosphoryl)acetate 287b (600 
mg, 2.29 mmol), CH2Cl2 (17 mL) and Rh2(oct)4 (35.6 mg, 0.046 mmol). Purification by column 
chromatography (1:20 hexane:EtOAc) afforded the title compound 287c as a dark yellow oil (417 
mg, 78%); Rf 0.30 (1:8 hexane:EtOAc); νmax (thin film)/cm-1 2986w, 2920w, 2838w, 1764s, 
1376w, 1271w, 1243m, 1015s; δH (400 MHz, CDCl3) 1.18–1.22 (1 H, m, H-5), 1.27 (3 H, td, J = 
7.1, J = 0.5, H-7/7’), 1.29 (3 H, td, J = 7.1, J = 0.5, H-7/7’), 1.76 (1 H, ddd, J = 15.2, J = 7.8, J = 
4.7, H-5), 2.58–2.65 (1 H, m, H-3), 4.07–4.18 (5 H, m, H-4, 6,6’), 4.28 (1 H, dd, J = 9.5, J = 4.7, 
H-4); δC (100 MHz, CDCl3) 16.1 (d, J = 6.0, C-7,7’), 17.3 (d, J = 3.0, C-5), 22.5 (d, J = 207.0, C-
2), 24.3 (d, J = 1.4, C-3), 63.0 (d, J = 6.2, C-6/6’), 63.0 (d, J = 6.2, C-6/6’), 67.5 (d, J = 2.5, C-4), 
171.5 (d, J = 10.6, C-1); δP (162 MHz, CDCl3) 17.9; HRMS (ESI+): Found: 257.0552; C9H15NaO5P 
(MNa+) Requires 257.0549 (−1.2 ppm error), Found: 235.0737; C9H16O5P (MH+) Requires 
235.0730 (−3.0 ppm error). 
Lab notebook reference: MGL/03/28B 
Obtained data in accord with reported literature.127 
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(E)-But-2-en-1-yl 2-(diethoxyphosphoryl)acetate (288a) 
 
 
 
Synthesised using general procedure A with 2-buten-1-ol 288 (2.16 g, 30.0 mmol), toluene (150 
mL), DEPAA (5.06 mL, 31.5 mmol), DIPEA (13.6 mL, 78.0 mmol) and T3P (24.8 g, 39.0 mmol, 
50% w/w solution in EtOAc) affording the title compound 288a as an orange oil (7.41 g, 99%). No 
further purification was required; Rf 0.29 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2983w, 1737s, 
1446w, 1394w, 1266s, 1164w, 1115m, 1052m, 10234, 968s; δH (400 MHz, CDCl3) 1.33 (6 H, t, J 
= 7.1, H-4), 1.70–1.72 (3 H, m, H-8), 2.96 (2 H, d, J = 21.5, H-2), 4.12–4.20 (4 H, m, H-3), 4.56 (2 
H, d, J = 6.6, H-5), 5.54–5.62 (1 H, m, H-6), 5.77 –5.86 (1 H, m, H-7); δC (100 MHz, CDCl3) 16.3 
(d, J = 6.2, C-4), 17.7 (C-8), 34.3 (d, J = 134.3, C-2), 62.7 (d, J = 6.3, C-3), 66.2 (C-5), 124.5 (C-
6), 132.0 (C-7), 165.6 (d, J = 6.2, C-1); δP (162 MHz, CDCl3) 20.3; HRMS (ESI+): Found: 
273.0872; C10H19NaO5P (MNa+) Requires 273.0862 (−3.5 ppm error), Found: 251.1039; C10H20O5P 
(MH+) Requires 251.1043 (1.4 ppm error). 
Lab notebook reference: MGL/04/49 
(E)-But-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (288b) 
 
 
 
Synthesised using general procedure B with (E)-but-2-en-1-yl 2-(diethoxyphosphoryl)acetate 288a 
(2.50 g, 10.0 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) and p-
ABSA (2.88 g, 12.0 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded 
the title compound 288b as a yellow oil (1.50 g, 54%); Rf 0.57 (1:1 petrol:EtOAc); νmax (thin 
film)/cm-1 2984w, 2126s, 1704s, 1446w, 1376w, 1274s, 1215w, 1164w, 1113w, 1090w, 1020s, 
970m; δH (400 MHz, CDCl3) 1.34 (6 H, t, J = 7.1, J = 0.7, H-4), 1.70–1.72 (3 H, m, H-8), 4.10–
4.25 (4 H, m, H-3), 4.59–4.62 (2 H, m, H-5), 5.52–5.61 (1 H, m, H-6), 5.76–5.85 (1 H, m, H-7); δC 
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(100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 17.7 (C-8), 53.7 (d, J = 228.3, C-2), 63.6 (d, J = 5.9, C-
3), 66.2 (C-5), 124.5 (C-6), 132.1 (C-7), 163.2 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.6; 
HRMS (ESI+): Found: 299.0776; C10H17N2NaO5P (MNa+) Requires 299.0767 (−2.9 ppm error). 
Lab notebook reference: MGL/04/60 
But-2-yn-1-yl 2-(diethoxyphosphoryl)acetate (S5) 
 
 
 
Synthesised using general procedure A with 2-butyn-1-ol S4 (1.40 g, 20.0 mmol), toluene (100 
mL), DEPAA (3.38 mL, 21.0 mmol), DIPEA (9.06 mL, 52.0 mmol) and T3P (16.5 g, 26.0 mmol, 
50% w/w solution in EtOAc) affording the title compound S5 as an orange oil (4.89 g, 99%). No 
further purification was required; Rf 0.32 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2985w, 2242w, 
1742s, 1444w, 1394w, 1370w, 1266s, 1161w, 1113m, 1050w, 1023s, 973s, 838w; δH (400 MHz, 
CDCl3) 1.34 (6 H, td, J = 7.1, J = 0.5, H-4), 1.84 (3 H, t, J = 2.4, H-8), 2.90 (2 H, d, J = 21.5, H-2), 
4.14–4.21 (4 H, m, H-3), 4.68–4.70 (2 H, m, H-5); δC (100 MHz, CDCl3) 3.6 (C-8), 16.3 (d, J = 
6.4, C-4), 34.1 (d, J = 134.3, C-2), 53.8 (C-5), 62.8 (d, J = 6.2, C-3), 72.5 (C-57, 83.6 (C-6), 165.3 
(d, J = 6.0, C-1); δP (162 MHz, CDCl3) 19.7; HRMS (ESI+): Found: 249.0890; C10H18O5P (MH+) 
Requires 249.0886 (−1.4 ppm error). 
Lab notebook reference: MGL/04/77 
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(Z)-But-2-en-1-yl 2-(diethoxyphosphoryl)acetate (289a), (E)-But-2-en-1-yl 2-
(diethoxyphosphoryl)acetate (288a) and Butyl 2-(diethoxyphosphoryl)acetate (S6) 
 
 
 
To a solution of but-2-yn-1-yl 2-(diethoxyphosphoryl)acetate S5 (4.88 g, 19.7 mmol) in MeOH 
(200 mL) under an argon atmosphere was added Lindlar catalyst (400 mg). The flask was purged 4 
times with argon then 4 times with hydrogen and stirred for 2 h. The mixture was filtered through a 
pad of Celite and washed with CH2Cl2 (200 mL). The filtrate was concentrated in vacuo to afford 
the title compounds as an inseparable mixture (289a:288a:S6 6:1.5:1) as a yellow oil (4.62 g, 
94%); Rf 0.29 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2983w, 2934w, 1733w, 1445w, 1394w, 
1257s, 1113m, 1049w, 1018s, 963s, 838m, 781m; δH (400 MHz, CDCl3) 0.92 (3 H, t, J = 7.4, H-
8sat), 1.27–1.72 (28 H, m, H-(4Z,E,sat),(6sat),(7sat),(8Z,E)), 2.93–2.99 (6 H, m, H-2Z,E,sat), 4.11–
4.15 (14 H, m, H-(3Z,E,sat),(5sat)), 4.54–4.56 (2 H, m, H-5E), 4.68–4.70 (2 H, m, H-5Z), 5.50–
5.61 (2 H, m, H-7Z,E), 5.68–5.85 (2 H, m, H-6Z,E); δC (100 MHz, CDCl3) 13.1, 13.6, 16.2, 16.3, 
17.7, 18.9, 30.5, 33.6, 33.6, 34.9, 35.0, 61.1, 62.6, 62.6, 62.7, 62.7, 62.7, 65.4, 66.2, 123.6, 124.5, 
130.1, 132.0, 165.7, 165.7, 165.9; δP (162 MHz, CDCl3) 20.3, 20.3, 20.5; HRMS (ESI+): 289a and 
288a: Found: 273.0860; C10H19NaO5P (MNa+) Requires 273.0862 (0.9 ppm error), Found: 
251.1039; C10H20O5P (MH+) Requires 251.1043 (1.6 ppm error); S6: Found: 275.1009; 
C10H21NaO5P (MNa+) Requires 275.1019 (3.5 ppm error), Found: 253.1190; C10H22O5P (MH+) 
Requires 253.1199 (3.7 ppm error). 
Lab notebook reference: MGL/04/78 
Note: NMR assignment labels; Z = 289a, E = 288a, sat = S6. 
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(Z)-But-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (289b), (E)-But-2-en-1-yl 2-
diazo-2-(diethoxyphosphoryl)acetate (288b) and Butyl 2-diazo-2-
(diethoxyphosphoryl)acetate (S7) 
 
  
 
Synthesised using general procedure B with (Z)-but-2-en-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate (289a), (E)-but-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate 
(288a) and butyl 2-diazo-2-(diethoxyphosphoryl)acetate (S6) as a 6:1.5:1 mixture (2.50 g, 10.0 
mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) and p-ABSA (2.88 
g, 12.0 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title 
compounds as an inseparable mixture (289b:288b:S7 4.8:1.2:1) as an orange oil (1.19 g, 43%); Rf 
0.57 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 2984w, 2124s, 1800s, 1445w, 1381w, 1350w, 1271s, 
1214w, 1164w, 1112w, 1015s, 975s, 796m, 743s, 588s, 555s; δH (400 MHz, CDCl3) 0.87 (3 H, t, J 
= 7.4, H-8sat), 1.23–1.67 (28 H, m, H-(4Z,E,sat),(6sat),(7sat),(8Z,E)), 4.04–4.21 (14 H, m, H-
(3Z,E,sat),(5sat)), 4.54–4.56 (2 H, m, H-5E), 4.68–4.70 (2 H, m, H-5Z), 5.44–5.55 (2 H, m, H-
7Z,E), 5.64–5.79 (2 H, m, H-6Z,E); δC (100 MHz, CDCl3) 13.2, 13.6, 16.1, 16.2, 17.8, 19.0, 30.7, 
52.6, 52.6, 52.6, 54.8, 54.9, 61.1, 63.6, 63.6, 63.7, 65.5, 66.2, 123.6, 124.6, 130.4, 132.1, 163.2, 
163.3, 163.4, 163.5, 163.6; δP (162 MHz, CDCl3) 10.5, 10.5, 10.7; HRMS (ESI+): 289b and 288b: 
Found: 299.0760; C10H17N2NaO5P (MNa+) Requires 299.0767 (2.4 ppm error), Found: 277.0945; 
C10H18N2O5P (MH+) Requires 277.0948 (0.9 ppm error); S7: Found: 301.0915; C10H19N2NaO5P 
(MNa+) Requires 301.0924 (2.8 ppm error), Found: 279.1099; C10H20N2O5P (MH+) Requires 
279.1104 (1.8 ppm error). 
Lab notebook reference: MGL/04/92 
Note: NMR assignment labels; Z = 289b, E = 288b, sat = S7. 
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(E)-Hex-2-en-1-yl 2-(diethoxyphosphoryl)acetate (290a) 
 
 
 
Synthesised using general procedure A with (E)-hex-2-en-1-ol 290 (3.00 g, 30.0 mmol), toluene 
(150 mL), DEPAA (5.06 mL, 31.5 mmol), DIPEA (13.6 mL, 78.0 mmol) and T3P (24.8 g, 39.0 
mmol, 50% w/w solution in EtOAc) affording the title compound 290a as a yellow oil (8.34 g, 
100%). No further purification was required; Rf 0.34 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2961m, 2933m, 2872w, 1738s, 1445w, 1393w, 1267s, 1164w, 1115m, 1052m, 1025s, 971s, 839w, 
783w; δH (400 MHz, CDCl3) 0.89 (3 H, t, J = 7.4, H-10), 1.31–1.45 (8 H, m, H-4,9), 2.00–2.05 (2 
H, m, H-8), 2.97 (2 H, d, J = 21.5, H-2), 4.13–4.20 (4 H, m, H-3), 4.58 (2 H, d, J = 6.5, H-5), 5.56 
(1 H, dtt, J = 15.3, J = 6.5, J = 1.4, H-6), 5.79 (1 H, dtt, J = 15.3, J = 6.9, J = 1.2, H-7); δC (100 
MHz, CDCl3) 13.6 (C-10), 16.3 (d, J = 6.2, C-4), 22.0 (C-9), 34.3 (d, J = 134.3, C-2), 34.3 (C-8), 
62.7 (d, J = 6.3, C-3), 66.3 (C-5), 123.3 (C-6), 137.0 (C-7), 165.6 (d, J = 6.2, C-1); δP (162 MHz, 
CDCl3) 20.3; HRMS (ESI+): Found: 301.1183; C12H23NaO5P (MNa+) Requires 301.1175 (−2.7 
ppm error), Found: 279.1365; C12H24O5P (MH+) Requires 279.1356 (−3.3 ppm error). 
Lab notebook reference: MGL/04/63 
(E)-Hex-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (290b) 
 
 
 
Synthesised using general procedure B with (E)-hex-2-en-1-yl 2-(diethoxyphosphoryl)acetate 290a 
(2.78 g, 10.0 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) and p-
ABSA (2.88 g, 12.0 mmol). Purification by column chromatography (2:1 hexane:EtOAc) afforded 
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the title compound 290b as a yellow oil (1.64 g, 54%); Rf 0.55 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2961w, 2933w, 2125s, 1703s, 1445w, 1380w, 1273s, 1215w, 1164w, 1114w, 1019s, 
974s, 797w, 745m, 590m, 560m; δH (400 MHz, CDCl3) 0.88 (3 H, t, J = 7.4, H-10), 1.31–1.43 (8 
H, m, H-4,9), 1.99–2.05 (2 H, m, H-8), 4.10–4.25 (4 H, m, H-3), 4.62 (2 H, app. dq, J = 6.5, J = 
1.0, H-5), 5.54 (1 H, dtt, J = 15.3, J = 6.5, J = 1.4, H-6), 5.78 (1 H, dtt, J = 15.3, J = 6.9, J = 1.2, H-
7); δC (100 MHz, CDCl3) 13.5 (C-10), 16.1 (d, J = 7.1, C-4), 21.9 (C-9), 34.2 (C-8), 53.6 (d, J = 
225.1, C-2), 63.6 (d, J = 6.0, C-3), 66.3 (C-5), 123.3 (C-6), 137.2 (C-7), 163.2 (d, J = 12.2, C-1); δP 
(162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 327.1095; C12H21N2NaO5P (MNa+) Requires 
327.1080 (−4.3 ppm error). 
Lab notebook reference: MGL/04/70 
(Z)-Hex-2-en-1-yl 2-(diethoxyphosphoryl)acetate (291a) 
 
 
 
Synthesised using general procedure A with (Z)-hex-2-en-1-ol 291 (2.16 g, 21.6 mmol), toluene 
(110 mL), DEPAA (3.65 mL, 22.7 mmol), DIPEA (9.78 mL, 56.2 mmol) and T3P (17.8 g, 28.0 
mmol, 50% w/w solution in THF) affording the title compound 291a as a yellow oil (1.87 g, 79%). 
No further purification was required; Rf 0.70 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2963m, 
2933m, 2874w, 1738s, 1460w, 1394w, 1267s, 1115m, 1056m, 1026s, 971s, 842w, 782w; δH (400 
MHz, CDCl3) 0.90 (3 H, t, 3JHH 7.4, H-10), 1.32–1.44 (8 H, m, H-4,9), 2.05–2.11 (2 H, m, H-8), 
2.97 (2 H, d, 2JHP 21.5, H-2), 4.13–4.21 (4 H, m, H-3), 4.69 (2 H, dd, 3JHH 6.9, H-5), 5.54 (1 H, dtt, 
3JHH 10.9, 3JHH 6.9, 4JHH 1.4, H-6), 5.66 (1 H, dtt, 3JHH 10.9, 3JHH 7.5, 4JHH 1.2, H-7); δC (100 MHz, 
CDCl3) 13.6 (C-10), 16.3 (d, 3JCP 6.2, C-4), 22.5 (C-9), 29.5 (C-8), 34.3 (d, 1JCP 134.3, C-2), 61.4 
(C-5), 62.7 (d, 2JCP 6.2, C-3), 122.8 (C-6), 135.6 (C-7), 165.7 (d, 2JCP 6.2, C-1); δP (162 MHz, 
CDCl3) 20.3; HRMS (ESI+): Found: 301.1181; C12H23NaO5P (MNa+) Requires 301.1175 (−1.8 
ppm error), Found: 279.1361; C12H24O5P (MH+) Requires 279.1356 (−2.0 ppm error). 
Note: This compound was synthesised by William P. Unsworth. 
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(Z)-Hex-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (291b) 
 
 
 
Synthesised using general procedure B with (Z)-hex-2-en-1-yl 2-(diethoxyphosphoryl)acetate 291a 
(385 mg, 1.38 mmol), THF (50 mL), NaH (66.4 mg, 1.66 mmol, 60% dispersion in mineral oil).   
and p-ABSA (399 mg, 1.66 mmol). Purification by column chromatography (3:1 petrol:EtOAc) 
afforded the title compound 291b as a yellow oil (315 mg, 75%); Rf 0.52 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2962w, 2128s, 1709s, 1445w, 1361w, 1279s, 1164w, 1023s, 978m; δH (400 MHz, 
CDCl3) 0.88 (3 H, t, J = 7.4, H-10), 1.30–1.43 (8 H, m, H-4,9), 2.07 (2 H, qd, J = 7.4, J = 1.3, H-8), 
4.09–4.25 (4 H, m, H-3), 4.72–4.74 (2 H, m, H-5), 5.52 (1 H, dtt, J = 10.9, J = 6.9, J = 1.5, H-6), 
5.65 (1 H, dtt, J = 10.9, J = 7.6, J = 1.3, H-7); δC (100 MHz, CDCl3) 13.5 (C-10), 16.1 (d, J = 6.9, 
C-4), 22.4 (C-9), 29.4 (C-8), 53.8 (d, J = 227.5, C-2), 61.3 (C-5), 63.6 (d, J = 6.0, C-3), 122.8 (C-
6), 136.0 (C-7), 163.3 (d, J = 12.3, C-1); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 
327.1087; C12H21N2NaO5P (MNa+) Requires 327.1080 (−2.1 ppm error), Found: 305.1262; 
C12H22N2O5P (MH+) Requires 305.1261 (−0.5 ppm error). 
Note: This compound was synthesised by William P. Unsworth. 
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Diethyl ((1RS,5SR,6SR)-2-oxo-6-propyl-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 
(291c) 
 
 
 
Synthesised using general procedure F with (Z)-hex-2-en-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 291b (212 mg, 0.697 mmol), CH2Cl2 (7.0 mL) and Rh2(oct)4 (10.8 
mg, 13.9 µmol). Purification by column chromatography (1:10 hexane:EtOAc) afforded the title 
compound 291c as a pale yellow oil (128 mg, 66%); Rf 0.15 (1:2 hexane:EtOAc); νmax (thin 
film)/cm-1 2963w, 2934w, 2874w, 1764s, 1468w, 1371w, 1254m, 1197w, 1164w, 1130w, 1022s, 
976m; δH (400 MHz, CDCl3) 0.97 (3 H, t, J = 7.1, H-10), 1.29–1.56 (10 H, m, H-7/7’,8,9), 2.02–
2.11 (1 H, m, H-5), 2.70 (1 H, dddd, J = 11.2, J = 8.0, J = 5.4, J = 0.9, H-3), 4.13–4.29 (5 H, m, H-
4/4’,6,6’), 4.42 (1 H, dd, J = 10.0, J = 5.4, H-4/4’); δC (100 MHz, CDCl3) 13.7 (C-10), 16.3 (d, J = 
6.1, C-7/7’), 16.3 (d, J = 6.1, C-7/7’), 21.9 (C-9), 24.9 (C-8), 28.1 (d, J = 2.3, C-5), 28.1 (d, J = 
203.3, C-2), 29.5 (d, J = 2.5, C-3), 63.1 (d, J = 6.3, C-6/6’), 63.2 (d, J = 6.2, C-6/6’), 64.6 (d, J = 
3.0, C-4), 170.5 (d, J = 10.0, C-1); δP (162 MHz, CDCl3) 18.8; HRMS (ESI+): Found: 299.1026; 
C12H21NaO5P (MNa+) Requires 299.1019 (−2.5 ppm error), Found: 277.1212; C12H22O5P (MH+) 
Requires 277.1199 (−4.5 ppm error). 
Lab notebook reference: MGL/04/89 
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(2E,4E)-Hexa-2,4-dien-1-yl 2-(diethoxyphosphoryl)acetate (292a) 
 
 
 
Synthesised using general procedure A with (2E,4E)-hexa-2,4-dien-1-ol 292 (491 mg, 5.00 mmol), 
toluene (25.0 mL), DEPAA (1.03 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 292a as an orange oil (1.36 
g, 98%). No further purification was required; Rf 0.26 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2984w, 2934w, 1735s, 1444w, 1393w, 1258s, 1112s, 1020s, 965s; δH (400 MHz, CDCl3) 1.31 (6 
H, t, J = 7.1, H-4), 1.73 (3 H, d, J = 6.7, H-10), 2.95 (2 H, d, J = 21.5, H-2), 4.14 (4 H, app. quin., J 
= 7.5, H-3), 4.61 (2 H, d, J = 6.7, H-5), 5.58 (1 H, dt, J = 15.2, J = 6.7, H-6), 5.73 (1 H, dq, J = 
15.2, J = 6.7, H-9), 6.01 (1 H, ddd, J = 15.2, J = 10.5, J = 1.2, H-8), 6.24 (1 H, dd, J = 15.2, J = 
10.5, H-7); δC (100 MHz, CDCl3) 16.2 (d, J = 6.6, C-4), 18.1 (C-10), 34.3 (d, J = 134.2, C-2), 62.6 
(d, J = 6.6, C-3), 65.9 (C-5), 122.8 (C-6), 130.2 (C-8), 131.6 (C-9), 135.4 (C-7), 165.5 (d, J = 6.1, 
C-1); δP (162 MHz, CDCl3) 20.2; HRMS (ESI+): Found: 299.1026; C12H21NaO5P (MNa+) Requires 
299.1019 (−2.4 ppm error). 
Lab notebook reference: MGL/08/76 
(2E,4E)-Hexa-2,4-dien-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (292b) 
 
 
 
Synthesised using general procedure C with (2E,4E)-hexa-2,4-dien-1-yl 2-
(diethoxyphosphoryl)acetate 292a (1.36 g, 4.92 mmol), DBSA (2.47 g, 7.38 mmol), DBU (1.10 
mL, 7.38 mmol) and CH2Cl2 (49.0 mL). Purification by column chromatography (2:1 
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hexane:EtOAc) afforded the title compound 292b as a yellow oil (1.54 g, 75%); Rf 0.43 (1:1 
hexane:EtOAc); νmax (thin film)/cm-1 2985w, 2127s, 1705s, 1445w, 1375w, 1274s, 1113m, 1020s, 
797m, 745m, 590m, 561m; δH (400 MHz, CDCl3) 1.34 (6 H, td, J = 7.1, J = 0.7, H-4), 1.75 (3 H, 
dd, J = 6.7, J = 1.0, H-10), 4.09–4.25 (4 H, m, H-3), 4.68 (2 H, d, J = 6.7, H-5), 5.60 (1 H, dt, J = 
15.2, J = 6.7, H-6), 5.75 (1 H, dq, J = 15.2, J = 6.7, H-9), 6.00–6.07 (1 H, m, H-8), 6.26 (1 H, dd, J 
= 15.2, J = 10.5, H-7); δC (100 MHz, CDCl3) 16.1 (d, J = 7.1, C-4), 18.1 (C-10), 63.6 (d, J = 5.9, 
C-3), 66.0 (C-5), 122.8 (C-6), 130.2 (C-8), 131.8 (C-9), 135.6 (C-7), 163.2 (d, J = 12.6, C-1); δP 
(162 MHz, CDCl3) 10.6; HRMS (ESI+): Found: 325.0930; C12H19N2NaO5P (MNa+) Requires 
325.0924 (−1.9 ppm error). 
Lab notebook reference: MGL/08/82 
Note: C-2 not observed in 13C NMR spectrum. 
Diethyl ((1RS,5SR,6RS)-2-oxo-6-((E)-prop-1-en-1-yl)-3-oxabicyclo[3.1.0]hexan-1-
yl)phosphonate (292c) 
 
 
 
Synthesised using general procedure F with (2E,4E)-hexa-2,4-dien-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 292b (68.6 mg, 0.250 mmol), CH2Cl2 (5.0 mL) and Rh2(oct)4 (4.0 mg, 
5.0 µmol). Purification by column chromatography (1:10 hexane:EtOAc) afforded the title 
compound 292c as a pale yellow oil (33 mg, 48%); Rf 0.34 (EtOAc); νmax (thin film)/cm-1 2983w, 
1767s, 1370w, 1276m, 1246s, 1157m, 1025s, 971s, 590m; δH (400 MHz, CDCl3) 1.32 (3 H, t, J = 
7.1, H-4/4’), 1.33 (3 H, t, J = 7.1, H-4/4’), 1.72 (3 H, dd, J = 6.5, J = 1.6, H-10), 2.17 (1 H, ddd, J = 
9.4, J = 6.0, J = 5.3, H-7), 2.73 (1 H, app. dt, J = 10.3, J = 5.0, H-6), 4.14–4.22 (4 H, m, H-3,3’), 
4.27 (1 H, dd, J = 9.4, J = 3.0, H-5), 4.34 (1 H, dd, J = 9.4, J = 4.6, H-5), 5.60 (1 H, ddq, J = 15.3, 
J = 9.4, J = 1.6, H-8), 5.80 (1 H, dq, J = 15.3, J = 6.5, H-9); δC (100 MHz, CDCl3) 16.2 (C-4/4’), 
16.3 (C-4/4’), 17.9 (C-10), 29.5 (d, J = 202.7, C-2), 30.3 (C-6), 34.6 (d, J = 2.8, C-7), 62.8 (d, J = 
6.5, C-3/3’), 63.1 (d, J = 6.4, C-3/3’), 67.7 (d, J = 2.9, C-5), 124.3 (d, J = 4.8, C-8), 130.8 (C-9), 
171.7 (d, J = 9.1, C-1); δP (162 MHz, CDCl3) 16.5; HRMS (ESI+): Found: 297.0866; C12H19NaO5P 
(MNa+) Requires 297.0862 (−1.1 ppm error), Found: 275.1044; C12H20O5P (MH+) Requires 
275.1043 (−0.3 ppm error). 
Lab notebook reference: MGL/08/90 
Rh2(oct)4
CH2Cl2
292b
O
O
P O
O
O
Me
N2
4'
7
1 2
65
292c
3'
O
O
P
H
O O
O 4
3
Me
8
9 10
  303 
3-Methyl-but-2-en-1-yl 2-(diethoxyphosphoryl)acetate (293a) 
 
 
 
Synthesised using general procedure A with 3-methyl-but-2-en-1-ol 293 (431 mg, 5.00 mmol), 
toluene (25.0 mL), DEPAA (1.03 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 
6.50 mmol, 50% w/w solution in EtOAc) affording the title compound 293a as a yellow oil (1.25 g, 
95%). No further purification was required; Rf 0.24 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2982m, 2933w, 1734s, 1445w, 1392w, 1264s, 1113m, 1051w, 1029s, 968s; δH (400 MHz, CDCl3) 
1.33 (6 H, t, J = 7.1, H-4), 1.70 (3 H, s, H-8/9), 1.74 (3 H, s, H-8/9), 2.95 (2 H, d, J = 21.5, H-2), 
4.12–4.19 (4 H, m, H-3), 4.62 (2 H, d, J = 7.3, H-5), 5.31–5.36 (1 H, m, H-6); δC (100 MHz, 
CDCl3) 16.3 (d, J = 6.7, C-4), 18.0 (C-8/9), 25.7 (C-8/9), 34.3 (d, J = 134.5, C-2), 62.4 (C-5), 62.6 
(d, J = 6.6, C-3), 118.0 (C-6), 139.7 (C-7), 165.8 (d, J = 6.5, C-1); δP (162 MHz, CDCl3) 20.4; 
HRMS (ESI+): Found: 287.1021; C11H21NaO5P (MNa+) Requires 287.1019 (−0.9 ppm error). 
Lab notebook reference: MGL/08/87-1 
3-Methyl-but-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (293b) 
 
 
 
Synthesised using general procedure C with 3-methyl-but-2-en-1-yl 2-(diethoxyphosphoryl)acetate 
293a (1.24 g, 4.69 mmol), DBSA (2.35 g, 7.04 mmol), DBU (1.05 mL, 7.04 mmol) and CH2Cl2 
(47.0 mL). Purification by column chromatography (2:1 hexane:EtOAc) afforded the title 
compound 293b as a pale yellow oil (1.15 g, 85%); Rf 0.39 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2983m, 2933w, 2124s, 1700s, 1445w, 1374w, 1271s, 1110w, 1016s, 976s, 746s, 588s, 
556s; δH (400 MHz, CDCl3) 1.34 (6 H, t, J = 7.1, H-4), 1.70 (3 H, s, H-8/9), 1.74 (3 H, s, H-8/9), 
4.09–4.25 (4 H, m, H-3), 4.68 (2 H, d, J = 7.3, H-5), 5.29–5.35 (1 H, m, H-6); δC (100 MHz, 
CDCl3) 16.1 (d, J = 7.3, C-4), 18.0 (C-8/9), 25.7 (C-8/9), 62.4 (C-5), 63.6 (d, J = 5.9, C-3), 118.0 
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(C-6), 139.9 (C-7), 163.4 (d, J = 12.7, C-1); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 
313.0928; C11H19N2NaO5P (MNa+) Requires 313.0924 (−1.4 ppm error). 
Lab notebook reference: MGL/08/87-2 
Note: C-2 not observed in 13C NMR spectrum. 
Diethyl ((1SR,5SR)-6,6-dimethyl-2-oxo-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 
(293c) 
 
 
 
ynthesised using general procedure F with 3-methyl-but-2-en-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 293b (74.0 mg, 0.255 mmol), CH2Cl2 (5.1 mL) and Rh2(oct)4 (4.0 mg, 
5.1 µmol). Purification by column chromatography (1:10 hexane:EtOAc) afforded the title 
compound 293c as a pale yellow oil (39 mg, 58%); Rf 0.27 (EtOAc); νmax (thin film)/cm-1 2985w, 
1764s, 1389w, 1364w, 1260s, 1181s, 1052s, 1025s, 995s, 971s, 591m; δH (400 MHz, CDCl3) 1.24 
(3 H, s, H-8/9), 1.32 (3 H, t, J = 7.1, H-4/4’), 1.35 (3 H, t, J = 7.1, H-4/4’), 1.50 (3 H, s, H-8/9), 
2.58 (1 H, dd, J = 12.2, J = 5.3, H-6), 4.12–4.27 (5 H, m, H-3,3’,5), 4.38 (1 H, dd, J = 10.0, J = 5.3, 
H-5); δC (100 MHz, CDCl3) 16.3 (d, J = 6.2, C-4/4’), 16.3 (d, J = 6.8, C-4/4’), 16.5 (C-8/9), 21.6 
(d, J = 4.8, C-8/9), 30.0 (d, J = 2.8, C-7), 33.9 (d, J = 197.6, C-2), 36.3 (d, J = 3.8, C-6), 62.6 (d, J 
= 6.5, C-3/3’), 62.9 (d, J = 6.8, C-3/3’), 65.2 (d, J = 2.9, C-5), 171.4 (d, J = 9.8, C-1); δP (162 MHz, 
CDCl3) 18.6; HRMS (ESI+): Found: 285.0865; C11H19NaO5P (MNa+) Requires 285.0862 (−1.1 
ppm error), Found: 263.1043; C11H20O5P (MH+) Requires 263.1043 (−0.2 ppm error). 
Lab notebook reference: MGL/08/92 
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(E)-3,7-Dimethylocta-2,6-dien-1-yl 2-(diethoxyphosphoryl)acetate (294a) 
 
 
 
Synthesised using general procedure A with geraniol 294 (771 mg, 5.00 mmol), toluene (25.0 mL), 
DEPAA (1.03 mL, 5.25 mmol), DIPEA (2.26 mL, 13.0 mmol) and T3P (4.14 g, 6.50 mmol, 50% 
w/w solution in EtOAc) affording the title compound 294a as an orange oil (1.65 g, 99%). No 
further purification was required; Rf 0.27 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2980w, 2928w, 
1735s, 1444w, 1391w, 1263s, 1112m, 1051w, 1025s, 966s; δH (400 MHz, CDCl3) 1.32 (6 H, t, J = 
7.1, H-4), 1.58 (3 H, s, H-13/14), 1.67 (3 H, d, J = 0.9, H-13/14), 1.69 (3 H, d, J = 0.9, H-8), 2.00–
2.09 (4 H, m, H-9,10), 2.96 (2 H, d, J = 21.5, H-2), 4.16 (4 H, app. quin., J = 7.4, H-3), 4.64 (2 H, 
d, J = 7.2, H-5), 5.04–5.08 (1 H, m, H-11), 5.31–5.36 (1 H, m, H-6); δC (100 MHz, CDCl3) 16.3 (d, 
J = 6.6, C-4), 16.4 (C-8), 17.6 (C-13/14), 25.6 (C-13/14), 26.2 (C-10), 34.3 (d, J = 134.2, C-2), 
39.5 (C-9), 62.4 (C-5), 62.6 (d, J = 6.2, C-3), 117.7 (C-6), 123.6 (C-11), 131.9 (C-7/12), 142.9 (C-
7/12), 165.8 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): Found: 355.1644; 
C16H29NaO5P (MNa+) Requires 355.1645 (0.3 ppm error). 
Lab notebook reference: MGL/08/59 
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(E)-3,7-Dimethylocta-2,6-dien-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (294b) 
 
 
 
Synthesised using general procedure C with (E)-3,7-dimethylocta-2,6-dien-1-yl 2-
(diethoxyphosphoryl)acetate 294a (1.65 g, 4.96 mmol), p-ABSA (1.79 g, 7.45 mmol), DBU (1.11 
mL, 7.45 mmol) and CH2Cl2 (50.0 mL). Purification by column chromatography (2:1 
hexane:EtOAc) afforded the title compound 294b as a yellow oil (1.12 g, 63%); Rf 0.56 (1:1 
hexane:EtOAc); νmax (thin film)/cm-1 2981w, 2915w, 2124s, 1701s, 1444w, 1378w, 1273s, 1021s, 
975s, 797m, 744m, 588m, 559m; δH (400 MHz, CDCl3) 1.32 (6 H, td, J = 7.1, J = 0.8, H-4), 1.56 (3 
H, s, H-13/14), 1.64 (3 H, d, J = 1.0, H-13/14), 1.68 (3 H, d, J = 1.1, H-8), 1.98–2.08 (4 H, m, H-
9,10), 4.08–4.23 (4 H, m, H-3), 4.68 (2 H, d, J = 7.2, H-5), 5.01–5.05 (1 H, m, H-11), 5.28–5.32 (1 
H, m, H-6); δC (100 MHz, CDCl3) 16.0 (d, J = 6.9, C-4), 16.4 (C-8), 17.5 (C-13/14), 25.5 (C-
13/14), 26.1 (C-10), 39.4 (C-9), 53.5 (d, J = 227.1, C-2), 62.3 (C-5), 63.5 (d, J = 5.9, C-3), 117.6 
(C-6), 123.5 (C-11), 131.8 (C-7/12), 143.0 (C-7/12), 163.3 (d, J = 12.6, C-1); δP (162 MHz, CDCl3) 
10.7; HRMS (ESI+): Found: 381.1549; C16H27N2NaO5P (MNa+) Requires 381.1550 (0.3 ppm 
error). 
Lab notebook reference: MGL/08/61 
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Diethyl ((1SR,5SR,6RS)-6-methyl-6-(4-methylpent-3-en-1-yl)-2-oxo-3-
oxabicyclo[3.1.0]hexan-1-yl)phosphonate (294c) 
 
 
 
Synthesised using general procedure F with (E)-3,7-dimethylocta-2,6-dien-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 294b (71.7 mg, 0.200 mmol), CH2Cl2 (4.0 mL) and Rh2(oct)4 (3.1 mg, 
4.0 µmol). Purification by column chromatography (2:1 → 1:1 hexane:EtOAc) afforded the title 
compound 294c as a pale yellow oil (42 mg, 64%); Rf 0.20 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2977w, 2912w, 1764s, 1445w, 1391w, 1366w, 1255s, 1172s, 1051s, 1023s, 993m, 
970m, 597m; δH (400 MHz, CDCl3) 1.24 (3 H, d, J = 0.6, H-8), 1.33 (3 H, t, J = 7.1, H-4/4’), 1.36 
(3 H, t, J = 7.1, H-4/4’), 1.60 (3 H, s, H-13/14), 1.65 (3 H, d, J = 0.5, H-13/14), 1.76–1.93 (2 H, m, 
H-9), 2.03–2.12 (1 H, m, H-10), 2.17–2.26 (1 H, m, H-10), 2.59 (1 H, ddd, J = 12.5, J = 5.3, J = 
0.5, H-6), 4.11–4.29 (5 H, m, H-3,3’,5), 4.40 (1 H, dd, J = 10.0, J = 5.3, H-5), 5.05–5.10 (1 H, m, 
H-11); δC (100 MHz, CDCl3) 13.4 (C-8), 16.3 (C-4/4’), 16.3 (C-4/4’), 17.6 (C-13/14), 25.3 (C-10), 
25.6 (C-13/14), 33.8 (d, J = 1.9, C-7), 34.2 (d, J = 198.2, C-2), 34.4 (d, J = 4.2, C-9), 35.7 (d, J = 
3.6, C-6), 62.6 (d, J = 6.6, C-3/3’), 63.0 (d, J = 6.6, C-3/3’), 65.2 (d, J = 2.1, C-5), 123.2 (C-11), 
132.2 (C-12), 171.4 (d, J = 9.6, C-1); δP (162 MHz, CDCl3) 18.8; HRMS (ESI+): Found: 353.1493; 
C16H27NaO5P (MNa+) Requires 353.1488 (−1.2 ppm error), Found: 331.1668; C16H28O5P (MH+) 
Requires 331.1669 (0.1 ppm error). 
Lab notebook reference: MGL/08/62 
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Cyclohex-2-en-1-yl 2-(diethoxyphosphoryl)acetate (295a) 
 
 
 
Synthesised using general procedure A with cyclohex-2-en-1-ol 295 (481 mg, 4.90 mmol), toluene 
(24.5 mL), DEPAA (1.01 mL, 5.15 mmol), DIPEA (2.22 mL, 12.7 mmol) and T3P (4.05 g, 6.37 
mmol, 50% w/w solution in EtOAc) affording the title compound 295a as an orange oil (1.26 g, 
93%). No further purification was required; Rf 0.23 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2937s, 1730s, 1394w, 1270s, 1113m, 1050m, 1025s, 968s; δH (400 MHz, CDCl3) 1.29–1.33 (6 H, 
m, H-4,4’), 1.55–1.64 (1 H, m), 1.66–1.77 (2 H, m), 1.79–1.87 (1 H, m), 1.91–2.10 (2 H, m), 2.93 
(2 H, d, J = 21.5, H-2), 4.10–4.17 (4 H, m, H-3,3’), 5.25–5.29 (1 H, m, H-5), 5.67 (1 H, ddt, J = 
10.1, J = 3.8, J = 2.0, H-6), 5.94 (1 H, m, H-7); δC (100 MHz, CDCl3) 16.2 (2C, d, J = 6.8, C-4,4’), 
16.3 (C-8/9/10), 24.7 (C-8/9/10), 28.0 (C-8/9/10), 34.5 (d, J = 133.4, C-2), 62.5 (2C, d, J = 6.4, C-
3,3’), 69.2 (C-5), 124.9 (C-6), 133.1 (C-7), 165.5 (d, J = 6.6, C-1); δP (162 MHz, CDCl3) 20.5; 
HRMS (ESI+): Found: 299.1018; C12H21NaO5P (MNa+) Requires 299.1019 (0.1 ppm error). 
Lab notebook reference: MGL/08/56 
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Cyclohex-2-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate (295b) 
 
 
 
Synthesised using general procedure C with cyclohex-2-en-1-yl 2-(diethoxyphosphoryl)acetate 
295a (1.26 g, 4.56 mmol), p-ABSA (1.64 g, 6.84 mmol), DBU (1.02 mL, 6.84 mmol) and CH2Cl2 
(46.0 mL). Purification by column chromatography (1:1 hexane:EtOAc) afforded the title 
compound 295b as a yellow oil (1.04 g, 75%); Rf 0.49 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2984w, 2939w, 2124s, 1694s, 1270s, 1118m, 1016s, 976s, 908m, 794m, 747m, 588m, 557m; δH 
(400 MHz, CDCl3) 1.31 (3 H, td, J = 7.1, J = 0.8, H-4/4’), 1.32 (3 H, td, J = 7.1, J = 0.8, H-4/4’), 
1.56–1.78 (3 H, m), 1.80–1.88 (1 H, m), 1.91–2.10 (2 H, m), 4.07–4.23 (4 H, m, H-3,3’), 5.29–5.33 
(1 H, m, H-5), 5.69 (1 H, ddt, J = 10.1, J = 3.9, J = 2.0, H-6), 5.94 (1 H, m, H-7); δC (100 MHz, 
CDCl3) 16.0–16.2 (2C, m, C-4,4’), 16.4 (C-8/9/10), 24.7 (C-8/9/10), 28.2 (C-8/9/10), 53.8 (d, J = 
224.3, C-2), 63.4–63.5 (2C, m, C-3,3’), 69.4 (C-5), 124.9 (C-6), 133.3 (C-7), 163.1 (d, J = 12.4, C-
1); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 325.0932; C12H19N2NaO5P (MNa+) Requires 
325.0924 (−2.5 ppm error). 
Lab notebook reference: MGL/08/57 
Diethyl ((2a1SR,2bSR,5aRS)-2-oxooctahydrocyclopropa[cd]benzofuran-2a-
yl)phosphonate (295c) 
 
 
 
Synthesised using general procedure F with cyclohex-2-en-1-yl 2-diazo-2-
(diethoxyphosphoryl)acetate 295b (60 mg, 0.200 mmol), CH2Cl2 (4.0 mL) and Rh2(oct)4 (3.1 mg, 
4.0 µmol). Purification by column chromatography (1:1 hexane:EtOAc) afforded the title 
compound 295c as a pale yellow oil (13 mg, 24%); Rf 0.10 (1:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2952w, 1759s, 1252m, 1161m, 1023s, 970s, 586m; δH (400 MHz, CDCl3) 1.35 (3 H, t, J 
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= 7.0, H-4/4’), 1.37 (3 H, td, J = 7.0, H-4/4’), 1.44–1.66 (3 H, m), 1.73–1.81 (1 H, m), 1.87–1.95 (1 
H, m), 2.10–2.27 (2 H, m, H-7,8/9), 2.79 (1 H, ddd, J = 11.7, J = 7.9, J = 6.0, H-6), 4.15–4.28 (4 H, 
m, H-3,3’), 4.93 (1 H, app. dt, J = 5.7, J = 2.7, H-5); δC (100 MHz, CDCl3) 14.1 (C-9), 16.3 (d, J = 
6.1, C-4,4’), 17.7 (d, J = 2.8, C-8), 24.4 (d, J = 1.9, C-10), 24.6 (d, J = 1.8, C-7), 29.3 (d, J = 200.1, 
C-2), 29.3 (d, J = 3.7, C-6), 63.1–63.2 (m, C-3,3’) 72.5 (d, J = 4.8, C-5), 171.0 (d, J = 9.5, C-1); δP 
(162 MHz, CDCl3) 18.9; HRMS (ESI+): Found: 297.0857; C12H19NaO5P (MNa+) Requires 
297.0862 (1.8 ppm error). 
Lab notebook reference: MGL/08/60 
Cinnamyl 2-(diethoxyphosphoryl)acetate (296a) 
 
 
 
Synthesised using general procedure A with cinnamyl alcohol 296 (4.03 g, 30.0 mmol), toluene 
(150 mL), DEPAA (5.06 mL, 31.5 mmol), DIPEA (13.6 mL, 78.0 mmol) and T3P (24.8 g, 39.0 
mmol, 50% w/w solution in EtOAc) affording the title compound 296a as a yellow oil (7.14 g, 
76%). No further purification was required; Rf 0.23 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2984w, 1737s, 1449w, 1393w, 1264s, 1163w, 1114m, 1050m, 1023s, 968s; δH (400 MHz, CDCl3) 
1.33 (6 H, t, J = 7.0, H-4), 3.01 (2 H, d, J = 21.6, H-2), 4.13–4.21 (4 H, m, H-3), 4.80 (2 H, dd, J = 
6.5, J = 1.2, H-5), 6.27 (1 H, dt, J = 15.9, J = 6.5, H-6), 6.68 (1 H, d, J = 15.9, H-7), 7.24–7.28 (1 
H, m, H-11), 7.30–7.34 (2 H, m, H-10), 7.36–7.39 (2 H, m, H-9); δC (100 MHz, CDCl3) 16.3 (d, J 
= 6.2, C-4), 34.3 (d, J = 134.2, C-2), 62.7 (d, J = 6.5, C-3), 66.0 (C-5), 122.4 (C-6), 126.6 (C-9), 
128.1 (C-11), 128.6 (C-10), 134.7 (C-7), 136.0 (C-8), 165.6 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 
20.2; HRMS (ESI+): Found: 335.1027; C15H21NaO5P (MNa+) Requires 335.1019 (−2.4 ppm error), 
Found: 313.1197; C15H22O5P (MH+) Requires 313.1199 (0.7 ppm error). 
Lab notebook reference: MGL/04/48 
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Cinnamyl 2-diazo-2-(diethoxyphosphoryl)acetate (296b) 
 
 
 
Synthesised using general procedure B with cinnamyl 2-(diethoxyphosphoryl)acetate 296a (3.12 g, 
10.0 mmol), THF (50 mL), LHMDS (12.0 mL, 12.0 mmol, 1.0 M solution in THF) and p-ABSA 
(2.88 g, 12.0 mmol). Purification by column chromatography (2:1 petrol:EtOAc) afforded the title 
compound 296b as a yellow oil (1.41 g, 42%); Rf 0.50 (1:1 petrol:EtOAc); νmax (thin film)/cm-1 
2985w, 2128s, 1707s, 1496w, 1449w, 1380w, 1275s, 1214w, 1164w, 1120w, 1020s, 975m; δH 
(400 MHz, CDCl3) 1.36 (6 H, t, J = 7.1, J = 0.8, H-4), 4.11–4.29 (4 H, m, H-3), 4.86 (2 H, dd, J = 
6.5, J = 1.3, H-5), 6.28 (1 H, dt, J = 15.9, J = 6.5, H-6), 6.68 (1 H, d, J = 15.9, H-7), 7.25–7.40 (5 
H, m, H-9,10,11); δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 53.9 (d, J = 227.3, C-2), 63.7 (d, J = 
5.6, C-3), 66.0 (C-5), 122.4 (C-6), 126.6 (C-9), 128.2 (C-11), 128.6 (C-10), 134.9 (C-7), 135.9 (C-
8), 163.2 (d, J = 11.8, C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 361.0928; 
C15H19N2NaO5P (MNa+) Requires 361.0924 (−1.0 ppm error). 
Lab notebook reference: MGL/04/59 
Diethyl ((1RS,5SR,6SR)-2-oxo-6-phenyl-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 
(296c) 
 
 
 
To an oven dried 50 mL rbf containing cinnamyl 2-diazo-2-(diethoxyphosphoryl)acetate 296b (676 
mg, 2.00 mmol) flushed with argon was added CH2Cl2 (20 mL) followed by Rh2(oct)4 (31.1 mg, 
0.04 mmol). The solution was stirred at 45 °C for 18 h. Concentration in vacuo and purification by 
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column chromatography (1:10 hexane:EtOAc) afforded the title compound 296c as a pale yellow 
solid (490 mg, 79%); Rf 0.15 (1:2 hexane:EtOAc); m.p. 79–81 °C; νmax (thin film)/cm-1 2989w, 
2909w, 1762s, 1369w, 1251m, 1200w, 1163w, 1098w, 1049w, 1013s, 971s; δH (400 MHz, CDCl3) 
1.07 (3 H, td, J = 7.1, J = 0.5, H-7/7’), 1.21 (3 H, t, J = 7.1, H-7/7’), 2.81 (1 H, app. t, J = 6.1, H-5), 
3.30 (1 H, app. dt, J = 10.6, J = 5.2, H-3), 3.80 (2 H, dq, J = 8.2, J = 7.1, H-6/6’), 3.88–4.08 (2 H, 
m, H-6/6’), 4.41 (1 H, dd, J = 9.3, J = 2.8, H-4), 4.51 (1 H, dd, J = 9.3, J = 4.7, H-4), 7.26–7.39 (5 
H, m, H-9,10,11); δC (100 MHz, CDCl3) 16.0 (d, J = 6.3, C-7/7’), 16.2 (d, J = 5.9, C-7/7’), 28.1 (C-
3), 31.5 (d, J = 206.1, C-2), 34.9 (d, J = 3.0, C-5), 62.5 (d, J = 6.1, C-6/6’), 62.8 (d, J = 6.6, C-
6/6’), 68.0 (d, J = 2.4, C-4), 128.0 (C-11), 128.1 (C-10), 129.4 (C-9), 131.7 (d, J = 4.8, C-8), 171.9 
(d, J = 10.1, C-1); δP (162 MHz, CDCl3) 15.3; HRMS (ESI+): Found: 333.0861; C15H19NaO5P 
(MNa+) Requires 333.0862 (0.4 ppm error), Found: 311.1035; C15H20O5P (MH+) Requires 
311.1043 (2.5 ppm error). 
Lab notebook reference: MGL/04/67,61 
(E)-3-(4-Methoxyphenyl)allyl 2-(diethoxyphosphoryl)acetate (297a) 
 
 
 
Synthesised using general procedure A with (E)-3-(4-methoxyphenyl)prop-2-en-1-ol 297 (1.37 g, 
8.34 mmol), toluene (41.7 mL), DEPAA (1.72 g, 8.76 mmol), DIPEA (3.78 mL, 21.7 mmol) and 
T3P (6.90 g, 10.8 mmol, 50% w/w solution in EtOAc) affording the title compound 297a as an 
orange oil (2.79 g, 98%). No further purification was required; Rf 0.20 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2983w, 1733s, 1607m, 1512s, 1247s, 1176m, 1114m, 1023s, 966s, 841m; δH (400 
MHz, CDCl3) 1.32 (6 H, t, J = 7.1, H-4), 3.00 (2 H, d, J = 21.5, H-2), 3.80 (3 H, s, H-12), 4.13–
4.20 (4 H, m, H-3), 4.77 (2 H, d, J = 6.7, H-5), 6.14 (1 H, dt, J = 15.8, J = 6.7, H-6), 6.62 (1 H, d, J 
= 15.8, H-7), 6.85 (2 H, d, J = 8.3, H-10), 7.31 (2 H, d, J = 8.3, H-9); δC (100 MHz, CDCl3) 16.3 
(d, J = 6.6, C-4), 34.3 (d, J = 134.2, C-2), 55.2 (C-12), 62.7 (d, J = 6.7, C-3), 66.3 (C-5), 114.0 (C-
10), 120.0 (C-6), 127.8 (C-9), 128.7 (C-8), 134.5 (C-7), 160.0 (C-11), 165.7 (d, J = 6.5, C-1); δP 
(162 MHz, CDCl3) 20.2; HRMS (ESI+): Found: 365.1129; C16H23NaO6P (MNa+) Requires 
365.1124 (−1.2 ppm error). 
Lab notebook reference: MGL/08/74 
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(E)-3-(4-Methoxyphenyl)allyl 2-diazo-2-(diethoxyphosphoryl)acetate (297b) 
 
 
 
Synthesised using general procedure C with (E)-3-(4-methoxyphenyl)allyl 2-
(diethoxyphosphoryl)acetate 297a (2.79 g, 8.15 mmol), DBSA (4.09 mL, 12.2 mmol), DBU (1.82 
mL, 12.2 mmol) and CH2Cl2 (81.5 mL). Purification by column chromatography (2:1 
hexane:EtOAc) afforded the title compound 297b as a yellow oil (2.26 g, 75%); Rf 0.37 (1:1 
hexane:EtOAc); νmax (thin film)/cm-1 2985w, 2127s, 1704s, 1607m, 1512s, 1273s, 1250s, 1176w, 
1020s, 975s; δH (400 MHz, CDCl3) 1.35 (6 H, td, J = 7.1, J = 0.8, H-4), 3.80 (3 H, s, H-12), 4.11–
4.27 (4 H, m, H-3), 4.82 (2 H, dd, J = 6.7, J = 1.2, H-5), 6.14 (1 H, dt, J = 15.8, J = 6.7, H-6), 6.62 
(1 H, d, J = 15.8, H-7), 6.85 (2 H, d, J = 8.7, H-10), 7.32 (2 H, d, J = 8.7, H-9); δC (100 MHz, 
CDCl3) 16.1 (d, J = 6.9, C-4), 55.2 (C-12), 63.7 (d, J = 6.1, C-3), 66.3 (C-5), 114.0 (C-10), 120.0 
(C-6), 127.9 (C-9), 128.6 (C-8), 134.7 (C-7), 159.7 (C-11), 163.2 (d, J = 12.8, C-1); δP (162 MHz, 
CDCl3) 10.6; HRMS (ESI+): Found: 391.1032; C16H21N2NaO6P (MNa+) Requires 391.1029 (−0.6 
ppm error). 
Lab notebook reference: MGL/08/80 
Note: C-2 not observed in 13C NMR spectrum. 
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Diethyl ((1RS,5SR,6SR)-6-(4-methoxyphenyl)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-
yl)phosphonate (297c) 
 
 
 
Synthesised using general procedure F with (E)-3-(4-methoxyphenyl)allyl 2-diazo-2-
(diethoxyphosphoryl)acetate 297b (85 mg, 0.250 mmol), CH2Cl2 (5.0 mL) and Rh2(oct)4 (4.0 mg, 
5.0 µmol). Purification by column chromatography (EtOAc) afforded the title compound 297c as a 
pale yellow oil (45 mg, 53%); Rf 0.23 (EtOAc); νmax (thin film)/cm-1 2982w, 1764s, 1613w, 
1518m, 1370w, 1294w, 1249s, 1182m, 1052m, 1020s, 983s, 820m; δH (400 MHz, CDCl3) 1.09 (3 
H, td, J = 7.1, J = 0.4, H-4/4’), 1.20 (3 H, t, J = 7.1, H-4/4’), 2.73 (1 H, app. t, J = 6.1, H-7), 3.24 (1 
H, app. dt, J = 10.6, J = 5.2, H-6), 3.76 (3 H, s, H-12), 3.77–4.06 (4 H, m, H-3/3’), 4.36 (1 H, dd, J 
= 9.3, J = 2.8, H-5), 4.46 (1 H, dd, J = 9.3, J = 4.7, H-5), 6.83 (2 H, d, J = 8.8, H-10), 7.26 (2 H, d, 
J = 8.8, H-9); δC (100 MHz, CDCl3) 16.1 (d, J = 6.6, C-4/4’), 16.2 (d, J = 6.0, C-4/4’), 28.3 (C-6), 
31.6 (d, J = 206.2, C-2), 34.6 (d, J = 3.2, C-7), 55.2 (C-12), 62.5 (d, J = 6.6, C-3/3’), 62.8 (d, J = 
6.8, C-3/3’), 68.0 (d, J = 3.0, C-5), 113.4 (C-10), 123.5 (d, J = 5.6, C-8), 130.5 (C-9), 159.3 (C-11), 
171.9 (d, J = 10.2, C-1); δP (162 MHz, CDCl3) 15.5; HRMS (ESI+): Found: 363.0960; 
C16H21NaO6P (MNa+) Requires 363.0968 (2.1 ppm error), Found: 341.1140; C16H22O6P (MH+) 
Requires 341.1149 (2.6 ppm error). 
Lab notebook reference: MGL/08/88 
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(E)-3-(4-Bromophenyl)allyl 2-(diethoxyphosphoryl)acetate (298a) 
 
 
 
Synthesised using general procedure A with (E)-3-(4-bromophenyl)prop-2-en-1-ol 298 (1.58 g, 
7.43 mmol), toluene (37.2 mL), DEPAA (1.53 g, 7.80 mmol), DIPEA (3.36 mL, 19.3 mmol) and 
T3P (6.15 g, 9.66 mmol, 50% w/w solution in EtOAc) affording the title compound 298a as an 
orange oil (2.90 g, 100%). No further purification was required; Rf 0.20 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2982w, 1736w, 1488m, 1402w, 1258s, 1114m, 1049m, 1022s, 967s, 840m, 785m; 
δH (400 MHz, CDCl3) 1.32 (6 H, t, J = 7.1, H-4), 3.01 (2 H, d, J = 21.5, H-2), 4.13–4.20 (4 H, m, 
H-3), 4.78 (2 H, d, J = 6.3, H-5), 6.26 (1 H, dt, J = 15.9, J = 6.3, H-6), 6.62 (1 H, d, J = 15.9, H-7), 
7.24 (2 H, d, J = 8.5, H-9/10), 7.43 (2 H, d, J = 8.5, H-9/10); δC (100 MHz, CDCl3) 16.3 (d, J = 6.6, 
C-4), 34.3 (d, J = 134.2, C-2), 62.7 (d, J = 6.7, C-3), 65.7 (C-5), 122.0 (C-11), 123.3 (C-6), 128.1 
(C-9/10), 131.7 (C-9/10), 133.2 (C-7), 135.0 (C-8), 165.6 (d, J = 6.5, C-1); δP (162 MHz, CDCl3) 
20.1; HRMS (ESI+): Found: 413.0130; C15H2079BrNaO5P (MNa+) Requires 413.0124 (−1.4 ppm 
error). 
Lab notebook reference: MGL/08/75 
(E)-3-(4-Bromophenyl)allyl 2-diazo-2-(diethoxyphosphoryl)acetate (298b) 
 
 
 
Synthesised using general procedure C with (E)-3-(4-bromophenyl)allyl 2-
(diethoxyphosphoryl)acetate 298a (2.90 g, 7.41 mmol), DBSA (3.72 mL, 11.1 mmol), DBU (1.66 
mL, 11.1 mmol) and CH2Cl2 (74.1 mL). Purification by column chromatography (2:1 
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hexane:EtOAc) afforded the title compound 298b as a yellow oil (2.69 g, 87%); Rf 0.42 (1:1 
hexane:EtOAc); νmax (thin film)/cm-1 2984w, 2127s, 1705s, 1488m, 1275s, 1020s, 975s, 798w, 
744w, 590w, 560w; δH (400 MHz, CDCl3) 1.33–1.37 (6 H, m, H-4), 4.12–4.28 (4 H, m, H-3), 4.83 
(2 H, dd, J = 6.4, J = 1.3, H-5), 6.26 (1 H, dt, J = 15.9, J = 6.4, H-6), 6.61 (1 H, d, J = 15.9, H-7), 
7.24 (2 H, d, J = 8.5, H-9/10), 7.44 (2 H, d, J = 8.5, H-9/10); δC (100 MHz, CDCl3) 16.3 (d, J = 7.2, 
C-4), 63.8 (d, J = 6.1, C-3), 65.9 (C-5), 122.2 (C-11), 123.3 (C-6), 128.2 (C-9/10), 131.9 (C-9/10), 
133.6 (C-7), 135.0 (C-8), 163.3 (d, J = 12.6, C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): 
Found: 439.0019; C15H1879BrN2NaO5P (MNa+) Requires 439.0029 (2.3 ppm error). 
Lab notebook reference: MGL/08/81 
Note: C-2 not observed in 13C NMR spectrum. 
Diethyl ((1RS,5SR,6SR)-6-(4-bromophenyl)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-
yl)phosphonate (298c) 
 
 
 
Synthesised using general procedure F with (E)-3-(4-bromophenyl)allyl 2-diazo-2-
(diethoxyphosphoryl)acetate 298b (97 mg, 0.250 mmol), CH2Cl2 (5.0 mL) and Rh2(oct)4 (4.0 mg, 
5.0 µmol). Purification by column chromatography (EtOAc) afforded the title compound 298c as a 
pale yellow oil (72 mg, 74%); Rf 0.32 (EtOAc); νmax (thin film)/cm-1 2982w, 1768s, 1492w, 
1369w, 1252m, 1053s, 1019s, 974m, 810m, 590m; δH (400 MHz, CDCl3) 1.09 (3 H, t, J = 7.1, H-
4/4’), 1.21 (3 H, t, J = 7.1, H-4/4’), 2.71 (1 H, app. t, J = 6.0, H-7), 3.24 (1 H, app. dt, J = 10.7, J = 
5.2, H-6), 3.81–4.08 (4 H, m, H-3/3’), 4.38 (1 H, dd, J = 9.4, J = 2.8, H-5), 4.48 (1 H, dd, J = 9.4, J 
= 4.8, H-5), 7.22 (2 H, d, J = 8.5, H-9/10), 7.43 (2 H, d, J = 8.5, H-9/10); δC (100 MHz, CDCl3) 
16.0 (d, J = 6.6, C-4/4’), 16.1 (d, J = 6.0, C-4/4’), 28.1 (C-6), 31.4 (d, J = 205.8, C-2), 34.0 (d, J = 
3.7, C-7), 62.6 (d, J = 6.6, C-3/3’), 62.9 (d, J = 6.8, C-3/3’), 67.8 (d, J = 3.1, C-5), 122.0 (C-11), 
130.9 (d, J = 5.7, C-8), 131.0 (C-9/10), 131.1 (C-9/10), 171.5 (d, J = 10.2, C-1); δP (162 MHz, 
CDCl3) 15.0; HRMS (ESI+): Found: 410.9970; C15H1879BrNaO5P (MNa+) Requires 410.9967 (−0.6 
ppm error), Found: 389.0154; C15H1979BrO5P (MH+) Requires 389.0148 (−1.5 ppm error). 
Lab notebook reference: MGL/08/89 
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(E)-3-(1,3-Benzodioxol-5-yl)allyl 2-(diethoxyphosphoryl)acetate (299a) 
 
 
 
Synthesised using general procedure A with (E)-3-(1,3-benzodioxol-5-yl)prop-2-en-1-ol 299 (1.95 
g, 10.9 mmol), toluene (55 mL), DEPAA (1.85 mL, 11.5 mmol), DIPEA (4.95 mL, 28.4 mmol) and 
T3P (9.05 g, 14.2 mmol, 50% w/w solution in EtOAc) affording the title compound 299a as a 
yellow oil (3.89 g, 100%). No further purification was required; Rf 0.17 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2986w, 2908w, 1733s, 1654w, 1607w, 1504m, 1491m, 1446m, 1398w, 1354w, 
1248s, 1195w, 1164w, 1021s, 965s; δH (400 MHz, CDCl3) 1.32 (6 H, t, J = 7.1, J = 0.4, H-4), 2.99 
(2 H, d, J = 21.5, H-2), 4.12–4.20 (4 H, m, H-3), 4.75 (2 H, dd, J = 6.6, J = 1.0, H-5), 5.95 (2 H, s, 
H-14), 6.09 (1 H, dt, J = 15.8, J = 6.6, H-6), 6.58 (1 H, d, J = 15.8, H-7), 6.74 (1 H, d, J = 8.0, H-
10), 6.81 (1 H, dd, J = 8.0, J = 1.6, H-9), 6.91 (1 H, d, J = 1.6, H-13); δC (100 MHz, CDCl3) 16.3 
(d, J = 6.2, C-4), 34.3 (d, J = 134.2, C-2), 62.7 (d, J = 6.2, C-3), 66.1 (C-5), 101.1 (C-14), 105.7 
(C-13), 108.3 (C-10), 120.5 (C-6), 121.5 (C-9), 130.4 (C-8), 134.5 (C-7), 147.7 (C-11/12), 148.0 
(C-11/12), 165.6 (d, J = 6.1, C-1); δP (162 MHz, CDCl3) 20.2; HRMS (ESI+): Found: 379.0920; 
C16H21NaO7P (MNa+) Requires 379.0917 (−0.8 ppm error). 
Lab notebook reference: MGL/04/65 
(E)-3-(1,3-Benzodioxol-5-yl)allyl 2-diazo-2-(diethoxyphosphoryl)acetate (299b) 
 
 
 
Synthesised using general procedure B with purification by column chromatography (1:1 
hexane:EtOAc) affording the title compound as a pale yellow solid (1.71 g, 46%); Rf 0.36 (1:1 
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hexane:EtOAc); m.p. 71–75 °C νmax (thin film)/cm-1 2985w, 2129s, 1703s, 1504m, 1491m, 1446m, 
1383w, 1355w, 1274s, 1250s, 1164w, 1101w, 1019s, 975m, 862w, 797m, 745m, 590m, 560m; δH 
(400 MHz, CDCl3) 1.36 (6 H, t, J = 7.1, J = 0.8, H-4), 4.12–4.28 (4 H, m, H-3), 4.82 (2 H, dd, J = 
6.6, J = 1.3, H-5), 5.96 (2 H, s, H-14), 6.10 (1 H, dt, J = 15.8, J = 6.6, H-6), 6.59 (1 H, d, J = 15.8, 
H-7), 6.76 (1 H, d, J = 8.0, H-10), 6.82 (1 H, dd, J = 8.0, J = 1.7, H-9), 6.92 (1 H, d, J = 1.7, H-13); 
δC (100 MHz, CDCl3) 16.1 (d, J = 6.9, C-4), 53.9 (d, J = 229.3, C-2), 63.7 (d, J = 5.6, C-3), 66.1 
(C-5), 101.2 (C-14), 105.7 (C-13), 108.3 (C-10), 120.5 (C-6), 121.6 (C-9), 130.3 (C-8), 134.8 (C-
7), 147.8 (C-11/12), 148.1 (C-11/12), 163.2 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.6; HRMS 
(ESI+): Found: 405.0820; C16H19N2NaO7P (MNa+) Requires 405.0822 (0.4 ppm error). 
Lab notebook reference: MGL/04/75 
Diethyl ((1RS,5SR,6SR)-6-(1,3-benzodioxol-5-yl)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-
yl)phosphonate (299c) 
 
 
 
Synthesised using general procedure F with (E)-3-(1,3-benzodioxol-5-yl)allyl 2-diazo-2-
(diethoxyphosphoryl)acetate 299b (68 mg, 0.178 mmol), CH2Cl2 (3.6 mL) and Rh2(oct)4 (2.8 mg, 
3.6 µmol). Purification by column chromatography (1:10 hexane:EtOAc) afforded the title 
compound 299c as a pale yellow solid (46 mg, 73%); Rf 0.17 (1:2 hexane:EtOAc); m.p. 96–99 °C; 
νmax (thin film)/cm-1 2980m, 2910m, 1754s, 1500m, 1489m, 1447m, 1395w, 1371m, 1311m, 
1233s, 1214w, 1180w, 1098w, 1014s, 832m, 807m, 585s; δH (400 MHz, CDCl3) 1.15 (3 H, t, J = 
7.1, H-7/7’), 1.24 (3 H, t, J = 7.1, H-7/7’), 2.74 (1 H, app. t, J = 6.1, H-5), 3.21 (1 H, app. dt, J = 
10.7, J = 5.2, H-3), 3.89–4.12 (4 H, m, H-6,6’), 4.38 (1 H, dd, J = 9.3, J = 2.8, H-4), 4.48 (1 H, dd, 
J = 9.3, J = 4.7, H-4), 5.94 (2 H, s, H-14), 6.75 (1 H, d, J = 7.9, H-10), 6.81–6.84 (2 H, m, H-9,13); 
δC (100 MHz, CDCl3) 16.1 (d, J = 6.5, C-7/7’), 16.3 (d, J = 6.0, C-7/7’), 28.4 (C-3), 31.5 (d, J = 
205.7, C-2), 34.9 (d, J = 3.0, C-5), 62.6 (d, J = 6.1, C-6/6’), 62.9 (d, J = 6.6, C-6/6’), 68.0 (d, J = 
2.4, C-4), 101.2 (C-14), 107.9 (C-10), 109.8 (C-9/13), 123.0 (C-9/13), 125.3 (d, J = 5.1, C-8), 
147.4 (C-11/12), 147.4 (C-11/12), 171.8 (d, J = 10.2, C-1); δP (162 MHz, CDCl3) 15.4; HRMS 
(ESI+): Found: 377.0750; C16H19NaO7P (MNa+) Requires 377.0761 (2.8 ppm error), Found: 
355.0925; C16H20O7P (MH+) Requires 355.0941 (4.4 ppm error). 
Lab notebook reference: MGL/04/81 
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5.2.3.2.  Ring-openings 
Diethyl ((4SR)-4-((ethylthio)methyl)-2-oxotetrahydrofuran-3-yl)phosphonate (304)  
 
 
 
To a solution of diethyl ((1RS,5SR)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 287c (47.0 
mg, 0.201 mmol) in DMF (1 mL) was added sodium ethanethiolate (20.3 mg, 0.241 mmol). The 
solution was stirred at RT for 2 h then quenched with sat. aq. NH4Cl (10 mL) and the aqueous layer 
separated. The organic layer was washed with water (2 × 10 mL) and dried over MgSO4. 
Concentration in vacuo and purification by column chromatography (1:1 hexane:EtOAc) afforded 
the title compound 304 as a colourless oil (22 mg, 37%); Rf 0.44 (1:8 hexane:EtOAc); νmax (thin 
film)/cm-1 2979w, 2915w, 2838w, 1772s, 1251m, 1160w, 1047w, 1021s, 971m; δH (400 MHz, 
CDCl3) 1.25 (3 H, t, J = 7.4, H-7), 1.34 (3 H, td, J = 7.1, J = 0.6, H-9/9’), 1.36 (3 H, td, J = 7.1, J = 
0.6, H-9/9’), 2.55 (2 H, q, J = 7.4, H-6), 2.68 (1 H, ddd, J = 13.4, J = 7.8, J = 0.8, H-5), 2.74 (1 H, 
dd, J = 13.4, J = 7.8, H-5), 2.99–3.11 (1 H, m, H-3), 3.05 (1 H, dd, J = 24.6, J = 4.9, H-2), 4.13 (1 
H, dd, J = 9.2, J = 4.1, H-4), 4.16–4.26 (4 H, m, H-8,8’), 4.56 (1 H, dd, J = 9.2, J = 6.9, H-4); δC 
(100 MHz, CDCl3) 14.6 (C-7), 16.3 (d, J = 6.1, C-9/9’), 16.3 (d, J = 6.1, C-9/9’), 25.9 (C-6), 34.7 
(d, J = 10.1, C-5), 37.6 (d, J = 2.2, C-3), 44.2 (d, J = 141.1, C-2), 63.0 (d, J = 6.8, C-8/8’), 63.7 (d, 
J = 6.8, C-8/8’), 71.7 (d, J = 5.7, C-4), 171.4 (d, J = 3.2, C-1); δP (162 MHz, CDCl3) 20.1; HRMS 
(ESI+): Found: 319.0730; C11H21NaO5PS (MNa+) Requires 319.0740 (3.0 ppm error). 
Lab notebook reference: MGL/03/31 
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Diethyl ((4SR)-4-((SR)-(ethylthio)(phenyl)methyl)-2-oxotetrahydrofuran-3-
yl)phosphonate (305) 
 
 
 
To a solution of diethyl ((1RS,5SR,6SR)-2-oxo-6-phenyl-3-oxabicyclo[3.1.0]hexan-1-
yl)phosphonate 296c (62 mg, 0.200 mmol) in THF (1.0 mL) was added sodium ethanethiolate 
(33.6 mg, 0.400 mmol). The solution was stirred at RT for 18 h then quenched with sat. aq. NH4Cl 
(10 mL), diluted with diethyl ether (10 mL) and the aqueous layer separated. The aqueous layer 
was extracted once with diethyl ether (10 mL) then the combined organic extracts were washed 
with water (2 × 10 mL) and dried over MgSO4. Concentration in vacuo and purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 305 as a colourless oil (14 mg, 
19%); Rf 0.28 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2978m, 2928m, 1773s, 1453w, 1254s, 
1151m, 1048m, 1023s, 972m, 702w; δH (400 MHz, CDCl3) 1.14 (3 H, t, J = 7.4, H-13), 1.25–1.32 
(6 H, m, H-7,7’), 2.33 (2 H, q, J = 7.4, H-12), 2.89 (1 H, dd, J = 24.6, J = 3.0, H-2), 3.17–3.27 (1 
H, m, H-3), 3.84 (1 H, d, J = 9.7, H-5), 3.93–4.18 (4 H, m, H-6,6’), 4.53 (1 H, dd, J = 9.4, J = 6.7, 
H-4), 4.67 (1 H, dd, J = 9.4, J = 2.5, H-4), 7.27–7.37 (5 H, m, H-9,10,11); δC (100 MHz, CDCl3) 
14.3 (C-13), 16.2 (d, J = 6.5, C-7/7’), 16.3 (d, J = 6.5, C-7/7’), 25.3 (C-12), 43.5 (C-3), 43.9 (d, J = 
136.2, C-2), 52.1 (d, J = 12.3, C-5), 62.9 (d, J = 7.3, C-6/6’), 63.8 (d, J = 6.8, C-6/6’), 70.6 (d, J = 
3.3, C-4), 128.0 (C-11), 128.3 (C-9/10), 128.9 (C-9/10), 139.4 (C-8), 171.4 (d, J = 4.2, C-1); δP 
(162 MHz, CDCl3) 19.4; HRMS (ESI+): Found: 395.1065; C17H25NaO5PS (MNa+) Requires 
395.1053 (−3.0 ppm error), Found: 373.1243; C17H26O5PS (MH+) Requires 373.1233 (−2.6 ppm 
error). 
Lab notebook reference: MGL/08/98B 
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Diethyl ((4SR)-4-benzyl-2-oxotetrahydrofuran-3-yl)phosphonate (306) 
 
 
 
Cuprate method: To a stirred solution of CuBr·DMS (61.7 mg, 0.300 mmol) in THF (0.6 mL) and 
DMS (0.2 mL) at −40 °C was added phenylmagnesium bromide (0.2 mL, 0.600 mmol, 3.0 M 
solution in diethyl ether). The solution was stirred for 20 mins with warming to −20 °C. A solution 
of diethyl ((1RS,5SR)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 287c (52 mg, 0.222 
mmol) in THF (0.6 mL) was added via cannula over 5 mins. After stirring the solution for 2 h at 
RT the reaction was quenched with sat. aq. NH4Cl (5 mL). The organic layer was separated and the 
aqueous layer extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by column chromatography (1:2 hexane:EtOAc) 
afforded the title compound 306 as a pale yellow oil (44 mg, 63%).  
 
 
 
SmI2 method: To a solution of freshly prepared SmI2 (2.00 mL, 0.200 mmol, ~0.1 M in THF) in an 
oven dried sealable tube at −78 °C under an atmosphere of argon, was added a solution of diethyl 
((1RS,5SR,6SR)-2-oxo-6-phenyl-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 296c (31 mg, 0.100 
mmol) in THF (0.5 mL). The solution was stirred at −78 °C for 5 mins then quenched with sat. aq. 
NH4Cl (5 mL) and then allowed to warm at RT. The mixture was diluted with water (5 mL) and 
extrated with diethyl ether (3 × 10 mL). The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (1:2 hexane:EtOAc) 
afforded the title compound 306 as a pale yellow oil (15 mg, 48%). 
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Data for 306: Rf 0.52 (1:4 hexane:EtOAc); νmax (thin film)/cm-1 2983w, 2915w, 1771s, 1497w, 
1479w, 1455w, 1381w, 1252m, 1206w, 1160m, 1047w, 1020s, 972s, 753m, 703m; δH (400 MHz, 
CDCl3) 1.29–1.33 (6 H, m, H-7,7’), 2.81 (1 H, dd, J = 13.8, J = 8.6, H-5), 2.83 (1 H, dd, J = 23.9, J 
= 4.5, H-2), 2.93 (1 H, dd, J = 13.8, J = 7.1, H-5), 3.11–3.24 (1 H, m, H-3), 3.99–4.29 (5 H, m, H-
4,6,6’), 4.45 (1 H, dd, J = 9.1, J = 6.9, H-4), 7.15–7.18 (2 H, m, H-9/10), 7.23–7.27 (1 H, m, H-11), 
7.29–7.34 (2 H, m, H-9/10); δC (100 MHz, CDCl3) 16.3 (d, J = 6.1, C-7/7’), 16.3 (d, J = 6.1, C-
7/7’), 39.3 (d, J = 2.6, C-3), 39.3 (d, J = 10.1, C-5), 44.5 (d, J = 139.5, C-2), 62.9 (d, J = 6.8, C-
6/6’), 63.6 (d, J = 6.8, C-6/6’), 71.8 (d, J = 5.0, C-4), 127.0 (C-11), 128.8 (C-9/10), 129.0 (C-9/10), 
137.2 (C-8), 171.7 (d, J = 3.6, C-1); δP (162 MHz, CDCl3) 20.0; HRMS (ESI+): Found: 335.1030; 
C15H21NaO5P (MNa+) Requires 335.1019 (−3.4 ppm error), Found: 313.1205; C15H22O5P (MH+) 
Requires 313.1199 (−1.7 ppm error). 
 
Lab notebook reference: MGL/04/68, 07/83 
 
5.2.3.3.  Savinin and Gadain 
Diethyl ((3RS,4SR)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-2-oxotetrahydrofuran-3-
yl)phosphonate (149c) 
 
 
 
To a solution of freshly prepared SmI2 (4.00 mL, 0.400 mmol, ~0.1 M in THF) in an oven dried 
sealable tube at −78 °C under an atmosphere of argon, was added a solution of diethyl 
((1RS,5SR,6SR)-6-(1,3-benzodioxol-5-yl)-2-oxo-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 299c 
(70.9 mg, 0.200 mmol) in THF (1.0 mL). The solution was stirred at −78 °C for 30 mins then 
quenched with sat. aq. NH4Cl (1.70 mL) and then allowed to warm at RT. The mixture was diluted 
with water (10 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (1:4 hexane:EtOAc) afforded the title compound 149c as a yellow oil (27 mg, 
38%); Rf 0.55 (EtOAc); νmax (thin film)/cm-1 2983w, 2910w, 1768s, 1503w, 1490s, 1443m, 1245s, 
1196m, 1149m, 1018s, 971s, 809w, 549w; δH (400 MHz, CDCl3) 1.33 (6 H, t, J = 7.1, H-7,7’), 
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2.69–2.87 (3 H, m, H-2,5),  3.04–3.16 (1 H, m, H-3), 4.04–4.22 (5 H, m, H-4,6,6’), 4.44 (1 H, dd, J 
= 9.1, J = 6.9, H-4), 5.94 (2 H, s, H-14), 6.60 (1 H, dd, J = 7.9, J = 1.4, H-9), 6.65 (1 H, d, J = 1.4, 
H-13), 6.74 (1 H, d, J = 7.9, H-10); δC (100 MHz, CDCl3) 16.3 (app. t, J = 6.4, C-7/7’), 39.0 (d, J = 
10.0, C-5), 39.3 (d, J = 3.0, C-3), 44.5 (d, J = 139.9, C-2), 62.9 (d, J = 7.3, C-6/6’), 63.7 (d, J = 7.0, 
C-6/6’), 71.7 (d, J = 5.3, C-4), 101.1 (C-14), 108.4 (C-13), 109.1 (C-10), 122.2 (C-9), 130.8 (C-8), 
146.6 (C-11/12), 148.0 (C-11/12), 171.7 (d, J = 3.8, C-1); δP (162 MHz, CDCl3) 20.1; HRMS 
(ESI+): Found: 379.0923; C16H21NaO7P (MNa+) Requires 379.0917 (−1.6 ppm error), Found: 
357.1100; C16H22O7P (MH+) Requires 357.1098 (−0.8 ppm error). 
Lab notebook reference: MGL/08/96 
(RS,E)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(benzo[d][1,3]dioxol-5-
ylmethylene)dihydrofuran-2(3H)-one ((±)-savinin) (174) and (RS,Z)-4-
(benzo[d][1,3]dioxol-5-ylmethyl)-3-(benzo[d][1,3]dioxol-5-ylmethylene)dihydrofuran-
2(3H)-one ((±)-gadain) (307) 
 
 
To a solution of diethyl ((3RS,4SR)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-2-oxotetrahydrofuran-3-
yl)phosphonate 149c (59 mg, 0.166 mmol) in THF (3.3 mL) at 0 °C was added KOBu-t (27.9 mg, 
0.248 mmol). The solution was stirred at 0 °C for 60 mins, after which, piperonal (49.8 mg, 0.332 
mmol) was added to the solution, which was refluxed for 2 h. After cooling at RT, the solution was 
quenched with sat. aq. NH4Cl (10 mL). The organic layer was separated and the aqueous extracted 
with EtOAc (2 × 10 mL). The organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (5:1 hexane:EtOAc → 3:1 hexane:EtOAc) afforded 
the title compounds as mixture (174:307 1.9:1) (31 mg, 53%). 
 
Small quantities of each compound were isolated separately for characterisation purposes. 
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Data for savinin, 174; White solid; Rf 0.20 (4:1 hexane:EtOAc); m.p. 127–129 °C (lit.95 146.4–
148.4 °C); νmax (thin film)/cm-1 2908m, 1744s, 1646m, 1503s, 1490s, 1447s, 1341m, 1250s, 1214s, 
1180s, 1037s, 927m, 810w; δH (400 MHz, CDCl3) 2.59 (1 H, dd, J = 14.2, J = 10.1, H-13), 2.99 (1 
H, dd, J = 14.2, J = 4.5, H-13), 3.71–3.77 (1 H, m, H-3), 4.22–4.29 (2 H, m, H-4), 5.93 (1 H, d, J = 
1.4, H-20), 5.94 (1 H, d, J = 1.4, H-20), 6.05 (2 H, s, H-12), 6.64 (1 H, dd, J = 7.8, J = 1.6, H-15), 
6.67 (1 H, d, J = 1.6, H-19), 6.74 (1 H, d, J = 7.8, H-16), 6.88 (1 H, d, J = 8.1, H-8), 7.05 (1 H, d, J 
= 1.7, H-11), 7.08 (1 H, dd, J = 8.1, J = 1.7, H-7), 7.50 (1 H, d, J = 1.9, H-5); δC (100 MHz, CDCl3) 
37.5 (C-13), 39.9 (C-3), 69.5 (C-4), 101.0 (C-20), 101.7 (C-12), [108.5, 108.6, 108.8, 109.2 (C-
8,11,16,19)], 122.2 (C-15), 125.8 (C-2), 126.1 (C-7), 128.2 (C-6), 131.5 (C-14), 137.5 (C-5), 146.5 
(C-17/18), 147.9 (C-17/18), 148.3 (C-9/10), 149.2 (C-9/10), 172.6 (C-1); HRMS (ESI+): Found: 
375.0833; C20H16NaO6 (MNa+) Requires 375.0839 (1.5 ppm error), Found: 353.1019; C20H17O6 
(MH+) Requires 353.1020 (0.3 ppm error). 
Obtained data in accord with reported literature.95,140-141 
 
Data for gadain, 307; White solid; Rf 0.26 (4:1 hexane:EtOAc); m.p. 136–139 °C (lit.143 145 °C); 
νmax (thin film)/cm-1 2906w, 1741s, 1634w, 1600w, 1503s, 1488s, 1446s, 1246s, 1171s, 1083s, 
1037s, 928s, 810m; δH (400 MHz, CDCl3) 2.78 (1 H, dd, J = 13.8, J = 8.9, H-13), 2.91 (1 H, dd, J = 
13.8, J = 6.9, H-13), 3.29 (1 H, app. dtdd, J = 8.9, J = 7.1, J = 3.8, J = 1.7, H-3), 4.10 (1 H, dd, J = 
9.1, J = 3.8, H-4), 4.32 (1 H, dd, J = 9.1, J = 7.3, H-4), 5.95 (1 H, d, J = 1.4, H-20), 5.96 (1 H, d, J 
= 1.4, H-20), 6.00 (2 H, s, H-12), 6.59 (1 H, d, J = 1.7, H-5), 6.62 (1 H, dd, J = 7.9, J = 1.7, H-15), 
6.69 (1 H, d, J = 1.7, H-19), 6.76 (1 H, d, J = 7.9, H-16), 6.79 (1 H, d, J = 8.1, H-8), 7.15 (1 H, dd, 
J = 8.1, J = 1.7, H-7), 7.74 (1 H, d, J = 1.7, H-11); δC (100 MHz, CDCl3) 40.7 (C-13), 44.2 (C-3), 
69.8 (C-4), 101.0 (C-20), 101.4 (C-12), 107.9 (C-8), 108.4 (C-16), 109.3 (C-19), 110.7 (C-11), 
122.3 (C-15), 125.2 (C-2), 126.9 (C-7), 127.9 (C-6), 131.4 (C-14), 140.4 (C-5), 146.5 (C-17/18), 
147.6 (C-17/18), 147.9 (C-9/10), 149.0 (C-9/10), 169.3 (C-1); HRMS (ESI+): Found: 375.0843; 
C20H16NaO6 (MNa+) Requires 375.0839 (−1.2 ppm error), Found: 353.1027; C20H17O6 (MH+) 
Requires 353.1020 (−2.0 ppm error). 
Obtained data in accord with reported literature.143 
 
Lab notebook reference: MGL/08/100 
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5.2.3.4.  Peperomin E 
Ethyl 3,3-diphenylacrylate (329) 
 
 
 
Prepared according to a modified literature procedure.152  
To a suspension of AgOAc (2.59 g, 15.5 mmol) and Pd(OAc)2 (11.2 mg, 0.05 mmol) in AcOH (15 
mL) was added iodobenzene (1.73 mL, 15.5 mmol) and ethyl acrylate 328 (0.54 mL, 5.00 mmol). 
The mixture was stirred under an atmosphere of argon, at 110 °C for 6 h then allowed cool at RT 
and diluted with EtOAc (20 mL). The mixture was filtered through a pad of Celite, washed with 
EtOAc (200 mL) and the filtrate concentrated in vacuo. Purification by column chromatography 
(15:1 hexane:EtOAc) afforded the title compound 329 as a yellow oil (1.26 g, 100%); Rf 0.26 (15:1 
hexane:EtOAc); νmax (thin film)/cm-1 2980, 1722, 1618, 1446, 1369, 1264, 1164, 1038, 771, 697; 
δH (400 MHz, CDCl3) 1.12 (3 H, t, J = 7.1, H-13), 4.06 (2 H, q, J = 7.1, H-12), 6.37 (1 H, s, H-2), 
7.20–7.24 (2 H, m, ArH), 7.29–7.40 (8 H, m, ArH); δC (100 MHz, CDCl3) 14.0, 60.0, 117.5, 127.8, 
128.1, 128.3, 128.3, 129.1, 129.4, 139.0, 140.8, 156.5, 166.1; MS (ESI+): 275.10 (MNa+), 253.12 
(MH+). 
Lab notebook reference: MGL/04/82 
Obtained data in accord with reported literature.152 
3,3-Diphenylprop-2-en-1-ol (330) 
 
 
 
To a solution of ethyl 3,3-diphenylacrylate 329 (1.33 g, 5.27 mmol) in THF (19 mL) cooled to −78 
°C was added dropwise DIBAL (21.1 mL, 21.1 mmol, 1.0 M in hexane) and stirred for 2 h. The 
solution was quenched with water (15 mL) dropwise and stirred for 30 mins at RT before being 
filtered through a pad of Celite and silica and washed with diethyl ether (500 mL). The filtrate was 
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concentrated in vacuo. Purification by column chromatography (4:1 hexane:EtOAc) afforded the 
title compound 330 as a white solid (886 mg, 80%); Rf 0.33 (4:1 hexane:EtOAc); m.p. 60–62 °C 
(lit.172 61–63 °C); νmax (thin film)/cm-1 3325, 3056, 3024, 1598, 1494, 1444, 1074, 1013, 758, 692; 
δH (400 MHz, CDCl3) 1.50 (1 H, br s, OH), 4.23 (2 H, d, J = 6.9, H-1), 6.26 (1 H, t, J = 6.9, H-2), 
7.16–7.19 (2 H, m, ArH), 7.24–7.40 (8 H, m, ArH); δC (100 MHz, CDCl3) 60.7, 127.4, 127.5, 
127.6, 127.6, 128.2, 128.2, 129.7, 139.0, 141.8, 144.2; MS (ESI+): 249.07 (MK+), 233.09 (MNa+). 
Lab notebook reference: MGL/04/83 
Obtained data in accord with reported literature.172-173 
3,3-Diphenylallyl 2-(diethoxyphosphoryl)acetate (331) 
 
 
 
Synthesised using general procedure A with 3,3-diphenylprop-2-en-1-ol (862 mg, 4.10 mmol), 
toluene (20.5 mL), DEPAA (0.69 mL, 4.30 mmol), DIPEA (1.86 mL, 10.7 mmol) and T3P (3.40 g, 
5.33 mmol, 50% w/w solution in EtOAc) affording the title compound 331 as an orange oil (1.59 g, 
100%). No further purification was required; Rf 0.26 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2983w, 1736s, 1445w, 1265s, 1113m, 1025s, 969m, 774m, 702m; δH (400 MHz, CDCl3) 1.33 (6 H, 
t, J = 7.1, J = 0.5, H-4), 3.00 (2 H, d, J = 21.5, H-2), 4.13–4.21 (4 H, m, H-3), 4.71 (2 H, d, J = 7.1, 
H-5), 6.18 (1 H, t, J = 7.1, H-6), 7.16–7.19 (2 H, m, H-9/10/11/13/14/15), 7.23–7.40 (8 H, m, H-
9/10/11/13/14/15); δC (100 MHz, CDCl3) 16.3 (d, J = 6.3, C-4), 34.5 (d, J = 134.2, C-2), 62.7 (d, J 
= 6.2, C-3), 63.7 (C-5), 121.5 (C-6), [127.7, 127.9, 127.9, 128.2, 128.3, 129.7 (C-
9,10,11,13,14,15)], [138.4, 141.4, 147.0 (C-7,8,12)], 165.7 (d, J = 6.3, C-1); δP (162 MHz, CDCl3) 
20.2; HRMS (ESI+): Found: 411.1325; C21H25NaO5P (MNa+) Requires 411.1332 (1.8 ppm error). 
Lab notebook reference: MGL/04/84 
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3,3-Diphenylallyl 2-diazo-2-(diethoxyphosphoryl)acetate (332) 
 
 
 
Synthesised using general procedure B with 3,3-diphenylallyl 2-(diethoxyphosphoryl)acetate 331 
(1.59 g, 4.10 mmol), THF (20.5 mL), LHMDS (4.92 mL, 4.92 mmol, 1.0 M solution in THF) and 
p-ABSA (1.18 g, 4.92 mmol). Purification by column chromatography (2:1 hexane:EtOAc) 
afforded the title compound 332 as a yellow oil (823 g, 48%); Rf 0.52 (1:1 hexane:EtOAc); νmax 
(thin film)/cm-1 2984w, 2126s, 1703s, 1494w, 1444w, 1377w, 1348w, 1271s, 1214w, 1163w, 
1117w, 1099w, 1017s, 976s, 796m, 729s, 699s, 585s, 558s; δH (400 MHz, CDCl3) 1.35 (6 H, t, J = 
7.1, J = 0.8, H-4), 4.12–4.28 (4 H, m, H-3), 4.77 (2 H, d, J = 7.2, H-5), 6.19 (1 H, t, J = 7.2, H-6), 
7.16–7.19 (2 H, m, H-9/10/11/13/14/15), 7.22–7.39 (8 H, m, H-9/10/11/13/14/15); δC (100 MHz, 
CDCl3) 15.9 (d, J = 6.9, C-4), 53.5 (d, J = 227.1, C-2), 63.3 (C-5), 63.4 (d, J = 5.7, C-3), 121.1 (C-
6), [127.4, 127.7, 127.8, 128.0, 128.1, 129.3 (C-9,10,11,13,14,15)], [138.1, 141.0, 147.1 (C-
7,8,12)], 162.9 (d, J = 12.2, C-1); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 437.1242; 
C21H23N2NaO5P (MNa+) Requires 437.1237 (−1.1 ppm error). 
Lab notebook reference: MGL/04/85 
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Diethyl ((1SR,5SR)-2-oxo-6,6-diphenyl-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 
(333) 
 
 
 
Synthesised using general procedure F with 3,3-diphenylallyl 2-diazo-2-
(diethoxyphosphoryl)acetate 332 (78 mg, 0.188 mmol), CH2Cl2 (3.8 mL) and Rh2(oct)4 (2.9 mg, 
3.8 µmol). Purification by column chromatography (1:10 hexane:EtOAc) afforded the title 
compound 333 as a pale yellow oil (38 mg, 51%); Rf 0.18 (1:2 hexane:EtOAc); νmax (thin film)/cm-
1 2982w, 2908w, 1761s, 1600w, 1495w, 1474w, 1449w, 1388w, 1365w, 1252m, 1221w, 1195w, 
1162w, 1071w, 1054s, 1019s, 973m, 710m; δH (400 MHz, CDCl3) 1.11 (3 H, t, J = 7.1, H-7/7’), 
1.22 (3 H, t, J = 7.1, H-7/7’), 3.53 (1 H, dd, J = 12.3, J = 5.3, H-3), 3.68 (1 H, ddq, J = 10.2, J = 
9.5, J = 7.1, H-6/6’), 3.89–3.99 (1 H, m, H-6/6’), 4.04–4.13 (2 H, m, H-6/6’), 4.27 (1 H, ddd, J = 
9.9, J = 2.8, J = 0.7, H-4/4’), 4.54 (1 H, dd, J = 9.9, J = 5.3, H-4/4’), 7.16–7.34 (6 H, m, H-
9/10/11/13/14/15), 7.42–7.50 (4 H, m, H-9/10/11/13/14/15); δC (100 MHz, CDCl3) 16.2 (d, J = 6.1, 
C-7/7’), 16.2 (d, J = 6.3, C-7/7’), 33.7 (d, J = 3.2, C-3), 37.3 (d, J = 203.9, C-2), 46.5 (d, J = 2.5, 
C-5), 62.4 (d, J = 6.2, C-6/6’), 63.4 (d, J = 6.5, C-6/6’), 65.4 (d, J = 2.5, C-4), [127.6, 128.0, 128.4, 
128.6, 129.1, 129.3 (C-9/10/11/13/14/15)], 136.5 (C-8/12), 138.7 (d, J = 4.6, C-8/12), 171.3 (d, J = 
10.4, C-1); δP (162 MHz, CDCl3) 16.1; HRMS (ESI+): Found: 409.1172; C21H23NaO5P (MNa+) 
Requires 409.1175 (0.9 ppm error), Found: 387.1352; C21H24O5P (MH+) Requires 387.1356 (0.9 
ppm error). 
Lab notebook reference: MGL/04/86 
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Diethyl ((3RS,4SR)-4-benzhydryl-2-oxotetrahydrofuran-3-yl)phosphonate (335) 
 
 
 
To a solution of freshly prepared SmI2 (1.70 mL, 0.170 mmol, ~0.1 M in THF) in an oven dried 
sealable tube at −78 °C under an atmosphere of argon, was added a solution of diethyl ((1SR,5SR)-
2-oxo-6,6-diphenyl-3-oxabicyclo[3.1.0]hexan-1-yl)phosphonate 333 (33 mg, 0.085 mmol) in THF 
(0.5 mL). The solution was stirred at −78 °C for 5 mins then quenched with sat. aq. NH4Cl (1.70 
mL) and then allowed to warm at RT. The mixture was diluted with water (5 mL) and extracted 
with diethyl ether (3 × 10 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (1:1 hexane:EtOAc) afforded the 
title compound 335 as a yellow oil (20 mg, 60%); Rf 0.29 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 
2982w, 1770s, 1493w, 1453m, 1251s, 1152s, 1046m, 1019s, 971s, 749m, 705s; δH (400 MHz, 
CDCl3) 1.29 (3 H, t, J = 7.1, H-11/11’), 1.31 (3 H, t, J = 7.1, H-11/11’), 2.84 (1 H, d, J = 24.6, H-
8), 3.69 (1 H, ddd, J = 17.3, J = 11.9, J = 5.7, H-6), 3.83–4.20 (6 H, m, H-5,7,10,10’), 4.55 (1 H, 
dd, J = 9.4, J = 6.1, H-7), 7.19–7.33 (10 H, m, H-1,1’,2,2’,3,3’); δC (100 MHz, CDCl3) 16.2 (d, J = 
6.7, C-11/11’), 16.3 (d, J = 6.5, C-11/11’), 42.1 (d, J = 3.0, C-6), 44.8 (d, J = 133.1, C-8), 54.5 (d, J 
= 13.5, C-5), 63.0 (d, J = 7.0, C-10/10’), 63.8 (d, J = 6.9, C-10/10’), 70.7 (C-7), [127.2, 127.2, 
127.9, 128.2, 129.0, 129.1 (C-1/1’/2/2’/3/3’)], 141.0 (C-4/4’), 141.5 (C-4/4’), 171.9 (d, J = 5.0, C-
9); δP (162 MHz, CDCl3) 19.5; HRMS (ESI+): Found: 411.1338; C21H25NaO5P (MNa+) Requires 
411.1332 (−1.6 ppm error), Found: 389.1519; C21H26O5P (MH+) Requires 389.1512 (−1.7 ppm 
error). 
Lab notebook reference: MGL/07/94 
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4-Benzhydryl-3-methylenedihydrofuran-2(3H)-one (336) 
 
 
 
To a solution of diethyl ((3RS,4SR)-4-benzhydryl-2-oxotetrahydrofuran-3-yl)phosphonate 335 (20 
mg, 51.5 µmol) in THF (0.25 mL) at 0 °C was added KOBu-t (8.7 mg, 0.772 mmol). The solution 
was stirred at 0 °C for 60 mins and then cooled to −78 °C. Paraformaldehyde (3.1 mg, 0.103 mmol) 
was added to the solution and stirred for 15 mins at −78 °C and a further 2 h at RT. The solution 
was quenched with sat. aq. NH4Cl (10 mL). The organic layer was separated and the aqueous 
extracted with EtOAc (2 × 10 mL). The organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (4:1 hexane:EtOAc) afforded the 
title compound 336 as a pale yellow oil (7 mg, 52%); Rf 0.35 (4:1 hexane:EtOAc); νmax (thin 
film)/cm-1 2023w, 1759s, 1656w, 1494m, 1451m, 1401m, 1262s, 1114s, 1030m, 813m, 748s, 703s, 
611s; δH (400 MHz, DMSO-d6) 3.82–3.87 (1 H, m), 4.05–4.10 (1 H, m), 4.26–4.35 (2 H, m), 4.65 
(1 H, d, J = 1.4), 5.88 (1 H, d, J = 1.8), 7.18–7.23 (2 H, m), 7.29–7.33 (4 H, m), 7.42–7.46 (4 H, 
m);174 δH (400 MHz, CDCl3) 3.88–4.02 (3 H, m, H-3,4,5), 4.33 (1 H, dd, J = 9.2, J = 7.1, H-4), 4.75 
(1 H, d, J = 1.9, H-6b), 6.09 (1 H, d, J = 2.1, H-6a), 7.20–7.34 (10 H, m, H-8,8’,9,9’,10,10’); δC 
(100 MHz, CDCl3) 42.3 (C-3), 55.5 (C-5), 69.8 (C-4), 124.7 (C-6), [127.2, 127.2, 127.7, 128.3, 
128.8, 129.1 (C-8,8’,9,9’,10,10’)], 136.0 (C-2), 141.5 (C-7/7’), 141.6 (C-7/7’), 170.9 (C-1); HRMS 
(ESI+): Found: 287.1044; C18H16NaO2 (MNa+) Requires 287.1043 (−0.5 ppm error), Found: 
265.1225; C18H17O2 (MH+) Requires 265.1223 (−0.6 ppm error). 
Lab notebook reference: MGL/07/94/2 
Obtained data in accord with reported literature.174 
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(E)-Ethyl 3-(7-methoxybenzo[d][1,3]dioxol-5-yl)acrylate (326) 
 
 
 
To a solution of 5-methoxypiperonal 324 (5.17 g, 28.7 mmol) in THF (86 mL) was added 
(carbethoxymethylene)triphenylphosphorane 337 (12.0 g, 34.4 mmol) and refluxed for 16 h. 
Concentration in vacuo and purification by column chromatography (4:1 hexane:EtOAc) afforded 
the title compound 326 as a crystalline white solid (6.78 g, 95%); Rf 0.46 (4:1 hexane:EtOAc); m.p. 
65–68 °C (lit.175 76 °C); νmax (thin film)/cm-1 2996w, 2975w, 2908w, 1702s, 1622s, 1593s, 1511s, 
1431s, 1324m, 1281s, 1171s, 1137s, 1093s, 1038s, 996s, 925s, 846s, 819s, 594s, 477s; δH (400 
MHz, CDCl3) 1.31 (3 H, t, J = 7.1, H-13), 3.90 (3 H, s, H-8), 4.23 (2 H, q, J = 7.1, H-12), 5.99 (2 
H, s, H-7), 6.25 (1 H, d, J = 15.9, H-10), 6.68 (1 H, d, J = 1.4, H-4/6), 6.72 (1 H, d, J = 1.4, H-4/6), 
7.54 (1 H, d, J = 15.9, H-9); δC (100 MHz, CDCl3) 14.3 (C-13), 56.5 (C-7), 60.4 (C-12), 101.2 (C-
4/6), 101.9 (C-8), 109.0 (C-4/6), 116.6 (C-10), 129.2 (C-1/2/3/5), 137.2 (C-1/2/3/5), 143.6 (C-
1/2/3/5), 144.2 (C-9), 149.2 (C-1/2/3/5), 167.0 (C-11); HRMS (ESI+): Found: 273.0731; 
C13H14NaO5 (MNa+) Requires 273.0733 (0.8 ppm error). 
Lab notebook reference: MGL/07/80 
Obtained data in accord with reported literature.175 
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4-Methoxy-6-nitrobenzo[d][1,3]dioxole (338) and 5-Iodo-7-methoxy-4-
nitrobenzo[d][1,3]dioxole (339’) or 6-Iodo-4-methoxy-5-nitrobenzo[d][1,3]dioxole 
(339’’) 
 
 
 
Prepared according to a modified literature procedure.176 
To a stirred flask containing concentrated nitric acid (70% solution, 100 mL) cooled to 0 °C was 
added 5-methoxypiperonal 324 (10.81 g, 60.0 mmol) portionwise over 2 h. After a further 1 h the 
yellow mixture was poured onto ice water (1 L) to precipitate a pale yellow solid, which was 
collected by suction filitration and washed with water (3 × 100 mL). Purification by column 
chromatography (7:1 hexane:EtOAc) afforded the title compound 338 (6.92 g, 59%) along with 
compound 339’ or 339’’ (3.96 g, 29%). 
 
Data for 338; Pale yellow solid; Rf 0.45 (4:1 hexane:EtOAc); m.p. 130–132 °C (lit.177 145–146 °C); 
νmax (thin film)/cm-1 3109w, 1645m, 1521s, 1491s, 1451m, 1435m, 1347s, 1316s, 1218m, 1198m, 
1112s, 1090m, 970m, 918m, 861m, 770m, 742m; δH (400 MHz, DMSO-d6) 3.93 (3 H, s, OCH3), 
6.24 (2 H, s, OCH2O), 7.53 (1 H, d, J = 2.2, ArH), 7.62 (1 H, d, J = 2.2, ArH); δH (400 MHz, 
CDCl3) 3.96 (3 H, s, OCH3), 6.14 (2 H, s, OCH2O), 7.42 (1 H, d, J = 2.1, ArH), 7.56 (1 H, d, J = 
2.1, ArH); δC (100 MHz, CDCl3) 56.8, 99.0, 103.3, 104.9, 141.1, 142.8, 142.9, 148.7; HRMS 
(ESI+): Found: 220.0218; C8H7NNaO5 (MNa+) Requires 220.0216 (–0.6 ppm error). 
 
Data for 339’/339’’; Yellow solid; Rf 0.19 (4:1 hexane:EtOAc); m.p. 105–108 °C; νmax (thin 
film)/cm-1 2952w, 16988s, 1622m, 1593s, 1523s, 1484s, 1451m, 1418s, 1357s, 1300s, 1231m, 
1151m, 1092s, 1047m, 1020s, 956m, 893s, 864s, 793m, 787m, 762m, 669m, 627m; δH (400 MHz, 
CDCl3) 4.09 (3 H, s, OCH3), 6.17 (2 H, s, OCH2O), 7.03 (1 H, s, ArH), 9.73 (1 H, s, CHO); δC (100 
MHz, CDCl3) 60.9, 102.0, 103.5, 123.2 (2 C), 136.0, 141.8, 150.6, 185.1; HRMS (ESI+): Found: 
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248.0172; C9H7NNaO6 (MNa+) Requires 248.0166 (–2.6 ppm error), Found: 226.0353; C9H8NO6 
(MH+) Requires 226.0346 (–3.2 ppm error). 
 
Lab notebook reference: MGL/07/33 
NMR data in accord with reported literature.178 
Note: The correct regioisomer of compound 339 could not be determined; as such, it is assigned as 
either compound 339’ or 339’’. 
7-Methoxybenzo[d][1,3]dioxol-5-amine (340) 
 
 
 
To a suspension of 4-methoxy-6-nitrobenzo[d][1,3]dioxole 338 (6.86 g, 34.8 mmol) in MeOH (174 
mL) under an atmosphere of argon, was added ammonium formate (11.0 g, 174.0 mmol) and 
palladium on carbon (10% wt. % loading, 1.74 g). The solution was stirred for 16 h then filtered 
through a pad of Celite and washed with MeOH (100 mL). The filtrate was concentrated in vacuo. 
The residue was diluted with brine (250 mL) and extracted with EtOAc (2 × 250 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification 
by column chromatography (1:1 hexane:EtOAc) afforded the title compound 340 as an off-white 
solid (5.41 g, 93%); Rf 0.45 (1:1 hexane:EtOAc); m.p. 75–76 °C (lit.154 85–86 °C); νmax (thin 
film)/cm-1 3397, 3312, 3210, 2886, 1640, 1508, 1459, 1183, 1144, 1087, 1037, 958, 924, 802, 703, 
618; δH (400 MHz, DMSO-d6) 3.71 (3 H, s, OCH3), 4.83 (2 H, br. s, NH2), 5.75 (2 H, s, OCH2O), 
5.82 (1 H, d, J = 2.0, ArH), 5.86 (1 H, d, J = 2.0, ArH); δH (400 MHz, CDCl3) 3.49 (2 H, br. s br. s, 
NH2), 3.84 (3 H, s, OCH3), 5.85 (2 H, s, OCH2O), 5.86 (1 H, d, J = 2.0, ArH), 5.96 (1 H, d, J = 2.0, 
ArH); δC (100 MHz, CDCl3) 56.4, 91.0, 94.3, 100.8, 128.0, 142.1, 143.9, 149.3; HRMS (ESI+): 
Found: 169.0657; C8H10NO3 (MNa+) Requires 168.0655 (−0.8 ppm error). 
Lab notebook reference: MGL/07/19,22,35 
Obtained data in accord with reported literature.154 
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7-Methoxybenzo[d][1,3]dioxole-5-diazonium tetrafluoroborate (341) 
 
 
 
Procedure developed from literature precedent.155  
To a solution of 7-methoxybenzo[d][1,3]dioxol-5-amine 340 (5.22 g, 31.2 mmol) in ethanol (10.3 
mL), cooled to 0 °C was added an aqueous solution of HBF4 (50% w/w, 11.0 g, 62.5 mmol) 
followed by tert-butyl nitrite (7.43 mL, 62.5 mmol) dropwise. The solution was stirred for 1 h after 
which diethyl ether (50 mL) was added, forming a precipitate. The solution was filtered and the 
solid washed with diethyl ether (3 × 100 mL). The solid was dried in vacuo, affording the title 
compound 341 as a yellow solid (7.57 g, 91%). No further purification was required. Rf 0.00 (1:1 
hexane:EtOAc); m.p. decomposes at 126 °C; νmax (thin film)/cm-1 3119w, 2257s, 1624m, 1587m, 
1495s, 1454s, 1442s, 1308s, 1240s, 1223m, 1114s, 1072s, 1023s, 962m, 854s, 522m; δH (400 
MHz, DMSO-d6) 3.94 (3 H, s, OCH3), 6.45 (2 H, s, OCH2O), 7.95 (1 H, d, J = 2.0, ArH), 8.29 (1 
H, d, J = 2.0, ArH); δC (100 MHz, DMSO-d6) 57.5, 104.1, 105.9, 106.5, 116.2, 143.2, 148.0, 148.9; 
HRMS (ESI+): Found: 179.0447; C8H7N2O3 (MNa+) Requires 179.0451 (2.1 ppm error). 
Lab notebook reference: MGL/07/36 
6-Iodo-4-methoxybenzo[d][1,3]dioxole (325) 
 
 
 
To a solution of KI (10.4 g, 62.5 mmol) in water (187 mL) and acetone (125 mL) was added 7-
methoxybenzo[d][1,3]dioxole-5-diazonium tetrafluoroborate 341 (7.57 g, 28.3 mmol) over 15 
mins. The mixture was stirred for 1 h and the acetone removed in vacuo. The residue was extracted 
with diethyl ether (3 × 250 mL). The combined organic extracts were washed with sat. aq. Na2S2O3 
(250 mL) then water (250 mL) then dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (8:1 hexane:EtOAc) afforded the title compound 325 as 
white crystals (4.78 g, 61%); Rf 0.63 (4:1 hexane:EtOAc); m.p. 55–58 °C (lit.179 71–72 °C); νmax 
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(thin film)/cm-1 3098, 2939, 2893, 2775, 1623, 1483, 1443, 1414, 1288, 1230, 1175, 1097, 1031, 
966, 928, 811, 764, 709, 564; δH (400 MHz, CDCl3) 3.85 (3 H, s, OCH3), 5.94 (2 H, s, OCH2O), 
6.81–6.82 (2 H, m, ArH); δC (100 MHz, CDCl3) 56.6, 82.0, 101.7, 111.6, 116.8, 135.7, 144.4, 
149.4; HRMS (ESI+): Found: 277.9441; C8H7IO3 (MNa+) Requires 277.9434 (−2.3 ppm error). 
Lab notebook reference: MGL/07/36, 05/72 
Ethyl 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)acrylate (327) 
 
 
 
Procedure developed from literature precedent.157 
 
To an oven dried sealable tube was added (E)-ethyl 3-(7-methoxybenzo[d][1,3]dioxol-5-yl)acrylate 
326 (500 mg, 2.00 mmol), 6-iodo-4-methoxybenzo[d][1,3]dioxole 325 (834 mg, 3.00 mmol), 
TBAB (709 mg, 2.20 mmol), NaHCO3 (420 mg, 5.00 mmol), Pd(OAc)2 (44.9 mg, 0.20 mmol) and 
DMF (5 mL). The tube was sealed and flushed with argon then heated at 120 °C for 16 h. The 
mixture was cooled at RT, diluted with water (50 mL) and extracted with diethyl ether (3 × 50 
mL). The combined organic extracts were washed with brine (50 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The residue was purified by column chromatography (4:1 
hexane:EtOAc) affording the title compound 327 as an orange oil that later crystallised (695 mg, 
87%); Rf 0.22 (4:1 hexane:EtOAc); m.p. 72–76 °C; νmax (thin film)/cm-1 2976w, 2939w, 2900w, 
1715s, 1627s, 1600m, 1506s, 1426s, 1377s, 1290m, 1222s, 1171m, 1112s, 1083s, 1044s, 968m, 
929s, 844s, 730s; δH (400 MHz, CDCl3) 1.16 (3 H, t, J = 7.1, H-13), 3.84 (6 H, app. s, H-7,7’), 4.07 
(2 H, q, J = 7.1, H-12), 5.97 (2 H, s, H-8/8’), 5.99 (2 H, s, H-8/8’), 6.18 (1 H, s, H-10), 6.36 (1 H, 
d, J = 1.3, H-4/4’/6/6’), 6.38 (1 H, d, J = 1.3, H-4/4’/6/6’), 6.48 (1 H, d, J = 1.5, H-4/4’/6/6’), 6.51 
(1 H, d, J = 1.5, H-4/4’/6/6’); δC (100 MHz, CDCl3) 14.0 (C-13), 56.5 (C-7/7’), 56.7 (C-7/7’), 59.9 
(C-12), 101.5 (C-8/8’), 101.8 (C-8/8’), 102.2 (C-4/4’/6/6’), 103.8 (C-4/4’/6/6’), 108.7 (C-
4/4’/6/6’), 109.0 (C-4/4’/6/6’), 116.2 (C-10), 132.9 (C-5/5’), 132.9 (C-5/5’), 135.3 (C-1/1’/2/2’), 
135.4 (C-5/5’), 136.5 (C-1/1’/2/2’), 143.1 (C-3/3’), 143.1 (C-3/3’), 148.3 (C-1/1’/2/2’), 148.8 (C-
1/1’/2/2’), 155.5 (C-9), 165.9 (C-11); HRMS (ESI+): Found: 423.1048; C21H20NaO8 (MNa+) 
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Requires 423.1050 (0.5 ppm error), Found: 401.1220; C21H21O8 (MH+) Requires 401.1231 (2.8 
ppm error). 
Lab notebook reference: MGL/07/85 
3,3-Bis(7-methoxybenzo[d][1,3]dioxol-5-yl)prop-2-en-1-ol (344) 
 
 
 
To a solution of ethyl 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)acrylate 327 (1.32 g, 3.30 mmol) 
in THF (16 mL) cooled to −78 °C was added dropwise DIBAL (6.60 mL, 6.60 mmol, 1.0 M in 
hexane) and stirred for 2 h. The solution was quenched with water (15 mL) dropwise and stirred for 
30 mins at RT before being filtered through a pad of Celite and washed with diethyl ether (500 
mL). The filtrate was concentrated in vacuo. Purification by column chromatography (4:1 
hexane:EtOAc) afforded the title compound 344 as a yellow gum (1.08 g, 91%); Rf 0.31 (4:1 
hexane:EtOAc); νmax (thin film)/cm-1 3360br, 2889w, 1626s, 1505s, 1447w, 1424s, 1376m, 1191m, 
1153m, 1085s, 1042s, 967m, 928s, 844s, 728s; δH (400 MHz, CDCl3) 2.15 (1 H, br. s, OH), 3.80 (3 
H, s, H-7/7’), 3.82 (3 H, s, H-7/7’), 4.16 (2 H, d, J = 6.8, H-11), 5.91 (2 H, s, H-8/8’), 5.95 (2 H, s, 
H-8/8’), 6.04 (1 H, t, J = 6.8, H-10), 6.31 (1 H, d, J = 1.4, H-4/4’/6/6’), 6.31 (1 H, d, J = 1.4, H-
4/4’/6/6’), 6.41 (1 H, d, J = 1.5, H-4/4’/6/6’), 6.42 (1 H, d, J = 1.5, H-4/4’/6/6’); δC (100 MHz, 
CDCl3) 56.4 (C-7/7’), 56.5 (C-7/7’), 60.4 (C-11), 101.4 (2 C, C-8,8’), [101.8, 103.8, 107.5, 109.1 
(C-4/4’/6/6’)], 126.5 (C-10), [133.1, 134.5, 134.8, 136.5, 142.9, 143.1, 143.2, 148.4, 148.5 (C-
1,1’,2,2’,3,3’,5,5’,9)]; HRMS (ESI+): Found: 381.0938; C19H18NaO7 (MNa+) Requires 381.0945 
(1.7 ppm error). 
Lab notebook reference: MGL/07/86 
327 344
DIBAL
THF
OMe
1
24 3
5
6
8
7
O
O
OMe
O
O 3'
6'
4'
5'1'
2'
7'
8'
9
1011
OH
OMe
O
O
O
O
OMe
O
O
  337 
3,3-Bis(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-(diethoxyphosphoryl)acetate (345) 
 
 
 
Synthesised using general procedure A with 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)prop-2-en-
1-ol 344 (973 mg, 2.72 mmol), toluene (13.6 mL), DEPAA (559 mg, 2.85 mmol), DIPEA (1.23 
mL, 7.07 mmol) and T3P (2.25 g, 3.54 mmol, 50% w/w solution in THF) affording the title 
compound 345 as a yellow oil (1.45 g, 99%); Rf 0.26 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 
2984w, 2936w, 2902w, 1733s, 1626s, 1507s, 1426s, 1262s, 1160m, 1107s, 1042s, 1020s, 965s, 
929m, 839s, 728s; δH (400 MHz, CDCl3) 1.29 (6 H, td, J = 7.1, J = 0.4, H-15), 2.95 (2 H, d, J = 
21.5, H-13), 3.81 (3 H, s, H-8/8’), 3.83 (3 H, s, H-8/8’), 4.09–4.17 (4 H, m, H-14), 4.65 (2 H, d, J = 
7.2, H-11), 5.91 (2 H, s, H-2/2’), 5.96 (2 H, s, H-2/2’), 5.98 (1 H, t, J = 7.2, H-10), 6.31 (1 H, d, J = 
1.4, H-4/4’/6/6’), 6.33 (1 H, d, J = 1.4, H-4/4’/6/6’), 6.39 (1 H, d, J = 1.6, H-4/4’/6/6’), 6.41 (1 H, 
d, J = 1.6, H-4/4’/6/6’); δC (100 MHz, CDCl3) 16.2 (d, J = 6.6, C-15), 34.2 (d, J = 134.2, C-13), 
56.5 (C-8/8’), 56.5 (C-8/8’), 62.6 (d, J = 6.5, C-14), 63.6 (C-11), 101.4 (2 C, C-2,2’), [101.9, 103.8, 
107.7, 109.2 (C-4/4’/6/6’)], 120.5 (C-10), [132.5, 134.8, 135.2, 136.0, 143.0, 143.2, 146.2, 148.6, 
148.6 (C-1,1’,3,3’,5,5’,7,7’,9)], 165.5 (d, J = 6.5, C-12); δP (162 MHz, CDCl3) 20.2; HRMS (ESI+): 
Found: 559.1348; C25H29NaO11P (MNa+) Requires 559.1340 (−1.5 ppm error). 
Lab notebook reference: MGL/07/87 
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3,3-Bis(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl 2-(diethoxyphosphoryl)acetate 
(346) and 6,6'-(Propane-1,1-diyl)bis(4-methoxybenzo[d][1,3]dioxole) (347) 
 
 
 
To a solution of 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-(diethoxyphosphoryl)acetate 
345 (457 mg, 0.852 mmol) in methanol (4.26 mL) was added palladium on carbon (10% wt. % 
loading, 17 mg). The flask was purged 4 times with argon then 4 times with hydrogen. The mixture 
was stirred at RT for 16 h. The mixture was filtered through a pad of Celite and washed with 
methanol (50 mL) and the filtrate concentrated in vacuo. Purification by column chromatography 
(1:2 hexane:EtOAc) afforded the title compounds 346 (280 mg, 61%) and 347 (86 mg, 29%). 
 
Data for 346; Yellow oil; Rf 0.21 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 2982w, 2940w, 2905w, 
1733s, 1632s, 1507s, 1449m, 1430s, 1266s, 1193s, 1128s, 1091s, 1019s, 964s, 929w, 834s; δH (400 
MHz, CDCl3) 1.30 (6 H, t, J = 7.1, H-15), 2.24 (2 H, app. q, J = 7.2, H-10), 2.94 (2 H, d, J = 21.6, 
H-13), 3.85 (6 H, s, H-8), 3.87 (1 H, t, J = 7.9, H-9), 4.05 (2 H, t, J = 6.5, H-11), 4.14 (4 H, dq, J = 
8.3, J = 7.1, H-14), 5.88 (4 H, s, H-2), 6.37 (2 H, d, J = 1.4, H-4/6), 6.38 (2 H, d, J = 1.4, H-4/6); δC 
(100 MHz, CDCl3) 16.2 (d, J = 6.1, C-15), 34.2 (d, J = 133.6, C-13), 34.2 (C-10),  46.9 (C-9), 56.6 
(C-8), 62.6 (d, J = 6.4, C-14), 63.6 (C-11), 101.2 (C-2), 101.4 (C-4/6), 107.3 (C-4/6), [133.6, 138.3, 
143.3, 148.9 (C-1,3,5,7)], 165.5 (d, J = 5.9, C-12); δP (162 MHz, CDCl3) 20.4; HRMS (ESI+): 
Found: 561.1503; C25H31NaO11P (MNa+) Requires 561.1496 (−1.1 ppm error). 
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Data for 347; Yellow oil; Rf 0.86 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 2961w, 2933w, 2874w, 
1632s, 1506s, 1449s, 1428s, 1366w, 1312m, 1193s, 1133s, 1092s, 1043s, 930s; δH (400 MHz, 
CDCl3) 0.89 (3 H, t, J = 7.3, H-11), 1.95 (2 H, app. quin., J = 7.4, H-10), 3.58 (1 H, t, J = 7.8, H-9), 
3.88 (6 H, s, H-8), 5.91–5.92 (4 H, m, H-2) 6.39 (2 H, d, J = 1.3, H-4/6), 6.42 (2 H, d, J = 1.3, H-
4/6); δC (100 MHz, CDCl3) 12.7 (C-11), 28.8 (C-10), 53.1 (C-9), 56.6 (C-8), 101.2 (C-2), 101.6 (C-
4/6), 107.3 (C-4/6), [133.4, 139.8, 143.3, 148.8 (C-1,3,5,7)]; HRMS (ESI+): Found: 367.1149; 
C19H20NaO6 (MNa+) Requires 367.1152 (0.7 ppm error). 
Lab notebook reference: MGL/07/88 
3,3-Bis(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl 2-diazo-2-
(diethoxyphosphoryl)acetate (342) 
 
 
 
Synthesised using general procedure B with 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl 2-
(diethoxyphosphoryl)acetate 346 (278 mg, 0.516 mmol), THF (2.58 mL), LHMDS (0.620 mL, 
0.620 mmol, 1.0 M solution in THF) and DBSA (0.21 mL, 0.620 mmol). Purification by column 
chromatography (1:2 hexane:EtOAc) afforded the title compound 342 as a yellow oil (147 mg, 
51%); Rf 0.70 (1:4 hexane:EtOAc); νmax (thin film)/cm-1 2982w, 2941w, 2906w, 2129s, 1704s, 
1633s, 1508m, 1451m, 1431m, 1369w, 1279s, 1194m, 1131s, 1092s, 1041s, 1019s, 977m; δH (400 
MHz, CDCl3) 1.36 (6 H, td, J = 7.1, J = 0.7, H-15), 2.27 (2 H, app. q, J = 7.2, H-10), 3.85 (1 H, t, J 
= 7.8, H-9), 3.87 (6 H, s, H-8), 4.11–4.27 (6 H, m, H-11,14), 5.92 (4 H, s, H-2), 6.37 (2 H, d, J = 
1.4, H-4/6), 6.39 (2 H, d, J = 1.4, H-4/6); δC (100 MHz, CDCl3) 16.2 (d, J = 6.8, C-15), 34.5 (C-
10), 47.2 (C-9), 53.7 (d, J = 231.7, C-13), 56.8 (C-8), 63.6 (d, J = 5.7, C-14), 63.9 (C-11), 101.5 
(C-2), 101.5 (C-4/6), 107.4 (C-4/6), [133.8, 138.3, 143.4, 149.1 (C-1,3,5,7)], 163.2 (d, J = 11.8, C-
12); δP (162 MHz, CDCl3) 10.7; HRMS (ESI+): Found: 587.1406; C25H29N2NaO11P (MNa+) 
Requires 587.1401 (−0.8 ppm error). 
Lab notebook reference: MGL/07/89 
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3,3-Bis(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-diazo-2-
(diethoxyphosphoryl)acetate (322) 
 
 
 
Synthesised using general procedure B with 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-
(diethoxyphosphoryl)acetate 345 (996 mg, 1.86 mmol), THF (9.30 mL), LHMDS (2.23 mL, 2.23 
mmol, 1.0 M solution in THF) and DBSA (0.75 mL, 2.23 mmol). Purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 322 as a yellow oil (665 mg, 
63%); Rf 0.27 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 2984w, 2943w, 2905w, 2129s, 1703s, 
1627s, 1507s, 1427s, 1275s, 1162m, 1108m, 1094m, 1044s, 1020s, 970s, 932m; δH (400 MHz, 
CDCl3) 1.34 (6 H, td, J = 7.1, J = 0.6, H-15), 3.84 (3 H, s, H-8/8’), 3.86 (3 H, s, H-8/8’), 4.08–4.27 
(4 H, m, H-14), 4.74 (2 H, d, J = 7.2, H-11), 5.95 (2 H, s, H-2/2’), 5.99 (2 H, s, H-2/2’), 6.01 (1 H, 
t, J = 7.2, H-10), 6.34–6.35 (2 H, m, H-4/4’/6/6’), 6.42 (1 H, d, J = 1.6, H-4/4’/6/6’), 6.43 (1 H, d, J 
= 1.6, H-4/4’/6/6’); δC (100 MHz, CDCl3) 16.1 (2 C, d, J = 6.9, C-15), 53.6 (d, J = 228.1, C-13), 
56.6 (C-8/8’), 56.7 (C-8/8’), 63.6–63.7 (3C, m, C-11,14), 101.6 (2 C, C-2,2’), [102.1, 103.9, 107.9, 
109.2 (C-4/4’/6/6’)], 120.3 (C-10), [132.5, 135.0, 135.4, 136.0, 143.1, 143.4, 146.9, 148.7, 148.8 
(C-1,1’,3,3’,5,5’,7,7’,9)], 163.3 (d, J = 12.7, C-12); δP (162 MHz, CDCl3) 10.6; HRMS (ESI+): 
Found: 585.1240; C25H27N2NaO11P (MNa+) Requires 585.1245 (0.7 ppm error). 
Lab notebook reference: MGL/07/91 
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Diethyl ((1SR,5SR)-6,6-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)-2-oxo-3-
oxabicyclo[3.1.0]hexan-1-yl)phosphonate (323) 
 
 
 
Synthesised using general procedure F with 3,3-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-
diazo-2-(diethoxyphosphoryl)acetate 322 (368 mg, 0.654 mmol), CH2Cl2 (13.1 mL) and Rh2(tpa)4 
(18.8 mg, 13.1 µmol). Purification by column chromatography (1:4 hexane:EtOAc → EtOAc) 
afforded the title compound 323 as an off-white solid (153 mg, 44%); Rf 0.24 (1:4 hexane:EtOAc); 
m.p. 81–84 °C; νmax (thin film)/cm-1 2926w, 1758s, 1632s, 1507m, 1429s, 1364m, 1240s, 1192s, 
1155m, 1093s, 1042s, 1015s, 968s, 929m, 728s; δH (400 MHz, CDCl3) 1.14 (3 H, t, J = 7.1, H-
15/15’), 1.27 (3 H, t, J = 7.1, H-15/15’), 3.36 (1 H, dd, J = 12.5, J = 4.8, H-10), 3.69–3.81 (1 H, m, 
H-14/14’), 3.88 (3 H, s, H-8/8’), 3.89 (3 H, s, H-8/8’), 3.91–4.01 (1 H, m, H-14/14’), 4.06–4.23 (2 
H, m, H-14/14’), 4.28 (1 H, dd, J = 9.9, J = 2.2, H-9), 4.50 (1 H, dd, J = 9.9, J = 5.3, H-9), 5.89–
5.93 (4 H, m, H-2,2’), 6.51 (1 H, br. s, H-4/4’/6/6’), 6.60–6.61 (2 H, m, H-4/4’/6/6’), 6.72 (1 H, d, 
J = 1.6, H-4/4’/6/6’); δC (100 MHz, CDCl3) 16.2 (d, J = 6.1, C-15/15’), 16.3 (d, J = 6.5, C-15/15’), 
34.5 (d, J = 4.0, C-10), 37.8 (d, J = 203.9, C-12), 46.4 (d, J = 2.8, C-11), 56.7 (C-8/8’), 56.7 (C-
8/8’), 62.3 (d, J = 6.5, C-14/14’), 63.5 (d, J = 6.9, C-14/14’), 65.5 (d, J = 3.5, C-9), 101.5 (C-2/2’), 
101.6 (C-2/2’), [102.4, 102.9, 108.1, 109.3 (C-4/4’/6/6’)], 130.6 (d, J = 1.8, C-5/5’), 133.2 (d, J = 
5.5, C-5/5’), [134.6, 135.0, 143.1, 143.9, 148.7, 149.2 (C-1/1’/3/3’/7/7’)], 171.2 (d, J = 10.5, C-13); 
δP (162 MHz, CDCl3) 16.2; HRMS (ESI+): Found: 557.1169; C25H27NaO11P (MNa+) Requires 
557.1183 (2.5 ppm error), Found: 535.1362; C25H28O11P (MH+) Requires 535.1364 (0.2 ppm error). 
Lab notebook reference: MGL/07/96,92 
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Diethyl ((3RS,4SR)-4-(bis(7-methoxybenzo[d][1,3]dioxol-5-yl)methyl)-2-
oxotetrahydrofuran-3-yl)phosphonate (343) 
 
 
 
To an oven dried sealable tube containing SmI2 (10.6 mL, 1.06 mmol, ~0.1 M solution in THF) 
under an atmosphere of argon, atmosphere and cooled to −78 °C was added dropwise a solution of 
diethyl ((1SR,5SR)-6,6-bis(7-methoxybenzo[d][1,3]dioxol-5-yl)-2-oxo-3-oxabicyclo[3.1.0]hexan-
1-yl)phosphonate 323 (142 mg, 0.266 mmol) in THF (2.66 mL). The mixture was stirred at −78 °C 
for 10 mins then quenched by addition of sat. aq. NH4Cl (5 mL) and allowed to warm at RT. The 
biphasic mixture was extracted with EtOAc (3 × 25 mL) and the combined organic extracts dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (1:2 
hexane:EtOAc) afforded the title compound 343 as a white solid (78 mg, 55%); Rf 0.44 (1:2 
hexane:EtOAc); m.p. 59–62 °C; νmax (thin film)/cm-1 2981w, 2909w, 1770s, 1633s, 1508s, 1451s, 
1433s, 1370m, 1316s, 1248s, 1197m, 1156m, 1132m, 1091s, 1042s, 1021s, 968s, 731s; δH (400 
MHz, CDCl3) 1.31 (3 H, t, J = 7.1, H-15/15’), 1.31 (3 H, t, J = 7.1, H-15/15’), 2.84 (1 H, d, J = 
24.5, H-11), 3.44–3.53 (1 H, m, H-12), 3.61 (1 H, d, J = 12.4, H-9), 3.88 (3 H, s, H-8/8’), 3.90 (3 
H, s, H-8/8’), 3.99–4.21 (5 H, m, H-13,14,14’), 4.49 (1 H, dd, J = 9.4, J = 6.0, H-13), 5.90–5.92 (4 
H, m, H-2,2’), 6.37 (1 H, d, J = 1.4, H-4/4’/6/6’), 6.41 (1 H, d, J = 1.4, H-4/4’/6/6’), 6.45 (1 H, d, J 
= 1.3, H-4/4’/6/6’), 6.46 (1 H, d, J = 1.3, H-4/4’/6/6’); δC (100 MHz, CDCl3) 16.1 (d, J = 6.5, C-
15/15’), 16.2 (d, J = 6.2, C-15/15’), 42.1 (d, J = 2.6, C-12), 44.8 (d, J = 133.0, C-11), 54.2 (d, J = 
13.9, C-9), 56.7 (C-8/8’), 56.8 (C-8/8’), 63.1 (d, J = 7.0, C-14/14’), 63.7 (d, J = 7.1, C-14/14’), 
70.6 (C-13), 101.2 (C-4/4’/6/6’), 101.4 (C-2/2’), 101.5 (C-2/2’), 101.9 (C-4/4’/6/6’), 107.6 (C-
4/4’/6/6’), 107.9 (C-4/4’/6/6’), 134.2 (C-1/1’/3/3’), 134.3 (C-1/1’/3/3’), 135.3 (C-5/5’), 136.2 (d, J 
= 1.8, C-5/5’), 143.6 (C-7/7’), 143.6 (C-7/7’), 149.2 (C-1/1’/3/3’), 149.4 (C-1/1’/3/3’), 171.7 (d, J 
= 5.4, C-10); δP (162 MHz, CDCl3) 19.7; HRMS (ESI+): Found: 559.1329; C25H29NaO11P (MNa+) 
Requires 559.1340 (1.8 ppm error). 
Lab notebook reference: MGL/08/06 
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(±)-Peperomin E (308) 
 
 
 
To a solution of diethyl ((3RS,4SR)-4-(bis(7-methoxybenzo[d][1,3]dioxol-5-yl)methyl)-2-
oxotetrahydrofuran-3-yl)phosphonate 343 (66 mg, 0.123 mmol) in THF (2.5 mL) cooled to 0 °C 
under an argon atmosphere was added KOBu-t (16.6 mg, 0.148 mmol). The solution was stirred for 
30 mins after which paraformaldehyde (18.5 mg, 0.615 mmol) was added in one portion. The 
mixture was stirred for 30 mins at 0°C then 1 h at RT then quenched by addition of sat. aq. NH4Cl 
(5 mL). The mixture was extracted with EtOAc (3 × 25 mL) and the combined organic extracts 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (2:1 
hexane:EtOAc) afforded the title compound 308 as a white crystalline solid (44 mg, 87%); Rf 0.68 
(1:1 hexane:EtOAc); m.p. 56–59 °C (lit.145 140 °C); νmax (thin film)/cm-1 2903w, 1760s, 1633s, 
1508s, 1451s, 1432s, 1363m, 1315s, 1195s, 1130s, 1092s, 1042s, 927m, 730m; δH (400 MHz, 
CDCl3) 3.66 (1 H, d, J = 11.6, H-9), 3.75 (1 H, app. dddt, J = 11.6, J = 7.7, J = 4.4, J = 2.2, H-12), 
3.88 (3 H, s, H-8/8’), 3.89 (3 H, s, H-8/8’), 3.98 (1 H, dd, J = 9.5, J = 4.4, H-13), 4.32 (1 H, dd, J = 
9.5, J = 7.7, H-13), 4.93 (1 H, d, J = 2.0, H-14b), 5.93–5.95 (4 H, m, H-2,2’), 6.14 (1 H, d, J = 2.3, 
H-14a), 6.36 (1 H, d, J = 1.5, H-4/4’/6/6’), 6.38 (1 H, d, J = 1.5, H-4/4’/6/6’), 6.45 (1 H, d, J = 1.5, 
H-4/4’/6/6’), 6.46 (1 H, d, J = 1.5, H-4/4’/6/6’); δC (100 MHz, CDCl3) 42.4 (C-12), 55.3 (C-9), 
56.8 (C-8/8’), 56.9 (C-8/8’), 69.7 (C-13), 101.1 (C-4/4’/6/6’), 101.5 (2C, C-2,2’), 101.5 (C-
4/4’/6/6’), 107.9 (C-4/4’/6/6’), 108.3 (C-4/4’/6/6’), 124.9 (C-14), 134.2, 134.3, 135.8, 136.0, 136.1, 
143.4 (C-7/7’), 143.6 (C-7/7’), 149.2, 149.5, 170.7 (C-10); HRMS (ESI+): Found: 435.1050; 
C22H20NaO8 (MNa+) Requires 435.1050 (0.1 ppm error). 
Lab notebook reference: MGL/08/09  
Obtained data in accord with reported literature.145 
Note: Obtained melting point does not match the literature value. 
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(E)-3-(7-Methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-(diethoxyphosphoryl)acetate (S9) 
 
 
 
Synthesised using general procedure A with (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)prop-2-en-
1-ol S8 (1.92 g, 9.22 mmol), toluene (46.1 mL), DEPAA (1.90 g, 9.68 mmol), DIPEA (4.18 mL, 
24.0 mmol) and T3P (7.62 g, 12.0 mmol, 50% w/w solution in toluene) affording the title 
compound S9 as a yellow oil (3.56 g, 100%); Rf 0.33 (1:2 hexane:EtOAc); νmax (thin film)/cm-1 
2983w, 1733s, 1626s, 1509s, 1430s, 1259s, 1199s, 1136m, 1092m, 1041w, 1021s, 965s; δH (400 
MHz, CDCl3) 1.30 (6 H, t, J = 7.1, H-15), 2.98 (2 H, d, J = 21.5, H-13), 3.87 (3 H, s, H-8), 4.11–
4.18 (4 H, m, H-14), 4.74 (2 H, dd, J = 6.6, J = 1.0, H-11), 5.94 (2 H, s, H-2), 6.09 (1 H, dt, J = 
15.8, J = 6.6, H-10), 6.51 (1 H, d, J = 1.5, H-4/6), 6.53 (1 H, br. d, J = 15.8, H-9), 6.58 (1 H, d, J = 
1.5, H-4/6); δC (100 MHz, CDCl3) 16.2 (d, J = 6.3, C-15), 34.2 (d, J = 134.3, C-13), 56.4 (C-8), 
62.6 (d, J = 6.5, C-14), 65.9 (C-11), 100.1 (C-4/6), 101.5 (C-2), 106.9 (C-4/6), 121.0 (C-10), 130.9 
(C-1/3/5/7), 134.5 (C-9), 135.3 (C-1/3/5/7), 143.4 (C-1/3/5/7), 149.0 (C-1/3/5/7), 165.5 (d, J = 6.1, 
C-12); δP (162 MHz, CDCl3) 20.2; HRMS (ESI+): Found: 409.1018; C17H23NaO8P (MNa+) 
Requires 409.1023 (1.2 ppm error). 
Lab notebook reference: MGL/08/04 
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(E)-3-(7-Methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-diazo-2-(diethoxyphosphoryl)acetate 
(320) 
 
 
 
To a solution of (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-(diethoxyphosphoryl)acetate S9 
(386 mg, 1.00 mmol) and DBSA (422 mg, 1.5 mmol) in CH2Cl2 (10.0 mL), cooled to 0 °C under 
an argon atmosphere was added DBU (0.22 mL, 1.50 mmol) dropwise. The solution was allowed 
to warm to RT and stirred for 2 h. Concentration in vacuo and purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 320 as a pale yellow oil (397 mg, 
96%); Rf 0.29 (1:1 hexane:EtOAc); νmax (thin film)/cm-1 2984w, 2940w, 2907w, 2127s, 1702s, 
1625m, 1509m, 1430m, 1270s, 1199m, 1092m, 1015s, 965s, 813m, 743m, 589m, 560m; δH (400 
MHz, CDCl3) 1.35 (6 H, t, J 7.1, H-15), 3.89 (3 H, s, H-8), 4.11–4.27 (4 H, m, H-14), 4.81 (2 H, d, 
J 6.6, H-11), 5.96 (2 H, s, H-2), 6.11 (1 H, dt, J 15.7, J 6.6, H-10), 6.52 (1 H, d, J 1.2, H-4/6), 6.55 
(1 H, br. d, J 15.7, H-9), 6.60 (1 H, d, J 1.2, H-4/6); δC (100 MHz, CDCl3) 16.1 (d, J 7.1, C-15), 
53.8 (d, J 225.8, C-13), 56.5 (C-8), 63.7 (d, J 5.9, C-14), 66.0 (C-11), 100.2 (C-4/6), 101.6 (C-2), 
107.0 (C-4/6), 121.0 (C-10), 130.8 (C-1/3/5/7), 134.8 (C-9), 135.5 (C-1/3/5/7), 143.5 (C-1/3/5/7), 
149.1 (C-1/3/5/7), 163.2 (d, J 12.4, C-12); δP (162 MHz, CDCl3) 10.5; HRMS (ESI+): Found: 
435.0917; C17H21N2NaO8P (MNa+) Requires 435.0928 (2.5 ppm error). 
Lab notebook reference: MGL/08/11 
 
DBSA
DBU
CH2Cl2
S9
OMe
3
16 7
5
4
2
8
O
O9
1011
O P
O
O
O
O
12
13
14
15
320
OMe
O
O
O P
O
O
O
O
N2
 346
Diethyl ((1RS,5SR,6SR)-6-(7-methoxybenzo[d][1,3]dioxol-5-yl)-2-oxo-3-
oxabicyclo[3.1.0]hexan-1-yl)phosphonate (321) 
 
 
 
Synthesised using general procedure F with (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)allyl 2-
diazo-2-(diethoxyphosphoryl)acetate 320 (80 mg, 0.194 mmol), CH2Cl2 (3.9 mL) and Rh2(oct)4 
(3.0 mg, 3.9 µmol). Purification by column chromatography (1:4 hexane:EtOAc → EtOAc) 
afforded the title compound 321 as a yellow solid (48 mg, 64%); Rf 0.14 (1:4 hexane:EtOAc); m.p. 
95–97 °C; νmax (thin film)/cm-1 2982w, 2909w, 1762s, 1634m, 1514m, 1432m, 1370m, 1249m, 
1195m, 1140m, 1093m, 1017s, 971s, 812m, 589m; δH (400 MHz, CDCl3) 1.16 (3 H, t, J = 7.1, H-
15/15’), 1.21 (3 H, t, J = 7.1, H-15/15’), 2.73 (1 H, app. t, J = 6.0, H-9), 3.17 (1 H, app. dt, J = 
10.6, J = 5.2, H-10), 3.88 (3 H, s, H-8), 3.91–4.09 (4 H, m, H-14/14’), 4.37 (1 H, dd, J = 9.4, J = 
2.8, H-11), 4.47 (1 H, dd, J = 9.4, J = 4.7, H-11), 5.94 (1 H, d, J = 1.4, H-2), 5.94 (1 H, d, J = 1.4, 
H-2), 6.51 (1 H, d, J = 1.0, H-4/6), 6.61 (1 H, d, J = 1.0, H-4/6); δC (100 MHz, CDCl3) 16.1 (d, J = 
6.2, C-15/15’), 16.2 (d, J = 6.2, C-15/15’), 28.7 (C-10), 31.6 (d, J = 206.1, C-13), 35.0 (d, J = 3.3, 
C-9), 56.5 (C-8), 62.5 (d, J = 6.2, C-14/14’), 63.0 (d, J = 6.7, C-14/14’), 68.0 (d, J = 3.0, C-11), 
101.5 (C-2), 103.4 (C-4/6), 109.3 (C-4/6), 126.1 (d, J = 5.6, C-5), 135.0 (C-1/3/7), 143.1 (C-1/3/7), 
148.4 (C-1/3/7), 171.8 (d, J = 10.5, C-12); δP (162 MHz, CDCl3) 15.5; HRMS (ESI+): Found: 
407.0860; C17H21NaO8P (MNa+) Requires 407.0866 (1.5 ppm error), Found: 385.1040; C17H22O8P 
(MH+) Requires 385.1047 (1.8 ppm error). 
Lab notebook reference: MGL/08/23 
 
 
 
 
Rh2(oct)4
CH2Cl2
320
5
6 7
321
15'
9
12 13
1011
14'
O
O
P
H
O O
O 15
14
O
O
P O
O
ON2
1
3
O
O
O
O
4
2
OMe8OMe
  347 
Appendices 
Appendix I:  Natural product NMR spectra and literature comparison tables 
Cedarmycin A 
Table 10: Comparison table of the 1H NMR data of the natural (δH ref)98 and synthetic (δH obs) 
cedarmycin A 189.  
 
Table 11: Comparison table of the 13C NMR data of the natural (δC ref)98 and synthetic (δC obs) 
cedarmycin A 189.  
 
 
1H NMR data of cedarmycin A (CDCl3) 
Label δH ref
98 
(400 MHz) 
δH obs 
(400 MHz) 
12 0.89 6 H, d, J = 6.6 0.88 6 H, d, J = 6.6 
10 1.19 2 H, m 1.15–1.21 2 H, m 
9,11 1.55  1 H, m 1.51–1.65 3 H, m 1.62 2 H, m 
8 2.31 2 H, t, J = 7.6 2.31 2 H, t, J = 7.6 
3 3.43 1 H, m 3.39–3.47 1 H, m 
6 4.18 1 H, dd,  J = 11.2, J = 7.3 4.16 
1 H, dd, 
 J = 11.2, J = 7.3 
4 4.19 1 H, dd,  J = 9.4, J = 5.1 4.18 
1 H, dd,  
J = 9.4, J = 4.9 
6 4.25 1 H, dd,  J = 10.9, J = 5.6 4.25 
1 H, dd,  
J = 11.2, J = 5.6 
4 4.48 1 H, dd,  J = 9.6, J = 8.5 4.48 
1 H, dd,  
J = 9.4, J = 8.4 
5b 5.76 1 H, d, J = 2.4 5.76 1 H, d, J = 2.3 
5a 6.39 1 H, d, J = 2.7 6.39 1 H, d, J = 2.7 
13C NMR data of cedarmycin A (CDCl3) 
Label δC ref
98 
(100 MHz) 
δC obs 
(100 MHz) ∆δC 
12 22.5 22.4 −0.1 
9 22.8 22.7 −0.1 
11 27.7 27.7 0.0 
8 34.3 34.3 0.0 
3 38.1 38.0 −0.1 
10 38.3 38.3 0.0 
6 64.7 64.7 0.0 
4 68.1 68.1 0.0 
5 124.1 124.2 +0.1 
2 134.6 134.5 −0.1 
1 169.8 169.8 0.0 
7 173.5 173.5 0.0 
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1H NMR spectrum of Cedarmycin A 189 (400 MHz, CDCl3)  
 
  349 
13C NMR spectrum of Cedarmycin A 189 (100 MHz, CDCl3) 
 
 350
Cedarmycin B 
Table 12: Comparison table of the 1H NMR data of the natural (δH ref)98 and synthetic (δH obs) 
cedarmycin B 190.  
 
Table 13: Comparison table of the 13C NMR data of the natural (δC ref)98 and synthetic (δC obs) 
cedarmycin B 190.  
 
1H NMR data of cedarmycin B (CDCl3) 
Label δH ref
98 
(400 MHz) 
δH obs 
(400 MHz) 
12 0.90 3 H, t, J = 7.1 0.90 3 H, t, J = 7.0 
10,11 1.32 4 H, m 1.25–1.36 4 H, m 
9 1.62 2 H, quin., J = 7.6 1.62 
2 H, app. quin., 
J = 7.5 
8 2.34 2 H, t, J = 7.8 2.32 2 H, t, J = 7.5 
3 3.43 1 H, m 3.39–3.47 1 H, m 
6 4.18 1 H, dd,  J = 11.2, J = 7.3 4.16 
1 H, dd, 
 J = 11.2, J = 7.3 
4 4.19 1 H, dd,  J = 9.4, J = 5.2 4.18 
1 H, dd,  
J = 9.4, J = 4.9 
6 4.25 1 H, dd,  J = 11.2, J = 5.6 4.25 
1 H, dd,  
J = 11.2, J = 5.6 
4 4.48 1 H, dd,  J = 9.4, J = 8.3 4.48 
1 H, dd,  
J = 9.4, J = 8.4 
5b 5.76 1 H, d, J = 2.2 5.76 1 H, d, J = 2.4 
5a 6.39 1 H, d, J = 2.7 6.38 1 H, d, J = 2.7 
13C NMR data of cedarmycin B (CDCl3) 
Label δC ref
98 
(100 MHz) 
δC obs 
(100 MHz) ∆δC 
12 13.9 13.9 0.0 
11 22.3 22.3 0.0 
9 24.6 24.5 −0.1 
10 31.3 31.2 −0.1 
8 34.0 34.0 0.0 
3 38.1 38.1 0.0 
6 64.7 64.7 0.0 
4 68.1 68.1 0.0 
5 124.1 124.1 0.0 
2 134.6 134.5 −0.1 
1 169.9 169.8 −0.1 
7 173.5 173.5 0.0 
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1H NMR spectrum of Cedarmycin B 190 (400 MHz, CDCl3)  
 
 352
13C NMR spectrum of Cedarmycin B 190 (100 MHz, CDCl3) 
 
  353 
  α-Cyclocostunolide 
Table 14: Comparison table of the 1H NMR data of the natural (δH ref)120b and synthetic (δH obs) α-
cyclocostunolide 256.  
 
Table 15: Comparison table of the 13C NMR data of the natural (δC ref)120a and synthetic (δC obs) 
α-cyclocostunolide 256.  
13C NMR data of (±)-α-cyclocostunolide (CDCl3) 
Label δC ref
120a 
(25.2 MHz) 
δC obs 
(100 MHz) ∆δC 
11 17.4 17.4 0.0 
6 21.5 21.5 0.0 
3 22.9 22.8 −0.1 
12 23.7 23.7 0.0 
10 36.0 35.9 −0.1 
4 37.8 37.7 −0.1 
5 39.2 39.2 0.0 
7 51.2 51.2 0.0 
9 51.3 51.5 +0.2 
8 82.1 82.2 +0.1 
15 116.3 116.4 +0.1 
2 122.3 122.4 +0.1 
1 132.9 133.0 +0.1 
14 139.3 139.4 +0.1 
13 170.8 171.0 +0.2 
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1H NMR data of (±)-α-cyclocostunolide (CDCl3) 
Label δH ref
120b 
(100 MHz) 
δH obs 
(400 MHz) 
11 0.90 1 H, s 0.90 1 H, s 
12 1.84 1 H, s 1.83 1 H, s 
8 3.87 1 H, t, J = 11.0 3.87 1 H, t, J = 11.0 
15b, 2 5.38 2 H, d, J 3.0 5.38 2 H, d, J 3.1 
15a 6.05 1 H, d, J 3.0 6.05 1 H, d, J 3.2 
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1H NMR spectrum of α-cyclocostunolide 256 (400 MHz, CDCl3)  
 
  355 
13C NMR spectrum of α-cyclocostunolide 256 (100 MHz, CDCl3) 
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 (±)-Savinin 
Table 16: Comparison table of the 1H NMR data of the natural (δH ref)141 and synthetic (δH obs) 
savinin 174.  
 
Table 17: Comparison table of the 13C NMR data of the natural (δC ref)140 and synthetic (δC obs) 
savinin 174.  
 
1H NMR data of savinin (CDCl3) 
Label δH ref
141 
(400 MHz) 
δH obs 
(400 MHz) 
13 
2.60 1 H, dd,  J = 14.6, J = 10.4 2.59 
1 H, dd,  
J = 14.2, J = 10.1 
3.00 1 H, dd,  J = 14.6, J = 5.0 2.99 
1 H, dd,  
J = 14.2, J = 4.5 
3 3.73 1 H, m 3.71–3.77 1 H, m 
4 4.21–4.26 2 H, m 4.22–4.29 2 H, m 
20 5.93 2 H, s 5.93 1 H, d, J = 1.4 5.94 1 H, d, J = 1.4 
12 6.04 2 H, s 6.05 2 H, s 
15 
6.62–6.75 3 H, m 
6.64 1 H, dd,  J = 7.8, J = 1.6 
19 6.67 1 H, d, J = 1.6 
16 6.74 1 H, d, J = 7.8 
8 6.88 1 H, d, J = 8.5 6.88 1 H, d, J = 8.1 
11 
7.04–7.09 2 H, m 
7.05 1 H, d, J = 1.7 
7 7.08 1 H, dd,  J = 8.1, J = 1.7 
5 7.49 1 H, s 7.50 1 H, d, J = 1.9 
13C NMR data of savinin (CDCl3) 
Label 
ref 
δC ref140 
(100 MHz) 
Label 
obs 
δC obs 
(100 MHz) ∆δC 
13 37.4 13 37.5 +0.1 
3 39.8 3 39.9 +0.1 
4 69.4 4 69.5 +0.1 
20 101.0 20 101.0 0.0 
12 101.7 12 101.7 0.0 
8 108.4 
8, 11,  
16, 19 
108.5 +0.1 
11 108.6 108.6 0.0 
16 108.7 108.8 +0.1 
19 109.1 109.2 +0.1 
15 122.0 15 122.2 +0.2 
2 125.7 2 125.8 +0.1 
7 126.0 7 126.1 +0.1 
6 128.1 6 128.2 +0.1 
14 131.4 14 131.5 +0.1 
5 137.2 5 137.5 +0.3 
17 146.4 17, 18 146.5 +0.1 18 147.8 147.9 +0.1 
10 148.2 9,10 148.3 +0.1 9 149.1 149.2 +0.1 
1 172.5 1 172.6 +0.1 
O
O
O
O
O
O
savinin, 174
16
51 2
34
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17
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8 9
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1H NMR spectrum of Savinin 174 (400 MHz, CDCl3)  
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13C NMR spectrum of Savinin 174 (400 MHz, CDCl3) 
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(±)-Gadain 
Table 18: Comparison table of the 1H NMR data of the natural (δH ref)143 and synthetic (δH obs) 
gadain 307.  
 
 
 
 
 
 gadain, 307
O
O
O
O
O
O
16
5
1
2
34
14
15
17
18
19
20
6
7
8 9
11
12
10
13
1H NMR data of gadain (CDCl3) 
Label 
ref 
δH ref143 
(300 MHz) 
Label 
obs 
δH obs 
(400 MHz) 
13 
2.82 
1 H, dd,  
J = 16.8, J = 
10.8 13 
2.78 1 H, dd,  J = 13.8, J = 8.9 
2.92 1 H, dd,  J = 16.8, J = 8.4 2.91 
1 H, dd,  
J = 13.8, J = 6.9 
3 3.31 1 H, m 3 3.29 
1 H, app. dtdd, 
J = 8.9, J = 7.1, 
J = 3.8, J = 1.7 
4 
4.12 1 H, dd,  J = 10.8, J = 4.8 4 
4.10 1 H, dd,  J = 9.1, J = 3.8 
4.34 1 H, dd,  J = 10.8, J = 8.4 4.32 
1 H, dd,  
J = 9.1, J = 7.3 
12, 
20 
5.96 1 H, dd,  J = 3.0, J = 1.4 20 
5.95 1 H, d, J = 1.4 
5.96 1 H, d, J = 1.4 
6.00 2 H, s 12 6.00 2 H, s 
5 6.59 1 H, d, J = 1.6 5 6.59 1 H, d, J = 1.7 
15 6.77 1 H, dd,  J = 8.0, J = 1.5 15 6.62 
1 H, dd,  
J = 7.9, J = 1.7 
19 6.70 1 H, d, J = 1.5 19 6.69 1 H, d, J = 1.7 
16 6.66 1 H, d, J = 8.0 16 6.76 1 H, d, J = 7.9 
8 6.80 1 H, d, J = 8.0 8 6.79 1 H, d, J = 8.1 
7 7.17 1 H, dd,  J = 8.0, J = 1.5 7 7.15 
1 H, dd,  
J = 8.1, J = 1.7 
11 7.75 1 H, d, J = 1.5 11 7.74 1 H, d, J = 1.7 
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1H NMR spectrum of Gadain 307 (400 MHz, CDCl3)  
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Table 19: Comparison table of the 13C NMR data of the natural (δC ref)143 and synthetic (δC obs) 
gadain 307.  
13C NMR data of gadain (CDCl3) 
Label 
ref 
δC ref143 
(100 MHz) 
Label 
obs 
δC obs 
(100 MHz) ∆δC 
13 40.7 13 40.7 0.0 
3 44.2 3 44.2 0.0 
4 69.8 4 69.8 0.0 
12, 20 101.0 20 101.0 0.0 101.4 12 101.4 0.0 
19 107.9 8 107.9 0.0 
11 108.4 16 108.4 0.0 
16 109.3 19 109.3 0.0 
8 110.3 11 110.7 +0.4 
15 122.7 15 122.3 −0.4 
7 125.2 2 125.2 0.0 
2 126.9 7 126.9 0.0 
14 127.9 6 127.9 0.0 
6 131.4 14 131.4 0.0 
5 140.3 5 140.4 +0.1 
18 146.5 17, 18 146.5 0.0 17 147.6 147.6 0.0 
10 147.9 9,10 147.9 0.0 9 149.0 149.0 0.0 
1 169.3 1 169.3 0.0 
 
Note: Whilst the observed data points match extremely well with the reference data points, there is 
a discrepancy in the assignment of the peaks in the 13C NMR spectra, despite a complete agreement 
of the assignments in the 1H NMR spectra. 
gadain, 307
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13C NMR spectrum of Gadain 307 (400 MHz, CDCl3) 
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 (±)-Peperomin E 
 
Table 20: Comparison table of the 1H NMR data of the natural (δH ref)145 and synthetic (δH obs) 
(±)-peperomin E 308.  
 
 
O
O
O
O
O
O
OMe
OMe
13 12
10
9
11 14
1
84'
1'
2'
5'
6'
7'
8'
5
6 7
34
2
3'
peperomin E, 308
Ha
Hb
1H NMR data of (±)-Peperomin E (CDCl3) 
Label δH ref
145  
(200 MHz) 
δH obs 
(400 MHz) 
9 3.65 1 H, d, J = 11.5 3.66 1 H, d, J = 11.6 
12 3.70 1 H, m 3.75 
1 H, ddddd,   
J = 11.6,  
J = 7.7, J = 4.4,  
J = 2.3, J = 2.0 
8/8’ 3.88 3 H, s 3.88 3 H, s 
8/8’ 3.89 3 H, s 3.89 3 H, s 
13 3.99 1 H, dd, J = 9.4, J = 4.1, 3.98 
1 H, dd, J = 9.5, J 
= 4.4, 
13 4.32 1 H, dd, J = 9.4, J = 7.3, 4.32 
1 H, dd, J = 9.5, J 
= 7.7, 
14b 4.94 1 H, d, J = 1.7 4.93 1 H, d, J = 2.0 
2,2’ 5.92 4 H, s 5.93–5.95 4 H, m 
14a 6.15 1 H, d, J = 2.0 6.14 1 H, d, J = 2.3 
4/4’/6/6’ 6.37 1 H, d, J = 1.5 6.36 1 H, d, J = 1.5 
4/4’/6/6’ 6.43 1 H, d, J = 1.5 6.38 1 H, d, J = 1.5 
4/4’/6/6’ 6.50 1 H, d, J = 1.5 6.45 1 H, d, J = 1.5 
4/4’/6/6’ 6.60 1 H, d, J = 1.5 6.46 1 H, d, J = 1.5 
 364
1H NMR spectrum of peperomin E 308 (400 MHz, CDCl3) 
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Table 21: Comparison table of the 13C NMR data of the natural (δC ref)145 and synthetic (δC obs) 
(±)-peperomin E 308.  
13C NMR data of (±)-Peperomin E (CDCl3) 
Label ref120a δC ref
145  
(50 MHz) Label obs 
δC obs 
(100 MHz) ∆δC 
12 42.4 12 42.4 0.0 
9 55.3 9 55.3 0.0 
8/8’ 56.8 8/8’ 56.8 0.0 
8/8’ 56.9 8/8’ 56.9 0.0 
13 69.6 13 69.7 +0.1 
4/4’ 101.5 4/4’/6/6’ 101.1 −0.4 
2,2’ 102.0 2,2’ (2 C) 101.5 −0.5 
4/4’ 101.5 4/4’/6/6’ 101.5 0.0 
6/6’ 108.4 4/4’/6/6’ 107.9 −0.5 
6/6’ 108.8 4/4’/6/6’ 108.3 −0.5 
14 125.2 14 124.9 −0.3 
5,5’ (2 C) 134.3 1/1’/3/3’/5/5’/11 134.2 0.0 1/1’/3/3’/5/5’/11 134.3 
11 135.8 1/1’/3/3’/5/5’/11 135.8 0.0 
1/1’ 136.0 1/1’/3/3’/5/5’/11 136.0 0.0 
1/1’ 136.1 1/1’/3/3’/5/5’/11 136.1 0.0 
7/7’ 143.4 7/7’ 143.4 0.0 
7/7’ 143.6 7/7’ 143.6 0.0 
3/3’ 149.2 1/1’/3/3’/5/5’/11 149.2 0.0 
3/3’ 149.5 1/1’/3/3’/5/5’/11 149.5 0.0 
10 170.7 10 170.7 0.0 
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Appendix II:  Crystallographic data 
Compound 116c  
 
CCDC Number 980606 
Identification code  rjkt1212  
Empirical formula  C14H19O5P  
Formula weight  298.26  
Temperature/K  110.00(10)  
Crystal system  monoclinic  
Space group  P21/c 
a/Å  10.12764(18) 
b/Å  8.97571(13)  
c/Å  15.9855(3)  
α/°  90.00  
β/°  94.4074(16)  
γ/°  90.00  
Volume/Å3  1448.83(4) 
Z  4 
ρcalcg/cm3  1.367  
µ/mm-1  0.206  
F(000)  632.0  
Crystal size/mm3  0.225 × 0.1634 × 0.0635 
2Θ range for data collection/° 6.08 to 64.4 
Index ranges  -15 ≤ h ≤ 13, -13 ≤ k ≤ 13, -23 ≤ l ≤ 23  
Reflections collected  13784 
Independent reflections  4681[R(int) = 0.0270]  
Data/restraints/parameters  4681/0/183  
Goodness-of-fit on F2  1.037  
Final R indexes [I>=2σ (I)]  R1 = 0.0362, wR2 = 0.0894 
Final R indexes [all data]  R1 = 0.0431, wR2 = 0.0953  
Largest diff. peak/hole / e Å-3  0.40/-0.358 
 
The crystal was grown by evaporation of diethyl ether layered on chloroform inside a standard 
NMR tube. 
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Compound 153e  
 
CCDC Number 1013524 
Identification code  rjkt1306  
Empirical formula  C26H27O5P  
Formula weight  450.45  
Temperature/K  110.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.5981(5)  
b/Å  11.0011(9)  
c/Å  12.4360(9)  
α/°  68.604(7)  
β/°  72.191(5)  
γ/°  79.237(6)  
Volume/Å3  1159.82(14)  
Z  2  
ρcalcg/cm3  1.290  
µ/mm-1  0.153  
F(000)  476.0  
Crystal size/mm3  0.2995 × 0.1557 × 0.0689  
2Θ range for data collection/° 5.74 to 60.06 
Index ranges  -13 ≤ h ≤ 12, -14 ≤ k ≤ 15, -17 ≤ l ≤ 12  
Reflections collected  10694  
Independent reflections  6704[R(int) = 0.0282]  
Data/restraints/parameters  6704/18/446  
Goodness-of-fit on F2  1.043  
Final R indexes [I>=2σ (I)]  R1 = 0.0719, wR2 = 0.1760  
Final R indexes [all data]  R1 = 0.1018, wR2 = 0.1993  
Largest diff. peak/hole / e Å-3  0.63/-0.35  
 
The crystal was grown by evaporation of diethyl ether layered on chloroform inside a standard 
NMR tube. 
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Compound 240  
 
CCDC Number 1421158 
Identification code  rjkt1516  
Empirical formula  C15H18O2  
Formula weight  230.29  
Temperature/K  132(30)  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.4631(4)  
b/Å  8.1068(4)  
c/Å  10.7071(5)  
α/°  89.047(4)  
β/°  89.710(4)  
γ/°  89.044(4)  
Volume/Å3  647.61(6)  
Z  2  
ρcalcg/cm3  1.181  
µ/mm-1  0.608  
F(000)  248.0  
Crystal size/mm3  0.2239 × 0.1846 × 0.0284  
Radiation  CuKα (λ = 1.54181)  
2Θ range for data collection/°  8.26 to 142.02  
Index ranges  -8 ≤ h ≤ 9, -9 ≤ k ≤ 7, -12 ≤ l ≤ 13  
Reflections collected  4954  
Independent reflections  2399 [Rint = 0.0157, Rsigma = 0.0212]  
Data/restraints/parameters  2399/1/176  
Goodness-of-fit on F2  1.030  
Final R indexes [I>=2σ (I)]  R1 = 0.0395, wR2 = 0.1082  
Final R indexes [all data]  R1 = 0.0439, wR2 = 0.1122  
Largest diff. peak/hole / e Å-3  0.27/-0.19  
 
The crystal was grown by evaporation of diethyl ether layered on chloroform inside a standard 
NMR tube. 
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Compound 241  
 
CCDC Number 1421154 
Identification code  rjkt1506  
Empirical formula  C15H20O2  
Formula weight  232.31  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  6.95182(16)  
b/Å  12.2280(3)  
c/Å  30.5046(6)  
α/°  90  
β/°  95.654(2)  
γ/°  90  
Volume/Å3  2580.47(10)  
Z  8  
ρcalcg/cm3  1.196  
µ/mm-1  0.611  
F(000)  1008.0  
Crystal size/mm3  0.1215 × 0.081 × 0.0366  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.794 to 134.144  
Index ranges  -8 ≤ h ≤ 7, -10 ≤ k ≤ 14, -32 ≤ l ≤ 36  
Reflections collected  8613  
Independent reflections  4600 [Rint = 0.0192, Rsigma = 0.0302]  
Data/restraints/parameters  4600/0/309  
Goodness-of-fit on F2  1.039  
Final R indexes [I>=2σ (I)]  R1 = 0.0487, wR2 = 0.1285  
Final R indexes [all data]  R1 = 0.0633, wR2 = 0.1362  
Largest diff. peak/hole / e Å-3  0.35/-0.21  
 
The crystal was grown by evaporation of diethyl ether layered on chloroform inside a standard 
NMR tube. 
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Compound 261  
 
CCDC Number 1421164 
Identification code  rjkt1515  
Empirical formula  C17H32O2Si  
Formula weight  296.51  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  23.0721(10)  
b/Å  6.5804(2)  
c/Å  26.2324(11)  
α/°  90  
β/°  117.509(5)  
γ/°  90  
Volume/Å3  3532.4(3)  
Z  8  
ρcalcg/cm3  1.115  
µ/mm-1  1.161  
F(000)  1312.0  
Crystal size/mm3  0.1481 × 0.0793 × 0.0664  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.6 to 134.142  
Index ranges  -27 ≤ h ≤ 27, -5 ≤ k ≤ 7, -31 ≤ l ≤ 30  
Reflections collected  9587  
Independent reflections  3146 [Rint = 0.0255, Rsigma = 0.0246]  
Data/restraints/parameters  3146/0/187  
Goodness-of-fit on F2  1.043  
Final R indexes [I>=2σ (I)]  R1 = 0.0349, wR2 = 0.0925  
Final R indexes [all data]  R1 = 0.0386, wR2 = 0.0961  
Largest diff. peak/hole / e Å-3  0.34/-0.29  
 
The crystal was grown by evaporation of the hexane solution which was left standing in a round-
bottom flask. 
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Compound 296c  
 
 
CCDC Number 1465173 
Identification code  rjkt1408  
Empirical formula  C15H19O5P  
Formula weight  310.27  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  12.11290(15)  
b/Å  10.43581(14)  
c/Å  11.94338(15)  
α/°  90  
β/°  90.0578(13)  
γ/°  90  
Volume/Å3  1509.74(3)  
Z  4  
ρcalcg/cm3  1.365  
µ/mm-1  0.201  
F(000)  656.0  
Crystal size/mm3  0.2985 × 0.1689 × 0.1447  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.178 to 60.064  
Index ranges  -17 ≤ h ≤ 17, -14 ≤ k ≤ 13, -16 ≤ l ≤ 16  
Reflections collected  13086  
Independent reflections  4207 [Rint = 0.0209, Rsigma = 0.0210]  
Data/restraints/parameters  4207/0/197  
Goodness-of-fit on F2  1.080  
Final R indexes [I>=2σ (I)]  R1 = 0.0328, wR2 = 0.0859  
Final R indexes [all data]  R1 = 0.0368, wR2 = 0.0886  
Largest diff. peak/hole / e Å-3  0.39/-0.34  
 
The crystal was grown by evaporation of diethyl ether layered on chloroform inside a standard 
NMR tube. 
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A system for the synthesis of a-alkylidene-g-butyrolactones via a one-pot CeH insertion/oleﬁnation
sequence is described. The process is based on the rhodium catalysed CeH insertion reaction of a-diazo-
a-(diethoxyphosphoryl)acetates. The mild reaction conditions, operational simplicity and ready avail-
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(41 examples) highlighting the generality of the method. The application of this method in the total
synthesis of the natural products (!)-cedarmycins A and B is also described.
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1. Introduction
The synthesis of a-alkylidene-g-butyrolactones has captured
the interest of synthetic chemists for many years1 and remains an
extremely important endeavour today.2 One reason for the sus-
tained high level of interest in this ﬁeld is that a vast number of
natural products have been isolated containing this structural motif
(a-methylene-g-butyrolactones are particularly prominent) and
this area has been well reviewed.3 Much of the reported synthetic
methodology was developed with such targets in mind, and has
facilitated many completed total syntheses. In addition, there is
signiﬁcant interest in the biological activity of a-alkylidene-g-
butyrolactones: this stems from the fact that they are typically very
good Michael acceptors, in particular for cysteine residues, thus
imparting broad therapeutic potential and the capability to mod-
ulate a range of biological processes.4
Our research group became interested in the synthesis of
a-alkylidene-g-butyrolactones as part of a research program to
develop improved synthetic procedures using tandem/telescoped
reaction sequences.5 In particular a method for a-alkylidene-g-
butyrolactone synthesis based on an intramolecular Michael addi-
tion of a phosphonate6 followed by oleﬁnation, either via a Hor-
nereWadswortheEmmons (HWE)6a,b or Wittig-type oleﬁnation.6c,d
These telescoped intramolecular Michael/oleﬁnation protocols
(TIMO) enable functionalised hydroxy-enone derivatives to be con-
verted into alkylidene-g-butyrolactones in one-pot, in good overall
yield (e.g., 1/3, Scheme 1).6 More recently, we reported a modiﬁed
version of this protocol in which the key CeC bond is installed via
a rhodium(II) catalysed CeH insertion reaction of a diazo-
phosphonate, before performing the oleﬁnation via HWE oleﬁnation
in the same way (4/6, Scheme 1).7
A key advantage of the new CeH insertion methodology is the
comparative simplicity of the requisite starting materials. Unfunc-
tionalised alcohol derivatives can be used in place of the hydroxyl-
enone derivatives required for the TIMO reaction, which greatly
increases the generality and synthetic potential of this method. The
key CeH insertion step utilises a small amount of a relatively be-
nign, air-stable rhodium(II) carboxylate and furthermore, by using
a transition metal catalyst to effect this transformation, the
* Corresponding authors. E-mail addresses: richard.taylor@york.ac.uk (R.J.K.
Taylor), william.unsworth@york.ac.uk (W.P. Unsworth).
Contents lists available at ScienceDirect
Tetrahedron
journal homepage: www.elsevier .com/locate/ tet
http://dx.doi.org/10.1016/j.tet.2014.09.054
0040-4020/! 2014 Elsevier Ltd. All rights reserved.
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possibility of developing an asymmetric variant is introduced.8 In
a recent preliminary communication7 in this area we described the
optimisation of the key procedure, initial scoping studies and the
application of the methodology towards the synthesis of a Staphy-
lococcus aureus (MRSA) virulence inhibitor (7, Fig. 1).2g,7 Herein we
report signiﬁcantly expanded substrate scope results and discuss
the strengths and limitations of the methodology along with some
stereochemical, regiochemical and stereoelectronic aspects. The
successful application of this methodology towards the ﬁrst total
synthesis of the natural product (!)-cedarmycin A (8a), as well as
the synthesis of closely related (!)-cedarmycin B (8b), is also
described.9
2. Results and discussion
The requisite diazophosphonate substrates 11aeaf were made
in two steps from alcohols 9aeaf. The alcohols were ﬁrst coupled
with diethyl phosphonoacetic acid (DEPAA) using propyl phos-
phonic anhydride (T3P)10 and N,N-diisopropylethylamine (DIPEA);
we have found T3P to be an excellent coupling reagent for a variety
of applications5c,e,11 and in the majority of cases the esters 10aeaf
were formed in excellent yields (usually >95%) and required no
puriﬁcation other than aqueous work-up (Scheme 2). This was
followed by a Regitz diazo-transfer reaction to furnish the required
diazophosphonates, typically in good unoptimised yield
(23e89%).12 Note that LHMDS was used as the base for these
transformations as, in our hands, it generally afforded higher yields
of the diazo product than more common procedures, in which ei-
ther sodium hydride, KOBu-t or triethylamine are typically used.13
Initial efforts focused on the reactions of homobenzyl alcohol
derivatives, along with their heteroaromatic analogues. This was
because related rhodium carbenoids are reported to undergo CeH
insertion preferentially into electron-rich positions (e.g., benzylic
CeH bonds).14 The formation of unwanted four-membered ring side
products was considered to be a genuine concern during this pro-
cess, based on literature precedent for similar transformations,13a,15
and hence these substrates, which were expected to be biased to-
wards the formation of the desired ﬁve-membered ring g-lactones,
were chosen in order to probe the key reaction. Optimisation ex-
periments were ﬁrst performed using diazophosphonate 11a
(Scheme 3). It was found that the CeH insertion reaction worked
best when performed at 45 "C for 20 h using 2 mol % of Rh2(oct)4 in
DCM.7 Conditions for the HWE oleﬁnation were based on those
developed as part of the TIMO reaction sequence described above;6
minor modiﬁcations made were to increase the number of equiv-
alents of KOBu-t (from 0.9 up to 1.2e1.5 equiv) and to reduce the
excess of paraformaldehyde used (from typically 5 equiv down to
2). The use of more than 1 equiv of base is noteworthy as related
HWE reactions are known to proceed better with sub-
stoichiometric amounts of base.6,17 Given that nitrogen gas is the
only byproduct formed during the CeH insertion step, it was pre-
dicted that these two steps could be performed in the one-pot
without work-up or puriﬁcation. Indeed, this proved to be the
case; the most straightforward procedure is performed by con-
ducting the CeH insertion step in DCM as described above, before
cooling the crude reaction mixture and directly adding KOBu-t
(1.2e1.5 equiv), followed by paraformaldehyde (2 equiv). When
applied to diazophosphonate 11a, this telescoped one-pot sequence
resulted in the formation of a-methylene-g-butyrolactone 12a in
65% overall yield (Scheme 3). It was later found that performing
a solvent switch (DCM toTHF) between the CeH insertion and HWE
steps, led to a small increase in yield to 71%. HWE reactions aremost
commonly performed in ethereal solvents rather than chlorinated,
and this most likely accounts for the observed improvement.16 Note
that no further manipulation was performed during this solvent
switch; the DCM was simply removed under vacuum and THF was
added back into the same reaction vessel, before the HWE reaction
was completed as described above.
These conditions were then applied to a range of homobenzyl
alcohol derivatives, as well as some heteroaromatic variants
(Table 1). Electron-rich/neutral benzene derivatives generally react
well in the two-step telescoped procedure, furnishing a-methylene-
g-butyrolactones 12aee in moderate to good yields (45e74%). As
already discussed, related rhodium carbenoids are reported to insert
preferentially into electron-rich CeH bonds, hence electron-
deﬁcient benzene derivatives were expected to be poorer sub-
strates in comparison. Pleasingly, substitution with a para-bromo
group appears not to signiﬁcantly impair the reaction as product 12f
was formed in reasonable yield (55%) under the standard conditions;
the incorporation of a bromo-substituent in this example is
Fig. 1. MSRA inhibitor 7 and (!)-cedarmycins A and B.
Scheme 1. Telescoped approaches to a-alkylidene-g-butyrolactones.
Scheme 2. Formation of diazophosphonates.
Scheme 3. Formation of a-methylene-g-butyrolactone 12a. *A solvent switch (DCM to
THF) was performed following step (i).
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important as it should facilitate the installation of additional func-
tionality (e.g., in cross-coupling reactions). The yield does drop when
a more strongly electron withdrawing triﬂuoromethyl group is
present (12g, 29%) and decreases further in the case of para-nitro-
substituted product (12h). In these two examples the yield was in-
creased marginally by using a higher catalyst loading and a greater
excess paraformaldehyde, but the overall yields remained relatively
low. Thus, a trend is revealed,whereby the isolated yields of products
12feh decrease as the electron withdrawing ability of the para-
substituent increases. Nonetheless, the fact that some product was
isolated in all of these electronically diverse systems is positive. In-
deed, the only homobenzylic substrate that failed to react at all was
the para-dimethylamine-substituted system (11i/12i); this result is
not at all that surprising, given that Lewis basic residues capable of
coordinating to the vacant axial sites of the dirhodium(II) carboxyl-
ates are known to deactivate the catalyst.18,19 Pyridine nitrogen
atoms also appear to be incompatible (0% conversion for 11j/12j),
presumably for the same reason. Sulfur heteroatoms are better tol-
erated as evidenced by the formation of thiophene derivative 12k,
albeit in modest yield.
Substrates with additional substitution were next examined
(Table 1, 12leo). Compound 12l was generated in good yield under
the standard conditions, demonstrating that insertion into steri-
cally hindered tertiary CeH bonds can take place (for other ex-
amples, see Table 2,12abeaf). The conversion of dibenzyl substrate
Table 1
One-pot CeH insertion/oleﬁnation sequence for the formation of a-methylene-g-
butyrolactones: aromatic substratesa
a Conditions (A) i) 2 mol % Rh2(oct)4, DCM (0.1 M), 45 °C, 20 h; ii) Remove 
DCM in vacuo then add THF; iii) 1.5 equiv KOBu-t, 0 °C to –78 °C; iv) 2 
equiv (CH2O)n, –78 °C to RT. (B) i) 2 mol % Rh2(oct)4, DCM (0.1 M), 45 °C, 
20 h; ii) 1.2 equiv KOBu-t, 0 °C to –78 °C; iii) 2 equiv (CH2O)n, –78 °C to 0 
°C. (C) i) 5 mol % Rh2(oct)4, DCM (0.1 M), 45 °C, 20 h; ii) 0.9 equiv KOBu-
t, 0 °C to –78 °C; iii) 10 equiv (CH2O)n, –78 °C to 0 °C.
b Rh2(esp)2 used in place of Rh2(oct)4.
Table 2
One-pot CeH insertion/oleﬁnation sequence for the formation of a-methylene-g-
butyrolactones: aliphatic substratesa
a Conditions i) 2 mol % Rh2(oct)4, DCM (0.1 M), 45 °C, 20 h; ii) Remove 
DCM in vacuo then add THF; iii) 1.5 equiv KOBu-t, 0 °C to –78 °C; iv) 2 
equiv (CH2O)n, –78 °C to RT.
b HWE performed at 0 °C
c 1.2 equiv KOBu-t used.
d The comparatively low yield is this case may result from the high volatility 
of the product
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11m into lactone 12m is noteworthy as it proceeds with excellent
diasterocontrol, furnishing compound 12m as single trans-
diastereoisomer in excellent overall yield. Excellent regiocontrol
was also observed during the formation of the related product 12n;
in this example, the CeH insertion reaction of unsymmetrical
starting material 11n took place exclusively a-to the 4-MeO-C6H4
group,20 further highlighting the preference for insertion into
electron-rich CeH bonds. The reaction of dimethylated substrate
11o also proceeded in excellent overall yield, but gave a 1.45:1
mixture of the desired product 12o and its regioisomer 13, inwhich
insertion into one of the methyl CeH bonds has taken place. The
partial formation of lactone 13 highlights the importance of steric
factors on the key CeH insertion step. On electronic grounds, the
formation of product 12o is expected, but it appears likely that an
interplay between electronic factors and steric hindrance in the
CeH insertion step results in the partial formation of isomer 13 in
this case. Indeed, the CeH insertion step was found to be sensitive
to steric effects in a number of other examples (see later, Table 2),
which is reasonable, considering the combined bulk of phospho-
nate group and the intermediate rhodium carbenoid.
The reaction of the triphenyl substrate 14a, which did not pro-
ceed as planned, is an interesting example (Scheme 4). In this case,
treating diazo compound 14a under our standard CeH insertion
conditions resulted in almost complete recovery of the starting
material and the formation of a trace amount of an unknown side
product, which was not the expected lactone 14b. To generate
a larger amount of this product, in order to conﬁrm its structure,
compound 14awas heated to 100 !C using the more stable catalyst
Rh2(esp)2 in place of Rh2(oct)4; this led to the complete con-
sumption of the starting material and the isolation of the same
product (15) in 50% yield, which was assigned as a rapidly equili-
brating mixture of two tautomers, norcaradiene 15a and cyclo-
heptatriene 15b. This reaction pathway (known as the Buchner
reaction) proceeds via cyclopropanation of one of the phenyl rings,
followed by reversible electrocyclic ring opening/closing. Rhodium
carbenoid mediated variants of this reaction are well-known,21 and
the ratio of the two components in anymixture is dependent on the
substituents present.21c In this case the equilibrium is biased to-
wards the cycloheptatriene tautomer, as evidenced by the high
NMR chemical shifts (dH 5.31, dC 119.0 in CDCl3) of the position la-
belled (*) in Scheme 4.21c In the solid phase, the product appears to
exist exclusively in the cycloheptatriene form 15b, as the single
diastereoisomer shown: this assignment is supported by X-ray
crystallographic data (Fig. 2).22
Attention then turned to the synthesis of a-methylene-g-
butyrolactones from non-aromatic precursors (Table 2). For the
reasons described above,13a,15 it was considered that attempting to
direct the rhodium catalysed CeH insertion into less reactive, non-
benzylic CeH bonds may lead to competing side reactions (e.g., the
formation of b- and/or d-lactones). However, we are pleased to
report that in most cases, efﬁcient a-methylene-g-butyrolactone
synthesis can be achieved. For example, lactones 12per were all
generated using the standard two-step sequence, with no evidence
for the formation of competing b- or d-lactone products in any of
these reactions. The sensitivity of the CeH insertion step to steric
factors was highlighted above and further evidence for this can be
found in the syntheses of lactones 12s and 12t; the desired a-
methylene-g-butyrolactone products were isolated in both cases,
but the yields were lower than those of substrate 12per, seemingly
decreasing in line with the steric bulk of the substituent a-to the
CeH insertion site. A similar trend was observed during the syn-
theses of homologues 12u and 12v. The lower homologue 12u was
formed in low yield, along with a signiﬁcant amount of b-lactone
side product 16a. However, the higher homologue 12v, inwhich the
bulky OTBS group is more remote from the CeH insertion site, was
formed in amuchmore respectable yield (49%), with no evidence of
b-lactone formation. The formation of lactone 12w, via insertion
into an allylic CeH bond, is noteworthy as cyclopropanation may
have been expected to compete with CeH insertion in this case.
Pleasingly, no evidence for the formation of the alternative cyclo-
propane product was observed, although a small amount of known
butenolide 17,23 which presumably forms via isomerisation of the
methylene alkene of 12w, was also isolated.
Next, attention turned to the synthesis of bicyclic ring scaffolds
(12xeaa). Unfortunately the cyclopentane-fused bicyclic product
12xwas not formed under the standard reaction conditions, which
instead furnished a complex mixture of unidentiﬁed products. The
analogous cyclohexane-fused product proceeded better, although
the CeH insertion was not as regioselective as most other exam-
ples, generating a mixture of g-lactone and b-lactone products
(12y/16b 1.8:1). More positively, the a-methylene-g-butyrolactone
12y was formed with very good diasterocontrol; a 10:1 trans/cis
ratio of the two possible fused ring systems was observed, with
CeH insertion taking place predominantly into the equatorial CeH
bond. The process worked extremely well for the formation of
adamantanol-derived lactone 12z, which was formed in very good
yield over the two-step sequence (79%). Lactone 12aa, which is
derived from cycloheptanol, was also formed in good yield, with
reasonable diastereoselectivity (trans/cis 3.5:1), with no evidence
of b-lactone formation. This example is likely to be important in
target synthesis, given that a-methylene-g-butyrolactone scaffolds
based on fused ﬁve- and seven-membered rings of this type are
particularly prevalent in nature.3
g-Lactone products formed via insertion into tertiary CeH
bonds typically proceed well. First, known lactone 12ab24 was
formed via insertion into an iso-butyl CeH bond. Note that the
Fig. 2. X-ray crystal structure of cycloheptatriene 15b.
Scheme 4. Buchner cyclisation of diazo compound 14a.
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isolated yield in this casewas low (23%) but that no side products or
starting material were detected in the crude 1H NMR spectra for
this reaction; the poor yield is likely to be a result of the high
volatility of the product. We then went on to examine the forma-
tion of spirocyclic products 12aceaf. Attempts to form the spi-
rocyclic cyclopropane adduct 12ac failed under the standard
conditions, but pleasingly the analogous four-, ﬁve- and six-
membered ring variants all furnished the desired products 12adeaf
in good overall yields (50e79%).
As described in our previous communication,7 a-alkylidene-g-
butyrolactones may also accessed using the same procedure
(Table 3). Diazophosphonate 11a can treated under the standard
conditions for CeH insertion, before performing the HWE step
using a range of aromatic and aliphatic aldehydes in place of
paraformaldehyde, affording products 18aeg as mixtures of E- and
Z-isomers in fair to excellent overall yield (36e91%).
We have since gone on to show that three other diazo-
phosphonates (11d, 11p, 11ae) can also be used to furnish alkyli-
dene-g-butyrolactones (Table 4). The substrates chosen include one
benzylic, one aliphatic and one spirocyclic system and each was
reacted with an aromatic and aliphatic aldehyde, to demonstrate
the generality of the methodology. As above, the products 18hem
were formed as mixtures of E- and Z-isomers, with partial dia-
stereoselectivity for the Z-isomer in some cases, typically in good
overall yields (32e77%). Note that all of these examples are unop-
timised and were performed using the standard reaction condi-
tions, with the exception of lactone 18m. In this case, the HWE
reaction did not proceed at room temperature (as indicated by TLC
analysis) hence this step was performed at reﬂux.
As described above, there is an abundance of biologically im-
portant compounds containing the a-alkylidene-g-butyrolactone
motif found in nature.1e4 Future applications of this methodology
in the synthesis of such natural product targets are anticipated, as
demonstrated by the successful total syntheses of (!)-cedarmycins
A and B (8a and 8b, Scheme 5).9 Thus, lactone 12u (for its synthesis,
see Table 2 above) was ﬁrst treated with TBAF to cleave the silyl
protecting group to furnish alcohol 19, before coupling it with each
of the acid chlorides 20a and 20b under standard conditions to
complete both syntheses. Both sets of spectral data were in full
agreement with those published9 and in the case of (!)-cedarmycin
A, this is its ﬁrst reported total synthesis and thus conﬁrms the
proposed structure.25 Of course, both of these syntheses are very
simple, but they do serve to highlight the relative ease with which
natural product targets can be accessed from simple precursors
using CeH activation chemistry.
3. Conclusion
The telescoped CeH insertion/oleﬁnation sequence described
has been used to convert simple alcohol derivatives into a wide
range of a-alkylidene-g-butyrolactones, typically in good overall
yield (in total, the formation of 41 distinct a-alkylidene-g-butyr-
olactone products are described). The reaction conditions are mild,
straightforward to perform and applicable to a wide range of sub-
strates. Furthermore, the products themselves are biologically im-
portant, hence the methods developed are expected to be widely
used by academic and industrial research groups. The application of
these methods in natural product synthesis has also been demon-
strated during the synthesis of (!)-cedarmycins A and B. The
methodology appears to be very well suited to natural product
synthesis and more complex biologically important targets are
currently under investigation, the results of which will be reported
in due course.
Table 3
One-pot CeH insertion/oleﬁnation sequence for the formation of a-alkylidene-g-
butyrolactones from 11aa
Entry R Product E/Z Yield (%)
1 Ph 18a 1:1 65
2 4-NO2eC6H4 18bb 1:1.3 69
3 2-FeC6H4 18c 1:1.5 91
4 4-PheC6H4 18d 1:1 61
5 3,4-OCH2OeC6H3 18ec 1:1.2 56
6 CH3 18f 1.2:1 39
7 n-Butyl 18g 1:3.7 67
a Conditions: (i) 2 mol % Rh2(oct)4, DCM (0.1 M), 45 "C, 20 h; (ii) remove DCM in
vacuo then add THF; (iii) 1.5 equiv KOBu-t, 0 "C to#78 "C; (iv) 2 equiv RCHO,#78 "C
to rt.
b HWE was performed at 0 "C.
c HWE was performed at reﬂux.
Table 4
One-pot CeH insertion/oleﬁnation sequence for the formation of a-alkylidene-g-
butyrolactonesa
a Conditions (A) i) 2 mol % Rh2(oct)4, DCM (0.1 M), 45 °C, 20 h; ii) Remove 
DCM in vacuo then add THF; iii) 1.5 equiv KOBu-t, 0 °C to –78 °C; iv) 2 
equiv (CH2O)n, –78 °C to RT.
b HWE was performed at reflux
Scheme 5. The total syntheses of (!)-cedarmycins A and B.
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4. Experimental
4.1. General aspects
Except where stated, all reagents were purchased from com-
mercial sources and used without further puriﬁcation and all ex-
perimental procedures were carried out under an atmosphere of
argon. Anhydrous CH2Cl2, toluene and diethyl ether were obtained
from an Innovative Technology Inc. PureSolv! solvent puriﬁcation
system. Anhydrous THF was obtained by distillation over sodium
benzophenone ketyl immediately before use. 1H NMR and 13C NMR
spectra were recorded on a JEOL ECX400 or JEOL ECS400 spec-
trometer, operating at 400 MHz and 100 MHz, respectively. All
spectral data was acquired at 295 K. Chemical shifts (d) are quoted
in parts per million (ppm). The residual solvent peak, dH 7.26 and dC
77.0 for CDCl3 was used as a reference. Coupling constants (J) are
reported in hertz (Hz) to the nearest 0.1 Hz. The multiplicity ab-
breviations used are: s singlet, d doublet, t triplet, q quartet, m
multiplet. Signal assignment was achieved by analysis of DEPT,
COSY, HMBC and HSQC experiments where required. Infrared (IR)
spectra were recorded on either a ThermoNicolet IR-100 spec-
trometer with NaCl plates as a thin ﬁlm dispersed from either
CH2Cl2 or CDCl3, or a PerkinElmer UATR II spectrometer and the
data are assigned as being strong (s), medium (m), weak (w) or
broad (br) signals. Mass spectra (low- and high-resolution) were
obtained by the University of York Mass Spectrometry Service,
using electrospray ionisation (ESI) on a Bruker Daltonics, Micro-tof
spectrometer. Melting points were determined using Gallenkamp
apparatus and are uncorrected. Thin layer chromatography was
carried out on Merck silica gel 60F254 pre-coated aluminium foil
sheets and were visualised using UV light (254 nm) and stained
with basic aqueous potassium permanganate. Flash column chro-
matography was carried out using slurry packed Fluka silica gel
(SiO2), 35e70 mm, 60!A, under a light positive pressure, eluting with
the speciﬁed solvent system. Petrol refers to petroleum ether
boiling point 40e60 !C. Ether refers to diethyl ether. Experimental
procedures and characterisation data for compounds 7, 9m, 9n,
10a,b,10d,10leo, 10per,10ae, 11a,b, 11d,11leo,11per, 11ae, 12a,b,
12d,121eo,12per,12ae,13 and 18aeg can be found in our previous
communication.7
4.2. General experimental procedures
The majority of alcohols were commercially available. Alcohols
9c,26 9i,27 9j28 and 9k29 were prepared by LiAlH4 reduction of the
corresponding carboxylic acids and gave spectral data consistent
with those in the literature.
General procedure A: esteriﬁcations using T3P (9/10)
To a stirred solution of alcohol 9 (8.00 mmol) in toluene (40 mL)
under argonwere added sequentially diethyl phosphonoacetic acid
(1.35 mL, 8.40 mmol), DIPEA (3.62 mL, 20.8 mmol) and propyl
phosphonic anhydride (6.62 g, 10.4 mmol, 50% w/w solution in
ethyl acetate/THF). The solution was stirred at rt for 4 h after which
time it was diluted with water (50 mL) and extracted with ethyl
acetate (3"100 mL) followed by sequential washing of the com-
bined organic extracts with 10% aq HCl (50 mL), satd aq NaHCO3
(50 mL) and brine (50 mL). The organic extracts were dried over
MgSO4 and concentrated in vacuo, affording the a-(diethox-
yphosphoryl)acetate product 10, which was used without further
puriﬁcation.
General procedure B: diazotisation reactions (10/11)
To a stirred solution of a-(diethoxyphosphoryl)acetate 10
(5.0mmol) in THF (25mL), cooled to#78 !C under argonwas added
LHMDS (6.0 mL, 6.0 mmol, 1.0 M solution in THF). The solution was
allowed to warm to rt and stirred for 10 min. 4-
Acetamidobenzenesulfonylazide (1.44 g, 6.0 mmol) was added to
the solution forming a suspension. After stirring for 1 h at rt the
mixture was diluted with ether (100mL) andwater (25mL) prior to
extraction with ether (3"50 mL). The combined organic extracts
were washed with satd aq NaHCO3 (2"25 mL), dried over MgSO4,
concentrated in vacuo and puriﬁed by column chromatography
affording the a-diazo-a-(diethoxyphosphoryl)acetate product 11.
General procedure C: one-pot Rh(II)-catalysed CeH insertion/HWE
(11/12, DCM)
To an oven dried sealable tube containing a-diazo-a-(dialkox-
yphosphoryl)acetate 11 (0.200 mmol) ﬂushed with argon was
added DCM (4.0 mL) followed by Rh2(oct)4 or Rh2(esp)2 (2 or
5mol %). The solutionwas stirred at 45 !C for 20 h. The solutionwas
cooled to 0 !C prior to the addition of KOBu-t (0.9, 1.2 or 1.5 equiv),
which was stirred at 0 !C for 60 min and then cooled to #78 !C.
Aldehyde (2.0, 5.0 or 10.0 equiv) was added to the solution and
stirred for 15 min at #78 !C and a further 2 h at either 0 !C, rt or
reﬂux. The solution was quenched with satd aq NH4Cl (10 mL) and
then diluted with DCM (20 mL). The organic layer was separated
and the aqueous extracted with EtOAc (2"20 mL). The combined
organic extracts were dried over Na2SO4, concentrated in vacuo and
puriﬁed by column chromatography affording the a-methylene/
alkylidene-g-butyrolactone product 12.
General procedure D: one-pot Rh(II)-catalysed CeH insertion/HWE
(11/12, DCM with THF switch)
To an oven dried sealable tube containing a-diazo-a-(dialkox-
yphosphoryl)acetate 11 (0.200 mmol) ﬂushed with argon was
added DCM (4.0 mL) followed by Rh2(oct)4 or Rh2(esp)2 (2 or
5 mol %). The solution was stirred at 45 !C for 20 h and then con-
centrated in vacuo. The residue was diluted with THF (4.0 mL) and
cooled to 0 !C prior to the addition of KOBu-t (0.9, 1.2 or 1.5 equiv),
which was stirred at 0 !C for 60 min and then cooled to #78 !C.
Aldehyde (2.0, 5.0 or 10.0 equiv) was added to the solution and
stirred for 15 min at #78 !C and a further 2 h at either 0 !C, rt or
reﬂux. The solution was quenched with satd aq NH4Cl (10 mL) and
then diluted with DCM (20 mL). The organic layer was separated
and the aqueous extracted with EtOAc (2"20 mL). The organic
extracts were dried over Na2SO4, concentrated in vacuo and puri-
ﬁed by column chromatography affording the a-methylene/alkyli-
dene-g-butyrolactone product 12.
4.3. 3,4,5-Trimethoxyphenethyl 2-(diethoxyphosphoryl)ace-
tate (10c)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (360 mg, 95%); Rf 0.10 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm#1 2939w, 2841w, 1733s, 1590s, 1508m,
1459m, 1422m, 1852w, 1238s, 1154w, 1123s, 1047w, 1018s, 967s,
827m, 778m; dH (400 MHz, CDCl3) 1.28e1.31 (6H, m), 2.88 (2H, t, J
7.2), 2.94 (2H, d, J 21.5), 3.79 (3H, s), 3.82 (6H, s), 4.07e4.15 (4H, m),
4.32 (2H, t, J 7.2), 6.41 (2H, s); dC (100 MHz, CDCl3) 16.2 (d, J 6.2),
34.2 (d, J 134.3), 35.2, 56.0, 60.7, 62.6 (d, J 6.3), 65.9, 105.7, 132.9,
136.6, 153.1, 165.7 (d, J 6.0); dP (162 MHz, CDCl3) 20.2; HRMS (ESIþ):
found: 413.1351; C17H27NaO8P (MNaþ) requires 413.1336.
4.4. 2-(Naphthalen-1-yl)ethyl 2-(diethoxyphosphoryl)acetate
(10e)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.74 g, 99%); Rf 0.20 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2982w, 1735s, 1598w, 1510w, 1496w,
1445w, 1395w, 1257s, 1163w, 1113m, 1048w, 1019s, 965s, 838w,
798w, 777s, 731s, 696m; dH (400 MHz, CDCl3) 1.31 (6H, t, J 7.1), 2.97
(2H, d, J 21.6), 3.44 (2H, t, J 7.5), 4.10e4.17 (4H, m), 4.48 (2H, t, J 7.5),
7.36e7.43 (2H, m), 7.47e7.56 (2H, m), 7.75e7.77 (1H, m), 7.85e7.87
(1H, m), 8.07e8.09 (1H, m); dC (100MHz, CDCl3) 16.3 (d, J 6.2), 32.0,
34.3 (d, J 134.2), 62.6 (d, J 6.2), 65.4, 123.4, 125.4, 125.6, 126.2, 127.0,
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127.5, 128.8, 131.9, 133.2, 133.8, 165.8 (d, J 6.1); dP (162 MHz, CDCl3)
20.3; HRMS (ESIþ): found: 373.1171; C18H23NaO5P (MNaþ) requires
373.1175.
4.5. 4-Bromophenethyl 2-(diethoxyphosphoryl)acetate (10f)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.80 g, 96%); Rf 0.23 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2982w, 1735s, 1489m, 1443w, 1393w,
1256s, 1163w, 1114m, 1049w, 1020s, 964s, 804m; dH (400 MHz,
CDCl3) 1.29 (6H, td, J 7.1, 0.5), 2.89 (2H, t, J 6.9), 2.92 (2H, d, J 21.6),
4.06e4.13 (4H, m), 4.30 (2H, t, J 6.9), 7.08 (2H, d, J 8.5), 7.39 (2H, d, J
8.5); dC (100 MHz, CDCl3) 16.2 (d, J 6.2), 34.2 (d, J 134.3), 34.2, 62.6
(d, J 6.2), 65.5, 120.4, 130.6, 131.5, 136.4, 165.6 (d, J 6.1); dP (162 MHz,
CDCl3) 20.1; HRMS (ESIþ): found: 401.0124; C14H2079BrNaO5P (MNaþ)
requires 401.0124.
4.6. 4-Triﬂuoromethylphenethyl 2-(diethoxyphosphoryl)ace-
tate (10g)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (963 mg, 100%); Rf 0.19 (1:1 petrol/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2940s, 2890w, 1712s, 1307m, 1251m,
1146w,1099m,1007m, 956w; dH (400MHz, CDCl3) 1.30 (6H, td, J 7.1,
0.5), 2.94 (2H, d, J 21.6), 3.02 (2H, t, J 6.8), 4.11 (4H, dq, J 8.8, 7.1), 4.37
(2H, t, J 6.8), 7.35 (2H, d, J 8.0), 8.17 (2H, d, J 8.0); dC (100MHz, CDCl3)
16.3 (d, J 6.2), 34.3 (d, J 134.4), 34.7, 62.7 (d, J 6.2), 65.3, 125.4 (q, J
3.7), 126.9 (q, J 271.1), 129.2, 129.7 (q, J 32.5), 141.7, 165.7 (d, J 6.1); dF
(376 MHz, CDCl3) "62.4; dP (162 MHz, CDCl3) 20.1; HRMS (ESIþ):
found: 391.0878; C15H20F3NaO5P (MNaþ) requires 391.0893.
4.7. 4-Nitrophenethyl 2-(diethoxyphosphoryl)acetate (10h)
Synthesised using general procedure A affording the title com-
pound as an orange oil (4.72 g, 91%); Rf 0.12 (1:1 petrol/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2936s, 1712s, 1577m, 1495s, 1371m,
1325m, 1249m, 1145w, 1095m, 1009m, 955w, 842w; dH (400 MHz,
CDCl3) 1.31 (6H, t, J 7.1), 2.94 (2H, d, J 21.6), 3.08 (2H, t, J 6.7), 4.13
(4H, dq, J 8.3, 7.1), 4.39 (2H, t, J 6.7), 7.41 (2H, d, J 8.8), 8.17 (2H, d, J
8.8); dC (100 MHz, CDCl3) 16.3 (d, J 6.2), 34.3 (d, J 134.6), 34.7, 62.7
(d, J 6.2), 64.9, 123.7, 129.8,145.3, 146.9, 165.6 (d, J 6.0); dP (162MHz,
CDCl3) 20.0; HRMS (ESIþ): found: 368.0875; C14H20NNaO7P (MNaþ)
requires 368.0870 ("1.3 ppm error).
4.8. 4-(Dimethylamino)phenethyl 2-(diethoxyphosphoryl)ac-
etate (10i)
Synthesised using general procedure A affording the title com-
pound as an orange oil (1.77 g, 100%); Rf 0.44 (1:2 petrol/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2988w, 1733s, 1522s, 1258s, 1114w,
1019s; dH (400MHz, CDCl3) 1.32 (6H, td, J 7.1, J 0.5), 2.86 (2H, t, J 7.3),
2.91 (6H, s), 2.96 (2H, d, J 21.5), 4.14 (4H, dq, J 8.2, 7.1), 4.29 (2H, t, J
7.3), 6.69 (2H, d, J 8.7), 7.10 (2H, d, J 8.7); dC (100MHz, CDCl3) 16.3 (d,
J 6.4), 33.9, 34.3 (d, J 134.2), 40.7, 62.6 (d, J 6.2), 66.5, 112.8, 125.1,
129.5, 149.5, 165.8 (d, J 6.1); dP (162 MHz, CDCl3) 20.4; HRMS (ESIþ):
found: 366.1444; C16H26NNaO5P (MNaþ) requires 366.1441.
4.9. 2-(Pyridin-3-yl)ethyl 2-(diethoxyphosphoryl)acetate (10j)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (4.49 g, 92%); Rf 0.44 (10:1 DCM/MeOH); nmax
(thin ﬁlm)/cm"1 2938s, 2887w,1711s, 1468m,1249s, 1100w,1034w,
1010m, 957w; dH (400 MHz, CDCl3) 1.31 (6H, td, J 7.1, 0.5), 2.95 (2H,
d, J 21.6), 2.97 (2H, t, J 6.8), 4.13 (4H, dq, J 8.3, 7.1), 4.36 (2H, t, J 6.8),
7.25 (1H, ddd, J 7.8, 4.8, 0.8), 7.60 (1H, ddd, J 7.8, 2.3, 1.7), 8.48e8.51
(2H, m); dC (100 MHz, CDCl3) 16.3 (d, J 6.1), 32.1, 34.3 (d, J 134.3),
62.7 (d, J 6.5), 65.2, 123.5, 133.1, 136.5, 148.0, 150.1, 165.7 (d, J 6.1); dP
(162 MHz, CDCl3) 20.0; HRMS (ESIþ): found: 324.0976;
C13H20NNaO5P (MNaþ) requires 324.0971.
4.10. 2-(Thiophen-3-yl)ethyl 2-(diethoxyphosphoryl)acetate
(10k)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (2.41 g, 99%); Rf 0.33 (1:1 petrol/ethyl acetate);
nmax (thin ﬁlm)/cm"1 2983w, 1734s, 1393w, 1258s, 1115w, 1049w,
1020s, 968s; dH (400 MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.5), 2.97 (2H, d,
J 21.6), 3.00 (2H, t, J 6.9), 4.14 (4H, dq, J 8.3, 7.1), 4.35 (2H, td, J 6.9,
0.5), 6.98 (1H, dd, J 4.9,1.3), 7.06 (1H, ddt, J 3.0,1.3, 0.9), 7.27 (1H, dd,
J 4.9, 3.0); dC (100 MHz, CDCl3) 16.3 (d, J 6.4), 29.4, 34.3 (d, J 134.4),
62.7 (d, J 6.5), 65.4, 121.7, 125.6, 128.2, 137.6, 165.8 (d, J 6.2); dP
(162 MHz, CDCl3) 20.2; HRMS (ESIþ): found: 329.0582;
C12H19NaO5PS (MNaþ) requires 329.0583.
4.11. 3-Methylbutyl 2-(diethoxyphosphoryl)acetate (10s)
Synthesised using general procedure A affording the title com-
pound as an orange oil (2.67 g, 100%); Rf 0.28 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2960w, 1735s, 1466w, 1392w, 1261s,
1116m, 1021s, 969m; dH (400 MHz, CDCl3) 0.90 (6H, d, J 6.6), 1.33
(6H, td, J 7.1, 0.4), 1.52 (2H, app. q, J 6.9), 1.63e1.76 (1H, m), 2.94 (2H,
d, J 21.6), 4.12e4.19 (6H, m); dC (100MHz, CDCl3) 16.3 (d, J 6.2), 22.3,
24.8, 34.3 (d, J 134.2), 37.1, 62.6 (d, J 6.2), 64.2, 165.9 (d, J 6.2); dP
(162 MHz, CDCl3) 20.5; HRMS (ESIþ): found: 289.1356;
C11H23NaO5P (MNaþ) requires 289.1175.
4.12. 3,3-Dimethylbutyl 2-(diethoxyphosphoryl)acetate (10t)
Synthesised using general procedure A affording the title com-
pound as an orange oil (2.70 g, 97%); Rf 0.41 (1:2 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2958w, 2870w, 1736s, 1478w, 1396w,
1261s, 1116m, 1023s, 971m; dH (400 MHz, CDCl3) 0.92 (9H, s), 1.33
(6H, td, J 7.1, 0.5), 1.57 (2H, t, J 7.7), 2.94 (2H, d, J 21.6), 4.12e4.19 (6H,
m); dC (100 MHz, CDCl3) 16.3 (d, J 6.3), 29.5, 29.6, 34.3 (d, J 134.3),
41.5, 62.6 (d, J 6.3), 63.4, 165.9 (d, J 6.0); dP (162 MHz, CDCl3) 20.5;
HRMS (ESIþ): found: 303.1323; C12H25NaO5P (MNaþ) requires
303.1332.
4.13. 3-((tert-Butyldimethylsilyl)oxy)propyl 2-(diethox-
yphosphoryl)acetate (10u)
To a solution of NaH (480 mg, 12.0 mmol, 60% dispersion in
mineral oil) in THF (20 mL) cooled to 0 #C was added 1,3-
propanediol (0.80 mL, 11.0 mmol) dropwise over 5 min. The solu-
tion was allowed to warm to rt and stirred for 30 min after which
TBSCl (1.51 g, 10.0 mmol) was added then stirred at rt for 1 h. The
solution was diluted with water (25 mL), extracted with ether
(2$25 mL), washed with brine (25 mL), dried over MgSO4 and
concentrated in vacuo. The crude alcohol (1.96 g) was then treated
under the conditions of general procedure A affording the title
compound as a yellow oil (3.32 g, 90% over two steps); Rf 0.22 (1:1
hexane/ethyl acetate); nmax (thin ﬁlm)/cm"1 2956w, 2930m,
2857w, 1738s, 1473w, 1392w, 1258s, 1100m, 1054w, 1025s, 970m,
836s, 777m; dH (400 MHz, CDCl3) 0.04 (6H, s), 0.88 (9H, s), 1.34 (6H,
t, J 7.1), 1.85 (2H, tt, J 6.5, 6.0), 2.96 (2H, d, J 21.6), 3.69 (2H, t, J 6.0),
4.13e4.20 (4H, m), 4.24 (2H, t, J 6.5); dC (100 MHz, CDCl3) "5.4, 16.3
(d, J 6.2), 18.2, 25.8, 31.7, 34.3 (d, J 134.3), 59.2, 62.6 (d, J 6.3), 62.6,
165.8 (d, J 6.1); dP (162 MHz, CDCl3) 20.4; HRMS (ESIþ): found:
391.1691; C15H33NaO6PSi (MNaþ) requires 391.1676.
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4.14. 4-((tert-Butyldimethylsilyl)oxy)butyl 2-(diethox-
yphosphoryl)acetate (10v)
To a solution of NaH (240 mg, 6.00 mmol, 60% dispersion in
mineral oil) in THF (10 mL) cooled to 0 !C was added 1,4-butanediol
(0.44 mL, 5.50 mmol) dropwise over 5 min. The solution was
allowed to warm to rt and stirred for 30 min after which TBSCl
(754 mg, 5.00 mmol) was added then stirred at rt for 1 h. The so-
lution was diluted with water (25 mL), extracted with ether
(2"25 mL), washed with brine (25 mL), dried over MgSO4 and
concentrated in vacuo. The crude alcohol (1.20 g) was then treated
under the conditions of general procedure A affording the title
compound as a yellow oil (1.76 g, 92% over two steps); Rf 0.43 (1:1
hexane/ethyl acetate); nmax (thin ﬁlm)/cm#1 2955w, 2929w, 2857w,
1737s, 1472w, 1391w, 1255s, 1164w, 1097s, 1052w, 1023s, 968s,
892w, 834s, 774s; dH (400MHz, CDCl3) 0.01 (6H, s), 0.85 (9H, s), 1.31
(6H, td, J 7.1, 0.5), 1.51e1.58 (2H, m), 1.65e1.72 (2H, m), 2.93 (2H, d, J
21.6), 3.60 (2H, t, J 6.2), 4.10e4.17 (6H, m); dC (100MHz, CDCl3)#5.4,
16.3 (d, J 6.2), 18.2, 25.1, 25.8, 28.9, 34.2 (d, J 134.2), 62.4, 62.6 (d, J
6.4), 65.5, 165.8 (d, J 6.2); dP (162 MHz, CDCl3) 20.4; HRMS (ESIþ):
found: 405.1833; C16H35NaO6PSi (MNaþ) requires 405.1833.
4.15. But-3-en-1-yl 2-(diethoxyphosphoryl)acetate (10w)
Synthesised using general procedure A affording the title com-
pound as a pale yellow oil (1.24 g, 99%); Rf 0.20 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2983w,1735s,1643w,1445w,1393w,
1257s, 1163w, 1115m, 1049w, 1019s, 964s, 839w, 782w, 733w; dH
(400 MHz, CDCl3) 1.33 (6H, td, J 7.1, 0.4), 2.40 (2H, app. qt, J 6.8, 1.4),
2.96 (2H, d, J 21.6), 4.12e4.20 (6H, m), 5.05e5.14 (2H, m), 5.78 (1H,
ddt, J 17.1, 10.3, 6.8); dC (100MHz, CDCl3) 16.3 (d, J 6.2), 32.8, 34.2 (d,
J 134.3), 62.6 (d, J 6.3), 64.6, 117.4, 133.6, 165.8 (d, J 6.1); dP (162MHz,
CDCl3) 20.3; HRMS (ESIþ): found: 273.0868; C10H19NaO5P (MNaþ)
requires 273.0862.
4.16. Cyclopentyl 2-(diethoxyphosphoryl)acetate (10x)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.12 g, 85%); Rf 0.24 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2974m, 2874w, 1730s, 1443w, 1393w,
1368w, 1259s, 1165m, 1114m, 1050w, 1019s, 966s, 839m, 780m; dH
(400MHz, CDCl3) 1.34 (6H, td, J 7.1, 0.4),1.54e1.90 (8H, m), 2.92 (2H,
d, J 21.6), 4.16 (4H, dq, J 8.1, 7.1), 5.20 (1H, tt, J 5.6, 2.7); dC (100 MHz,
CDCl3) 16.2 (d, J 6.2), 23.6, 32.4, 34.5 (d, J 133.5), 62.5 (d, J 6.2), 78.4,
165.5 (d, J 6.2); dP (162 MHz, CDCl3) 20.7; HRMS (ESIþ): found:
287.1020; C11H21NaO5P (MNaþ) requires 287.1019.
4.17. Cyclohexyl 2-(diethoxyphosphoryl)acetate (10y)
Synthesised using general procedure A affording the title com-
pound as a dark orange oil (4.43 g, 100%); Rf 0.33 (1:1 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2985w, 2937s, 2862m, 1729s, 1258s,
1114w, 1016s, 964s; dH (400 MHz, CDCl3) 1.16e1.52 (6H, m), 1.30
(6H, td, J 7.1, 0.5), 1.65e1.73 (2H, m), 1.77e1.84 (2H, m), 2.90 (2H, d, J
21.6), 4.12 (4H, dq, J 8.4, 7.1), 4.76 (1H, tt, J 8.7, 4.2); dC (100 MHz,
CDCl3) 16.2 (d, J 6.2), 23.5, 25.2, 31.3, 34.5 (d, J 133.4), 62.4 (d, J 6.3),
73.9, 165.1 (d, J 6.4); dP (162 MHz, CDCl3) 20.6; HRMS (ESIþ): found:
301.1162; C12H23NaO5P (MNaþ) requires 301.1175.
4.18. Adamantan-1-yl 2-(diethoxyphosphoryl)acetate (10z)
Synthesised using general procedure A affording the title com-
pound as a colourless oil (1.53 g, 93%); Rf 0.30 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2981w, 2910s, 2853w, 1728s, 1584w,
1457w, 1393w, 1369w, 1355w, 1321w, 1259s, 1164w, 1103m, 1049w,
1020s, 967s, 890m, 836w, 814w; dH (400 MHz, CDCl3) 1.32 (6H, td, J
7.1, 0.5), 1.57e1.69 (6H, m), 2.09e2.14 (9H, m), 2.85 (2H, d, J 21.4),
4.10e4.18 (4H, m); dC (100 MHz, CDCl3) 16.3 (d, J 6.2), 30.7, 35.7 (d, J
132.8), 36.0, 41.1, 62.4 (d, J 6.2), 82.0, 164.5 (d, J 6.3); dP (162 MHz,
CDCl3) 21.2; HRMS (ESIþ): found: 353.1489; C16H27NaO5P (MNaþ)
requires 353.1488.
4.19. Cycloheptyl 2-(diethoxyphosphoryl)acetate (10aa)
Synthesised using general procedure A affording the title com-
pound as a colourless oil (1.45 g, 99%); Rf 0.31 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2982w, 2929m, 2861w, 1728s,
1446w, 1394w, 1266s, 1113m, 1051w, 1021s, 969s; dH (400 MHz,
CDCl3) 1.32 (6H, td, J 7.1, 0.5), 1.35e1.69 (10H, m), 1.85e1.92 (2H, m),
2.91 (2H, d, J 21.5), 4.10e4.18 (4H, m), 4.95 (1H, tt, J 8.3, 4.3); dC
(100 MHz, CDCl3) 16.3 (d, J 6.5), 22.7, 28.2, 33.5, 34.6 (d, J 133.5),
62.5 (d, J 6.2), 76.5, 165.1 (d, J 6.2); dP (162 MHz, CDCl3) 20.7; HRMS
(ESIþ): found: 293.1502; C13H26O5P (MHþ) requires 293.1512.
4.20. 2-Methylpropyl 2-(diethoxyphosphoryl)acetate
(10ab)15a
Synthesised using general procedure A affording the title com-
pound as a yellow oil (2.02 g, 100%); Rf 0.24 (1:1 petrol/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2965m, 1735s, 1394w, 1265s, 1117w,
1052w, 1024s; dH (400 MHz, CDCl3) 0.94 (6H, d, J 6.7), 1.32 (6H, t, J
7.1), 1.95 (1H, app. nonet, J 6.7), 2.97 (2H, d, J 21.6), 3.92 (2H, d, J 6.7),
4.17 (4H, dq, J 8.3, 7.1); dC (100 MHz, CDCl3) 16.3 (d, J 6.5), 19.0, 27.6,
34.3 (d, J 134.0), 62.6 (d, J 6.2), 71.6, 165.9 (d, J 6.4); dP (162 MHz,
CDCl3) 20.5; HRMS (ESIþ): found: 275.1018; C10H21NaO5P (MNaþ)
requires 275.1019.
4.21. Cyclopropylmethyl 2-(diethoxyphosphoryl)acetate
(10ac)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.23 g, 98%); Rf 0.23 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2984w, 1731s, 1446w, 1394w, 1369w,
1346w, 1257s, 1164w, 1115m, 1049w, 1018s, 966s, 943w, 889w,
839m; dH (400 MHz, CDCl3) 0.27e0.31 (2H, m), 0.55e0.59 (2H, m),
1.09e1.20 (1H, m), 1.34 (6H, t, J 7.1), 2.98 (2H, d, J 21.5), 3.97 (2H, d, J
7.3), 4.14e4.21 (4H, m); dC (100 MHz, CDCl3) 3.3, 9.6, 16.3 (d, J 6.4),
34.4 (d, J 134.2), 62.7 (d, J 6.3), 70.3, 165.9 (d, J 6.1); dP (162 MHz,
CDCl3) 20.4; HRMS (ESIþ): found: 273.0862; C10H19NaO5P (MNaþ)
requires 273.0862.
4.22. Cyclobutylmethyl 2-(diethoxyphosphoryl)acetate (10ad)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.31 g, 99%); Rf 0.22 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2980w, 2941w, 1733s, 1445w, 1393w,
1334w, 1259s, 1163w, 1115m, 1049w, 1019s, 964s, 838m, 783m,
609m; dH (400 MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.5), 1.71e1.96 (4H,
m), 2.00e2.08 (2H, m), 2.61 (1H, app. heptet, J 7.4), 2.95 (2H, d, J
21.6), 4.08e4.19 (6H, m); dC (100 MHz, CDCl3) 16.3 (d, J 6.2), 18.3,
24.6, 33.9, 34.3 (d, J 133.8), 62.6 (d, J 6.2), 69.2, 165.9 (d, J 6.2); dP
(162 MHz, CDCl3) 20.4; HRMS (ESIþ): found: 287.1033;
C11H21NaO5P (MNaþ) requires 287.1019.
4.23. Cyclohexylmethyl 2-(diethoxyphosphoryl)acetate (10af)
Synthesised using general procedure A affording the title com-
pound as a yellow oil (1.44 g, 99%); Rf 0.53 (ethyl acetate); nmax (thin
ﬁlm)/cm#1 2927s, 2854m,1737s,1269s,1053w,1026s; dH (400MHz,
CDCl3) 0.86e0.96 (2H, m), 1.04e1.24 (3H, m), 1.28 (6H, t, J 7.1),
M.G. Lloyd et al. / Tetrahedron 71 (2015) 7107e71237114
  385 
 
 
1.54e1.70 (6H, m), 2.91 (2H, d, J 21.6), 3.89 (2H, d, J 6.6), 4.07e4.14
(4H, m); dC (100 MHz, CDCl3) 16.2 (d, J 6.2), 25.5, 26.1, 29.3, 34.1 (d, J
134.2), 36.8, 62.5 (d, J 6.2), 70.5, 165.7 (d, J 6.2); dP (162 MHz, CDCl3)
20.5; HRMS (ESIþ): found: 315.1338; C13H25NaO5P (MNaþ) requires
315.1332.
4.24. 3,4,5-Trimethoxyphenethyl 2-diazo-2-(diethox-
yphosphoryl)acetate (11c)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (202 mg, 54%); Rf 0.21 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2983w, 2940w, 2841w, 2125s, 1704s,
1590s, 1508m, 1459s, 1422m, 1389m, 1352w, 1274s, 1238s, 1155w,
1124s, 1012s, 977s, 815m, 745m, 589m, 559m; dH (400 MHz, CDCl3)
1.29 (6H, td, J 7.1, 0.7), 2.87 (2H, t, J 6.9), 3.77 (3H, s), 3.80 (6H, s),
4.02e4.19 (4H, m), 4.36 (2H, t, J 6.9), 6.38 (2H, s); dC (100 MHz,
CDCl3) 16.0 (d, J 6.9), 35.4, 53.5 (d, J 227.1), 55.9, 60.6, 63.5 (d, J 5.6),
65.9, 105.6, 132.8, 136.6, 153.1, 163.1 (d, J 12.5); dP (162 MHz, CDCl3)
10.4; HRMS (ESIþ): found: 439.1234; C17H25N2NaO8P (MNaþ) re-
quires 439.1241.
4.25. 2-(Naphthalen-1-yl)ethyl 2-diazo-2-(diethox-
yphosphoryl)acetate (11e)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (859 mg, 47%); nmax (thin ﬁlm)/cm"1 2984w,
2127s, 1708s, 1597w, 1511w, 1445w, 1388w, 1279s, 1215s, 1164w,
1095w, 1020s, 978m, 799m, 778m, 745w; dH (400 MHz, CDCl3) 1.32
(6H, td, J 7.1, 0.8), 3.45 (2H, t, J 7.2), 4.04e4.22 (4H, m), 4.55 (2H, t, J
7.2), 7.35e7.43 (2H, m), 7.47e7.57 (2H, m), 7.76e7.78 (1H, m),
7.85e7.88 (1H, m), 8.06e8.08 (1H, m); dC (100MHz, CDCl3) 16.1 (d, J
6.9), 32.2, 53.5 (d, J 226.9), 63.6 (d, J 5.9), 65.5, 123.4, 125.4, 125.7,
126.3, 127.1, 127.6, 128.8, 131.9, 133.1, 133.8, 163.2 (d, J 12.2); dP
(162 MHz, CDCl3) 10.5; HRMS (ESIþ): found: 399.1075;
C18H21N2NaO5P (MNaþ) requires 399.1080.
4.26. 4-Bromophenethyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11f)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (969 mg, 51%); Rf 0.48 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2983w, 2129s, 1708s, 1489w, 1384w,
1279s, 1216w, 1164w, 1094w, 1022s, 979m, 815w, 596w, 560w; dH
(400MHz, CDCl3) 1.30 (6H, td, J 7.1, 0.8), 2.90 (2H, t, J 6.7), 4.02e4.19
(4H, m), 4.36 (2H, t, J 6.7), 7.07 (2H, d, J 8.5), 7.40 (2H, d, J 8.5); dC
(100 MHz, CDCl3) 16.0 (d, J 6.8), 34.5, 53.8 (d, J 228.5), 63.5 (d, J 5.8),
65.4, 120.5, 130.6, 131.5, 136.2, 163.1 (d, J 12.3); dP (162 MHz, CDCl3)
10.4; HRMS (ESIþ): found: 427.0038; C14H1879BrN2NaO5P (MNaþ)
requires 427.0029.
4.27. 4-Triﬂuoromethylphenethyl 2-diazo-2-(diethox-
yphosphoryl)acetate (11g)
Synthesised using general procedure B affording the title com-
pound as a pale yellow oil (386 mg, 36%); Rf 0.44 (1:1 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2941s, 2099s, 1686s, 1308m, 1262m,
1147w,1106w,1051w,1006w; dH (400MHz, CDCl3) 1.31 (6H, td, J 7.1,
0.8), 3.03 (2H, t, J 6.7), 4.03e4.21 (4H, m), 4.43 (2H, t, J 6.7), 7.34 (2H,
d, J 8.0), 7.56 (2H, d, J 8.0); dC (100 MHz, CDCl3) 16.1 (d, J 6.8), 34.9,
53.9 (d, J 228.8), 63.6 (d, J 5.6), 65.3, 125.4 (q, J 3.8), 124.1 (q, J 271.9),
129.1 (q, J 32.3), 129.3, 141.5, 163.3 (d, J 11.6); dF (376 MHz, CDCl3)
"62.4; dP (162 MHz, CDCl3) 10.4; HRMS (ESIþ): found: 417.0779;
C15H18F3N2NaO5P (MNaþ) requires 417.0798.
4.28. 4-Nitrophenethyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11h)
Synthesised using general procedure B affording the title com-
pound as a colourless oil (111 mg, 49%); Rf 0.53 (1:2 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2099s, 1681s, 1497s, 1326s, 1261s,
1006m; dH (400 MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.8), 3.09 (2H, t, J
6.6), 4.05e4.23 (4H, m), 4.45 (2H, t, J 6.6), 7.40 (2H, d, J 8.8), 8.18 (2H,
d, J 8.8); dC (100 MHz, CDCl3) 16.1 (d, J 6.8), 34.9, 53.8 (d, J 228.4),
63.6 (d, J 5.7), 64.9, 123.7, 129.8, 145.1, 146.9, 163.2 (d, J 12.2); dP
(162 MHz, CDCl3) 10.3; HRMS (ESIþ): found: 394.0762;
C14H18N3NaO7P (MNaþ) requires 394.9775.
4.29. 4-(Dimethylamino)phenethyl 2-diazo-2-(diethox-
yphosphoryl)acetate (11i)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (327 mg, 30%); Rf 0.48 (1:1 petrol/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2985w, 2128s, 1704s, 1616w, 1523m,
1277s,1020s; dH (400MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.6), 2.85 (2H, t,
J 7.0), 2.90 (6H, s), 4.04e4.21 (4H, m), 4.33 (2H, t, J 7.0), 6.67 (2H, d, J
8.7), 7.06 (2H, d, J 8.7); dC (100MHz, CDCl3) 15.9 (d, J 6.9), 34.0, 40.5,
53.4 (d, J 226.5), 63.4 (d, J 5.8), 66.3, 112.6, 124.8, 129.4, 149.3, 163.1
(d, J 12.3); dP (162 MHz, CDCl3) 10.6; HRMS (ESIþ): found: 392.1338;
C16H24N3NaO5P (MNaþ) requires 392.1346.
4.30. 2-(Pyridin-3-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)
acetate (11j)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (497 mg, 23%); Rf 0.44 (7% MeOH in DCM);
nmax (thin ﬁlm)/cm"1 2939s, 2098s, 1684s, 1262s, 1104w, 1078w,
1008s, 964w; dH (400MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.8), 2.98 (2H, t,
J 6.7), 4.05e4.22 (4H, m), 4.41 (2H, t, J 6.7), 7.24 (1H, ddd, J 7.8, 4.8,
0.7), 7.56 (1H, ddd, J 7.8, 2.3, 1.7), 8.47e8.51 (2H, m); dC (100 MHz,
CDCl3) 15.8 (d, J 6.9), 32.0, 53.5 (d, J 226.1), 63.3 (d, J 5.8), 65.0, 123.1,
132.7, 136.1, 147.9, 149.9, 162.9 (d, J 12.1); dP (162 MHz, CDCl3) 10.4;
HRMS (ESIþ): found: 350.0876; C13H18N3NaO5P (MNaþ) requires
350.0876.
4.31. 2-(Thiophen-3-yl)ethyl 2-diazo-2-(diethoxyphosphoryl)
acetate (11k)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (871 mg, 52%); Rf 0.43 (1:1 petrol/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2989w, 2126s, 1703s, 1274s, 1017s,
977m; dH (400 MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.8), 2.99 (2H, t, J 6.8),
4.05e4.22 (4H, m), 4.39 (2H, t, J 6.8), 6.95 (1H, dd, J 4.9, 1.3), 7.03
(1H, ddt, J 2.9, 1.3, 0.7), 7.25 (1H, dd, J 4.9, 2.9); dC (100 MHz, CDCl3)
16.0 (d, J 6.9), 29.5, 53.8 (d, J 228.2), 63.5 (d, J 5.6), 65.3, 121.7, 125.6,
128.1,137.4,163.3 (d, J 12.2); dP (162MHz, CDCl3) 10.5; HRMS (ESIþ):
found: 355.0488; C12H17N2NaO5PS (MNaþ) requires 355.0488.
4.32. 3-Methylbutyl 2-diazo-2-(diethoxyphosphoryl)acetate
(11s)
Synthesised using general procedure B affording the title com-
pound as a pale yellow oil (1.18 g, 67%); Rf 0.65 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2960w, 2125s, 1701s, 1389w, 1272s,
1215w, 1164w, 1116w, 1091w, 1016s, 977m; dH (400 MHz, CDCl3)
0.91 (6H, d, J 6.6), 1.35 (6H, td, J 7.1, 0.8), 1.54 (2H, app. q, J 6.8),
1.62e1.75 (1H, m), 4.10e4.26 (4H, m), 4.22 (2H, t, J 6.8); dC
(100 MHz, CDCl3) 16.0 (d, J 6.9), 22.2, 24.8, 37.2, 53.5 (d, J 228.2),
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63.4 (d, J 5.7), 64.1, 163.3 (d, J 12.0); dP (162 MHz, CDCl3) 10.8; HRMS
(ESIþ): found: 315.1084; C11H21N2NaO5P (MNaþ) requires 315.1080.
4.33. 3,3-Dimethylbutyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11t)
Synthesised using general procedure B affording the title com-
pound as a pale yellow oil (1.22 g, 66%); Rf 0.49 (1:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2959m, 2880w, 2125s, 1702s, 1276s,
1216w, 1164w, 1119w, 1095w, 1016s, 976m; dH (400 MHz, CDCl3)
0.89 (9H, s), 1.31 (6H, td, J 7.1, 0.8), 1.54 (2H, t, J 7.4), 4.06e4.22 (4H,
m), 4.21 (2H, t, J 7.4); dC (100 MHz, CDCl3) 16.0 (d, J 6.9), 29.4, 29.6,
41.6, 53.5 (d, J 228.5), 63.3, 63.4 (d, J 5.6), 163.3 (d, J 12.3); dP
(162 MHz, CDCl3) 10.7; HRMS (ESIþ): found: 329.1223;
C12H23N2NaO5P (MNaþ) requires 329.1237.
4.34. 3-((tert-Butyldimethylsilyl)oxy)propyl 2-diazo-2-(dieth-
oxyphosphoryl) acetate (11u)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (1.42 g, 60%); Rf 0.30 (2:1 petrol/ethyl acetate);
nmax (thin ﬁlm)/cm"1 2964w, 2931w, 2866w, 2128s, 1707s, 1474w,
1395w, 1281s, 1097m, 1024s, 838m, 777w; dH (400 MHz, CDCl3)
"0.05 (6H, s), 0.79 (9H, s), 1.26 (6H, td, J 7.1, 0.8), 1.77 (2H, tt, J 6.4,
6.0), 3.69 (2H, t, J 6.0), 4.02e4.17 (4H, m), 4.24 (2H, t, J 6.4); dC
(100 MHz, CDCl3) "5.7, 15.9 (d, J 6.9), 18.0, 25.6, 31.6, 53.5 (d, J
230.0), 58.8, 62.4, 63.3 (d, J 5.9),163.1 (d, J 11.6); dP (162MHz, CDCl3)
10.6; HRMS (ESIþ): found: 417.1590; C15H31N2NaO6PSi (MNaþ) re-
quires 417.1581.
4.35. 4-((tert-Butyldimethylsilyl)oxy)butyl 2-diazo-2-(dieth-
oxyphosphoryl)acetate (11v)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (1.05 g, 58%); Rf 0.74 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2954w, 2930w, 2857w, 2126s, 1703s,
1473w, 1389w, 1275s, 1257w, 1164w, 1095s, 1019s, 977s, 892w,
834s, 813w, 774s, 746w, 662w, 589m, 560m; dH (400 MHz, CDCl3)
"0.05 (6H, s), 0.79 (9H, s), 1.26 (6H, td, J 7.1, 0.8), 1.45e1.52 (2H, m),
1.61e1.68 (2H, m), 3.54 (2H, t, J 6.2), 4.02e4.18 (6H, m); dC
(100 MHz, CDCl3) "5.6, 15.9 (d, J 6.9), 18.0, 25.2, 25.7, 28.7, 53.5 (d, J
227.3), 62.2, 63.3 (d, J 6.0), 65.4,163.2 (d, J 11.9); dP (162MHz, CDCl3)
10.6; HRMS (ESIþ): found: 431.1748; C16H33N2NaO6PSi (MNaþ) re-
quires 431.1738.
4.36. But-3-en-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate
(11w)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (790 mg, 60%); Rf 0.43 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2984w, 2126s, 1702s, 1643w, 1445w,
1384w, 1276s, 1164w, 1117w, 1092w, 1019s, 978s, 797m, 746m; dH
(400 MHz, CDCl3) 1.32 (6H, td, J 7.1, 0.8), 2.38 (2H, app. qt, J 6.7, 1.3),
4.07e4.23 (6H, m), 5.03e5.11 (2H, m), 5.74 (1H, ddt, J 17.1, 10.3, 6.7);
dC (100 MHz, CDCl3) 16.0 (d, J 6.9), 33.0, 53.7 (d, J 226.3), 63.5 (d, J
5.9), 64.5, 117.5, 133.4, 163.3 (d, J 12.1); dP (162 MHz, CDCl3) 10.6;
HRMS (ESIþ): found: 299.0768; C10H17N2NaO5P (MNaþ) requires
299.0767.
4.37. Cyclopentyl 2-diazo-2-(diethoxyphosphoryl)acetate
(11x)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (1.00 g, 83%); Rf 0.54 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2972m, 2875w, 2125s, 1696s, 1478w,
1443w, 1393w, 1321w, 1274s, 1218w, 1165m, 1121m, 1089w, 1018s,
977m, 959m, 796m, 749m; dH (400 MHz, CDCl3) 1.29 (6H, td, J 7.1,
0.8), 1.49e1.86 (8H, m), 4.04e4.19 (4H, m), 5.21 (1H, tt, J 5.6, 2.7); dC
(100 MHz, CDCl3) 16.0 (d, J 7.0), 23.4, 32.6, 53.8 (d, J 227.0), 63.3 (d, J
5.6), 78.6, 163.0 (d, J 11.7); dP (162 MHz, CDCl3) 10.9; HRMS (ESIþ):
found: 313.0930; C11H19N2NaO5P (MNaþ) requires 313.0924.
4.38. Cyclohexyl 2-diazo-2-(diethoxyphosphoryl)acetate (11y)
Synthesised using general procedure B affording the title com-
pound as a pale yellow oil (2.68 g, 88%); Rf 0.50 (1:1 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2990w, 2937s, 2864m, 2124s, 1694s,
1279s, 1260s, 1115w, 1013s, 976s; dH (400 MHz, CDCl3) 1.18e1.50
(6H, m), 1.31 (6H, td, J 7.1, 0.8), 1.64e1.71 (2H, m), 1.77e1.82 (2H, m),
4.06e4.22 (4H, m), 4.84 (1H, tt, J 8.4, 4.1); dC (100 MHz, CDCl3) 16.0
(d, J 7.2), 23.2, 25.1, 31.4, 53.8 (d, J 228.0), 63.4 (d, J 5.7), 74.0, 162.8
(d, J 11.8); dP (162 MHz, CDCl3) 10.9; HRMS (ESIþ): found: 327.1082;
C12H21N2NaO5P (MNaþ) requires 327.1010.
4.39. Adamantan-1-yl 2-diazo-2-(diethoxyphosphoryl)acetate
(11z)
Synthesised using general procedure B affording the title com-
pound as a white solid (1.21 g, 74%); Rf 0.63 (1:1 hexane/ethyl ac-
etate); mp 51e54 #C; nmax (thin ﬁlm)/cm"1 2912s, 2855w, 2125s,
1697s, 1457w,1321m,1269s, 1219w,1164w,1122w,1023s, 966m; dH
(400 MHz, CDCl3) 1.30 (6H, td, J 7.1, 0.8), 1.60e1.61 (6H, m),
2.07e2.15 (9H, m), 4.05e4.20 (4H, m); dC (100MHz, CDCl3) 16.0 (d, J
6.8), 30.7, 35.9, 41.4, 53.9 (d, J 228.4), 63.3 (d, J 5.6), 82.9, 162.0 (d, J
12.0); dP (162 MHz, CDCl3) 11.3; HRMS (ESIþ): found: 379.1384;
C16H25N2NaO5P (MNaþ) requires 379.1393.
4.40. Cycloheptyl 2-diazo-2-(diethoxyphosphoryl)acetate
(11aa)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (1.35 g, 89%); Rf 0.52 (1:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm"1 2987w, 2930m, 2861w, 2125s, 1694s,
1446w, 1369w, 1322w, 1270s, 1215w, 1164w, 1120m, 1015s, 961s,
885w, 974m, 746s, 590s, 555s; dH (400 MHz, CDCl3) 1.26 (6H, td, J
7.1, 0.8), 1.31e1.66 (10H, m), 1.77e1.85 (2H, m), 4.01e4.17 (4H, m),
4.96 (1H, tt, J 8.1, 4.2); dC (100 MHz, CDCl3) 15.8 (d, J 7.0), 22.4, 27.9,
33.5, 53.7 (d, J 227.0), 63.2 (d, J 6.0), 76.5, 162.7 (d, J 11.9); dP
(162 MHz, CDCl3) 10.9; HRMS (ESIþ): found: 341.1226;
C13H23N2NaO5P (MNaþ) requires 341.1237.
4.41. 2-Methylpropyl 2-diazo-2-(diethoxyphosphoryl)acetate
(11ab)15a
Synthesised using general procedure B affording the title com-
pound as a pale yellow oil (1.62 g, 73%); Rf 0.50 (1:1 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2966m, 2127s, 1702s, 1276s, 1115w,
1019s, 978m; dH (400 MHz, CDCl3) 0.89 (6H, d, J 6.7), 1.31 (6H, td, J
7.1, 0.8), 1.91 (1H, app. nonet, J 6.7), 3.93 (2H, d, J 6.6), 4.06e4.22
(4H, m); dC (100 MHz, CDCl3) 16.0 (d, J 6.9), 18.7, 27.7, 53.7 (d, J
227.9), 63.4 (d, J 5.7), 71.5, 163.4 (d, J 11.9); dP (162MHz, CDCl3) 10.8;
HRMS (ESIþ): found: 301.0913; C10H19N2NaO5P (MNaþ) requires
301.0924.
4.42. Cyclopropylmethyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11ac)
Synthesised using general procedure B affording the title com-
pound as a yellow oil (850 mg, 64%); Rf 0.43 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2986w, 2908w, 2125s, 1700s, 1446w,
1394w, 1348m, 1275s, 1216w, 1164w, 1115w, 1082w, 1018s, 977w,
958s, 796m, 746m, 590m, 560m; dH (400 MHz, CDCl3) 0.25e0.29
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(2H, m), 0.52e0.57 (2H, m), 1.07e1.17 (1H, m), 1.33 (6H, t, J 7.1), 4.01
(2H, d, J 7.3), 4.10e4.25 (4H, m); dC (100MHz, CDCl3) 3.2, 9.8,16.1 (d,
J 6.9), 53.9 (d, J 226.8), 63.6 (d, J 5.6), 70.3, 163.5 (d, J 12.2); dP
(162 MHz, CDCl3) 10.6; HRMS (ESIþ): found: 299.0771;
C10H17N2NaO5P (MNaþ) requires 299.0767.
4.43. Cyclobutylmethyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11ad)
Synthesised using general procedure B affording the title com-
pound as a brown oil (949 mg, 68%); Rf 0.50 (1:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm"1 2981w, 2942w, 2869w, 2125s, 1700s,
1445w, 1391w, 1335w, 1276s, 1216w, 1164w, 1117w, 1095w, 1019w,
977m, 797m, 747m, 590m, 560m; dH (400 MHz, CDCl3) 1.34 (6H, td,
J 7.1, 0.8), 1.72e1.97 (4H, m), 1.99e2.08 (2H, m), 2.57e2.68 (1H, m),
4.09e4.25 (6H, m); dC (100 MHz, CDCl3) 16.1 (d, J 7.0), 18.3, 24.5,
34.0, 53.8 (d, J 228.6), 63.5 (d, J 5.9), 69.2, 163.6 (d, J 12.0); dP
(162 MHz, CDCl3) 10.8; HRMS (ESIþ): found: 313.0917;
C11H19N2NaO5P (MNaþ) requires 313.0924.
4.44. Cyclohexylmethyl 2-diazo-2-(diethoxyphosphoryl)ace-
tate (11af)
Synthesised using general procedure B with NaH (1.2 equiv, 60%
dispersion in mineral oil) in place of LHMDS affording the title
compound as a yellow oil (410 mg, 68%); Rf 0.85 (ethyl acetate); nmax
(thin ﬁlm)/cm"1 2930s, 2131s, 1705s, 1280s, 1024s; dH (400 MHz,
CDCl3) 0.93e1.04 (2H, m), 1.11e1.30 (3H, m), 1.36 (6H, td, J 7.1, 0.8),
1.55e1.77 (6H, m), 4.01 (2H, d, J 6.5), 4.11e4.27 (4H, m); dC
(100MHz, CDCl3) 16.0 (d, J 7.1), 25.5, 26.2, 29.3, 37.1, 53.7 (d, J 227.4),
63.5 (d, J 5.6), 70.6, 163.5 (d, J 12.0); dP (162MHz, CDCl3) 10.9; HRMS
(ESIþ): found: 341.1228; C13H23N2NaO5P (MNaþ) requires 341.1237.
4.45. (SR)-3-Methylene-4-(3,4,5-trimethoxyphenyl)dihy-
drofuran-2(3H)-one (12c)
Synthesised using general procedure D with 3,4,5-
trimethoxyphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate 11c
(77 mg, 0.185 mmol), DCM (3.7 mL), Rh2(oct)4 (2.9 mg, 3.7 mmol),
THF (3.7 mL), KOBu-t (31.1 mg, 0.278 mmol) and paraformaldehyde
(11.1 mg, 0.370 mmol). The HWE was performed at rt. Puriﬁcation
by column chromatography (2:1 hexane/ethyl acetate) afforded the
title compound as a colourless oil (22 mg, 45%); Rf 0.26 (2:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm"1 2937w, 1763s, 1660w, 1591m,
1509m, 1461m, 1425m, 1347w, 1242m, 1124s, 1013m; dH (400 MHz,
CDCl3) 3.83 (3H, s), 3.84 (6H, s), 4.17e4.24 (2H, m), 4.68e4.75 (1H,
m), 5.56 (1H, d, J 2.6), 6.40e6.41 (3H, m); dC (100 MHz, CDCl3) 45.9,
56.2, 60.8, 72.7, 104.7, 124.3, 135.2, 137.4, 138.5, 153.7, 170.1; HRMS
(ESIþ): found: 287.0892; C14H16NaO5 (MNaþ) requires 287.0890.
4.46. (SR)-3-Methylene-4-(naphthalen-1-yl)dihydrofuran-
2(3H)-one (12e)
Synthesised using general procedure D with 2-(naphthalen-1-
yl)ethyl 2-diazo-2-(diethoxyphosphoryl)acetate 11e (82 mg,
0.218 mmol), DCM (4.4 mL), Rh2(oct)4 (3.4 mg, 4.4 mmol), THF
(4.4 mL), KOBu-t (36.7 mg, 0.327 mmol) and paraformaldehyde
(13.1 mg, 0.436 mmol). The HWE was performed at rt. Puriﬁcation
by column chromatography (4:1 hexane/ethyl acetate) afforded the
title compound as a colourless oil (28 mg, 57%); Rf 0.45 (4:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm"1 3050w, 2918w, 1759s, 1662w,
1598w, 1511w, 1398m, 1261w, 1230w, 1111s, 1022m, 948w, 802m,
780s; dH (400 MHz, CDCl3) 4.36 (1H, dd, J 9.0, 6.3), 4.89 (1H, app. t, J
9.0), 5.03e5.08 (1H, m), 5.60 (1H, d, J 2.7), 6.51 (1H, d, J 3.0),
7.38e7.40 (1H, m), 7.47 (1H, app. t, J 7.7), 7.53e7.60 (2H, m),
7.81e7.88 (2H, m), 7.91e7.95 (1H, m); dC (100 MHz, CDCl3) 41.6,
72.0, 124.5, 122.6, 125.0, 125.5, 126.1, 126.7, 128.5, 129.3, 131.0, 134.2,
135.6, 137.6, 170.4; HRMS (ESIþ): found: 247.0728; C15H12NaO2
(MNaþ) requires 247.0730.
4.47. (SR)-4-(4-Bromophenyl)-3-methylenedihydrofuran-
2(3H)-one (12f)
Synthesised using general procedure D with 4-bromophenethyl
2-diazo-2-(diethoxyphosphoryl)acetate 11f (90 mg, 0.222 mmol),
DCM (4.4 mL), Rh2(oct)4 (3.5 mg, 4.4 mmol), THF (4.4 mL), KOBu-t
(37.4 mg, 0.333 mmol) and paraformaldehyde (13.3 mg,
0.444 mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (8:1 hexane/ethyl acetate) afforded the title com-
pound as a pale yellow oil (31 mg, 55%); Rf 0.40 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm"1 2972w, 2913w,1761s,1666w,1590w,
1489m, 1412m, 1274w, 1231m, 1107s, 1010s, 947w, 825s; dH
(400 MHz, CDCl3) 4.17e4.27 (2H, m), 4.71 (1H, app. t, J 8.4), 5.48
(1H, d, J 2.7), 6.39 (1H, d, J 3.0), 7.11 (2H, d, J 8.5), 7.50 (2H, d, J 8.5); dC
(100 MHz, CDCl3) 45.1, 72.3, 121.8, 124.3, 129.5, 132.3, 138.3, 138.5,
169.8; HRMS (ESIþ): found: 274.9679; C11H979BrNaO2 (MNaþ) re-
quires 274.9678.
4.48. (SR)-3-Methylene-4-(4-(triﬂuoromethyl)phenyl)dihy-
drofuran-2(3H)-one (12g)
Synthesised using general procedure D with 4-
triﬂuoromethylphenethyl 2-diazo-2-(diethoxyphosphoryl)acetate
11g (83 mg, 0.162 mmol), DCM (4.2 mL), Rh2(oct)4 (3.3 mg,
4.2 mmol), KOBu-t (28.4 mg, 0.253 mmol) and paraformaldehyde
(12.7 mg, 0.422 mmol). The HWE was performed at 0 #C. Puriﬁca-
tion by column chromatography (4:1 hexane/ethyl acetate) affor-
ded the title compound as a colourless oil (15 mg, 29%); Rf 0.59 (2:1
petrol/ethyl acetate); nmax (thin ﬁlm)/cm"1 2875w, 1741s, 1307s,
1097m, 1053w; dH (400 MHz, CDCl3) 4.24 (1H, dd, J 9.0, 7.1),
4.33e4.38 (1H, m), 4.75 (1H, app. t, J 9.0), 5.50 (1H, d, J 2.9), 6.44
(1H, d, J 2.9), 7.37 (2H, d, J 8.0), 7.65 (2H, d, J 8.0); dC (100 MHz,
CDCl3) 45.3, 72.2,123.8 (q, J 272.2),124.7,126.2 (q, J 3.8),128.3,130.2
(q, J 32.1), 138.1, 143.7, 169.6; dF (376 MHz, CDCl3) "62.6; HRMS
(ESIþ): found: 265.0447; C12H9F3NaO2 (MNaþ) requires 265.0447.
4.49. (SR)-3-Methylene-4-(4-nitrophenyl)dihydrofuran-
2(3H)-one (12h)
Synthesised using general procedure Cwith 4-nitrophenethyl 2-
diazo-2-(diethoxyphosphoryl)acetate 11h (37 mg, 0.100 mmol),
DCM (2.0 mL), Rh2(esp)2 (3.8 mg, 5.0 mmol), KOBu-t (10.1 mg,
0.090 mmol) and paraformaldehyde (30.0 mg, 0.997 mmol). The
HWE was performed at 0 #C. Puriﬁcation by column chromatog-
raphy (2:1 petrol/ethyl acetate) afforded the title compound as
a colourless oil (4 mg, 18%); Rf 0.58 (1:1 petrol/ethyl acetate); nmax
(thin ﬁlm)/cm"1 2878s, 2809s,1737s,1575w,1496m,1327m,1092w,
1004w, 843w; dH (400 MHz, CDCl3) 4.27 (1H, dd, J 9.1, 6.8),
4.39e4.45 (1H, m), 4.78 (1H, app. t, J 9.1), 5.53 (1H, d, J 2.7), 6.48
(1H, d, J 3.1), 7.44 (2H, d, J 8.8), 8.26 (2H, d, J 8.8); dC (100 MHz,
CDCl3) 45.2, 71.9, 124.5, 125.1, 128.8, 137.7, 147.0, 147.6, 169.2; HRMS
(ESIþ): found: 242.0427; C11H9NNaO4 (MNaþ) requires 242.0424.
4.50. (SR)-3-Methylene-4-(thiophen-3-yl)dihydrofuran-
2(3H)-one (12k)
Synthesised using general procedure C with 2-(thiophen-3-yl)
ethyl 2-diazo-2-(diethoxyphosphoryl)acetate 11k (69 mg,
0.208 mmol), DCM (4.2 mL), Rh2(oct)4 (3.2 mg, 4.2 mmol), KOBu-t
(28.0 mg, 0.250 mmol) and paraformaldehyde (12.5 mg,
0.416 mmol). The HWE was performed at 0 #C. Puriﬁcation by
column chromatography (5:1 petrol/ethyl acetate) afforded the title
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compound as a colourless oil (12 mg, 32%); Rf 0.59 (2:1 petrol/ethyl
acetate); nmax (thin ﬁlm)/cm!1 3110w, 2910w,1761s, 1404w,1250m,
1109m, 1018m; dH (400 MHz, CDCl3) 4.23 (1H, dd, J 8.9, 7.3),
4.38e4.44 (1H, m), 4.68 (1H, app. t, J 8.9), 5.56 (1H, d, J 2.8), 6.38
(1H, d, J 3.1), 6.95 (1H, dd, J 5.0, 1.4), 7.15 (1H, ddd, J 3.0, 1.4, 0.5), 7.38
(1H, dd, J 5.0, 3.0); dC (100MHz, CDCl3) 41.0, 71.9, 122.6, 123.8, 126.1,
127.4, 138.1, 139.4, 170.0; HRMS (ESIþ): found: 203.0134;
C9H8NaO2S (MNaþ) requires 203.0137.
4.51. (SR)-4-Isopropyl-3-methylenedihydrofuran-2(3H)-one
(12s)
Synthesised using general procedure D with 3-methylbutyl 2-
diazo-2-(diethoxyphosphoryl)acetate 11s (56 mg, 0.191 mmol),
DCM (3.8 mL), Rh2(oct)4 (3.0 mg, 3.8 mmol), THF (3.8 mL), KOBu-t
(25.7 mg, 0.229 mmol) and paraformaldehyde (11.5 mg,
0.382 mmol). The HWE was performed at 0 #C. Puriﬁcation by
column chromatography (8:1 pentane/ether) afforded the title
compound as a colourless oil (15 mg, 56%); Rf 0.30 (8:1 pentane/
ether); nmax (thin ﬁlm)/cm!1 2963m, 1762s, 1409w, 1267w, 1117m,
1039w, 979w; dH (400 MHz, CDCl3) 0.92 (3H, d, J 6.8), 0.95 (3H, d, J
6.8), 1.87e1.99 (1H, m), 2.93e2.99 (1H, m), 4.16 (1H, dd, J 9.3, 4.0),
4.35 (1H, dd, J 9.3, 8.1), 5.62 (1H, d, J 2.2), 6.34 (1H, d, J 2.5); dC
(100 MHz, CDCl3) 17.7, 19.1, 31.4, 44.6, 68.3, 123.1, 136.9, 171.2;
HRMS (ESIþ): found: 163.0722; C8H12NaO2 (MNaþ) requires
163.0730.
4.52. (SR)-4-(tert-Butyl)-3-methylenedihydrofuran-2(3H)-one
(12t)
Synthesised using general procedure D with 3,3-dimethylbutyl
2-diazo-2-(diethoxyphosphoryl)acetate 11t (58 mg, 0.189 mmol),
DCM (3.8 mL), Rh2(oct)4 (3.0 mg, 3.8 mmol), THF (3.8 mL), KOBu-t
(25.5 mg, 0.227 mmol) and paraformaldehyde (11.4 mg,
0.378 mmol). The HWE was performed at 0 #C. Puriﬁcation by
column chromatography (8:1 pentane/ether) afforded the title
compound as a colourless oil (10 mg, 34%); Rf 0.24 (8:1 pentane/
ether); nmax (thin ﬁlm)/cm!1 2962m, 1765s, 1492w, 1401w, 1364w,
1274m, 1250w, 1119m, 1041w, 969w, 822w; dH (400 MHz, CDCl3)
0.94 (9H, s), 2.74e2.78 (1H, m), 4.26e4.34 (2H, m), 5.66 (1H, dd, J
1.9, 0.7), 6.38 (1H, d, J 2.1); dC (100MHz, CDCl3) 26.3, 33.5, 49.1, 67.8,
124.5, 136.2, 171.3; HRMS (ESIþ): found: 177.0878; C9H14NaO2
(MNaþ) requires 177.0886.
4.53. (SR)-4-(((tert-Butyldimethylsilyl)oxy)methyl)-3-
methylenedihydrofuran-2(3H)-one (12u) and (SR)-4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-3-methyleneoxetan-2-one (16a)
Synthesised using general procedure D with 3-((tert-butyldi-
methylsilyl)oxy)propyl 2-diazo-2-(diethoxyphosphoryl)acetate
11u (83 mg, 0.210 mmol), DCM (4.2 mL), Rh2(oct)4 (3.3 mg,
4.2 mmol), THF (4.2 mL), KOBu-t (35.3 mg, 0.315 mmol) and para-
formaldehyde (12.6 mg, 0.420 mmol). The HWE was performed at
rt. Puriﬁcation by column chromatography (8:1 hexane/ethyl ace-
tate) afforded the title compounds 4-(((tert-butyldimethylsilyl)oxy)
methyl)-3-methylenedihydrofuran-2(3H)-one 12u (9 mg, 18%) and
4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methyleneoxetan-2-
one 16a (8 mg, 16%) as colourless oils.
4.53.1. Data for 12u. Rf 0.49 (4:1 hexane/ethyl acetate); nmax (thin
ﬁlm)/cm!1 2955m, 2930m, 2857m, 1766s, 1663w, 1472m, 1408w,
1362w, 1258m, 1115s, 1039m, 1004m, 940w, 837s, 815w, 778m; dH
(400 MHz, CDCl3) 0.05 (3H, s), 0.05 (3H, s), 0.88 (9H, s), 3.20e3.27
(1H, m), 3.65 (1H, dd, J 9.9, 7.2), 3.72 (1H, dd, J 9.9, 5.9), 4.21 (1H, dd,
J 9.3, 4.3), 4.42 (1H, dd, J 9.3, 8.2), 5.69 (1H, d, J 2.2), 6.31 (1H, d, J
2.5); dC (100 MHz, CDCl3) !5.6, !5.5, 18.2, 25.7, 41.2, 64.8, 68.4,
123.2, 135.6, 170.6; HRMS (ESIþ): found: 265.1223; C12H22NaO3Si
(MNaþ) requires 265.1230.
4.53.2. Data for 16a. Rf 0.60 (4:1 hexane/ethyl acetate); nmax (thin
ﬁlm)/cm!1 2955m, 2930m, 2858m, 1826s, 1472w, 1408w, 1362w,
1257m, 1208w, 1099s, 1049m, 946w, 834s, 778m; dH (400 MHz,
CDCl3) 0.07 (3H, s), 0.07 (3H, s), 0.90 (9H, s), 2.00e2.09 (2H, m), 3.80
(2H, app. dd, J 6.6, 5.2), 5.16 (1H, app. ddt, J 7.5, 5.7, 1.8), 5.47 (1H,
app. t, J 1.7), 5.93 (1H, app. t, J 1.9); dC (100 MHz, CDCl3) !5.5, !5.4,
18.3, 25.9, 36.5, 58.6, 77.1, 115.3, 146.4, 163.6; HRMS (ESIþ): found:
265.1227; C12H22NaO3Si (MNaþ) requires 265.1230.
4.54. (SR)-4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-3-
methylenedihydrofuran-2(3H)-one (12v)
Synthesised using general procedure D with 4-((tert-butyldi-
methylsilyl)oxy)butyl 2-diazo-2-(diethoxyphosphoryl)acetate 11v
(87 mg, 0.213 mmol), DCM (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 mol),
THF (4.2 mL), KOBu-t (35.9 mg, 0.320mmol) and paraformaldehyde
(12.8 mg, 0.426 mmol). The HWE was performed at rt. Puriﬁcation
by column chromatography (4:1 hexane/ethyl acetate) afforded the
title compound as a colourless oil (27 mg, 49%); Rf 0.50 (4:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm!1 2954m, 2929m, 2857m, 1767s,
1472w, 1257s, 1103s, 1020m, 940w, 836s, 777m; dH (400 MHz,
CDCl3) 0.05 (3H, s), 0.05 (3H, s), 0.89 (9H, s), 1.72 (1H, dddd, J 14.0,
9.1, 7.5, 5.1), 1.91 (1H, app. ddt, J 14.0, 5.7, 4.9), 3.17e3.26 (1H, m),
3.65e3.76 (2H, m), 4.07 (1H, dd, J 9.1, 6.1), 4.51 (1H, dd, J 9.1, 8.4),
5.60 (1H, d, J 2.6), 6.27 (1H, d, J 2.9); dC (100MHz, CDCl3)!5.5,!5.5,
18.2, 25.8, 36.3, 36.8, 60.5, 71.7, 121.7, 138.4, 170.8; HRMS (ESIþ):
found: 279.1393; C13H24NaO3Si (MNaþ) requires 279.1387.
4.55. (SR)-3-Methylene-4-vinyldihydrofuran-2(3H)-one
(12w)30 and 3-methyl-4-vinylfuran-2(5H)-one (17)23
Synthesised using general procedure D with but-3-en-1-yl 2-
diazo-2-(diethoxyphosphoryl)acetate 11w (58 mg, 0.210 mmol),
DCM (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 mmol), THF (4.2 mL), KOBu-t
(35.3 mg, 0.315 mmol) and paraformaldehyde (12.6 mg,
0.420mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (8:1 pentane/ether) afforded the title compounds
3-methylene-4-vinyldihydrofuran-2(3H)-one 12w as a colourless
oil (10 mg, 38%) and 3-methyl-4-vinylfuran-2(5H)-one 17 as a col-
ourless oil (2.3 mg, 9%).
4.55.1. Data for 12w.31 Rf 0.54 (4:1 pentane/ether); nmax (thin ﬁlm)/
cm!1 2965, 2919, 2851, 1766, 1238, 1112; dH (400 MHz, CDCl3)
3.68e3.76 (1H, m), 4.02 (1H, dd, J 9.1, 7.4), 4.53 (1H, app. t, J 9.0),
5.23e5.28 (2H, m), 5.62 (1H, d, J 2.8), 5.71 (1H, ddd, J 16.6, 10.4, 8.2),
6.33 (1H, d, J 3.2); dC (100MHz, CDCl3) 44.0, 70.0,119.2, 123.4, 135.0,
137.0, 170.1; HRMS (ESIþ): found: 147.0411; C7H8NaO2 (MNaþ) re-
quires 147.0417.
4.55.2. Data for 17.23 Rf 0.29 (4:1 pentane/ether); nmax (thin ﬁlm)/
cm!1 2925, 2855, 1752, 1663, 1432, 1337, 1208, 1077, 1045; dH
(400 MHz, CDCl3) 1.94 (3H, s), 4.88e4.89 (2H, m), 5.49e5.56 (2H,
m), 6.72 (1H, dd, J 17.8, 11.0); dC (100 MHz, CDCl3) 8.8, 69.2, 121.0,
124.3, 126.9, 152.0, 178.1; HRMS (ESIþ): found: 147.0417; C7H8NaO2
(MNaþ) requires 147.0417.
4.56. 3-Methylene-1-oxaspiro[3.5]nonan-2-one (16b),31 (3aS-
R,7aRS)-3-methylenehexahydrobenzofuran-2(3H)-one (trans-
12y)32 and (3aRS,7aRS)-3-methylenehexahydrobenzofuran-
2(3H)-one (cis-12y)32
Synthesised using general procedure C with cyclohexyl 2-diazo-
2-(diethoxyphosphoryl)acetate 11y (84 mg, 0.276 mmol), DCM
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(5.4 mL), Rh2(oct)4 (4.3 mg, 0.006 mmol), KOBu-t (37.2 mg,
0.331 mmol) and paraformaldehyde (16.6 mg, 0.552 mmol). The
HWE was performed at 0 !C. Puriﬁcation by column chromatog-
raphy (20:1 hexane/ethyl acetate) afforded the title compounds
(18 mg, 43%) (16b/trans-12y/cis-12y 6:10:1); HRMS (ESIþ): found:
175.0726; C9H12NaO2 (MNaþ) requires 175.0730. Small quantities of
each compound were isolated separately for characterisation
purposes.
4.56.1. Data for 16b.32 Rf 0.70 (4:1 hexane/ethyl acetate); nmax (thin
ﬁlm)/cm#1 2937, 2861, 1814, 1450, 1177, 1107, 1011; dH (400 MHz,
CDCl3) 1.41e1.96 (10H, m), 5.41 (1H, d, J 1.9), 5.80 (1H, d, J 1.9); dC
(100 MHz, CDCl3) 23.0, 24.6, 34.5, 87.2, 113.0, 150.1, 163.8.
4.56.2. Data for trans-12y.33 Rf 0.65 (4:1 hexane/ethyl acetate);
nmax (thin ﬁlm)/cm#1 2940, 2864, 1770, 1251, 1132, 1026, 996; dH
(400 MHz, CDCl3) 1.32e1.44 (3H, m), 1.57e1.67 (1H, m), 1.83e1.87
(1H, m), 1.95e1.98 (1H, m), 2.11e2.15 (1H, m), 2.24e2.29 (1H, m),
2.37e2.44 (1H, m), 3.71 (1H, ddd, J 11.5, 10.8, 3.7), 5.38 (1H, d, J 3.1),
6.06 (1H, d, J 3.3); dC (100 MHz, CDCl3) 24.0, 24.8, 25.8, 30.4, 48.9,
83.1, 117.1, 139.6, 170.7.
4.56.3. Data for cis-12y.33 Rf 0.57 (4:1 hexane/ethyl acetate); nmax
(thin ﬁlm)/cm#1 2936, 2864, 1763, 1263, 1127, 965; dH (400 MHz,
CDCl3) 1.31e1.94 (8H, m), 2.99e3.05 (1H, m), 4.52e4.56 (1H, m),
5.51 (1H, d, J 2.3), 6.20 (1H, d, J 2.5); dC (100 MHz, CDCl3) 20.5, 21.1,
26.3, 28.9, 39.6, 76.9, 119.8, 139.9, 171.0.
4.57. 6-Methylene-4-oxatetracyclo[6.3.1.13,10.03,7]tridecan-5-
one (12z)
Synthesised using general procedure D with adamantan-1-yl 2-
diazo-2-(diethoxyphosphoryl)acetate 11z (75 mg, 0.210 mmol),
DCM (4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 mmol), THF (4.2 mL), KOBu-t
(35.3 mg, 0.315 mmol) and paraformaldehyde (12.6 mg,
0.420mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (4:1 hexane/ethyl acetate) afforded the title com-
pound as a white solid (34 mg, 79%); Rf 0.47 (4:1 hexane/ethyl ac-
etate); mp 88e90 !C; nmax (thin ﬁlm)/cm#1 2921s, 2856m, 1967w,
1764s, 1675w, 1451w, 1279w, 1262m, 1242w, 1211m, 1151m, 1042s,
949s; dH (400 MHz, CDCl3) 1.57e1.89 (8H, m), 1.99e2.15 (3H, m),
2.30e2.35 (1H, m), 2.44e2.48 (1H, m), 2.81e2.84 (1H, m), 5.36 (1H,
d, J 3.2), 6.14 (1H, d, J 3.4); dC (100MHz, CDCl3) 29.2, 29.2, 29.6, 30.9,
35.8, 37.6, 39.8, 41.1, 53.5, 80.4, 117.4, 138.6, 170.8; HRMS (ESIþ):
found: 227.1050; C13H16NaO2 (MNaþ) requires 227.1043.
4.58. (3aSR,8aRS)-3-Methyleneoctahydro-2H-cyclohepta[b]fu-
ran-2-one (trans-12aa)33 and (3aRS,8aRS)-3-
methyleneoctahydro-2H-cyclohepta[b]furan-2-one (cis-
12aa)34
Synthesised using general procedure D with cycloheptyl 2-
diazo-2-(diethoxyphosphoryl)acetate 11aa (72 mg, 0.226 mmol),
DCM (4.5 mL), Rh2(oct)4 (3.5 mg, 4.5 mmol), THF (4.5 mL), KOBu-t
(38.0 mg, 0.339 mmol) and paraformaldehyde (13.6 mg,
0.452mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (4:1 hexane/ethyl acetate) afforded the title com-
pounds as mixture of trans and cis isomers (trans-12aa/cis-12aa
3.5:1) (19mg, 51%). A small quantity of the major (trans) compound
was separated for characterisation. The minor (cis) compound was
characterised from a mixture.
4.58.1. Data for trans-12aa.34 Colourless oil; Rf 0.50 (4:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm#1 2929, 2861, 1761, 1667, 1454,
1400,1313,1262,1246, 998; dH (400MHz, CDCl3) 1.40e1.82 (8H, m),
2.12e2.20 (1H, m), 2.33e2.42 (1H, m), 2.73e2.81 (1H, m), 4.15 (1H,
ddd, J 10.6, 9.3, 4.4), 5.46 (1H, d, J 3.2), 6.18 (1H, d, J 3.5); dC
(100 MHz, CDCl3) 25.1, 25.3, 27.3, 28.0, 33.0, 45.6, 83.3, 119.6, 141.0,
170.5; HRMS (ESIþ): found: 189.0889; C10H14NaO2 (MNaþ) requires
189.0886.
4.58.2. Data for cis-12aa.35 Rf 0.43 (4:1 hexane/ethyl acetate); dH
(400 MHz, CDCl3) 1.17e1.97 (9H, m), 2.03e2.09 (1H, m), 3.19e3.27
(1H, m), 4.71 (1H, ddd, J 10.6, 8.6, 3.6), 5.55 (1H, d, J 2.7), 6.27 (1H, d,
J 3.1); dC (100 MHz, CDCl3) 24.2, 27.4, 30.6, 31.2, 31.8, 43.1, 82.3,
122.0, 140.3, 170.4.
4.59. 4,4-Dimethyl-3-methylenedihydrofuran-2(3H)-one
(12ab)24
Synthesised using general procedure D with 2-methylpropyl 2-
diazo-2-(diethoxyphosphoryl)acetate 11ab (85 mg, 0.305 mmol),
DCM (6.1 mL), Rh2(oct)4 (3.4 mg, 6.1 mmol), KOBu-t (41.1 mg,
0.366 mmol) and paraformaldehyde (18.3 mg, 0.610 mmol). The
HWE was performed at 0 !C. Puriﬁcation by column chromatog-
raphy (8:1 hexane/ethyl acetate) afforded the title compound as
a colourless oil (9 mg, 23%); Rf 0.39 (4:1 hexane/ethyl acetate); nmax
(thin ﬁlm)/cm#1 2966w, 2929w, 1760s, 1668w, 1464w, 1410w,
1371w, 1294m, 1169w, 1107m, 1014m; dH (400 MHz, CDCl3) 1.26
(6H, s), 4.03 (2H, s), 5.54 (1H, s), 6.20 (1H, s); dC (100 MHz, CDCl3)
26.9, 38.9, 78.3, 119.9, 144.7, 170.8; HRMS (ESIþ): found: 127.0758;
C7H11O2 (MHþ) requires 127.0754.
4.60. 8-Methylene-6-oxaspiro[3.4]octan-7-one (12ad)
Synthesised using general procedure D with cyclobutylmethyl
2-diazo-2-(diethoxyphosphoryl)acetate 11ad (59 mg, 0.203 mmol),
DCM (4.0 mL), Rh2(oct)4 (3.2 mg, 4.1 mmol), THF (4.0 mL), KOBu-t
(34.2 mg, 0.305 mmol) and paraformaldehyde (12.2 mg,
0.406mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (4:1 hexane/ethyl acetate) afforded the title com-
pound as a colourless oil (22 mg, 78%); Rf 0.42 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2935w, 1760s, 1662w, 1408w,
1296m,1117m,1005m, 942w, 814w; dH (400MHz, CDCl3) 1.95e2.04
(2H, m), 2.18e2.30 (4H, m), 4.32 (2H, s), 5.80 (1H, s), 6.26 (1H, s); dC
(100 MHz, CDCl3) 15.3, 34.5, 44.5, 78.1, 119.9, 143.1, 169.8; HRMS
(ESIþ): found: 161.0571; C8H10NaO2 (MNaþ) requires 161.0573.
4.61. 4-Methylene-2-oxaspiro[4.5]decan-3-one (12af)
Synthesised using general procedure D with cyclohexylmethyl
2-diazo-2-(diethoxyphosphoryl)acetate 11af (57 mg, 0.179 mmol),
DCM (3.6 mL), Rh2(oct)4 (2.8 mg, 3.6 mmol), THF (3.6 mL), KOBu-t
(30.2 mg, 0.269 mmol) and paraformaldehyde (10.8 mg,
0.358 mmol). The HWEwas performed at rt. Puriﬁcation by column
chromatography (4:1 hexane/ethyl acetate) afforded the title com-
pound as a colourless oil (15 mg, 50%); Rf 0.63 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2926m, 2854w, 1759s, 1661w,
1451m, 1407w, 1305m, 1254m, 1113s, 1013s, 943m, 815m; dH
(400 MHz, CDCl3) 1.24e1.75 (10H, m), 4.15 (2H, s), 5.54 (1H, s), 6.22
(1H, s); dC (100 MHz, CDCl3) 22.5, 25.0, 36.2, 42.4, 75.3, 120.7, 144.4,
171.3; HRMS (ESIþ): found: 189.0891; C10H14NaO2 (MNaþ) requires
189.0886.
4.62. 1,1,2-Triphenylethyl 2-diazo-2-(diethoxyphosphoryl)ac-
etate (14a)
Procedure for Grignard addition followed according to the lit-
erature procedure.35 To benzylmagnesium chloride solution
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(20 mL, 40mmol, 2 M in THF) cooled to 0 !C under argonwas added
benzophenone (5.47 g, 30 mmol). After 2 h stirring at rt a further
addition of benzylmagnesium chloride (10 mL, 20 mmol) was
made. The suspension was stirred overnight at rt. The suspension
was quenched with satd aq NH4Cl. The organic layer was removed
and the aqueous extracted with ethyl acetate (3"25 mL). The
combined organic extracts were dried over MgSO4 and concen-
trated in vacuo to afford the crude product as a white powder
(9.03 g). A portion of the crude material (3.35 g) was taken forward
to the following step without further puriﬁcation. To a solution of
the crude material in toluene (60 mL) under argon was added se-
quentially diethyl phosphonoacetic acid (2.06 mL, 12.8 mmol),
DIPEA (5.52 mL, 31.7 mmol) and propyl phosphonic anhydride
(10.1 g, 15.8 mmol, 50% w/w solution in ethyl acetate). The solution
was stirred at 50 !C for 1.5 h. The solution was diluted with water
(50 mL) and extracted with ethyl acetate (3"25 mL) followed by
sequential washing of the combined organic extracts with 10%
aq HCl (10 mL), satd aq NaHCO3 (10 mL) and brine (10 mL), dried
overMgSO4 and concentrated in vacuo to afford and dark orange oil
(4.60 g) as crude. Puriﬁcation by column chromatography (1:2
petrol/ethyl acetate) afforded 1,1,2-triphenylethyl 2-(diethox-
yphosphoryl)acetate as a colourless oil (389mg, 8% over two steps);
Rf 0.25 (1:2 petrol/ethyl acetate); nmax (thin ﬁlm)/cm#1 2937s,
1711s, 1251s, 1218w, 1012s; dH (400 MHz, CDCl3) 1.25 (6H, td, J 7.1,
0.3), 2.94 (2H, d, J 21.5), 4.02e4.13 (6H, m), 6.60e6.65 (2H, m),
7.06e7.18 (3H, m), 7.20e7.35 (10H, m); dC (100 MHz, CDCl3) 16.2 (d,
J 6.3), 35.2 (d, J 134.4), 42.7, 62.4 (d, J 6.2), 87.6, 126.3, 126.4, 127.1,
127.5, 127.8, 130.4, 135.3, 143.9, 163.8 (d, J 6.4); dP (162 MHz, CDCl3)
20.3; HRMS (ESIþ): found: 475.1636; C26H29NaO5P (MNaþ) requires
475.1645. 1,1,2-Triphenylethyl 2-(diethoxyphosphoryl)acetate
(308 mg, 0.681 mmol) was then treated under the conditions of
general procedure B with THF (3.4 mL), LHMDS (0.82 mL,
0.82 mmol, 1.0 M solution in THF) and 4-
acetamidobenzenesulfonylazide (196 mg, 0.82 mmol). Puriﬁcation
by column chromatography (2:1 petrol/ethyl acetate) afforded the
title compound as a white crystalline solid (171 mg, 53%); Rf 0.77
(1:2 petrol/ethyl acetate); nmax (thin ﬁlm)/cm#1 2938w, 2884w,
2100s, 1675s, 1264s, 1219w, 1005m; mp 68e72 !C; dH (400 MHz,
CDCl3) 1.19 (6H, td, J 7.1, 0.7), 3.81e3.93 (2H, m), 4.03e4.13 (2H, m),
4.14 (2H, s), 6.61e6.65 (2H, m), 7.06e7.18 (3H, m), 7.22e7.34 (10H,
m); dC (100 MHz, CDCl3) 15.9 (d, J 7.6), 43.3, 55.2 (d, J 227.8), 63.1 (d,
J 5.4), 88.3, 126.1, 126.5, 127.2, 127.5, 128.0, 130.3, 135.3, 144.1, 162.2
(d, J 10.2); dP (162 MHz, CDCl3) 11.0; HRMS (ESIþ): found: 501.1527;
C26H27N2NaO5P (MNaþ) requires 501.1550.
4.63. Diethyl ((1SR,3aSR)-1-benzyl-3-oxo-1-phenyl-3,3a-dihy-
dro-1H-cyclohepta[c]furan-3a-yl)phosphonate (15b)
To a solution of 1,1,2-triphenylethyl 2-diazo-2-(diethox-
yphosphoryl)acetate 14a (47 mg, 0.098 mmol) in toluene (5 mL)
ﬂushed with argon was added Rh2(esp)2 (3.7 mg, 4.9 mmol). The
mixture was stirred at 100 !C for 4 h. Concentration in vacuo and
puriﬁcation by column chromatography (1:1 petrol/ethyl acetate)
afforded the title compound as an off-white solid (22 mg, 50%); Rf
0.22 (1:1 petrol/ethyl acetate); mp 92e95 !C; nmax (thin ﬁlm)/cm#1
2936w,1744s,1230m,1034w,1009m; dH (400MHz, CDCl3) 1.35 (3H,
td, J 7.1, 0.4), 1.38 (3H, td, J 7.1, 0.4), 3.65 (1H, d, J 14.6), 4.10e4.28
(4H, m), 4.11 (1H, d, J 14.6), 5.31 (1H, dd, J 10.0, 6.3), 6.15e6.22 (2H,
m), 6.27e6.36 (2H, m), 7.09e7.16 (5H, m), 7.19e7.30 (3H, m),
7.32e7.36 (2H, m); dC (100 MHz, CDCl3) 16.4 (d, J 5.6), 16.7 (d, J 5.3),
45.6, 56.0 (d, J 145.2), 63.8 (d, J 7.5), 64.4 (d, J 7.3), 90.0 (d, J 3.8),
119.1, 124.2 (d, J 7.2), 125.6, 126.6, 127.7, 127.8, 128.4, 128.5 (d, J 7.4),
129.0, 129.9, 130.7, 134.4, 135.0, 141.3, 172.7 (d, J 3.6); dP (162 MHz,
CDCl3) 17.3; HRMS (ESIþ): found: 473.1477; C26H27NaO5P (MNaþ)
requires 473.1488.
4.64. (SR,Z)-3-(4-Nitrobenzylidene)-4-phenyldihydrofuran-
2(3H)-one (Z-18h) and (SR,E)-3-(4-nitrobenzylidene)-4-
phenyldihydrofuran-2(3H)-one (E-18h)
Synthesised using general procedure D with phenethyl 2-diazo-
2-(diethoxyphosphoryl)acetate 11d (75 mg, 0.230 mmol), DCM
(4.6 mL), Rh2(oct)4 (3.6 mg, 4.6 mmol), THF (4.6 mL), KOBu-t
(38.7 mg, 0.345 mmol) and 4-nitrobenzaldehyde (69.5 mg,
0.460 mmol). The HWE was performed at 0 !C. Puriﬁcation by
column chromatography (10:1 hexane/ethyl acetate) afforded the
title compounds as mixture of (Z) and (E) isomers (Z-18h/E-18h 1:1)
(44 mg, 65%). Small quantities of each compound were isolated
separately for characterisation purposes.
4.64.1. Data for Z-18h. Pale yellow oil; Rf 0.40 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2920w, 1754s, 1597w, 1518s, 1345s,
1161s, 1074w, 1023w; dH (400 MHz, CDCl3) 4.39 (1H, app. t, J 8.0),
4.45 (1H, app. td, J 7.8, 2.7), 4.78 (1H, app. t, J 8.4), 6.72 (1H, d, J 2.7),
7.30e7.32 (2H, m), 7.35e7.39 (1H, m), 7.41e7.46 (2H, m), 7.88 (2H, d,
J 8.9), 8.19 (2H, d, J 8.9); dC (100 MHz, CDCl3) 48.8, 72.4, 123.2, 128.2,
128.2, 129.5, 131.3, 133.2, 138.5, 139.2, 139.3, 147.8, 168.0; HRMS
(ESIþ): found: 318.0749; C17H13NNaO4 (MNaþ) requires 318.0737.
4.64.2. Data for E-18h. Pale yellow oil; Rf 0.32 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2923w, 2854w, 1755s, 1691w,
1653w, 1598m, 1518s, 1343s, 1300w, 1226m, 1173s, 1021w; dH
(400MHz, CDCl3) 4.33 (1H, dd, J 8.9, 3.5), 4.61 (1H, app. dt, J 8.1, 3.0),
4.78 (1H, app. t, J 8.5), 7.17e7.19 (2H, m), 7.24e7.34 (3H, m), 7.45
(2H, d, J 8.8), 7.84 (1H, d, J 2.4), 8.08 (2H, d, J 8.8); dC (100 MHz,
CDCl3) 44.5, 73.8, 123.6, 127.0, 128.0, 129.5, 130.8, 131.4, 136.3, 139.6,
139.6, 147.9, 171.4; HRMS (ESIþ): found: 318.0746; C17H13NNaO4
(MNaþ) requires 318.0737.
4.65. (SR,Z)-3-Pentylidene-4-phenyldihydrofuran-2(3H)-one
(Z-18i) and (SR,E)-3-pentylidene-4-phenyldihydrofuran-
2(3H)-one (E-18i)
Synthesised using general procedure D with phenethyl 2-diazo-
2-(diethoxyphosphoryl)acetate 11d (73 mg, 0.224 mmol), DCM
(4.5 mL), Rh2(oct)4 (3.5 mg, 4.5 mmol), THF (4.5 mL), KOBu-t
(37.7 mg, 0.336 mmol) and valeraldehyde (44.8 mL, 0.448 mmol).
The HWE was performed at reﬂux. Puriﬁcation by column chro-
matography (8:1 hexane/ethyl acetate) afforded the title com-
pounds as mixture of (Z) and (E) isomers (Z-18i/E-18i 3.3:1) (29 mg,
56%). Small quantities of each compound were isolated separately
for characterisation purposes.
4.65.1. Data for Z-18i. Pale yellow oil; Rf 0.53 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2957m, 2928m, 2871w, 1755s,
1667w, 1455w, 1373w, 1175m, 1127m, 1025s; dH (400 MHz, CDCl3)
0.88 (3H, t, J 7.1), 1.25e1.43 (4H, m), 2.66e2.82 (2H, m), 4.18e4.24
(2H, m), 4.61e4.67 (1H, m), 5.99 (1H, td, J 7.8, 2.2), 7.20e7.23 (2H,
m), 7.28e7.32 (1H, m), 7.34e7.39 (2H, m); dC (100 MHz, CDCl3) 13.8,
22.3, 27.2, 31.1, 46.9, 72.5, 127.6, 128.0, 128.8, 129.1, 140.7, 146.9,
169.8; HRMS (ESIþ): found: 253.1188; C15H18NaO2 (MNaþ) requires
253.1199.
4.65.2. Data for E-18i. Pale yellow oil; Rf 0.44 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2957m, 2928s, 2858m, 1759s,
1672w, 1456w, 1378w, 1184m, 1026m; dH (400 MHz, CDCl3) 0.76
(3H, t, J 7.2), 1.10e1.33 (4H, m), 1.88e2.01 (2H, m), 4.20e4.29 (2H,
m), 4.70 (1H, app. t, J 8.2), 6.92 (1H, td, J 7.7, 2.3), 7.19e7.21 (2H, m),
7.26e7.29 (1H, m), 7.31e7.36 (2H, m); dC (100 MHz, CDCl3) 13.6,
22.2, 29.2, 29.9, 43.4, 73.5, 127.2, 127.4, 129.0, 129.1, 141.7, 144.3,
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171.2; HRMS (ESIþ): found: 253.1187; C15H18NaO2 (MNaþ) requires
253.1199.
4.66. (SR,Z)-3-(4-Nitrobenzylidene)-4-pentyldihydrofuran-
2(3H)-one (Z-18j) and (SR,E)-3-(4-nitrobenzylidene)-4-
pentyldihydrofuran-2(3H)-one (E-18j)
Synthesised using general procedure D with heptyl 2-diazo-2-
(diethoxyphosphoryl)acetate 11p (68 mg, 0.212 mmol), DCM
(4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 mmol), THF (4.2 mL), KOBu-t
(35.7 mg, 0.318 mmol) and 4-nitrobenzaldehyde (62.6 mg,
0.424 mmol). The HWE was performed at 0 "C. Puriﬁcation by
column chromatography (8:1 hexane/ethyl acetate) afforded the
title compounds as mixture of (Z) and (E) isomers (Z-18j/E-18j 1:1)
(42 mg, 68%). Small quantities of each compound were isolated
separately for characterisation purposes.
4.66.1. Data for Z-18j. Yellow oil; Rf 0.46 (4:1 hexane/ethyl ace-
tate); nmax (thin ﬁlm)/cm#1 2928m, 2857m, 1752s, 1651w, 1597m,
1518s,1466w,1378w,1344s,1175s,1112w; dH (400MHz, CDCl3) 0.91
(3H, t, J 7.0), 1.25e1.45 (6H, m), 1.57e1.68 (1H, m), 1.73e1.82 (1H,
m), 3.15e3.22 (1H, m), 4.09 (1H, dd, J 8.9, 5.1), 4.52 (1H, dd, J 8.9,
7.7), 6.93 (1H, d, J 2.2), 7.89 (2H, d, J 8.8), 8.21 (2H, d, J 8.8); dC
(100 MHz, CDCl3) 14.0, 22.5, 26.0, 31.7, 34.1, 42.0, 70.8, 123.2, 131.1,
133.0, 136.1, 139.7, 147.6, 168.6; HRMS (ESIþ): found: 312.1210;
C16H19NNaO4 (MNaþ) requires 312.1206.
4.66.2. Data for E-18j. Pale yellow solid; Rf 0.41 (4:1 hexane/ethyl
acetate); mp 114e117 "C; nmax (thin ﬁlm)/cm#1 2929m, 2858m,
1754s, 1598m, 1520s, 1344s, 1225m, 1183s, 1112w; dH (400 MHz,
CDCl3) 0.86 (3H, t, J 7.0), 1.18e1.42 (6H, m), 1.50e1.67 (2H, m),
3.53e3.60 (1H, m), 4.28 (1H, dd, J 9.1, 2.0), 4.45 (1H, ddd, J 9.1, 7.0,
0.7), 7.56 (1H, d, J 2.1), 7.67 (2H, d, J 8.8), 8.29 (2H, d, J 8.8); dC
(100 MHz, CDCl3) 13.0, 22.4, 26.4, 31.4, 32.4, 38.1, 70.7, 124.1, 130.3,
133.4, 133.8, 140.3, 147.8, 171.6; HRMS (ESIþ): found: 312.1205;
C16H19NNaO4 (MNaþ) requires 312.1206.
4.67. (SR,Z)-4-Pentyl-3-pentylidenedihydrofuran-2(3H)-one
(Z-18k) and (SR,E)-4-pentyl-3-pentylidenedihydrofuran-
2(3H)-one (E-18k)
Synthesised using general procedure D with heptyl 2-diazo-2-
(diethoxyphosphoryl)acetate 11p (67 mg, 0.209 mmol), DCM
(4.2 mL), Rh2(oct)4 (3.3 mg, 4.2 mmol), THF (4.2 mL), KOBu-t
(35.2 mg, 0.314 mmol) and valeraldehyde (45.0 mL, 0.418 mmol).
The HWE was performed at rt. Puriﬁcation by column chroma-
tography (8:1 hexane/ethyl acetate) afforded the title compounds as
mixture of (Z) and (E) isomers (Z-18k/E-18k 2.7:1) (36 mg, 77%).
Small quantities of each compound were isolated separately for
characterisation purposes.
4.67.1. Data for Z-18k. Colourless oil; Rf 0.75 (4:1 hexane/ethyl ac-
etate); nmax (thin ﬁlm)/cm#1 2957s, 2928s, 2858s, 1754s, 1668m,
1466m, 1378m, 1185m, 1127s, 1027s; dH (400 MHz, CDCl3) 0.87e0.92
(6H, m), 1.24e1.49 (11H, m), 1.56e1.65 (1H, m), 2.69e2.75 (2H, m),
2.88e2.97 (1H, m), 3.92 (1H, dd, J 8.8, 5.3), 4.37 (1H, dd, J 8.8, 7.9),
6.12 (1H, td, J 7.7, 1.6); dC (100 MHz, CDCl3) 13.9, 14.0, 22.3, 22.5, 25.9,
27.1, 31.3, 31.7, 34.2, 40.1, 70.8, 128.3, 144.1, 170.5; HRMS (ESIþ):
found: 247.1670; C14H24NaO2 (MNaþ) requires 247.1669.
4.67.2. Data for E-18k. Colourless oil; Rf 0.66 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2961s, 2930s, 2859m, 1760s, 1676m,
1466m, 1380w, 1193m, 1021m; dH (400 MHz, CDCl3) 0.87e0.94 (6H,
m), 1.22e1.57 (12H, m), 2.15e2.28 (2H, m), 3.04e3.10 (1H, m), 4.12
(1H, dd, J 9.1, 2.2), 4.31 (1H, dd, J 9.1, 7.3), 6.73 (1H, td, J 7.7, 2.0); dC
(100 MHz, CDCl3) 13.8, 14.0, 22.4, 22.5, 26.1, 29.4, 30.7, 31.7, 34.2,
37.1, 70.8, 129.8, 141.5, 171.7; HRMS (ESIþ): found: 247.1666;
C14H24NaO2 (MNaþ) requires 247.1669.
4.68. (SR,Z)-4-(4-Nitrobenzylidene)-2-oxaspiro[4.4]nonan-3-
one (Z-18l) and (SR,E)-4-(4-nitrobenzylidene)-2-oxaspiro[4.4]
nonan-3-one (E-18l)
Synthesised using general procedure D with cyclopentylmethyl
2-diazo-2-(diethoxyphosphoryl)acetate 11ae (61 mg, 0.200 mmol),
DCM (4.0 mL), Rh2(oct)4 (3.1 mg, 4.0 mmol), THF (4.0 mL), KOBu-t
(33.7 mg, 0.300 mmol) and 4-nitrobenzaldehyde (60.5 mg,
0.400 mmol). The HWE was performed at 0 "C. Puriﬁcation by
column chromatography (8:1 hexane/ethyl acetate) afforded the
title compounds as an inseparable mixture of (Z) and (E) isomers (Z-
18l/E-18l 1:1.4), as a white solid (30 mg, 55%); Rf 0.32 (4:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm#1 2959w, 2874w, 1755s, 1646w,
1597m, 1518s, 1492w, 1453w, 1344s, 1257w, 1227w, 1201w, 1160m,
1096m, 1023m, 910w, 851m; dH (400 MHz, CDCl3) 1.61e1.96 (16H,
m, E,Z), 4.04 (3H, s, E), 4.16 (3H, s, Z), 6.87 (1H, s, Z), 7.52 (2H, dd, J
8.9, 0.6, E), 7.65 (1H, s, E), 7.86 (2H, dd, J 8.9, 0.5, Z), 8.19 (2H, d, J 8.9,
Z), 8.25 (2H, d, J 8.9, E); dC (100 MHz, CDCl3) 24.6 (E/Z), 25.3 (E/Z),
37.1 (E), 39.3 (Z), 50.3 (E), 52.5 (Z), 77.5 (Z), 79.4 (E), 123.1 (Z), 123.5
(E), 130.0 (E), 131.1 (Z), 134.0 (Z), 134.3 (E), 136.6 (E), 137.3 (Z), 139.8
(Z), 140.9 (E), 147.5 (E/Z), 147.6 (E/Z), 168.9 (Z), 171.9 (E); HRMS
(ESIþ): found: 296.0899; C15H15NNaO4 (MNaþ) requires 296.0893.
4.69. (SR,Z)-4-Pentylidene-2-oxaspiro[4.4]nonan-3-one (Z-
18m) and (SR,E)-4-pentylidene-2-oxaspiro[4.4]nonan-3-one
(E-18m)
Synthesised using general procedure D with cyclopentylmethyl
2-diazo-2-(diethoxyphosphoryl)acetate 11ae (63 mg, 0.207 mmol),
DCM (4.2 mL), Rh2(oct)4 (3.2 mg, 4.1 mmol), THF (4.2 mL), KOBu-t
(34.8 mg, 0.311 mmol) and valeraldehyde (44.0 mL, 0.414 mmol).
The HWE was performed at reﬂux. Puriﬁcation by column chro-
matography (8:1 hexane/ethyl acetate) afforded the title com-
pounds as mixture of (Z) and (E) isomers (Z-18m/E-18m 2.4:1)
(14 mg, 32%). Small quantities of each compound were isolated
separately for characterisation purposes.
4.69.1. Data for Z-18m. Colourless oil; Rf 0.67 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2956m, 2929w, 2871m, 1752s,
1665m, 1453m, 1370m, 1164w, 1128w, 1105m, 1025s; dH (400 MHz,
CDCl3) 0.91 (3H, t, J 7.2), 1.24e1.46 (4H, m), 1.62e1.81 (8H, m), 2.72
(2H, app. q, J 7.4), 4.02 (2H, s), 6.08 (1H, t, J 7.7); dC (100MHz, CDCl3)
13.9, 22.3, 24.5, 26.9, 31.4, 39.2, 50.8, 77.7, 132.8, 141.9, 170.1; HRMS
(ESIþ): found: 231.1354; C13H20NaO2 (MNaþ) requires 231.1356.
4.69.2. Data for E-18m. Colourless oil; Rf 0.54 (4:1 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm#1 2956s, 2934s, 2872s, 1758s, 1668m,
1455m,1383w,1362w,1164w,1028s; dH (400MHz, CDCl3) 0.93 (3H,
t, J 7.1), 1.20e2.00 (12H, m), 2.29 (2H, app. q, J 7.5), 4.00 (2H, s), 6.70
(1H, t, J 8.0); dC (100 MHz, CDCl3) 13.8, 22.5, 25.5, 27.7, 31.0, 38.6,
48.8, 79.8, 132.5, 141.6, 171.4; HRMS (ESIþ): found: 231.1352;
C13H20NaO2 (MNaþ) requires 231.1356.
4.70. (SR)-4-(Hydroxymethyl)-3-methylenedihydrofuran-
2(3H)-one (19)9b
To a solution of 4-(((tert-butyldimethylsilyl)oxy)methyl)-3-
methylenedihydrofuran-2(3H)-one 12u (29 mg, 0.120 mmol) in
THF (0.6 mL) cooled to 0 "C under argon was added TBAF (144 mL,
0.144, 1.0 M in THF) dropwise. The solution was stirred at 0 "C for
1 h then quenched with satd aq NH4Cl (10 mL) and extracted with
ether (2$25 mL). The combined organic extracts were dried over
Na2SO4 and concentrated in vacuo. Puriﬁcation by column
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chromatography (1:2 hexane/ethyl acetate) afforded the title com-
pound as a pale yellow oil (12 mg, 78%); Rf 0.29 (1:2 hexane/ethyl
acetate); nmax (thin ﬁlm)/cm!1 3417br, 2924m, 1756s, 1407w,
1268m, 1120m, 1017m, 816m; dH (400 MHz, CDCl3) 3.26e3.34 (1H,
m), 3.76e3.78 (2H, m), 4.27 (1H, dd, J 9.4, 4.5), 4.47 (1H, dd, J 9.4,
8.2), 5.75 (1H, d, J 2.3), 6.36 (1H, d, J 2.6); dC (100 MHz, CDCl3) 40.9,
64.1, 68.2, 123.6, 135.2, 170.4; HRMS (ESIþ): found: 151.0360;
C6H8NaO3 (MNaþ) requires 151.0366.
4.71. (±)-Cedarmycin A (8a)9a
Preparation of 5-methylhexanoyl chloride 20a: to a solution of 5-
methylhexanoic acid (130.2 mg,1.00 mmol) in DCM (2.5 mL) at 0 #C
was added oxalyl chloride (253 mL, 3.00mmol) dropwise. Stirred for
30 min at 0 #C followed by 2 h at rt then concentrated in vacuo to
afford a colourless oil. To a solution of 4-(hydroxymethyl)-3-
methylenedihydrofuran-2(3H)-one 19 (5 mg, 0.039 mmol) and
triethylamine (8.2 mL, 0.059 mmol) in DCM (0.20 mL) was added 5-
methylhexanoyl chloride (10 mL). After 2 h additional 5-
methylhexanoyl chloride (10 mL) was added and stirred for 16 h.
The solution was quenched with satd aq NH4Cl (1 mL) and
extracted with DCM (3$10 mL). The combined organic extracts
were dried over Na2SO4 and concentrated in vacuo. Puriﬁcation by
column chromatography (4:1 hexane/ethyl acetate) afforded the
title compound as a colourless oil (6 mg, 85%); Rf 0.75 (1:1 hexane/
ethyl acetate); nmax (thin ﬁlm)/cm!1 2956m, 2871w, 1768s, 1739s,
1468w, 1252w, 1170m, 1115m, 1019w; dH (400 MHz, CDCl3) 0.88
(6H, t, J 6.6), 1.15e1.21 (2H, m), 1.51e1.65 (3H, m), 2.31 (2H, t, J 7.6),
3.39e3.47 (1H, m), 4.16 (1H, dd, J 11.2, 7.3), 4.18 (1H, dd, J 9.4, 4.9),
4.25 (1H, dd, J 11.2, 5.6), 4.48 (1H, dd, J 9.4, 8.4), 5.76 (1H, d, J 2.3),
6.39 (1H, d, J 2.7); dC (100 MHz, CDCl3) 22.4, 22.7, 27.7, 34.3, 38.0,
38.3, 64.7, 68.1, 124.2, 134.5, 169.8, 173.5; HRMS (ESIþ): found:
263.1251; C13H20NaO4 (MNaþ) requires 263.1254.
4.72. (±)-Cedarmycin B (8b)9
To a solution of 4-(hydroxymethyl)-3-methylenedihydrofuran-
2(3H)-one 19 (3 mg, 0.023 mmol) and triethylamine (4.8 mL,
0.035 mmol) in DCM (0.12 mL) was added hexanoyl chloride
(3.9 mL, 0.035 mmol). The solution was stirred at rt for 10 min then
quenched with satd aq NH4Cl (1 mL) and extracted with DCM
(3$10 mL). The combined organic extracts were dried over Na2SO4
and concentrated in vacuo. Puriﬁcation by column chromatography
(4:1 hexane/ethyl acetate) afforded the title compound as a colour-
less oil (3 mg, 57%); Rf 0.76 (1:1 hexane/ethyl acetate); nmax (thin
ﬁlm)/cm!1 2959m, 2936m, 2864w, 1768s, 1738s, 1270w, 1246w,
1168m, 1115m, 1018w; dH (400 MHz, CDCl3) 0.90 (3H, t, J 7.0),
1.25e1.36 (4H, m), 1.62 (2H, app. quin, J 7.5), 2.32 (2H, t, J 7.5),
3.39e3.47 (1H, m), 4.16 (1H, dd, J 11.2, 7.3), 4.18 (1H, dd, J 9.4, 4.9),
4.25 (1H, dd, J 11.2, 5.6), 4.48 (1H, dd, J 9.4, 8.4), 5.76 (1H, d, J 2.4),
6.38 (1H, d, J 2.7); dC (100 MHz, CDCl3) 13.9, 22.3, 24.5, 31.2, 34.0,
38.1, 64.7, 68.1, 124.1, 134.5, 169.8, 173.5; HRMS (ESIþ): found:
249.1099; C12H18NaO4 (MNaþ) requires 249.1097.
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A selective C–H insertion/oleﬁnation protocol
for the synthesis of α-methylene-γ-butyrolactone
natural products†
Matthew G. Lloyd,a Mariantonietta D’Acunto,b Richard J. K. Taylor*a and
William P. Unsworth*a
A regio- and stereoselective one-pot C–H insertion/oleﬁnation protocol has been developed for the late
stage installation of α-methylene-γ-butyrolactones into conformationally restricted cyclohexanol-deriva-
tives. The method has been successfully applied in the total synthesis of eudesmanolide natural product
frameworks, including α-cyclocostunolide.
The selective functionalization of sp3 centres via the activation
of unfunctionalised C–H bonds is of much current interest,1
given that it facilitates the synthesis of complex molecular
architectures from relatively simple precursors. Over the last
two decades, rhodium(II)-catalysed C–H insertions have
become a mainstay in this field; an array of useful reaction
modes with well-established reactivity patterns have been deve-
loped, including asymmetric variants, based on the C–H inser-
tion of rhodium-stabilised carbenoids.2 In particular, the
donor/acceptor carbenoid systems popularised by Davies have
proved to be especially valuable.2d
The acceptor/acceptor carbenoid class has received less
attention in comparison,3 although there are prominent excep-
tions.4 A useful feature of carbenoids of this type is the fact
that the additional acceptor substituent may be used as a
handle for further chemical modification; this is exemplified
by work published by our own group, in which a one-pot
rhodium(II)-catalysed C–H insertion/Horner–Wadsworth–
Emmons olefination (HWE) sequence for the conversion of
α-diazo-α-(diethoxy)phosphoryl acetates 1 into α-methylene-
γ-butyrolactones 2 was reported (Fig. 1a).5 This research
focused primarily on substrates with electron rich C–H bonds
(e.g. benzylic reaction system 1) that are well-suited to react
with electrophilic carbenoids. The work described herein con-
cerns the extension of this method to cyclohexanol derivatives
(3, Fig. 1b). These are much more challenging substrates com-
pared to those examined previously, as there is no electronic
bias to direct the C–H insertion, but the products 4 are argu-
ably more important given that a huge number of bioactive
cyclohexane-based α-methylene-γ-butyrolactone natural pro-
ducts have been isolated.6 Our aim (Fig. 1b) was to design the
cyclohexane precursors so that C–H insertion (and subsequent
olefination) occurs exclusively into equatorial C–H bonds,7 to
selectively form fused γ-lactones 4. The success of this
approach, and its application in the total synthesis of three
natural product targets and one isomeric analogue, are
described.
Our only previous attempt at performing a C–H insertion/
olefination of this type was not encouraging; when the diazo-
phosphonate derivative of cyclohexanol (i.e. compound 3, with
R = H) was treated under the standard reaction conditions
[Rh2(oct)4 (2 mol%), CH2Cl2, 45 °C, 16 h; (ii) KOBu-t, THF, −78
– 0 °C, 1 h; (iii) (CH2O)n, 0 °C – rt, 1 h]5 a diastereomeric
mixture of γ-lactones, as well as some β-lactone product, was
obtained (corresponding to insertion into all three of the high-
lighted C–H bonds in 3) and the overall yield was low.5b It was
postulated that the poor selectivity in this case may be related
Fig. 1 C–H insertion/oleﬁnation approach to α-methylene-
γ-butyrolactones.
†Electronic supplementary information (ESI) available: Experimental, spectral
and crystallographic data. CCDC 1421154, 1421158 and 1421164. For ESI and
crystallographic data in CIF or other electronic format see DOI: 10.1039/
c5ob02579f
aDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
E-mail: richard.taylor@york.ac.uk, william.unsworth@york.ac.uk
bUniversity of Salerno, Department of Chemistry and Biology, Via Giovanni Paolo II,
132, Salerno, 84084 Fisciano, Italy
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to the flexible nature of the substrate, and that by restricting
its conformation, the regio- and stereoselectivity may be
improved.
To test this idea, 4-tert-butyl cyclohexyl derivatives 5a and
5b were formed and reacted under the standard one-pot C–H
insertion/olefination conditions (Fig. 2). The expectation was
that the tert-butyl group would lock the cyclohexane scaﬀold in
a chair conformation to better distinguish the two γ-C–H inser-
tion sites, and improve the diastereoselectivity. Greater control
was indeed observed in both cases; γ-lactones 6a and 6b were
each isolated as single diastereoisomers, with the stereochemi-
cal outcome consistent with insertion into the equatorial C–H
bonds. However, in both reactions the overall yield was rela-
tively low, which is partly explained by the formation of
β-lactone side-products 7a and 7b (not shown, see ESI†). Pleas-
ingly, by moving the tert-butyl group closer to the C–H inser-
tion site, a significant improvement was observed; 2-tert-butyl
substrates 5c and 5d furnished α-methylene-γ-butyrolactones
6c and 6d respectively, with complete diastereoselectivity and a
significant increase in isolated yield (76% and 90%), with no
β-lactone side-products being formed in either case. The tert-
butyl group is likely to be playing two roles in these substrates,
both fixing the conformation of the cyclohexane ring and pro-
viding a steric barrier to competing β-insertion reactions. To
further probe this cooperative eﬀect, other 2-subtituted confor-
mationally restricted systems based on menthol and decalinol
(5e, 5f and 5g) were treated under the standard conditions and
all aﬀorded the expected γ-lactone products selectively (6e, 6f
and 6g). It is noteworthy that in all cases, there is complete
selectivity for equatorial C–H insertion, irrespective of whether
the diazoester substituent itself has an equatorial (6a, 6c, 6e,
6f ) or axial (6b, 6d, 6g) configuration.
In view of the excellent regio- and stereoselectivity observed
in these reactions, attention turned to their application in
natural product synthesis. Sesquiterpene lactones are the most
common class of α-methylene-γ-butyrolactone found in
Nature6e,8 and selected compounds from a sub-class of this
family collectively known as the eudesmanolides, are shown in
Fig. 3 (8–13).
First, compounds 8 and 9 (labelled morifolins A and B,
Fig. 3) were targeted. As the C–H insertion procedure had not
previously been tested on a cis-decalin framework (which can
potentially ring flip), they were considered to be an interesting
challenge to the methodology. An additional reason for
performing the synthesis of the morifolins was to clear up con-
fusion that exists in the literature about their structural assign-
ments. In 1985, Dominguez and co-workers isolated a series of
sesquiterpene lactones, two of which were named morifolin
A and B and assigned the structures 8 and 9 above.9 However,
in a 2004 publication,10 Herz suggested that these products
had been assigned incorrectly, and proposed that they were in
fact identical to isocritonilide 10 and critonilide 11, respecti-
vely, described by Bohlmann and co-workers in 1983.11 The
spectral data in the Dominguez publication were insuﬃcient
to draw a definitive conclusion, and hence it was decided to
complete the total syntheses of lactones 8 and 9 to clarify the
anomaly.
The synthesis began with a lithium naphthalenide
mediated 1,2-addition of chloride 14 into cyclohexenone,12
which was followed by oxidative rearrangement with PCC,
furnishing α,β-unsaturated ketone 16 (Scheme 1). Next, the
1,4-addition of methylmagnesium chloride under Gilman-type
conditions aﬀorded doubly-masked keto-aldehyde 17. This was
followed by an intramolecular aldol reaction under acidic con-
ditions, which furnished cis-β-hydroxyketone 18 as a single dia-
stereoisomer, as reported in the literature.13 Next, silyl
protection of the alcohol, vinyl triflate formation and iron-
catalysed cross-coupling14 with methylmagnesium chloride
furnished alkene 21 in excellent overall yield. Desilylation
using TBAF followed by a T3P-mediated acylation and Regitz
diazo transfer reaction, generated the key diazo substrate 24.
This was then primed to undergo the one-pot C–H insertion/
olefination sequence, which was performed under the
Fig. 2 C–H insertion/oleﬁnation sequence for conformationally
restricted cyclohexane derivatives 5a–g. Reaction conditions: (i)
Rh2(oct)4 (2 mol%), CH2Cl2, 45 °C, 16 h; (ii) KOBu-t, THF, −78 – 0 °C, 1 h;
(iii) (CH2O)n, 0 °C – rt, 1 h. Yields of isolated product.
a β-lactone
product 7a, (12%) was also isolated; b β-lactone product 7b, (19%) was
also isolated. Fig. 3 Eudesmanolide natural products 8–13.
Paper Organic & Biomolecular Chemistry
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standard conditions, aﬀording α-methylene-γ-butyrolactone 8
in 64% yield with complete stereo- and regiocontrol. The
relative configuration of 8 was found to be in line with that
observed in the model studies and was assigned unambi-
guously by X-ray crystallography.15 With the identity of our syn-
thetic sample 8 confirmed, its spectral data were then
compared with those reported for the natural product mori-
folin A; significant diﬀerences between the 1H NMR data of
cis-decalin 8 and the natural product were clearly observed,
thus confirming that morifolin A had indeed been incorrectly
assigned. Thus it appears most likely that the natural isolated
material named morifolin A 8 is in fact the same as isocritoni-
lide 10, as suggested previously by Herz.10
The synthesis of the proposed structure of morifolin B 9
started with a common intermediate from the morifolin A
route, ketone 19, which was treated with TMSCH2Li to form
alcohol 25 (Scheme 2). This was followed by a base-mediated
Peterson olefination to generate exocyclic alkene 26, and sub-
sequent desilylation, acylation and diazotization as before, to
generate diazo substrate 29 in excellent overall yield. Then,
Rh2(OAc)4 catalysed C–H insertion16 and olefination in the
usual way, furnished lactone 9 as a single diastereoisomer
(which was again verified by X-ray crystallography),15 along
with a small amount of a cyclopropane side-product 30 (not
shown, see ESI†). The 1H NMR data of synthetic material 9
were again significantly diﬀerent to those published for the
natural product,9 confirming that morifolin B was also in-
correctly assigned in the literature. Therefore, similarly to
morifolin A, it again seems most likely that the isolated
material named morifolin B 9 is in fact the same as critonilide
11, again as suggested previously by Herz.10
Next, attention turned to the synthesis of α-cyclocostunolide
12,17 a cytotoxic18 trans-decalin eudesmanolide natural
product with anti-trypanosomal19 and anti-coagulant activity.20
Its synthesis began with a two-step epimerisation of cis-
β-hydroxyketone 18 via an oxidation–reduction sequence,
which provided the desired trans-β-hydroxyketone 32,
in addition to diastereoisomeric cis-β-hydroxyketone 33
(Scheme 3).21
Then, the same sequence shown in Scheme 2 was per-
formed on each of these β-hydroxyketones, aﬀording diazo
substrates 34 and 35 without complication. We were then
pleased to isolate α-cyclocostunolide 12 as the sole product
from the reaction of diazophosphonate 34 under the standard
one-pot C–H insertion/olefination conditions, with its spectral
data fully matching those of natural α-cyclocostunolide.17 In
addition, diastereomeric lactone 36 was also isolated from dia-
zophosphonate 35, and was again formed in good yield, via
selective equatorial C–H insertion.22
In summary, a highly regio- and stereoselective one-pot
C–H insertion/olefination protocol for the late-stage functiona-
lisation of conformationally restricted cyclohexanol-derivatives
has been developed. Exclusive formation of γ-lactones via
insertion into equatorial C–H bonds was observed and the
method was validated in natural product synthesis. Eudesma-
nolide sesquiterpene natural product α-cyclocostunolide 12
was synthesised in racemic form in high yield using this proto-
col. In addition, structures 8 and 9, originally assigned to the
natural products morifolin B and morifolin A, were prepared
and it was demonstrated unambiguously that the original
Scheme 1 Synthesis of α-methylene-γ-butyrolactone 8. Reagents and
conditions: (a) (1) 14, Li, naphthalene, THF, −78 °C; (2) 2-cyclohexen-1-
one, −78 °C – rt, 100%; (b) PCC, Al2O3, CH2Cl2, 0 °C – rt, 52%; (c) CuI,
LiCl, TMSCl, MeMgCl, THF, −78 °C – rt, 98%; (d) 10% aq. HCl, MeOH,
80 °C, 65%; (e) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C – rt, 99%; (f ) LHMDS,
Tf2O, THF, −40 °C, 80%; (g) Fe(acac)3, MeMgCl, THF : NMP (1 : 3), 82%;
(h) TBAF, THF, 65 °C, 88%; (i) diethylphosphonoacetic acid, DIPEA, T3P,
PhMe, rt, 100%; ( j) LHMDS, p-ABSA, THF, −78 °C – rt, 89%; (k) (1)
Rh2(oct)4 (2 mol%), CH2Cl2, 45 °C, 16 h; (2) KOBu-t, THF, 0 °C, 1 h; (3)
(CH2O)n, −78 °C – rt, 1 h, 64%.
Scheme 2 Synthesis of α-methylene-γ-butyrolactone 9. Reagents and
conditions: (a) TMSCH2Li, THF, −78 °C, 84%; (b) NaH, THF, 65 °C, 100%;
(c) TBAF, THF, 65 °C, 81%; (d) diethylphosphonoacetic acid, DIPEA, T3P,
PhMe, rt, 82%; (e) LHMDS, p-ABSA, THF, −78 °C – rt, 78%; (f ) (1)
Rh2(OAc)4 (2 mol%), CH2Cl2, 45 °C, 16 h; (2) KOBu-t, THF, 0 °C, 1 h; (3)
(CH2O)n, −78 °C – rt, 1 h, 45% (9) and 11% (30).
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structural assignments were in error. Finally, a fourth isomeric
α-methylene-γ-butyrolactone 36, which is apparently novel, was
also prepared.22 This chemistry is expected to be applicable to
a variety of synthetic targets possessing the α-methylene-
γ-butyrolactone motif.
The authors wish to thank Elsevier Foundation (M. G. L.),
the University of Salerno (M. D.) and the University of York
(W. P. U.) for funding, Dr Adrian C. Whitwood (University of
York) for X-ray crystallography and Euticals for providing T3P.
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Abbreviations 
Ac acetyl 
acac acetylacetonate 
acam acetamidate 
AIBN 2,2′-azobis(2-
methylpropionitrile) 
app. apparent 
aq. aqueous 
Ar aryl  
Bn benzyl 
br broad 
Bu n-butyl 
BtH 1H-benzotriazole 
conc. concentrated  
COSY correlation spectroscopy 
δ chemical shift 
d doublet 
DBSA 4-n-
dodecylbenzenesulfonyl 
azide 
DBU 1,8-
diazabicyclo[5.4.0]undec-
7-ene 
DCC N,N’-
dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
DCM dichloromethane 
de diastereomeric excess 
DEAD diethyl azodicarboxylate 
DEPAA diethylphosphonoacetic 
acid 
DEPT distortionless enhancement 
by polarisation transfer 
DIBAL diisobutylaluminium 
hydride 
DIPEA N,N-diisopropylethylamine 
DMAP N,N-dimethyl-4-
aminopyridine 
DMF N,N-dimethylformamide 
DMP Dess-Martin periodinane 
DMS dimethylsulfide 
DMSO dimethylsulfoxide 
dr diastereomeric ratio 
DTBMP 2,6-di-tert-
butylmethylpyridine 
EDG electron-donating group 
ee enantiomeric excess 
eq. equivalent(s) 
ESI electrospray ionisation 
esp α,α,α’,α’-tetramethyl-1,3,-
benzenedipropionic acid 
Et ethyl 
ether diethyl ether 
EtOAc ethyl acetate 
EWG electron-withdrawing 
group 
FGI functional group 
interconversion 
h 
hex 
hour(s) 
n-hexyl 
HMBC heteronuclear multiple 
bond correlation 
HOMO Highest Occupied 
Molecular Orbital 
HPLC high performance liquid 
chromatography 
HRMS high resolution mass 
spectrometry 
HSQC heteronuclear single 
quantum coherence 
HWE Horner–Wadsworth–
Emmons  
IR infrared  
 400
J coupling constant (Hz) 
KHMDS potassium 
bis(trimethylsilyl)amide 
LDA lithium diisopropylamide 
LHMDS lithium 
bis(trimethylsilyl)amide 
lit. literature 
LUMO Lowest Unoccupied 
Molecular Orbital 
m meta 
m multiplet 
M molar 
Me methyl 
min(s) minute(s) 
m.p. melting point 
MRSA Methicillin-resistant 
Staphylococcus aureus 
n normal 
NaHMDS sodium 
bis(trimethylsilyl)amide 
NBS N-bromosuccinimide 
NMR nuclear magnetic 
resonance 
[O] oxidation 
o/n overnight 
o ortho 
OAc acetate 
oct octanoate 
p para 
p-ABSA 4-
acetamidobenzenesulfonyl 
azide 
PCC pyridinium chlorochromate 
petrol petroleum diethyl ether 
40–60 °C 
pfb perfluorobutyrate 
Ph phenyl 
PMP 4-methoxyphenyl 
ppm 
Pr 
parts per million 
n-propyl 
q quartet 
quin. quintet 
rbf round-bottom flask 
Rf retention factor 
RT room temperature 
s singlet 
sat. saturated  
sex. sextet 
t tertiary 
t triplet 
T3P propyl phosphonic 
anhydride 
TBAF tetra-n-butylammonium 
fluoride 
TBS tert-butyldimethylsilyl 
TEA N,N,N-triethylamine 
tert tertiary 
TFA trifluoroacetic acid 
Tf trifluoromethanesulfonyl 
(triflyl) 
THF tetrahydrofuran 
TIMO telescoped intramolecular 
Michael/olefination 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMEDA  N,N,N’,N’-tetramethyl-
ethane-1,2-diamine 
TMS trimethylsilyl 
tpa triphenylacetate 
trityl triphenylmethyl 
Ts p-toluenesulfonyl (tosyl) 
UV ultraviolet 
vis visible 
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